<?xml version="1.0" encoding="UTF-8" ?><xml><records><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>132</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">132</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zwoliñska, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatric Nephrology, Medical University of Wroclaw, Borowska 213, Wrocaw, 50-556, Poland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Treatment of urinary tract infection in children</style></title><secondary-title><style face="normal" font="default" size="100%">Pediatria i Medycyna Rodzinna</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pediatria i Medycyna Rodzinna</style></full-title></periodical><pages><style face="normal" font="default" size="100%">264-275</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Children</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infection is the most frequent bacterial infection in children. Its prevalence in the population younger than 14 years of age has been estimated at 5.10%. Its high recurrence, especially in patients with risk factors, poses a significant problem. The risk factors most common in the group of children ≤3 years are congenital defects blocking the flow of urine to the bladder, whereas in older children they most typically include a tendency for constipation and dysfunction of the lower urinary tract. The clinical picture is variable and depends on the child&apos;s age, immunity status, pathogen virulence and localisation of infection. The mildest form of urinary tract infection is asymptomatic bacteriuria, whereas more severe presentations include acute pyelonephritis, acute focal bacterial nephritis and urosepsis. Prognosis is usually good, but under certain circumstances hypertension, proteinuria and chronic kidney disease may develop. Therefore, early introduced appropriate treatment is essential. According to the Polish Society for Paediatric Nephrology guidelines, asymptomatic bacteriuria does not warrant treatment, whereas febrile patients (&gt;38°C) under 24 months old with a suspicion for urinary tract infection must be promptly administered antibiotic therapy, after a urine specimen has been obtained for culture. For many years, urinary tract infection has remained a topic of controversy in terms of therapy duration and administration route. Inpatient treatment of children under 3 months of age is an accepted rule. Acute pyelonephritis necessitates a longer therapy, lasting from 7 to 10 days, whereas the duration of treatment of lower urinary tract infection has been cut down to 3 up to 5 days. Routine prophylactic antimicrobial therapy is not recommended following the initial urinary tract infection episode, yet should be considered in special circumstances. Alternative prophylactic methods, such as immunostimulating agents, probiotics or cranberry, may be used, but their efficacy has not been confirmed in large clinical studies. © 2016 Pediatr Med Rodz.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85015097472&amp;doi=10.15557%2fPiMR.2016.0027&amp;partnerID=40&amp;md5=8a903fbd6106d10f28ab3dd40113fe93</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.15557/PiMR.2016.0027</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>451</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">451</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zorc, J. J.</style></author><author><style face="normal" font="default" size="100%">Kiddoo, D. A.</style></author><author><style face="normal" font="default" size="100%">Shaw, K. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Div. of Pediatric Emergency Medicine, Department of Pediatrics, Univ. of Pennsylvania Sch. of Med., Philadelphia, PA, United States&#xD;Department of Urology, Children&apos;s Hospital of Philadelphia, Philadelphia, PA, United States&#xD;Division of Emergency Medicine, Children&apos;s Hospital of Philadelphia, 34th St. and Civic Center Boulevard, Philadelphia, PA 19104-4399, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diagnosis and management of pediatric urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Microbiology Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Microbiology Reviews</style></full-title></periodical><pages><style face="normal" font="default" size="100%">417-422</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infection (UTI) is among the most commonly diagnosed bacterial infections of childhood. Although frequently encountered and well researched, diagnosis and management of UTI continue to be a controversial issue with many challenges for the clinician. Prevalence studies have shown that UTI may often be missed on history and physical examination, and the decision to screen for UTI must balance the risk for missed infections with the cost and inconvenience of testing. Interpretation of rapid diagnostic tests and culture is complicated by issues of contamination, false test results, and asymptomatic colonization of the urinary tract with nonpathogenic bacteria. The appropriate treatment of UTI has been controversial and has become more complex with the emergence of resistance to commonly used antibiotics. Finally, the anatomic evaluation and long-term management of a child after a UTI have been based on limited evidence, and newer studies question some of the tenets of prior recommendations. The goal of this review is to provide an up-to-date summary of the literature with particular attention to practical questions about diagnosis and management for the clinician. Copyright © 2005, American Society for Microbiology. All Rights Reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :134&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-17444413066&amp;doi=10.1128%2fCMR.18.2.417-422.2005&amp;partnerID=40&amp;md5=319476f5c53ae8c33fbc01da685fa78e</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/CMR.18.2.417-422.2005</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>486</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">486</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zirk, M. M.</style></author><author><style face="normal" font="default" size="100%">Aluko, R. E.</style></author><author><style face="normal" font="default" size="100%">Taylor, C. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dept. of Human Nutritional Sciences, University of Manitoba, Winnipeg, Man. R3T 2N2, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry (Vaccinium Macrocarpon) proanthocyanidins and their effects on urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Current Topics in Nutraceutical Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Topics in Nutraceutical Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">153-160</style></pages><volume><style face="normal" font="default" size="100%">2</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Fimbriae</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidins</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberries have been used for centuries as a therapeutic agent. The most popular curative effect of cranberries is its proposed benefits in preventing urinary tract infections (UTI). Benefits of cranberries have been claimed to be due to the acidity of the berry, and to the specific acids or sugars in the berry. Recently it has been shown that the beneficial effects of cranberries in prevention of UTI are due to two of its constituents, fructose and proanthocyanidins (PAs), which function as anti-adherence agents. PAs are stable polyphenolic compound; and possess various qualities including antiviral, antibacterial, anti-adhesive, and antioxidant properties. The PAs found in cranberries are polymers of epicatechin. PAs prevent UTI by binding to epithelial cells lining the urinary tract and in the process block adhesion of Escherichia coli fimbriae. Administration of cranberry juice or cranberry concentrate tablets have been shown to reduce the recurrence and antibiotic requirements of UTI in women, though there is no conclusive evidence that it can be used as a curative agent. Cranberry tablets have been shown to have similar prophylactic effectiveness but more cost effective when compared to the juice. This review discusses the extraction, purification and bioactive properties of cranberry PAs Copyright © 2004 by New Century Health Publishers, LLC.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :5&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-4043112060&amp;partnerID=40&amp;md5=2e66678e9d9ef21a5743ce71570f9625</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>528</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">528</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zheng, W.</style></author><author><style face="normal" font="default" size="100%">Wang, S. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Fruit Laboratory, Beltsville Agricultural Research Center, Agricultural Research Service, Department of Agriculture, Beltsville, MD 20705, United States&#xD;Institute of Environmental Science, Zhejiang University at Yuquan, Hangzhou, Zhejiang 310027, China</style></auth-address><titles><title><style face="normal" font="default" size="100%">Oxygen radical absorbing capacity of phenolics in blueberries, cranberries, chokeberries, and lingonberries</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">502-509</style></pages><volume><style face="normal" font="default" size="100%">51</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anthocyanins</style></keyword><keyword><style face="normal" font="default" size="100%">Antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">Aronia</style></keyword><keyword><style face="normal" font="default" size="100%">Flavonoid</style></keyword><keyword><style face="normal" font="default" size="100%">Flavonol</style></keyword><keyword><style face="normal" font="default" size="100%">Phenolics</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">The antioxidant activity of phenolics in fruits of blueberry (Vaccinium corymbosum cv. Sierra), cranberry (Vaccinium macrocarpon cv. Ben Lear), wild chokeberry (Aronia melanocarpa), and lingonberry (Vaccinium vitis-idaea cv. Amberland) was determined in this study. The phenolic constituents and contents among the different berries varied considerably. Anthocyanins were found to be the main components in all these berries. Chlorogenic acid in blueberry, quercetin glycosides in cranberry and lingonberry, and caffeic acid and its derivative in chokeberry were also present in relatively high concentrations. Chlorogenic acid, peonidin 3-galactoside, cyanidin 3-galactoside, and cyanidin 3-galactoside were the most important antioxidants in blueberry, cranberry, wild chokeberry, and lingonberry, respectively. The contribution of individual phenolics to the total antioxidant capacity was generally dependent on their structure and content in the berries. Phenolics such as quercetin and cyanidin, with 3′,4′-dihydroxy substituents in the B ring and conjugation between the A and B rings, had highly effective radical scavenging structures in blueberries, cranberries, chokeberries, and lingonberries. Phenolic acids such as caffeic acid also showed high antioxidant activity, probably due to its dihydroxylation in the 3,4 positions as hydrogen donors.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :494&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037438997&amp;doi=10.1021%2fjf020728u&amp;partnerID=40&amp;md5=6cddc17816b99accca55fa25643b2de2</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/jf020728u</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>455</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">455</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Ma, J.</style></author><author><style face="normal" font="default" size="100%">Pan, K.</style></author><author><style face="normal" font="default" size="100%">Go, V. L. W.</style></author><author><style face="normal" font="default" size="100%">Chen, J.</style></author><author><style face="normal" font="default" size="100%">You, W. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Oncology, Peking University, Beijing Inst. for Cancer Research, Beijing, China&#xD;David Geffen Sch. of Med. at UCLA, Torrance, CA, United States&#xD;ILSI Focal Point in China, China&#xD;School of Oncology, Peking University, Beijing Inst. for Cancer Research, 52 Fu-cheng Road, Hai-dian District, Beijing 100036, China</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of cranberry juice on Helicobacter pylori infection: A double-blind, randomized placebo-controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Helicobacter</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Helicobacter</style></full-title></periodical><pages><style face="normal" font="default" size="100%">139-145</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry juice</style></keyword><keyword><style face="normal" font="default" size="100%">Helicobacter pylori</style></keyword><keyword><style face="normal" font="default" size="100%">Intervention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">Background. Helicobacter pylori infection is a major cause of peptic ulcer disease and gastric cancer. This study postulated that cranberry juice would be effective in the suppression of H. pylori in an endemically infected population at high risk for gastric cancer. Materials and methods. A prospective, randomized, double-blind, placebo-controlled trial was conducted in Linqu County of Shandong Province, China, where 189 adults aged 48.9 ± 11.2 years (mean ± SD) with H. pylori infection were randomly divided into two groups: cranberry juice (n = 97) and placebo (n = 92). Participants were assigned to orally receive two 250-ml juice boxes of cranberry juice or matching placebo beverage daily for 90 days. The degree of H. pylori infection was determined using the 13C-urea breath test before randomization at 35 and 90 days of intervention to assess the efficacy of cranberry juice in alleviating infection. Results. A total of 189 subjects with positive 13C-urea breath test results prior to randomization completed the study. At day 35 of intervention, 14 of the 97 (14.43%) from the the cranberry juice treatment group and 5 of the 92 (5.44%) of the placebo recipients had negative 13C-urea breath test results. After 90 days, the study concluded that 14 of the 97 subjects in the cranberry juice treatment group versus 5 of the 92 in the placebo group yielded negative test results. Eleven individuals from the cranberry juice treatment group and only two from the placebo group were negative at 35 and 90 days of experiment. These results are significant (p &amp;lt; .05). Conclusions. Regular consumption of cranberry juice can suppress H. pylori infection in endemically afflicted populations. © 2005 Blackwell Publishing Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :83&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-16444369986&amp;doi=10.1111%2fj.1523-5378.2005.00301.x&amp;partnerID=40&amp;md5=d0fc6ebeed61900dbaa57cc22bb5459f</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1523-5378.2005.00301.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>507</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">507</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Foxman, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Epidemiology, University of Michigan, School of Public Health, United States&#xD;Department of Epidemiology, 109 Observatory Street, Ann Arbor, MI 48109-2029, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Molecular epidemiology of Escherichia coli mediated urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Frontiers in Bioscience</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Frontiers in Bioscience</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e236-e245</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Review</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infection</style></keyword><keyword><style face="normal" font="default" size="100%">Virulence Factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infection (UTI) is one of the most frequently acquired bacterial infections and Escherichia coli accounts for as many as 90% of all UTIs seen among ambulatory populations. Risk factors for UTIs include host behaviors, host characteristics and bacterial characteristics. Sexual activity and contraceptive method are the strongest determinant of a symptomatic UTI episode. The characteristics of cell receptors, anatomical differences and genetic predisposition in the host may be important determinants of increased risk for recurrent infections. Uropathogenic E. coli have special characteristics causing urovirulence. They most likely belong to phylogenic lineage B2. They usually possess specific adhesins such as P, S or Dr to facilitate their colonization in the urinary tract, and toxins such as hemolysin and cytotoxic necrotizing factor 1 to provoke inflammatory response that possibly are responsible for the development of UTI symptoms. Interestingly, virulence genes in uropathogenic E. coli are often co-located on pathogenicity islands. Currently, however, none of the known virulence genes or set of genes can clearly define the prototypic uropathogenic E. coli. Additional studies are needed to identify factors that promote uropathogen transmission and persistent colonization, and to investigate potential different modes of pathogenesis by E. coli strains with different compositions of virulence genes.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :19&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-3142677329&amp;partnerID=40&amp;md5=2fc975d3c95a816746794871d9c008d4</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>67</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">67</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhang, D.</style></author><author><style face="normal" font="default" size="100%">Chia, C.</style></author><author><style face="normal" font="default" size="100%">Jiao, X.</style></author><author><style face="normal" font="default" size="100%">Jin, W.</style></author><author><style face="normal" font="default" size="100%">Kasagi, S.</style></author><author><style face="normal" font="default" size="100%">Wu, R.</style></author><author><style face="normal" font="default" size="100%">Konkel, J. E.</style></author><author><style face="normal" font="default" size="100%">Nakatsukasa, H.</style></author><author><style face="normal" font="default" size="100%">Zanvit, P.</style></author><author><style face="normal" font="default" size="100%">Goldberg, N.</style></author><author><style face="normal" font="default" size="100%">Chen, Q.</style></author><author><style face="normal" font="default" size="100%">Sun, L.</style></author><author><style face="normal" font="default" size="100%">Chen, Z. J.</style></author><author><style face="normal" font="default" size="100%">Chen, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Mucosal Immunology Section, NIDCR, US National Institutes of Health, Bethesda, MD, United States&#xD;State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Sichuan University, Sichuan, China&#xD;Center for Reproductive Medicine, Shandong University, Jinan, China&#xD;Department of Rheumatology and Immunology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China</style></auth-address><titles><title><style face="normal" font="default" size="100%">D-mannose induces regulatory T cells and suppresses immunopathology</style></title><secondary-title><style face="normal" font="default" size="100%">Nature Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nature Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1036-1045</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">9</style></number><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">D-mannose, a C-2 epimer of glucose, exists naturally in many plants and fruits, and is found in human blood at concentrations less than one-fiftieth of that of glucose. However, although the roles of glucose in T cell metabolism, diabetes and obesity are well characterized, the function of D-mannose in T cell immune responses remains unknown. Here we show that supraphysiological levels of D-mannose safely achievable by drinking-water supplementation suppressed immunopathology in mouse models of autoimmune diabetes and airway inflammation, and increased the proportion of Foxp3 + regulatory T cells (T reg cells) in mice. In vitro, D-mannose stimulated T reg cell differentiation in human and mouse cells by promoting TGF-β activation, which in turn was mediated by upregulation of integrin α v β 8 and reactive oxygen species generated by increased fatty acid oxidation. This previously unrecognized immunoregulatory function of D-mannose may have clinical applications for immunopathology. © Nature America, Inc., part of Springer Nature. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :10&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85029054389&amp;doi=10.1038%2fnm.4375&amp;partnerID=40&amp;md5=ee0d8aabe9ab352d9836c4f6a6eaf323</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/nm.4375</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>445</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">445</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zhanel, G. G.</style></author><author><style face="normal" font="default" size="100%">Hisanaga, T. L.</style></author><author><style face="normal" font="default" size="100%">Laing, N. M.</style></author><author><style face="normal" font="default" size="100%">DeCorby, M. R.</style></author><author><style face="normal" font="default" size="100%">Nichol, K. A.</style></author><author><style face="normal" font="default" size="100%">Palatnick, L. P.</style></author><author><style face="normal" font="default" size="100%">Johnson, J.</style></author><author><style face="normal" font="default" size="100%">Noreddin, A.</style></author><author><style face="normal" font="default" size="100%">Harding, G. K. M.</style></author><author><style face="normal" font="default" size="100%">Nicolle, L. E.</style></author><author><style face="normal" font="default" size="100%">Hoban, D. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Man., Canada&#xD;Department of Internal Medicine, Faculty of Medicine, University of Manitoba, Winnipeg, Man., Canada&#xD;Department of Medicine, Health Sciences Centre, Winnipeg, Man., Canada&#xD;Department of Clinical Microbiology, Health Sciences Centre, Winnipeg, Man., Canada&#xD;International Health Management Associates (IHMA), Chicago, IL, United States&#xD;Clinical Microbiology, Health Sciences Centre, Microbiology MS673, 820 Sherbrook St., Winnipeg, Man. R3A 1R9, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antibiotic resistance in outpatient urinary isolates: Final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA)</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Antimicrobial Agents</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Antimicrobial Agents</style></full-title></periodical><pages><style face="normal" font="default" size="100%">380-388</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Outpatients</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">The goal of the North American Urinary Tract Infection Collaborative Alliance (NAUTICA) study was to determine antibiotic susceptibility to commonly used agents for urinary tract infections against outpatient urinary isolates obtained in various geographic regions in the USA and Canada. Forty-one medical centres (30 from the USA and 11 from Canada) participated, with each centre submitting up to 50 consecutive outpatient midstream urine isolates. Isolates were identified to species level by the standard protocol of each laboratory. Susceptibility testing was determined using the National Committee for Clinical Laboratory Standards (NCCLS) microdilution method. Resistance breakpoints used were those published by the NCCLS, including: ampicillin (resistant ≥32 μg/mL), sulphamethoxazole/trimethoprim (SMX/TMP) (resistant ≥4 μg/mL), nitrofurantoin (resistant ≥128 μg/mL), ciprofloxacin (resistant ≥4 μg/mL) and levofloxacin (resistant ≥8 μg/mL). Of the 1990 isolates collected, 75.1% (1494) were collected from the USA and 24.9% (496) were collected from Canada. The mean age of the patients was 48.3 years (range 1 month to 99 years), and 79.5% and 20.5% of isolates were obtained from women and men, respectively. The most common organisms were Escherichia coli (57.5%), Klebsiella pneumoniae (12.4%), Enterococcus spp. (6.6%), Proteus mirabilis (5.4%), Pseudomonas aeruginosa (2.9%), Citrobacter spp. (2.7%), Staphylococcus aureus (2.2%), Enterobacter cloacae (1.9%), coagulase-negative staphylococci (1.3%), Staphylococcus saprophyticus (1.2%), Klebsiella spp. (1.2%), Enterobacter aerogenes (1.1%) and Streptococcus agalactiae (1.0%). Among all 1990 isolates, 45.9% were resistant to ampicillin, 20.4% to SMX/TMP, 14.3% to nitrofurantoin, 9.7% to ciprofloxacin and 8.1% to levofloxacin. Fluoroquinolone resistance was highest in patients ≥65 years of age. For the 1142 E. coli isolates, resistance rates were: ampicillin 37.7%, SMX/TMP 21.3%, ciprofloxacin 5.5%, levofloxacin 5.1% and nitrofurantoin 1.1%. For all 1990 isolates and for the 1142 E. coli only, resistance rates were significantly higher in US compared with Canadian medical centres. This study reports higher rates of antibiotic resistance in US versus Canadian outpatient urinary isolates and demonstrates the continuing evolution of resistance to antimicrobial agents. © 2005 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :143&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-26944435913&amp;doi=10.1016%2fj.ijantimicag.2005.08.003&amp;partnerID=40&amp;md5=ee787c5d973dc41d33b58efc78f0e9db</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ijantimicag.2005.08.003</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>300</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">300</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zalmanovici Trestioreanu, A.</style></author><author><style face="normal" font="default" size="100%">Green, H.</style></author><author><style face="normal" font="default" size="100%">Paul, M.</style></author><author><style face="normal" font="default" size="100%">Yaphe, J.</style></author><author><style face="normal" font="default" size="100%">Leibovici, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Family Medicine, Beilinson Campus, Rabin Medical Center, 39 Jabotinski Street, Petah Tikva, Israel, 49100.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antimicrobial agents for treating uncomplicated urinary tract infection in women</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane database of systematic reviews (Online)</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane database of systematic reviews (Online)</style></full-title></periodical><number><style face="normal" font="default" size="100%">10</style></number><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><abstract><style face="normal" font="default" size="100%">Acute uncomplicated lower urinary tract infection (UTI) is one of the most common problems for which young women seek medical attention. To compare the efficacy, resistance development and safety of different antimicrobial treatments for acute uncomplicated lower UTI. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Renal Group&apos;s Specialised Register, MEDLINE, EMBASE and bibliographies of included studies. Randomised controlled trials (RCTs) comparing different classes of antimicrobials for acute uncomplicated UTI in women were included. The outcomes of interest were symptomatic and bacteriological cure at short and long-term follow-up, resistance development, number of days to symptom resolution, days of work loss, adverse events and complications. Two authors independently extracted the data and assessed study quality. Statistical analyses were performed using the random effects model and the results expressed as risk ratios (RR) with 95% confidence intervals (CI). Trimethoprim-sulfamethoxazole (TMP-SMX) was as effective as fluoroquinolones in achieving short-term (RR 1.00, 95% CI 0.97 to 1.03) and long-term (RR 0.99, 95% CI 0.94 to 1.05) symptomatic cure. Beta-lactam drugs were as effective as TMP-SMX for short-term (RR 0.95&apos; 95% CI 0.81 to 1.12) and long-term (RR 1.06&apos; 95% CI 0.93 to 1.21) symptomatic cure. Short-term cure for nitrofurantoin was similar to that of TMP-SMX (RR 0.99&apos; 95% CI 0.95 to 1.04) as was long-term symptomatic cure (RR 1.01&apos; 95% CI 0.94 to 1.09).Fluoroquinolones were more effective than beta-lactams (RR 1.22, 95% CI 1.13 to 1.31) for short-term bacteriological cure. Rashes were more frequent in patients treated with TMP-SMX than with nitrofurantoin or fluoroquinolones and in patients treated with beta-lactam drugs compared to fluoroquinolones. Minimal data were available on the emergence of resistant strains during or after antimicrobial treatment. No differences were observed between the classes of antimicrobials included in this review for the symptomatic cure of acute uncomplicated UTI. Fluoroquinolones proved more effective than beta-lactams for the short-term bacteriological outcome, probably with little clinical significance. Individualised treatment should take into consideration the predictable susceptibility of urinary pathogens in local areas, possible adverse events and resistance development, and patient preference.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :52&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84855427936&amp;partnerID=40&amp;md5=0f3dc8e39eecf755948ed305e18f67ad</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>272</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">272</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zalewska-Pia̧tek, B. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology, Gdańsk University of Technology, G. Narutowicza 11/12, 80-952 Gdańsk, Poland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections of Escherichia coli strains of chaperone-usher system</style></title><secondary-title><style face="normal" font="default" size="100%">Polish Journal of Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Polish Journal of Microbiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">279-285</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Chaperone-usher</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Pyelonephritis</style></keyword><keyword><style face="normal" font="default" size="100%">Uropathogenic E. Coli</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections are a very serious health and economic problem affecting millions of people each year worldwide. The most common etiologic agent of this type of bacterial infections, involving the upper and lower urinary tract, are E. coli strains representing approximately 80% of cases. Uropathogenic E. coli strains produce several urovirulence factors which can be divided into two main types, surface virulence factors and exported virulence factors. Surface-exposed structures include mainly extracellular adhesive organelles such as fimbriae/pili necessary in adhesion, invasion, biofilm formation and cytokine induction. Among the surface-exposed polymeric adhesive structures there are three most invasive groups, type 1 pili, type P pili and Dr family of adhesins which are bioassembled via the conserved, among Gram-negative bacteria, chaperone-usher secretion system. Type 1 and P-piliated E. coli cause cystitis and pyelonephritis. The Dr family of adhesins recognizing DAF receptor is responsible for cystitis, pyelonephritis (especially in pregnant women) and diarrhoea (in infants). In addition, Dr-positive E. coli strains carry the risk of recurrent urinary tract infections. Pyelonephritis in pregnant women leads to a series of complications such as bacteremia, urosepsis, acute respiratory distress syndrome and even death. In the era of increasing drug resistance of bacteria, the development of vaccines, drugs termed pilicides and inhibitors of adhesion may be a promising tool in the fight against urogenital infections.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :6&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Short Survey</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84855663326&amp;partnerID=40&amp;md5=36ba6609078f49e2951dfa828b3c8a4f</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>602</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">602</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zafriri, D.</style></author><author><style face="normal" font="default" size="100%">Ofek, I.</style></author><author><style face="normal" font="default" size="100%">Adar, R.</style></author><author><style face="normal" font="default" size="100%">Pocino, M.</style></author><author><style face="normal" font="default" size="100%">Sharon, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Human Microbiology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inhibitory activity of cranberry juice on adherence of type 1 and type P fimbriated Escherichia coli to eucaryotic cells</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">92-98</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">1989</style></year></dates><abstract><style face="normal" font="default" size="100%">Inhibition of bacterial adherence to bladder cells has been assumed to account for the beneficial action ascribed to cranberry juice and cranberry juice cocktail in the prevention of urinary tract infections (A.E. Sobota, J. Urol. 131:1013-1016, 1984). We have examined the effect of the cocktail and juice on the adherence of Escherichia coli expressing surface lectins of defined sugar specificity to yeasts, tissue culture cells, erythrocytes, and mouse peritoneal macrophages. Cranberry juice cocktail inhibited the adherence of urinary isolates expressing type 1 fimbriae (mannose specific) and P fimbriae [specific for α-D-Gal(1→4)-β-D-Gal] but had no effect on a diarrheal isolate expressing a CFA/I adhesin. The cocktail also inhibited yeast agglutination by purified type 1 fimbriae. The inhibitory activity for type 1 fimbriated E. coli was dialyzable and could be ascribed to the fructose present in the cocktail; this sugar was about 1/10 as active as methyl α-D-mannoside in inhibiting the adherence of type 1 fimbriated bacteria. The inhibitory activity for the P fimbriated bacteria was nondialyzable and was detected only after preincubation of the bacteria with the cocktail. Cranberry juice, orange juice, and pineapple juice also inhibited adherence of type 1 fimbriated E. coli, most likely because of their fructose content. However, the two latter juices did not inhibit the P fimbriated bacteria. We conclude that cranberry juice contains at least two inhibitors of lectin-mediated adherence of uropathogens to eucaryotic cells. Further studies are required to establish whether these inhibitors play a role in vivo.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :264&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0024491318&amp;doi=10.1128%2fAAC.33.1.92&amp;partnerID=40&amp;md5=9b424ca1988a841c2cfda5213267af4b</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/AAC.33.1.92</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>118</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">118</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zacchè, M. M.</style></author><author><style face="normal" font="default" size="100%">Giarenis, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urogynaecology, Norfolk and Norwich University Hospital, Norwich, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Therapies in early development for the treatment of urinary tract inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Expert Opinion on Investigational Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Expert Opinion on Investigational Drugs</style></full-title></periodical><pages><style face="normal" font="default" size="100%">531-540</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Early development</style></keyword><keyword><style face="normal" font="default" size="100%">novel treatments</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">uropathogens</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Introduction: Urinary tract inflammation is a very common clinical condition. It is caused by several pathogens and antibiotic treatment is the mainstay of therapy. Increasing antimicrobial resistance and high recurrence rates represent a challenge. Consequently, there is an unmet need for new therapeutic options.Areas covered: The authors discuss the rationale of emerging management strategies and current experimentation. Furthermore, they focus on both acute and recurrent urinary tract infections (UTIs) and examine a range of therapeutics, including new antibiotics, vaccines, mannosides, hyaluronic acid, probiotics, immunomodulant agents and novel compounds derived from nanotechnology.Expert opinion: Basic science studies have elucidated the pathogenesis of UTIs and built up the ground for the development of new therapies. Evidence is mainly derived from animal studies on murine models of bacterial cystitis. However, clinical trials are scanty and cannot provide us with robust evidence. Hetereogeneity and virulence of uropathogens pose a threat that scientists and clinicians are struggling to overcome. © 2016 Informa UK Limited.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84961392524&amp;doi=10.1517%2f13543784.2016.1161024&amp;partnerID=40&amp;md5=d3d6bc40f19fe3c434f4e4304b0d2c42</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1517/13543784.2016.1161024</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>36</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">36</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yuste Ara, J. R.</style></author><author><style face="normal" font="default" size="100%">del Pozo, J. L.</style></author><author><style face="normal" font="default" size="100%">Carmona-Torre, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departamento de Medicina Interna, Clínica Universidad de Navarra, Pamplona, Spain&#xD;Área de Enfermedades Infecciosas, Clínica Universidad de Navarra, Pamplona, Spain&#xD;Servicio de Microbiología. Clínica Universidad de Navarra, Pamplona, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Medicine (Spain)</style></secondary-title><short-title><style face="normal" font="default" size="100%">Infecciones del tracto urinario</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Medicine (Spain)</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2991-2999</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">51</style></number><keywords><keyword><style face="normal" font="default" size="100%">Diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Introduction.: Urinary tract infections (UTI) are the most common infectious diseases that present in outpatient and hospital settings; in the latter case they are principally associated with urinary catheters. Pathogenesis and clinical manifestations.: Urinary tract infections are caused by uropathogens travelling upwards and colonising the periurethral mucosa, generally from the bowel. They principally present with voiding symptoms. Most UTI are uncomplicated infections that present in young, sexually active women. Upper urinary tract infections that include infections that affect the renal and/or prostatic parenchyma-pelvis can also spread upwards and, less often, haematogenously, and are usually clinically associated with an infectious syndrome. Diagnosis and treatment.: Diagnosis is essentially based on clinical symptoms and urine culture. Haemoculture is only recommended in certain situations and in most cases no complementary diagnostic tests are required. Treatment can usually be given as an outpatient and is empirical according to the local sensitivity pattern of Escherichia coli, which is the causative agent of more than 80% of these infections. Asymptomatic bacteriuria (AB) and complicated UTI are other forms in which UTI present. © 2018</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85043393005&amp;doi=10.1016%2fj.med.2018.03.004&amp;partnerID=40&amp;md5=f1597c23362acbae92b1ad23271dc32e</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.med.2018.03.004</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>351</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">351</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Young, E. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Infectious Diseases, VA Medical Center, 2002 Holcombe Bivd, Houston, TX, United States&#xD;Dept. of Medicine, Baylor College of Medicine, Houston, TX, United States&#xD;Dept. of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Family studies in brucellosis</style></title><secondary-title><style face="normal" font="default" size="100%">Infection</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infection</style></full-title></periodical><pages><style face="normal" font="default" size="100%">578-579</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">6</style></number><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :5&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Note</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-62249097773&amp;doi=10.1007%2fs15010-008-8090-3&amp;partnerID=40&amp;md5=78d5b69b6a3704b48b5acf6a0ca06fdf</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s15010-008-8090-3</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>263</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">263</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, S. S. D.</style></author><author><style face="normal" font="default" size="100%">Chiang, I. N.</style></author><author><style face="normal" font="default" size="100%">Lin, C. D.</style></author><author><style face="normal" font="default" size="100%">Chang, S. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Urology, Buddhist Tzu Chi General Hospital, Taipei Branch, No. 289 Chienkuo Road, Xindian City, Taipei 231, Taiwan&#xD;Department of Urology, Medical College of Buddhist Tzu Chi University, Hualien, Taiwan&#xD;Division of Urology, Department of Surgery Keelung Hospital, Keelung, Taiwan&#xD;Department of Urology, National Taiwan University Hospital, Taipei, Taiwan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Advances in non-surgical treatments for urinary tract infections in children</style></title><secondary-title><style face="normal" font="default" size="100%">World Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">World Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">69-75</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Children</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: With growing antibiotics failure due to emerging resistance of bacteria, non-surgical management of pediatric UTI plays a more important role because of its non-invasive characteristics and little adverse effects. Methods: We searched the Pubmed for management of UTI in children other than surgical correction and antibiotics using terms: risk factor, prepuce/phimosis, steroid cream/steroid, behavioral therapy, urotherapy, biofeedback/pelvic floor exercise, adrenergic antagonist, anticholinergics, diet/dietary, dysfunctional voiding/dysfunctional elimination syndrome, constipation, dietary, clean intermittent catheterization, probiotics/lactobacillus, cranberry, vitamin supplement, breastfeeding, breast milk, with infant/child/children/pediatrics/pediatrics and urinary tract infection. Results: The proposed non-surgical management of pediatric UTI included behavioral modification (timed voiding and adequate fluids intake), topical steroid for phimosis, nutrient supplements (breast milk, cranberry, probiotics, and vitamin A), biofeedback training for dysfunctional voiding, anticholinergics for reducing intravesical pressure, alpha-blockers in dysfunctional voiding and neurogenic bladder, and intermittent catheterization for children with large PVR. Conclusion: The published reports usually included small number of patients and were lacking of randomization and controlled group. Further well-designed studies are warranted to support the concepts of non-operative management for pediatric UTI. © 2011 Springer-Verlag.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :9&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84856212254&amp;doi=10.1007%2fs00345-011-0700-5&amp;partnerID=40&amp;md5=b7fc35d0099f56b90b3a228ee245bbfb</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00345-011-0700-5</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>24</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">24</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, G.</style></author><author><style face="normal" font="default" size="100%">Zhou, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">College of Resources and Environment, Southwest University, Chongqing, 400715, China&#xD;Schuit Institute of Catalysis, Eindhoven University of Technology, Eindhoven, 5600MB, Netherlands</style></auth-address><titles><title><style face="normal" font="default" size="100%">Glucose Conversions Catalyzed by Zeolite Sn-BEA: Synergy among Na+ Exchange, Solvent, and Proximal Silanol Nest as Well as Critical Specifics for Catalytic Mechanisms</style></title><secondary-title><style face="normal" font="default" size="100%">ACS Catalysis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">ACS Catalysis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">6691-6698</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">biomass transformation</style></keyword><keyword><style face="normal" font="default" size="100%">epimerization</style></keyword><keyword><style face="normal" font="default" size="100%">Na+ exchange</style></keyword><keyword><style face="normal" font="default" size="100%">periodic density functional theory</style></keyword><keyword><style face="normal" font="default" size="100%">silanol nest</style></keyword><keyword><style face="normal" font="default" size="100%">solvent effects</style></keyword><keyword><style face="normal" font="default" size="100%">synergetic effects</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Sn-BEA zeolite shows excellent catalytic performances for biomass transformation, and herein periodic density functional theory calculations accounting for the effect of zeolite framework are conducted to address the mechanistic aspects of glucose catalytic conversions. It is the synergistic effects of Na+ exchange, proximal silanol nest, and solvent (water/methanol) that cause the epimerization path via the Bilik mechanism to occur facilely at ambient conditions, and each of them plays a definite while disparate role. Na+ exchange reverses the relative stabilities of critical intermediates for the epimerization vs isomerization paths and drives the reaction toward the epimerization path with production of mannose. The proximal silanol nest participates in the Bilik reactions through the synchronous proton transfer to the sugar fragment, which is indispensable to promote the reaction thermodynamics and reduce the activation barriers. The activation barriers are generally lowered with increase of solvent (water/methanol) contents, and water (n = 4-6) achieves comparable catalytic results as methanol (n = 3). The difference between water and methanol solvents lies mainly in their divergent interactions with zeolite framework. Methanol rather than water constructs multiple methyl-H and lattice-O pairs and shows higher capability to retain Na+ ions, which account for its superior catalytic performances. At any solvent (water/methanol) content, the perfectly tetrahedral Sn(IV) site shows an apparently inferior catalytic effects than defect with the proximal silanol nest, owing the absence of the synchronous proton transfer. © 2018 American Chemical Society.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048711852&amp;doi=10.1021%2facscatal.8b01157&amp;partnerID=40&amp;md5=f9dd848e5cb966d6de23bb2946c7841e</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/acscatal.8b01157</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>505</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">505</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Xiao, S. D.</style></author><author><style face="normal" font="default" size="100%">Shi, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Shanghai Institute of Digestive Dis., Renji Hospital, Shanghai Second Medical University, Shanghai 20001, China</style></auth-address><titles><title><style face="normal" font="default" size="100%">Is cranberry juice effective in the treatment and prevention of Helicobacter pylori infection of mice?</style></title><secondary-title><style face="normal" font="default" size="100%">Chinese Journal of Digestive Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Chinese Journal of Digestive Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">136-139</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry juice</style></keyword><keyword><style face="normal" font="default" size="100%">Helicobacter pylori</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: It is well known that eradication of Helicobacter pylori infection results in healing of peptic ulcer and regression of gastric mucosal inflammation. Cranberry juice beverages have been shown to achieve good results in the prevention of recurrent urinary tract infection. The present study aimed to investigate whether a cranberry juice cocktail could eradicate or prevent H. pylori infection in mice. Methods: In the therapeutic trial, C57BL/6 mice were infected with H. pylori and 2 weeks later, 80 mice were randomly allocated into four groups: Group A, cranberry juice (0.5 mL/mouse, p.o. daily for 30 days); Group B, triple therapy (amoxycillin 50 mg/kg, bismuth subcitrate 6.15 mg/kg, and metronidazole 22.5 mg/kg, daily for 14 days); Group C, a combination of cranberry juice and triple therapy; Control Group, the mice were infected with H. pylori and left untreated. The mice were killed after 24 h and 4 weeks and H. pylori infection status was assessed by rapid urease test and by culture and histology, respectively. In the prevention trial, 40 mice had oral cranberry juice for 30 days. In the last 5 days (days 26-30), the mice were divided into four groups: Group A, challenged orally with H. pylori three times on days 26, 28 and 30 when the mice were not given cranberry juice; Group B, challenged with H. pylori suspended in cranberry juice; Group C, challenged with H. pylori 6 h after receiving juice; Control group, no cranberry juice, but challenged with H. pylori. Two weeks later, the mice were killed to assess the status of H. pylori infection. Results: The clearance rates at 24 h after treatment in groups A, B and C were 80%, 100%, and 90%, respectively (P &lt; 0.01 as compared with Control group, two tailed Fisher&apos;s Exact Probability Test). Four weeks after cessation of treatment the eradication rates in groups A, B and C were 20% (P = 0.474, two tailed Fisher&apos;s Exact Probability Test), 80% and 80%, respectively (P &lt; 0.01). None of the mice were clear of H. pylori infection. Conclusions: Cranberry juice can clear H. pylori infection in mice with a clearance rate of 80%, but the eradication rate was low (20%). Cranberry juice was not effective in preventing H. pylori infection in the mice used in this study.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :9&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0344896820&amp;doi=10.1046%2fj.1443-9573.2003.00127.x&amp;partnerID=40&amp;md5=872aeda68a4541eaf2f77b02b8480daa</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1046/j.1443-9573.2003.00127.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>427</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">427</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wyndham, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Concord and Nepean Hospitals, Sydney, NSW, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry juice and urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Medicine Today</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Medicine Today</style></full-title></periodical><pages><style face="normal" font="default" size="100%">72-73</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">5</style></number><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33744516387&amp;partnerID=40&amp;md5=083528061674ffe54bf961b40fb3192f</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>472</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">472</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wu, X.</style></author><author><style face="normal" font="default" size="100%">Gu, L.</style></author><author><style face="normal" font="default" size="100%">Prior, R. L.</style></author><author><style face="normal" font="default" size="100%">McKay, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Agriculture Research Service, U.S. Department of Agriculture, Arkansas Children&apos;s Nutrition Center, 1120 Marshall Street, Little Rock, AR 72202, United States&#xD;Cornell Univ. Coop. Exten. Service, Hudson, NY 12534, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Characterization of anthocyanins and proanthocyanidins in some cultivars of Ribes, Aronia, and Sambucus and their antioxidant capacity</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">7846-7856</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">26</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anthocyanin</style></keyword><keyword><style face="normal" font="default" size="100%">Antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">Black currant</style></keyword><keyword><style face="normal" font="default" size="100%">Chokeberry</style></keyword><keyword><style face="normal" font="default" size="100%">Elderberry</style></keyword><keyword><style face="normal" font="default" size="100%">Gooseberry</style></keyword><keyword><style face="normal" font="default" size="100%">ORAC</style></keyword><keyword><style face="normal" font="default" size="100%">Phenolics</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidin</style></keyword><keyword><style face="normal" font="default" size="100%">Red currant</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Anthocyanins and proanthocyanidins were characterized by HPLC-ESI-MS/MS coupled with a diode array and/or fluorescent detector in seven cultivars of Ribes nigrum (black currant) and Ribes rubrum (red currant, Red Lake), six cultivars of Ribes grossularia (gooseberries), Aronia melanocarpa (chokeberry), and Sambucus nigra (elderberry). Thirty-one different anthocyanins were detected in these berries, but not every anthocyanin was observed in each berry. A number of minor anthocyanins were identified from these berries for the first time. The concentrations of individual anthocyanins in all of the berries were quantified using relevant anthocyanidin 3-glucoside standards. Among the berries studied in this paper and in berries in general, chokeberry has the highest total anthocyanin concentrations [1480 mg/100 g of fresh weight (FW)], whereas the lowest total anthocyanin concentration in the berries studied was found in the gooseberry cv. Careless, which contained only 0.07 mg/100 g of FW. Two cultivars of gooseberries (Marigold and Leveller) did not contain any anthocyanins. Total proanthocyanidin concentrations in the berries studied ranged from 23 to 664 mg/100 g of FW in elderberry and chokeberry, respectively. Procyanidin or prodelphinidin polymers were the predominant components (&gt;65% w/w) in most of the berries. The lipophilic and hydrophilic antioxidant capacities were measured by the oxygen radical absorbance capacity (ORACFL) procedure. The total antioxidant capacity varied from 21 μmol of TE/g of FW in Careless gooseberry to 161 μmol of TE/g of FW in chokeberry. Total phenolics in the berries in general paralleled hydrophilic antioxidant capacity.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :455&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-11144234817&amp;partnerID=40&amp;md5=fafa8410598b24857c33e37780545510</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>270</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">270</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wootton-Beard, P. C.</style></author><author><style face="normal" font="default" size="100%">Ryan, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Functional Food Centre, Oxford Brookes University, Gipsy Lane, Oxford, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Improving public health?: The role of antioxidant-rich fruit and vegetable beverages</style></title><secondary-title><style face="normal" font="default" size="100%">Food Research International</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Food Research International</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3135-3148</style></pages><volume><style face="normal" font="default" size="100%">44</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">Beverage</style></keyword><keyword><style face="normal" font="default" size="100%">Fruit</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative stress</style></keyword><keyword><style face="normal" font="default" size="100%">Public health</style></keyword><keyword><style face="normal" font="default" size="100%">Vegetable</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">Recent evaluations of diet quality in the UK reveal that two thirds of people still do not consume the recommended five portions of fruit and vegetables per day. Fruit and vegetables contain high concentrations of bioactive compounds including antioxidants which may be beneficial to health. The precise nature of the health benefits which are to be gained from the consumption of antioxidant-rich foods is yet to be fully elucidated. There has been a visually evident increase in the number of beverages which use their antioxidant capacity as a marketing tool in recent years. This poses the question as to whether or not this is an entirely positive change. The aims of this review are to 1) summarise the current evidence supporting the health benefits of antioxidant-rich foods in CVD, cancer, neurological decline and diabetes, 2) summarise the antioxidant components of commonly consumed beverages, 3) investigate the emergence of new and novel beverage ingredients within the context of functional foods and 4) establish the potential role of antioxidant-rich beverages in human health. In conclusion, the evidence for specific health benefits which can be attributed to the antioxidant content of foods is still limited. However, antioxidant rich foods are most commonly from plant sources which contain a number of healthy components which make them a positive addition to the diet. Many compounds which display antioxidant activity (such as polyphenolic compounds) also have many other positive effects in the human system and therefore if consuming them on the basis of their antioxidant content increases consumption, then this can be viewed as a positive change in diet. Furthermore, the synergistic and interactive effects of antioxidant combinations from a mixed diet has not been adequately simulated in a research setting and the true nature of these interactions remains largely unknown. © 2011 Elsevier Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :99&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84859630458&amp;doi=10.1016%2fj.foodres.2011.09.015&amp;partnerID=40&amp;md5=074b217a348cec4a3d80a42acf778e86</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.foodres.2011.09.015</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>73</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">73</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wollner, J.</style></author><author><style face="normal" font="default" size="100%">Krebs, J.</style></author><author><style face="normal" font="default" size="100%">Pannek, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Neuro-Urology, Schweizer Paraplegiker-Zentrum, Guido A. Zach Strasse 1, Nottwil, 6207, Switzerland&#xD;Clinical Trial Unit, Schweizer Paraplegiker-Zentrum, Guido A. Zach Strasse 1, Nottwil, 6207, Switzerland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Neuro-urology in spinal cord injury</style></title><secondary-title><style face="normal" font="default" size="100%">Neurological Aspects of Spinal Cord Injury</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">363-396</style></pages><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Storage and evacuation of urine is regulated by a neural control system that precisely coordinates the reciprocal activity of these two functional phases of the lower urinary tract (LUT) to achieve continence and to ensure a periodic, controlled voiding. This complex control system includes the sympathetic, parasympathetic, and somatic nervous system, with close interaction of cortical, subcortical, spinal cord neural networks and peripheral nerves. Damage to spinal cord structures results in a dysfunction of storage and evacuation, which can lead to incontinence, incomplete bladder drainage, and deterioration of the upper urinary tract. A straightforward categorization of neurogenic lower urinary tract dysfunction (NLUTD) is almost impossible due to the heterogeneity of spinal cord injuries (SCI) in terms of segmental levels of injury and completeness. An individual diagnostic and therapeutic approach is mandatory for successful treatment of NLUTD. This chapter summarizes the physiological and pathophysiological aspects of a SCI and the diagnostic and therapeutic approaches in different phases after the SCI. The diagnostic assessment includes noninvasive procedures like clinical examinations and determination of post-voiding residual volume by ultrasound and invasive procedures such as urodynamic investigation and cystoscopy. The therapeutic interventions contain conservative therapies like drugs and percutaneous electrical stimulation and minimal invasive therapies such as injections of onabotulinumtoxin in the detrusor and sacral neuromodulation. In cases of failure of conservative treatment, invasive treatments among them bladder augmentation and implantation of an artificial sphincter might be necessary. A lifelong surveillance of the neuro-urological function of individuals with SCI is highly recommended to avoid complications and irreversible alterations of the lower urinary tract. © Springer International Publishing Switzerland 2017.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85033205449&amp;doi=10.1007%2f978-3-319-46293-6_15&amp;partnerID=40&amp;md5=4a2323e529435d91aaca2c77b38d1cae</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/978-3-319-46293-6_15</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>395</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">395</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wolf, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Traminer Straße 13, 63322 Rödermark</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cystitis</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmazeutische Zeitung</style></secondary-title><short-title><style face="normal" font="default" size="100%">Zystitis: Brennpunkt blase</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pharmazeutische Zeitung</style></full-title></periodical><pages><style face="normal" font="default" size="100%">14-20</style></pages><volume><style face="normal" font="default" size="100%">152</style></volume><number><style face="normal" font="default" size="100%">35</style></number><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-34548663922&amp;partnerID=40&amp;md5=24128b4441f3059eb316da397cb6f329</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>326</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">326</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wilson, T.</style></author><author><style face="normal" font="default" size="100%">Bauer, B. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biology, 232 Pasteur Hall, Winona State University, Winona, MN, United States&#xD;Complementary and Integrative Medicine Program, Mayo Clinic, 200 1st St. SW, Rochester, MN 55905, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Advising consumers about dietary supplements: Lessons from cranberry products</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Dietary Supplements</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Dietary Supplements</style></full-title></periodical><pages><style face="normal" font="default" size="100%">377-384</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Consumer protection</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary supplement</style></keyword><keyword><style face="normal" font="default" size="100%">Nutraceutical</style></keyword><keyword><style face="normal" font="default" size="100%">Nutritional supplement</style></keyword><keyword><style face="normal" font="default" size="100%">Phenolic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Consumers are continuing to incorporate dietary supplements as part of their routine health care. Yet, even as the market continues to grow, questions regarding safety, efficacy, and quality remain. Clinicians are increasingly being asked to advise their patients about the safe and efficacious use of such products. Cranberry is a commonly encountered supplement that has been studied comprehensively. We review some of the findings from the evaluation of cranberry as a dietary supplement and suggest how such findings can be shared effectively with patients and consumers. © 2009 by Informa Healthcare USA, Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-70749099666&amp;doi=10.3109%2f19390210903280298&amp;partnerID=40&amp;md5=54d7fdb32548628c7f7dc169f1cd1fc8</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3109/19390210903280298</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>495</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">495</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wilson, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Genitourinary Medicine, General Infirmary at Leeds, Great George Street, Leeds, LS1 3 EX, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Managing recurrent bacterial vaginosis</style></title><secondary-title><style face="normal" font="default" size="100%">Sexually Transmitted Infections</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Sexually Transmitted Infections</style></full-title></periodical><pages><style face="normal" font="default" size="100%">8-11</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Bacterial vaginosis (BV) is the most frequently found condition of the female genital tract. It increases a woman&apos;s risk of acquiring HIV, is associated with increased complications in pregnancy, and may be involved in the pathogenesis of pelvic inflammatory disease. Yet there are many unanswered questions about its aetiology, making management of recurrent infection difficult and often idiosyncratic. This paper discusses the current knowledge and possible management of recurrent BV.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :78&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-1242292259&amp;doi=10.1136%2fsti.2002.002733&amp;partnerID=40&amp;md5=2d9092d7a0377b1eebdb7f675e499138</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/sti.2002.002733</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>302</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">302</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Williamson, G.</style></author><author><style face="normal" font="default" size="100%">Clifford, M. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Food Science and Nutrition, University of Leeds, Leeds LS2 9JT, United Kingdom&#xD;Division of Nutritional Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey GU2 7XH, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Colonic metabolites of berry polyphenols: The missing link to biological activity?</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Journal of Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S48-S66</style></pages><volume><style face="normal" font="default" size="100%">104</style></volume><number><style face="normal" font="default" size="100%">SUPPL.3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anthocyanins</style></keyword><keyword><style face="normal" font="default" size="100%">Berry</style></keyword><keyword><style face="normal" font="default" size="100%">Blackcurrant</style></keyword><keyword><style face="normal" font="default" size="100%">Chlorogenic acids</style></keyword><keyword><style face="normal" font="default" size="100%">Flavonoids</style></keyword><keyword><style face="normal" font="default" size="100%">Gut microflora</style></keyword><keyword><style face="normal" font="default" size="100%">Phenylacetic acid</style></keyword><keyword><style face="normal" font="default" size="100%">Phenylpropionic acid</style></keyword><keyword><style face="normal" font="default" size="100%">Protocatechuic acid</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><abstract><style face="normal" font="default" size="100%">The absorption of dietary phenols, polyphenols and tannins (PPT) is an essential step for biological activity and effects on health. Although a proportion of these dietary bioactive compounds areabsorbed intact, depending on their chemical structure and the nature of any attached moiety (e.g. sugar, organic acid), substantial amounts of lower molecular weight catabolites are absorbedafterbiotransformation by the colon microflora. The main products in the colon are (a) benzoic acids (C6-C1), especially benzoic acid and protocatechuic acid; (b) phenylaceticacids(C6-C 2), especially phenylacetic acid per se; (c) phenylpropionic acids (C6-C3), where the latter are almost entirely in the dihydro form, notablydihydrocaffeicacid, dihydroferulic acid, phenylpropionic acid and 3-(3́-hydroxyphenyl)-propionic acid. As a result of this biotransformation, some of these compounds can each reach mmconcentrations in faecalwater. Many of these catabolites are efficiently absorbed in the colon, appear in the blood and are ultimately excreted in the urine. In the case of certain polyphenols, such asanthocyanins, these catabolites are major products in vivo; protocatechuic acid is reported to represent a substantial amount of the ingested dose of cyanidin-3-O-glucoside. The major catabolites of berries, and especially blackcurrants, arepredicted based on compositional data for polyphenols from berries and other sources. Since microbial catabolites may be present at many sites of the body in higherconcentration than the parent compound,it is proposed that at least a part of the biological activities ascribed to berry polyphenols and other PPT are due to their colonic catabolites. © The Authors 2010.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :219&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-78049432112&amp;doi=10.1017%2fS0007114510003946&amp;partnerID=40&amp;md5=11ae3e95ca9f29e1e8b95ab3e53c3527</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1017/S0007114510003946</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>221</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">221</key></foreign-keys><ref-type name="Serial">57</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Williams, G. J.</style></author><author><style face="normal" font="default" size="100%">Craig, J. C.</style></author><author><style face="normal" font="default" size="100%">Carapetis, J. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Telethon Institute for Child Health Research, University of Western Australia, Perth, Australia&#xD;Centre for Kidney Research, University of Sydney, Children&apos;s Hospital at Westmead, Sydney, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Preventing urinary tract infections in early childhood</style></title><secondary-title><style face="normal" font="default" size="100%">Advances in Experimental Medicine and Biology</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">211-218</style></pages><volume><style face="normal" font="default" size="100%">764</style></volume><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infection (UTI) is common in children, causes them considerable discomfort, as well as distress to parents and has a tendency to recur. Approximately 20 % of those children who experience one infection will have a repeat episode. Since 1975, 11 trials of long-term antibiotics compared with placebo or no treatment in 1,550 children have been published. Results have been heterogeneous, but the largest trial demonstrated a small reduction (6 % absolute risk reduction, risk ratio 0.65) in the risk of repeat symptomatic UTI over 12 months of treatment. This effect was consistent across sub groups of children based upon age, gender, vesicoureteric reflux status and number of prior infections. Trials involving re-implantation surgery (and antibiotics compared with antibiotics alone) for the sub-group of children with vesicoureteric reflux have not shown a reduction in repeat UTI, with the possible exception of a very small benefit for febrile UTI. Systematic reviews have shown that circumcision reduces the risk of repeat infection but 111 circumcisions would need to be performed to prevent one UTI in unpredisposed boys. Given the need for anaesthesia and the risk of surgical complication, net clinical benefit is probably restricted to those who are predisposed (such as those with recurrent infection). Many small trials in complementary therapies have been published and many suggest some benefit, however inclusion of children is limited. Only three trials involving 394 children for cranberry products, two trials with a total of 252 children for probiotics and one trial with 24 children for vitamin A are published. Estimates of efficacy vary widely and imprecision is evident. Multiple interventions to prevent UTI in children exist. Of those, long-term low dose antibiotics has the strongest evidence base, but the benefit is small. Circumcision in boys reduces the risk substantially, but should be restricted to those at risk. There is little evidence of benefit of re-implantation alone, and the benefit of this procedure over antibiotics alone is very small. Cranberry concentrate is probably effective. © Springer Science+Business Media New York 2013.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :11&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84873604585&amp;doi=10.1007%2f978-1-4614-4726-9-18&amp;partnerID=40&amp;md5=565ea22a7a1d95ea18f52bd06b497bac</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/978-1-4614-4726-9-18</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>494</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">494</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Williams, D. H.</style></author><author><style face="normal" font="default" size="100%">Schaeffer, A. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IL, United States&#xD;Department of Urology, Northwestern University, Feinberg School of Medicine, 303 East Chicago Avenue, Chicago, IL 60611, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Current concepts in urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Minerva Urologica e Nefrologica</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Minerva Urologica e Nefrologica</style></full-title></periodical><pages><style face="normal" font="default" size="100%">15-31</style></pages><volume><style face="normal" font="default" size="100%">56</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">Drug resistance, microbial</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Prostatitis</style></keyword><keyword><style face="normal" font="default" size="100%">Pyelonephritis</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections, diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Virulence</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTIs) are common infectious diseases that can be associated with substantial morbidity and significant expenditures. This review highlights the current concepts and recent advances in our understanding and management of this condition. Specific topics include pathogenesis, host factors, antimicrobial resistance, recurrent UTIs in women, diagnosis, treatment of uncomplicated and complicated UTIs, prophylaxis, catheter associated bacteriuria, pregnancy, diabetes, UTIs in men, prostatitis, and the chronic pelvic pain syndrome. UTIs can be viewed as an interaction between specific bacterial virulence factors and the patient. A new model explaining the pathogenesis of recurrent UTIs has been presented. There is a need to reconsider traditional treatment recommendations in the face of local resistance patterns, as well as the need to make better use of drugs that are currently available. Prospects for prevention of recurrent UTI include natural compounds, bacterial interference and immunization. With regard to UTI risk in women, patients can be classified based on age, and functional and hormonal status. Appropriate treatment approaches must be based on this classification. In contrast to uncomplicated UTIs, management of most complicated infections depends on clinical experience and resources at individual institutions rather than on evidence based guidelines. Asymptomatic bacteriuria generally should not be treated except in high-risk catheterized patients and in pregnancy. UTIs in men generally require formal urologic evaluation. Our understanding of the etiologies, diagnostic strategies, and treatment options for prostatitis and the chronic pelvic pain syndrome in men continues to evolve.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :33&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-3142699128&amp;partnerID=40&amp;md5=24339d4c80f25ece3d7b318dc33b7031</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>84</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">84</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wilhelmi, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">München, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Natural protection in frequent bladder infections</style></title><secondary-title><style face="normal" font="default" size="100%">Journal fur Pharmakologie und Therapie</style></secondary-title><short-title><style face="normal" font="default" size="100%">Natürlicher schutz bei häufigen blasenentzündungen</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal fur Pharmakologie und Therapie</style></full-title></periodical><pages><style face="normal" font="default" size="100%">7</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Note</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85030655458&amp;partnerID=40&amp;md5=2776cab26096d63567f8d71694876347</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>365</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">365</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wiles, T. J.</style></author><author><style face="normal" font="default" size="100%">Kulesus, R. R.</style></author><author><style face="normal" font="default" size="100%">Mulvey, M. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Cell Biology and Immunology, Pathology Department, University of Utah, Salt Lake City, UT 84112-0565, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Origins and virulence mechanisms of uropathogenic Escherichia coli</style></title><secondary-title><style face="normal" font="default" size="100%">Experimental and Molecular Pathology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Experimental and Molecular Pathology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">11-19</style></pages><volume><style face="normal" font="default" size="100%">85</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">ABU</style></keyword><keyword><style face="normal" font="default" size="100%">APEC</style></keyword><keyword><style face="normal" font="default" size="100%">Biofilm</style></keyword><keyword><style face="normal" font="default" size="100%">Capsule</style></keyword><keyword><style face="normal" font="default" size="100%">ExPEC</style></keyword><keyword><style face="normal" font="default" size="100%">Fimbriae</style></keyword><keyword><style face="normal" font="default" size="100%">Flagella</style></keyword><keyword><style face="normal" font="default" size="100%">Invasion</style></keyword><keyword><style face="normal" font="default" size="100%">Meningitis</style></keyword><keyword><style face="normal" font="default" size="100%">Pili</style></keyword><keyword><style face="normal" font="default" size="100%">Siderophore</style></keyword><keyword><style face="normal" font="default" size="100%">Toxins</style></keyword><keyword><style face="normal" font="default" size="100%">UPEC</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">Strains of uropathogenic E. coli (UPEC) are the primary cause of urinary tract infections, including both cystitis and pyelonephritis. These bacteria have evolved a multitude of virulence factors and strategies that facilitate bacterial growth and persistence within the adverse settings of the host urinary tract. Expression of adhesive organelles like type 1 and P pili allow UPEC to bind and invade host cells and tissues within the urinary tract while expression of iron-chelating factors (siderophores) enable UPEC to pilfer host iron stores. Deployment of an array of toxins, including hemolysin and cytotoxic necrotizing factor 1, provide UPEC with the means to inflict extensive tissue damage, facilitating bacterial dissemination as well as releasing host nutrients and disabling immune effector cells. These toxins also have the capacity to modulate, in more subtle ways, host signaling pathways affecting myriad processes, including inflammatory responses, host cell survival, and cytoskeletal dynamics. Here, we discuss the mechanisms by which these and other virulence factors promote UPEC survival and growth within the urinary tract. Comparisons are also made between UPEC and other strains of extraintestinal pathogenic E. coli that, although closely related to UPEC, are distinct in their abilities to colonize the host and cause disease. © 2008 Elsevier Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :272&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-46749131414&amp;doi=10.1016%2fj.yexmp.2008.03.007&amp;partnerID=40&amp;md5=eb7135503f8ced0c3939a3221d096de3</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.yexmp.2008.03.007</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>587</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">587</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wick, G.</style></author><author><style face="normal" font="default" size="100%">Grubeck-Loebenstein, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Inst. for Biomedical Aging Research, Austrian Academy of Sciences, Innsbruck, Austria&#xD;Inst. for Gen. and Exp. Pathology, University of Innsbruck, Medical School, Innsbruck, Austria&#xD;Inst. for Biomedical Aging Research, Austrian Academy of Sciences, Rennweg 10, 6020 Innsbruck, Austria</style></auth-address><titles><title><style face="normal" font="default" size="100%">The aging immune system: Primary and secondary alterations of immune reactivity in the elderly</style></title><secondary-title><style face="normal" font="default" size="100%">Experimental Gerontology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Experimental Gerontology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">401-413</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">4-5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aging</style></keyword><keyword><style face="normal" font="default" size="100%">Alzheimer&apos;s disease</style></keyword><keyword><style face="normal" font="default" size="100%">Atherosclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">Immune system</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccination</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1997</style></year></dates><abstract><style face="normal" font="default" size="100%">The function of the immune system is known to decline in the elderly. The present communication will show that, similar to the situation in children, it is necessary to distinguish between primary and secondary alterations of the immune reactivity in the elderly. The primary immunological change in the elderly is the age-dependent intrinsic decline of immune responsiveness that is also observed in healthy persons, i.e., those selected according to the criteria of the SENIEUR Protocol of EURAGE (European Community Concerted Action on Aging). Secondary immunological changes are due to underlying diseases and various environmental factors, including diet, drug intake, physical activity, etc. While primary immunodeficiencies of the elderly are not, or only to a very minor extent, presently influenced by therapeutic measures, secondary alterations of the immune function offer further possibilities for corrective measures. Clinically, the consequences of impaired immune function in the elderly include increased susceptibility to infectious disease, the emergence of tumors, and increased autoimmune reactions, the latter albeit often without concomitant autoimmune disease. In fact, autoimmune diseases in generally begin to develop at younger ages, but their consequences are major factors affecting the quality of life of the elderly. Investigations of basic molecular and cellular aspects of the aging immune system are, therefore, of theoretical, clinical and socioeconomic interest.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :120&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Conference Paper</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030860733&amp;doi=10.1016%2fS0531-5565%2896%2900152-0&amp;partnerID=40&amp;md5=d817fe507178421a2c5f27a4eaf8e1c9</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0531-5565(96)00152-0</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>164</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">164</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Whiteside, S. A.</style></author><author><style face="normal" font="default" size="100%">Razvi, H.</style></author><author><style face="normal" font="default" size="100%">Dave, S.</style></author><author><style face="normal" font="default" size="100%">Reid, G.</style></author><author><style face="normal" font="default" size="100%">Burton, J. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology and Immunology, University of Western Ontario, London, ON N6A 3K7, Canada&#xD;Division of Urology, Department of Surgery, University of Western Ontario, 1151 Richmond Street, London, ON N6A 3K7, Canada&#xD;Canadian Centre for Human Microbiome and Probiotic Research, Lawson Health Research Institute, 268 Grosvenor Street, London, ON N6A 4V2, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">The microbiome of the urinary tract - A role beyond infection</style></title><secondary-title><style face="normal" font="default" size="100%">Nature Reviews Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nature Reviews Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">81-90</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Urologists rarely need to consider bacteria beyond their role in infectious disease. However, emerging evidence shows that the microorganisms inhabiting many sites of the body, including the urinary tract - which has long been assumed sterile in healthy individuals - might have a role in maintaining urinary health. Studies of the urinary microbiota have identified remarkable differences between healthy populations and those with urologic diseases. Microorganisms at sites distal to the kidney, bladder and urethra are likely to have a profound effect on urologic health, both positive and negative, owing to their metabolic output and other contributions. Connections between the gut microbiota and renal stone formation have already been discovered. In addition, bacteria are also used in the prevention of bladder cancer recurrence. In the future, urologists will need to consider possible influences of the microbiome in diagnosis and treatment of certain urological conditions. New insights might provide an opportunity to predict the risk of developing certain urological diseases and could enable the development of innovative therapeutic strategies. © 2015 Macmillan Publishers Limited. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :108&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84926409737&amp;doi=10.1038%2fnrurol.2014.361&amp;partnerID=40&amp;md5=af3fbe9d8799c13a0370ee3ff80d91c3</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/nrurol.2014.361</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>384</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">384</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wells, A. L.</style></author><author><style face="normal" font="default" size="100%">Saulnier, D. M. A.</style></author><author><style face="normal" font="default" size="100%">Gibson, G. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Food Biosciences, University of Reading, Reading, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Gastrointestinal microflora and interactions with gut mucosa</style></title><secondary-title><style face="normal" font="default" size="100%">Handbook of Prebiotics</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">32-57</style></pages><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">The intestinal mucosa is the main site of interaction with the external environment and therefore has an important role in maintaining good health. Formation of the gut is one of the first outcomes ofmulticellularity.1 It appears on first impression to be quite a simple organ as it is an epithelial tube comprising different cells surrounded by a layer of muscle. However, the human gastrointestinal tract is a highly dynamic ecosystem. The total area of the mucosal surface of the human gastrointestinal tract is 300m2 which makes it the largest surface area in the body that interacts with the external environment.2 The gut houses an enormous microbial community with total estimates in the region of 1014 microorganisms. The distal large intestine is the area of highest colonization with more than 500 different culturable species and up to 100 billion microbial inhabitants.3 The total number of microorganisms present in the gastrointestinal tract varies according to location (see Figure 2.1). For example stomach contents (per gram) could be less than 103 cfu, reaching 104-107 in the small intestine and 1010-1012 per gram in the colonwhere themicrobial numbers are highest.4 The endproduct of digestion (feces) is approximately 60% composed of bacteria.5 The whole microbiome is thought to contain approximately 100 times the number of genes in the human genome.6 There are four main microhabitats in the gastrointestinal Small intestine Bacterial numbers: c.a. 104-106/ml contents e.g., lactobacilli, Gram-positive cocci Stomach Bacterial numbers: c.a. 103/ml contents e.g., Helicobacter pylori Colon Bacterial numbers: c.a. 1012/g contents e.g., bacteroides, bifidobacteria, clostridia, peptostreptococci, fusobacteria, lactobacilli, enterobacteria, enterococci, eubacteria, methanogens, sulphate reducers, etc. © 2008 by Taylor and Francis Group, LLC.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :6&#xD;Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85056065005&amp;partnerID=40&amp;md5=eab7efb69bbce9e96561d8b14204d86a</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>407</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">407</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Welch, J. M.</style></author><author><style face="normal" font="default" size="100%">Forster, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacy Practice, College of Pharmacy, Nursing and Allied Sciences, North Dakota State University, Fargo, ND, United States&#xD;Veterans Affairs Medical and Regional Office Center, Fargo, United States&#xD;Veterans Affairs Medical Center, United States&#xD;College of Pharmacy, Nursing and Allied Sciences, North Dakota State University, United States&#xD;Department of Pharmacy Practice, College of Pharmacy, Nursing and Allied Sciences, North Dakota State University, Fargo, ND 58105, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Probable elevation in international normalized ratio from cranberry juice</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Pharmacy Technology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Pharmacy Technology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">104-107</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: To report a case in which cranberry juice interacted with warfarin, resulting in an elevated international normalized ratio (INR). Case Summary: A 77-year-old male had maintained stable INR values for 6 months while on a warfarin maintenance dose of 24 mg/wk. On a routine follow-up examination, the INR was 5.9; one month prior to presentation, the INR had been 2.4. The patient reported several recent nosebleeds and a red mark on his left eye. He stated he had been adherent to therapy and denied any changes in medications or recent illnesses such as fever, flu, or diarrhea. His physical activity level and diet had been consistent, with no alcohol intake. The only change identified was the addition of daily cranberry juice (1-3 cups/day) for the last month. Cranberry juice was stopped, and the dose of warfarin was decreased to 22 mg/wk. Subsequently, the INR stabilized at the low end of the therapeutic range. Discussion: Whether cranberry juice interacts with warfarin is unclear. Three previously published case reports suggested a possible interaction. In at least 2 of these cases, confounding factors and incomplete information make assessing the influence of cranberry juice difficult. The interaction in our patient was scored as probable by the Naranjo probability scale, based on the temporal relationship, return to the therapeutic INR range after discontinuing cranberry juice, and elimination of alternative causes for the INR elevation. Conclusions: This case suggests that cranberry juice may interact with warfarin, leading to an elevated INR.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :7&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-34247208182&amp;doi=10.1177%2f875512250702300207&amp;partnerID=40&amp;md5=93153f11a4eb70da3d460944492118dd</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/875512250702300207</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>244</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">244</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Weichert, S.</style></author><author><style face="normal" font="default" size="100%">Schroten, H.</style></author><author><style face="normal" font="default" size="100%">Adam, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pediatric Infectious Diseases Unit, University Children&apos;s Hospital Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany&#xD;Pediatric Gastroenterology Unit, University Children&apos;s Hospital Mannheim, Heidelberg University, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">The role of prebiotics and probiotics in prevention and treatment of childhood infectious diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Pediatric Infectious Disease Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pediatric Infectious Disease Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">859-862</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">pediatric infectious diseases</style></keyword><keyword><style face="normal" font="default" size="100%">prebiotics</style></keyword><keyword><style face="normal" font="default" size="100%">probiotics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Infant formulae and food products marketed for children have been increasingly supplemented with probiotics and/or prebiotics. A vast number of studies have accounted for the transit of probiotic use from alternative to more evidence-based medicine. Data support the use of certain probiotics for the adjunct treatment of acute viral gastroenteritis, and for prevention of gastrointestinal diseases. Further roles of prebiotics and probiotics are seen in the prevention of overall infectious diseases and respiratory infections. Data from well-conducted randomized-controlled trials support the therapeutic role for probiotics toward necrotizing enterocolitis in preterm infants. However, it is difficult to translate heterogeneous-based study results, which are mainly due to varying genera, strains, doses, study settings and measured outcomes, into evidence-based recommendations. This article focuses on the evidence of clinical benefits of prebiotics, probiotics and synbiotics toward prevention and treatment of pediatric infectious diseases. © 2012 by Lippincott Williams &amp; Wilkins.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :25&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84863891029&amp;doi=10.1097%2fINF.0b013e3182620e52&amp;partnerID=40&amp;md5=43f748a7deb51b23062ba57b30b4b9ac</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/INF.0b013e3182620e52</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>37</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">37</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wei, Y. P.</style></author><author><style face="normal" font="default" size="100%">Lin, X. G.</style></author><author><style face="normal" font="default" size="100%">He, R. Q.</style></author><author><style face="normal" font="default" size="100%">Shen, J.</style></author><author><style face="normal" font="default" size="100%">Sun, S. L.</style></author><author><style face="normal" font="default" size="100%">Chen, G.</style></author><author><style face="normal" font="default" size="100%">Wang, Q. Y.</style></author><author><style face="normal" font="default" size="100%">Xu, J. F.</style></author><author><style face="normal" font="default" size="100%">Mo, Z. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China&#xD;Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China&#xD;Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China&#xD;Guangxi Key Laboratory for Genomic and Personalized Medicine, Nanning, Guangxi Zhuang Autonomous Region, China&#xD;Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, Guangxi Zhuang Autonomous Region, China&#xD;Guangxi Key Laboratory of Colleges and Universities, Nanning, Guangxi Zhuang Autonomous Region, China</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epidemiologic association of nonalcoholic fatty liver disease and urinary calculi a population-based cross-sectional study in Southern China</style></title><secondary-title><style face="normal" font="default" size="100%">Iranian Journal of Kidney Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Iranian Journal of Kidney Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">112-119</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">China</style></keyword><keyword><style face="normal" font="default" size="100%">Nonalcoholic fatty liver disease</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary calculus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Introduction. Nonalcoholic fatty liver disease (NAFLD) has been reported to have effects on kidney diseases; however, a link between NAFLD and urinary calculi remains to be confirmed. This study was conducted on a male population based on our previous Fangchenggang Area Male Health and Examination Survey in Guangxi, China in order to estimate the frequency of urinary calculi and assess the association between NAFLD and urinary calculi while controlling for possible confounders. Materials and Methods. This was a population-based cross-sectional study conducted in the Fangchenggang region in Guangxi, China. The diagnoses of NAFLD and urinary calculi were made by ultrasonography. Clinical and laboratory findings were analyzed to investigate whether NAFLD was a risk factor for urinary calculi. Results. A total of 3719 men were enrolled (age range, 17 to 88 years). Slightly more than a quarter (26.5%) of the participants were diagnosed with NAFLD. The percentage of urinary calculi in all participants was 6.9%, and the percentage of NAFLD patients with urinary calculi (8.4%) was significantly higher than that among patients without NAFLD (6.4%, P &lt;.05). Advanced age; high body mass index; elevated levels of blood glucose, cholesterol, triglycerides, and low-density lipoprotein cholesterol; low education; lower or higher physical activity; and NAFLD were independent risk factors for urinary calculi (P &lt;.05). Conclusions. Our results showed that NAFLD was associated with a higher incidence of urinary calculi in this cohort and NAFLD might represent a risk factor for urinary calculi. © 2018, Iranian Society of Nephrology. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85043338020&amp;partnerID=40&amp;md5=6fda2a3e826bceb29846e386247896f6</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>482</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">482</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Watson, A. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Children/Young People&apos;s Kidney Unit, Nottingham City Hospital NHS Trust, Hucknall Road, Nottingham NG5 1PB, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pediatric urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">EAU Update Series</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">EAU Update Series</style></full-title></periodical><pages><style face="normal" font="default" size="100%">94-100</style></pages><volume><style face="normal" font="default" size="100%">2</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Children</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Vesicoureteric reflux</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infection (UTI) in childhood affects many children but it can be difficult to diagnose, especially in infancy where it is believed that most renal damage occurs. UTI can point the way to underlying congenital abnormalities of the urinary tract which are uncommon, as are the long-term sequelae of renal scarring, hypertension and chronic renal failure. It is now appreciated that many infants have reflux associated damage before birth with associated renal dysplasia. Investigations in children with a UTI remain controversial with ultrasonography being sufficient in experienced hands and only selected patients undergoing cystography and radionuclide imaging. Gross vesicoureteric reflux (VUR) is rare and most mild to moderate VUR resolves spontaneously. Although there is no randomised controlled trial to date low dose prophylactic antibiotics are used in the majority of children in whom VUR is detected with surgery being reserved for those with problematical infections or anatomical abnormalities. Familial reflux is increasingly recognised. © 2004 Elsevier B.V. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :6&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-4544222025&amp;doi=10.1016%2fj.euus.2004.06.005&amp;partnerID=40&amp;md5=20d41ee5b8aa1388f32412626e60b4b8</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.euus.2004.06.005</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>497</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">497</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Watermann, D.</style></author><author><style face="normal" font="default" size="100%">Kunze, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universitäts-Frauenklinik, Freiburg, Germany&#xD;Universitäts-Frauenklinik, Hugstetter Straße 55, 79106 Freiburg, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent urinary tract infection in women</style></title><secondary-title><style face="normal" font="default" size="100%">Geburtshilfe und Frauenheilkunde</style></secondary-title><short-title><style face="normal" font="default" size="100%">Rezidivierende zystitis der frau</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Geburtshilfe und Frauenheilkunde</style></full-title></periodical><pages><style face="normal" font="default" size="100%">473-478</style></pages><volume><style face="normal" font="default" size="100%">64</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Recurrent urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Recurrent urinary tract infections (RUTI) are very common in women and substantially affect the quality of life of these patients. RUTI is strongly associated with predisposing risk factors occurring especially in elderly women, including functional or anatomical changes such as mucosal atrophy, cystocele, increased post-void residual volume and oliguria. The colonization of the vaginal and periurethral mucosa with virulent, persistent bacteria represents an additional cause for RUTI. The clinical symptoms together with dipstick urine analysis and urine culture lead to the diagnosis. Therapy and prophylaxis of RUTI are based on the elimination of the mentioned risk factors. Long-term or intermittent antibiotic treatment are pertinent therapeutic options. The first choice antibiotic regimen for prophylaxis of RUTI is trimethoprim. Behavioral changes and supportive measures such as acidification of the urine or local hormone therapy also reduce the incidence rates of RUTI. In addition, alternative therapeutic approaches including herbal or bacterial extracts and acupuncture showed promising effects, but need further evaluation.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-2942536379&amp;doi=10.1055%2fs-2004-817836&amp;partnerID=40&amp;md5=9552f3910a2cb642b72f28dc76cdcaec</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1055/s-2004-817836</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>104</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">104</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, Y.</style></author><author><style face="normal" font="default" size="100%">Singh, A. P.</style></author><author><style face="normal" font="default" size="100%">Nelson, H. N.</style></author><author><style face="normal" font="default" size="100%">Kaiser, A. J.</style></author><author><style face="normal" font="default" size="100%">Reker, N. C.</style></author><author><style face="normal" font="default" size="100%">Hooks, T. L.</style></author><author><style face="normal" font="default" size="100%">Wilson, T.</style></author><author><style face="normal" font="default" size="100%">Vorsa, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Plant Biology and Pathology, Rutgers University, New Brunswick, NJ 08901, United States&#xD;Biology Department, Winona State University, Winona, MN 55987, United States&#xD;Mathematics and Statistics Department, Winona State University, Winona, MN 55987, United States&#xD;Philip E. Marucci Center for Blueberry and Cranberry Research and Extension, Rutgers University, Chatsworth, NJ 08019, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary Clearance of Cranberry Flavonol Glycosides in Humans</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">7931-7939</style></pages><volume><style face="normal" font="default" size="100%">64</style></volume><number><style face="normal" font="default" size="100%">42</style></number><keywords><keyword><style face="normal" font="default" size="100%">cranberry juice</style></keyword><keyword><style face="normal" font="default" size="100%">flavan-3-ols</style></keyword><keyword><style face="normal" font="default" size="100%">flavonols</style></keyword><keyword><style face="normal" font="default" size="100%">glycosides</style></keyword><keyword><style face="normal" font="default" size="100%">human urine</style></keyword><keyword><style face="normal" font="default" size="100%">MS-MS</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry is reported to have health benefits, including prevention of urinary tract infections and other chronic diseases, due to the high content of polyphenols, including flavonols and flavan-3-ols. The aim of this study was to determine the clearance of flavonol glycosides and flavan-3-ols and/or their metabolites in human urine. Ten healthy women volunteers ingested 240 mL of cranberry juice containing flavonol glycosides. Urine samples were collected at 0, 90, 225, and 360 min postingestion. While flavan-3-ols were not detected, five flavonol glycosides common in cranberry were identified. Quercetin-3-galactoside, the most abundant cranberry flavonol, exhibited the highest peak urine concentration (Cmax) of 1315 pg/mg creatinine, followed by quercetin-3-rhamnoside, quercetin-3-arabinoside, myricetin-3-arabinoside, and myricetin-3-galactoside. Quercetin-3-arabinoside showed delayed clearance, Cmax at 237 min (Tmax), relative to other flavonols (90-151 min). Both aglycone and the conjugated sugar moiety structure mediate the flavonol&apos;s bioavailability. Interindividual variation for bioavailability and clearance is also apparent. Metabolites, e.g. glucoronides, were not detected. © 2016 American Chemical Society.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :6&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84992718255&amp;doi=10.1021%2facs.jafc.6b03611&amp;partnerID=40&amp;md5=70fd7968ff4a1bacd8e92ea6b34d9461</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/acs.jafc.6b03611</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>163</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">163</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, S.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Mou, H.</style></author><author><style face="normal" font="default" size="100%">Luo, B.</style></author><author><style face="normal" font="default" size="100%">Jiang, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Food Science and Engineering, Ocean University of China, 5 Yushan Road, Qingdao, China&#xD;Qingdao University Medical College, Qingdao, China</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inhibition of adhesion of intestinal pathogens (Escherichia coli, Vibrio cholerae, Campylobacter jejuni, and Salmonella Typhimurium) by common oligosaccharides</style></title><secondary-title><style face="normal" font="default" size="100%">Foodborne Pathogens and Disease</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Foodborne Pathogens and Disease</style></full-title></periodical><pages><style face="normal" font="default" size="100%">360-365</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">4</style></number><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Inhibition of the binding of pathogenic adhesins to host glycans by suitable oligosaccharides forms the basis of antiadhesion therapies. Experiments were carried out to study the inhibition capability of oligosaccharides on the adhesion of four microorganisms (Escherichia coli, Vibrio cholerae, Campylobacter jejuni, and Salmonella Typhimurium) to HT-29 cells. Results showed that, in the absence of oligosaccharides, all of the four pathogens efficiently adhered to the cells. Cell adhesion with different bacteria was inhibited by distinct oligosaccharides (e.g., the adhesion number relative to control of V. cholerae could be significantly decreased by pectin oligosaccharide and chitooligosaccharide to about 16.1% and 18.9%, respectively). Saturation studies showed that the extent of antiadhesive effect for most of the suitable carbohydrates was dependent on their concentration. The observations from the study suggest that various carbohydrates may have antiadhesive activity and may be useful in future therapeutic study. © Copyright 2015, Mary Ann Liebert, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :6&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84926452559&amp;doi=10.1089%2ffpd.2014.1835&amp;partnerID=40&amp;md5=e299ab48935a6fb81647b4ddd65a5463</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1089/fpd.2014.1835</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>246</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">246</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wang, C. H.</style></author><author><style face="normal" font="default" size="100%">Fang, C. C.</style></author><author><style face="normal" font="default" size="100%">Chen, N. C.</style></author><author><style face="normal" font="default" size="100%">Liu, S. S. H.</style></author><author><style face="normal" font="default" size="100%">Yu, P. H.</style></author><author><style face="normal" font="default" size="100%">Wu, T. Y.</style></author><author><style face="normal" font="default" size="100%">Chen, W. T.</style></author><author><style face="normal" font="default" size="100%">Lee, C. C.</style></author><author><style face="normal" font="default" size="100%">Chen, S. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Emergency Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan&#xD;Department of Emergency Medicine, National Taiwan University Hospital Yunlin Branch #579, Sec 2, Yunlin Rd., Douliou 640, Yunlin, Taiwan&#xD;Department of Epidemiology, Harvard School of Public Health, Boston, MA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry-containing products for prevention of urinary tract infections in susceptible populations: A systematic review and meta-analysis of randomized controlled trials</style></title><secondary-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">988-996</style></pages><volume><style face="normal" font="default" size="100%">172</style></volume><number><style face="normal" font="default" size="100%">13</style></number><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Urinary tract infection (UTI) is one of the most commonly acquired bacterial infections. Cranberry-containing products have long been used as a folk remedy to prevent UTIs. The aims of this study were to evaluate cranberry-containing products for the prevention of UTI and to examine the factors influencing their effectiveness.Methods: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were systemically searched from inception to November 2011 for randomized controlled trials that compared prevention of UTIs in users of cranberry-containing products vs placebo or nonplacebo controls. There were no restrictions for language, population, or publication year. Results: Thirteen trials, including 1616 subjects, were identified for qualitative synthesis from 414 potentially relevant references; 10 of these trials, including a total of 1494 subjects, were further analyzed in quantitative synthesis. The random-effects pooled risk ratio (RR) for cranberry users vs nonusers was 0.62 (95% CI, 0.49-0.80), with amoderate degree of heterogeneity (I 2=43%) after the exclusion of 1 outlier study. On subgroup analysis, cranberry-containing products seemed to be more effective in several subgroups, including women with recurrent UTIs (RR, 0.53; 95% CI, 0.33-0.83) (I 2=0%), female populations (RR, 0.49; 95% CI, 0.34-0.73) (I 2=34%), children (RR, 0.33; 95% CI, 0.16-0.69) (I 2=0%), cranberry juice drinkers (RR, 0.47; 95% CI, 0.30-0.72) (I 2=2%), and subjects using cranberry-containing products more than twice daily (RR, 0.58; 95% CI, 0.40-0.84) (I 2=18%). Conclusions: Our findings indicate that cranberry-containing products are associated with protective effect against UTIs. However, this result should be interpreted in the context of substantial heterogeneity across trials. © 2012 American Medical Association. All Rights Reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :94&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84863667572&amp;doi=10.1001%2farchinternmed.2012.3004&amp;partnerID=40&amp;md5=da5f0155f167743bd946b5424bd55b31</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/archinternmed.2012.3004</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>100</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">100</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wan, K. S.</style></author><author><style face="normal" font="default" size="100%">Liu, C. K.</style></author><author><style face="normal" font="default" size="100%">Lee, W. K.</style></author><author><style face="normal" font="default" size="100%">Ko, M. C.</style></author><author><style face="normal" font="default" size="100%">Huang, C. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Taipei City Hospital-Renai Branch, Taipei City, Taiwan&#xD;Department of Pediatrics, Taipei City Hospital-Renai Branch, Taiwan&#xD;Department of Urology, Taipei City Hospital- Zhongxing Branch, Fu Jen Catholic University School of Medicine, New Taipei City, Taiwan&#xD;Fu Jen Catholic University School of Medicine, Taiwan&#xD;Department of Urology at Taipei City Hospital- Zhongxing Branch, Taipei City, Taiwan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberries for preventing recurrent urinary tract infections in uncircumcised boys</style></title><secondary-title><style face="normal" font="default" size="100%">Alternative Therapies in Health and Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Alternative Therapies in Health and Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">20-23</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">6</style></number><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Background • Highly concentrated cranberry juice has long been considered to have protective properties against urinary tract infections (UTIs), on the basis of its content of cranberry proanthocyanidins, with A-type interflavan bonds. Objective • This study intended to evaluate the benefits of a highly concentrated cranberry juice for the prevention of repeated episodes of UTI in uncircumcised boys. Design • The study was a randomized, controlled trial. Setting • The study took place at Taipei City Hospital, Renai and Zhongxing Branches (Taipei City, Taiwan). Participants • Participants were 55 uncircumcised boys and 12 circumcised boys, aged 6 to 18 y, with histories of uncomplicated UTI, who were patients at the hospital. Intervention • The uncircumcised boys were randomly divided into 2 groups: (1) group 1 (n = 28) took 4 oz (120 mL) daily of cranberry juice for 6 mo; and (2) group 2 (n = 27), the negative control group, drank a placebo juice for 6 months. The circumcised boys in group 3, a positive control group, also drank a placebo juice for 6 mo. Outcome Measures • The time to UTI (ie, to the appearance of symptoms plus pyuria) was the main outcome. Asymptomatic bacteriuria, adherence to the treatment, and adverse effects were assessed at monthly visits. Results • After 6 mo of a prophylactic treatment with cranberry juice, the incidence of bacteriuria, mainly Escherichia coli, as shown in urine cultures at ≥1 × 105, were 25% (7/28), 37% (10/27), and 33.3% (4/12) in groups 1, 2 and 3, respectively. The comparisons of the rate of prevention of a recurrence of UTI between group 1 and group 2 and between group 1 and group 3 showed that group 1 had fewer recurrent episodes of UTI. No children withdrew from the study. No adverse events or side effects were recorded. Conclusions • Cranberry juice may reduce the number of repeated episodes of UTI in uncircumcised boys and may have beneficial effects against the growth of Gram-negative bacterial pathogens. Its preventive benefits against UTI in the uncircumcised boys were even higher than those of circumcision for the circumcised boys. © 2016 InnoVision Communications. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84996538489&amp;partnerID=40&amp;md5=f3822a2e19b52bf33fe70e1d3c4d485c</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>176</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">176</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wagenlehner, F. M. E.</style></author><author><style face="normal" font="default" size="100%">Pilatz, A.</style></author><author><style face="normal" font="default" size="100%">Naber, K.</style></author><author><style face="normal" font="default" size="100%">Weidner, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie, Justus-Liebig-Universität Gieß;en, Rudolf-Buchheim-Straße 7, 35385 Gieen, Germany&#xD;Technische Universität München, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Aktuelle Urologie</style></secondary-title><short-title><style face="normal" font="default" size="100%">Harnwegsinfektionen</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Aktuelle Urologie</style></full-title></periodical><pages><style face="normal" font="default" size="100%">135-146</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic treatment regime</style></keyword><keyword><style face="normal" font="default" size="100%">cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">pyelonephritis</style></keyword><keyword><style face="normal" font="default" size="100%">urosepsis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTI) are amongst the most frequent bacterial infections and therefore responsible for a great amount of antibiotic administration. UTI may present as benign, uncomplicated cystitis or severe, life-threatening urosepsis. Due to the heterogeneity of UTI the European Section of Infections in Urology (ESIU) has introduced a phenotypical classification, based upon the clinical presentation, the risk factors and the antibiotic susceptibility of the causative pathogens. Antibiotic treatment of the UTI varies accordingly. In uncomplicated cystitis antibiotics with low potential for collateral damage are recommended, which are mainly indicated for these infections. In uncomplicated pyelonephritis fluoroquinolones and 3rd generation cephalosporines are recommended. Antibiotic treatment regimens of complicated UTI depend very much on the antibiotic susceptibility according to regional resistance statistics. In urosepsis an early diagnosis and therapy is mandatory. In this regard a procalcitonin level &gt;0.25μg/l has a good sensitivity and acceptable specificity in predicting bacteremia. Apart from the early antibiotic therapy successful decompression of the obstructed urinary tract is a predictor of survival. In children UTI are also amongst the most important bacterial infections, although symptoms are frequently not characteristic. The correct sampling of urine for microbiological investigations is critical. Due to the increasing fluoroquinolone resistance, infectious complications after transrectal prostate biopsy are becoming more frequent. Strategies to decrease complications encompass, amongst others, microbiological screening of the faecal flora for fluoroquinolone resistance, administration of alternative antibiotics for prophylaxis and alternative techniques for biopsy, such as perineal prostate biopsy. © Georg Thieme Verlag KG Stuttgart New York.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :5&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84898765508&amp;doi=10.1055%2fs-0034-1368176&amp;partnerID=40&amp;md5=6fb6b49763f46828c0787672aa5cd451</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1055/s-0034-1368176</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>43</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">43</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wagenlehner, F.</style></author><author><style face="normal" font="default" size="100%">Wullt, B.</style></author><author><style face="normal" font="default" size="100%">Ballarini, S.</style></author><author><style face="normal" font="default" size="100%">Zingg, D.</style></author><author><style face="normal" font="default" size="100%">Naber, K. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinic for Urology, Pediatric Urology and Andrology, Justus-Liebig University, Giessen, Germany&#xD;Section of MIG, Lund University, Lund, Sweden&#xD;Vifor Pharma, Geneva, Switzerland&#xD;Technical University of Munich, Munich, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT)</style></title><secondary-title><style face="normal" font="default" size="100%">Expert Review of Pharmacoeconomics and Outcomes Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Expert Review of Pharmacoeconomics and Outcomes Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">107-117</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Disease burden</style></keyword><keyword><style face="normal" font="default" size="100%">economic burden</style></keyword><keyword><style face="normal" font="default" size="100%">health-related quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">mental health</style></keyword><keyword><style face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">recurrent urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Uncomplicated lower urinary tract infections (UTIs) occur in approximately 50% of women, and 20–30% experience recurrent UTI. Data on UTIs and quality of life (QoL) in Europe are limited. Methods: This was an anonymous, self-administered web-based survey conducted in 5 countries (Germany, Switzerland, Poland, Russia and Italy), on adult women who had experienced recurrent UTI and were affected by acute UTI currently or within 4 weeks of study entry. Questions covered disease course; management; social and economic burden; education, income, and health insurance status. QoL was evaluated using the SF-12v2. Results: Participants reported a mean of 5.15 UTI symptoms, ranging from 4.85 − 5.38 in Russia and Germany. There was a mean of 2.78 doctor visits per year (1.74 − 3.71 in Russia and Germany; p &lt; 0.0001). 80.3% of participants had been treated with antibiotics, mean prescriptions ranged from 2.17 (Poland) to 3.36 (Germany) per person per year. A mean of 3.09 days sick leave due to UTIs, and 3.45 days of limited activities, were reported. Although 73.8% of participants had tried prophylaxis recurrence was common and associated with mental stress for a high proportion of women. Conclusions: Our results indicate that recurrent UTIs have a significant impact on QoL of women in Europe. © 2017 Informa UK Limited, trading as Taylor &amp; Francis Group.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :5&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85026512051&amp;doi=10.1080%2f14737167.2017.1359543&amp;partnerID=40&amp;md5=8b98141d91b367bd4c3c79aaf25fc15a</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/14737167.2017.1359543</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>210</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">210</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vyas, P.</style></author><author><style face="normal" font="default" size="100%">Kalidindi, S.</style></author><author><style face="normal" font="default" size="100%">Chibrikova, L.</style></author><author><style face="normal" font="default" size="100%">Igamberdiev, A. U.</style></author><author><style face="normal" font="default" size="100%">Weber, J. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biology, Memorial University of Newfoundland, St. John&apos;s, NL A1B 3V6, Canada&#xD;School of Pharmacy, Health Sciences Centre, Memorial University of Newfoundland, 300 Prince Philip Drive, St. John&apos;s, NL A1B 3V6, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Chemical analysis and effect of blueberry and lingonberry fruits and leaves against glutamate-mediated excitotoxicity</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">7769-7776</style></pages><volume><style face="normal" font="default" size="100%">61</style></volume><number><style face="normal" font="default" size="100%">32</style></number><keywords><keyword><style face="normal" font="default" size="100%">antioxidants</style></keyword><keyword><style face="normal" font="default" size="100%">berries</style></keyword><keyword><style face="normal" font="default" size="100%">oxidative stress</style></keyword><keyword><style face="normal" font="default" size="100%">phenolic compounds</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Phenolic compounds are a large class of phytochemicals that are widespread in the plant kingdom and known to have antioxidant capacities. This study aimed to determine the antioxidant capacities as well as the content of total soluble phenolics, anthocyanins, tannins, and flavonoids in the fruits and leaves of blueberries and lingonberries growing in Newfoundland. This study also determined the potential neuroprotective effect of extracts from fruits and leaves against glutamate-mediated excitotoxicity, which is believed to contribute to disorders such as stroke and neurodegenerative diseases. Lingonberry and blueberry plants were found to be rich sources of phenolic compounds. Total antioxidant capacities in terms of radical scavenging activity and reducing power were much higher in leaves of both plants as compared to their fruits. These results were in correlation with phenolic contents including total flavonoids, anthocyanins, and tannins. Brain-derived cell cultures from rats were prepared and grown for about 2 weeks. Cell cultures were treated with glutamate (100 μM) for 24 h, and the effect of extracts was determined on cells subjected to this excitotoxicity. Glutamate treatment caused a ∼23% cell loss when measured after 24 h of exposure. Whereas lingonberry fruit extract did not provide protection from glutamate toxicity, blueberry fruit extracts were extremely protective. Leaf extracts of both lingonberry and blueberry showed a significant neuroprotective effect. The greater protective effect of leaf extracts was in correlation with the levels of phenolics and antioxidant capacity. These findings suggest that berries or their components may contribute to protecting the brain from various pathologies. © 2013 American Chemical Society.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :19&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84881648634&amp;doi=10.1021%2fjf401158a&amp;partnerID=40&amp;md5=5003d31d89b9c48f813616a64a32ae8a</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/jf401158a</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>425</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">425</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vuong, T.</style></author><author><style face="normal" font="default" size="100%">Martin, L.</style></author><author><style face="normal" font="default" size="100%">Matar, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemistry and Biochemistry, Université de Moncton, Moncton, NB E1A 3E9, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antioxidant activity of fermented berry juices and their effects on nitric oxide and tumor necrosis factor-alpha production in macrophages 264.7 gamma NO(-) cell line</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Food Biochemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Food Biochemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">249-268</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">Serratia vaccinii, a novel bacterium isolated from blueberry microflora, increased the phenolic content of berry juices, and thus increased antioxidant activities. The fermentation capacity of Serratia was investigated with Saskatoon berries, cranberries, strawberries and grapes in both aerobic and anaerobic conditions. It was shown to be compatible with wine yeast in anaerobic fermentations, producing wine with high antioxidant activity. The effects of fermented berry juices were tested on lipopolysaccharideinferon-gamma-activated macrophages 264.7 NO(-). Data indicated that fermented berry juices strongly inhibited activated-macrophage NO production but induced tumor necrosis factor-alpha production. © 2006, Blackwell Publishing.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :10&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33744542596&amp;doi=10.1111%2fj.1745-4514.2006.00054.x&amp;partnerID=40&amp;md5=b9c0ef02f67f50523899e38caf593994</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1745-4514.2006.00054.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>146</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">146</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vostalova, J.</style></author><author><style face="normal" font="default" size="100%">Vidlar, A.</style></author><author><style face="normal" font="default" size="100%">Simanek, V.</style></author><author><style face="normal" font="default" size="100%">Galandakova, A.</style></author><author><style face="normal" font="default" size="100%">Kosina, P.</style></author><author><style face="normal" font="default" size="100%">Vacek, J.</style></author><author><style face="normal" font="default" size="100%">Vrbkova, J.</style></author><author><style face="normal" font="default" size="100%">Zimmermann, B. F.</style></author><author><style face="normal" font="default" size="100%">Ulrichova, J.</style></author><author><style face="normal" font="default" size="100%">Student, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, Olomouc, 77515, Czech Republic&#xD;Department of Urology, University Hospital, I.P. Pavlova 5, Olomouc, 77500, Czech Republic&#xD;Institute of Molecular and Translational Medicine Department, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, Olomouc, 77515, Czech Republic&#xD;Department of Nutritional and Food Sciences, University of Bonn, Römmerstrasse 164, Bonn, 53117, Germany&#xD;Institut Prof. Dr. Georg Kurz GmbH, Stöckheimer Weg 1, Köln, 50829, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Are high proanthocyanidins key to cranberry efficacy in the prevention of recurrent urinary tract infection?</style></title><secondary-title><style face="normal" font="default" size="100%">Phytotherapy Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Phytotherapy Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1559-1567</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">clinical chemistry markers</style></keyword><keyword><style face="normal" font="default" size="100%">haematology</style></keyword><keyword><style face="normal" font="default" size="100%">recurrent</style></keyword><keyword><style face="normal" font="default" size="100%">urinary metabolites</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Most research on American cranberry in the prevention of urinary tract infection (UTI) has used juices. The spectrum of components in juice is limited. This study tested whether whole cranberry fruit powder (proanthocyanidin content 0.56%) could prevent recurrent UTI in 182 women with two or more UTI episodes in the last year. Participants were randomized to a cranberry (n-=-89) or a placebo group (n-=-93) and received daily 500-mg of cranberry for 6-months. The number of UTI diagnoses was counted. The intent-to-treat analyses showed that in the cranberry group, the UTIs were significantly fewer [10.8% vs. 25.8%, p-=-0.04, with an age-standardized 12-month UTI history (p-=-0.01)]. The Kaplan-Meier survival curves showed that the cranberry group experienced a longer time to first UTI than the placebo group (p-=-0.04). Biochemical parameters were normal, and there was no significant difference in urinary phenolics between the groups at baseline or on day180. The results show that cranberry fruit powder (peel, seeds, pulp) may reduce the risk of symptomatic UTI in women with a history of recurrent UTIs. Copyright © 2015 John Wiley &amp; Sons, Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :16&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84943583055&amp;doi=10.1002%2fptr.5427&amp;partnerID=40&amp;md5=28eff8b2aa54bd3c2efe4f3037867b38</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/ptr.5427</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>240</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">240</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vitetta, L.</style></author><author><style face="normal" font="default" size="100%">Briskey, D.</style></author><author><style face="normal" font="default" size="100%">Hayes, E.</style></author><author><style face="normal" font="default" size="100%">Shing, C.</style></author><author><style face="normal" font="default" size="100%">Peake, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Medicine, Centre for Integrative Clinical and Molecular Medicine, University of Queensland, 199 Ipswich Road, Woolloongabba, Brisbane QLD 4102, Australia&#xD;School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia&#xD;FitBioceuticals Ltd., Sydney, Australia&#xD;School of Human Life Sciences, University of Tasmania, Launceston, TAS, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">A review of the pharmacobiotic regulation of gastrointestinal inflammation by probiotics, commensal bacteria and prebiotics</style></title><secondary-title><style face="normal" font="default" size="100%">Inflammopharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Inflammopharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">251-266</style></pages><volume><style face="normal" font="default" size="100%">20</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bacteria</style></keyword><keyword><style face="normal" font="default" size="100%">Commensal</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacobiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Prebiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Symbiotics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">The idea that microbes induce disease has steered medical research toward the discovery of antibacterial products for the prevention and treatment of microbial infections. The twentieth century saw increasing dependency on antimicrobials as mainline therapy accentuating the notion that bacterial interactions with humans were to be avoided or desirably controlled. The last two decades, though, have seen a refocusing of thinking and research effort directed towards elucidating the critical inter-relationships between the gut microbiome and its host that control health/wellness or disease. This research has redefined the interactions between gut microbes and vertebrates, now recognizing that the microbial active cohort and its mammalian host have shared co-evolutionary metabolic interactions that span millennia. Microbial interactions in the gastrointestinal tract provide the necessary cues for the development of regulated pro- and anti-inflammatory signals that promotes immunological tolerance, metabolic regulation and other factors which may then control local and extraintestinal inflammation. Pharmacobiotics, using nutritional and functional food additives to regulate the gut microbiome, will be an exciting growth area of therapeutics, developing alongside an increased scientific understanding of gutmicrobiome symbiosis in health and disease. © 2012 Springer Basel AG.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :16&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84866892599&amp;doi=10.1007%2fs10787-012-0126-8&amp;partnerID=40&amp;md5=d9768674bbfac77f47f614ab66492ab4</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10787-012-0126-8</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>140</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">140</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vidal, E.</style></author><author><style face="normal" font="default" size="100%">Cervera, C.</style></author><author><style face="normal" font="default" size="100%">Cordero, E.</style></author><author><style face="normal" font="default" size="100%">Armiñanzas, C.</style></author><author><style face="normal" font="default" size="100%">Carratalá, J.</style></author><author><style face="normal" font="default" size="100%">Cisneros, J. M.</style></author><author><style face="normal" font="default" size="100%">Fariñas, M. C.</style></author><author><style face="normal" font="default" size="100%">López-Medrano, F.</style></author><author><style face="normal" font="default" size="100%">Moreno, A.</style></author><author><style face="normal" font="default" size="100%">Muñoz, P.</style></author><author><style face="normal" font="default" size="100%">Origüen, J.</style></author><author><style face="normal" font="default" size="100%">Sabé, N.</style></author><author><style face="normal" font="default" size="100%">Valerio, M.</style></author><author><style face="normal" font="default" size="100%">Torre-Cisneros, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unidad Clínica de Gestión de Enfermedades Infecciosas, Instituto Maimónides de Investigación en Biomedicina de Córdoba, Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain&#xD;Servicio de Enfermedades Infecciosas, Hospital Clínic, Institut d&apos;Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universidad de Barcelona, Barcelona, Spain&#xD;Unidad Clínica de Gestión de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen Del Rocío, Universidad de Sevilla, Sevilla, Spain&#xD;Unidad de Enfermedades Infecciosas, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, IDIVAL, Santander, Spain&#xD;Servicio de Enfermedades Infecciosas, Hospital Universitario de Bellvitge, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Universidad de Barcelona, Barcelona, Spain&#xD;Unidad de Enfermedades Infecciosas, Hospital Universitario 12 de Octubre, Instituto de Investigación Biomédica 12 de Octubre, Departamento de Medicina, Universidad Complutense, Madrid, Spain&#xD;Departamento de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Management of urinary tract infection in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI)</style></title><secondary-title><style face="normal" font="default" size="100%">Enfermedades Infecciosas y Microbiologia Clinica</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Enfermedades Infecciosas y Microbiologia Clinica</style></full-title></periodical><pages><style face="normal" font="default" size="100%">679.e1-679.e21</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">10</style></number><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Background Urinary tract infections (UTIs) are one of the most common infections in solid organ transplant (SOT) recipients. Methods Experienced SOT researchers and clinicians have developed and implemented this consensus document in support of the optimal management of these patients. A systematic review was conducted, and evidence levels based on the available literature are given for each recommendation. This article was written in accordance with international recommendations on consensus statements and the recommendations of the Appraisal of Guidelines for Research and Evaluation II (AGREE II). Results Recommendations are provided on the management of asymptomatic bacteriuria, and prophylaxis and treatment of UTI in SOT recipients. The diagnostic-therapeutic management of recurrent UTI and the role of infection in kidney graft rejection or dysfunction are reviewed. Finally, recommendations on antimicrobials and immunosuppressant interactions are also included. Conclusions The latest scientific information on UTI in SOT is incorporated in this consensus document. © 2015 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y MicrobiologíaClínica. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84952874745&amp;doi=10.1016%2fj.eimc.2015.03.024&amp;partnerID=40&amp;md5=1d5f8ff66cf457e72177b5573d299a1e</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.eimc.2015.03.024</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>168</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">168</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vicariotto, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Gynaecology Unit San Pio X Nursing Home, Via Francesco Nava, Milan, 31-20159, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effectiveness of an association of a cranberry dry extract, D-mannose, and the two microorganisms Lactobacillus plantarum LP01 and Lactobacillus paracasei LPC09 in women affected by cystitis: A pilot study</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical Gastroenterology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Clinical Gastroenterology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S96-S101</style></pages><volume><style face="normal" font="default" size="100%">48</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Acute cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Barrier effect</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry extract</style></keyword><keyword><style face="normal" font="default" size="100%">Gelling complex</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacilli</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Urinary tract infections (UTIs) are the most common bacterial infection in women. Most UTIs are acute uncomplicated cystitis caused by Escherichia coli (86%). This study was undertaken to assess the effectiveness of an association of a cranberry dry extract, D-mannose, a gelling complex composed of the exopolysaccharides produced by Streptococcus thermophilus ST10 (DSM 25246) and tara gum, as well as the 2 microorganisms Lactobacillus plantarum LP01 (LMG P-21021) and Lactobacillus paracasei LPC09 (DSM 24243) in women affected by acute uncomplicated cystitis. Materials and Methods: Thirty-three premenopausal, nonpregnant women diagnosed with acute uncomplicated cystitis were enrolled in a pilot prospective study and completed the treatment protocol. Subjects were instructed to take 2 doses per day during the first month, and then to continue with 1 sachet per day until the sixtieth day. Nitrites and leukocyte esterase on urine dipstick testing were used as indicators of cystitis, with analysis performed at enrollment, after 30 and 60 days, and after 1 month of follow-up. Typical UTI symptoms, namely dysuria, frequent voiding of small volumes, urinary urgency, suprapubic pain, and gross hematuria were scored 0 to 3 and evaluated at each visit. Results: Positive results for the presence of nitrites and leukocyte esterase were found in 14 and 20 subjects after 30 days and in 9 and 14 women after 60 days, respectively (P&lt;0.001). At the end of the follow-up period, positive results for nitrites and leukocyte esterase were recorded in only 4 and 3 of 24 and 19 subjects (16.7%, P=0.103; 15.8%, P=0.325, respectively), with negative results after 60 days. Typical symptoms of cystitis, specifically dysuria, frequent voiding, urgency, and suprapubic pain were significantly improved as well. No significant differences were recorded in the incidence and severity of hematuria at any visit. Conclusion: The long-term ability of an association of cranberry, Dmannose, an innovative gelling complex, and the 2 microorganisms tested to significantly improve the uncomfortable symptoms reported by women with acute cystitis has been suggested. © 2014 by Lippincott Williams &amp; Wilkins.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :8&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Conference Paper</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84916604379&amp;doi=10.1097%2fMCG.0000000000000224&amp;partnerID=40&amp;md5=2278459ea471c3e17ef7aad688388689</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/MCG.0000000000000224</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>211</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">211</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vasileiou, I.</style></author><author><style face="normal" font="default" size="100%">Katsargyris, A.</style></author><author><style face="normal" font="default" size="100%">Theocharis, S.</style></author><author><style face="normal" font="default" size="100%">Giaginis, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Food Science and Nutrition, University of the Aegean, Myrina, Lemnos 81400, Greece&#xD;First Department of Pathology, Medical School, University of Athens, Athens 11527, Greece</style></auth-address><titles><title><style face="normal" font="default" size="100%">Current clinical status on the preventive effects of cranberry consumption against urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Nutrition Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nutrition Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">595-607</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antimicrobial activity</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical trials</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Immune response</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammatory reaction</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTIs) represent a common and quite costly medical problem, primarily affecting the female population which may be due to a shorter urethra. The bacterium Escherichia coli are mainly responsible for most uncomplicated UTIs. Cranberry antibacterial effects have widely been studied in vitro, and laboratory and clinical studies have also been performed to elucidate the mechanisms of cranberry actions and the clinical benefits of cranberry consumption against UTIs. The present review aimed to summarize the proposed mechanisms of cranberry actions against UTIs and the clinical trials that evaluated the efficacy of supplementing cranberry products in different subpopulations. Taking into consideration the existing data, cranberry consumption may prevent bacterial adherence to uroepithelial cells which reduces the development of UTI. Cranberry consumption could also decreasing UTI related symptoms by suppressing inflammatory cascades as an immunologic response to bacteria invasion. The existing clinical trials suggest that the beneficial effects of cranberry against UTIs seem to be prophylactic by preventing the development of infections; however, they exert low effectiveness in populations at increased risk for contracting UTIs. Additional well-designed, double-blind, placebo-controlled clinical trials that use standardized cranberry products are strongly justified in order to determine the efficiency of cranberry on the prevention of UTIs in susceptible populations. © 2013 Elsevier Inc..</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :43&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84880721691&amp;doi=10.1016%2fj.nutres.2013.05.018&amp;partnerID=40&amp;md5=5b79221ef1772d655a29b52f5b6dd538</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.nutres.2013.05.018</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>429</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">429</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Van Pinxteren, B.</style></author><author><style face="normal" font="default" size="100%">Van Vliet, S. M.</style></author><author><style face="normal" font="default" size="100%">Wiersma, Tj</style></author><author><style face="normal" font="default" size="100%">Goudswaard, A. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Nederlands Huisartsen Genootschap, Afd. Richtlijnontwikkeling en Wetenschap, Postbus 3231, 3502 GE Utrecht, Netherlands</style></auth-address><titles><title><style face="normal" font="default" size="100%">Summary of the practice guideline &apos;Urinary-tract infections&apos; (second revision) from the Dutch College of General Practitioners</style></title><secondary-title><style face="normal" font="default" size="100%">Nederlands Tijdschrift voor Geneeskunde</style></secondary-title><short-title><style face="normal" font="default" size="100%">Samenvatting van de standaard &apos;Urineweginfecties&apos; (tweede herziening) van het Nederlands Huisartsen Genootschap</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nederlands Tijdschrift voor Geneeskunde</style></full-title></periodical><pages><style face="normal" font="default" size="100%">718-722</style></pages><volume><style face="normal" font="default" size="100%">150</style></volume><number><style face="normal" font="default" size="100%">13</style></number><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">The 1999 practice guideline &apos;Urinary-tract infections&apos; from the Dutch College of General Practitioners has been revised. Not only febrile urinary-tract infections are now regarded as &apos;complicated&apos;, but also all urinary-tract infections in men, pregnant women, children, and patients with kidney or urinary-tract disease, impaired immune response or an indwelling catheter. Under certain conditions, in women recognising the symptoms of an earlier uncomplicated urinary-tract infection, treatment may be instituted without performing supplementary urinalysis. The nitrite dipstick test and dipslide culturing are recommended for the diagnosis of urinary-tract infections; the value of the leukocyte esterase dipstick test is limited. A group-B streptococcal urinary-tract infection during pregnancy is an indication for intravenous antibiotic prophylaxis during the delivery. The recommended duration of treatment with nitrofurantoin is extended from three to five days. Both increased bacterial resistance to trimethoprim and the intention to reduce the use of fluoroquinolones in the treatment of uncomplicated urinary-tract infections were reasons for including phosphomycin in the guideline. In addition to antibiotic prophylaxis, cranberry products may be of value in the prevention of recurrent urinary-tract infections.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :20&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33645683618&amp;partnerID=40&amp;md5=660184f583f2523ae6ceaedeecf92360</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>404</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">404</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Valentová, K.</style></author><author><style face="normal" font="default" size="100%">Stejskal, D.</style></author><author><style face="normal" font="default" size="100%">Bednář, P.</style></author><author><style face="normal" font="default" size="100%">Vostálová, J.</style></author><author><style face="normal" font="default" size="100%">Číhalík, Č</style></author><author><style face="normal" font="default" size="100%">Večeřová, R.</style></author><author><style face="normal" font="default" size="100%">Koukalová, D.</style></author><author><style face="normal" font="default" size="100%">Kolář, M.</style></author><author><style face="normal" font="default" size="100%">Reichenbach, R.</style></author><author><style face="normal" font="default" size="100%">Škňouřil, L.</style></author><author><style face="normal" font="default" size="100%">Ulrichová, J.</style></author><author><style face="normal" font="default" size="100%">Šimánek, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Hněvotínská 3, CZ-77515 Olomouc, Czech Republic&#xD;Department of Clinical Biochemistry, Šternberk Hospital, Jívavská 20, CZ-78501 Šternberk, Czech Republic&#xD;Department of Analytical Chemistry, Faculty of Science, Palacký University, Třída Svobody 8, CZ-77146 Olomouc, Czech Republic&#xD;Clinic of Exercise and Sports Medicine, University Hospital, I.P. Pavlova 6, CZ-77520 Olomouc, Czech Republic&#xD;Department of Internal Medicine, Regional Bata Hospital, Havlickovo nabrezi 600, CZ-76001 Zlín, Czech Republic&#xD;Department of Microbiology, Faculty of Medicine and Dentistry, Palacký University, CZ-77515 Olomouc, Czech Republic&#xD;Walmark a.s., Oldřichovice 44, CZ-73961 Třinec, Czech Republic</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biosafety, antioxidant status, and metabolites in urine after consumption of dried cranberry juice in healthy women: A pilot double-blind placebo-controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3217-3224</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adherence</style></keyword><keyword><style face="normal" font="default" size="100%">AOPP</style></keyword><keyword><style face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style face="normal" font="default" size="100%">Blood</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Human study</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolites</style></keyword><keyword><style face="normal" font="default" size="100%">Urine</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">This study assessed the effect of an 8 week consumption of dried cranberry juice (DCJ) on 65 healthy young women. Basic biochemical and hematological parameters, antioxidant status, presence of metabolites in urine, and urine ex vivo antiadherence activity were determined throughout the trial. A 400 mg amount of DCJ/day had no influence on any parameter tested. A 1200 mg amount of DCJ/day resulted in a statistically significant decrease in serum levels of advanced oxidation protein products. This specific protective effect against oxidative damage of proteins is described here for the first time. Urine samples had an inhibitory effect on the adhesion of uropathogenic Escherichia coli strains, but no increase in urine acidity was noted. Hippuric acid, isomers of salicyluric and dihydroxybenzoic acids, and quercetin glucuronide were identified as the main metabolites. In conclusion, cranberry fruits are effective not only in the prevention of urinary tract infection but also for the prevention of oxidative stress. © 2007 American Chemical Society.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :63&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-34247633963&amp;doi=10.1021%2fjf0636014&amp;partnerID=40&amp;md5=16126cef3a959430e94e413b937c8bb3</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/jf0636014</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>364</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">364</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Valdevenito, S. J. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Hospital Clínico Universidad de Chile, Santiago, Chile&#xD;Servicio de Urología, Departamento de Urología</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent urinary tract infection in women</style></title><secondary-title><style face="normal" font="default" size="100%">Revista Chilena de Infectologia</style></secondary-title><short-title><style face="normal" font="default" size="100%">Infección urinaria recurrente en la mujer</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Revista Chilena de Infectologia</style></full-title></periodical><pages><style face="normal" font="default" size="100%">268-276</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">Recurrent urinary tract infections (R-UTI) are common among women even though they generally have a normal urinary tract. Women with R-UTI have an increased susceptibility to vaginal colonization with uropathogens due to a greater propensity for them to adhere to their epithelial cells. Risk factors include frequent sexual intercourse, spermicide use, first UTI at an early age and maternal history of UTI. Prevention of recurrences can be done with low-dose continuous antimicrobial prophylaxis or with post-coital antimicrobial prophylaxis, a method that may be more efficient and acceptable. Estrogen replacement therapy using a vaginal administration in postmenopausal women is also effective in preventing R-UTI. The vaginal vaccine only diminishes percentage of women with Escherichia coli UTI. The oral vaccine reduces R-UTI with inferior results than antimicrobial prophylaxis; Cranberry intake shows some evidence in favor, although further trials are needed. Finally R-UTI can also be effectively managed with self-start antimicrobial therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-49749098387&amp;partnerID=40&amp;md5=709a692688782cc9826f03d693ccb70f</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>413</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">413</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Valcheva-Kuzmanova, S. V.</style></author><author><style face="normal" font="default" size="100%">Belcheva, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Preclinical and Clinical Pharmacology and Biochemistry, Medical University, Varna, Bulgaria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Current knowledge of Aronia melanocarpa as a medicinal plant</style></title><secondary-title><style face="normal" font="default" size="100%">Folia medica</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Folia medica</style></full-title></periodical><pages><style face="normal" font="default" size="100%">11-17</style></pages><volume><style face="normal" font="default" size="100%">48</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">Aronia melanocarpa, native to eastern North America, has become popular in Eastern Europe and Russia. Aronia melanocarpa fruits are one of the richest plant sources of phenolic substances, mainly anthocyanins--glycosides of cyanidin. Anthocyanins are water soluble pigments accounting for the dark blue and even black color of the fruits. Administered orally they can be absorbed as intact glycosides. Aronia melanocarpa fruit juice and anthocyanins derived from the fruits have been studied intensively for the last 15 years. Most of the effects of Aronia melanocarpa anthocyanins are due to their high antioxidative activity. Our investigations have demonstrated a remarkable hepatoprotective, a very good gastroprotective and a pronounced anti-inflammatory effect of Aronia melanocarpa fruit juice in rats as well as a bacteriostatic activity in vitro against Staphylococcus aureus and Escherichia coli and an antiviral activity against type A influenza virus. Research of other authors has demonstrated that Aronia melanocarpa anthocyanins can normalize the carbohydrate metabolism in diabetic patients and in streptozotocin-diabetic rats, have an in vitro antimutagenic activity and exhibit a distinct immunomodulatory activity in human lymphocyte cultures and in patients with breast cancer, suppress the growth of human HT-29 colon cancer cells, inhibit the N-nitrosamine formation in rats and decrease the toxicity and cumulation of cadmium in liver and kidneys. Currently, there are no data in literature about any unwanted and toxic effects of Aronia melanocarpa fruits, juice and extracts.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :48&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-34248553609&amp;partnerID=40&amp;md5=4ea1c510b10502e052013e82edce464c</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>110</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">110</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vahlensieck, W.</style></author><author><style face="normal" font="default" size="100%">Perepanova, T.</style></author><author><style face="normal" font="default" size="100%">Bjerklund Johansen, T. E.</style></author><author><style face="normal" font="default" size="100%">Tenke, P.</style></author><author><style face="normal" font="default" size="100%">Naber, K. G.</style></author><author><style face="normal" font="default" size="100%">Wagenlehner, F. M. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Hospital for Rehabilitation Kurpark-Klinik, Bad Nauheim, Germany&#xD;Department of UTI and Clinical Pharmacology, N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology, Branch of the Nat. Med. Res. Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russian Federation&#xD;Urology Department, Oslo University Hospital, Oslo, Norway&#xD;Department of Urology, Jahn Ference Del-Pesti Korhaz, Budapest, Hungary&#xD;Department of Urology, Technical University of Munich, Munich, Germany&#xD;Clinic for Urology, Pediatric Urology and Andrology, Justus-Liebig University of Giessen, Giessen, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Management of Uncomplicated Recurrent Urinary Tract Infections</style></title><secondary-title><style face="normal" font="default" size="100%">European Urology, Supplements</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Urology, Supplements</style></full-title></periodical><pages><style face="normal" font="default" size="100%">95-101</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Mostly young but also postmenopausal women are often affected by recurrent urinary tract infections (rUTIs), defined as three or more symptomatic UTI episodes per year or two or more UTIs within 6 mo. Approximately 20-30% of women with a UTI have a recurrence. UTIs are associated with considerable morbidity. Treatable predisposing factors in uncomplicated rUTI are rare but have to be considered. According to the 2015 European Association of Urology guidelines, the recommendations for prophylaxis of rUTI are first, behavioral changes and second, nonantimicrobial measures. Antibiotic prophylaxis should only be considered if the former recommendations are not sufficiently effective, to avoid adverse events and the collateral damage of unnecessary long-term antibiotic use. General behavioral recommendations can lower the recurrence rate by about 30%. Of the nonantimicrobial measures, immunoprophylaxis and local estriol substitution are effective to lower the recurrence rate, especially in postmenopausal women. Cranberry products on the market are widely variable and seem to have too low a proanthocyanidin content to prevent rUTI effectively. Other promising modalities need to be tested in further controlled trials to prove their preventive benefit. For long-term antibiotic prophylaxis, oral fosfomycin, nitrofurantoin, trimethoprim, cotrimoxazole, and oral cephalosporins (especially during pregnancy) are recommended. Placebo-controlled studies show a high efficacy of long-term antibiotic prophylaxis, but this strategy does not appear to modify the natural history of rUTI, and most of the studies were performed at a time when antibiotic resistance was not an issue. Patient summary: Women of all ages experience recurrent urinary tract infections (rUTIs) that cause considerable morbidity. Treatable predisposing factors in uncomplicated rUTI are rare but have to be considered. Guidelines for the prophylaxis of rUTI episodes recommend behavioral changes followed by nonantimicrobial measures and only then by antibiotic prophylaxis to avoid adverse events and the collateral damage of unnecessary long-term antibiotic use. Women of all ages experience recurrent urinary tract infections (rUTIs) that cause considerable morbidity. Guidelines for the prophylaxis of rUTI episodes recommend behavioral changes followed by nonantimicrobial measures and only then by antibiotic prophylaxis to avoid adverse events and the collateral damage of unnecessary long-term antibiotic use. © 2016 European Association of Urology.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :8&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84964677453&amp;doi=10.1016%2fj.eursup.2016.04.007&amp;partnerID=40&amp;md5=10bdf5b37febe54a4a247d94f6bda824</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.eursup.2016.04.007</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>196</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">196</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vahlensieck, W.</style></author><author><style face="normal" font="default" size="100%">Bauer, H. W.</style></author><author><style face="normal" font="default" size="100%">Piechota, H. J.</style></author><author><style face="normal" font="default" size="100%">Ludwig, M.</style></author><author><style face="normal" font="default" size="100%">Wagenlehner, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Fachklinik Urologie, Kurpark-Klinik, Kurstraße 41–45, Bad Nauheim, 61231, Germany&#xD;Urologische Praxis München, München, Germany&#xD;Klinik für Urologie, Pädiatrische Urologie und urologische Onkologie, Johannes Wesling-Klinikum Minden, Minden, Germany&#xD;Urologische Praxis Marburg, Marburg, Germany&#xD;Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie, UKGM GmbH, Standort Gießen, Justus-Liebig-Universität Gießen, Gießen, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prophylaxis of recurrent urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Urologe</style></secondary-title><short-title><style face="normal" font="default" size="100%">Prophylaxe rezidivierender Harnwegsinfektionen</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Urologe</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1468-1475</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Alternative prophylactic measures</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Immunization</style></keyword><keyword><style face="normal" font="default" size="100%">Lifestyle modifications</style></keyword><keyword><style face="normal" font="default" size="100%">Long-term prophylaxis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Methods: General recommendations to reduce rUTIs lower the recurrence rate by up to approximately two thirds. Continuous long-term prophylaxis (LP) with low dose antibiotics or single postcoital doses can reduce the recurrence rate of rUTIs to as low as 5%. According to the European Association of Urology guidelines nitrofurantoin, trimethoprim and co-trimoxazole are the first-line drugs and cephalosporins or fluoroquinolones should be restricted to specific indications. Oral and parenteral immunotherapy were found to be effective in several controlled studies for prevention of rUTIs and can be combined with acute antibiotic therapy. Conclusions: Vaginal prophylaxis with estriol has proven its positive effect without serious gynecological side effects and there is also increasing evidence that cranberries prevent rUTIs but the exact mode of this therapy remains to be defined. There are also other promising modalities, such as phytotherapeutics, mannose, urine acidification, influencing bacterial intestinal and vaginal flora and the general immune response by e.g. acupuncture and inpatient rehabilitation, the therapeutic value of which still has to be proven. Background: Recurrent urinary tract infections (rUTI), defined as ≥3 UTIs per year, mostly affect young and postmenopausal women. Treatable predisposing factors are rare. © 2014, Springer-Verlag Berlin Heidelberg.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :6&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84910129051&amp;doi=10.1007%2fs00120-014-3562-9&amp;partnerID=40&amp;md5=f06fb6fc06797826d74b680bb9f8b79f</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00120-014-3562-9</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>391</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">391</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vahlensieck, W.</style></author><author><style face="normal" font="default" size="100%">Bauer, H. W.</style></author><author><style face="normal" font="default" size="100%">Hoyme, U. B.</style></author><author><style face="normal" font="default" size="100%">Ludwig, M.</style></author><author><style face="normal" font="default" size="100%">Naber, K. G.</style></author><author><style face="normal" font="default" size="100%">Wagenlehner, F.</style></author><author><style face="normal" font="default" size="100%">Weidner, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Rehabilitationsklinik Wildetal, Bad Wildungen, Germany&#xD;Urologische Praxis, München, Germany&#xD;Klinik für Frauenheilkunde und Geburtshilfe, HELIOS Klinikum, Erfurt, Germany&#xD;Urologische Praxis Dresden Dres. A. Von Keitz, M. Schwickardi M. Ludwig, Marburg, Germany&#xD;Prof. Dr. Med. Kurt G. Naber, Straubing, Germany&#xD;Klinik und Poliklinik für Urologie und Kinderurologie, Universitätskliniken Gießen und Marburg, Standort Gießen, Germany&#xD;Abteilung Urologie/Onkologie/Nephrologie, Klinik Wildetal, Mühlenstraße 8, D-34537 Bad Wildungen, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prophylaxis of recurrent urinary tract infections (rUTI)</style></title><secondary-title><style face="normal" font="default" size="100%">Nieren- und Hochdruckkrankheiten</style></secondary-title><short-title><style face="normal" font="default" size="100%">Prophylaxe rezidivierender harnwegsinfektionen (RHWI)</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nieren- und Hochdruckkrankheiten</style></full-title></periodical><pages><style face="normal" font="default" size="100%">501-513</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acidifying the urine</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberries</style></keyword><keyword><style face="normal" font="default" size="100%">Life-style</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Side effects</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTI) are among the most frequent bacterial infections in women. Mostly young and, to some extend, postmenopausal women are affected by recurrent UTI (rUTI) defined as ≥ 3 UTI/year. Modifiable predisposing factors are rare. General recommendations to prevent recurrent urinary tract infections (rUTI) result in about one third patients remaining free of recurrences. Antibiotic prophylaxis has emerged as one of the most important therapeutic principles in rUTI. Depending on the drug utilized the various principles of action are described as reducing the number of uropathogens in the gut and vaginal flora, respectively, and/or in repeatedly eliminating bacteria from the urine. According to the EAU guidelines nitrofurantoin, trimethoprim, and cotrimoxazole are available as first-line drugs. Cephalexin and the quinolones should be restricted to specific indications. Depending on the case, long-term antibiotic prophylaxis for 6 months, postcoital single dose prophylaxis, or patient-initiated self-start therapy all can be used successfully. Given the correct indication, the recurrence rate of rUTI can be reduced by 95%. Urine acidifying or oral and parenteral immunotherapy were effective in several controlled studies for prevention of rUTI. These therapies can be combined with acute antibiotic therapy. Also there is increasing evidence that cranberries prevent rUTI, the exact mode (juice, tablets or preserved berries), dosage and duration of this therapy remain to be defined. Vaginal prophylaxis with oestriol has proven its positive effect without serious gynaecological side effects. There are also other therapy modalities such as changing bacterial gut flora and general immune response (acupuncture, inpatient rehabilitation). © 2007 Dustri-Verlag Dr. Karl Feistle.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-36148970094&amp;partnerID=40&amp;md5=e606202ccdb5e552ad434d8b30a5811d</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>428</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">428</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vahlensieck, W.</style></author><author><style face="normal" font="default" size="100%">Bauer, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Abteilung Urologie-Onkologie-Nephrologie, Klink Wildetal, Bad Wildungen, Germany&#xD;Abteilung Urologie-Onkologie-Nephrologie, Klink Wildetal, Mühlenstraße 8, 34537 Bad Wildungen, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevention and alternative methods for prophylaxis of recurrent urinary tract infections in women</style></title><secondary-title><style face="normal" font="default" size="100%">Urologe - Ausgabe A</style></secondary-title><short-title><style face="normal" font="default" size="100%">Vorbeugung und alternative methoden der prophylaxe rezidivierender harnweginfektionen der frau</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Urologe - Ausgabe A</style></full-title></periodical><pages><style face="normal" font="default" size="100%">443-450</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acidifying the urine</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberries</style></keyword><keyword><style face="normal" font="default" size="100%">Life style</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">General recommendations to prevent recurrent urinary tract infections (rUTI) result in about one-third of patients remaining free of recurrences. Oral and parenteral immunotherapy were effective in several controlled studies for prevention of rUTI. These therapies can be combined with acute antibiotic therapy. Vaginal prophylaxis with oestriol has proven its positive effect without serious gynaecological side effects. Also there is increasing evidence that cranberries prevent rUTI. The exact mode (juice, tablets or preserved berries), dosage and duration of this therapy remain to be defined.There are also promising therapy modalities such as changing bacterial gut flora, general immune response (acupuncture, inpatient rehabilitation) and urine acidity. © Springer Medizin Verlag 2006.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33646258014&amp;doi=10.1007%2fs00120-006-1013-y&amp;partnerID=40&amp;md5=8b6d2f81d205160033ccf083351ab8b4</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00120-006-1013-y</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>160</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">160</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vahlensieck, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Fachklinik Urologie, Kurpark-Klinik, Kurstraße 41-45, Bad Nauheim, D-61231, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Therapy strategies in recurrent urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">Nieren- und Hochdruckkrankheiten</style></secondary-title><short-title><style face="normal" font="default" size="100%">Therapiestrategien bei chronisch rezidivierenden Harnwegsinfektionen</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nieren- und Hochdruckkrankheiten</style></full-title></periodical><pages><style face="normal" font="default" size="100%">299-306</style></pages><volume><style face="normal" font="default" size="100%">44</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Alternative prophylactic measures</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Behavioral modifications</style></keyword><keyword><style face="normal" font="default" size="100%">Immunization</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent urinary tract infection (rUTI)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Young and postmenopausal women are often affected by recurrent urinary tract infections (rUTI), defined as ≥ 3 UTI/year. Treatable predisposing factors are rare. General recommendations lower the recurrence rate (RT) by ~ 30%. Continuous long-term prophylaxis (LP) with low dose antibiotics or postcoital single dose can reduce the RT of rUTI to as deep as 5%. The European Association of Urology guideline recommends fosfomycin, nitrofurantoin, trimethoprim and co-trimoxazole as first-line drugs and cephalexin or fluoroquinolones for specific indications. Oral and parenteral immunotherapies were effective to lower the RT of rUTI. Vaginal estriol for postmenopausal women has proven its positive effect without serious gynecological side effects. Cranberry products on the market seem to have a too low proanthocyanidin content to prevent rUTI effectively. Other promising modalities have to be tested in further controlled trials to prove their therapeutical benefit. © 2015 Dustri-Verlag Dr. Karl Feistle.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84938862669&amp;doi=10.5414%2fNHX01723&amp;partnerID=40&amp;md5=48d878c9511fde2efe8643d01786c3ba</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.5414/NHX01723</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>186</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">186</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Urrútia, G.</style></author><author><style face="normal" font="default" size="100%">Selva, A.</style></author><author><style face="normal" font="default" size="100%">Calaf, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Servei d&apos;Epidemiologia Clínica i Salut Pública, Hospital de la Santa Creu i Sant Pau (IIB Sant Pau), Barcelona, Spain&#xD;Servei de Ginecologia i Obstetricia, Hospital de la Santa Creu i Sant Pau (IIB Sant Pau), Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Review of the evidence on the efficacy of probiotics in the prevention of lower urinary tract infections and vaginal infections</style></title><secondary-title><style face="normal" font="default" size="100%">Progresos de Obstetricia y Ginecologia</style></secondary-title><short-title><style face="normal" font="default" size="100%">Revisión de la evidencia sobre la eficacia de los probióticos en la prevención de las infecciones del tracto urinario inferior y las infecciones vaginales</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Progresos de Obstetricia y Ginecologia</style></full-title></periodical><pages><style face="normal" font="default" size="100%">230-235</style></pages><volume><style face="normal" font="default" size="100%">57</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Female urogenital diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Genitourinary infections</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Objectives: To identify, critically evaluate and describe the available scientific evidence on the efficacy and safety of oral or vaginal administration of probiotics in preventing recurrent urinary tract infections and microbial or fungal vaginal infections. Methods: An electronic search was performed in PubMed Central, the Cochrane Library and the meta-searcher TRIP databases using the terms: &quot;. Lactobacillus&quot;, &quot;probiotics&quot;, &quot;female urogenital diseases&quot;, &quot;urinary tract infections&quot; and &quot;genitourinary infections&quot;. Results: Of 20 studies that met the selection criteria for this review, a tendency to favor the use of probiotics was observed, especially in the population at high risk of bacterial vaginosis and fungal vulvovaginitis. Conclusions: Probiotics are a promising option in the prevention of recurrences of lower urinary tract infections. Their use can be recommended as a safe and cost effective option especially in high risk subgroups. © 2012 SEGO.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Short Survey</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84899484449&amp;doi=10.1016%2fj.pog.2012.09.002&amp;partnerID=40&amp;md5=957267a7724d1eaab4353c5443c13f21</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.pog.2012.09.002</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>159</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">159</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Uberos, J.</style></author><author><style face="normal" font="default" size="100%">Rodríguez-Belmonte, R.</style></author><author><style face="normal" font="default" size="100%">Rodríguez-Pérez, C.</style></author><author><style face="normal" font="default" size="100%">Molina-Oya, M.</style></author><author><style face="normal" font="default" size="100%">Blanca-Jover, E.</style></author><author><style face="normal" font="default" size="100%">Narbona-Lopez, E.</style></author><author><style face="normal" font="default" size="100%">Muñoz-Hoyos, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unit of Clinical Paediatrics, San Cecilio University Hospital, Granada, 18012, Spain&#xD;Unit of Clinical Paediatrics, St Mary&apos;s Hospital, Imperial College NHS Trust, Praed Street, QEQM Wing, London, W2 NY1, United Kingdom&#xD;Research and Development Functional Food Centre (CIDAF), Health Science Technological Park, Avenida del Conocimiento s/n, Edificio BioRegión, Granada, 18017, Spain&#xD;Department of Analytical Chemistry, Faculty of Sciences, University of Granada, Avenida Fuentenueva s/n, Granada, 18071, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Phenolic acid content and antiadherence activity in the urine of patients treated with cranberry syrup (Vaccinium macrocarpon) vs. trimethoprim for recurrent urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Functional Foods</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Functional Foods</style></full-title></periodical><pages><style face="normal" font="default" size="100%">608-616</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Biofilm</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">E. coli</style></keyword><keyword><style face="normal" font="default" size="100%">Phenolic acid</style></keyword><keyword><style face="normal" font="default" size="100%">Surface hydrophobicity</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">The effectiveness of cranberry in the treatment of urinary tract infection (UTI) has been associated with its polyphenol content, particularly proanthocyanidins (PACs) and the inhibition of adherence of Escherichia coli to the uroepithelium. This paper describes a controlled, double blind, clinical trial of children aged over one month with recurrent urinary tract infection. The study aims were to evaluate the safety and efficacy of cranberry syrup in children and to investigate the relationship between the excretion of phenolic acids in urine with the antiadherent activity of cranberry syrup.In the study population, cranberry syrup was found to be similar to trimethoprim, with a rate of UTI (reinfection) of 26% (95% CI 12-41). The administration of cranberry syrup was associated with high levels of hydroxycinnamic and hydroxybenzoic acids in urine; in both cases these molecules present activity in the biofilm inhibition or reduction of surface hydrophobicity of E. coli (Clinical Trials Registry ISRCTN16968287). © 2015 Elsevier Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84942511646&amp;doi=10.1016%2fj.jff.2015.08.009&amp;partnerID=40&amp;md5=8061af14b5aadc299b8ba85eb018cb44</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">1256</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jff.2015.08.009</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>251</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">251</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Uberos, J.</style></author><author><style face="normal" font="default" size="100%">Nogueras-Ocana, M.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Puentes, V.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Belmonte, R.</style></author><author><style face="normal" font="default" size="100%">Narbona-López, E.</style></author><author><style face="normal" font="default" size="100%">Molina-Carballo, A.</style></author><author><style face="normal" font="default" size="100%">Munoz-Hoyos, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Paediatric Clinical Management Unit, San Cecilio University Clinical Hospital, Avda de Madrid s/n, Granada, Spain&#xD;Paediatric Urology, San Cecilio University Clinical Hospital, Avda de Madrid s/n, Granada, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry syrup vs trimethoprim in the prophylaxis of recurrent urinary tract infections among children: A controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Open Access Journal of Clinical Trials</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Open Access Journal of Clinical Trials</style></full-title></periodical><pages><style face="normal" font="default" size="100%">31-38</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Antibiotic prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Trimethoprim</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">Vesicoureteral reflux</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Objectives: The present study forms part of the ISRCTN16968287 clinical assay. The objective of this study was to determine the effectiveness of cranberry syrup in the prophylaxis of recurrent urinary tract infection (UTI). Design: Phase III randomized clinical trial. Setting: The study was conducted at the San Cecilio Clinical Hospital (Granada, Spain). Participants: A total of 192 patients were recruited. The subjects were aged between 1 month and 13 years. Criteria for inclusion were a background of recurrent UTI (more than two episodes of infection in the last 6 months), associated or otherwise with vesicoureteral reflux of any degree, or renal pelvic dilatation associated with UTI. Criteria for exclusion from recruitment to the study included the co-existence of UTI with other infectious diseases or with metabolic diseases, chronic renal insufficiency, and the presence of allergy or intolerance to any of the components of cranberry syrup or trimethoprim. Primary outcome measures: The primary objective was to determine the risk of UTI associated with each intervention. Results: Of the 198 patients initially eligible, 192 were finally included in the study to receive either cranberry syrup or trimethoprim. UTI was observed in 47 patients, 17 of whom were males and 30 females. We recruited 95 patients diagnosed with recurrent UTI on entry; during follow-up, 26 patients had a UTI (27.4%, 95% CI: 18.4%-36.3%). Six patients (6.3%) were male and 20 (21.1%) were female. Eighteen patients (18.9% of the total, 95% CI: 11%-26.3%) receiving trimethoprim had a UTI and eight patients (8.4% of the total, 95% CI: 2.8%-13.9%) were given cranberry. Sixty-six percent of the episodes of UTI recurrence were caused by Escherichia coli, with no significant differences being found between the two treatment branches. No differences were observed between the two treatment branches in the rate of resistance to antibiotics. Conclusion: Our study confirms that cranberry syrup is a safe treatment for the pediatric population. Cranberry prophylaxis has noninferiority with respect to trimethoprim in recurrent UTI. (European Clinical Trials Registry EuDract 2007-004397-62) (ISRCTN16968287). © 2012 Uberos et al, publisher and licensee Dove Medical Press Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :11&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84862572621&amp;doi=10.2147%2fOAJCT.S31734&amp;partnerID=40&amp;md5=a9ed06a5b9e6dbd6196c41e8c30527fa</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2147/OAJCT.S31734</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>576</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">576</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Twaij, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Paediatric Department, East Surrey Hospital, Redhill, Surrey RH1 5RH, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infection in children: A review of its pathogenesis and risk factors</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of The Royal Society for the Promotion of Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of The Royal Society for the Promotion of Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">220-226</style></pages><volume><style face="normal" font="default" size="100%">120</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Dysuria</style></keyword><keyword><style face="normal" font="default" size="100%">Frequency</style></keyword><keyword><style face="normal" font="default" size="100%">Reflux nephropathy (RN)</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection (UTI)</style></keyword><keyword><style face="normal" font="default" size="100%">Vesico-ureteric reflux (VUR)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2000</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infection (UTI) is one of the commonest bacterial infections seen in children, ranking second only to those of the respiratory tract. A steady flow of urine, complete emptying of the bladder and various host defences provide the principal means of protection. Urinary stasis, on the other hand, provides an opportunistic environment for bacterial multiplication; several other factors also contribute to UTI, such as urinary obstruction, vesico-ureteric reflux (VUR) and other urinary tract malformations. UTI, especially in the presence of VUR, may lead to scarring of the kidney and progressive renal disease. It is vital, therefore, to diagnose such anomalies at an early stage, the overall aim being to identify those at high risk so that measures may be taken to prevent serious complications and preserve renal function. Those at low risk of UTI, however, should not be over investigated; this is in order to keep invasive procedures down to a minimum. Whenever possible, the management of high risk cases is best discussed between paediatrician, microbiologist, radiologist, urologist and the general practitioner.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :29&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034534275&amp;doi=10.1177%2f146642400012000408&amp;partnerID=40&amp;md5=9e361df6a7107e87fe2f27ac6970c9f7</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/146642400012000408</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>373</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">373</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Trinkaus, M.</style></author><author><style face="normal" font="default" size="100%">Chin, S.</style></author><author><style face="normal" font="default" size="100%">Wolfman, W.</style></author><author><style face="normal" font="default" size="100%">Simmons, C.</style></author><author><style face="normal" font="default" size="100%">Clemons, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Hematology and Medical Oncology, Princess Margaret Hospital, Toronto, ON, Canada&#xD;Department of Obstetrics and Gynaecology, Mount Sinai Hospital, Toronto, ON, Canada&#xD;Princess Margaret Hospital, 610 University Avenue, Toronto, ON M5G 2M9, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?</style></title><secondary-title><style face="normal" font="default" size="100%">Oncologist</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Oncologist</style></full-title></periodical><pages><style face="normal" font="default" size="100%">222-231</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aromatase inhibitor</style></keyword><keyword><style face="normal" font="default" size="100%">Breast cancer</style></keyword><keyword><style face="normal" font="default" size="100%">Estrogen replacement therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Tamoxifen</style></keyword><keyword><style face="normal" font="default" size="100%">Toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Urogenital atrophy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">Breast cancer survivors represent a unique patient population with a high prevalence of menopausal symptoms. Given the improved longevity of cancer patients, the consequences of menopause have become an increasingly important and challenging management issue. To date, considerable attention has been paid to the management of menopausal vasomotor symptoms and bone health among breast cancer patients. As a result, numerous nonhormonal treatment options have been developed for the management of these issues. The treatment of urogenital symptoms among this population is poorly understood and relatively understudied. Although systemic or topical estrogen replacement is the most effective method for treating hypoestrogenemic urogenital symptoms, women with a prior diagnosis of breast cancer are cautioned from taking exogenous estrogens in order to avoid a potential contribution to recurrent breast cancer risk. This review focuses on the urogenital consequences of estrogen deprivation therapy in breast cancer patients and provides practitioners with a simple guide of current and future strategies for managing these symptoms. ©AlphaMed Press.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :48&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-43549105380&amp;doi=10.1634%2ftheoncologist.2007-0234&amp;partnerID=40&amp;md5=fc8d35de6239b4fb96481458f5ac7434</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1634/theoncologist.2007-0234</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>470</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">470</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Trautner, B. W.</style></author><author><style face="normal" font="default" size="100%">Hull, R. A.</style></author><author><style face="normal" font="default" size="100%">Darouiche, R. O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, TX, United States&#xD;Department of Physical Medicine and Rehabilitation, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, TX, United States&#xD;Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States&#xD;Spinal Cord Injury (128), MEDVAMC, 2002 Holcombe Boulevard, Houston, TX 77030, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevention of catheter-associated urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">Current Opinion in Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Opinion in Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">37-41</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Biofilm</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary catheter</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">Purpose of review: The underlying cause of catheter-associated urinary tract infection is biofilm formation by uropathogens on the urinary catheter. Biofilm is a relatively new concept in medicine, and current measures to prevent biofilm formation are inadequate. Considerable work is being done in this area, but little clinical progress has been made. The purpose of this review is to analyze recent publications concerning prevention of catheter-associated urinary tract infection. Recent findings: Several recent studies have elucidated aspects of biofilm formation in catheter-associated urinary tract infection. Other researchers are working on methods to disrupt biofilm formation on catheter surfaces. At the same time, the magnitude of the problem of catheter-associated urinary tract infection has increased awareness of the effectiveness of basic infection control measures. A modern approach to infection control may include computerized ordering systems that minimize unnecessary days of catheterization. Finally, consumption of cranberry juice products and bacterial interference are two novel approaches to urinary tract infection prevention. Summary: Biofilm-disrupting strategies offer promise for the future but have little immediate applicability. Implementation of infection control measures to improve catheter function and remove unnecessary catheters can be done at the present time. In general, prevention of catheter-associated urinary tract infection remains an elusive goal. More basic research at the level of pathogenesis is needed so that novel strategies can be designed. © 2005 Lippincott Williams &amp; Wilkins.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :61&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-17544368146&amp;doi=10.1097%2f00001432-200502000-00007&amp;partnerID=40&amp;md5=7f0413abc0655ea3f4eb1b62332c5903</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/00001432-200502000-00007</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>460</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">460</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Toughill, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Visiting Nurse Association, Central Jersey Community Health Center, Asbury Park, NJ, United States&#xD;Visiting Nurse Association, Central Jersey Community Health Center, Keyport, NJ, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Indwelling urinary catheters</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Nursing</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Nursing</style></full-title></periodical><pages><style face="normal" font="default" size="100%">35-37</style></pages><volume><style face="normal" font="default" size="100%">105</style></volume><number><style face="normal" font="default" size="100%">5</style></number><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :14&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Short Survey</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-18644362693&amp;doi=10.1097%2f00000446-200505000-00025&amp;partnerID=40&amp;md5=f21c1a201c9ed4250f124e829037d83b</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/00000446-200505000-00025</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>113</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">113</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tian, Y.</style></author><author><style face="normal" font="default" size="100%">Cai, X.</style></author><author><style face="normal" font="default" size="100%">Wazir, R.</style></author><author><style face="normal" font="default" size="100%">Wang, K.</style></author><author><style face="normal" font="default" size="100%">Li, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China&#xD;Department of Urology, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, China&#xD;Field Hospital, Mari Petroleum Company Limited, District Ghotki, Daharki, Sindh, Pakistan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Water consumption and urinary tract infections: an in vitro study</style></title><secondary-title><style face="normal" font="default" size="100%">International Urology and Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Urology and Nephrology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">949-954</style></pages><volume><style face="normal" font="default" size="100%">48</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adjuvant therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">Water consumption</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Objectives: To address to a better understanding of whether increased water consumption is associated with beneficial effects of urinary tract infections prophylaxis and treatment, and if so, the mechanism involved in this process. Methods: Models of the catheterized bladder were infected with Escherichia coli. Artificial urine was supplied at various flow rates and various concentrations to separately assess the “flushing effect” and “dilution effect” of increased water consumption on catheter blockage time, encrustation formation, and bacterial growth. Results: There were no statistical significances regarding catheter blockage time (P = 0.92), encrustation formation, and bacterial growth among bladder models supplied with various flow rates. When the flow rate was set as 1 ml/min, however, there showed significant decrease trend of the time to blockage (P = 0.0005), encrustation formation, and bacterial growth as the concentration of the artificial urine increased except the twofold-concentration urine group. Conclusions: Increased water consumption is associated with beneficial effects of urinary tract infection prophylaxis and treatment, and dilution effect of bacteria nutrition in the urine is at least partly involved in this process if not all, rather than the “flushing effect”. Considering the flaws and the in vitro design of the current study, however, an in vivo study is warranted. © 2016, Springer Science+Business Media Dordrecht.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84961205525&amp;doi=10.1007%2fs11255-016-1262-7&amp;partnerID=40&amp;md5=c4d6712c26564074ef378393d16135f2</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s11255-016-1262-7</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>14</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">14</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Thi, N. D.</style></author><author><style face="normal" font="default" size="100%">Hwang, E. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Nutrition and Culinary Science, Hankyong National University, 327 Chungang-ro, Anseong-si, Gyeonggi-do, 456-749, South Korea</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anti-cancer and anti-inflammatory activities of aronia (Aronia melanocarpa) leaves</style></title><secondary-title><style face="normal" font="default" size="100%">Asian Pacific Journal of Tropical Biomedicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Asian Pacific Journal of Tropical Biomedicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">586-592</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aronia leaf</style></keyword><keyword><style face="normal" font="default" size="100%">Cancer</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Lipopolysaccharides-induced</style></keyword><keyword><style face="normal" font="default" size="100%">Metatasis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: To determine the anti-cancer effect of aronia leaf extract on SK-Hep1 cells using migration, metallo metrix proteinase-2/-9 (MMP-2/-9) and MT-1 MMP expression and to evaluate the anti-inflammatory activities of the leaf extract. Methods: The effect of aronia leaf extract on cancer prevention was investigated. SK-Hep1 human liver cancer cell line was treated with aronia leaf extract at various concentractions. MTT assay was used to measure cancer cell growth inhibition, and wound migration assay was used for metastasis determination. The expression of MMP-2/-9 was measured at the protein level using zymography and the expression of MMP-2/-9 and MT-1 MMP was examined at the gene level by RT-PCR. Raw 264.7 macrophage cells were stimulated with lipopolysaccharides to induce inflammation, and then the inhibition of inflammation was evaluated by treatment of aronia leaf extract. Expressions of interleukin-6, tumor factor-α, and nitric oxide (NO) were also determined. Results: SK-Hep1 cell growth was inhibited in proportion to the concentration of aronia leaf extract. In migration assay, aronia leaf extract showed 61.3%-96.3% wound size inhibtion after treating 50-200 μg/mL of aronia leaf extract for 24 h. At the protein level, the expression of MMP-2 and MMP-9 decreased as the concentration of aronia leaf extract treated with SK-Hep1 cells increased. In addition, the same pattern as in the protein was also observed in the mRNA levels. The expressions of MMP-2 and MMP-9 protein were inhibited by 92.2% and 53.8%, respectively after treatment with 200 μg/mL aronia leaf extract. In addition, Raw 264.7 cells treated with aronia leaf extract did not affect cell survival. There was dose dependent inhibition of interleukine-6, tumor necrosis factor-α and nitric oxide after treating aronia leaf extract in lipopolysaccharides-treated Raw 264.7 cell. Conclusions: The results show that aronia leaf has anticancer and and antimetastatic properties in SK-Hep1 and Raw 264.7 cells. © 2018 Asian Pacific Journal of Tropical Biomedicine Produced by Wolters Kluwer Medknow.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059486143&amp;doi=10.4103%2f2221-1691.248095&amp;partnerID=40&amp;md5=ab208346dfbcfb49263207366b67e66d</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.4103/2221-1691.248095</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>354</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">354</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Teughels, W.</style></author><author><style face="normal" font="default" size="100%">Van Essche, M.</style></author><author><style face="normal" font="default" size="100%">Sliepen, I.</style></author><author><style face="normal" font="default" size="100%">Quirynen, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Probiotics and oral healthcare</style></title><secondary-title><style face="normal" font="default" size="100%">Periodontology 2000</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Periodontology 2000</style></full-title></periodical><pages><style face="normal" font="default" size="100%">111-147</style></pages><volume><style face="normal" font="default" size="100%">48</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :67&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-49349099557&amp;doi=10.1111%2fj.1600-0757.2008.00254.x&amp;partnerID=40&amp;md5=59e0e9f5ea59f7d4d1be2ef3ddd94ca6</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1600-0757.2008.00254.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>569</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">569</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Terris, M. K.</style></author><author><style face="normal" font="default" size="100%">Issa, M. M.</style></author><author><style face="normal" font="default" size="100%">Tacker, J. Ronald</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Stanford University Medical Center, Stanford, United States&#xD;Section of Urology, Palo Alto Veterans Affairs Health Care System, Palo Alto, United States&#xD;Department of Urology, Emory University School of Medicine, Atlanta, Georgia, United States&#xD;Division of Urology, Santa Clara Valley Medical Center, San Jose, United States&#xD;Section of Urology (112C), Veterans Affairs Palo Alto Heath Care System, 3801 Miranda Avenue, Palo Alto, CA 94304, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis</style></title><secondary-title><style face="normal" font="default" size="100%">Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">26-29</style></pages><volume><style face="normal" font="default" size="100%">57</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2001</style></year></dates><abstract><style face="normal" font="default" size="100%">Objectives. Cranberry juice has been recommended for patients with recurrent urinary tract infections. However, cranberry juice has a moderately high concentration of oxalate, a common component of kidney stones, and should be limited in patients with a history of nephrolithiasis. Cranberry concentrate tablets are currently available at nutrition stores and are sold as promoters of urinary tract health. After one of our patients with a distant history of calcium oxalate nephrolithiasis developed recurrent stones following self-administration of cranberry concentrate tablets, we sought to investigate the potential lithogenic properties of cranberry supplements. Methods. Five healthy volunteers on a normal diet provided 24-hour urine collection for pH, volume, creatinine, oxalate, calcium, phosphate, uric acid, sodium, citrate, magnesium, and potassium. Cranberry tablets were administered to these volunteers at the manufacturer&apos;s recommended dosage for 7 days. On the seventh day, a second 24-hour urine collection was obtained. Results. The urinary oxalate levels in the volunteers significantly increased (P = 0.01) by an average of 43.4% while receiving cranberry tablets. The excretion of potential lithogenic ions calcium, phosphate, and sodium also increased. However, inhibitors of stone formation, magnesium and potassium, rose as well. Conclusions. Cranberry concentrate tablets are marketed for urinary tract ailments. Physicians and manufacturers of cranberry products should make an effort to educate patients at risk for nephrolithiasis against ingestion of these dietary supplements. Copyright © 2001 Elsevier Science Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :86&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035148122&amp;doi=10.1016%2fS0090-4295%2800%2900884-0&amp;partnerID=40&amp;md5=89a15f050616b5df55288343f8e09c6c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0090-4295(00)00884-0</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>70</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">70</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Terlizzi, M. E.</style></author><author><style face="normal" font="default" size="100%">Gribaudo, G.</style></author><author><style face="normal" font="default" size="100%">Maffei, M. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Life Sciences and Systems Biology, University of Turin, Torino, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">UroPathogenic Escherichia coli (UPEC) infections: Virulence factors, bladder responses, antibiotic, and non-antibiotic antimicrobial strategies</style></title><secondary-title><style face="normal" font="default" size="100%">Frontiers in Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Frontiers in Microbiology</style></full-title></periodical><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">AUG</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Bladder</style></keyword><keyword><style face="normal" font="default" size="100%">Non-antibiotic remedies</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">Uropathogenic Escherichia coli</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTIs) are one of the most common pathological conditions in both community and hospital settings. It has been estimated that about 150 million people worldwide develop UTI each year, with high social costs in terms of hospitalizations and medical expenses. Among the common uropathogens associated to UTIs development, UroPathogenic Escherichia coli (UPEC) is the primary cause. UPEC strains possess a plethora of both structural (as fimbriae, pili, curli, flagella) and secreted (toxins, iron-acquisition systems) virulence factors that contribute to their capacity to cause disease, although the ability to adhere to host epithelial cells in the urinary tract represents the most important determinant of pathogenicity. On the opposite side, the bladder epithelium shows a multifaceted array of host defenses including the urine flow and the secretion of antimicrobial substances, which represent useful tools to counteract bacterial infections. The fascinating and intricate dynamics between these players determine a complex interaction system that needs to be revealed. This review will focus on the most relevant components of UPEC arsenal of pathogenicity together with the major host responses to infection, the current approved treatment and the emergence of resistant UPEC strains, the vaccine strategies, the natural antimicrobial compounds along with innovative anti-adhesive and prophylactic approaches to prevent UTIs. © 2017 Terlizzi, Gribaudo and Maffei.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :16&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85027726949&amp;doi=10.3389%2ffmicb.2017.01566&amp;partnerID=40&amp;md5=5e51726f74a3bc21edbd344eeb6f8901</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">1566</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.3389/fmicb.2017.01566</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>316</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">316</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tempera, G.</style></author><author><style face="normal" font="default" size="100%">Corsello, S.</style></author><author><style face="normal" font="default" size="100%">Genovese, C.</style></author><author><style face="normal" font="default" size="100%">Caruso, F. E.</style></author><author><style face="normal" font="default" size="100%">Nicolosi, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiological and Gynaecological Sciences, University of Catania, Via Androne 81, 95124 Catania, Italy&#xD;Gynaecology Unit, S.S. Paternò Hospital, Catania, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inhibitory activity of cranberry extract on the bacterial adhesiveness in the urine of women: An ex-vivo study</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Immunopathology and Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Immunopathology and Pharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">611-618</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-adhesiveness activity</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry extract</style></keyword><keyword><style face="normal" font="default" size="100%">E. coli</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent cystitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><abstract><style face="normal" font="default" size="100%">Strains of uropathogenic E. coli are responsible for approximately 90% of community-acquired, uncomplicated cystitis, and fimbriae represent the adhesive factors enabling E. coli to be anchored to uroepithelial cells in the first step of the infectious process. Recently, a few studies have shown that a correlation between the consumption of cranberry (Vaccinium macrocarpon) and prevention of UTI is related to the ability of proanthocyanidins to reduce the bacterial adhesion to uroepithelial cells. In this study we evaluate the inhibitory activity of urine of healthy women treated with tablets containing cranberry extract on the adhesiveness of E. coli to uroepithelial human cells. Two groups of 12 female volunteers each, aged between 18 and 65 years, were enrolled, one group with negative history and one group with positive history of recurrent cystitis. Subjects were treated with the active product or placebo in a random, cross-over, double-blinded sequence for one week in each of the two treatment sequences. Urine samples were collected at the beginning and the end of each study period. Tests of bacterial adhesiveness were performed with two strains of E. coli (ATCC 25922 and ATCC 35218) on HT1376 human bladder carcinoma cells. Significant reductions of bacterial adhesiveness were observed in women who received cranberry extract (-50.9%; p&lt;0.0001), regardless of their medical history and the treatment period in the cross-over sequence. No changes were observed with placebo (-0.29%; n.s.). This ex-vivo study showed that the assumption of cranberry extract in suitable amounts can have an anti-adhesive activity on uropathogenic E. coli. Copyright © by BIOLIFE, s.a.s.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :15&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-77955342928&amp;doi=10.1177%2f039463201002300223&amp;partnerID=40&amp;md5=2f1c8216b1ee85860a9473ad5698ba19</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/039463201002300223</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>50</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">50</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Teichmann-Knorrn, S.</style></author><author><style face="normal" font="default" size="100%">Dorsch, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medizinische Kleintierklinik, Ludwig-Maximilians-Universität München, München, 80539, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Significant bacteriuria in cats: Urinary tract infection and subclinical bacteriuria: A current review</style></title><secondary-title><style face="normal" font="default" size="100%">Tierarztliche Praxis Ausgabe K: Kleintiere - Heimtiere</style></secondary-title><short-title><style face="normal" font="default" size="100%">Signifikante Bakteriurie der Katze: bakterielle Harnwegsinfektion und subklinische Bakteriurie: Eine aktuelle Übersicht</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Tierarztliche Praxis Ausgabe K: Kleintiere - Heimtiere</style></full-title></periodical><pages><style face="normal" font="default" size="100%">247-259</style></pages><volume><style face="normal" font="default" size="100%">46</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">antimicrobial resistance</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">asymptomatic bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">feline</style></keyword><keyword><style face="normal" font="default" size="100%">feline lower urinary tract disease (FLUTD)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infection (UTI) refers to the adherence and multiplication of an infectious agent within the urinary system. In 8-19 % of cats with clinical signs of lower urinary tract disease, bacterial UTI is identified as a cause. Subclinical bacteriuria is defined as the isolation of a significant number of bacteria in a urine specimen obtained from a patient without symptoms related to UTI. Subclinical bacteriuria has been reported in 1-29 % of cats. The most commonly isolated pathogen in feline urine is Escherichia coli. Other frequently isolated microorganisms are Streptococcus species (spp.), Enterococcus spp. and Staphylococcus spp. Antimicrobials are frequently used to treat UTIs. To prevent the development of antibiotic resistance, results of urine culture and susceptibility testing should be first obtained and antimicrobials with a narrow spectrum of activity should be used. Currently, there is insufficient evidence as to whether subclinical bacteriuria in cats should be treated or not. However, treatment of subclinical bacteriuria is only recommended in patients with an increased risk of ascending infections. © Georg Thieme Verlag KG 2018.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052704725&amp;doi=10.15654%2fTPK-180521&amp;partnerID=40&amp;md5=3a5e546aec213becd93de0669c1dd52a</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.15654/TPK-180521</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>174</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">174</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tapiainen, T.</style></author><author><style face="normal" font="default" size="100%">Paalanne, N.</style></author><author><style face="normal" font="default" size="100%">Arkkola, T.</style></author><author><style face="normal" font="default" size="100%">Renko, M.</style></author><author><style face="normal" font="default" size="100%">Pokka, T.</style></author><author><style face="normal" font="default" size="100%">Kaijalainen, T.</style></author><author><style face="normal" font="default" size="100%">Uhari, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Oulu University Hospital, Oulu, Finland&#xD;Department of Pediatrics, University of Oulu, Oulu, Finland&#xD;National Institute for Health and Welfare, Oulu, Finland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diet as a risk factor for pneumococcal carriage and otitis media: A cross-sectional study among children in day care centers</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS ONE</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS ONE</style></full-title></periodical><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Pharyngeal bacteria are exposed to different sugar conditions depending on the diet of the child. We hypothesized that dietary factors such as daily intake of carbohydrates could be associated with pneumococcal carriage and the occurrence of otitis media in children. Methods: Our study design was a cross-sectional study among 1006 children attending child day care centers. Parents filled in a food frequency questionnaire. Oropharyngeal swabs were collected from each child. The primary outcome was the occurrence of pneumococcal carriage and the secondary outcome the number of acute otitis media episodes during life. Principal component analysis was used to group dietary intake into nine factors. The models were adjusted for age, gender of the child and educational level of the mother. Results: The dietary factor which included high consumption of sweet pastries and jam was associated with an increased risk of pneumococcal carriage (OR 1.17, 95% CI 1.01 to 1.36, P-value 0.04). The factor including frequent consumption of fruit and berries was associated with a decreased risk of acute otitis (regression coefficient -0.51, 95% CI -0.98 to -0.03, P = 0.04). A high intake of consumption of sweets and snacks (OR 1.36, 95% CI 1.03 to 1.80, P = 0.03) was associated with an increased risk of caries. Conclusions: Diet was associated with a risk of pneumococcal carriage and the occurrence of otitis media. Diet may thus be a modifiable risk factor for the occurrence of acute otitis media. © 2014 Tapiainen et al.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84897126667&amp;doi=10.1371%2fjournal.pone.0090585&amp;partnerID=40&amp;md5=82e56ac9d0c98621a79ef5252ee93357</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">e90585</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0090585</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>252</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">252</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tapiainen, T.</style></author><author><style face="normal" font="default" size="100%">Jauhiainen, H.</style></author><author><style face="normal" font="default" size="100%">Jaakola, L.</style></author><author><style face="normal" font="default" size="100%">Salo, J.</style></author><author><style face="normal" font="default" size="100%">Sevander, J.</style></author><author><style face="normal" font="default" size="100%">Ikäheimo, I.</style></author><author><style face="normal" font="default" size="100%">Pirttilä, A. M.</style></author><author><style face="normal" font="default" size="100%">Hohtola, A.</style></author><author><style face="normal" font="default" size="100%">Uhari, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, University of Oulu, P.O. Box 5000, 90014 Oulu, Finland&#xD;Department of Biology, University of Oulu, Oulu, Finland&#xD;Microbiology Laboratory, Oulu University Hospital, Oulu, Finland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biofilm formation and virulence of uropathogenic Escherichia coli in urine after consumption of cranberry-lingonberry juice</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Clinical Microbiology and Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Clinical Microbiology and Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">655-662</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">5</style></number><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry-lingonberry juice (CLJ) was effective in preventing urinary tract infections (UTIs) in our earlier randomized clinical trial. We aimed to test whether consumption of CLJ at a similar dose to earlier reduces the biofilm formation and virulence of uropathogenic Escherichia coli in urine. Twenty healthy women drank 100 ml of CLJ daily for two weeks. Urine samples were obtained 2-4 hours after the last dose. Control samples were taken after a one-week period without berry consumption. Biofilm formation of 20 E. coli strains was measured at 72 hours by the polystyrene microtitre plate method. Quantitative real-time PCR analyses were performed for selected genes. Four of the 20 clinical strains produced more biofilm in urine after CLJ consumption (P&lt;0.05) and one produced less. Expression levels of the pga, cpxA, fimA and papF genes did not differ between bacteria grown in control urine and urine obtained after CLJ consumption, except for pga gene expression, which was reduced in one strain after CLJ (P=0.04). It appears that the effect of CLJ in preventing UTIs is not explained by mechanisms that reduce biofilm formation or the expression of selected virulence genes of Escherichia coli in urine. © 2011 Springer-Verlag.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :8&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84862892279&amp;doi=10.1007%2fs10096-011-1355-2&amp;partnerID=40&amp;md5=c7304dce23dab95c7515898fd1985dfb</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10096-011-1355-2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>280</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">280</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tao, Y.</style></author><author><style face="normal" font="default" size="100%">Pinzón-Arango, P. A.</style></author><author><style face="normal" font="default" size="100%">Howell, A. B.</style></author><author><style face="normal" font="default" size="100%">Camesano, T. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemical Engineering, Worcester Polytechnic Institute, Bioengineering Center at Gateway Park, 100 Institute Road, Worcester, MA 01609, United States&#xD;Marucci Center for Blueberry Cranberry Research, Rutgers University, Chatsworth, NJ, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Oral consumption of cranberry juice cocktail inhibits molecular-scale adhesion of clinical uropathogenic escherichia coli</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Medicinal Food</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Medicinal Food</style></full-title></periodical><pages><style face="normal" font="default" size="100%">739-745</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">7-8</style></number><keywords><keyword><style face="normal" font="default" size="100%">anti-adhesion</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry juice cocktail (CJC) has been shown to inhibit the formation of biofilm by uropathogenic Escherichia coli. In order to investigate whether the anti-adhesive components could reach the urinary tract after oral consumption of CJC, a volunteer was given 16 oz of either water or CJC. Urine samples were collected at 0, 2, 4, 6, and 8 hours after consumption of a single dose. The ability of compounds in the urine to influence bacterial adhesion was tested for six clinical uropathogenic E. coli strains, including four P-fimbriated strains (B37, CFT073, BF1023, and J96) and two strains not expressing P-fimbriae but exhibiting mannose-resistant hemagglutination (B73 and B78). A non-fimbriated strain, HB101, was used as a control. Atomic force microscopy (AFM) was used to measure the adhesion force between a silicon nitride probe and bacteria treated with urine samples. Within 2 hours after CJC consumption, bacteria of the clinical strains treated with the corresponding urine sample demonstrated lower adhesion forces than those treated with urine collected before CJC consumption. The adhesion forces continued decreasing with time after CJC consumption over the 8-hour measurement period. The adhesion forces of bacteria after exposure to urine collected following water consumption did not change. HB101 showed low adhesion forces following both water and CJC consumption, and these did not change over time. The AFM adhesion force measurements were consistent with the results of a hemagglutination assay, confirming that oral consumption of CJC could act against adhesion of uropathogenic E. coli. © 2011, Mary Ann Liebert, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :27&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79960438793&amp;doi=10.1089%2fjmf.2010.0154&amp;partnerID=40&amp;md5=cfd8282fde82f15130877bd76b976973</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1089/jmf.2010.0154</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>225</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">225</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Takahashi, S.</style></author><author><style face="normal" font="default" size="100%">Hamasuna, R.</style></author><author><style face="normal" font="default" size="100%">Yasuda, M.</style></author><author><style face="normal" font="default" size="100%">Arakawa, S.</style></author><author><style face="normal" font="default" size="100%">Tanaka, K.</style></author><author><style face="normal" font="default" size="100%">Ishikawa, K.</style></author><author><style face="normal" font="default" size="100%">Kiyota, H.</style></author><author><style face="normal" font="default" size="100%">Hayami, H.</style></author><author><style face="normal" font="default" size="100%">Yamamoto, S.</style></author><author><style face="normal" font="default" size="100%">Kubo, T.</style></author><author><style face="normal" font="default" size="100%">Matsumoto, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Sapporo Medical University School of Medicine, S1, W16, Chuo-ku, Sapporo 0608543, Japan&#xD;Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan&#xD;Department of Urology, Graduate School of Medicine, Gifu University, Gifu, Japan&#xD;Department of Surgery Related, Kobe University, Graduate School of Medicine, Kobe, Japan&#xD;Department of Urology, School of Medicine, Fujita Health University, Toyoake, Japan&#xD;Department of Urology, Jikei University Katsushika Medical Center, Tokyo, Japan&#xD;Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan&#xD;Department of Urology, Hyogo College of Medicine, Nishinomiya, Japan&#xD;Department of Public Health, University of Occupational and Environmental Health, Kitakyushu, Japan&#xD;Japanese UTI Research Group, Kitakyushu, Japan</style></auth-address><titles><title><style face="normal" font="default" size="100%">A randomized clinical trial to evaluate the preventive effect of cranberry juice (UR65) for patients with recurrent urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Infection and Chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Infection and Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">112-117</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">We examined the rate of relapse, as a variable index, in patients with urinary tract infection (UTI) who suffered from multiple relapses when using cranberry juice (UR65). A randomized, placebo-controlled, double-blind study was conducted from October 2007 to September 2009 in Japan. The subjects were outpatients aged 20 to 79 years who were randomly divided into two groups. One group received cranberry juice (group A) and the other a placebo beverage (group P). To keep the conditions blind, the color and taste of the beverages were adjusted. The subjects drank 1 bottle (125 mL) of cranberry juice or the placebo beverage once daily, before going to sleep, for 24 weeks. The primary endpoint was relapse of UTI. In the group of females aged 50 years or more, there was a significant difference in the rate of relapse of UTI between groups A and P (log-rank test; p = 0.0425). In this subgroup analysis, relapse of UTI was observed in 16 of 55 (29.1 %) patients in group A and 31 of 63 (49.2 %) in group P. In this study, cranberry juice prevented the recurrence of UTI in a limited female population with 24-week intake of the beverage. © 2012 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :33&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84874112980&amp;doi=10.1007%2fs10156-012-0467-7&amp;partnerID=40&amp;md5=72b5ca18a1c4ea2ef3590028fe7639a9</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10156-012-0467-7</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>131</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">131</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Szajdak, L. W.</style></author><author><style face="normal" font="default" size="100%">Inisheva, L. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Agricultural and Forest Environment, Polish Academy of Sciences, Str. Bukowska 19, Poznań, 60-809, Poland&#xD;Tomsk State Pedagogical University, Tomsk, 634041, Russian Federation</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry: A plant growing on organic soils with a broad spectrum of pharmaceutical and medical use</style></title><secondary-title><style face="normal" font="default" size="100%">Bioactive Compounds in Agricultural Soils</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">273-286</style></pages><keywords><keyword><style face="normal" font="default" size="100%">Biologically active substances</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Health benefits</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry is a significant example of a plant which is growing on peat soils and has a high content and a rich spectrum of biologically active substances. The organic compounds in the plant are responsible for its wide medical and pharmaceutical use. The beneficial impact of cranberries on human health is caused by the presence of the following substances in the berries: anthocyanins, proanthocyanidins (condensed tannins), flavonol glycosides, low-molecular-weight phenolic acids, organic acids, and sugars. Cranberry juice and fruits are reported to display a number of health benefits including: potent antioxidant activity, cholesterol reduction, vasorelaxant effects, the prevention of urinary tract infections, the reduction of biofilm formation, and in vivo anticancer effects. © Springer International Publishing Switzerland 2016.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85009684360&amp;doi=10.1007%2f978-3-319-43107-9_11&amp;partnerID=40&amp;md5=1cb51c12c74f715b40f636c212400752</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/978-3-319-43107-9_11</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>28</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">28</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Švarc-Gajić, J.</style></author><author><style face="normal" font="default" size="100%">Cerdà, V.</style></author><author><style face="normal" font="default" size="100%">Clavijo, S.</style></author><author><style face="normal" font="default" size="100%">Suárez, R.</style></author><author><style face="normal" font="default" size="100%">Mašković, P.</style></author><author><style face="normal" font="default" size="100%">Cvetanović, A.</style></author><author><style face="normal" font="default" size="100%">Delerue-Matos, C.</style></author><author><style face="normal" font="default" size="100%">Carvalho, A. P.</style></author><author><style face="normal" font="default" size="100%">Novakov, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Technology, Department for Applied and Engineering Chemistry, University of Novi Sad, Serbia&#xD;University of the Balearic Islands, Laboratory of Environmental Analytical Chemistry-LQA, Palma de Mallorca, Spain&#xD;Faculty of Agriculture, University of Kragujevac, Cara Dušana, Čačak, Serbia&#xD;REQUIMTE/LAQV, Instituto Superior de Engenharia, Porto Polytechnic Institute, Porto, Portugal</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bioactive compounds of sweet and sour cherry stems obtained by subcritical water extraction</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Chemical Technology and Biotechnology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Chemical Technology and Biotechnology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1627-1635</style></pages><volume><style face="normal" font="default" size="100%">93</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">bioactivity</style></keyword><keyword><style face="normal" font="default" size="100%">cherry stems</style></keyword><keyword><style face="normal" font="default" size="100%">GC MS</style></keyword><keyword><style face="normal" font="default" size="100%">subcritical water</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">BACKGROUND: Sweet cherries (Prunus avium L.) and sour cherries (Prunus cerasus L.) contain substantial amounts of anthocyanins and polyphenolics, and their stems have been used in traditional medicine for centuries. However, comparative data on the composition of sweet and sour cherry stems using the same analytical methodologies are limited. Moreover, there is no data in terms of biological activity of subcritical water extracts of cherry stems. RESULTS AND DISSCUSION: Results obtained by using several assays that focused on different mechanisms showed that subcritical water extracts of sour and sweet cherry stems were powerful antiradicals and antioxidants. Anti-proliferative properties measured by MTT (3-[4,5- dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) test showed prominent cytotoxicity against different tumor cell lines. Inhibitory concentrations obtained were in the range 8.38–11.40 µg mL-1. GC–MS (gas chromatography mass spectrometry) analysis showed the presence of alcohols, fatty acids, organic acids and other organic compounds. However, the chemical compositions of the two samples observed were similar, indicating similar chemical composition of sour and sweet cherry stems. CONCLUSION: Subcritical water extracts of cherry stem demonstrated excellent biological activity and the potential to be used for pharmaceuticals or supplements due to confirmed high antioxidant, antiradical and antitumor activity. © 2017 Society of Chemical Industry. © 2017 Society of Chemical Industry</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041121682&amp;doi=10.1002%2fjctb.5532&amp;partnerID=40&amp;md5=b452313e3be0b998900160af9678f248</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/jctb.5532</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>504</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">504</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Suvarna, R.</style></author><author><style face="normal" font="default" size="100%">Pirmohamed, M.</style></author><author><style face="normal" font="default" size="100%">Henderson, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pharmacovigilance Risk Assess. Unit, Medicines Hlthcare. Prod. R., London SW8 5NQ, United Kingdom&#xD;Department of Pharmacology, University of Liverpool, Liverpool L69 3GE, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Possible interaction between warfarin and cranberry juice</style></title><secondary-title><style face="normal" font="default" size="100%">British Medical Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Medical Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1454</style></pages><volume><style face="normal" font="default" size="100%">327</style></volume><number><style face="normal" font="default" size="100%">7429</style></number><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :102&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Short Survey</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0347360102&amp;partnerID=40&amp;md5=989600ea97fe843817eade241cfbab7a</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>62</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">62</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sun, X.</style></author><author><style face="normal" font="default" size="100%">Wu, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Agricultural, Food and Nutritional Science, University of Alberta, 4-10 Ag/For Building, Edmonton, Alberta T6G 2P5, Canada&#xD;College of Food and Biological Engineering, Qiqihar University, Qiqihar, Heilongjiang 161006, China</style></auth-address><titles><title><style face="normal" font="default" size="100%">Food derived anti-adhesive components against bacterial adhesion: Current progresses and future perspectives</style></title><secondary-title><style face="normal" font="default" size="100%">Trends in Food Science and Technology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Trends in Food Science and Technology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">148-156</style></pages><volume><style face="normal" font="default" size="100%">69</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Anti-adhesive component</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotics alternative</style></keyword><keyword><style face="normal" font="default" size="100%">Pathogen adhesion</style></keyword><keyword><style face="normal" font="default" size="100%">Perspective</style></keyword><keyword><style face="normal" font="default" size="100%">Progress</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Background The widespread use of antibiotics has led to an alarming increase in drug-resistant bacteria, which prompted develop alternative approaches against infectious diseases. Pathogen adhesion to host cells is considered as an essential first step in infection process; therefore, interfering or inhibiting pathogen adhesion to host cells could prevent and/or treat infectious diseases. Most effective anti-adhesive components reported so far are food derived. This review aims to provide an update on the study of anti-adhesive food components, and to discuss the challenges and perspectives for the application of these anti-adhesive components against infectious diseases. Scope and approach Progresses on the development of anti-adhesive food components against infectious diseases are reviewed based on the phases of clinical research, which are in vitro study, animal study and clinical trial. The challenges and future perspectives on developing food-derived anti-adhesive therapy against infectious diseases are discussed. Key findings and conclusions: Cranberry extracts are the most extensively studied anti-adhesive components and have been marketed as nutraceuticals. Most anti-adhesive studies were based on in vitro studies, therefore more in vivo studies and clinical trials are needed to test the safety and efficacy. Future research is also needed to discover better anti-adhesive components from foodstuffs with commercial potential. Purification of the anti-adhesive components for practical application is not always encouraged as a crude mixture may provide greater benefit for binding to bacteria with multi-adhesins, in addition to its increased cost of production. Anti-adhesive therapy shows promises as alternative to antibiotic treatments. © 2017 Elsevier Ltd</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85030468502&amp;doi=10.1016%2fj.tifs.2017.09.002&amp;partnerID=40&amp;md5=4f88bd979663e6caf163816bf59c32eb</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.tifs.2017.09.002</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>341</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">341</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sumukadas, D.</style></author><author><style face="normal" font="default" size="100%">Davey, P.</style></author><author><style face="normal" font="default" size="100%">McMurdo, M. E. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Cardiovascular and Lung Biology, Division of Medical Sciences Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, United Kingdom&#xD;Division of Community and Population Sciences and Education MacKenzie Building, University of Dundee, Kirsty Semple Way, Dundee DD2 4BF, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent urinary tract infections in older people: The role of cranberry products</style></title><secondary-title><style face="normal" font="default" size="100%">Age and Ageing</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Age and Ageing</style></full-title></periodical><pages><style face="normal" font="default" size="100%">255-257</style></pages><volume><style face="normal" font="default" size="100%">38</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :6&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Editorial</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-65449124315&amp;doi=10.1093%2fageing%2fafp034&amp;partnerID=40&amp;md5=0319b3cf353157924fd96a0c2c3b4a11</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/ageing/afp034</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>309</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">309</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Su, X.</style></author><author><style face="normal" font="default" size="100%">Howell, A. B.</style></author><author><style face="normal" font="default" size="100%">D&apos;Souza, D. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Food Science and Technology, University of Tennessee-Knoxville, Knoxville, TN 37996, United States&#xD;Marucci Center for Blueberry Cranberry Research, Rutgers University, Chatsworth, NJ, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">The effect of cranberry juice and cranberry proanthocyanidins on the infectivity of human enteric viral surrogates</style></title><secondary-title><style face="normal" font="default" size="100%">Food Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Food Microbiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">535-540</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bacteriophage φ{symbol}-X174</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteriophage MS2</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Feline calicivirus F9</style></keyword><keyword><style face="normal" font="default" size="100%">Murine norovirus MNV-1</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><abstract><style face="normal" font="default" size="100%">The effect of cranberry juice (CJ) and cranberry proanthocyanidins (PAC) on the infectivity of human enteric virus surrogates, murine norovirus (MNV-1), feline calicivirus (FCV-F9), MS2(ssRNA) bacteriophage, and phiX-174(ssDNA) bacteriophage was studied. Viruses at high (∼7 log10 PFU/ml) or low (∼5 log10 PFU/ml) titers were mixed with equal volumes of CJ, 0.30, 0.60, and 1.20 mg/ml final PAC concentration, or water and incubated for 1 h at room temperature. Viral infectivity after treatments was evaluated using standardized plaque assays. At low viral titers, FCV-F9 was undetectable after exposure to CJ or the three tested PAC solutions. MNV-1 was reduced by 2.06 log10 PFU/ml with CJ, and 2.63, 2.75, and 2.95 log10 PFU/ml with 0.15, 0.30, and 0.60 mg/ml PAC, respectively. MS2 titers were reduced by 1.14 log10 PFU/ml with CJ, and 0.55, 0.80, and 0.96 log10 PFU/ml with 0.15, 0.30, and 0.60 mg/ml PAC, respectively. φ{symbol}-X174 titers were reduced by 1.79 log10 PFU/ml with CJ, and 1.95, 3.67, and 4.98 log10 PFU/ml with PAC at 0.15, 0.30, and 0.60 mg/ml, respectively. Experiments using high titers showed similar trends but with decreased effects. CJ and PAC show promise as natural anti-virals that could potentially be exploited for foodborne viral illness treatment and prevention. © 2010 Elsevier Ltd. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :63&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-77951025695&amp;doi=10.1016%2fj.fm.2010.01.001&amp;partnerID=40&amp;md5=9ebb211261f46b8a14e735716a8edb4a</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.fm.2010.01.001</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>301</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">301</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Su, X.</style></author><author><style face="normal" font="default" size="100%">Howell, A. B.</style></author><author><style face="normal" font="default" size="100%">D&apos;Souza, D. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Food Science and Technology, University of Tennessee-Knoxville, Knoxville, TN 37996, United States&#xD;Marucci Center for Blueberry Cranberry Research, Rutgers University, Chatsworth, NJ, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antiviral effects of cranberry juice and cranberry proanthocyanidins on foodborne viral surrogates - A time dependence study in vitro</style></title><secondary-title><style face="normal" font="default" size="100%">Food Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Food Microbiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">985-991</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bacteriophage φ-X174</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteriophage MS2</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Feline calicivirus F-9</style></keyword><keyword><style face="normal" font="default" size="100%">Murine norovirus MNV-1</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry juice (CJ) and cranberry proanthocyanidins (PAC) are widely known for their antibacterial, antiviral, and pharmacological activities. The effect of CJ and cranberry PAC on the infectivity of foodborne viral surrogates, murine norovirus (MNV-1), feline calicivirus (FCV-F9), MS2 (ssRNA) bacteriophage, and φX-174 (ssDNA) bacteriophage after 0min to 1h at room temperature was evaluated. Viruses at titers of ∼5log10PFU/ml were mixed with equal volumes of CJ at pH 2.6, CJ at pH 7.0, 0.30mg/ml CJ PAC, 0.60mg/ml PAC, or water and incubated for 0, 10, 20, 30, 40, 50min, and 1h at room temperature. Infectivity was determined using standard plaque assays. The viral reduction rates of the four tested viruses were found to vary considerably. Among the tested viruses, FCV-F9 titers were decreased the most by ∼5log10PFU/ml within 30min. MS2 titers were decreased the least by only ∼1log10PFU/ml after 1h with CJ at pH 2.6 and 0.30mg/ml PAC, and ∼0.5log10PFU/ml with CJ at pH 7.0 and 0.15mg/ml PAC. MNV-1 and φ-X174 showed comparable titer reductions which was between that of FCV-F9 and MS2. In most cases, viral reduction within the first 10min of treatment accounted for ≥50% of the total reduction. Transmission electron microscopy on FCV-F9 treated with CJ and PAC revealed structural changes. This study shows potential of using natural bioactive compounds for controlling foodborne viral diseases. Further studies are necessary to elucidate the mechanism of action of CJ components and to understand the differences in viral titer reduction profiles. © 2010.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :56&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79952843424&amp;doi=10.1016%2fj.fm.2010.05.027&amp;partnerID=40&amp;md5=a56d6351d5012a200f4717c13091f60c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.fm.2010.05.027</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>418</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">418</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Su, S. B.</style></author><author><style face="normal" font="default" size="100%">Wang, J. N.</style></author><author><style face="normal" font="default" size="100%">Lu, C. W.</style></author><author><style face="normal" font="default" size="100%">Guo, H. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Occupational and Environmental Medicine, Medical College, National Cheng Kung University, Tainan, Taiwan&#xD;Tainan Science-Based Industrial Park Clinic, Chi-Mei Medical Center, Tainan, Taiwan&#xD;Department of Family Medicine, Chi-Mei Medical Center, Tainan, Taiwan&#xD;Graduate Institute of Occupational Safety and Health, Kaohsiung Medical University, Kaohsiung, Taiwan&#xD;Department of Environmental and Occupational Health, National Cheng Kung University, Medical College, 138 Sheng-Li Road, Tainan 70428, Taiwan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reducing urinary tract infections among female clean room workers</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Women&apos;s Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Women&apos;s Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">870-876</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">7</style></number><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">Objectives: A higher prevalence of urinary tract infection (UTI) was observed among clean room workers than among others in our previous study in 2001. We implemented intervention programs for reducing UTI and evaluated their effects 2 years later. Methods: We conducted an intervention study in four factories in the industrial park where the previous study was conducted and recruited participants from women workers who received annual health examinations at the clinic of the park. The intervention included health education programs during the new employee orientation and seasonal on-the-job training. We also implemented other measures, including placing posters in the workplace and disseminating knowledge of UTI prevention through e-mail and oral communications. One-on-one education was provided to workers who were found to have UTI in the previous study. Results: All the 1666 qualified workers, including 1414 clean room workers and 252 nonclean room workers, agreed to participate. We found a similar prevalence (both 0.8%) of symptomatic UTIs (patients with clinical symptoms, such as voiding frequency, urgency, and burning sensation during voiding) in clean room and nonclean room workers. In the 366 participants who also participated in the previous study, we found a significant decrease in the prevalence of UTI (from 9.8% to 1.6%) and significant increases in the prevalence of water intake and urine voiding, three times or more during a shift (p &lt; 0.001 for all McNemar tests). Conclusions: The interventions had achieved behavior modification and decreases in the prevalence of UTI. © Mary Ann Liebert, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :20&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33847772389&amp;doi=10.1089%2fjwh.2006.15.870&amp;partnerID=40&amp;md5=ef3da966ce009d9c13a93521ef5fda50</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1089/jwh.2006.15.870</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>17</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">17</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Storm, D. W.</style></author><author><style face="normal" font="default" size="100%">Braga, L. H.</style></author><author><style face="normal" font="default" size="100%">Cooper, C. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, University of Iowa, Carver College of Medicine, 200 Hawkins Drive, 3RCP, Iowa City, IA 5224, United States&#xD;Department of Surgery, Division of Urology, Mcmaster University, McMaster Children&apos;s Hospital, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Continuous Antibiotic Prophylaxis in Pediatric Urology</style></title><secondary-title><style face="normal" font="default" size="100%">Urologic Clinics of North America</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Urologic Clinics of North America</style></full-title></periodical><pages><style face="normal" font="default" size="100%">525-538</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotic prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Megaureter</style></keyword><keyword><style face="normal" font="default" size="100%">Microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Prenatal hydronephrosis</style></keyword><keyword><style face="normal" font="default" size="100%">Side effects</style></keyword><keyword><style face="normal" font="default" size="100%">Vesicoureteral reflux</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Continuous antibiotic prophylaxis (CAP) for urinary tract infection prevention in children with vesicoureteral reflux, hydronephrosis, and hydroureteronephrosis is reviewed. A more selective use of CAP is advocated based on a review of known individual risk factors in each of these conditions that subsequently helps identify the children most likely to benefit from CAP. Both short-term and potential long-term side effects of CAP are reviewed, including the impact of prophylactic antibiotics on bacterial resistance and the microbiome. Alternatives to continuous antibiotic prophylaxis including Vaccinium macrocarpon (Cranberry), probiotics, and vaccines are reviewed. © 2018 Elsevier Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052920741&amp;doi=10.1016%2fj.ucl.2018.06.001&amp;partnerID=40&amp;md5=487542d4c123ea49d89ae59667e0797f</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ucl.2018.06.001</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>378</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">378</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stieber, D.</style></author><author><style face="normal" font="default" size="100%">Gupta, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacy, University of Washington, Seattle, WA 98195-6523, United States&#xD;Department of Medicine, University of Washington, Division of Allergy and Infectious Diseases, Seattle, WA 98195-6523, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Treatment of Simple Urinary Tract Infection</style></title><secondary-title><style face="normal" font="default" size="100%">Drug Treatment in Urology</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">75-95</style></pages><keywords><keyword><style face="normal" font="default" size="100%">Adult woman</style></keyword><keyword><style face="normal" font="default" size="100%">Bladder</style></keyword><keyword><style face="normal" font="default" size="100%">Microscopy</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84889378508&amp;doi=10.1002%2f9780470755853.ch5&amp;partnerID=40&amp;md5=b388389115788d4bbf88e147b9225eae</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/9780470755853.ch5</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>487</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">487</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Steinberg, D.</style></author><author><style face="normal" font="default" size="100%">Feldman, M.</style></author><author><style face="normal" font="default" size="100%">Ofek, I.</style></author><author><style face="normal" font="default" size="100%">Weiss, E. I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Dental Sciences, Faculty of Dentistry, Hebrew University-Hadassah, PO Box 12272, Jerusalem 91120, Israel&#xD;Department of Prosthodontics, Faculty of Dentistry, Hebrew University-Hadassah, PO Box 12272, Jerusalem 91120, Israel&#xD;Department of Human Microbiology, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of a high-molecular-weight component of cranberry on constituents of dental biofilm</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Antimicrobial Chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Antimicrobial Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">86-89</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-adhesion</style></keyword><keyword><style face="normal" font="default" size="100%">Fructosyltransferases</style></keyword><keyword><style face="normal" font="default" size="100%">Glucosyltransferases</style></keyword><keyword><style face="normal" font="default" size="100%">Mutans streptococci</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Previous studies have shown that high molecular-weight non-dialysable material derived from cranberry juice (NDM) inhibits co-aggregation of a variety of oral bacteria. Objectives: In the present study, we examined the effect of NDM on several constituents of the dental biofilm, glucosyltransferase (GTF) and fructosyltransferase (FTF), as well as on the adhesion of Streptococcus sobrinus. Results: The activity of immobilized and soluble GTF and FTF was inhibited by NDM (P &gt; 0.05). NDM also inhibited adhesion of S. sobrinus to hydroxyapatite (P &lt; 0.05). Conclusions: Our results indicate that NDM may affect biofilm formation. One of the proposed mechanisms is via inhibition of extracellular polysaccharide synthesis, which promote the sucrose-dependent adhesion of oral bacteria as S. sobrinus. © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :91&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-3543133031&amp;doi=10.1093%2fjac%2fdkh254&amp;partnerID=40&amp;md5=8561d9a6f09f20a4af2283229642cefa</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/jac/dkh254</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>600</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">600</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stapleton, A.</style></author><author><style face="normal" font="default" size="100%">Moseley, S.</style></author><author><style face="normal" font="default" size="100%">Stamm, W. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Depts. of Medicine and Microbiology, University of Washington, Seattle, WA, United States&#xD;Department of Medicine, Harborview Medical Center, 325 Ninth Ave., Seattle, WA 98104, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urovirulence determinants in Escherichia coli isolates causing first-episode and recurrent cystitis in women</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">773-779</style></pages><volume><style face="normal" font="default" size="100%">163</style></volume><number><style face="normal" font="default" size="100%">4</style></number><dates><year><style face="normal" font="default" size="100%">1991</style></year></dates><abstract><style face="normal" font="default" size="100%">To assess the prevalence of urovirulence determinants among Escherichia coli isolates from women with acute uncomplicated cystitis, 121 isolates from 87 women with first-episode or recurrent cystitis and 156 fecal isolates from 52 women without recent urinary tract infection were tested using DNA probes for P fimbriae, hemolysin, aerobactin, and diffuse adhesin and for expression of hemolysin and P and F adhesins. P fimbrial genotype (P = .002), hemolysin phenotype (P = .007), and the diffuse adhesin determinant (P = .03), but not aerobactin, were found more frequently in E. coli from women with acute cystitis, and expression of the F adhesin (41%) was more common than the P adhesin (24%; P = .001). E. coli isolates that caused cystitis in women using diaphragms had fewer virulence determinants than those from nonusers (P = .04), suggesting that diaphragm use may allow infection with less virulent E. coli.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :95&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025804550&amp;doi=10.1093%2finfdis%2f163.4.773&amp;partnerID=40&amp;md5=7fc57d5c10fcde26b3c31b7abe7412b1</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/infdis/163.4.773</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>533</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">533</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stapleton, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Div. of Allerg./Infectious Diseases, University of Washington, 1959 NE Pacific Avenue, Seattle, WA 98195, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Novel approaches to prevention of urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Infectious Disease Clinics of North America</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infectious Disease Clinics of North America</style></full-title></periodical><pages><style face="normal" font="default" size="100%">457-471</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections are common clinical entities occurring in a variety of patient groups, most frequently caused by uropathogenic E coli. Novel methods of preventing UTI currently under development are focused on three key approaches: (1) use of cranberry products, (2) restoration of the normal flora using Lactobacillus-based probiotic preparations, and (3) vaccine development. Although promising studies in each of these areas have been published or are ongoing, additional properly designed and powered clinical studies based on solid scientific evidence are needed.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :32&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038270567&amp;doi=10.1016%2fS0891-5520%2803%2900010-2&amp;partnerID=40&amp;md5=6d63a2fd63a8ca0a063bf6e5b348edfb</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0891-5520(03)00010-2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>124</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">124</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Spaulding, C. N.</style></author><author><style face="normal" font="default" size="100%">Hultgren, S. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, United States&#xD;Center for Women’s Infectious Disease Research, Washington University School of Medicine, St. Louis, MO 63110, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adhesive Pili in UTI pathogenesis and drug development</style></title><secondary-title><style face="normal" font="default" size="100%">Pathogens</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pathogens</style></full-title></periodical><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotic-resistance</style></keyword><keyword><style face="normal" font="default" size="100%">CAUTI</style></keyword><keyword><style face="normal" font="default" size="100%">Chaperone-usher pathway (CUP) pili</style></keyword><keyword><style face="normal" font="default" size="100%">Enterococcus</style></keyword><keyword><style face="normal" font="default" size="100%">Pili</style></keyword><keyword><style face="normal" font="default" size="100%">RUTI</style></keyword><keyword><style face="normal" font="default" size="100%">UPEC</style></keyword><keyword><style face="normal" font="default" size="100%">UTI</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTIs) are one of the most common bacterial infections, affecting 150 million people each year worldwide. High recurrence rates and increasing antimicrobial resistance among uropathogens are making it imperative to develop alternative strategies for the treatment and prevention of this common infection. In this Review, we discuss how understanding the: (i) molecular and biophysical basis of host-pathogen interactions; (ii) consequences of the molecular cross-talk at the host pathogen interface in terms of disease progression; and (iii) pathophysiology of UTIs is leading to efforts to translate this knowledge into novel therapeutics to treat and prevent these infections. © 2016 by the authors; licensee MDPI, Basel, Switzerland.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :17&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85026821650&amp;doi=10.3390%2fpathogens5010030&amp;partnerID=40&amp;md5=e1699a493edb4f0adf79a4bd6999b5c8</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">30</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/pathogens5010030</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>134</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">134</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sokurenko, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Washington, Seattle, WA 98195, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pathoadaptive mutations in uropathogenic Escherichia coli</style></title><secondary-title><style face="normal" font="default" size="100%">Microbiology Spectrum</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Microbiology Spectrum</style></full-title></periodical><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Uropathogenic Escherichia coli (UPEC) are opportunistic human pathogens that primarily circulate as part of commensal intestinal microbiota. Though they have the ability to survive and proliferate in various urinary tract compartments, the urinary tract is a transient, occasional habitat for UPEC. Because of this, most of the UPEC traits have originally evolved to serve in intestinal colonization and transmission. Some of these bacterial traits serve as virulence factors - they are critical to or assist in survival of UPEC as pathogens, and the structure and/or function may be specialized for the infection. Other traits could serve as anti-virulence factors - they represent liability in the urinary tract and are under selection to be lost or inactivated during the infection. Inactivation, variation, or other changes of the bacterial genes that increase the pathogen&apos;s fitness during the infection are called pathoadaptive mutations. This chapter describes examples of pathoadaptive mutations in UPEC and provides rationale for their further in-depth study. © 2016 American Society for Microbiology. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85011296006&amp;doi=10.1128%2fmicrobiolspec.UTI-0020-2015&amp;partnerID=40&amp;md5=275b4c2db5a043f810b2ec9ebe4a9b6b</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">Uti-0020-2015</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/microbiolspec.UTI-0020-2015</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>608</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">608</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sobota, A. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biological Sciences, Youngstown State University, Youngstown, OH 44555, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inhibition of bacterial adherence by cranberry juice: Potential use for the treatment of urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1013-1016</style></pages><volume><style face="normal" font="default" size="100%">131</style></volume><number><style face="normal" font="default" size="100%">5</style></number><dates><year><style face="normal" font="default" size="100%">1984</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry juice has been widely used for the treatment and prevention of urinary tract infections and is reputed to give symptomatic relief from these infections. Attempts to account for the potential benefit derived from the juice have focused on urine acidification and bacteriostasis. In this investigation it is demonstrated that cranberry juice is a potent inhibitor of bacterial adherence. A total of 77 clinical isolates of Escherichia coli were tested. Cranberry juice inhibited adherence by 75 per cent or more in over 60 per cent of the clinical isolates. Cranberry cocktail was also given to mice in the place of their normal water supply for a period of 14 days. Urine collected from these mice inhibited adherence of E. coli to uroepithelial cells by approximately 80 per cent. Antiadherence activity could also be detected in human urine. Fifteen of 22 subjects showed significant antiadherence activity in the urine 1 to 3 hours after drinking 15 ounces of cranberry cocktail. It is concluded that the reported benefits derived from the use of cranberry juice may be related to its ability to inhibit bacterial adherence.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :212&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021277791&amp;doi=10.1016%2fS0022-5347%2817%2950751-X&amp;partnerID=40&amp;md5=72d3a787a212c2ff6269de37d34e6b39</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0022-5347(17)50751-X</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>214</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">214</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Snodgrass, W. T.</style></author><author><style face="normal" font="default" size="100%">Bush, N. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatric Urology, University of Texas, Southwestern Medical Center, 1935 Medical District Drive, Dallas, TX 75235, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">Pediatric Urology: Evidence for Optimal Patient Management</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1-17</style></pages><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Primary goals in the diagnosis of urinary tract infection (UTI) and the subsequent evaluation of underlying factors predisposing to UTI: 1. Reduce recurrent UTI. 2. Prevent acquired renal damage. Summary of evidence for these aims: After first febrile UTI (fUTI), less than one-third of patients will develop a second fUTI within 1-2 years. Approximately 15 % of children will develop renal scarring after fUTI. Vesicoureteral reflux (VUR) increases risk for renal scarring by approximately 2.5 times, but no evidence demonstrates management reduces future acquired renal damage. Patients with negative DMSA after UTI have ≤5 % risk for future abnormal DMSA with recurrent UTI. Potential interventions to reduce risk for recurrent UTI include circumcision and therapy for voiding dysfunction and/or constipation. However, no RCT demonstrates circumcision after infection is more effective than the natural history of diminishing UTI occurrence in males. No RCTs have been reported concerning efficacy of therapy for voiding dysfunction or constipation to reduce UTI. Observations that renal scars occur in a minority of patients after fUTI, and that those without scarring on DMSA scan have &lt;5 % risk for developing scars with recurrent UTI suggest there are two general populations of children-those with a greater versus a lesser risk for scarring. © 2013 Springer Science+Business Media New York. All rights are reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84899094272&amp;doi=10.1007%2f978-1-4614-6910-0_1&amp;partnerID=40&amp;md5=d102b0f319d4077420f2fc9d4d477f2e</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/978-1-4614-6910-0_1</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>12</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">12</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Smith, A. L.</style></author><author><style face="normal" font="default" size="100%">Brown, J.</style></author><author><style face="normal" font="default" size="100%">Wyman, J. F.</style></author><author><style face="normal" font="default" size="100%">Berry, A.</style></author><author><style face="normal" font="default" size="100%">Newman, D. K.</style></author><author><style face="normal" font="default" size="100%">Stapleton, A. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Urology, University of Pennsylvania, Philadelphia, PA, United States&#xD;School of Nursing, University of Pennsylvania, Philadelphia, PA, United States&#xD;Children&apos;s Hospital of Philadelphia, Philadelphia, PA, United States&#xD;School of Nursing, University of Minnesota, Minneapolis, MN, United States&#xD;Division of Allergy and Infectious Disease, University of Washington, Seattle, WA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Treatment and Prevention of Recurrent Lower Urinary Tract Infections in Women: A Rapid Review with Practice Recommendations</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1174-1191</style></pages><volume><style face="normal" font="default" size="100%">200</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">anti-bacterial agents</style></keyword><keyword><style face="normal" font="default" size="100%">prevention and control</style></keyword><keyword><style face="normal" font="default" size="100%">recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">women</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Purpose: Recurrent lower urinary tract infections in women are a highly prevalent and burdensome condition for which best practice guidelines for treatment and prevention that minimize harm and optimize well-being are greatly needed. To inform development of practice recommendations, a rapid literature review of original research, systematic reviews, meta-analyses and practice guidelines was conducted. Materials and Methods: PubMed® Embase® Opus, Scopus® Google Scholar, The Cochrane Library and the U.S. National Guideline Clearinghouse electronic databases were searched from inception to September 22, 2017. Articles and practice guidelines were included if they were in English, were peer reviewed, included women, involved treatment or prevention strategies for recurrent urinary tract infection and reported an outcome related to recurrence rates of urinary tract infection. Critical appraisal of original studies was conducted using the Cochrane risk of bias tool, and of systematic reviews using the AMSTAR 2 tool. Results: Of 1,582 citations identified 74 met our study inclusion criteria. These comprised 49 randomized controlled trials, 23 systematic reviews (16 with meta-analyses) and 2 practice guidelines. No study reported a multi-targeted treatment approach. There was a lack of high quality studies and systematic reviews evaluating prevention strategies for recurrent urinary tract infection. Conclusions: We recommend an algorithmic approach to care that includes education on lifestyle and behavioral modifications, and addresses specific populations of women with antimicrobial based and nonantibiotic alternatives. This approach includes the use of vaginal estrogen with or without lactobacillus containing probiotics in postmenopausal women, low dose post-coital antibiotics for recurrent urinary tract infection associated with sexual activity in premenopausal women, low dose daily antibiotic prophylaxis in premenopausal women with infections unrelated to sexual activity, and methenamine hippurate and/or lactobacillus containing probiotics as nonantibiotic alternatives. Future research should involve consistent use of terminology, validated instruments to assess response to interventions and patient perspectives on care. Our treatment algorithm is based on the best available evidence, and fills a gap in the literature and practice regarding effective strategies to prevent recurrent urinary tract infection in women. © 2018 American Urological Association Education and Research, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055040760&amp;doi=10.1016%2fj.juro.2018.04.088&amp;partnerID=40&amp;md5=4da3c9df6ebff2da5b91476d3fa8af81</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.juro.2018.04.088</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>321</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">321</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Slimestad, R.</style></author><author><style face="normal" font="default" size="100%">Vangdal, E.</style></author><author><style face="normal" font="default" size="100%">Brede, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">PlantChem, Særheim Research Center, N-4353 Klepp Stasjon, Norway&#xD;Bioforsk Vest Ullensvang, N-5781 Lofthus, Norway&#xD;Department of Medical Biochemistry, Stavanger University Hospital, N-4068 Stavanger, Norway</style></auth-address><titles><title><style face="normal" font="default" size="100%">Analysis of phenolic compounds in six norwegian plum cultivars (Prunus domestica L.)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">11370-11375</style></pages><volume><style face="normal" font="default" size="100%">57</style></volume><number><style face="normal" font="default" size="100%">23</style></number><keywords><keyword><style face="normal" font="default" size="100%">ABTS</style></keyword><keyword><style face="normal" font="default" size="100%">Anthocyanins</style></keyword><keyword><style face="normal" font="default" size="100%">Chlorogenic acids</style></keyword><keyword><style face="normal" font="default" size="100%">European plum</style></keyword><keyword><style face="normal" font="default" size="100%">Flavonols</style></keyword><keyword><style face="normal" font="default" size="100%">Folin-ciocalteu assay</style></keyword><keyword><style face="normal" font="default" size="100%">HPLC</style></keyword><keyword><style face="normal" font="default" size="100%">LCMS</style></keyword><keyword><style face="normal" font="default" size="100%">Phenolic content</style></keyword><keyword><style face="normal" font="default" size="100%">Prussian blue assay</style></keyword><keyword><style face="normal" font="default" size="100%">TEAC</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Six European plum cultivars (Prunus domestica L.) grown in Norway have been studied with respect to phenolic composition. Neochlorogenic acid was found to be the most important phenolic acid in all cultivars. Together with other phenolic acids, this compound varied significantly in amount among the cultivars. Cyanidin 3-rutinoside was found to account for &amp;gt;60% of the total anthocyanin content. Minor amounts of flavonols (rutin and quercetin 3-glucoside) were detected in all cultivars. Total antioxidant capacity varied from 814 to 290 μmol of Trolox 100 g-1 of fresh weight. Measurement of total phenolic content in terms of Prussian blue complex formation revealed a method failure of magnitude order compared to results obtained by HPLC. Comparison of the response factors of a range of phenolic compounds obtained upon analysis by the Prussian blue and Folin-Ciocalteu assays revealed that the latter method returned higher yields in terms of gallic acid (GAE). ©2009 American Chemical Society.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :47&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-72449207106&amp;doi=10.1021%2fjf902054x&amp;partnerID=40&amp;md5=c0a7eda5adae259f106d9db363cde932</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/jf902054x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>348</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">348</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Slimestad, R.</style></author><author><style face="normal" font="default" size="100%">Vågen, I. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">PlantChem, Særheim Research Centre, N-4353 Klepp station, Norway&#xD;Norwegian Institute for Agricultural and Environmental Research - Bioforsk Øst Landvik, Reddalsveien 215, N-4886 Grimstad, Norway</style></auth-address><titles><title><style face="normal" font="default" size="100%">Distribution of non-structural carbohydrates, sugars, flavonols and pyruvate in scales of onions, Allium cepa L</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Food, Agriculture and Environment</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Food, Agriculture and Environment</style></full-title></periodical><pages><style face="normal" font="default" size="100%">289-294</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">3-4</style></number><keywords><keyword><style face="normal" font="default" size="100%">4′-diglucoside</style></keyword><keyword><style face="normal" font="default" size="100%">Allium cepa L.</style></keyword><keyword><style face="normal" font="default" size="100%">Flavonols</style></keyword><keyword><style face="normal" font="default" size="100%">Fructo oligosaccharides</style></keyword><keyword><style face="normal" font="default" size="100%">Fructose</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose</style></keyword><keyword><style face="normal" font="default" size="100%">Pyruvate</style></keyword><keyword><style face="normal" font="default" size="100%">Quercetin</style></keyword><keyword><style face="normal" font="default" size="100%">Quercetin 3</style></keyword><keyword><style face="normal" font="default" size="100%">Quercetin 4′-glucoside</style></keyword><keyword><style face="normal" font="default" size="100%">Sucrose</style></keyword><keyword><style face="normal" font="default" size="100%">TEAC</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Onions, Allium cepa L., have been investigated with respect to distribution of sugars, fructo-oligosaccharides (FOS), flavonols, total antioxidant capacity (TEAC), pyruvate, dry weight content and total soluble solids (SSC) in the different edible scales of the bulbs. Six scales from the cultivars &apos;Red Baron&apos; and &apos;Hytech&apos; were analyzed in fresh onions. The red cultivar &apos;Red Baron&apos; showed an increase in SSC from 10.1 in the outermost to 12.8 °Brix in the innermost scales. The content of fructose decreased inwards whereas the content of sucrose showed a slight increase (both p &lt; 0.001). The level of glucose was nearly the same in the different scales. FOS was found to increase inwards (p &lt; 0.001). The total amount of flavonols in &apos;Red Baron&apos; was found to decrease inwards from 368 to 45 mg/100 g FW. The greatest drop in flavonol concentration was found between the first and the second scales in all samples. Quercetin 3,4′-diglucoside was the most predominant flavonol in all samples. Strong correlations (r = 0.90) were found between the total amounts of quercetins and the antioxidant capacities.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :6&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-73949142263&amp;partnerID=40&amp;md5=bb22737dffc69f54309d9b4a71ac7c3b</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>458</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">458</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Slimestad, R.</style></author><author><style face="normal" font="default" size="100%">Torskangerpoll, K.</style></author><author><style face="normal" font="default" size="100%">Nateland, H. S.</style></author><author><style face="normal" font="default" size="100%">Johannessen, T.</style></author><author><style face="normal" font="default" size="100%">Giske, N. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">PlantChem, P.O. Box 3082, N-4392 Ganddal, Sandnes, Norway&#xD;Department of Chemistry, University of Bergen, Allégt. 41, N-5007 Bergen, Norway&#xD;Polyphenols Laboratories AS, Hanaveien 4-6, N-4327 Sandnes, Norway&#xD;Rogaland Research, P.O. Box 8046, N-4068 Stavanger, Norway</style></auth-address><titles><title><style face="normal" font="default" size="100%">Flavonoids from black chokeberries, Aronia melanocarpa</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Food Composition and Analysis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Food Composition and Analysis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">61-68</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aronia melanocarpa</style></keyword><keyword><style face="normal" font="default" size="100%">Black chokeberries</style></keyword><keyword><style face="normal" font="default" size="100%">Flavanone</style></keyword><keyword><style face="normal" font="default" size="100%">Flavonols</style></keyword><keyword><style face="normal" font="default" size="100%">Rosaceae</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">Black chokeberry, Aronia melanocarpa (Michx.) Elliott (Rosaceae), was investigated for its flavonoid content. The flavanone eriodictyol 7-O-β-glucuronide (1) together with the quercetin derivatives 3-O-(6″-O-β-arabinosyl-β-glucoside) (2), 3-O-(6″-α-rhamnosyl-β-galactoside) (3), 3-O-(6″-α-rhamnosyl-β-glucoside) (4), 3-O-β-galactoside (5) and 3-O-β-glucoside (6), were detected in the fruits and flower umbels. The rare compounds 1-3 were isolated and structurally elucidated by use of 1D- and 2D-nuclear magnetic resonance experiments together with electrospray mass spectrometry. Compounds 4-6 were characterized by co-chromatography and by liquid chromatography-mass spectrometry. The black chokeberries contained &gt; 71 mg flavonols per 100 g fresh weight. © 2004 Elsevier Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :132&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-10344243487&amp;doi=10.1016%2fj.jfca.2003.12.003&amp;partnerID=40&amp;md5=7f3b2279f14a1c460be16edd457da073</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jfca.2003.12.003</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>304</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">304</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Slačanac, V.</style></author><author><style face="normal" font="default" size="100%">Hardi, J.</style></author><author><style face="normal" font="default" size="100%">Lučan, M.</style></author><author><style face="normal" font="default" size="100%">Božanić, R.</style></author><author><style face="normal" font="default" size="100%">Galić, S.</style></author><author><style face="normal" font="default" size="100%">Koceva-Komlenić, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Food Technology, J. J. Strossmayer University, Franje Kuhača 20, Osijek, Croatia&#xD;Faculty of Food Technology and Biotechnology, University in Zagreb, Pierottijeva 6, Zagreb, Croatia&#xD;Faculty of Medicine, J. J. Strossmayer University, J. Huttlera 4, Osijek, Croatia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevention of urogenital infections by oral administration of probiotic lactobacilli</style></title><secondary-title><style face="normal" font="default" size="100%">Mljekarstvo</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Mljekarstvo</style></full-title></periodical><pages><style face="normal" font="default" size="100%">156-165</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Oral ingestion</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotic lactobacilli</style></keyword><keyword><style face="normal" font="default" size="100%">Protective effect</style></keyword><keyword><style face="normal" font="default" size="100%">Urogenital infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><abstract><style face="normal" font="default" size="100%">In general, lactobacilli are nonpathogenic part of the normal urogenital microflora and have been recognized as a barrier against colonization of unwanted (pathogen) microflora. The results of many in vitro studies suggest following mechanisms of probiotic lactobacilli action in urogenital tract: adhesion to urogenital cells, competition with pathogens for adhesive sites, production of biosurfactants, co-aggregation with pathogens, production of antimicrobial substances (organic acids, hydrogen peroxide and bacteriocins) and stimulation of immune system. From 80 different lactobacilli species isolated from human or animal intestinal and urogenital tract, only few lactobacilli strains possess optimal properties to be effective as probiotic therapeutics against infections in the urogenital tract. Combination of Lactobacillus rhamnosus GR-1 and Lactobacillus fermentum RC-14 was proposed as the best one for epithelial vaginal cells colonization and inhibition of uropathogens adhesion. The results of a number of clinical studies confirmed beneficial role of oral lactobacilli. However, the most of commercially available Lactobacillus strains, which are ordinary used in fermented dairy products, are seriously limited in protection of urogenital tract when they are ingested orally.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-78650738668&amp;partnerID=40&amp;md5=673068ce9cd0735f73bfc91e0183780e</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>477</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">477</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Škerk, V.</style></author><author><style face="normal" font="default" size="100%">Krhen, I.</style></author><author><style face="normal" font="default" size="100%">Kalenić, S.</style></author><author><style face="normal" font="default" size="100%">Francetić, I.</style></author><author><style face="normal" font="default" size="100%">Baršić, B.</style></author><author><style face="normal" font="default" size="100%">Kuzmić, A. C.</style></author><author><style face="normal" font="default" size="100%">Derežić, D.</style></author><author><style face="normal" font="default" size="100%">Jeren, T.</style></author><author><style face="normal" font="default" size="100%">Kes, P.</style></author><author><style face="normal" font="default" size="100%">Kraus, O.</style></author><author><style face="normal" font="default" size="100%">Kuvačić, I.</style></author><author><style face="normal" font="default" size="100%">Andrašević, A. T.</style></author><author><style face="normal" font="default" size="100%">Tešović, G.</style></author><author><style face="normal" font="default" size="100%">Vrčić, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Klinika za Infektivne Bolesti Dr. F., Croatia&#xD;Klinika za Urologiju KBC-a Zagreb, Croatia&#xD;Klinicki Zavod za Klinicku I M., Croatia&#xD;Klinika za Unutrasnje B.&#xD;Klinika za Djecje Bolesti Klaiceva&#xD;Zavod za Dijalizu KBC-a Zagreb, Croatia&#xD;Klinika za Urologiju KB Sestre M.&#xD;Klinika za Zenske Bolesti I P., Croatia&#xD;Klinika za Infektivne Bolesti, Mirogojska c. 8, 10 000 Zagreb, Croatia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Guidelines for antimicrobial treatment and prophylaxis of urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Lijecnicki Vjesnik</style></secondary-title><short-title><style face="normal" font="default" size="100%">Smjernice antimikrobnog liječenja i profilakse infekcija mokraćnog sustava</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lijecnicki Vjesnik</style></full-title></periodical><pages><style face="normal" font="default" size="100%">169-181</style></pages><volume><style face="normal" font="default" size="100%">126</style></volume><number><style face="normal" font="default" size="100%">7-8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-infective agents, urinary - therapeutic use, administration and dosage</style></keyword><keyword><style face="normal" font="default" size="100%">Practice guidelines</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections - microbiology, drug therapy, prevention and control</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Recommendations for antimicrobial treatment and prophylaxis of urinary tract infections (UTI) have been made according to the results of investigation of resistance of the most frequent causative agents of UTI to antimicrobial drugs. This investigation has been conducted for the past seven years by the Committee for monitoring bacterial resistance to antibiotics in the Republic of Croatia, with consensus of eight professional societies of the Croatian Medical Association. Uncomplicated cystitis is treated 1, 3, or 7 days, complicated 7 days, pyelonephritis 10-14 days, and complicated UTI 7 to 14 days, rarely longer. For the treatment of cystitis fluorokinolons, nitrofurantoin, betalactam antibiotics, and in the fields of lower resistance trimethoprim/sulfamethoxazol are being used. Single treatment with fluorokinolons is administered to otherwise healthy young women with normal urinary tract in whom cystitis symptoms have been present for less than 7 days. Empiric antimicrobial treatment of pyelonephritis, recurrent and all complicated UTI must be reviewed after urine culture finding is obtained. In the treatment of bacterial prostatitis and febrile UTI in males, the drug of first choice is ciprofloxacin. Asymptomatic bacteriuria (AB) is treated in pregnant women, newborns, preschool children with urinary tract abnormalities, before invasive urologic and gynecologic procedures, in kidney transplant recipients, and in the first days of short term urinary bladder catheterization. Recommendations for the treatment of AB in patients with diabetes mellitus have been controversial in the past two years. Antimicrobial prophylaxis is administered mostly one hour prior to the diagnostic or therapeutic invasive urological procedure, using selected antimicrobial agents.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :25&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-19944432498&amp;partnerID=40&amp;md5=0b954c5e9eb4f5e18c41523f2bd9207f</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>336</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">336</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Škerk, V.</style></author><author><style face="normal" font="default" size="100%">Andrašević, A. T.</style></author><author><style face="normal" font="default" size="100%">Andrašević, S.</style></author><author><style face="normal" font="default" size="100%">Sušić, E.</style></author><author><style face="normal" font="default" size="100%">Džepina, M.</style></author><author><style face="normal" font="default" size="100%">Madarić, V.</style></author><author><style face="normal" font="default" size="100%">Milutinović, S.</style></author><author><style face="normal" font="default" size="100%">Ivan, K.</style></author><author><style face="normal" font="default" size="100%">Perić, L.</style></author><author><style face="normal" font="default" size="100%">Jugoslav, B.</style></author><author><style face="normal" font="default" size="100%">Ćorić, M.</style></author><author><style face="normal" font="default" size="100%">Daniel, F.</style></author><author><style face="normal" font="default" size="100%">Irina, C.</style></author><author><style face="normal" font="default" size="100%">Gordana, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Zavod za Infekcije I Mokraćnog Sustava i Nejasna Febrilna Stanja, Klinika za Infektivne Bolesfi, Mirogojska 8, 10000 Zagreb, Croatia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Iskra guidelines on antimicrobial treatment and prophylaxis of urinary tract infections - Croatian national guidelines</style></title><secondary-title><style face="normal" font="default" size="100%">Lijecnicki Vjesnik</style></secondary-title><short-title><style face="normal" font="default" size="100%">Iskra smjernice antimikrobnog liječenja iprofilakseinfekcija mokraćnog sustava - Hrvatske nacionalne smjernice</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lijecnicki Vjesnik</style></full-title></periodical><pages><style face="normal" font="default" size="100%">105-118</style></pages><volume><style face="normal" font="default" size="100%">131</style></volume><number><style face="normal" font="default" size="100%">5-6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antiinfective agents, urinary - therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial infections - drug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Croatia</style></keyword><keyword><style face="normal" font="default" size="100%">Practice guidelines as topic</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections - classification, diagnosis, drug therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">These guidelines refer to diagnosis, antimicrobial treatment and prophylaxis of urinary tract infections in adults and children older than 12 years of age and cover lower urinary tract in females, uncomplicated pyelonephritis, complicated UTI with or without pyelonephritis, asymptomatic bacteriuria and recurrent UTI. These guidelines do not cover sexually transmitted diseases. The guidelines are primarily intended for use by general practitioners and specialists working in primary health care and hospitals. The members of the Working Group for the development of guidelines on antimicrobial treatment and prophylaxis of urinary tract infections were appointed by the Croatian Ministry of Health and Social Welfare. The project was financially supported by the Dutch government and professional assistance was provided by international consultants. The evidence for this guidelines is based on a systematic review of the literature, local antibiotic resistance data, the existing clinical protocols on the treatment and prophylaxis of UTIs, as well as suggestions and comments made by colleagues physicians during more than 50 continuous medical education courses held in the last three years on antimicrobial treatment and prophylaxis of UTIs. Draft version of the guidelines was available for comments on the web site http://iskra.bfm.hr and during the two-month piloting period the guidelines were widely presented to general practitioners, specialists working in primary care and hospitals - urologists, gynecologists, infectious disease specialists, nephrologists. The final version of the guidelines was approved by the Intersectoral Coordination Mechanism for the Control of Antimicrobial Resistance (ISKRA) Board.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :26&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-68149160958&amp;partnerID=40&amp;md5=a43b7891412576c14f9380d15affbb12</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>79</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">79</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Singh, R.</style></author><author><style face="normal" font="default" size="100%">Multani, A.</style></author><author><style face="normal" font="default" size="100%">Cmar, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Geriatrie Pelvic Medicine and Neurourology, Department of Internal Medicine, Sinai Hospital of Baltimore, Baltimore, MD 21215, United States&#xD;Department of Medicine, Sinai Hospital of Baltimore, 2435 West Belvedere Ave, Hoffberger Bldg, Ste 56, Baltimore, MD 21215, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Microbiology of virulence: Urinary tract infection versus colonization</style></title><secondary-title><style face="normal" font="default" size="100%">Pelvic Floor Dysfunction and Pelvic Surgery in the Elderly: An Integrated Approach</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">77-89</style></pages><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85056509296&amp;doi=10.1007%2f978-1-4939-6554-0_6&amp;partnerID=40&amp;md5=51517eb42bad838296bf5c3773855ae9</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/978-1-4939-6554-0_6</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>109</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">109</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Singh, I.</style></author><author><style face="normal" font="default" size="100%">Gautam, L. K.</style></author><author><style face="normal" font="default" size="100%">Kaur, I. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departments of Surgery (Urology), University College of Medical Sciences (University of Delhi) &amp; GTB Hospital, Shahdara, Dilshad Garden, New Delhi, Delhi 110095, India&#xD;Departments of Microbiology, University College of Medical Sciences (University of Delhi) &amp; GTB Hospital, New Delhi, 95, India</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of oral cranberry extract (standardized proanthocyanidin-A) in patients with recurrent UTI by pathogenic E. coli: a randomized placebo-controlled clinical research study</style></title><secondary-title><style face="normal" font="default" size="100%">International Urology and Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Urology and Nephrology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1379-1386</style></pages><volume><style face="normal" font="default" size="100%">48</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">Non-antibiotic strategies</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidin-A</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Purpose: To evaluate the effect of cranberry extract (PAC-A ~ proanthocyanidin-A) on the in vitro bacterial properties of uropathogenic (E. coli) and its efficacy/tolerability in patients with subclinical or uncomplicated recurrent UTI (r-UTI). Materials and methods: After obtaining clearance from the ethics committee and administering a written informed consent, 72 patients with r-UTI were enrolled as per protocol (November 2011 to March 2013) in this prospective study, to randomly receive (PAC-A: group I, 36) or (placebo: group II, 36), for 12 weeks. Any change/reduction in the incidence of r-UTI at 12 weeks was construed to be the primary endpoint of this study. Results: After 12 weeks, bacterial adhesion scoring decreased (0.28)/(2.14) in group I/II (p &lt; 0.001); 32/36 (88.8 %) and 2/36 (5.5 %) in groups I and II, respectively, turned MRHA negative (p &lt; 0.001); biofilm (p &lt; 0.01) and bacterial growth (p &lt; 0.001) decreased in group I; microscopic pyuria score was 0.36/2.0 in group I/II (p &lt; 0.001); r-UTI decreased to 33.33 versus 88.89 % in group I/II (p &lt; 0.001); mean subjective dysuria score was 0.19 versus 1.47 in group I/II (p &lt; 0.001), while mean urine pH was 5.88 versus 6.30 in group I/II (p &lt; 0.001). No in vitro antibacterial activity of cranberry could be demonstrated, and no adverse events were noted. Conclusions: The overall efficacy and tolerability of standardized cranberry extract containing (PAC-A) as a food supplement were superior to placebo in terms of reduced bacterial adhesion; bacterial MRHA negativity; urine pH reduction; and in preventing r-UTI (dysuria, bacteriuria and pyuria). Larger randomized controlled trials are needed to elucidate the precise role, exact dose and optimal duration of PAC-A therapy in patients at risk of r-UTI. © 2016, Springer Science+Business Media Dordrecht.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :8&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84975109859&amp;doi=10.1007%2fs11255-016-1342-8&amp;partnerID=40&amp;md5=0547b7dc1202683ccf6e36343e2dc639</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s11255-016-1342-8</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>206</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">206</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Singer, S.</style></author><author><style face="normal" font="default" size="100%">Oberdorfer, K.</style></author><author><style face="normal" font="default" size="100%">Schwarz, R.</style></author><author><style face="normal" font="default" size="100%">Schütt, S.</style></author><author><style face="normal" font="default" size="100%">Bertsch, D.</style></author><author><style face="normal" font="default" size="100%">Holfelder, M.</style></author><author><style face="normal" font="default" size="100%">Wendt, C.</style></author><author><style face="normal" font="default" size="100%">Hof, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">MVZ Labor Dr. Limbach und Kollegen, Im Breitspiel 15, 69126 Heidelberg, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Calculated antibiotic therapy of urinary tract infections in elderly women: Importance of ciprofloxacin and other quinolones</style></title><secondary-title><style face="normal" font="default" size="100%">Gynakologe</style></secondary-title><short-title><style face="normal" font="default" size="100%">Kalkulierte Antibiotikatherapie von Harnwegsinfektionen bei älteren Frauen: Stellenwert von Ciprofloxacin und anderen Chinolonen</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Gynakologe</style></full-title></periodical><pages><style face="normal" font="default" size="100%">847-857</style></pages><volume><style face="normal" font="default" size="100%">46</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Asymptomatic bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">Cephalosporin</style></keyword><keyword><style face="normal" font="default" size="100%">Fosfomycin</style></keyword><keyword><style face="normal" font="default" size="100%">Nitrofurantoin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections are relatively frequent in older women over the age of 60 years. The most prevalent pathogen is Escherichia coli but the resistance to quinolones steadily increases with the age of the patient and reaches a rate of about 30% in patients over 80 years old. The side effects of quinolones, such as QT-time prolongation, tendopathy and central nervous system (CNS) disturbances are particularly pronounced in the elderly. Furthermore, quinolones produce collateral damage with serious consequences. As quinolones are concentrated in sweat and mucous secretions, the susceptible autochthonous flora will be eliminated opening the way for colonization by methicillin-resistant Staphylococcus aureus (MRSA). Some quinolones, especially those which are eliminated predominantly via the enteral pathway, such as ciprofloxacin, alter the fecal flora. In summary, quinolones are not suitable for the therapy of urinary tract infections in elderly women. Alternative antibiotics for the therapy of urinary tract infections in the elderly are cephalosporins and especially fosfomycin. For fosfomycin some limitations for use, namely age &gt;65 years and creatinine clearance &lt;80 ml/min have recently been lifted. © 2013 Springer-Verlag Berlin Heidelberg.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84888256015&amp;doi=10.1007%2fs00129-013-3271-2&amp;partnerID=40&amp;md5=a34ac94a6f4541b3208b079eb350fbe8</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00129-013-3271-2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>552</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">552</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Simeonov, S. B.</style></author><author><style face="normal" font="default" size="100%">Botushanov, N. P.</style></author><author><style face="normal" font="default" size="100%">Karahanian, E. B.</style></author><author><style face="normal" font="default" size="100%">Pavlova, M. B.</style></author><author><style face="normal" font="default" size="100%">Husianitis, H. K.</style></author><author><style face="normal" font="default" size="100%">Troev, D. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinic of Endocrinology, Medical University, Plovdiv, Bulgaria.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of Aronia melanocarpa juice as part of the dietary regimen in patients with diabetes mellitus</style></title><secondary-title><style face="normal" font="default" size="100%">Folia medica</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Folia medica</style></full-title></periodical><pages><style face="normal" font="default" size="100%">20-23</style></pages><volume><style face="normal" font="default" size="100%">44</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><abstract><style face="normal" font="default" size="100%">The low calorie juice Aronia melanocarpa (sugar free, with artificial sweeteners) could be a valuable adjunct to the complex therapy of patients with diabetes mellitus. In this study no increased blood glucose levels were established 60 min. following ingestion of 200 ml Aronia juice. On the contrary, lower fasting blood glucose concentrations were measured in 16 patients with insulin dependent diabetes and in 25 patients with non-insulin dependent diabetes (25 women and 16 men, 3 to 62 years of age, median age 38.8 +/- 4.7) with duration of the disease from 1 month to 13 years. Serial blood glucose measurements showed: 14.23 +/- 1.32 mmol/l at baseline and 11.4 +/- 0.89 mmol/l blood glucose level after 60 min., the difference being statistically significant (p&lt;0.05). The ingestion of 200 ml Aronia juice combined with a standard breakfast produced similar results (the basal concentration of glucose was 13.43 +/- 1.12 mmol/l; it decreased to 11.94 +/- 1.02 mmol/l at 60 min., the difference did not reach statistical significance. The daily intake of 200 ml Aronia juice over a period of 3 months was effective in lowering fasting blood glucose levels from 13.28 +/- 4.55 mmol/l to 9.10 +/- 3.05 mmol/l (p&lt;0.001) in 21 patients with non-insulin dependent diabetes--13 women and 8 men aged from 42 to 62 (median age 53.6 +/- 3.65) with disease duration from 6 to 17 years. Aronia had a beneficial effect on HbA1c, total cholesterol and lipid levels. They dropped from 9.39 +/- 2.16% to 7.49 +/- 1.33% (p&lt;0.001), from 6.45 +/- 1.59 mmol/l to 5.05 +/- 0.96 mmol/l (p&lt;0.001) and from 2.92 +/- 2.15 mmol/l to 1.7 +/- 1.07 mmol/l (p&lt;0.001), respectively. Results were compared with those obtained in 23 patients with non-insulin dependent diabetes (15 women and 8 men aged from 48 to 67 years, median age 54.9 +/- 3.34) with disease duration from 6 to 17 years. The above mentioned parameters remained unchanged in these patients. Accumulated data illustrated the hypoglycemic potential of Aronia juice. The precise mechanism of its action is unknown but its beneficial effects and good taste make it a valuable adjunct to the dietary treatment of patients with diabetes mellitus.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :50&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036987534&amp;partnerID=40&amp;md5=d91f6b66f1a6219b540c96b3c8fa5e5a</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>15</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">15</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sihra, N.</style></author><author><style face="normal" font="default" size="100%">Goodman, A.</style></author><author><style face="normal" font="default" size="100%">Zakri, R.</style></author><author><style face="normal" font="default" size="100%">Sahai, A.</style></author><author><style face="normal" font="default" size="100%">Malde, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom&#xD;Department of Infectious Diseases, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nonantibiotic prevention and management of recurrent urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">Nature Reviews Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nature Reviews Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">750-776</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">12</style></number><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTIs) are highly prevalent, lead to considerable patient morbidity, incur large financial costs to health-care systems and are one of the most common reasons for antibiotic use worldwide. The growing problem of antimicrobial resistance means that the search for nonantibiotic alternatives for the treatment and prevention of UTI is of critical importance. Potential nonantibiotic measures and treatments for UTIs include behavioural changes, dietary supplementation (such as Chinese herbal medicines and cranberry products), NSAIDs, probiotics, d-mannose, methenamine hippurate, estrogens, intravesical glycosaminoglycans, immunostimulants, vaccines and inoculation with less-pathogenic bacteria. Some of the results of trials of these approaches are promising; however, high-level evidence is required before firm recommendations for their use can be made. A combination of these agents might provide the optimal treatment to reduce recurrent UTI, and trials in specific population groups are required. © 2018, Springer Nature Limited.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055517701&amp;doi=10.1038%2fs41585-018-0106-x&amp;partnerID=40&amp;md5=3d01fff26e1c41d08427ec3eef0db7b6</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/s41585-018-0106-x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>359</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">359</key></foreign-keys><ref-type name="Serial">57</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shoaf-Sweeney, K. D.</style></author><author><style face="normal" font="default" size="100%">Hutkins, R. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Molecular Biosciences, Washington State University, Pullman, WA 99164, United States&#xD;Department of Food Science and Technology, University of Nebraska-Lincoln, Lincoln, NE 68583, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Chapter 2 Adherence, Anti-Adherence, and Oligosaccharides. Preventing Pathogens from Sticking to the Host</style></title><secondary-title><style face="normal" font="default" size="100%">Advances in Food and Nutrition Research</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">101-161</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">For many pathogenic bacteria, infections are initiated only after the organism has first adhered to the host cell surface. If adherence can be inhibited, then the subsequent infection can also be inhibited. This approach forms the basis of anti-adherence strategies, which have been devised to prevent a variety of bacterial infections. In this chapter, the molecular basis by which respiratory, urinary, and gastrointestinal tract pathogens adhere to host cells will be described. The five general types of anti-adherence agents will also be reviewed. The most well-studied are the receptor analogs, which include oligosaccharides produced synthetically or derived from natural sources, including milk, berries, and other plants. Their ability to inhibit pathogen adherence may lead to development of novel, food-grade anti-infective agents that are inexpensive and safe. © 2009 Elsevier Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :63&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-50349100592&amp;doi=10.1016%2fS1043-4526%2808%2900402-6&amp;partnerID=40&amp;md5=6eabcec1acd2913427ab0d0b5d7cbcbd</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S1043-4526(08)00402-6</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>401</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">401</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shmuely, H.</style></author><author><style face="normal" font="default" size="100%">Yahav, J.</style></author><author><style face="normal" font="default" size="100%">Samra, Z.</style></author><author><style face="normal" font="default" size="100%">Chodick, G.</style></author><author><style face="normal" font="default" size="100%">Koren, R.</style></author><author><style face="normal" font="default" size="100%">Niv, Y.</style></author><author><style face="normal" font="default" size="100%">Ofek, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Helicobacter Pylori Research Institute, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel&#xD;Department of Epidemiology and Preventive Medicine, School of Public Health, Tel Aviv University, Tel Aviv, Israel&#xD;Department of Human Microbiology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel&#xD;Department of Human Microbiology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 69978, Israel</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of cranberry juice on eradication of Helicobacter pylori in patients treated with antibiotics and a proton pump inhibitor</style></title><secondary-title><style face="normal" font="default" size="100%">Molecular Nutrition and Food Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Molecular Nutrition and Food Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">746-751</style></pages><volume><style face="normal" font="default" size="100%">51</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Eradication therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Helicobacter pylori</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry constituents are known to exert anti-adhesion activity on H. pylori in vitro. To determine their possible additive effect to triple therapy with omeprazole, amoxicillin and clarithromycin (OAC), a double-blind randomized clinical study was carried out. One-hundred-seventy-seven patients with H. pylori infection treated with OAC for 1 week were randomly allocated to receive 250 mL of either cranberry juice (cranberry-OAC, n = 89) or placebo beverage (placebo-OAC, n = 88) twice daily and only cranberry juice or placebo beverage for the next 2 weeks. Treatment outcome was determined with the 13C urea breath test (13C-UBT). An additional control group consisted of patients referred to the same center during the same period who were treated with OAC alone for 1 week (non-placebo-OAC, n = 712). Overall, the rate of H. pylori eradication (13C-UBT &amp;lt; 3.5) was 82.5%, with no statistically significant difference among the three arms. Analysis by gender revealed that for female subjects, the eradication rate was higher in the cranberry-OAC arm (n = 42, 95.2%) than in the placebo-OAC arm (n = 53, 86.8%) and significantly higher than in the non-placebo-OAC group (n = 425, 80%; p = 0.03). For males, the rate was nonsignificantly lower in the cranberry-OAC arm (n = 35, 73.9%) than in the placebo-OAC arm (n = 45, 80.0%) and non-placebo-OAC group (n = 287, 85.0%). These results suggest that the addition of cranberry to triple therapy improves the rate of H. pylori eradication in females. © 2007 WILEY-VCH Verlag GmbH &amp;amp; Co. KGaA, Weinheim.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :52&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-34447558532&amp;doi=10.1002%2fmnfr.200600281&amp;partnerID=40&amp;md5=864b81402d7710bfc8ba3644c0c48e5a</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/mnfr.200600281</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>476</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">476</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shmuely, H.</style></author><author><style face="normal" font="default" size="100%">Burger, O.</style></author><author><style face="normal" font="default" size="100%">Neeman, I.</style></author><author><style face="normal" font="default" size="100%">Yahav, J.</style></author><author><style face="normal" font="default" size="100%">Samra, Z.</style></author><author><style face="normal" font="default" size="100%">Niv, Y.</style></author><author><style face="normal" font="default" size="100%">Sharon, N.</style></author><author><style face="normal" font="default" size="100%">Weiss, E.</style></author><author><style face="normal" font="default" size="100%">Athamna, A.</style></author><author><style face="normal" font="default" size="100%">Tabak, M.</style></author><author><style face="normal" font="default" size="100%">Ofek, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Helicobacter Pylori Res. Institute, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel&#xD;Fac. of Food Eng. and Biotechnology, Israel Inst. of Technology-Technion, Haifa, Israel&#xD;Department of Biological Chemistry, The Weizmann Institute of Science, Rehovot, Israel&#xD;Department of Prosthodontics, Hadassah Hebrew Univ. Medical Center, Jerusalem, Israel&#xD;Triangle R. and D. Center, Kfar Qaraa, Israel&#xD;Department of Human Microbiology, Tel Aviv University, Tel Aviv, Israel</style></auth-address><titles><title><style face="normal" font="default" size="100%">Susceptibility of Helicobacter pylori isolates to the antiadhesion activity of a high-molecular-weight constituent of cranberry</style></title><secondary-title><style face="normal" font="default" size="100%">Diagnostic Microbiology and Infectious Disease</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Diagnostic Microbiology and Infectious Disease</style></full-title></periodical><pages><style face="normal" font="default" size="100%">231-235</style></pages><volume><style face="normal" font="default" size="100%">50</style></volume><number><style face="normal" font="default" size="100%">4</style></number><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">The sensitivity of a large number of antibiotic-resistant and nonresistant Helicobacter pylori isolates to the antiadhesion effect of a high-molecular-mass, nondialysable constituent of cranberry juice was tested. Confluent monolayers of gastric cell line in microtiter plate wells were exposed to bacterial suspensions prepared from 83 H. pylori isolates from antibiotic-treated and untreated patients in the presence and absence of the cranberry constituent. Urease assay was used to calculate the percentage of adhesion inhibition. In two thirds of the isolates, adhesion to the gastric cells was inhibited by 0.2 mg/mL of the nondialysable material. There was no relationship between the antiadhesion effect of the cranberry material and metronidazole resistance in isolates from either treated or untreated patients (N = 35). Only 13 isolates (16%) were resistant to both the nondialysable material and metronidazole, and 30 (36%) were resistant to the nondialysable material alone. There was no cross-resistance to the nondialysable material and metronidazole. These data suggest that a combination of antibiotics and a cranberry preparation may improve H. pylori eradication. © 2004 Elsevier Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :64&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-9944236359&amp;doi=10.1016%2fj.diagmicrobio.2004.08.011&amp;partnerID=40&amp;md5=e148c1ca243ad669d694a05836ad3d6b</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.diagmicrobio.2004.08.011</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>178</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">178</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shin, C. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Indiana State University, Terre Haute, IN, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Effects of Cranberries on Preventing Urinary Tract Infections</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Nursing Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Nursing Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">54-79</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">cranberries</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Despite considerable controversy about their effects, cranberries in various forms have been used widely for several decades to prevent as well as treat urinary tract infections (UTIs). The purpose of this article is to present a review of research-based information regarding the ability of cranberries to prevent UTIs in adults at risk for UTIs. Current evidence suggests that cranberries decrease bacterial adherence to uroepithelial cells and thus decrease the incidence of UTIs without adverse effects in most individuals. Thus clinicians may safely advise patients that cranberries are helpful in preventing UTIs. Cranberries may be a viable adjunct to antibiotics for patients with repeated UTIs. © The Author(s) 2013.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84893131467&amp;doi=10.1177%2f1054773813475448&amp;partnerID=40&amp;md5=34fdf63ceb8789bf214e937c491d887b</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/1054773813475448</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>108</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">108</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shim, Y. H.</style></author><author><style face="normal" font="default" size="100%">Lee, S. J.</style></author><author><style face="normal" font="default" size="100%">Lee, J. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Ewha Women&apos;s University School of Medicine, Seoul, South Korea</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antimicrobial activity of lactobacillus strains against uropathogens</style></title><secondary-title><style face="normal" font="default" size="100%">Pediatrics International</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pediatrics International</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1009-1013</style></pages><volume><style face="normal" font="default" size="100%">58</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">antibiotic disc</style></keyword><keyword><style face="normal" font="default" size="100%">inhibitory zone</style></keyword><keyword><style face="normal" font="default" size="100%">lactobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">uropathogen</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: The use of lactobacillus probiotics has been proposed as an alternative to prophylactic antibiotics for preventing urinary tract infection (UTI) in the era of antibiotic resistance. In this study, the antimicrobial activity of lactobacillus strains against uropathogens, was evaluated and compared with that of antibiotics. Methods: To evaluate inhibitory activities of lactobacilli against uropathogens, six lactobacillus strains (L. gasseri, L. rhamnosus, L. acidophilus, L. plantarum, L. paracasei, L. acidophilus) and four representative uropathogens of infantile UTI (extended-spectrum beta-lactamase [ESBL](−) Escherichia coli, ESBL(+) E. coli, Proteus vulgaris, Enterococcus fecalis) were selected. Lactobacillus strain in vitro inhibition of each uropathogen was evaluated on MRS agar well diffusion assay and compared with that of commercial antibiotic discs. Results: Average inhibitory zone for each of the six lactobacillus strains against the four uropathogens showed slightly different but consistent inhibition (inhibitory zone diameter, 10.5–20.0 mm). This was different to that of the antibiotic discs, which had a wider range of inhibition (inhibitory zone diameter, &lt;6.0–27.5 mm) depending on the uropathogen resistance pattern. The inhibitory zone of the six lactobacillus strains was between that of sensitive and resistant antibiotics (P &lt; 0.05). Conclusions: Lactobacillus strains had similar moderate antimicrobial activities against uropathogens. Further research is needed to ascertain the strains with the best probiotic potential. © 2016 Japan Pediatric Society</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :9&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84994165714&amp;doi=10.1111%2fped.12949&amp;partnerID=40&amp;md5=0a349e8c337e8165964a674f6ca2c679</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/ped.12949</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>64</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">64</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shi, Y. B.</style></author><author><style face="normal" font="default" size="100%">Yin, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Institute of Child Health and Human Development, National Institutes of Health, Molecular Morphogenesis, Bethesda, MD, United States&#xD;East Tennessee State University, Department of Internal Medicine, College of Medicine, Johnson City, TN, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">A good sugar, d-mannose, suppresses autoimmune diabetes</style></title><secondary-title><style face="normal" font="default" size="100%">Cell and Bioscience</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cell and Bioscience</style></full-title></periodical><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Autoimmune disease</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes</style></keyword><keyword><style face="normal" font="default" size="100%">Glucose</style></keyword><keyword><style face="normal" font="default" size="100%">Immunosuppression</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Mannose</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">It is well known that too much sugar uptake causes many health problems, including diabetes and obesity (Lustig et al. in Nature 482:27-29, 2012). However, a team of researchers led by Dr. Wanjun Chen of the National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), USA, have recently shown that d-mannose, a naturally occurring C-2 epimer of glucose is likely beneficial to human health. Their studies have revealed that supraphysiological levels of d-mannose that are safely achievable via drinking-water supplementation can be preventive and therapeutic to experimental autoimmune diabetes and asthmatic lung inflammation (Zhang et al. in Nat Med 23:1036-1045, 2017). © 2017 The Author(s).</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85029831660&amp;doi=10.1186%2fs13578-017-0175-1&amp;partnerID=40&amp;md5=26ecde91ddb8967be9d1076bd004e30b</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">48</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s13578-017-0175-1</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>508</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">508</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shi, T.</style></author><author><style face="normal" font="default" size="100%">Xiao, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Shanghai Sec. Med. Univ. Renji Hosp., Shanghai Inst. of Digestive Disease, Shanghai 200001, China</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry juice cocktail for prevention and treatment of helicobacter pylori infection in mice model</style></title><secondary-title><style face="normal" font="default" size="100%">Chinese Journal of Gastroenterology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Chinese Journal of Gastroenterology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">265-268</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry juice coctail</style></keyword><keyword><style face="normal" font="default" size="100%">Helicobacter infections/prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Helicobacter infections/therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Helicobacter pylori</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: It is well known that eradication of Helicobacter pylori (H. pylori) infection results in healing of peptic ulcer and regression of gastric mucosal inflammation. Cranberry juice cocktail has been shown to achieve good results in prevention of recurrent urinary tract infection. Aims: To investigate whether cranberry juice cocktail can eradicate or prevent H. pylori infection. Methods: In therapeutic trial, C57BL/6 mice were infected with H. pylori. Two weeks after infection, 80 mice were randomly allocated into four groups (20 mice per group). In group A, cranberry juice cocktail (0.5 ml/mouse, once a day) was administered orally for 30 days; In group B, triple therapy (amoxycillin 50 mg/kg, bismuth subcitrate 6.15 mg/kg, and metronidazole 22.5 mg/kg, once a day) was given for 14 days; In group C, a combination of cranberry juice cocktail and triple therapy was administered; In control group, the mice were infected with H. pylori but untreated. The mice (10 per group) were sacrificed and H. pylori infection was assessed by rapid urease test, culture and histopathology 24 hours and 4 weeks after therapeutic trial, respectively. In prevention trial, 40 mice were orally administered with cranberry juice cocktail (0.5 ml/mouse, once a day) for 25 days. In day 26-day 30, the mice were randomly divided into four groups (10 mice per group). In group A, challenged orally with H. pylori three times on the day 26, 28, 30 when the mice were not given cranberry juice cocktail; In group B, challenged with H. pylori suspended in juice for 30 min; In group C, challenged with H. pylori 6 hours after receiving juice; In control group, the mice were not given juice, but challenged with H. pylori. On the day 27 and 29, the juice was still administered in all groups. Two weeks later, the mice were sacrificed to assess the status of H. pylori infection. Results: In therapeutic trial, the clearance rates at 24 hours after treatment in group A, B and C were 80%, 100% and 90%, respectively (P&lt;0.01 compared with the controls). Four weeks after cessation of treatment the eradication rates in group A, B and C were 20% (P=0.474 compared with the controls), 80% and 80% (P&lt;0.01 compared with the controls), respectively. In prevention trial, no mice were prevented from H. pylori infection. Conclusions: Cranberry juice cocktail can clear H. pylori in mice model with the clearance rate 80%, but the eradication rate is low (20%). Cranberry juice cocktail is not effective in the prevention against H. pylori infection in the mice used in this study.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0346895503&amp;partnerID=40&amp;md5=cde35f4a657196d17a5a6aaa1c0e5a2d</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>213</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">213</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shepherd, A. K.</style></author><author><style face="normal" font="default" size="100%">Pottinger, P. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, University of Washington, 1959 Northeast Pacific Street, Box #356421, Seattle, WA 98195, United States&#xD;Division of Allergy and Infectious Diseases, University of Washington, 1959 Northeast Pacific Street, Box #356130, Seattle, WA 98195, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Management of Urinary Tract Infections in the Era of Increasing Antimicrobial Resistance</style></title><secondary-title><style face="normal" font="default" size="100%">Medical Clinics of North America</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Medical Clinics of North America</style></full-title></periodical><pages><style face="normal" font="default" size="100%">737-757</style></pages><volume><style face="normal" font="default" size="100%">97</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acute cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Fosfomycin</style></keyword><keyword><style face="normal" font="default" size="100%">Nitrofurantoin</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent UTI</style></keyword><keyword><style face="normal" font="default" size="100%">Resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Trimethoprim-sulfamethoxazole</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Antimicrobial resistance of urinary pathogens is increasing. Most urinary tract infections (UTIs) should still be treated empirically. However, patients with recurrence or other risk factors for resistance may benefit from urine culture. Patients with recurrent UTI often resort to antibiotic prevention, a risky proposition in terms of resistance. Non-antimicrobial preventative methods should be considered first. If preventative antibiotics must be used, postcoital patient-initiated protocols are effective and reduce overall antibiotic exposure compared with continuous prophylaxis. Consider referring patients for urologic evaluation when at risk for complicated UTIs or when recurrence continues despite conservative interventions. © 2013 Elsevier Inc..</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :27&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84879780307&amp;doi=10.1016%2fj.mcna.2013.03.006&amp;partnerID=40&amp;md5=f241a9694e20bc660925141a467f7e92</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.mcna.2013.03.006</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>431</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">431</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sharon, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biological Chemistry, The Weizmann Institute of Science, Rehovot, 76100, Israel</style></auth-address><titles><title><style face="normal" font="default" size="100%">Carbohydrates as future anti-adhesion drugs for infectious diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Biochimica et Biophysica Acta - General Subjects</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biochimica et Biophysica Acta - General Subjects</style></full-title></periodical><pages><style face="normal" font="default" size="100%">527-537</style></pages><volume><style face="normal" font="default" size="100%">1760</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bacterial lectin</style></keyword><keyword><style face="normal" font="default" size="100%">Combining site</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Fimbriae (pili)</style></keyword><keyword><style face="normal" font="default" size="100%">Three-dimensional strcuture</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">Adhesion of pathogenic organisms to host tissues is the prerequisite for the initiation of the majority of infectious diseases. In many systems, it is mediated by lectins present on the surface of the infectious organism that bind to complementary carbohydrates on the surface of the host tissues. Lectin-deficient mutants often lack the ability to initiate infection. The bacterial lectins are typically in the form of elongated submicroscopic multi-subunit protein appendages, known as fimbriae (or pili). The best characterized of these are the mannose-specific type 1 fimbriae, the galabiose-specific P fimbriae and the N-acetylglucosamine-specific fimbriae of Escherichia coli. Soluble carbohydrates recognized by the bacterial surface lectins block the adhesion of the bacteria to animal cells in vitro. Aromatic α-mannosides are potent inhibitors of type 1 fimbriated E. coli, being up to 1000 times more active than MeαMan, with affinities in the nanomolar range. This is due to the presence of a hydrophobic region next to the monosaccharide-binding site of the fimbriae, as recently demonstrated by X-ray studies. Polyvalent saccharides (e.g., neoglycoproteins or dendrimers) are also powerful inhibitors of bacterial adhesion in vitro. Very significantly, lectin-inhibitory saccharides have been shown to protect mice, rabbits, calves and monkeys against experimental infection by lectin-carrying bacteria. Since anti-adhesive agents do not act by killing or arresting the growth of the pathogens, it is very likely that strains resistant to such agents will emerge at a markedly lower rate than of strains that are resistant to antibiotics. Suitable sugars also inhibit the binding to cells of carbohydrate-specific toxins, among them those of Shigella dysenteriae Type 1, and of the homologous Verotoxins of E. coli, specific for galabiose. Appropriately designed polyvalent ligands are up to six orders of magnitude stronger inhibitors of toxin binding in vitro than the monovalent ones, and they protect mice against the Shigella toxin. The above data provide clear proof for the feasibility of anti-adhesion therapy of infectious diseases, although this has not yet been successful in humans. All in all, however, there is little doubt that inhibitors of microbial lectins will in the near future join the arsenal of drugs for therapy of infectious diseases. © 2006 Elsevier B.V. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :347&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33646103431&amp;doi=10.1016%2fj.bbagen.2005.12.008&amp;partnerID=40&amp;md5=59b6b112a012161a88af0647239d4d31</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.bbagen.2005.12.008</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>22</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">22</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sharma, V.</style></author><author><style face="normal" font="default" size="100%">Smolin, J.</style></author><author><style face="normal" font="default" size="100%">Nayak, J.</style></author><author><style face="normal" font="default" size="100%">Ayala, J. E.</style></author><author><style face="normal" font="default" size="100%">Scott, D. A.</style></author><author><style face="normal" font="default" size="100%">Peterson, S. N.</style></author><author><style face="normal" font="default" size="100%">Freeze, H. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA 92037, United States&#xD;Sanford-Burnham-Prebys Medical Discovery Institute, Orlando, FL 32827, United States&#xD;Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mannose Alters Gut Microbiome, Prevents Diet-Induced Obesity, and Improves Host Metabolism</style></title><secondary-title><style face="normal" font="default" size="100%">Cell Reports</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cell Reports</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3087-3098</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">16S</style></keyword><keyword><style face="normal" font="default" size="100%">gut microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">high-fat diet</style></keyword><keyword><style face="normal" font="default" size="100%">mannose</style></keyword><keyword><style face="normal" font="default" size="100%">metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">obesity</style></keyword><keyword><style face="normal" font="default" size="100%">prebiotic</style></keyword><keyword><style face="normal" font="default" size="100%">RNA-seq</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Mannose is an important monosaccharide for protein glycosylation in mammals but is an inefficient cellular energy source. Using a C57BL6/J mouse model of diet-induced obesity, we show that mannose supplementation of high-fat-diet-fed mice prevents weight gain, lowers adiposity, reduces liver steatosis, increases endurance and maximal O2 consumption, and improves glucose tolerance. Mannose-supplemented mice have higher fecal energy content, suggesting reduced caloric absorption by the host. Mannose increases the Bacteroidetes to Firmicutes ratio in the gut microbiota, a signature associated with the lean phenotype. These beneficial effects of mannose are observed when supplementation is started early in life. Functional transcriptomic analysis of cecal microbiota revealed profound and coherent changes in microbial energy metabolism induced by mannose that are predicted to lead to reduced energy harvest from complex carbohydrates by gut microbiota. Our results suggest that the gut microbiota contributes to mannose-induced resistance to deleterious effects of a high-fat diet. Video Abstract: [Figure presented] Sharma et al. show that mannose supplementation prevents adverse outcomes of high-fat diet when initiated early in life, not when provided later. Beneficial effects correlate with changes in gut microbial composition and could be partly attributed to lower energy harvest by the gut microbiota and host energy absorption. © 2018 The Authors</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052987665&amp;doi=10.1016%2fj.celrep.2018.08.064&amp;partnerID=40&amp;md5=1af3e3328499e57f079a688d5820fd1c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.celrep.2018.08.064</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>190</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sharma, V.</style></author><author><style face="normal" font="default" size="100%">Nayak, J.</style></author><author><style face="normal" font="default" size="100%">DeRossi, C.</style></author><author><style face="normal" font="default" size="100%">Charbono, A.</style></author><author><style face="normal" font="default" size="100%">Ichikawa, M.</style></author><author><style face="normal" font="default" size="100%">Ng, B. G.</style></author><author><style face="normal" font="default" size="100%">Grajales-Esquivel, E.</style></author><author><style face="normal" font="default" size="100%">Srivastava, A.</style></author><author><style face="normal" font="default" size="100%">Wang, L.</style></author><author><style face="normal" font="default" size="100%">He, P.</style></author><author><style face="normal" font="default" size="100%">Scott, D. A.</style></author><author><style face="normal" font="default" size="100%">Russell, J.</style></author><author><style face="normal" font="default" size="100%">Contreras, E.</style></author><author><style face="normal" font="default" size="100%">Guess, C. M.</style></author><author><style face="normal" font="default" size="100%">Krajewski, S.</style></author><author><style face="normal" font="default" size="100%">Del Rio-Tsonis, K.</style></author><author><style face="normal" font="default" size="100%">Freeze, H. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sanford-Burnham Medical Research Institute (SBMRI), 10901 North Torrey Pines Road, San Diego, CA 92037, United States&#xD;Department of Biology, Miami University, Oxford, OH, United States&#xD;Center for Child and Adolescent Medicine, Center for Metabolic Diseases Heidelberg, Department Kinderheilkunde I, Heidelberg, Germany&#xD;Global Institute of Stem Cell Therapy and Research, 4370 La Jolla Village Dr., San Diego, CA 92122, United States&#xD;Janssen Research and Development, LLC, 3210 Merryfield Row, San Diego, CA 92121, United States&#xD;Riley Children&apos;s Specialists, 11725 N. Illinois St., Carmel, IN 46032, United States&#xD;St. Jude Children&apos;s Research Hospital, 262 Danny Thomas Pl., Memphis, TN 38105-2794, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mannose supplements induce embryonic lethality and blindness in phosphomannose isomerase hypomorphic mice</style></title><secondary-title><style face="normal" font="default" size="100%">FASEB Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">FASEB Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1854-1869</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Congenital disorder of glycosylation</style></keyword><keyword><style face="normal" font="default" size="100%">Eye defects</style></keyword><keyword><style face="normal" font="default" size="100%">Lens</style></keyword><keyword><style face="normal" font="default" size="100%">MPI-CDG</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Patients with congenital disorder of glycosylation (CDG), type Ib (MPI-CDG or CDG-Ib) have mutations in phosphomannose isomerase (MPI) that impair glycosylation and lead to stunted growth, liver dysfunction, coagulopathy, hypoglycemia, and intestinal abnormalities. Mannose supplements correct hypoglycosylation and most symptoms by providing mannose- 6-P (Man-6-P) via hexokinase. We generated viable Mpi hypomorphic mice with residual enzymatic activity comparable to that of patients, but surprisingly, these mice appeared completely normal except for modest (̃15%) embryonic lethality. To overcome this lethality, pregnant dams were provided 1-2% mannose in their drinking water. However, mannose further reduced litter size and survival to weaning by 40 and 66%, respectively. Moreover, ̃50% of survivors developed eye defects beginning around midgestation. Mannose started at birth also led to eye defects but had no effect when started after eye development was complete. Man-6-P and related metabolites accumulated in the affected adult eye and in developing embryos and placentas. Our results demonstrate that disturbing mannose metabolic flux in mice, especially during embryonic development, induces a highly specific, unanticipated pathological state. It is unknown whether mannose is harmful to human fetuses during gestation; however, mothers who are at risk for having MPI-CDG children and who consume mannose during pregnancy hoping to benefit an affected fetus in utero should be cautious. © FASEB.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :10&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84898940011&amp;doi=10.1096%2ffj.13-245514&amp;partnerID=40&amp;md5=35019e876548d0e8d82498055e873779</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1096/fj.13-245514</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>169</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">169</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sharma, V.</style></author><author><style face="normal" font="default" size="100%">Ichikawa, M.</style></author><author><style face="normal" font="default" size="100%">Freeze, H. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sanford-Burnham Medical Research Institute, La Jolla, CA 92037, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mannose metabolism: More than meets the eye</style></title><secondary-title><style face="normal" font="default" size="100%">Biochemical and Biophysical Research Communications</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biochemical and Biophysical Research Communications</style></full-title></periodical><pages><style face="normal" font="default" size="100%">220-228</style></pages><volume><style face="normal" font="default" size="100%">453</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Congenital disorders of glycosylation</style></keyword><keyword><style face="normal" font="default" size="100%">Mannose</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">N-glycosylation</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphomannomutase</style></keyword><keyword><style face="normal" font="default" size="100%">Phosphomannose isomerase</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Mannose is a simple sugar with a complex life. It is a welcome therapy for genetic and acquired human diseases, but it kills honeybees and blinds baby mice. It could cause diabetic complications. Mannose chemistry, metabolism, and metabolomics in cells, tissues and mammals can help explain these multiple systemic effects. Mannose has good, bad or ugly outcomes depending on its steady state levels and metabolic flux. This review describes the role of mannose at cellular level and its impact on organisms. © 2014 Elsevier Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :33&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84908460711&amp;doi=10.1016%2fj.bbrc.2014.06.021&amp;partnerID=40&amp;md5=7b619418290c7f2f1eb9f6502346887c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.bbrc.2014.06.021</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>396</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">396</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shamseer, L.</style></author><author><style face="normal" font="default" size="100%">Vohra, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Complementary and Alternative Research and Education (CARE) Program, Department of Pediatrics, University of Alberta, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Complementary, holistic, and integrative medicine: Cranberry</style></title><secondary-title><style face="normal" font="default" size="100%">Pediatrics in Review</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pediatrics in Review</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e43-e45</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><number><style face="normal" font="default" size="100%">8</style></number><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">The use of cranberries and cranberry juice in UTI prophylaxis has been explored and confirmed to have a benieficial effect in adult populations. In contrast, these findings have not been evaluated fully and cannot be confirmed in pediatric populations; the only studies to date have been in patients who have neurogenic bladder and required intermittent catheterization and who may not reflect other pediatric populations. In the absence of high-quality, well-designed trials in children, it is premature to prescribe cranberry as a sole means for preventing UTI in high-risk populations. However, given the mild nature of documented adverse effects of cranberries, their use as a natural constituent of the diet can be encouraged to maintain health.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Short Survey</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-34548012192&amp;doi=10.1542%2fpir.28-8-e43&amp;partnerID=40&amp;md5=8961f4c660346a25d3e98aa66965bbd8</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1542/pir.28-8-e43</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>228</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">228</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shaikh, T.</style></author><author><style face="normal" font="default" size="100%">Dasgupta, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Charing Cross Hospital, Imperial College Healthcare NHS Trust, Fulham Palace Road, London, W6 8RF, United Kingdom&#xD;Department of Urology, Imperial College Healthcare NHS Trust, St Mary&apos;s Hospital, Praed Street, London, W2 1NY, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infection in diabetic patients</style></title><secondary-title><style face="normal" font="default" size="100%">Urinary Tract Infection: Clinical Perspectives on Urinary Tract Infection</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">45-51</style></pages><keywords><keyword><style face="normal" font="default" size="100%">Diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetic</style></keyword><keyword><style face="normal" font="default" size="100%">Emphysematous pyelonephritis</style></keyword><keyword><style face="normal" font="default" size="100%">Papillary necrosis</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Certain groups of patient are at higher risk of UTI, for example, diabetics. We discuss the reasons why they are more prone in this chapter. We also touch upon the more severe complications, which the reader should be aware of, such as emphysematous pyelonephritis. Some of these cases require urgent surgery, and therefore it is essential that the clinician has a low threshold of suspicion in cases of urosepsis in diabetics, and therefore early involvement of urological input is justified. © Springer-Verlag London 2013.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84956621946&amp;doi=10.1007%2f978-1-4471-4709-1_5&amp;partnerID=40&amp;md5=fa65ce58de559d65dd0025668cdb4493</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/978-1-4471-4709-1_5</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>382</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">382</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shaikh, N.</style></author><author><style face="normal" font="default" size="100%">Morone, N. E.</style></author><author><style face="normal" font="default" size="100%">Bost, J. E.</style></author><author><style face="normal" font="default" size="100%">Farrell, M. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of General Academic Pediatrics, Center for Research on Health Care, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States&#xD;Division of General Internal Medicine, Center for Research on Health Care, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States&#xD;Center for Research on Health Care, University of Pittsburgh, Pittsburgh, PA, United States&#xD;Children&apos;s Hospital of Pittsburgh, General Academic Pediatrics, 3705 Fifth Ave., Pittsburgh, PA 15213-2583, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevalence of urinary tract infection in childhood: A meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Pediatric Infectious Disease Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pediatric Infectious Disease Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">302-308</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Meta-analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Pediatrics</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">BACKGROUND: Knowledge of baseline risk of urinary tract infection can help clinicians make informed diagnostic and therapeutic decisions. We conducted a meta-analysis to determine the pooled prevalence of urinary tract infection (UTI) in children by age, gender, race, and circumcision status. METHODS: MEDLINE and EMBASE databases were searched for articles about pediatric urinary tract infection. Search terms included urinary tract infection, cystitis, pyelonephritis, prevalence and incidence. We included articles in our review if they contained data on the prevalence of UTI in children 0-19 years of age presenting with symptoms of UTI. Of the 51 articles with data on UTI prevalence, 18 met all inclusion criteria. Two evaluators independently reviewed, rated, and abstracted data from each article. RESULTS: Among infants presenting with fever, the overall prevalence (and 95% confidence interval) of UTI was 7.0% (CI: 5.5-8.4). The pooled prevalence rates of febrile UTIs in females aged 0-3 months, 3-6 months, 6-12 months, and &gt;12 months was 7.5%, 5.7%, 8.3%, and 2.1% respectively. Among febrile male infants less than 3 months of age, 2.4% (CI: 1.4-3.5) of circumcised males and 20.1% (CI: 16.8-23.4) of uncircumcised males had a UTI. For the 4 studies that reported UTI prevalence by race, UTI rates were higher among white infants 8.0% (CI: 5.1-11.0) than among black infants 4.7% (CI: 2.1-7.3). Among older children (&lt;19 years) with urinary symptoms, the pooled prevalence of UTI (both febrile and afebrile) was 7.8% (CI: 6.6-8.9). CONCLUSIONS: Prevalence rates of UTI varied by age, gender, race, and circumcision status. Uncircumcised male infants less than 3 months of age and females less than 12 months of age had the highest baseline prevalence of UTI. Prevalence estimates can help clinicians make informed decisions regarding diagnostic testing in children presenting with signs and symptoms of urinary tract infection. © 2008 Lippincott Williams &amp; Wilkins, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :294&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-41649092088&amp;doi=10.1097%2fINF.0b013e31815e4122&amp;partnerID=40&amp;md5=b1cbd35766547fb31e2dc74c39e011c6</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/INF.0b013e31815e4122</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>248</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">248</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shah, P. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Infectious Diseases, Auf dem Muehlberg 30c, D-60599, Frankfurt am Main, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections in immunocompetent adult patients - an update</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Applied Therapeutic Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Applied Therapeutic Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">146-157</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Guidelines</style></keyword><keyword><style face="normal" font="default" size="100%">Management</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword><keyword><style face="normal" font="default" size="100%">Review</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">The term urinary tract infections (UTIs) is applied to diverse clinical conditions ranging from asymptomatic lower tract infections to complicated upper tract infections. They can be subdivided according to clinical presentation, anatomical location and complicating factors. The prevalence of UTI is highly dependent on age and gender. It is assumed that 40-50% of females experience at least one episode during life time and one-fifth of them at least one episode per year. Females are affected four times more often than males. Well-defined risk factors in women are: mode of contraception, recent sexual intercourse, menstrual cycle, menopausal status and history of recurrent infection. Recent urethral catheterisation is universally accepted risk factor for UTI in both gender. Careful assessment of symptoms helps diagnose and classification of UTI in routine practice and selected simple laboratory tests help confirm the diagnosis. It is essential to differentiate between an uncomplicated and a complicated UTI because of implications with regard to treatment, treatment duration and pre- and post-treatment evaluation. Guidelines for management of UTIs should be based on knowledge of local data on epidemiology and resistance of pathogens to antibiotics. © 2012 Euromed Communications Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84862219877&amp;partnerID=40&amp;md5=1d954d66069e016955eb382b37d537f8</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>471</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">471</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Senok, A. C.</style></author><author><style face="normal" font="default" size="100%">Ismaeel, A. Y.</style></author><author><style face="normal" font="default" size="100%">Botta, G. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology, Immunology and Infectious Diseases, College of Medicine and Medical Sciences, Arabian Gulf University, PO Box 22979, Manama, Bahrain&#xD;Department of Medical Research, Medical School, Udine, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Probiotics: Facts and myths</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Microbiology and Infection</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Microbiology and Infection</style></full-title></periodical><pages><style face="normal" font="default" size="100%">958-966</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Diarrhoea</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal health</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Review</style></keyword><keyword><style face="normal" font="default" size="100%">Urogenital infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">In recent years there has been a significant upsurge in research on the characterisation and verification of the potential health benefits associated with the use of probiotics. In addition, the market for probiotics continues to expand exponentially as consumers (mostly healthy individuals) rely on health claims made by manufacturers to make their choices. This review appraises the available evidence for and against the health claims associated with probiotics. The use of probiotics in promoting gastrointestinal health and immunity, and their use in the prevention of urogenital infections, allergies and cancer are reviewed. Furthermore, issues surrounding the use of probiotics in healthy individuals, the safety of probiotics and regulatory concerns are addressed. There is scientific evidence that specific strains of probiotic microorganisms confer health benefits on the host and are safe for human use. However, this evidence cannot be extrapolated to other strains, as these effects are strain-specific. Probiotics have potential health benefits for conditions such as gastrointestinal infections, genitourinary infections, allergies and certain bowel disorders, all of which afflict a considerable proportion of the global population. However, considerable work is still needed to confirm these potential health benefits. © 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :155&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-28644441328&amp;doi=10.1111%2fj.1469-0691.2005.01228.x&amp;partnerID=40&amp;md5=cb8ace5252a7491a5efa6b60fa1da735</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1469-0691.2005.01228.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>262</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">262</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Semins, M. J.</style></author><author><style face="normal" font="default" size="100%">Shore, A. D.</style></author><author><style face="normal" font="default" size="100%">Makary, M. A.</style></author><author><style face="normal" font="default" size="100%">Weiner, J.</style></author><author><style face="normal" font="default" size="100%">Matlaga, B. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Johns Hopkins University, School of Medicine, Baltimore, MD, United States&#xD;Department of Surgery, Johns Hopkins University, School of Medicine, Baltimore, MD, United States&#xD;Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD, United States&#xD;Departments of Health Policy and Management, Johns Hopkins School of Public Health, Baltimore, MD, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">The impact of obesity on urinary tract infection risk</style></title><secondary-title><style face="normal" font="default" size="100%">Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">266-269</style></pages><volume><style face="normal" font="default" size="100%">79</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: To perform a study to describe the way in which an increasingly obese body mass index (BMI) is associated with urinary tract infection (UTI). The association between UTI and obesity is not well characterized. In fact, previous investigations of this subject have yielded conflicting findings. UTI is increasingly being recognized as a preventable complication, and UTI rates are used to measure quality of surgical care. Materials and Methods: We evaluated claims over a 5-year period (2002-2006) in a national private claims database to identify patients diagnosed with UTI or pyelonephritis by ICD-9 coding. Descriptive analyses were performed and odds ratios were calculated. Results: A total of 95,598 subjects were identified for evaluation. Gender distribution was 42.9% male and 57.1% female. In the overall study cohort, the diagnosis of a UTI or pyelonephritis occurred in 13% and 0.84%, respectively. Women were 4.2 times more likely to be diagnosed with a UTI (19.3% vs 4.6%), and 3.6 times more likely to be diagnosed with pyelonephritis (1.22% vs 0.34%), than were men. At all stratifications of obesity, the obese were significantly more likely to be diagnosed with a UTI or pyelonephritis than nonobese patients. Conclusion: Elevated BMI appears to be associated with an increased risk for UTI and pyelonephritis. Further study is needed to determine whether this association may be attributed to a cause-and-effect relationship. However, these results may serve to guide clinicians who treat obese patients, because it may be an additional benefit of weight loss. © 2012 Elsevier Inc. All Rights Reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :54&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84856695855&amp;doi=10.1016%2fj.urology.2011.09.040&amp;partnerID=40&amp;md5=b4e4cafaac7ac4e1ba4ca9bc3d5d713d</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.urology.2011.09.040</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>54</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">54</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Segev, G.</style></author><author><style face="normal" font="default" size="100%">Sykes, J. E.</style></author><author><style face="normal" font="default" size="100%">Klumpp, D. J.</style></author><author><style face="normal" font="default" size="100%">Schaeffer, A. J.</style></author><author><style face="normal" font="default" size="100%">Antaki, E. M.</style></author><author><style face="normal" font="default" size="100%">Byrne, B. A.</style></author><author><style face="normal" font="default" size="100%">Yaggie, R. E.</style></author><author><style face="normal" font="default" size="100%">Westropp, J. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, Israel&#xD;Departments of Veterinary Medicine and Epidemiology, University of California Davis, Davis, CA, United States&#xD;Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States&#xD;Western Center for Food Safety, University of California Davis, Davis, CA, United States&#xD;Department of Pathology, Microbiology and Immunology, University of California Davis, Davis, CA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation of the Live Biotherapeutic Product, Asymptomatic Bacteriuria Escherichia coli 2-12, in Healthy Dogs and Dogs with Clinical Recurrent UTI</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Veterinary Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Veterinary Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">267-273</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antimicrobial resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Dog</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Antimicrobial resistance is an emerging problem. Hypothesis/Objective: To investigate the safety and efficacy of a live biotherapeutic product, ASB E. coli 2-12 for UTI treatment. Animals: Six healthy research dogs; nine client-owned dogs with recurrent UTI. Methods: Prospective noncontrolled clinical trial. For safety data, research dogs were sedated, a urinary catheter was inserted into the bladder; 1010 CFU/mL of ASB E. coli 2-12 was instilled. Urine was cultured on days 1, 3, and 8 post-instillation and dogs were observed for lower urinary tract signs (LUTS). For client-owned dogs, ASB E. coli 2-12 was instilled similarly and urine cultures analyzed on days 1, 7, and 14 days postinstillation. Results: No LUTS were noted in any of the 6 research dogs after ASB E. coli 2-12 infusion. Pulse field gel electrophoresis (PFGE) studies confirmed the bacterial strains isolated matched that ASB E. coli 2-12 strain. Four of the nine client-owned dogs had complete or nearly complete clinical cures by day 14. Of these four dogs, 3 also had microbiologic cures at day 14; one of these dogs had subclinical bacteriuria (in addition to ASB E. coli 2-12). Three of these four dogs had ASB E. coli 2-12 isolated from their urine at day 14. With the exception of mild, temporary, self-limiting, hyporexia in two dogs on the day of biotherapeutic administration, there were no major adverse effects. Conclusions and Clinical Importance: These results suggest ASB E. coli 2-12 is safe and should be investigated in a larger controlled study evaluating clinical UTI in dogs. Copyright © 2017 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040992044&amp;doi=10.1111%2fjvim.14851&amp;partnerID=40&amp;md5=76ee97158a916f4b36c4e243a1061552</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/jvim.14851</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>386</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">386</key></foreign-keys><ref-type name="Serial">57</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Seeram, N. P.</style></author><author><style face="normal" font="default" size="100%">Heber, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Human Nutrition, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of berry phytochemicals on human health: Effects beyond antioxidation</style></title><secondary-title><style face="normal" font="default" size="100%">ACS Symposium Series</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">326-336</style></pages><volume><style face="normal" font="default" size="100%">956</style></volume><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">It is now well accepted that a phytochemical rich diet contributes towards reducing the risk of oxidative-stress mediated diseases such as certain types of cancers, heart and neurodegenerative diseases. Phytochemical rich foods include fruits, vegetables, whole grains, spices, and certain beverages and other food products such as tea, wine, beer, chocolate, cocoa, etc. Among fruits, berries contain high levels of a diversity of phytochemicals known as phenolics including flavonoids (anthocyanins, flavonols and flavanols), proanthocyanidins, ellagitannins and gallotannins, stilbenoids and phenolic acids. Popularly consumed berries include blackberries, black raspberries, blueberries, cranberries, raspberries and strawberries. Although berry phenolics are potent in vitro antioxidants, they exert in vivo biological activities beyond antioxidation and can have complementary and overlapping mechanisms of action. For example, berry phenolics can impart preventive benefits through the regulation of enzymes important in metabolizing xenobiotics and carcinogens, by modulating nuclear receptors, gene expression and sub-cellular signaling of proliferation and apoptosis, and by acting indirectly through antioxidant actions that protect DNA from damage. This overview examines the impact of consumption of natural berry bioactive compounds on human health and disease prevention. © 2007 American Chemical Society.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :18&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Conference Paper</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-36749008497&amp;partnerID=40&amp;md5=fbdc3aec93b5d0a860ae99087185b555</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>137</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">137</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schwenger, E. M.</style></author><author><style face="normal" font="default" size="100%">Tejani, A. M.</style></author><author><style face="normal" font="default" size="100%">Loewen, P. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of British Columbia, Department of Pharmaceutical Sciences, 2146 East Mall, Vancouver, BC V6T 1Z3, Canada&#xD;University of British Columbia, Therapeutics Initiative, 2176 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada&#xD;University of British Columbia, 865 W. 10th Ave, Vancouver, BC V5Z 1M9, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Probiotics for preventing urinary tract infections in adults and children</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><volume><style face="normal" font="default" size="100%">2015</style></volume><number><style face="normal" font="default" size="100%">12</style></number><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Urinary tract infection (UTI) is a common bacterial infection that can lead to significant morbidity including stricture, abscess formation, fistula, bacteraemia, sepsis, pyelonephritis and kidney dysfunction. Mortality rates are reported to be as high as 1% in men and 3% in women due to development of pyelonephritis. Because probiotic therapy is readily available without a prescription, a review of their efficacy in the prevention of UTI may aid consumers in making informed decisions about potential prophylactic therapy. Institutions and caregivers also need evidence-based synopses of current evidence to make informed patient care decisions. Objectives: Compared to placebo or no therapy, did probiotics (any formulation) provide a therapeutic advantage in terms of morbidity and mortality, when used to prevent UTI in susceptible patient populations? Compared to other prophylactic interventions, including drug and non-drug measures (e.g. continuous antibiotic prophylaxis, topical oestrogen, cranberry juice), did probiotics (any formulation) provide a therapeutic advantage in terms of morbidity and mortality when used to prevent UTIs in susceptible patient populations? Search methods: We searched the Cochrane Kidney and Transplant Specialised Register to 21 September 2015 through contact with the Trials&apos; Search Co-ordinator using search terms relevant to this review. Selection criteria: Randomised controlled trials (RCTs) of susceptible patients (e.g. past history of UTI) or healthy people in which any strain, formulation, dose or frequency of probiotic was compared to placebo or active comparators were included. Data collection and analysis: All RCTs and quasi-RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at comparing probiotics to no therapy, placebo, or other prophylactic interventions were included. Summary estimates of effect were obtained using a random-effects model, and results were expressed as risk ratios (RR) and their 95% confidence intervals (CI) for dichotomous outcomes. Main results: We included nine studies that involved 735 people in this review. Four studies compared probiotic with placebo, two compared probiotic with no treatment, two compared probiotics with antibiotics in patients with UTI, and one study compared probiotic with placebo in healthy women. All studies aimed to measure differences in rates of recurrent UTI. Our risk of bias assessment found that most studies had small sample sizes and reported insufficient methodological detail to enable robust assessment. Overall, there was a high risk of bias in the included studies which lead to inability to draw firm conclusions and suggesting that any reported treatment effects may be misleading or represent overestimates. We found no significant reduction in the risk of recurrent symptomatic bacterial UTI between patients treated with probiotics and placebo (6 studies, 352 participants: RR 0.82, 95% CI 0.60 to 1.12; I2 = 23%) with wide confidence intervals, and statistical heterogeneity was low. No significant reduction in the risk of recurrent symptomatic bacterial UTI was found between probiotic and antibiotic treated patients (1 study, 223 participants: RR 1.12, 95% CI 0.95 to 1.33). The most commonly reported adverse effects were diarrhoea, nausea, vomiting, constipation and vaginal symptoms. None of the included studies reported numbers of participants with at least one asymptomatic bacterial UTI, all-cause mortality or those with at least one confirmed case of bacteraemia or fungaemia. Two studies reported study withdrawal due to adverse events and the number of participants who experienced at least one adverse event. One study reported withdrawal occurred in six probiotic participants (5.2%), 15 antibiotic participants (12.2%), while the second study noted one placebo group participant discontinued treatment due to an adverse event. Authors&apos; conclusions: No significant benefit was demonstrated for probiotics compare with placebo or no treatment, but a benefit cannot be ruled out as the data were few, and derived from small studies with poor methodological reporting. There was limited information on harm and mortality with probiotics and no evidence on the impact of probiotics on serious adverse events. Current evidence cannot rule out a reduction or increase in recurrent UTI in women with recurrent UTI who use prophylactic probiotics. There was insufficient evidence from one RCT to comment on the effect of probiotics versus antibiotics. © 2015 The Cochrane Collaboration.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :50&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84962392552&amp;doi=10.1002%2f14651858.CD008772.pub2&amp;partnerID=40&amp;md5=f5fbf594ffaf8e8720fe1af1417dd7df</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">Cd008772</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD008772.pub2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>577</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">577</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Scholes, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Health Studies, Group Health Cooperative of Puget Sound, Seattle, WA 98101, United States&#xD;Department of Epidemiology, School of Public Health and Community Medicine, United States&#xD;Department of Medicine, School of Medicine, University of Washington, Seattle, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Risk factors for recurrent urinary tract infection in young women</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1177-1182</style></pages><volume><style face="normal" font="default" size="100%">182</style></volume><number><style face="normal" font="default" size="100%">4</style></number><dates><year><style face="normal" font="default" size="100%">2000</style></year></dates><abstract><style face="normal" font="default" size="100%">To define host factors associated with an increased risk of recurrent urinary tract infection (RUTI), a case-control study was conducted in 2 populations: university women and health maintenance organization enrollees. Case patients were 229 women 18-30 years old with RUTIs; control subjects were 253 randomly selected women with no RUTI history. In a multivariate model, independent risk factors for RUTI included recent 1-month intercourse frequency (odds ratio [OR], 5.8; 95% confidence interval [CI], 3.1-10.6 for 4-8 episodes), 12-month spermicide use (OR, 1.8; 95% CI, 1.1-2.9), and new sex partner during the past year (OR, 1.9; 95% CI, 1.2-3.2). Two newly identified risk factors were age at first urinary tract infection (UTI) 15 years (OR, 3.9; 95% CI, 1.9-8.0) and UTI history in the mother (OR, 2.3; 95% CI, 1.5-3.7). Blood group and secretor phenotype were not associated with RUTI. In young women, risk factors for sporadic UTI are also risk factors for recurrence. Two predictors suggest that genetic/long-term environmental exposures also predispose to RUTI.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :269&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033800343&amp;doi=10.1086%2f315827&amp;partnerID=40&amp;md5=1206365877a109bd5a863286f1d7ab90</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/315827</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>237</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">237</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schmiemann, G.</style></author><author><style face="normal" font="default" size="100%">Gágyor, I.</style></author><author><style face="normal" font="default" size="100%">Hummers-Pradier, E.</style></author><author><style face="normal" font="default" size="100%">Bleidorn, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department for Health Services Research, Institute for Public Health and Nursing Science, Universität Bremen, Bremen, Germany&#xD;Department of General Practice and Family Medicine, University of Goettingen, Göttingen, Germany&#xD;Institute of General Practice and Family Medicine, Hanover Medical School, Hannover, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Resistance profiles of urinary tract infections in general practice - An observational study</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMC Urology</style></full-title></periodical><volume><style face="normal" font="default" size="100%">12</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Anti-bacterial agents</style></keyword><keyword><style face="normal" font="default" size="100%">Drug resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Primary care</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Guideline recommendations on therapy in urinary tract infections are based on antibiotic resistance rates. Due to a lack of surveillance data, little is known about resistance rates in uncomplicated urinary tract infection (UTI) in general practice in Germany. In a prospective observational study, urine cultures of all women presenting with urinary tract infections in general practice were analysed. Resistance rates against antibiotics recommended in German guidelines on UTI are presented. Methods. In a prospective, multi-center observational study general practitioner included all female patients ≥ 18 years with clinically suspected urinary tract infection. Only patients receiving an antibiotic therapy within the last two weeks were excluded. Results: 40 practices recruited 191 female patients (mean age 52 years; range 18-96) with urinary tract infections. Main causative agent was Escherichia coli (79%) followed by Enterococcus faecalis (14%) and Klebsiella pneumoniae (7.3%).Susceptibiliy of E.coli as the main causative agent was highest against fosfomycin and nitrofurantoin, with low resistance rates of 4,5%; 2,2%. In 17,5%, E.coli was resistant to trimethoprim and in 8,5% to ciprofloxacin. Conclusions: Resistance rates of uropathogens from unselected patients in general practice differ from routinely collected laboratory data. These results can have an impact on antibiotic prescribing and treatment recommendations. © 2012 Schmiemann et al.; licensee BioMed Central Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :42&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84869208223&amp;doi=10.1186%2f1471-2490-12-33&amp;partnerID=40&amp;md5=963e32fe6280591e6d16ee7400bb53dc</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">33</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/1471-2490-12-33</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>604</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">604</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schmidt, D. R.</style></author><author><style face="normal" font="default" size="100%">Sobota, A. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Alliance City Hospital, Youngstown State University, Youngstown, OH 44555, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">An examination of the anti-adherence activity of cranberry juice on urinary and nonurinary bacterial isolates</style></title><secondary-title><style face="normal" font="default" size="100%">Microbios</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Microbios</style></full-title></periodical><pages><style face="normal" font="default" size="100%">173-181</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><number><style face="normal" font="default" size="100%">224-225</style></number><dates><year><style face="normal" font="default" size="100%">1988</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :134&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023763230&amp;partnerID=40&amp;md5=c6f375371419a3b0a8b8078a393bf33d</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>580</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">580</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schlager, T. A.</style></author><author><style face="normal" font="default" size="100%">Anderson, S.</style></author><author><style face="normal" font="default" size="100%">Trudell, J.</style></author><author><style face="normal" font="default" size="100%">Hendley, J. O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Virginia, Dept. of Pediat./Emergency Med., Charlottesville, VA, United States&#xD;University of Virginia, Dept. of Pediat./Emergency Med., PO Box 10014, Charlottesville, VA 22906-0014, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of cranberry juice on bacteriuria in children with neurogenic bladder receiving intermittent catheterization</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Pediatrics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">698-702</style></pages><volume><style face="normal" font="default" size="100%">135</style></volume><number><style face="normal" font="default" size="100%">6</style></number><dates><year><style face="normal" font="default" size="100%">1999</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: To determine the effect of cranberry prophylaxis on rates of bacteriuria and symptomatic urinary tract infection in children with neurogenic bladder receiving clean intermittent catheterization. Design: Double-blind, placebo-controlled, crossover study of 15 children receiving cranberry concentrate or placebo concentrate for 6 months (3 months receiving one concentrate, followed by 3 months of the other). Weekly home visits were made. During each visit, a sample of bladder urine was obtained by intermittent catheterization. Signs and symptoms of urinary tract infection and all medications were recorded, and juice containers were counted. Results: During consumption of cranberry concentrate, the frequency of bacteriuria remained high. Cultures of 75% (114 of 151) of the 151 samples obtained during consumption of placebo were positive for a pathogen (≥ 104 colony-forming units/mL) compared with 75% (120 of 160) of the 160 samples obtained during consumption of cranberry concentrate. Escherichia coli remained the most common pathogen during placebo and cranberry periods. Three symptomatic infections each occurred during the placebo and cranberry periods. No significant difference was observed in the acidification of urine in the placebo group versus the cranberry group (median, 5.5 and 6.0, respectively). Conclusion: The frequency of bacteriuria in patients with neurogenic bladder receiving intermittent catheterization is 70%; cranberry concentrate had no effect on bacteriuria in this population.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :93&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033504611&amp;doi=10.1016%2fS0022-3476%2899%2970087-9&amp;partnerID=40&amp;md5=5d050c3dadc450922d47cad90aa702d9</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0022-3476(99)70087-9</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>327</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">327</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schito, G. C.</style></author><author><style face="normal" font="default" size="100%">Naber, K. G.</style></author><author><style face="normal" font="default" size="100%">Botto, H.</style></author><author><style face="normal" font="default" size="100%">Palou, J.</style></author><author><style face="normal" font="default" size="100%">Mazzei, T.</style></author><author><style face="normal" font="default" size="100%">Gualco, L.</style></author><author><style face="normal" font="default" size="100%">Marchese, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sezione di Microbiologia, DISCMIT, University of Genoa, Genoa, Italy&#xD;Technical University of Munich, Munich, Germany&#xD;Department of Urology, Hôpital Foch, Suresnes, France&#xD;Fundació Puigvert, Autonomous University of Barcelona, Barcelona, Spain&#xD;Department of Preclinical and Clinical Pharmacology, University of Florence, Florence, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Antimicrobial Agents</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Antimicrobial Agents</style></full-title></periodical><pages><style face="normal" font="default" size="100%">407-413</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Amoxicillin/clavulanic acid</style></keyword><keyword><style face="normal" font="default" size="100%">Ciprofloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Fosfomycin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">The ARESC (Antimicrobial Resistance Epidemiological Survey on Cystitis) study is an international survey to investigate the prevalence and susceptibility of pathogens causing cystitis. Female patients (n = 4264) aged 18-65 years with symptoms of uncomplicated cystitis were consecutively enrolled in nine European countries as well as Brazil during 2003-2006. Pathogens were identified and their susceptibility to nine antimicrobials was determined. Escherichia coli accounted for 76.7% of isolates. Among E. coli, 10.3% of the isolates were resistant to at last three different classes of antimicrobial agents. Resistance was most common to ampicillin (48.3%), trimethoprim/sulfamethoxazole (29.4%) and nalidixic acid (18.6%). Fosfomycin, mecillinam and nitrofurantoin were the most active drugs (98.1%, 95.8% and 95.2% susceptible strains, respectively) followed by ciprofloxacin, amoxicillin/clavulanic acid and cefuroxime (91.7%, 82.5% and 82.4%, respectively). Resistance to ciprofloxacin was &gt;10% in Brazil, Spain, Italy and Russia. Overall, Proteus mirabilis were more susceptible to β-lactams and less susceptible to non-β-lactams than E. coli, whereas Klebsiella pneumoniae strains, which are intrinsically resistant to ampicillin, were less susceptible to mecillinam (88.8%), fosfomycin (87.9%), cefuroxime (78.6%) and nitrofurantoin (17.7%). Resistance was rare in Staphylococcus saprophyticus, with the exception of ampicillin (36.4%) and trimethoprim/sulfamethoxazole (10.2%). In Italy, Spain, Brazil and Russia, the countries most affected by antimicrobial resistance, extended-spectrum β-lactamase (ESBL) enzymes (mainly CTX-M type) were detected in 48 strains (39 E. coli, 6 K. pneumoniae and 3 P. mirabilis). Despite wide intercountry variability in bacterial susceptibility rates to the other antimicrobials tested, fosfomycin and mecillinam have preserved their in vitro activity in all countries investigated against the most common uropathogens. © 2009 Elsevier B.V. and the International Society of Chemotherapy.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :187&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-69949132847&amp;doi=10.1016%2fj.ijantimicag.2009.04.012&amp;partnerID=40&amp;md5=94ad0456848cb1da3f17470deffa3efc</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ijantimicag.2009.04.012</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>41</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">41</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schiavi, M. C.</style></author><author><style face="normal" font="default" size="100%">Di Pinto, A.</style></author><author><style face="normal" font="default" size="100%">Sciuga, V.</style></author><author><style face="normal" font="default" size="100%">Faiano, P.</style></author><author><style face="normal" font="default" size="100%">Di Tucci, C.</style></author><author><style face="normal" font="default" size="100%">D’oria, O.</style></author><author><style face="normal" font="default" size="100%">Martoccia, A.</style></author><author><style face="normal" font="default" size="100%">Prata, G.</style></author><author><style face="normal" font="default" size="100%">Carraro, C.</style></author><author><style face="normal" font="default" size="100%">Ostuni, R.</style></author><author><style face="normal" font="default" size="100%">Zullo, M. A.</style></author><author><style face="normal" font="default" size="100%">Muzii, L.</style></author><author><style face="normal" font="default" size="100%">Benedetti Panici, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Gynecological and Obstetric Sciences, and Urological Sciences, University of Rome “Sapienza”, Umberto I Hospital, Rome, Italy&#xD;Department of Surgery-Week Surgery, University of Rome “Campus Biomedico”, Rome, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevention of recurrent lower urinary tract infections in postmenopausal women with genitourinary syndrome: outcome after 6 months of treatment with ospemifene</style></title><secondary-title><style face="normal" font="default" size="100%">Gynecological Endocrinology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Gynecological Endocrinology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">140-143</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">menopause</style></keyword><keyword><style face="normal" font="default" size="100%">ospemifene</style></keyword><keyword><style face="normal" font="default" size="100%">quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">recurrent lower urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">Vulvovaginal atrophy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Aim of this study was to evaluate the efficacy of ospemifene in the prevention of recurrent lower urinary tract infections in postmenopausal women with vulvovaginal atrophy. The study have a retrospective design. Thirty-nine patients were enrolled. Patients underwent clinical examination and urine culture. The urinary symptoms and the quality of life were evaluated with UTISA score, PUF and SF-36 questionnaires before and after treatment. All 39 patients received ospemifene 60 mg one tablet/daily for 6 months. Adverse effects and complications were assessed. Thirty-nine patients were enrolled in the study. Two patients experienced one new UTI episode and the mean number of positive urine culture decreased significantly after 6 months (3.65 ± 2.12 vs 0.25 ± 0.17, p &amp;lt;.0001). The mean number of urinary infection symptoms decreased significantly after treatment; dysuria reduced (4.76 ± 2.45 vs 0.89 ± 1.12). PUF score and SF-36 showed a statistically significant change (22.43 ± 5.89 vs 12.14 ± 3.21) and (52.86 ± 9.21 vs 83.43 ± 10.76). No adverse effects were reported and the total success rate was the 92.3% after 6 months at PGI-I. Ospemifene is a valid alternative with excellent tolerability for the UTIS prevention in postmenopausal patients. © 2017 Informa UK Limited, trading as Taylor &amp; Francis Group.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85028568521&amp;doi=10.1080%2f09513590.2017.1370645&amp;partnerID=40&amp;md5=0e222e5ba5b1c69bc6c6174593a3bd2b</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/09513590.2017.1370645</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>609</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">609</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schaeffer, A. J.</style></author><author><style face="normal" font="default" size="100%">Chmiel, J. S.</style></author><author><style face="normal" font="default" size="100%">Duncan, J. L.</style></author><author><style face="normal" font="default" size="100%">Falkowski, W. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Northwestern University Medical School, Chicago, IL 60611, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mannose-sensitive adherence of Escherichia coli to epithelial cells from women with recurrent urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">906-910</style></pages><volume><style face="normal" font="default" size="100%">131</style></volume><number><style face="normal" font="default" size="100%">5</style></number><dates><year><style face="normal" font="default" size="100%">1984</style></year></dates><abstract><style face="normal" font="default" size="100%">The effect of D-mannose on adherence of 73 Escherichia coli strains to vaginal and buccal epithelial cells from women with recurrent urinary tract infections, and on agglutination of human and guinea pig erythrocytes was tested. Urinary, vaginal or anal isolates from women with such infections were used. Of the strains 66 (90%) demonstrated adherence to epithelial cells. D-mannose inhibited completely the adherence of 25 strains (42%) that adhered to vaginal cells and inhibited an additional 11 strains (18%) by at least 50%. Similar results were obtained with buccal cells. The inhibitory effect of D-mannose was similar regardless of the origin of the strains. Hemagglutination frequently was inhibited by D-mannose but no consistent association between hemagglutination, and epithelial cell adherence and the effect of D-mannose was observed. The results suggest that mannose-sensitive as well as mannose-resistant adhesins frequently mediate Escherichia coli adherence to vaginal epithelial cells, and may contribute to vaginal colonization and cystitis.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :12&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021238647&amp;doi=10.1016%2fS0022-5347%2817%2950706-5&amp;partnerID=40&amp;md5=55e07d00acee2ab03b919ec27673f4d3</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0022-5347(17)50706-5</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>611</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">611</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schaeffer, A. J.</style></author><author><style face="normal" font="default" size="100%">Amundsen, S. K.</style></author><author><style face="normal" font="default" size="100%">Jones, J. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dept. Urol., Northwest. Univ. Med. Sch., Chicago, Ill. 60611, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of carbohydrates on adherence of Escherichia coli to human urinary tract epthelial cells</style></title><secondary-title><style face="normal" font="default" size="100%">Infection and Immunity</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infection and Immunity</style></full-title></periodical><pages><style face="normal" font="default" size="100%">531-537</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">1980</style></year></dates><abstract><style face="normal" font="default" size="100%">Adherence of Escherichia coli cells to voided uroepithelial cells from healthy women was measured by use of [3H]uridine-labeled bacteria filtered through a polycarbonate membrane filter (5-μm pore size). At a concentration of 2.5% (wt/vol), D-mannose, D-mannitol, αmethyl-D-mannoside, and yeast mannan completely inhibited adherence of the bacteria to the epithelial cells. At this same concentration, D-fructose, D-xylose, D-arabinose, and D-glyceraldehyde partially inhibited adherence. Reducing the concentration of D-mannose, or its derivatives, to between 1.0 and 0.1% resulted in partial inhibition in the adherence of the bacteria; a further reduction in the concentration to between 0.01 and 0.001% caused an enhancement of adherence up to 100% of the control level. Bacterial preincubation in 2.5% D-mannose for 1 min before epithelial cells were added completely inhibited adherence; similar treatment for the epithelial cells had no significant effect on subsequent adherence of the bacteria. Bacteria that were preincubated for 1 h with D-mannose at concentrations between 0.1 and 0.75% showed enhanced adherence. The inhibitory effect of D-mannose was decreased if bacterial adhesive ability, or cell receptivity, increased. A variety of other carbohydrates tested had no effect on the adherence of E. coli to the uroepithelial cells. These results suggest that adherence can be altered by interaction(s) between specific carbohydrate molecules and receptors on the bacterial surface.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :35&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0018957415&amp;partnerID=40&amp;md5=2c63020f7fd232406688c2e64d192d65</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>592</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">592</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Saxelin, M.</style></author><author><style face="normal" font="default" size="100%">Pessi, T.</style></author><author><style face="normal" font="default" size="100%">Salminen, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Valio Ltd., R and D, 00101 Helsinki, Finland&#xD;Department of Biochemistry and Food Chemistry, University of Turku, 20500 Turku, Finland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Fecal recovery following oral administration of Lactobacillus Strain GG (ATCC 53103) in gelatine capsules to healthy volunteers</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Food Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Food Microbiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">199-203</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Fecal recovery</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1995</style></year></dates><abstract><style face="normal" font="default" size="100%">Recovery of the suggested probiotic strain Lactobacillus GG in feces was studied after oral administration. Lactobacillus GG was given to 20 healthy human volunteers for 7 days in gelatine capsules with daily doses of 1.6 × 108 cfu and 1.2 × 1010 cfu. All the volunteers in the higher dose group had detectable numbers of Lactobacillus GG in their feces during the test period. The strain was detected in feces of all the volunteers after 3 days of administration. No effect was observed on the total number of fecal lactobacilli. Fecal detection of the strain may facilitate dose-response studies and provide a useful tool in dietary studies utilizing the strain in foods or food-type products. © 1995.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :93&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028908238&amp;doi=10.1016%2f0168-1605%2894%2900091-J&amp;partnerID=40&amp;md5=a4fa5a4f2899fe5a87c45ed366ce8983</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/0168-1605(94)00091-J</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>411</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">411</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Santillo, V. M.</style></author><author><style face="normal" font="default" size="100%">Lowe, F. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, St. Luke&apos;s-Roosevelt Hospital, Columbia University, New York, NY, United States&#xD;Department of Urology, Columbia University, College of Physicians and Surgeons, New York, NY, United States&#xD;425 W 59th St., #3A, New York, NY 10019, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry juice for the prevention and treatment of urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Drugs of Today</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drugs of Today</style></full-title></periodical><pages><style face="normal" font="default" size="100%">47-54</style></pages><volume><style face="normal" font="default" size="100%">43</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">There is widespread belief that cranberry juice can treat urinary tract infections (UTIs). There is no conclusive evidence from either in vitro or in vivo studies to confirm this. However, there is strong in vitro and in vivo evidence confirming the hypothesis that UTIs can be prevented by decreasing bacterial adherence to uroepithelial cells. For people with recurrent uncomplicated UTIs, routine utilization of cranberry products may offer an alternative methodology to antibiotic prophylaxis. © 2007 Prous Science. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :8&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33947421717&amp;doi=10.1358%2fdot.2007.43.1.1032055&amp;partnerID=40&amp;md5=c88f88dd313270bb3ca2b5d64c3a99e0</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1358/dot.2007.43.1.1032055</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>147</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">147</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sánchez-Patán, F.</style></author><author><style face="normal" font="default" size="100%">Barroso, E.</style></author><author><style face="normal" font="default" size="100%">Van De Wiele, T.</style></author><author><style face="normal" font="default" size="100%">Jiménez-Girón, A.</style></author><author><style face="normal" font="default" size="100%">Martín-Alvarez, P. J.</style></author><author><style face="normal" font="default" size="100%">Moreno-Arribas, M. V.</style></author><author><style face="normal" font="default" size="100%">Martínez-Cuesta, M. C.</style></author><author><style face="normal" font="default" size="100%">Peláez, C.</style></author><author><style face="normal" font="default" size="100%">Requena, T.</style></author><author><style face="normal" font="default" size="100%">Bartolomé, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Food Biotechnology and Microbiology, Institute of Food Science Research, CIAL (CSIC-UAM), Nicolás Cabrera 9, Madrid, 28049, Spain&#xD;LabMET, Faculty of Bioscience Engineering, Ghent University, Ghent, 9000, Belgium</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comparative in vitro fermentations of cranberry and grape seed polyphenols with colonic microbiota</style></title><secondary-title><style face="normal" font="default" size="100%">Food Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Food Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">273-282</style></pages><volume><style face="normal" font="default" size="100%">183</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Batch fermentations</style></keyword><keyword><style face="normal" font="default" size="100%">Colonic microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Grape seeds</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial modulation</style></keyword><keyword><style face="normal" font="default" size="100%">Phenolic metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Polyphenols</style></keyword><keyword><style face="normal" font="default" size="100%">SHIME</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">In this study, we have assessed the phenolic metabolism of a cranberry extract by microbiota obtained from the ascending colon and descending colon compartments of a dynamic gastrointestinal simulator (SHIME). For comparison, parallel fermentations with a grape seed extract were carried out. Extracts were used directly without previous intestinal digestion. Among the 60 phenolic compounds targeted, our results confirmed the formation of phenylacetic, phenylpropionic and benzoic acids as well as phenols such as catechol and its derivatives from the action of colonic microbiota on cranberry polyphenols. Benzoic acid (38.4 μg/ml), 4-hydroxy-5-(3′-hydroxyphenyl)-valeric acid (26.2 μg/ml) and phenylacetic acid (19.5 μg/ml) reached the highest concentrations. Under the same conditions, microbial degradation of grape seed polyphenols took place to a lesser extent compared to cranberry polyphenols, which was consistent with the more pronounced antimicrobial effect observed for the grape seed polyphenols, particularly against Bacteroides, Prevotella and Blautia coccoides-Eubacterium rectale. © 2015 Elsevier Ltd. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :17&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84925729051&amp;doi=10.1016%2fj.foodchem.2015.03.061&amp;partnerID=40&amp;md5=db3ac8fdc6f359636d75d421810a254c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.foodchem.2015.03.061</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>283</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">283</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Salvatore, S.</style></author><author><style face="normal" font="default" size="100%">Salvatore, S.</style></author><author><style face="normal" font="default" size="100%">Cattoni, E.</style></author><author><style face="normal" font="default" size="100%">Siesto, G.</style></author><author><style face="normal" font="default" size="100%">Serati, M.</style></author><author><style face="normal" font="default" size="100%">Sorice, P.</style></author><author><style face="normal" font="default" size="100%">Torella, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Obstetrics and Gynaecology, University of Insubria, Del Ponte Hospital, Piazza Biroldi 1, 21100 Varese, Italy&#xD;Department of Pediatrics, University of Insubria, Varese, Italy&#xD;Department of Gynecology, IRCCS, Humanitas Clinical Institute, Rozzano, Milano, Italy&#xD;Department of Obstetrics and Gynecology, 2nd Faculty, Naples, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections in women</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Obstetrics Gynecology and Reproductive Biology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Obstetrics Gynecology and Reproductive Biology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">131-136</style></pages><volume><style face="normal" font="default" size="100%">156</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Management</style></keyword><keyword><style face="normal" font="default" size="100%">Review</style></keyword><keyword><style face="normal" font="default" size="100%">Urine infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTIs) are conditions frequently complained by women both in the general population and in the hospital setting. Indeed it has been estimated that one woman out of three will experience at least an episode of UTI during lifetime. A comprehensive literature review of published experimental and clinical studies of UTI was carried out at the University of Insubria electronic library (SFX Bicocca-Insubria) with cross-search of seven different medical databases (AMED, BIOSIS Previews on Web of Knowledge, Cochrane Library, Embase and Medline on Web of Knowledge, OvidSP and PubMed). We aimed to draw a clinical guideline addressed to the management of UTI, based on the most recent evidence. © 2011 Elsevier Ireland Ltd. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :69&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79958288892&amp;doi=10.1016%2fj.ejogrb.2011.01.028&amp;partnerID=40&amp;md5=185a690844ad0ff3f64b95ffb198d621</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ejogrb.2011.01.028</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>261</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">261</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Salo, J.</style></author><author><style face="normal" font="default" size="100%">Uhari, M.</style></author><author><style face="normal" font="default" size="100%">Helminen, M.</style></author><author><style face="normal" font="default" size="100%">Korppi, M.</style></author><author><style face="normal" font="default" size="100%">Nieminen, T.</style></author><author><style face="normal" font="default" size="100%">Pokka, T.</style></author><author><style face="normal" font="default" size="100%">Kontiokari, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, Oulu University Hospital, Box 5000, Oulu, 90014, Finland&#xD;Department of Paediatrics, University of Oulu, Box 5000, Oulu, 90014, Finland&#xD;Department of Paediatrics, Tampere University Hospital, Finland&#xD;Department of Paediatrics, Kuopio University Hospital, Finland&#xD;Department of Paediatrics, Helsinki University Central Hospital, Finland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry juice for the prevention of recurrences of urinary tract infections in children: A randomized placebo-controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">340-346</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Background. Cranberry juice prevents recurrences of urinary tract infections (UTIs) in adult women. The objective of this study was to evaluate whether cranberry juice is effective in preventing UTI recurrences in children. Methods. A double-blind randomized placebo-controlled trial was performed in 7 hospitals in Finland. A total of 263 children treated for UTI were randomized to receive either cranberry juice (n = 129) or placebo (n = 134) for 6 months. Eight children were omitted because of protocol violations, leaving 255 children for the final analyses. The children were monitored for 1 year, and their recurrent UTIs were recorded. Results. Twenty children (16%) in the cranberry group and 28 (22%) in the placebo group had at least 1 recurrent UTI (difference, -6%; 95% confidence interval [CI], -16 to 4%; P =. 21). There were no differences in timing between these first recurrences (P =. 32). Episodes of UTI totaled 27 and 47 in the cranberry and placebo groups, respectively, and the UTI incidence density per person-year at risk was 0.16 episodes lower in the cranberry group (95% CI, -.31 to -.01; P =. 035). The children in the cranberry group had significantly fewer days on antimicrobials (-6 days per patient-year; 95% CI, -7 to -5; P &lt;. 001). Conclusions. The intervention did not significantly reduce the number of children who experienced a recurrence of UTI, but it was effective in reducing the actual number of recurrences and related antimicrobial use. © The Author 2011. Published by Oxford University Press on behalf of the Infectious.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :44&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84855892472&amp;doi=10.1093%2fcid%2fcir801&amp;partnerID=40&amp;md5=5361fd5b618deb15197f36bc7f23015b</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/cid/cir801</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>345</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">345</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Salo, J.</style></author><author><style face="normal" font="default" size="100%">Sevander, J. J.</style></author><author><style face="normal" font="default" size="100%">Tapiainen, T.</style></author><author><style face="normal" font="default" size="100%">Ikäheimo, I.</style></author><author><style face="normal" font="default" size="100%">Pokka, T.</style></author><author><style face="normal" font="default" size="100%">Koskela, M.</style></author><author><style face="normal" font="default" size="100%">Uhari, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Oulu University Hospital, PO-Box 5000, 90014 Oulu, Finland&#xD;Laboratory of Clinical Microbiology, Oulu University Hospital, PO-Box 5000, 90014 Oulu, Finland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biofilm formation by Escherichia coli isolated from patients with urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Nephrology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">501-507</style></pages><volume><style face="normal" font="default" size="100%">71</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Biofilms</style></keyword><keyword><style face="normal" font="default" size="100%">Drug resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Microbial</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Aims: The significance of biofilm formation for the clinical picture of urinary tract infections (UTI) is largely unknown. We wanted to find out whether Escherichia coli (E. coli) strains isolated from UTI patients differ in their ability to form biofilms and whether this ability is associated with the clinical presentation of UTI. Material and methods: 70 E. coli strains were isolated from patients with cystitis (43 strains), pyelonephritis (11 strains) and urosepsis (16 strains) and biofilm formation was assessed on polystyrene microtiter plates by measuring the optical density (OD) of the attached material after 72 h of incubation and crystal violet staining of the bacteria. The formation of organized biofilm structures and the viability of the attached bacteria were verified by scanning electron microscopy and confocal scanning laser microscopy in a subsample of 22 strains. Results: 31% of the E. coli strains formed a biofilm. The strains isolated from patients with pyelonephritis had higher ODs than those from patients with cystitis (difference of the means 0.19, 95% confidence limits (CL) 0.06 - 0.32, p = 0.02). The E. coli strains susceptible to antibiotics had higher ODs than the resistant strains (difference of the means 0.21, 95% CL 0.03 - 0.27, p = 0.016). Conclusions: The ability of bacteria to persist and grow in a biofilm seems to be one of the important factors in both the resistance to antibiotics and the severity of urinary tract inflammation. © 2009 Dustri-Verlag Dr. K. Feistle.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :22&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-67649397641&amp;doi=10.5414%2fCNP71501&amp;partnerID=40&amp;md5=965adc75615a4691537fddfc93f46a09</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.5414/CNP71501</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>394</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">394</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Salminen, A.</style></author><author><style face="normal" font="default" size="100%">Loimaranta, V.</style></author><author><style face="normal" font="default" size="100%">Joosten, J. A. F.</style></author><author><style face="normal" font="default" size="100%">Khan, A. S.</style></author><author><style face="normal" font="default" size="100%">Hacker, J.</style></author><author><style face="normal" font="default" size="100%">Pieters, R. J.</style></author><author><style face="normal" font="default" size="100%">Finne, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Biochemistry and Molecular Biology, University of Turku, FI-20520 Turku, Finland&#xD;Department of Medicinal Chemistry, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, PO Box 80082, NL-3508 TB Utrecht, Netherlands&#xD;Institute for Molecular Biology of Infectious Diseases, University of Würzburg, D-97070 Würzburg, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inhibition of P-fimbriated Escherichia coli adhesion by multivalent galabiose derivatives studied by a live-bacteria application of surface plasmon resonance</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Antimicrobial Chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Antimicrobial Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">495-501</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-adhesion</style></keyword><keyword><style face="normal" font="default" size="100%">Glycodendrimers</style></keyword><keyword><style face="normal" font="default" size="100%">Oligovalent inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Streptococcus suis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">Objectives: Uropathogenic P-fimbriated Escherichia coli adheres to host cells by specific adhesins recognizing galabiose (Galα1-4Gal)-containing structures on cell surfaces. In search of agents inhibiting this first step of infection, the inhibition potency of a set of synthetic mono- and multivalent galabiose compounds was evaluated. In order to mimic the flow conditions of natural infections, a live-bacteria application of surface plasmon resonance (SPR) was established. Methods and results: For the measurement of the binding of E. coli to a surface containing galabiose, live bacteria were injected over the flow cell, and the inhibition of adhesion caused by the galabiose inhibitors was recorded. Quantitative binding data were recorded in real-time for each inhibitor. The results were compared with those of conventional static haemagglutination and ELISA-based cell adhesion assays. Compared with the Gram-positive Streptococcus suis bacteria, which also bind to galabiose and whose binding inhibition is strongly dependent on the multivalency of the inhibitor, E. coli inhibition was only moderately affected by the valency. However, a novel octavalent compound was found to be the most effective inhibitor of E. coli PapGJ96 adhesion, with an IC50 value of 2 μM. Conclusions: Measurement of bacterial adhesion by SPR is an efficient way to characterize the adhesion of whole bacterial cells and allows the characterization of the inhibitory potency of adhesion inhibitors under dynamic flow conditions. Under these conditions, multivalency increases the anti-adhesion potency of galabiose-based inhibitors of P-fimbriated E. coli adhesion and provides a promising approach for the design of high-affinity anti-adhesion agents. © The Author 2007. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :54&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-34548125418&amp;doi=10.1093%2fjac%2fdkm251&amp;partnerID=40&amp;md5=545c614f6d132a1595a94567cde4d0be</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/jac/dkm251</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>34</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">34</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Salinas-Casado, J.</style></author><author><style face="normal" font="default" size="100%">Méndez-Rubio, S.</style></author><author><style face="normal" font="default" size="100%">Esteban-Fuertes, M.</style></author><author><style face="normal" font="default" size="100%">Gómez-RodríGuez, A.</style></author><author><style face="normal" font="default" size="100%">Vírseda-Chamorro, M.</style></author><author><style face="normal" font="default" size="100%">Luján-Galán, M.</style></author><author><style face="normal" font="default" size="100%">Rituman, Y. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Servicio de Urología, Hospital Clínico San Carlos, Madrid, Spain&#xD;Servicio de Urología, Hospital Universitario Sanitas La Moraleja, Madrid, Spain&#xD;Servicio de Urología, Hospital Nacional de Parapléjicos de Toledo, Toledo, Spain&#xD;Servicio de Urología, Complejo Hospitalario de Toledo, Toledo, Spain&#xD;Servicio de Urología., Hospital Universitario de Parla, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy and safety of D-mannose (2 g), 24h prolonged release, associated with proanthocyanidin (PAC), versus isolated PAC, in the management of a series of women with recurrent urinary infections</style></title><secondary-title><style face="normal" font="default" size="100%">Archivos Espanoles de Urologia</style></secondary-title><short-title><style face="normal" font="default" size="100%">Eficacia y tolerancia terapéutica de la d-manosa (2 g) de liberación prolongada 24 horas (asociada a proantocianidinas), frente a proantocianidinas aisladas en el manejo de una serie de mujeres con infecciones urinarias recurrentes</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archivos Espanoles de Urologia</style></full-title></periodical><pages><style face="normal" font="default" size="100%">169-177</style></pages><volume><style face="normal" font="default" size="100%">71</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">D-mannose</style></keyword><keyword><style face="normal" font="default" size="100%">PAC</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent Urinary Infection</style></keyword><keyword><style face="normal" font="default" size="100%">Women</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To compare the efficacy and safety of dietary supplement “Manosar®” composed of D-mannose (2 g), 24 h prolonged release, associated with Proanthocyanidin (PAC) (140 mg), ursolic acid (7.98 mg), A, C, and D vitamins and the oligoelement zinc, versus 240 mg of PAC in recurrent urinary tract infections (UTI), for a designed follow-up of 24 weeks, in women. METHODS: A multicenter randomized experimental double-blind study was carried out. The study was approved by review board of “Complejo Hospitalario de Toledo” (Spain), and all patients gave informed consent. A total of 150 women with non complicated UTI were screened for participation. Valid data was obtained from 93, with mean age of 48 years. Forty-four patients were assigned to the Manosar® group and 51 patients to the PAC group. Patients were followed during six months. A previous UTI was defined based on a combination of symptoms and a positive reactive urine trip. Confirmation of a new UTI was based on symptoms, reactive urine strip and urine culture. RESULTS: Thirty-three patients (35%) had an UTI during the six months follow-up. The percentage of UTI of the Manosar® group during this period was 24%, while the percentage of the PAC group was 45% (p&lt;0.05). The disease-free time for the Manosar® group was 95 days, while this time was 79 days for the PAC group. The incidence of side effects was low. Diarrhea was the most frequent side-effect in both groups. CONCLUSION: Manosar® (oral once a day) is more effective than single dose PAC (240 mg daily orally) to prevent recurrent UTI in women.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85043333897&amp;partnerID=40&amp;md5=26180a21db449466a31780680f9bf550</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>219</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">219</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Saliba, W.</style></author><author><style face="normal" font="default" size="100%">Barnett-Griness, O.</style></author><author><style face="normal" font="default" size="100%">Rennert, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Community Medicine and Epidemiology, Carmel Medical Center, Technion-Israel Institute of Technology, 7 Michal St., Haifa 34362, Israel&#xD;Internal Medicine C, Ha&apos;Emek Medical Center, Afula, Israel&#xD;Department of Epidemiology and Disease Prevention, Office of the Chief Physician, Clalit Health Services Headquarters, Tel Aviv, Israel</style></auth-address><titles><title><style face="normal" font="default" size="100%">The association between obesity and urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">127-131</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">25(OH)D</style></keyword><keyword><style face="normal" font="default" size="100%">BMI</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">Keywords</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin D</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Background Few studies examined the relationship between obesity and urinary tract infection (UTI), showing inconsistent results. This study aims to examine the association between obesity and UTI, and to assess whether this association is independent of diabetes mellitus and 25(OH)D level. Methods Using the computerized database of the largest healthcare provider in Israel, we identified a cohort of subjects ≥ 18 years old with available BMI and serum 25(OH)D level measurements between January 2009 and December 2009. The cohort was followed for the first UTI diagnosis from January 2010 through June 2011. Cox proportional hazard model was used to test the relationship between obesity and UTI. Results During follow-up, 25,145/110,736 (22.7%) females, and 4032/42,703 (9.4%) males had UTI. The crude HR for UTI in those with BMI ≥ 50 compared to BMI &lt; 25 was 2.54 (95% CI, 1.50-4.30) in males and 1.39 (1.14-1.69) in females. After adjusting for age, 25(OH)D level, and history of diabetes mellitus, the HR for UTI in those with BMI ≥ 50 compared to BMI &lt; 25 was 2.38 (1.40-4.03) in males and 1.25 (1.03-1.52) in females. The HR for those in the lowest quartile of serum 25(OH)D compared to the highest quartile was 1.23 (1.13-1.35) in males and 0.98 (0.95-1.02) in females. The HR for subjects with diabetes was 1.23 (1.16-1.32) in males, and 1.25 (1.20-1.28) in females. Conclusions Obesity is independently associated with UTI particularly in males. Low serum 25(OH)D levels are associated with increased risk of UTI in males. © 2012 European Federation of Internal Medicine.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :23&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84873711393&amp;doi=10.1016%2fj.ejim.2012.11.006&amp;partnerID=40&amp;md5=d4e6049cc321927ec4dcaf39961e45de</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ejim.2012.11.006</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>102</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">102</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Saad, A. M.</style></author><author><style face="normal" font="default" size="100%">Saad, M. M.</style></author><author><style face="normal" font="default" size="100%">Hassan, H. M.</style></author><author><style face="normal" font="default" size="100%">Ibrahim, N. A.</style></author><author><style face="normal" font="default" size="100%">El-Hadedy, D. E.</style></author><author><style face="normal" font="default" size="100%">Ibrahim, E. I.</style></author><author><style face="normal" font="default" size="100%">A-Karam El-Din, A. Z.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Microbial Chemistry Department, National Research Centre (NRC), 33 Bohouth St., Dokki, Giza, Egypt&#xD;Department of Microbiology, Faculty of Science, Ain Shams University, Egypt&#xD;Microbiology Department, National Center For Radiation Research and Technology,(NCRRT), 3 Ahmed El-zumor st., 8 th Sector, Madinat Nasr, Cairo, 11371, Egypt</style></auth-address><titles><title><style face="normal" font="default" size="100%">Optimization study for β-mannanase production from locust bean gum by a local Aspergillus tamarii NRC 3 isolate</style></title><secondary-title><style face="normal" font="default" size="100%">Research Journal of Pharmaceutical, Biological and Chemical Sciences</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Research Journal of Pharmaceutical, Biological and Chemical Sciences</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2597-2609</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aflatoxin</style></keyword><keyword><style face="normal" font="default" size="100%">Aspergillus tamarii</style></keyword><keyword><style face="normal" font="default" size="100%">Locust bean gum</style></keyword><keyword><style face="normal" font="default" size="100%">Protein content 5S rRNA</style></keyword><keyword><style face="normal" font="default" size="100%">β-mannanase activity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">A survey of forty locally isolated fungal isolates from Egyptian soil was carried out for the extracellular β-mannanase production by using both static and shaking cultures. Aspergillus tamarii NRC 3 recorded the highest β-mannanase activity (30.89 Um l-1) when grown statically on a medium contains locust bean gum. No aflatoxins were detected in the culture filtrate of Aspergillus tamarii NRC 3. Molecular identification of the isolate was carried out 5S rRNA using fungal ITS primer. Factors affecting β-mannanase Production were studied. From the obtained results, sodium nitrate at a concentration of 0.2%, inoculum age (6 days), inoculum size (one disk, 4 mm diameter, equal 2×107 spores), aeration ratio (4:1), 7 days of static incubation, pH 5.0 and 25 °C were the favorable parameters for β-mannanase production (31.00 Uml-1, 31.60 Uml-1, 31.67Uml-1, 31.70Uml-1, 31.75Uml-1, 31.75 Uml-1, 31.88 Uml-1, respectively). Surfactants used were, tween 20, 80 and SDS had no effect on β-mannanase production.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84996879891&amp;partnerID=40&amp;md5=446b5092ed30b696c9d8c6167fa5844f</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>328</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">328</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ruz, E. N.</style></author><author><style face="normal" font="default" size="100%">González, C. C.</style></author><author><style face="normal" font="default" size="100%">Jaen, S. D. L.</style></author><author><style face="normal" font="default" size="100%">Escoto, P. G.</style></author><author><style face="normal" font="default" size="100%">Urquiza, E. K.</style></author><author><style face="normal" font="default" size="100%">Ovadía Rosenfield, L.</style></author><author><style face="normal" font="default" size="100%">Ortiz C, C. S. L.</style></author><author><style face="normal" font="default" size="100%">Velázquez Castellanos, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Grupo Multidisciplinario para el Estudio del Arándano, Mexico</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry juice and its role in urinary infections</style></title><secondary-title><style face="normal" font="default" size="100%">Ginecologia y Obstetricia de Mexico</style></secondary-title><short-title><style face="normal" font="default" size="100%">El jugo de arándano y su papel en las infecciones de las vías urinarias</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Ginecologia y Obstetricia de Mexico</style></full-title></periodical><pages><style face="normal" font="default" size="100%">512-517</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">The urinary tract infection is a worldwide health problem, with a ratio of 9 to 1 in women compared with men. In 80% of the cases, the causing bacteria is Escherichia coli. During reproductive life this infection represents a great amount of work disabilities, hence the need to insist on its prophylaxis. The red cranberry juice is an option to prevent urinary tract infection, a quality demonstrated in several recent publications which emphasize that its mechanism of action lies in the effect exerted by proantocyanidines, especially those of type A, in the urothelium that prevent Escherichia coli from adhering to this and exerts its antibacterial action, which is achieved with the ingestion of at least 300 mL of juice every day.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-74049136534&amp;partnerID=40&amp;md5=4a27815dce4bfab0cbec2850353cba83</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>538</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">538</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Russo, T. A.</style></author><author><style face="normal" font="default" size="100%">Johnson, J. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dept. of Medicine and Microbiology, Center for Microbial Pathogenesis, University at Buffalo, 3435 Main Street, Buffalo, NY 14214-3001, United States&#xD;Department of Medicine, VA Medical Center, University of Minnesota, Minneapolis, MN, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Medical and economic impact of extraintestinal infections due to Escherichia coli: Focus on an increasingly important endemic problem</style></title><secondary-title><style face="normal" font="default" size="100%">Microbes and Infection</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Microbes and Infection</style></full-title></periodical><pages><style face="normal" font="default" size="100%">449-456</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Costs</style></keyword><keyword><style face="normal" font="default" size="100%">Economics</style></keyword><keyword><style face="normal" font="default" size="100%">Extraintestinal Escherichia coli infections</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence of infection</style></keyword><keyword><style face="normal" font="default" size="100%">Mortality</style></keyword><keyword><style face="normal" font="default" size="100%">Sepsis</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">Escherichia coli is probably the best-known bacterial species and one of the most frequently isolated organisms from clinical specimens. Despite this, underappreciation and misunderstandings exist among medical professionals and the lay public alike regarding E. coli as an extraintestinal pathogen. Underappreciated features include (i) the wide variety of extraintestinal infections E. coli can cause, (ii) the high incidence and associated morbidity, mortality, and costs of these diverse clinical syndromes, (iii) the pathogenic potential of different groups of E. coli strains for causing intestinal versus extraintestinal disease, and (iv) increasing antimicrobial resistance. In this era in which health news often sensationalizes uncommon infection syndromes or pathogens, the strains of E. coli that cause extraintestinal infection are an increasingly important endemic problem and underappreciated &quot;killers&quot;. Billions of health care dollars, millions of work days, and hundreds of thousands of lives are lost each year to extraintestinal infections due to E. coli. New treatments and prevention measures will be needed for improved outcomes and a diminished disease burden. © 2003 Éditions scientifiques et médicales Elsevier SAS. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :380&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038076041&amp;doi=10.1016%2fS1286-4579%2803%2900049-2&amp;partnerID=40&amp;md5=313b2be861e780818ced0043e77bbb02</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S1286-4579(03)00049-2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>448</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">448</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ruel, G.</style></author><author><style face="normal" font="default" size="100%">Pomerleau, S.</style></author><author><style face="normal" font="default" size="100%">Couture, P.</style></author><author><style face="normal" font="default" size="100%">Lamarche, B.</style></author><author><style face="normal" font="default" size="100%">Couillard, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Lipid Research Center, Laval University Medical Research Center, Laval University, Que. G1V 4G2, Canada&#xD;Institute of Nutraceuticals and Functional Foods, Laval University, Que. G1V 4G2, Canada&#xD;Department of Food Sciences and Nutrition, Laval University, Que. G1V 4G2, Canada&#xD;Department of Medecine, Laval University, Que. G1V 4G2, Canada&#xD;Lipid Research Center, CHUQ Research Center, CHUL Pavillon, Sainte-Foy, Que. G1V 4G2, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Changes in plasma antioxidant capacity and oxidized low-density lipoprotein levels in men after short-term cranberry juice consumption</style></title><secondary-title><style face="normal" font="default" size="100%">Metabolism: Clinical and Experimental</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Metabolism: Clinical and Experimental</style></full-title></periodical><pages><style face="normal" font="default" size="100%">856-861</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">7</style></number><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">Low-density lipoprotein (LDL) oxidation is closely implicated in the development of atherosclerotic cardiovascular disease (CVD), and thus, reducing LDL susceptibility to oxidation with antoxidants could be of importance in CVD prevention. Flavonoids, polyphenolic compounds found in a large selection of fruits and vegetables, have been characterized as having a strong antioxidant potential, and intake of flavonoid-rich foods has been related to decreased morbidity and mortality from heart disease. The present study was therefore undertaken to investigate the effect of flavonoid-rich cranberry juice supplementation on plasma lipoprotein levels and LDL oxidation. For that purpose, 21 men (age ± SD, 38 ± 8 years) were enrolled in a 14-day intervention and instructed to drink cranberry juice 7 mL/kg body weight per day. Physical and metabolic measures including plasma lipid and oxidized LDL (OxLDL) concentrations as well as antioxidant capacity were performed before and after the intervention. At baseline, we found that plasma OxLDL levels were significantly associated with waist circumference (r = 0.47, P =. 0296) as well as plasma triglyceride (r = 0.68, P =. 0007) and apolipoprotein B (r = 0.91, P &lt;. 0001) concentrations. The intervention led to a reduction in plasma OxLDL levels (-9.9% ± 17.8%, P =. 0131) and increase in antioxidant capacity (+6.5% ± 10.3%, P =. 0140). However, no relationship was found between both of these changes (r = -.01, not significant). The intervention did not result in any improvement of plasma lipoprotein-lipid or inflammatory marker concentrations. Our results show that short-term cranberry juice supplementation is associated with significant increase in plasma antioxidant capacity and reduction in circulating OxLDL concentrations. Although the physiological relevance of our observations needs to be further examined, our study supports the potential role of antioxidant-rich foods in maintaining health and preventing CVD. © 2005 Elsevier Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :96&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-20444475033&amp;doi=10.1016%2fj.metabol.2005.01.031&amp;partnerID=40&amp;md5=cb13877666ff1dfc25ecf32e2c1f13ff</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.metabol.2005.01.031</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>305</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">305</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rossi, R.</style></author><author><style face="normal" font="default" size="100%">Porta, S.</style></author><author><style face="normal" font="default" size="100%">Canovi, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sofar SpA, Via Firenze 40, 20060 Trezzano Rosa (Milan), Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Overview on cranberry and urinary tract infections in females</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical Gastroenterology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Clinical Gastroenterology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S61-S62</style></pages><volume><style face="normal" font="default" size="100%">44</style></volume><number><style face="normal" font="default" size="100%">SUPPL. 1</style></number><keywords><keyword><style face="normal" font="default" size="100%">UTIs in women</style></keyword><keyword><style face="normal" font="default" size="100%">UTIs prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry (Vaccinium macrocarpon) has been used for decades to prevent urinary tract infections (UTIs) that are among the most common bacterial infections in women. As to the traditional use of cranberry and its A-type proanthocyanidinse ability to inhibit adherence of the bacterial P fimbriae in a dose-dependent manner, clinical trials have been conducted on different subpopulations. A Cochrane meta-analysis in 244 females with symptomatic UTI suggests that the effect was more pronounced in women with recurrent UTIs than elderly males and females or people requiring catheterization. A first head-to-head trial in older females has been published comparing effectiveness of a low-dose antibiotic versus cranberry in which investigators suggest that cranberry products may have a role in older females with recurrent UTI. Still with regard to antibiotic treatment in women, a recently published study investigated also the potential cranberry juice interaction with β-lactam antibiotics supporting the hypothesis that cranberry juice in usual quantities as prophylaxis for UTI is not likely to alter the pharmacokinetics of these oral antibiotics. In addition, the effects of cranberry in pregnant female patients have been investigated. A first pilot trial has been published in which, while a possible protective effect was shown, more than one third of the females withdrew mainly for gastrointestinal upset. Copyright © 2010 by Lippincott Williams &amp; Wilkins.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :15&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Conference Paper</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-77956058965&amp;doi=10.1097%2fMCG.0b013e3181d2dc8e&amp;partnerID=40&amp;md5=b847b68e4d494f273b518fe7c98279f4</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/MCG.0b013e3181d2dc8e</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>60</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">60</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Roshdibonab, F.</style></author><author><style face="normal" font="default" size="100%">FazlJoo, S. M.</style></author><author><style face="normal" font="default" size="100%">Torbati, M.</style></author><author><style face="normal" font="default" size="100%">Mohammadi, G.</style></author><author><style face="normal" font="default" size="100%">Asadloo, M.</style></author><author><style face="normal" font="default" size="100%">Noshad, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Iranian Traditional Medicine, Tabriz University of Medical Sciences, Tabriz, Iran&#xD;Department of Psychiatry, Tabriz University of Medical Sciences, Tabriz, Iran&#xD;Chronic Kidney Disease Research Center, Department of Nephrology, Tabriz University of Medical Sciences, Tabriz, Iran</style></auth-address><titles><title><style face="normal" font="default" size="100%">The role of Cranberry in preventing Urinary tract infection in Children; A systematic review and Meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Pediatrics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">6457-6468</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Children</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Traditional medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Although effectiveness of cranberry for preventing urinary tract infection (UTI) has been reported in Iranian traditional medicine and recent studies there is still controversy in this regard. Therefore, the present study was designed with a meta-analytic approach aiming to evaluate the effect of prophylaxis prescription of cranberry in prevention of UTI in children. Materials and Methods: In this study, a thorough search was performed in Medline, Embase, Web of Sciences, Scopus and CINHAL databases by the end of August 2017. Using keywords related to urinary tract infection combined with words related to cranberry, search strategy was designed. The articles were summarized and finally, the role of cranberry extract consumption in decreasing the incidence of UTI was evaluated by reporting odds ratio (OR), and 95% confidence interval (95% CI). Results: In the end, 10 studies were included (414 cases in control group and 380 in cranberry extract treatment group). Analyses showed that prescription of cranberry significantly reduced the odds of UTI manifestation in children compared to placebo (OR=0.31; 95% CI: 0.21 to 0.46; p&lt;0.0001). On the other hand, it was determined that effectiveness of cranberry in decreasing UTI manifestation was similar to antibiotic treatment (OR=0.75; 95% CI: 0.34 to 1.70; p=0.495). Conclusion: In the present study, it was determined that prophylaxis prescription of cranberry extract leads to prevention of UTI manifestation in children and its effectiveness is similar to that of antibiotics.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85037362887&amp;doi=10.22038%2fijp.2017.27041.2327&amp;partnerID=40&amp;md5=64a25c1a7c3d307b15e622ad59967110</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.22038/ijp.2017.27041.2327</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>381</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">381</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rodríguez, G. M. F.</style></author><author><style face="normal" font="default" size="100%">Subias, J. E.</style></author><author><style face="normal" font="default" size="100%">Acin, E. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unidad de Nefrología Pediátrica, Hospital de la Santa Creu i Sant Pau, Universidad Autónoma de Barcelona, Barcelona, Spain&#xD;Unidad de Nefrología Pediátrica, Hospital Universitario Sant Joan, Universidad Rovira i Virgili, Reus, Spain&#xD;Servicio de Pediatría, Hospital de la Santa Creu i Sant Pau, C. Antoni Ma i Claret 167, 08025 Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Current status of antibiotic prophylaxis in primary vesicoureteral reflux in children</style></title><secondary-title><style face="normal" font="default" size="100%">Archivos Espanoles de Urologia</style></secondary-title><short-title><style face="normal" font="default" size="100%">Situación actual de la profilaxis antibiótica en el reflujo vesicoureteral primario en el niño</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archivos Espanoles de Urologia</style></full-title></periodical><pages><style face="normal" font="default" size="100%">236-243</style></pages><volume><style face="normal" font="default" size="100%">61</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibacterial prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Children</style></keyword><keyword><style face="normal" font="default" size="100%">Meta-analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Vesicoureteral reflux</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">OBJECTIVES: To assess the efficacy of antibiotic prophylaxis for prevention of urinary infections and renal parenchymal damage in children with primary vesicoureteral reflux (VUR). METHODS/RESULTS. A search based on MEDLINE and The Cochrane Library was performed selecting those cli-nical trials and meta-analysis which compared antibiotic prophylaxis (either continuous or intermittent) and place-bo or no treatment at all in children with primary VUR. Three systematic reviews were chosen for assessing the efficacy of prophylaxis of urinary infections including trials with a predominant paediatric population without known VUR. Results showed that the use of antibiotics decreased the risk of urinary infection. The quality of the trials was, however, insufficient and therefore of questionable results. We also selected two randomized controlled trials in children with reflux: one had limited information as the degree of reflux was not stated; the second assessed the results in a population of 113 children with VUR grade I to III (55 receiving prophylaxis and 58 not) fo-llowing acute pyelonephritis. There were no differences with regard to the risk of urinary infection or the risk of renal parenchymal damage. CONCLUSIONS. There is not enough evidence supporting generalized use of antibiotics to prevent urinary infections. No benefit in prophylaxis has been proven for VUR grades I to III. There is no data for high grade VUR. It will be necessary to perform more trials in order to establish more accurate recommendations on prevention of urinary infections in the presence of VUR.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-42149125577&amp;partnerID=40&amp;md5=f129bef77bd78851bacbe34edd1cbbbb</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>162</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">162</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Robinson, D.</style></author><author><style face="normal" font="default" size="100%">Giarenis, I.</style></author><author><style face="normal" font="default" size="100%">Cardozo, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urogynaecology, Kings College Hospital, Suite 8, 3rd Floor, Golden Jubilee, London, SE5 9RS, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">The management of urinary tract infections in octogenarian women</style></title><secondary-title><style face="normal" font="default" size="100%">Maturitas</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Maturitas</style></full-title></periodical><pages><style face="normal" font="default" size="100%">343-347</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Investigation</style></keyword><keyword><style face="normal" font="default" size="100%">Oestrogen</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Urogenital atrophy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary Tract Infections are common in women of all ages and the incidence increases with age. Whilst they are a common cause of lower urinary tract symptoms in all women they may be associated with increased morbidity in the elderly. Appropriate investigation and treatment in primary and secondary care are essential to effectively manage urinary tract infection and decrease morbidity and hospitalisation rates. Loss of endogenous oestrogen at the time of the menopause is associated with the urogenital atrophy and an increased incidence of urinary tract infection. Consequently vaginal oestrogen therapy may offer a rationale for treatment and prevent of urinary tract infection. The aim of this paper is to review the clinical management of elderly women presenting with primary and recurrent urinary tract infection. © 2015 Published by Elsevier Ireland Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84931575771&amp;doi=10.1016%2fj.maturitas.2015.04.014&amp;partnerID=40&amp;md5=d0da8ebc4e72425043a18f17506a7036</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.maturitas.2015.04.014</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>616</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">616</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Roberts, A. P.</style></author><author><style face="normal" font="default" size="100%">Robinson, R. E.</style></author><author><style face="normal" font="default" size="100%">Beard, R. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Obstetrics and Gynaecology, Queen Charlotte&apos;s Hospital, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Some Factors Affecting Bacterial Colony Counts in Urinary Infection</style></title><secondary-title><style face="normal" font="default" size="100%">British Medical Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Medical Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">400-403</style></pages><volume><style face="normal" font="default" size="100%">1</style></volume><number><style face="normal" font="default" size="100%">5537</style></number><dates><year><style face="normal" font="default" size="100%">1967</style></year></dates><abstract><style face="normal" font="default" size="100%">Vulval cleansing with a 1:2,000 solution of chlorhexidine (Hibitane) has been shown to result often in a marked reduction in the bacterial colony count of midstream urine. Cleansing with sterile water has been shown to provide a satisfactory alternative for this procedure. Urinary diuresis greatly reduces the colony count of infected urine. The early morning specimen of urine constantly has the highest level of infection, and this gradually declines during the day. © 1967, British Medical Journal Publishing Group. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :41&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0014209852&amp;doi=10.1136%2fbmj.1.5537.400&amp;partnerID=40&amp;md5=482954111d0a7fdffd3328302693b862</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/bmj.1.5537.400</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>149</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">149</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Risco Rodríguez, E.</style></author><author><style face="normal" font="default" size="100%">Álvarez-Sala Walther, L. A.</style></author><author><style face="normal" font="default" size="100%">Ramos, V. C.</style></author><author><style face="normal" font="default" size="100%">Bonet, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Phytonexus, S.L. Na Jordana, València, Spain&#xD;Universidad Complutense de Madrid, Plaza de Ramón y Cajal Ciudad Universitaria, Madrid, Spain&#xD;Teknon Clinic, Urology Department, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Concentration-dependent effect on adherence of escherichia coli to bladder epithelial cells of cysticlean capsules (240 mg/capsule of proanthocyanidins)</style></title><secondary-title><style face="normal" font="default" size="100%">Internet Journal of Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Internet Journal of Microbiology</style></full-title></periodical><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Background The proanthocyanidins (PACs) are the main components of cranberry (fruit of Vaccinium macrocarpon Aiton), and their content determines the effectiveness in the urinary tract infections (UTIs). The activity of PACS is related to inhibition of bacterial adherence. Cysticlean® is a cranberry extract product with a high quantity of proanthocyanidins (240 mg/capsule of PACs). Cysticlean® is used in the prevention and treatment of recurrent UTIs. The aim of this study is the comparison of different concentrations of Cysticlean® capsules on adherence of Escherichia coli to bladder epithelial cells. Methods In vitro, E. coli pre-incubated in different concentrations of Cysticlean® capsules was incubated with human urinary bladder carcinoma cells (T24 cells) for 1 hour and the number of bacteria adhered to cells was recorded. Results Cysticlean® has demonstrated a dose-dependent inhibition of bacterial adherence. At concentrations of 5, 25, 75 and 137 mg PACs/mL, Cysticlean® decreases the number of bacteria adhered to epithelial cells by 17%, 52%, 76 and 89%, respectively. Conclusions Cysticlean® capsules (240 mg/capsule of PACs) induces a dose-dependent significant decrease in the number of E. coli adhered. Previous clinical assays showed that Cysticlean® is a product highly recommended in the prophylaxis and treatment of UTIs. The present study confirms that the amount of proanthocyanidins is very important to achieve greatest effectiveness of the cranberry products. © 2015, Internet Scientific Publications, LLC. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84946593976&amp;doi=10.5580%2fIJMB.33094&amp;partnerID=40&amp;md5=895c79167a7ea8591f8453f3f683bbaf</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.5580/IJMB.33094</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>307</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">307</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Risco, E.</style></author><author><style face="normal" font="default" size="100%">Miguélez, C.</style></author><author><style face="normal" font="default" size="100%">De Badajoz, E. S.</style></author><author><style face="normal" font="default" size="100%">Rouseaud, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Facultad de Farmacia, Universidad de Barcelona, Barcelona, Spain&#xD;Servicio de Urología, Pediátrica Clinica Santa Elena, Universidad de Malaga, Malaga, Spain&#xD;Universidad de Malaga, Servicio de Urologia, Clinica Santa Elena, Malaga, Spain&#xD;Instituto Medico Tecnologico, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of american cranberry (cysticlean®®) on escherichia coli adherence to bladder epithelial cells. In vitro and in vivo study</style></title><secondary-title><style face="normal" font="default" size="100%">Archivos Espanoles de Urologia</style></secondary-title><short-title><style face="normal" font="default" size="100%">Efecto del arandano americano (cysticlean®), sobre la adherencia de escherichia coli a células epiteliales de vejiga. Estudio in vitro y ex vivo</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archivos Espanoles de Urologia</style></full-title></periodical><pages><style face="normal" font="default" size="100%">422-430</style></pages><volume><style face="normal" font="default" size="100%">63</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">American cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Ex vivo</style></keyword><keyword><style face="normal" font="default" size="100%">In vitro</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidins</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><abstract><style face="normal" font="default" size="100%">OBJECTIVES: The American cranberry proanthocyanidins (PACs) are the main responsible for its efficacy in urinary tract infections. Their mechanism of action is related to inhibition of Escherichia coli to urothelial cells. Cysticlean ® contains an extract of American cranberry which provides 118 mg of PACs per dose. The activity of Cysticlean® tablets on Escherichia Coli adherence to bladder epithelial cells has been studied in vitro. Moreover, the activity of Cistyclean® both in powder for oral suspension and tablets has been compared ex-vivo. METHODS: The rats received both Cysticlean® preparations per orem, and urine from each animal was collected during the following 16 hours and pre-incubated with E. coli. Subsequently, bacteria were incubated with T24 cells. After 1 hour the number of bacteria adhered per cell was calculated. For the in vitro study, E. Coli pre-incubated at various concentrations of the products were incubated with T24 cells and the same process previously referred was carried out. RESULTS: Urine samples from rats taking Cysticlean® powder for oral suspension and tablets (118 mg PACs/animal) showed an important inhibition of E. Coli adherence (83% and 52% respectively). The inferior dose of 59 mg PACs/animal also showed marked inhibition of E. Coli adherence (29% after Cysticlean® tablets intake and 40% for powder). In vitro, Cysticlean® showed inhibition of bacterial adherence in all tested concentrations: 5, 25 and 75 PACs mg/ml, diminishing the number og bacteria adhered to epithelial cells by 25%, 36% and 34% respectively. CONCLUSIONS: Cysticlean® shows a significant inhibition of E. Coli adherence to urothelial cells. Cysticlean® powder for suspensión preparation is more effective tha tablets. Cysticlean ® powder for suspensión is well tolerated, and compliance has been observed. Its use is very recommendable in pediatric urinary tract infection prophylaxis. Due to the variety of products with American cranberry extracts in the market, with different proanthocyanidins declared content, it would be interesting to compare their activity using established pharmacological methods.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :5&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-77957856005&amp;partnerID=40&amp;md5=a24e5bd04d631691cbcf68ea2e76f0d7</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>368</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">368</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Richards, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">Practice Nurse</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Practice Nurse</style></full-title></periodical><pages><style face="normal" font="default" size="100%">16-18</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">11</style></number><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-52249090006&amp;partnerID=40&amp;md5=bc2029183eb28c783f5ec18689836f06</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>483</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">483</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Richards, C. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Div. of Healthcare Quality Promotion, Natl. Center for Infectious Diseases, Centers for Dis. Control/Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections in the frail elderly: Issues for diagnosis, treatment and prevention</style></title><secondary-title><style face="normal" font="default" size="100%">International Urology and Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Urology and Nephrology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">457-463</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTIs) are among the most common infections in frail elderly adults, whether they are community dwelling, live in long term care facilities (LTCFs) or are hospitalized. UTIs cause substantial morbidity and mortality in frail elderly men and women. While many major risk factors in these individuals may not be modifiable, improved attention to incontinence management, judicious use of antimicrobials and urinary catheters, and, in women, appropriate use of topical estrogen may be useful in reducing UTIs. Future strategies may also include the appropriate use of new urinary catheter technology and emerging vaccines. © 2004 Kluwer Academic Publishers.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :26&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-12444259793&amp;doi=10.1007%2fs11255-004-4870-6&amp;partnerID=40&amp;md5=5abd0814c3be79a4f72627eb132f8e09</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s11255-004-4870-6</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>35</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">35</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ribić, R.</style></author><author><style face="normal" font="default" size="100%">Meštrović, T.</style></author><author><style face="normal" font="default" size="100%">Neuberg, M.</style></author><author><style face="normal" font="default" size="100%">Kozina, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Research and Development Department Tesla Ltd, Klenovnik, 42244, Croatia&#xD;Clinical Microbiology and Parasitology Unit Polyclinic dr. Zora Profozic, Zagreb, 10000, Croatia&#xD;Department of Biomedical Sciences University Centre Varazdin University North, Varazdin, 42000, Croatia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effective anti-adhesives of uropathogenic Escherichia coli</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Pharmaceutica</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Pharmaceutica</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-18</style></pages><volume><style face="normal" font="default" size="100%">68</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">mannosides</style></keyword><keyword><style face="normal" font="default" size="100%">P pili</style></keyword><keyword><style face="normal" font="default" size="100%">polyphenols</style></keyword><keyword><style face="normal" font="default" size="100%">type I fimbriae</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTIs) caused by uropathogenic Escherichia coli (UPEC) are among the most common infectious diseases in humans. Due to their frequent occurrence in the community and nosocomial settings, as well as the development of resistance to the commonly prescribed antimicrobial agents, an enormous financial burden is placed on healthcare systems around the world. Therefore, novel approaches to the prevention and treatment of UTIs are needed. Although UPEC may harbour a plethora of virulence factors, type I fimbriae and P pili are two of the most studied adhesive organelles, since the attachment to host cells in the urinary tract is a crucial step towards infection. Design of receptor analogues that competitively bind to UPEC surface adhesins placed at the top of pili organelles led to the development of anti-adhesive drugs that are increasingly recognized as important and promising alternatives to antibiotic treatment of UTIs. © by Rosana Ribić 2018.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042681051&amp;doi=10.2478%2facph-2018-0004&amp;partnerID=40&amp;md5=920f323ee3821d87652e095d1e6decfa</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2478/acph-2018-0004</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>605</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">605</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Remis, R. S.</style></author><author><style face="normal" font="default" size="100%">Gurwith, M. J.</style></author><author><style face="normal" font="default" size="100%">Gurwith, D.</style></author><author><style face="normal" font="default" size="100%">Hargrett-bean, N. T.</style></author><author><style face="normal" font="default" size="100%">Layde, P. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Field Services, Epidemiology Program Office, Centers for Disease Control, Atlanta, GA, United States&#xD;Department of Medicine, Michigan State Univer sity, East Lansing, MI, United States&#xD;Division of Bacterial Diseases, Center for Infec tious Diseases, Centers for Disease Control, Atlanta, GA, United States&#xD;Centers for Disease Control, Atlanta, GA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Risk factors for urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Epidemiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Epidemiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">685-694</style></pages><volume><style face="normal" font="default" size="100%">126</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Coitus</style></keyword><keyword><style face="normal" font="default" size="100%">Contraceptive devices</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">Women</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1987</style></year></dates><abstract><style face="normal" font="default" size="100%">Remis, R. S. (Bureau regional des maladies infectieuses, 980 rue Guy, Montreal, Quebec, Canada H3H 2K3), M. J. Gurwith, D. Gurwith, N. T. Hargrett-Bean, and P. M. Layde. Risk factors for urinary tract infection. Am J Epidemiol 1987;126:685-94.The authors carried out a case-control study in 1982-1983 to investigate the possible influence of behavioral factors on the risk of urinary tract infection. Study participants were college women attending a student health service. Cases were 43 women with culture-confirmed urinary tract infection. There were two control groups: 149 women with upper respiratory infection and 227 women visiting the gynecology clinic. Using each set of controls, the study confirmed that sexual intercourse is a risk factor and that there is a dose-response effect for increasing levels of coital frequency. The study also found that use of the diaphragm was significantly associated with urinary tract infection (odds ratios 3.0, 2.3), an association which remained significant even after controlling for possible confounding by coital frequency. The findings did not show an association with many of the factors commonly believed to be important such as type of clothing worn and volume of fluids consumed. © 1987 by The Johns Hopkins University School of Hygiene and Public Health.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :70&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023261747&amp;doi=10.1093%2foxfordjournals.aje.a114708&amp;partnerID=40&amp;md5=d1bb556e62a0dee5dbe63ddff3af8bb1</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/oxfordjournals.aje.a114708</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>105</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">105</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Reid, G.</style></author><author><style face="normal" font="default" size="100%">Burton, J. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departments of Microbiology AndImmunology and Surgery (Urology), Western University and Lawson Health Research Institute, 268 Grosvenor Street, London, ON N6A 4V2, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary incontinence: Making sense of the urinary microbiota in clinical urology</style></title><secondary-title><style face="normal" font="default" size="100%">Nature Reviews Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nature Reviews Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">567-568</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">10</style></number><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Short Survey</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84988423254&amp;doi=10.1038%2fnrurol.2016.182&amp;partnerID=40&amp;md5=dc3b1539036dc8e8fecc5c54c834a82a</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/nrurol.2016.182</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>474</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">474</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Reid, G.</style></author><author><style face="normal" font="default" size="100%">Burton, J.</style></author><author><style face="normal" font="default" size="100%">Devillard, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology and Immunology and Surgery, The University of Western Ontario, London, Ont., Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Contemporary issues in Ob/Gyn &amp; women&apos;s health - The rationale for probiotics in female urogenital healthcare</style></title><secondary-title><style face="normal" font="default" size="100%">MedGenMed Medscape General Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">MedGenMed Medscape General Medicine</style></full-title></periodical><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Urogenital infections are a major reason that women visit their family physician and are referred to gastroenterology, gynecology, urology, and infectious disease specialists. The association between abnormal vaginal microbiota and increased risk for sexually transmitted infections, bladder and vaginal infections per se, and a higher rate of preterm labor indicate the need to better understand and manage urogenital health. The concept of probiotics arose from the realization that humans are inhabited with microbes from birth and that these organisms play a role in preventing disease. Defined as &quot;live microorganisms, which when administered in adequate amounts confer a health benefit on the host,&quot; probiotic strains have already been shown to effectively prevent diarrhea and to hold potential in preventing and treating tonsillitis, caries, renal calculi, and respiratory infections. This review provides a rationale for the use of probiotics in maintaining female vaginal and bladder health and as a treatment option for recurrent bacterial vaginosis, urinary tract infection, yeast vaginitis, and sexually transmitted infections. We consider only probiotic strains that fulfill the United Nations/World Health Organization Guidelines for Probiotics in being fully characterized and clinically documented through scientific investigations describing known or presumed mechanisms of action. Although medical practitioners as yet are unable to access these probiotic strains, an awareness of recent and ongoing research for probiotics is important, as results are encouraging. The concept of probiotic therapy is familiar to many consumers and although it has historically lacked credibility in the medical community, perceptions are changing. © 2004 Medscape.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-25144450629&amp;partnerID=40&amp;md5=181d580cc1d136327a78948c0c1dbebd</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>598</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">598</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Reid, G.</style></author><author><style face="normal" font="default" size="100%">Bruce, A. W.</style></author><author><style face="normal" font="default" size="100%">Taylor, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dept. of Microbiology/Immunology, University of Western Ontario, London, Ont., Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Influence of three-day antimicrobial therapy and lactobacillus vaginal suppositories on recurrence or urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Therapeutics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Therapeutics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">11-16</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">1992</style></year></dates><abstract><style face="normal" font="default" size="100%">Forty-one adult women with acute lower urinary tract infections (UTI) were randomly treated for three days with norfloxacin or trimethoprim/sulfamethoxazole (TMP/SMX). Infection was eradicated in 100% of norfloxacin-treated patients and in 95% of TMP/SMX-treated patients. UTI recurred in 29% of patients treated with norfloxacin and in 41% of those treated with TMP/SMX. Post-therapy vaginal administration of lactobacillus suppositories resulted in a recurrence rate of UTI of only 21%, while in patients given sterilized skim-milk suppositories the recurrence rate was 47%. This study indicates that lactobacillus vaginal suppositories are safe and may be effective in reducing the recurrence of UTI following antimicrobial therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :105&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026549347&amp;partnerID=40&amp;md5=47ea7e952806a5bb62181d2b38a0740f</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>434</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">434</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Reid, G.</style></author><author><style face="normal" font="default" size="100%">Bruce, A. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Canadian Research and Development Centre for Probiotics, Lawson Health Research Institute, 268 Grosvenor Street, London, Ont. N6A 4V2, Canada&#xD;Department of Microbiology and Immunology, The University of Western Ontario, London, Ont., Canada&#xD;Department of Surgery, The University of Western Ontario, London, Ont., Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Probiotics to prevent urinary tract infections: The rationale and evidence</style></title><secondary-title><style face="normal" font="default" size="100%">World Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">World Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">28-32</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">For over 30 years, urologists have recognized in females, that urinary pathogens almost always infect the host through ascension from the rectum, vagina to the urethra and bladder. Likewise, the Lactobacillus organisms that predominate in the vagina of healthy women, spread from the rectum and perineum and form a barrier in the vagina to bladder entry by uropathogens. The concept of artificially boosting the lactobacilli numbers through probiotic instillation has long been conceived, but only in recent years shown to be possible. Not all lactobacilli are effective, and to date clinical efficacy only exists for Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri B-54 and RC-14. These strains are only commercially available in Austria, and therefore for most urologists, while some probiotic organisms may reduce the recurrences of bladder cancer or oxaluria, no probiotics can be recommended widely to prevent UTI at present. © Springer-Verlag 2005.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :104&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33644546686&amp;doi=10.1007%2fs00345-005-0043-1&amp;partnerID=40&amp;md5=202d225b537e13e2aa87794560bb5338</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00345-005-0043-1</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>414</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">414</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Reid, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Canadian R and D Centre for Probiotics, Lawson Health Research Institute, University of Western Ontario, London, Ont., Canada&#xD;Canadian R and D Centre for Probiotics, Lawson Health Research Institute, F2-116, 268 Grosvenor Street, London, Ont. N6A 4V2, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevention and treatment of urogenital infections and complications: Lactobacilli&apos;s multi-pronged effects</style></title><secondary-title><style face="normal" font="default" size="100%">Microbial Ecology in Health and Disease</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Microbial Ecology in Health and Disease</style></full-title></periodical><pages><style face="normal" font="default" size="100%">181-186</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">3-4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Lactobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">Mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Urogenital infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">The association between depletion of vaginal lactobacilli and increased risk of various urogenital infections and complications such as preterm labor, has been known for some time. Restoration of depleted lactobacilli by administration of probiotic strains has been demonstrated in humans using Lactobacillus rhamnosus GR-1 and L. reuteri RC-14. These organisms also augment antibiotic efficacy, lessen the side effects of these drugs, and alleviate diarrhea in AIDS patients. The mechanisms appear to be multi-factorial, and include production of: (i) anti-microbial factors such as lactic acid, bacteriocins, hydrogen peroxide, (ii) biosurfactants or other components that affect pathogen colonization and biofilm formation, (iii) signalling compounds that influence pathogen virulence expression, and (iv) signalling compounds that modulate immunity. Recombinant strains have been produced that inhibit or kill HIV, offering hope for microbicide applications that can be self-used by women. As more information becomes available about the &apos;normal&apos; versus &apos;disease prone&apos; vaginal microbiota and strains that confer the most benefits, current and new probiotic remedies will potentially provide improved restorative and therapeutic options to lower the one billion urogenital infections currently afflicting women around the world. © 2006 Taylor &amp; Francis.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33845648940&amp;doi=10.1080%2f08910600601072415&amp;partnerID=40&amp;md5=23a9fc6d1ca3675f4eb352ef71af9127</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/08910600601072415</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>556</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">556</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Reid, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Lawson Research Institute, London, ON, Canada&#xD;Department of Microbiology and Immunology, University of Western Ontario, London, ON, Canada&#xD;Department of Surgery, University of Western Ontario, London, ON, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">The role of cranberry and probiotics in intestinal and urogenital tract health</style></title><secondary-title><style face="normal" font="default" size="100%">Critical reviews in food science and nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Critical Reviews in Food Science and Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">293-300</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><abstract><style face="normal" font="default" size="100%">Several forces are driving an expanded use of nutraceuticals, particularly functional foods and probiotics, as instruments of the restoration and maintenance of well-being. These include consumer desire to use natural rather than pharmaceutical products, the mounting scientific evidence that shows efficacy of certain nutraceutical products, and the increasing cost and continued failure of drugs to cure or prevent disease. There is now a strong scientific basis for use of cranberries to reduce the risk of E. coli adhesion to bladder cells and the onset of urinary tract infection. There is also a mechanistic basis and clinical support for use of Lactobacillus strains such as L. rhamnosus GR-1 and L. fermentum RC-14 to colonize the intestine and vagina and reduce the risk of intestinal and urogenital infections. For such alternative approaches to be successful, scientific rigor must be backed by public education and physician acceptance. Given the emergence of virulent and multidrug-resistant pathogens, time is not on our side.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :15&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036049179&amp;doi=10.1080%2f10408390209351918&amp;partnerID=40&amp;md5=808df797c38f913331be89ffa4683ab5</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/10408390209351918</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>596</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">596</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Raz, R.</style></author><author><style face="normal" font="default" size="100%">Stamm, W. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Infectious Disease Unit, Central Emek Hospital, Technion Faculty of Medicine, Haifa, Israel&#xD;the Department of Medicine, University of Washington, Seattle, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">A Controlled Trial of Intravaginal Estriol in Postmenopausal Women with Recurrent Urinary Tract Infections</style></title><secondary-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">753-756</style></pages><volume><style face="normal" font="default" size="100%">329</style></volume><number><style face="normal" font="default" size="100%">11</style></number><dates><year><style face="normal" font="default" size="100%">1993</style></year></dates><abstract><style face="normal" font="default" size="100%">Recurrent urinary tract infections are a problem for many postmenopausal women. Estrogen replacement restores atrophic mucosa, lowers vaginal pH, and may prevent urinary tract infections. We enrolled 93 postmenopausal women with a history of recurrent urinary tract infections in a randomized, double-blind, placebo-controlled trial of a topically applied intravaginal estriol cream. Midstream urine cultures were obtained at enrollment, monthly for eight months, and whenever urinary symptoms occurred. Vaginal cultures and pH measurements were obtained at entry and after one and eight months. The women were assigned to receive either estriol (n = 50) or placebo (n = 43), both administered intravaginally; 36 and 24, respectively, completed the eight months of follow-up. The incidence of urinary tract infection in the group given estriol was significantly reduced as compared with that in the group given placebo (0.5 vs. 5.9 episodes per patient-year, P&amp;lt;0.001). Survival analysis showed that more of the women in the estriol group than in the placebo group remained free of urinary tract infection (P&amp;lt;0.001). Lactobacilli were absent in all vaginal cultures before treatment and reappeared after one month in 22 of 36 estriol-treated women (61 percent) but in none of the 24 placebo recipients (P&amp;lt;0.001). With estriol the mean vaginal pH declined from 5.5 to 3.8 (P&amp;lt;0.001), whereas there was no significant change with placebo. The rate of vaginal colonization with Enterobacteriaceae fell from 67 percent to 31 percent in estriol recipients but was virtually unchanged (from 67 to 63 percent) in the placebo recipients (P&amp;lt;0.005). Side effects were minor, but caused 10 estriol recipients (28 percent) and 4 placebo recipients (17 percent) to discontinue treatment. The intravaginal administration of estriol prevents recurrent urinary tract infections in postmenopausal women, probably by modifying the vaginal flora., An estimated 10 to 15 percent of women over 60 years of age have frequent urinary tract infections1. Hormonally induced changes in the vaginal flora associated with menopause are thought to play an important part in the pathogenesis of urinary tract infections in older women. In premenopausal women, circulating estrogens encourage colonization of the vagina by lactobacilli, which produce lactic acid from glycogen and maintain a low vaginal pH that inhibits the growth of many uropathogens2,3. After menopause, however, the vaginal pH increases, lactobacilli disappear from the vaginal flora, and the vagina is predominantly colonized by Enterobacteriaceae,… © 1993, Massachusetts Medical Society. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :588&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027296111&amp;doi=10.1056%2fNEJM199309093291102&amp;partnerID=40&amp;md5=c4cb5995327dd9d180d4e11c1ff1aee4</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1056/NEJM199309093291102</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>179</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">179</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rane, H. S.</style></author><author><style face="normal" font="default" size="100%">Bernardo, S. M.</style></author><author><style face="normal" font="default" size="100%">Howell, A. B.</style></author><author><style face="normal" font="default" size="100%">Lee, S. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Infectious Diseases, New Mexico Veterans Healthcare System, Albuquerque, NM, United States&#xD;Division of Infectious Diseases, University of New Mexico Health Science Centre, Albuquerque, NM, United States&#xD;Marucci Center for Blueberry and Cranberry Research and Extension, Rutgers University, Chatsworth, NJ, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry-derived proanthocyanidins prevent formation of Candida albicans biofilms in artificial urine through biofilm- and adherence-specific mechanisms</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Antimicrobial Chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Antimicrobial Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">428-436</style></pages><volume><style face="normal" font="default" size="100%">69</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry PACs</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary catheters</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon ait</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Objectives: Candida albicans is a common cause of nosocomial urinary tract infections (UTIs) and is responsible for increased morbidity and healthcare costs. Moreover, the US Centers for Medicare &amp; Medicaid Services no longer reimburse for hospital-acquired catheter-associated UTIs. Thus, development of specific approaches for the prevention of Candida urinary infections is needed. Cranberry juice-derived proanthocyanidins (PACs) have efficacy in the prevention of bacterial UTIs, partially due to anti-adherence properties, but there are limited data on their use for the prevention and/or treatment of Candida UTIs. Therefore, we sought to systematically assess the in vitro effect of cranberry-derived PACs on C. albicans biofilm formation in artificial urine. Methods: C. albicans biofilms in artificial urine were coincubated with cranberry PACs at serially increasing concentrations and biofilm metabolic activity was assessed using the XTT assay in static microplate and silicone disc models. Results: Cranberry PAC concentrations of ≥16 mg/L significantly reduced biofilm formation in all C. albicans strains tested, with a paradoxical effect observed at high concentrations in two clinical isolates. Further, cranberry PACs were additive in combination with traditional antifungals. Cranberry PACs reduced C. albicans adherence to both polystyrene and silicone. Supplementation of the medium with iron reduced the efficacy of cranberry PACs against biofilms. Conclusions: These findings indicate that cranberry PACs have excellent in vitro activity against C. albicans biofilm formation in artificial urine. We present preliminary evidence that cranberry PAC activity against C. albicans biofilm formation is due to anti-adherence properties and/or iron chelation. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy 2013. This work is written by US Government employees and is in the public domain in the US.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :28&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84892459298&amp;doi=10.1093%2fjac%2fdkt398&amp;partnerID=40&amp;md5=fe77144c8b9b9d2beec0a9971b57e670</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">dkt398</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/jac/dkt398</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>281</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">281</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rajbhandari, R.</style></author><author><style face="normal" font="default" size="100%">Peng, N.</style></author><author><style face="normal" font="default" size="100%">Moore, R.</style></author><author><style face="normal" font="default" size="100%">Arabshahi, A.</style></author><author><style face="normal" font="default" size="100%">Wyss, J. M.</style></author><author><style face="normal" font="default" size="100%">Barnes, S.</style></author><author><style face="normal" font="default" size="100%">Prasain, J. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacology and Toxicology, 456 McCallum Research Building, University of Alabama at Birmingham, 1918 University Boulevard, Birmingham, AL 35294, United States&#xD;Department of Cell Biology, University of Alabama at Birmingham, Birmingham, AL 35294, United States&#xD;Targeted Metabolomics and Proteomics Laboratory, University of Alabama at Birmingham, Birmingham, AL 35294, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Determination of cranberry phenolic metabolites in rats by liquid chromatography-tandem mass spectrometry</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">6682-6688</style></pages><volume><style face="normal" font="default" size="100%">59</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">analysis</style></keyword><keyword><style face="normal" font="default" size="100%">cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">LC-MS/MS</style></keyword><keyword><style face="normal" font="default" size="100%">metabolites</style></keyword><keyword><style face="normal" font="default" size="100%">rats</style></keyword><keyword><style face="normal" font="default" size="100%">urine recovery</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">The glycosides of flavonoid, anthocyanins and A type proanthocyanidins in cranberry concentrate were characterized and quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Cranberry concentrate (1 g/body weight) was orally gavaged to Fischer-344 rats (n = 6), and blood and urine samples were collected over 24 h periods. Quercetin, 3′-O- methylquercetin (isorhamnetin), myricetin, kaempferol, and proanthocyanidin dimer A2, together with thirteen conjugated metabolites of quercetin and methylquercetin and intact peonidin 3-O-galactoside and cyanidin 3-O-galactoside were identified in the rat urine after cranberry treatment. Very low levels of isorhamnetin (0.48 ± 0.09 ng/mL) and proanthocyanidin dimer A2 (0.541 ± 0.10 ng/mL) were found in plasma samples after 1 h of cranberry administration. Although no quercetin was detected in plasma, MRM analysis of the methanolic extract of urinary bladder showed that chronic administration of cranberry concentrate to rats resulted in accumulation of quercetin and isorhamnetin in the bladder. These results demonstrate that cranberry components undergo rapid metabolism and elimination into the urine of rats and are present in the urinary bladder tissue potentially allowing them to inhibit urinary bladder carcinogenesis. © 2011 American Chemical Society.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :20&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79959284374&amp;doi=10.1021%2fjf200673h&amp;partnerID=40&amp;md5=4b2ed25be754fe202f297200959c8ad7</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/jf200673h</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>85</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">85</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Quinlan, J. D.</style></author><author><style face="normal" font="default" size="100%">Jorgensen, S. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Family Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, United States&#xD;National Capital Consortium Family Medicine Residency Program, Fort Belvoir Community HospitalVA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent UTIs in women: How you can refine your care</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Family Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Family Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">94-99</style></pages><volume><style face="normal" font="default" size="100%">66</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85012188691&amp;partnerID=40&amp;md5=24d5d9f61c8309572f3b215d8187e4b9</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>454</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">454</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Puupponen-Pimiä, R.</style></author><author><style face="normal" font="default" size="100%">Nohynek, L.</style></author><author><style face="normal" font="default" size="100%">Hartmann-Schmidlin, S.</style></author><author><style face="normal" font="default" size="100%">Kähkönen, M.</style></author><author><style face="normal" font="default" size="100%">Heinonen, M.</style></author><author><style face="normal" font="default" size="100%">Määttä-Riihinen, K.</style></author><author><style face="normal" font="default" size="100%">Oksman-Caldentey, K. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">VTT Biotechnology, Espoo, Finland&#xD;Dept. of Appl. Chem. and Microbiol., Food Chemistry Division, University of Helsinki, Helsinki, Finland&#xD;Food and Health Research Centre, University of Kuopio, Kuopio, Finland&#xD;VTT Biotechnology, Tietotie 2, FI-02044 VTT Espoo, Finland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Berry phenolics selectively inhibit the growth of intestinal pathogens</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Applied Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Applied Microbiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">991-1000</style></pages><volume><style face="normal" font="default" size="100%">98</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antimicrobial activity</style></keyword><keyword><style face="normal" font="default" size="100%">Berry phenolics</style></keyword><keyword><style face="normal" font="default" size="100%">Cloudberry</style></keyword><keyword><style face="normal" font="default" size="100%">Ellagitannins</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal pathogens</style></keyword><keyword><style face="normal" font="default" size="100%">Raspberry</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">Aims: To investigate the effects of berries and berry phenolics on pathogenic intestinal bacteria and to identify single phenolic compounds being responsible for antimicrobial activity. Methods and Results: Antimicrobial activity of eight Nordic berries and their phenolic extracts and purified phenolic fractions were measured against eight selected human pathogens. Pathogenic bacterial strains, both Gram-positive and Gram-negative, were selectively inhibited by bioactive berry compounds. Cloudberry and raspberry were the best inhibitors, and Staphylococcus and Salmonella the most sensitive bacteria. Phenolic compounds, especially ellagitannins, were strong inhibitory compounds against Staphylococcus bacteria. Salmonella bacteria were only partly inhibited by the berry phenolics, and most of the inhibition seemed to originate from other compounds, such as organic acids. Listeria strains were not affected by berry compounds, with the exception of cranberry. Phenolic compounds affect the bacteria in different mechanisms. Conclusions: Berries and their phenolics selectively inhibit the growth of human pathogenic bacteria. Significance and Impact of the Study: Antimicrobial properties of berries could be utilized in functional foods. Furthermore these compounds would be of high interest for further evaluation of their properties as natural antimicrobial agents for food and pharmaceutical industry. © 2005 The Society for Applied Microbiology.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :237&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-16444377368&amp;doi=10.1111%2fj.1365-2672.2005.02547.x&amp;partnerID=40&amp;md5=11057b5e6105a6ae258bf8b7a3456abe</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1365-2672.2005.02547.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>182</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">182</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Proietti, S.</style></author><author><style face="normal" font="default" size="100%">Giannantoni, A.</style></author><author><style face="normal" font="default" size="100%">Luciani, L. G.</style></author><author><style face="normal" font="default" size="100%">Sortino, G.</style></author><author><style face="normal" font="default" size="100%">Graziotti, P.</style></author><author><style face="normal" font="default" size="100%">Giusti, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Stone Center at Department of Urology, Humanitas Clinical and Research Center, Rozzano, MI, Italy&#xD;Department of Urology, “Santa Maria della Misericordia” Hospital, University of Perugia, Perugia, Italy&#xD;Department of Urology, Santa Chiara Hospital, Trento, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cystoman® and calculi: A good alternative to standard therapies in preventing stone recurrence</style></title><secondary-title><style face="normal" font="default" size="100%">Urolithiasis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Urolithiasis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">285-290</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">d-Mannose</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Stones</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">To assess the efficacy and tolerability of d-mannose-containing product (Cystoman®) in preventing recurrence in patients who underwent surgical treatment for infection related urinary stones. From January 2011 to February 2013 we have enrolled all consecutive patients affected by staghorn calculi and recurrent urinary tract infections (UTIs). All patients recommended for surgery were scheduled for percutaneous nephrolithotomy. The study agent was administered daily for 5 months after surgical procedure. At baseline and 5-month follow-up all patients underwent abdominal Computed Tomography (CT) scan and they also completed Medical Outcomes Study shortform, 36-item questionnaire (SF-36). They performed urine and urine culture monthly. The primary endpoints were the assessment of the efficacy with regard to infection-related urinary stone recurrence and the tolerability of Cystoman®. The secondary endpoint was the evaluation of quality-of-life symptoms. During the study period, a total of 27 patients were included in the study. The data from 25 patients were analyzable. Seventeen patients (68 %) did not report UTIs during follow-up. Eight patients (32 %) remained infected and the average number of UTIs was 2.6 ± 1.6 in 5 months. At 5-month follow-up 17 (68 %) patients were free from stones recurrence; in 8 (32 %) cases CT scan revealed stone recurrence with an average stone diameter of 1.1 ± 0.4 cm. In nonrecurring patients, 2 (11.7 %) reported an average of 1.5 ± 0.7 UTIs episodes; in recurring patients, 6 (75 %) showed 3 ± 1.67 of UTIs episodes. Statistically significant differences were seen in the occurrence of UTIs episodes were detected between nonrecurring stone patients and recurring patients (p &lt; 0.05). Moreover, statistically significant changes were detected in SF-36 scores from baseline to month 5 in the categories of physical functioning and energy/fatigue (p &lt; 0.05). Cystoman® is effective in preventing infection-related urinary stones. © Springer-Verlag Berlin Heidelberg 2014.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84927558768&amp;doi=10.1007%2fs00240-014-0675-y&amp;partnerID=40&amp;md5=552220a26641ff1f16f6152218d69db0</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00240-014-0675-y</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>274</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">274</key></foreign-keys><ref-type name="Book">6</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pray, W. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">College of Pharmacy, Southwestern Oklahoma State University, Weatherford, OK, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nonprescription product therapeutics: Second edition</style></title><secondary-title><style face="normal" font="default" size="100%">Nonprescription Product Therapeutics: Second Edition</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1-887</style></pages><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">When it comes to helping customers make wiser and safer choices in their use of over-the-counter treatments, the pharmacist&apos;s best source of information is Nonprescription Product Therapeutics. This text emphasizes the pharmacist&apos;s role in triage--assessing the best nonprescription products for a client and knowing when medical conditions warrant a referral to another health professional. Organized by condition rather than by drug, the text is easy to consult, and complements a disease-based approach to therapeutics. Pharmacists will find useful information on ingredients, interactions, contraindications, and other essentials for helping customers choose appropriate nonprescription products. The Second Edition contains additional charts, drawings, illustrations, and tables. The book includes decision-making algorithms, case studies, patient counseling tips, and warnings on dangerous or life-threatening ingredients, actions, or situations. Another unique feature of this text is A Pharmacist&apos;s Journal--real-life reports from the front lines by an award-winning professor and researcher with over twenty years of experience in retail community pharmacy. © 2006 Lippincott Williams &amp; Wilkins. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Book</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84970028965&amp;partnerID=40&amp;md5=2e9d9fe12d90ae9e191b6db373ed3eee</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>607</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">607</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Porter, L. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Chemistry Division, DSIR, Petone, New Zealand</style></auth-address><titles><title><style face="normal" font="default" size="100%">Number- and Weight-Average Molecular Weights for Some Proanthocyanidin Polymers (Condensed Tannins)</style></title><secondary-title><style face="normal" font="default" size="100%">Australian Journal of Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Australian Journal of Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">557-562</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><number><style face="normal" font="default" size="100%">4</style></number><dates><year><style face="normal" font="default" size="100%">1985</style></year></dates><abstract><style face="normal" font="default" size="100%">The number-average molecular weights (Mn) and weight-average molecular weights (Mw) for proanthocyanidin polymers (condensed tannins) have been measured by vapour pressure osmometry and low-angle laser light-scattering measurements in methanol. These confirm earlier findings (based on gel permeation chromatography of the peracetate derivatives of these polymers) that they are polydisperse. The results also indicate that the incidence of branching in the polymer chains increases as the average chain length increases. © 1985 ASEG.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :16&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84970585070&amp;doi=10.1071%2fCH9860557&amp;partnerID=40&amp;md5=130f031d102ba611d514290bb6dee508</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1071/CH9860557</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>417</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">417</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Popov, S. V.</style></author><author><style face="normal" font="default" size="100%">Markov, P. A.</style></author><author><style face="normal" font="default" size="100%">Nikitina, I. R.</style></author><author><style face="normal" font="default" size="100%">Petrishev, S.</style></author><author><style face="normal" font="default" size="100%">Smirnov, V.</style></author><author><style face="normal" font="default" size="100%">Ovodov, Y. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Molecular Immunology and Biotechnology, Institute of Physiology, The Urals Branch of the Russian Academy of Sciences, 50 Pervomaiskaya Str., Syktyvkar 167982, Russian Federation</style></auth-address><titles><title><style face="normal" font="default" size="100%">Preventive effect of a peptic polysaccharide of the common cranberry Vaccinium oxycoccos L. on acetic acid-induced colitis in mice</style></title><secondary-title><style face="normal" font="default" size="100%">World Journal of Gastroenterology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">World Journal of Gastroenterology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">6646-6651</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">41</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-inflammatory</style></keyword><keyword><style face="normal" font="default" size="100%">Colitis</style></keyword><keyword><style face="normal" font="default" size="100%">Common cranberry Vaccinium oxycoccos L</style></keyword><keyword><style face="normal" font="default" size="100%">Mice</style></keyword><keyword><style face="normal" font="default" size="100%">Pectin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">Aim: To study isolation and chemical characterization of pectin derived from the common cranberry Vaccinium oxycoccos L. (oxycoccusan OP) and the testing of its preventive effect on experimental colitis. Methods: Mice were administrated orally with OP two days prior to a rectal injection of 5% acetic acid and examined for colonic damage 24 h later. Colonic inflammation was characterized by macroscopical injury and enhanced levels of myeloperoxidase activity measured spectrophotometrically with o-phenylene diamine as the substrate. The mucus contents of the colon were determined by the Alcian blue dye binding method. Vascular permeability was estimated using 4% Evans blue passage after i.p. injection of 0.05 mol/L acetic acid. Results: In the mice treated with OP, colonic macroscopic scores (1.1 ± 0.4 vs 2.7, P &lt; 0.01) and the total square area of damage (10 ± 2 vs 21 ± 7, P &lt; 0.01) were significantly reduced when compared with the vehicle-treated colitis group. OP was shown to decrease the tissue myeloperoxidase activity in colons (42 ± 11 vs 112 ± 40, P &lt; 0.01) and enhance the amount of mucus of colitis mice (0.9 ± 0.1 vs 0.4 ± 0.1, P &lt; 0.01). The level of colonic malondialdehyde was noted to decrease in OP-pretreated mice (3.6 ± 0.7 vs 5.1 ± 0.8, P &lt; 0.01). OP was found to decrease the inflammatory status of mice as was determined by reduction of vascular permeability (161 ± 34 vs 241 ± 21, P &lt; 0.01). Adhesion of peritoneal neutrophils and macrophages was also shown to decrease after administration of OP (141 ± 50 vs 235 ± 37, P &lt; 0.05). Conclusion: Thus, a preventive effect of pectin from the common cranberry, namely oxycoccusan OP, on acetic acid-induced colitis in mice was detected. A reduction of neutrophil infiltration and antioxidant action may be implicated in the protective effect of oxycoccusan. © 2006 The WJG Press. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :29&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33751297484&amp;doi=10.3748%2fwjg.v12.i41.6646&amp;partnerID=40&amp;md5=209e103d0fa33a619c311289ad50598a</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3748/wjg.v12.i41.6646</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>58</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">58</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Poosarla, V. G.</style></author><author><style face="normal" font="default" size="100%">Wood, T. L.</style></author><author><style face="normal" font="default" size="100%">Zhu, L.</style></author><author><style face="normal" font="default" size="100%">Miller, D. S.</style></author><author><style face="normal" font="default" size="100%">Yin, B.</style></author><author><style face="normal" font="default" size="100%">Wood, T. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemical Engineering, Pennsylvania State University, University Park, PA 16802, United States&#xD;Dow Microbial Control, Dow Chemical Company, Collegeville, PA 19426, United States&#xD;Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA 16802, United States&#xD;Department of Microbiology and Food Science and Technology, GITAM Institute of Science, GITAM University, Visakhapatnam, 530045, India</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dispersal and inhibitory roles of mannose, 2-deoxy-d-glucose and N-acetylgalactosaminidase on the biofilm of Desulfovibrio vulgaris</style></title><secondary-title><style face="normal" font="default" size="100%">Environmental Microbiology Reports</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Environmental Microbiology Reports</style></full-title></periodical><pages><style face="normal" font="default" size="100%">779-787</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">6</style></number><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Biofilms of sulfate-reducing bacteria (SRB) are often the major cause of microbiologically influenced corrosion. The representative SRB Desulfovibrio vulgaris has previously been shown to have a biofilm that consists primarily of protein. In this study, by utilizing lectin staining, we identified that the biofilm of D. vulgaris also consists of the matrix components mannose, fucose and N-acetylgalactosamine (GalNAc), with mannose predominating. Based on these results, we found that the addition of mannose and the nonmetabolizable mannose analog 2-deoxy-d-glucose inhibits the biofilm formation of D. vulgaris as well as that of D. desulfuricans; both compounds also dispersed the SRB biofilms. In addition, the enzyme N-acetylgalactosaminidase, which degrades GalNAc, was effective in dispersing D. vulgaris biofilms. Therefore, by determining composition of the SRB biofilm, effective biofilm control methods may be devised. © 2017 Society for Applied Microbiology and John Wiley &amp; Sons Ltd</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85033465107&amp;doi=10.1111%2f1758-2229.12595&amp;partnerID=40&amp;md5=60c10f17fa57249becd4e17903fec62e</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/1758-2229.12595</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>442</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">442</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Politi, P. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">U.O. Urologia, Ospedale Bassini, Cinisello Balsamo (MI), Italy&#xD;U.O. Urologia, Ospedale Bassini, Via Gorki 50, 20092 Cinisello Balsamo (MI), Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">Urodinamica</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Urodinamica</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-5</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Editorial</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33645965581&amp;partnerID=40&amp;md5=98afd44145e2b85633e1318851553d5e</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>197</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">197</key></foreign-keys><ref-type name="Book">6</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Playfair, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">America&apos;s founding fruit: The cranberry in a new environment</style></title><secondary-title><style face="normal" font="default" size="100%">America&apos;s Founding Fruit: The Cranberry in a New Environment</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1-244</style></pages><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">The cranberry, Vaccinium macrocarpon, is one of only three cultivated fruits native to North America. The story of this perennial vine began as the glaciers retreated about fifteen thousand years ago. Centuries later, it kept Native Americans and Pilgrims alive through the winter months, played a role in a diplomatic gesture to King Charles in 1677, protected sailors on board whaling ships from scurvy, fed General Grant’s men in 1864, and provided over a million pounds of sustenance per year to our World War II doughboys. Today, it is a powerful tool in the fight against various forms of cancer. This is America’s superfruit. This book poses the question of how the cranberry, and by inference other fruits, will fare in a warming climate. In her attempt to evaluate the effects of climate change, Susan Playfair interviewed growers from Massachusetts west to Oregon and from New Jersey north to Wisconsin, the cranberry’s temperature tolerance range. She also spoke with scientists studying the health benefits of cranberries, plant geneticists mapping the cranberry genome, a plant biologist who provided her with the first regression analysis of cranberry flowering times, and a migrant beekeeper trying to figure out why the bees are dying. Taking a broader view than the other books on cranberries, America’s Founding Fruit presents a brief history of cranberry cultivation and its role in our national history, leads the reader through the entire cultivation process from planting through distribution, and assesses the possible effects of climate change on the cranberry and other plants and animals. Could the American cranberry cease growing in the United States? If so, what would be lost? © 2014 University Press of New England. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Book</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84943233503&amp;partnerID=40&amp;md5=58ac3f54f58d8aeb1a41a23f5e155869</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>342</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">342</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pinzón-Arango, P. A.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Camesano, T. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemical Engineering, Worcester Polytechnic Institute, Worcester, MA, United States&#xD;Department of Chemical Engineering, WPI Life Sciences and Bioengineering Center at Gateway Park, 100 Institute Road, Worcester, MA 01609, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Role of cranberry on bacterial adhesion forces and implications for Escherichia coli-uroepithelial cell attachment</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Medicinal Food</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Medicinal Food</style></full-title></periodical><pages><style face="normal" font="default" size="100%">259-270</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Atomic force microscopy</style></keyword><keyword><style face="normal" font="default" size="100%">Fimbriae</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidins</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Previous clinical research has suggested that the consumption of cranberry products prevents the adhesion of Escherichia coli to uroepithelial cells by causing changes in bacterial fimbriae. Atomic force microscopy was used to probe the adhesion forces between E. coli (nonfimbriated strain HB101 and the P-fimbriated variant HB101pDC1) and a model surface (silicon nitride), to determine the effect of growth in cranberry products on bacterial adhesion. Bacteria were grown in tryptic soy broth supplemented with either light cranberry juice cocktail (L-CJC) or cranberry proanthocyanidins (PACs). Growth of E. coli HB101pDC1 and HB101 in L-CJC or PACs resulted in a decrease in adhesion forces with increasing number of cultures. In a macroscale bacteria-uroepithelial cell adhesion assay a decrease in bacterial attachment was observed for E. coli HB101pDC1 grown in L-CJC or PACs. This effect was reversible because bacteria that were regrown in cranberry-free medium regained their ability to attach to uroepithelial cells, and their adhesion forces reverted to the values observed in the control condition. Exposure to increasing concentrations of L-CJC resulted in a decrease of bacterial attachment to uroepithelial cells for the P-fimbriated strain after L-CJC treatment (27 by weight) and after PACs treatment (345.8 μg/mL). Cranberry products affect the surface properties, such as fimbriae and lipopolysaccharides, and adhesion of fimbriated and nonfimbriated E. coli. The concentration of cranberry products and the number of cultures the bacteria were exposed to cranberry determines how much the adhesion forces and attachment are altered. © 2009 Mary Ann Liebert, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :41&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-67649541809&amp;doi=10.1089%2fjmf.2008.0196&amp;partnerID=40&amp;md5=2f2ed5d817578800ba688efc28f47694</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1089/jmf.2008.0196</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>441</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">441</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pigrau-Serrallach, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d&apos;Hebron, Universidad Autónoma, Barcelona, Spain&#xD;Aribau 162, 2. L, 08036 Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Enfermedades Infecciosas y Microbiologia Clinica</style></secondary-title><short-title><style face="normal" font="default" size="100%">Infecciones urinarias recurrentes</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Enfermedades Infecciosas y Microbiologia Clinica</style></full-title></periodical><pages><style face="normal" font="default" size="100%">28-39</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">SUPPL.4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotic prophylaxis in recurrent urinary infections</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberries and urinary infection</style></keyword><keyword><style face="normal" font="default" size="100%">Intravaginal lactobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent urinary infections in young</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">Sexually active women and postmenopausal women</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">Recurrent urinary tract infections (RUTI) are a frequent clinical problem in sexually active young women, pregnant or postmenopausal women and in patients with underlying urological abnormalities. The present chapter reviews RUTI based on their classification: relapses, which usually occur early (&lt; 1 month), are caused by the same microorganism and are associated with underlying urological abnormalities, and reinfections, which usually occur later and are caused by a new distinct microorganism (or by the same microorganism usually located in the rectum or uroepithelial cells). The pathogenesis of RUTI is reviewed and the risk factors associated with RUTI in premenopausal women (usually related to sexual activity), postmenopausal women (in whom estrogen deficiency has a significant effect on the vaginal Lactobacillusflora), and in pregnant women are discussed. Likewise, an extensive review of the distinct therapeutic strategies to prevent RUTI is provided: self-treatment of cystitis, continuous antibiotic prophylaxis, postcoital antibiotic prophylaxis, topical vaginal estrogens, Lactobacillus, cranberry juice, intravesical administration of non-virulent E. colistrains and vaccines, among others. Several diagnostic-therapeutic algorithms are included. These algorithms are based on the type of urinary infection (relapse-reinfection), on the type of patient (young, postmenopausal, or pregnant women) and on the number of episodes of RUTI.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :10&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33749067827&amp;doi=10.1157%2f13091446&amp;partnerID=40&amp;md5=a7304223bdd89d3a8d273d64343927b1</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1157/13091446</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>136</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">136</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pietrucha-Dilanchian, P.</style></author><author><style face="normal" font="default" size="100%">Hooton, T. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diagnosis, treatment, and prevention of urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">Microbiology Spectrum</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Microbiology Spectrum</style></full-title></periodical><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">6</style></number><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">UTI may involve the lower or upper urinary tract and may be uncomplicated or complicated. The emphasis of this chapter is uncomplicated UTI. The diagnosis of uncomplicated cystitis (bladder infection) and pyelonephritis (kidney infection) is usually easily made based on the clinical presentation, whereas the diagnosis in patients with complicated UTI is often more complex. Thus uncomplicated cystitis is usually manifested by dysuria, frequency and/or urgency without fever, and pyelonephritis is usually manifested by fever and back pain/costovertebral angle tenderness. However, pyuria is usually present with UTI, regardless of location, and its absence suggests that another condition may be causing the patient&apos;s symptoms. Treatment of cystitis is usually straightforward with one of several effective short-course antimicrobial regimens, although antimicrobial resistance continues to increase and can complicate treatment choices in certain areas. Likewise, antimicrobial resistance has complicated our management of uncomplicated pyelonephritis since resistance of uropathogens to the fluoroquinolone class, the mainstay of oral treatment for pyelonephritis, is increasing worldwide, and some of the other agents used for cystitis are not recommended for pyelonephritis due to low tissue levels. The goal of prevention of recurrent cystitis is to minimize the use of antimicrobials and there are several research efforts in progress to develop effective and safe antimicrobial-sparing preventive approaches for this common condition. © 2016 American Society for Microbiology. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85011632920&amp;doi=10.1128%2fmicrobiolspec.UTI-0021-2015&amp;partnerID=40&amp;md5=8fd8514bc20e9517daf835430ec6b12e</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">Uti-0021-2015</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/microbiolspec.UTI-0021-2015</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>51</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">51</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Piechota, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Klinik für Urologie, Kinderurologie und Operative Uro-Onkologie, Johannes Wesling Klinikum Minden, Universitätsklinikum, Ruhr-Universität Bochum (RUB), Hans-Nolte-Straße 1, Minden, 32429, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent urinary tract infections in women</style></title><secondary-title><style face="normal" font="default" size="100%">Internistische Praxis</style></secondary-title><short-title><style face="normal" font="default" size="100%">Rezidivierende Harnwegsinfektionen der Frau</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Internistische Praxis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">609-617</style></pages><volume><style face="normal" font="default" size="100%">58</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Herbal medianes</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinay tract infection (UTI) as one of the most frequent bacterial infections in humans is of utmost individual and socio-economical relevance. Because of the rising prevalence of antimicrobial resistance urinalysis should always include urine culture and a resistogram in order to avoid an unspecific selection and overuse of antibiotics. Prevention of recurrent UTI must first of all rule out predisposing uropathogenic conditions. Nowadays a great variety of drugs, behavioural and supportive treatment options can effectively minimize UTI recurrence. The growing importance of vaccines (immunotherapy), probiotics (lactobacilli) and standardized herbal preparations meets the need of reducing antibiotic use and the development of antimicrobial resistance. © 2018 Hans Marseille Verlag GmbH. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042073901&amp;partnerID=40&amp;md5=84aab20707a4ebdd6448d8320a9300e7</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>87</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">87</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Piechota, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Klinik für Urologie, Johannes Wesling Klinikum Minden, Universitätsklinikum der Ruhr-Universität Bochum (RUB), Hans-Nolte-Straße 1, Minden, 32429, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent urinary tract infections in women</style></title><secondary-title><style face="normal" font="default" size="100%">Tagliche Praxis</style></secondary-title><short-title><style face="normal" font="default" size="100%">Rezidivierende Harnwegsinfektionen der Frau</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Tagliche Praxis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">52-60</style></pages><volume><style face="normal" font="default" size="100%">59</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Herbal medicines</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinay tract infection (UTI) as one of the most frequent bacterial infections in humans is of utmost individual and socio-econo-mical relevance. Because of the rising prevalence of antimicrobial resistance urinalysis should always include urine culture and a resistogram in order to avoid an unspecific selection and overuse of antibiotics. Prevention of recurrent UTI must first of all rule out predisposing uropathogenic conditions. Nowadays a great variety of drugs, behavioural and supportive treatment options can effectively minimize UTI recurrence. The growing importance of vaccines (immunotherapy), probiotics (lac-tobacilli) and standardized herbal preparations meets the need of reducing antibiotic use and the development of antimicrobial resistance.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85028518288&amp;partnerID=40&amp;md5=10d081f262de8302c96fb52751810761</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>88</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">88</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Piechota, Hj</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Klinik für Urologie, Kinderurologie und Operative Uro-Onkologie, Johannes Wesling Klinikum Minden, Universitätsklinikum der Ruhr-Universität Bochum (RUB), Hans-Nolte-Straße 1, Minden, 32429, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent urinary tract infections in women</style></title><secondary-title><style face="normal" font="default" size="100%">Gynakologische Praxis</style></secondary-title><short-title><style face="normal" font="default" size="100%">Rezidivierende Harnwegsinfektionen der Frau</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Gynakologische Praxis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">395-403</style></pages><volume><style face="normal" font="default" size="100%">41</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Herbal medicines</style></keyword><keyword><style face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinay tract infection (UTI) as one of the most frequent bacterial infections in humans is of utmost individual and socio-economical relevance. Because of the rising prevalence of antimicrobial resistance urinalysis should always include urine culture and a resistogram in order to avoid an unspecific selection and overuse of antibiotics. Prevention of recurrent UTI must first of all rule out predisposing uropathogenic conditions. Nowadays a great variety of drugs, behavioural and supportive treatment options can effectively minimize UTI recurrence. The growing importance of vaccines (immunotherapy), probiotics (Lactobacilli) and standardized herbal preparations meets the need of reducing antibiotic use and the development of antimicrobial resistance.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85014474704&amp;partnerID=40&amp;md5=1766d4ddd777aa4732cf1f313bc3630d</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>78</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">78</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Piechota, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Klinik für Urologie, Kinderurologie und Operative Uro-Onkologie, Johannes Wesling-Klinikum Minden, Universitätsklinikum der Ruhr-Universität Bochum, Hans Nolte Str. 1, Minden, 32429, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent and catheter-associated urinary tract infections: Prophylaxis and prevention</style></title><secondary-title><style face="normal" font="default" size="100%">Urologe</style></secondary-title><short-title><style face="normal" font="default" size="100%">Rezidivierende und katheterassoziierte Harnwegsinfektionen: Prophylaxe und Prävention</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Urologe</style></full-title></periodical><pages><style face="normal" font="default" size="100%">734-745</style></pages><volume><style face="normal" font="default" size="100%">56</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Catheter</style></keyword><keyword><style face="normal" font="default" size="100%">Herbal medicines</style></keyword><keyword><style face="normal" font="default" size="100%">Infection, bacterial</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinay tract infection (UTI) as one of the most frequent bacterial infections in humans is of utmost relevance. Because of the rising prevalence of antimicrobial resistance, urinalysis should always include urine culture and a resistogram in order to avoid an unspecific selection and overuse of antibiotics. Prevention of recurrent UTI must first of all rule out predisposing uropathogenic conditions. Nowadays, a great variety of drugs, behavioral, and supportive treatment options can effectively minimize UTI recurrence. The growing importance of vaccines (immunotherapy), probiotics (lactobacilli), and standardized herbal preparations meets the need of reducing antibiotic use and the development of antimicrobial resistance. Around 80% of all nosocomial UTIs (nUTIs) are associated with indwelling urinary catheters. It is estimated that up to 70% of all nUTIs occurring in Germany may be avoided by using appropriate preventative measures. Therefore, profound knowledge about the basics of catheter-associated nUTIs and the correct management of urinary catheters are of utmost individual and socioeconomic importance. © 2017, Springer Medizin Verlag GmbH.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018478429&amp;doi=10.1007%2fs00120-017-0386-4&amp;partnerID=40&amp;md5=7b307f153954a9293fc335b76613892c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00120-017-0386-4</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>303</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">303</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Phillips, M. M.</style></author><author><style face="normal" font="default" size="100%">Case, R. J.</style></author><author><style face="normal" font="default" size="100%">Rimmer, C. A.</style></author><author><style face="normal" font="default" size="100%">Sander, L. C.</style></author><author><style face="normal" font="default" size="100%">Sharpless, K. E.</style></author><author><style face="normal" font="default" size="100%">Wise, S. A.</style></author><author><style face="normal" font="default" size="100%">Yen, J. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Analytical Chemistry Division, Chemical Science and Technology Laboratory, National Institute of Standards and Technology, Gaithersburg, MD 20899, United States&#xD;Statistical Engineering Division, Information Technology Laboratory, National Institute of Standards and Technology, Gaithersburg, MD 20899, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Determination of organic acids in Vaccinium berry standard reference materials</style></title><secondary-title><style face="normal" font="default" size="100%">Analytical and Bioanalytical Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Analytical and Bioanalytical Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">425-434</style></pages><volume><style face="normal" font="default" size="100%">398</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Berry</style></keyword><keyword><style face="normal" font="default" size="100%">Gas chromatography</style></keyword><keyword><style face="normal" font="default" size="100%">Ion chromatography</style></keyword><keyword><style face="normal" font="default" size="100%">Isotope dilution</style></keyword><keyword><style face="normal" font="default" size="100%">Liquid chromatography</style></keyword><keyword><style face="normal" font="default" size="100%">Mass spectrometry</style></keyword><keyword><style face="normal" font="default" size="100%">Organic acids</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><abstract><style face="normal" font="default" size="100%">Nine organic acids (citric acid, galacturonic acid, glycolic acid, isocitric acid, malic acid, oxalic acid, quinic acid, shikimic acid, and tartaric acid) and two anions (phosphate and sulfate) were determined in a suite of Vaccinium berry-containing dietary supplement standard reference materials (SRMs). Following solvent extraction, three independent methods were utilized in the quantification of these compounds. The first method involved reversed-phase liquid chromatography with ultraviolet absorbance detection at 210 nm and isotope dilution mass spectrometry. The second method utilized ion chromatography with conductivity detection. Finally, gas chromatography with isotope dilution mass spectrometry detection was used following derivatization with N-methyl-N-trifluoroacetamide (MSTFA). The combined data from these methods was used for the assignment of organic acid levels in the seven candidate SRMs. © 2010 US Government.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :27&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-77955982525&amp;doi=10.1007%2fs00216-010-3916-0&amp;partnerID=40&amp;md5=e7de1ef7950ee560a306bb760c6a9bb2</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00216-010-3916-0</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>68</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">68</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Phé, V.</style></author><author><style face="normal" font="default" size="100%">Pakzad, M.</style></author><author><style face="normal" font="default" size="100%">Haslam, C.</style></author><author><style face="normal" font="default" size="100%">Gonzales, G.</style></author><author><style face="normal" font="default" size="100%">Curtis, C.</style></author><author><style face="normal" font="default" size="100%">Porter, B.</style></author><author><style face="normal" font="default" size="100%">Chataway, J.</style></author><author><style face="normal" font="default" size="100%">Panicker, J. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Uro-Neurology, The National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology, London, United Kingdom&#xD;Pitié-Salpêtrière Academic Hospital, Department of Urology, Assistance Publique-Hôpitaux de Paris, Pierre and Marie Curie Medical School, Paris 6 UniversityParis, France&#xD;Department of Clinical Microbiology, University College London HospitalLondon, United Kingdom&#xD;Queen Square Multiple Sclerosis Centre, The National Hospital for Neurology and Neurosurgery and UCL Institute of NeurologyLondon, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Open label feasibility study evaluating D-mannose combined with home-based monitoring of suspected urinary tract infections in patients with multiple sclerosis</style></title><secondary-title><style face="normal" font="default" size="100%">Neurourology and Urodynamics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neurourology and Urodynamics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1770-1775</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">antibiotics</style></keyword><keyword><style face="normal" font="default" size="100%">compliance</style></keyword><keyword><style face="normal" font="default" size="100%">D-mannose</style></keyword><keyword><style face="normal" font="default" size="100%">dipsticks</style></keyword><keyword><style face="normal" font="default" size="100%">multiple sclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">recurrent urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: To assess the feasibility of using D-mannose, a natural food supplement, in patients with multiple sclerosis (MS) reporting recurrent urinary tract infections (UTIs) as a preventative. Methods: A single-center, open-label, feasibility study enrolled patients with MS, using and not using urinary catheters, experiencing recurrent UTIs (≥3/year or ≥2/6 months). Participants were given D-mannose powder 1.5 grams twice daily for 16-weeks and were instructed to monitor suspected UTIs at home using urine dipsticks. Diaries were used to record compliance, number of prescriptions of antibiotics received for UTIs, results of urine dipsticks and cultures. Results: Overall, 22 patients with MS, median age 50 years (46–59) were enrolled: 10 were not using catheters and 12 were using catheters. The compliance rates for using D-mannose and dipsticks for testing suspected UTIs were 100% and 90.2%, respectively. Sixty-one episodes of suspected UTIs were recorded, 19/61 (31.1%) were confirmed UTIs and 29/61 (47.5%) prescriptions of antibiotics were made. The number of monthly proven UTIs decreased both in catheter users and non-users (P &lt; 0.01). No adverse effects were reported. Conclusion: Using D-mannose in patients with MS experiencing recurrent UTIs and self-monitoring for infections is feasible and safe. Further studies are required to establish efficacy. CinicalTrials.gov (identifier NCT02490046). © 2017 Wiley Periodicals, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84997109153&amp;doi=10.1002%2fnau.23173&amp;partnerID=40&amp;md5=bdbd2c61e0f4be6fbe527d3ab0a9314b</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/nau.23173</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>115</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">115</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Phé, V.</style></author><author><style face="normal" font="default" size="100%">Pakzad, M.</style></author><author><style face="normal" font="default" size="100%">Curtis, C.</style></author><author><style face="normal" font="default" size="100%">Porter, B.</style></author><author><style face="normal" font="default" size="100%">Haslam, C.</style></author><author><style face="normal" font="default" size="100%">Chataway, J.</style></author><author><style face="normal" font="default" size="100%">Panicker, J. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Uro-Neurology, National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, United Kingdom&#xD;Pitié-Salpêtrièe Academic Hospital, Department of Urology, Assistance Publique-Hôpitaux de Paris, Pierre and Marie Curie Medical School, Paris 6 University, Paris, France&#xD;Department of Clinical Microbiology, University College London Hospital, London, United Kingdom&#xD;Queen Square Multiple Sclerosis Centre, National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections in multiple sclerosis</style></title><secondary-title><style face="normal" font="default" size="100%">Multiple Sclerosis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Multiple Sclerosis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">855-861</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">culture</style></keyword><keyword><style face="normal" font="default" size="100%">Multiple sclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">recurrent</style></keyword><keyword><style face="normal" font="default" size="100%">relapse</style></keyword><keyword><style face="normal" font="default" size="100%">urinary dipstick</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Urinary tract infections (UTIs) are commonly reported by people with multiple sclerosis (PwMS) and significantly impact quality of life. Objective: To provide an overview of the problem of UTIs in PwMS and offer a practical approach for the diagnosis and management. Methods: A review of the literature through a Pubmed search up to October 2015 was performed using the following keywords: multiple sclerosis, neurogenic bladder, urinary tract infections, relapse, dipsticks, culture, recurrent and prevention. Results: Noteworthy topics include the definition of a confirmed symptomatic UTI as a positive urine culture defined by &amp;gt;105 colony-forming units (CFU)/mL or &amp;gt;104 CFU/mL if a urethral catheter urine sample is taken, or any count of bacteria in a suprapubic bladder puncture specimen, both in addition to symptoms including fever, pain, changes in lower urinary tract symptoms or neurological status. Urinalysis is useful to exclude a UTI; however, on its own is insufficient to confirm a UTI, for which urine culture is required. Experts advise asymptomatic UTIs should not be treated except in the context of an acute relapse. From international guidelines, there is no validated strategy to prevent recurrent UTIs in PwMS. Conclusion: This review provides an overview of the diagnosis, treatment and prevention of UTIs in the setting of multiple sclerosis (MS). © SAGE Publications.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :5&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84973465852&amp;doi=10.1177%2f1352458516633903&amp;partnerID=40&amp;md5=26cd82b0891673f5f758f0d155b9eebf</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/1352458516633903</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>371</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">371</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pettersson, E.</style></author><author><style face="normal" font="default" size="100%">Vernby, Å</style></author><author><style face="normal" font="default" size="100%">Mölstad, S.</style></author><author><style face="normal" font="default" size="100%">Lundborg, C. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Public Health Sciences, Division of International Health, Karolinska Institute, Stockholm, Sweden&#xD;Sunderby Hospital Pharmacy, Luleå, Sweden&#xD;Unit of Research and Development in Primary Care, Jönköping, Sweden&#xD;Nordic School of Public Health, Apoteket AB, Göteborg, Sweden</style></auth-address><titles><title><style face="normal" font="default" size="100%">Infections and antibiotic prescribing in Swedish nursing homes: A cross-sectional study</style></title><secondary-title><style face="normal" font="default" size="100%">Scandinavian Journal of Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Scandinavian Journal of Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">393-398</style></pages><volume><style face="normal" font="default" size="100%">40</style></volume><number><style face="normal" font="default" size="100%">5</style></number><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">The aim of this study was to present and assess the treatment of infections in Swedish nursing homes. It included 58 nursing homes with 3002 residents. During 3 months, nurses in the nursing homes recorded all infections requiring a physician&apos;s opinion. Of the 889 infectious episodes, 84% were treated with antibiotics. Many of the antibiotics were issued after indirect contact with the physician (38%). Indications for antibiotics were in 55% of the cases urinary tract infections (UTI), in 17% skin and soft-tissue infections and in 15% respiratory tract infections (RTI). The most common antibiotics were penicillins (38%), followed by quinolones (23%) and trimethoprim (18%). For the major indication, lower UTI in women, half of the cases were not treated according to the recommendations. The main concerns were length of treatment and overprescribing of quinolones. For the second major diagnosis, pneumonia, the high use of doxycycline could be questioned. Continuing education on infections and their treatment in nursing homes is needed. Training should preferably include both physicians and nurses as a high proportion of antibiotics is issued without direct contact with the physician.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :36&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-42449117619&amp;doi=10.1080%2f00365540701745279&amp;partnerID=40&amp;md5=e0a5a73d6acc53c95ca4b77125d9b9d2</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/00365540701745279</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>337</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">337</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pérez-López, F. R.</style></author><author><style face="normal" font="default" size="100%">Haya, J.</style></author><author><style face="normal" font="default" size="100%">Chedraui, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Obstetrics and Gynecology, University of Zaragoza, Faculty of Medicine, Domingo Miral s/n, Zaragoza 50009, Spain&#xD;Obstetrics and Gynecology Service, General Hospital of Ciudad Real, Ciudad Real, Spain&#xD;Institute for Women&apos;s Health, Guayaquil, Ecuador</style></auth-address><titles><title><style face="normal" font="default" size="100%">Vaccinium macrocarpon: An interesting option for women with recurrent urinary tract infections and other health benefits</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Obstetrics and Gynaecology Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Obstetrics and Gynaecology Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">630-639</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">American cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidin</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Aim: To review the scientific publications concerning the clinical use and mechanism of action of the North American cranberry (Vaccinium macrocarpon) for women with recurrent urinary tract infections (UTI) and other health conditions. Methods: This is a retrospective study of published information concerning Vaccinium macrocarpon retrieved from a PubMed and individual searches. Results: Urinary tract infections are very common in women, cause discomfort, and may aggravate other genitourinary conditions. The available scientific information supports a clinical benefit of Vaccinium macrocarpon in the prevention of recurrent UTI in women. There is a non-significant reduction of UTI associated with Vaccinium macrocarpon treatment during pregnancy. A group of proanthocyanidins (PAC) with A-type linkages have been isolated from Vaccinium macrocarpon which inhibit P-fimbriae synthesis and induce a bacterial deformation, on both antibiotic-susceptible and antibiotic-resistant uropathogenic Escherichia coli. It is plausible that cranberry PAC prevent bacteria from adhering to the uroepithelium of the bladder, thereby blocking the ability of E. coli to infect the urinary mucosa. Conclusion: Cranberry treatment is a safe, well-tolerated supplement that does not have significant drug interactions. Although investigations are in the early stages, experimental and preclinical studies suggest that cranberry components may have other potential benefits, including anti-infective, anticancer and antioxidant effects, which may be considered as positive for different age-related conditions. In addition, cranberry components may induce positive cardiovascular and metabolic changes, and may improve neuropsychological activity. These effects warrant further clinical research to better place the role of cranberry products for women. © 2009 Japan Society of Obstetrics and Gynecology.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :23&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-70049086408&amp;doi=10.1111%2fj.1447-0756.2009.01026.x&amp;partnerID=40&amp;md5=9344f76bfeb3fffd6075bcd30a61292c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1447-0756.2009.01026.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>480</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">480</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pérez, J. A. H.</style></author><author><style face="normal" font="default" size="100%">Ferrer, J. F. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Especialista en Urología Por la Universidad de Camagüey, Centro de Salud Villa de Mazo, La Palma, Tenerife, Cuba&#xD;Departamento de Ciencias Clínicas, Unidad Docente de Farmacología, Universdad de Las Palmas de Gran Canaria, Gran Canaria, Spain&#xD;Apartado Correos 42, El Paso. 38750 Tenerife, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Asymptomatic bacteriuria in women: Epidemiological, pathological and therapeutic study</style></title><secondary-title><style face="normal" font="default" size="100%">Archivos Espanoles de Urologia</style></secondary-title><short-title><style face="normal" font="default" size="100%">Bacteriuria asintomática en la mujer. Estudio epidemiológico, patológico y terapéutico</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archivos Espanoles de Urologia</style></full-title></periodical><pages><style face="normal" font="default" size="100%">784-804</style></pages><volume><style face="normal" font="default" size="100%">57</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Asymptomatic bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">Outpatient female population</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">OBJECTIVES: To perform an epidemiological, pathologic and therapeutic study of asymptomatic bacteriuria (AB) in a population of outpatient women. METHODS: Transversal study for detection of AB in 1718 outpatient women14-year-old or older. All patients complied with the inclusion/ exclusion criteria for the study. Two groups of patients, with AB (n = 113) and controls without AB (n = 200), underwent: 1) urine analysis: urine sediment, biochemical analysis, and culture; 2) blood tests: hemoglobin, red blood cell count, urea, creatinine, sedimentation rate velocity, C reactive protein, immunoglobulins (lg A, lg M, and lgG), HLA-A 3, blood group and Fh. The therapeutic management for AB was analyzed. Comparative statistical analyses of data were performed. RESULTS: AB prevalence was 6.34% The most frequently isolated germ was E.Coli (77.87% Diabetes mellitus was detected in 27.43% of patients with AB and 7.01% without AB (27.43% v&amp; 7.01%); coronary arterial disease and other heart disorders (9.73% vs. 4%p = 0.0206); general cardiovascular disorders excluding hypertension (46.9% vs. 31%p = 0.0025). Urine analysis showed leukocyturia in 81.41% of the patients with AB and 17.5% without AB (p = 0.0002); positive nitrites (77.87% vs 0% p &lt; 0.001); urine sediment showed bacteriuria in 86.72% of patients with AB and 0% of non-AB patients (p &lt; 0.0001), leukocytes (93.80% vs 6%p &lt; 0.0001), and pyuria (19.46% vs 2.5%). Low water intake (50.44% vs. 9.5%p &lt; 0.0001) was the most significant urinary tract infection hygienic-dietetic predisposing factor. Higher levels of IgA (15% vs. 2%p = 0.004). Postive HLA-A 3 (5% vs. 0%p = 0.039), Rh negative (16.66% vs. 13.33% and increased C reactive protein (15% vs. then%). Renal abnormalities detected by radiological tests (10.29%vs 1.47%p = 0.014). AB disappeared after treatment with cefuroxime, ceftibuten, trimetropin/ sulfametoxazole and amoxicillin in 100% of the patients receiving treatment. Topical vaginal estrogen therapy was effective in 38.09% of the patients. CONCLUSIONS: The prevalence of AB increases with age. The most frequent germ is Escherichia coli. A statistically significant greater number of coronary artery disease, other heart diseases, and cardiovascular disorders were found among patients with AB in comparison with non-AB controls Immunoglobulins levels disturbances, and HIA-A3 positivity suggest an immune systemic imbalance in certain patients with recurrent AB. Other therapeutic alternatives such as vaginal topical estrogens, fruit juices intake, vaccinations, etc. should be pursued in addition to antimicrobial therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :5&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-16544395971&amp;partnerID=40&amp;md5=bde9c66e7afbe2415c03dd700ae36e9f</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>253</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">253</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pavlakis, P. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Internal Medicine Practitioner, IKA Department, Lamia, Greece</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevention of recurrent cystitis in pre-menopausal women: From mechanisms to therapy</style></title><secondary-title><style face="normal" font="default" size="100%">Current Women&apos;s Health Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Women&apos;s Health Reviews</style></full-title></periodical><pages><style face="normal" font="default" size="100%">177-182</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antimicrobials</style></keyword><keyword><style face="normal" font="default" size="100%">D-mannose</style></keyword><keyword><style face="normal" font="default" size="100%">Immunization</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Uropathogens</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Recurrent cystitis is common among pre-menopausal, healthy, non-pregnant women. Each episode of urinary tract infection (UTI) results in loss of working hours and quality of personal life. Most of recurrent UTIs are caused by uropathogenic Escherichia coli (UPEC). Its infectivity is in part due to the acquisition of pilli with an adhesin for mannose-containing receptors of the bladder. UTI-prone women are believed to have a compromised immune response, so even after a successful resolution of the infection reinfection is common. Many risk factors contribute to recurrence of UTI, including frequency of intercourse, new sex partners, diaphragm use, and age of first UTI. Pivmecillinam, nitrofurantoin, trimethoprim/ sulfamethoxazole, and fofomycin are considered first-line agents against cystitis. Short-term 3-day antibacterial regimens with quinolones are used as second-line agents in order to prevent emergence of antimicrobial resistance to them. Low doses of any of the aforementioned anti bacterials can be used for prophylaxis against recurrences. An immuno stimulant extracted from 18 heat-killed Escherichia coli strains of 5 different serotypes (URO-VAXOM), given orally once daily for 3 months has been tested and shown to have good efficacy for prophylaxis of recurrent UTIs. Cranberry products are also effective for prophylaxis, however with high rates of withdrawal. Oral D-mannose can bind pilli and their adhesin, which are essential for binding, invasion and formation of bio film, however more clinical data are needed to support its use. Probiotics are the second most tested prophylactic agents after antibiotics; their efficacy varies according to the type of administered probiotic. © 2012 Bentham Science Publishers.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84860286108&amp;doi=10.2174%2f157340412800194876&amp;partnerID=40&amp;md5=b5051ed1d7e5b13fd0656456db5f0b1e</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2174/157340412800194876</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>120</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">120</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Patyk, E.</style></author><author><style face="normal" font="default" size="100%">Jenczak, A.</style></author><author><style face="normal" font="default" size="100%">Katrusiak, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Materials Chemistry, Faculty of Chemistry, Adam Mickiewicz University, Umultowska 89b, Poznań, Poland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Giant strain geared to transformable H-bonded network in compressed β-d-mannose</style></title><secondary-title><style face="normal" font="default" size="100%">Physical Chemistry Chemical Physics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Physical Chemistry Chemical Physics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">11474-11479</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">16</style></number><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Networks of OH⋯O bonds in sugars and H2O ices are hardly affected by temperature, but transform under pressure. Such a transition at 1.95 GPa in β-d-mannose induces strong strain, non-destructive for the single crystal and easily visible in its shape deformation. This transition occurs at the lowest pressure of all sugars investigated at high pressure so far. The giant strain propagates perpendicular to the clearly visible zero-strain planes. The transition reconstructs the 3-dimensional pattern of OH⋯O hydrogen bonds, changes the conformation of molecules and preserves the space-group symmetry, like the analogous transitions of α-d-glucose and d-sucrose. However, new repulsing O⋯O contacts have been generated at high pressure in d-mannose only. © the Owner Societies 2016.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :6&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84967189143&amp;doi=10.1039%2fc6cp01286h&amp;partnerID=40&amp;md5=2d3d6944aa0cba5ff77c2140bce777ea</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1039/c6cp01286h</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>314</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">314</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pascual, L.</style></author><author><style face="normal" font="default" size="100%">Ruiz, F.</style></author><author><style face="normal" font="default" size="100%">Giordano, W.</style></author><author><style face="normal" font="default" size="100%">Barberis, I. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departamento de Microbiología e Inmunología, Universidad Nacional de Río Cuarto (UNRC), 5800 Río Cuarto, Córdoba, Argentina&#xD;Departamento de Biología Molecular, UNRC, 5800 Río Cuarto, Córdoba, Argentina</style></auth-address><titles><title><style face="normal" font="default" size="100%">Vaginal colonization and activity of the probiotic bacterium Lactobacillus fermentum L23 in a murine model of vaginal tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Medical Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Medical Microbiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">360-364</style></pages><volume><style face="normal" font="default" size="100%">59</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><abstract><style face="normal" font="default" size="100%">A strain of Lactobacillus, identified as Lactobacillus fermentum L23, was selected from among 100 strains isolated from vaginal swabs of healthy, non-pregnant, pre-menopausal women. L. fermentum L23 was chosen on the basis of its bacteriocinogenic ability and its properties relevant to colonization, i.e. self-aggregation, adherence to vaginal epithelial cells and coaggregation with bacterial pathogens. The antimicrobial preventative and curative effects produced by the probiotic L. fermentum L23 administered locally against Escherichia coli in a murine vaginal tract infection model were studied. One dose of the human strain L23 containing 108 c.f.u. ml-1 colonized and persisted in the vaginal tract of the female BALB/c mice for 5 days. Infection with the pathogen at 106 c.f.u. ml-1 in the vaginal tract was maintained for more than 7 days. A single dose of L23 administered 24 h pre-infection inhibited E. coli growth on day 3 post-infection, showing the preventative effect displayed by this Lactobacillus strain. Treatment with L. fermentum L23 during the post-infection period showed complete inhibition of pathogen growth from day 5. Thus, this in vivo study indicated that the probiotic bacterium L. fermentum L23 produced both preventative and curative effects on E. coli growth. The beneficial properties and the production of antimicrobial metabolites may act in situ to inhibit a pathogenic microorganism within the vaginal environment. Strain L23 could be a good natural alternative to other therapies used for genital infections. © 2010 SGM.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :30&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-76649123899&amp;doi=10.1099%2fjmm.0.012583-0&amp;partnerID=40&amp;md5=c164f244432168664b89ff81e527430c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1099/jmm.0.012583-0</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>330</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">330</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pappas, E.</style></author><author><style face="normal" font="default" size="100%">Schaich, K. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Food Science, Rutgers University, 65 Dudley Rd., New Brunswick, NJ 08901-8520, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Phytochemicals of cranberries and cranberry products: Characterization, potential health effects, and processing stability</style></title><secondary-title><style face="normal" font="default" size="100%">Critical Reviews in Food Science and Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Critical Reviews in Food Science and Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">741-781</style></pages><volume><style face="normal" font="default" size="100%">49</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Absorption</style></keyword><keyword><style face="normal" font="default" size="100%">Anthocyanins</style></keyword><keyword><style face="normal" font="default" size="100%">Cancer</style></keyword><keyword><style face="normal" font="default" size="100%">Flavonols</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Phenols</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidins</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Emerging evidence is elucidating how non-nutrient phytochemicals underlie the health promotion afforded by fruits and vegetables. This review focuses on Vaccinium macrocarpon, the American cranberry, compiling a comprehensive list of its known phytochemical components, and detailing their prevalence in cranberry fruit and its products. Flavonoids, especially colored anthocyanins, abundant flavonols, and unique proanthocyanidins, have attracted major research attention. Other notable active components include phenolic acids, benzoates, hydroxycinnamic acids, terpenes and organic acids. Health effects of cranberries, cranberry products, and isolated cranberry components in humans and animals, as well as in vitro, are debated. Evidence for protection from several bacterial pathogens, cancer, cardiovascular disease, and inflammation is compelling, while neuroprotection and anti-viral activity also have begun to draw new consideration. Emerging bioavailability data is considered and potential molecular mechanisms are evaluated, linking phytochemicals to health effects through their biochemical properties and reactions. Finally, the effects of processing and storage on cranberry phytochemicals is discussed, with a focus on identifying research gaps and novel means to preserve their natural, health-promoting components. © Taylor and Francis Group, LLC.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :135&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349653650&amp;doi=10.1080%2f10408390802145377&amp;partnerID=40&amp;md5=52d882cc3473e825db44c397ef287a13</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/10408390802145377</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>89</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">89</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Palleschi, G.</style></author><author><style face="normal" font="default" size="100%">Carbone, A.</style></author><author><style face="normal" font="default" size="100%">Zanello, P. P.</style></author><author><style face="normal" font="default" size="100%">Mele, R.</style></author><author><style face="normal" font="default" size="100%">Leto, A.</style></author><author><style face="normal" font="default" size="100%">Fuschi, A.</style></author><author><style face="normal" font="default" size="100%">Al Salhi, Y.</style></author><author><style face="normal" font="default" size="100%">Velotti, G.</style></author><author><style face="normal" font="default" size="100%">Al Rawashdah, S.</style></author><author><style face="normal" font="default" size="100%">Coppola, G.</style></author><author><style face="normal" font="default" size="100%">Maurizi, A.</style></author><author><style face="normal" font="default" size="100%">Maruccia, S.</style></author><author><style face="normal" font="default" size="100%">Pastore, A. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unit of Urology, Department of Sciences and Medico Surgical Biotechnologies, Sapienza, University of Rome, Latina, Italy&#xD;Uroresearch Association, Italy&#xD;Department of Surgical Sciences, Sapienza University of Rome, Rome, Italy&#xD;Urology Unit, Special Surgery Department, Faculty of Medicine, Mutah University, Karak, Jordan&#xD;Unit of Urology, IRCCS Policlinico San Donato Milanese, Milano, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prospective study to compare antibiosis versus the association of N-acetylcysteine, D-mannose and Morinda citrifolia fruit extract in preventing urinary tract infections in patients submitted to urodynamic investigation</style></title><secondary-title><style face="normal" font="default" size="100%">Archivio Italiano di Urologia e Andrologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archivio Italiano di Urologia e Andrologia</style></full-title></periodical><pages><style face="normal" font="default" size="100%">45-50</style></pages><volume><style face="normal" font="default" size="100%">89</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Biofilm</style></keyword><keyword><style face="normal" font="default" size="100%">D-mannose - N-acetylcysteine (NAC)</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infection (UTI)</style></keyword><keyword><style face="normal" font="default" size="100%">Urodynamic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: The abuse of antimicrobical drugs has increased the resistance of microorganisms to treatments, thus to make urinary tract infections (UTIs) more difficult to eradicate. Among natural substances used to prevent UTI, literature has provided preliminary data of the beneficial effects of D-mannose, N-acetylcysteine, and Morinda citrifolia fruit extract, due to their complementary mechanism of action which contributes respectively to limit bacteria adhesion to the urothelium, to destroy bacterial pathogenic biofilm, and to the anti-inflammatory and analgesic activity. The purpose of this study was to compare the administration of an association of D-mannose, N-acetylcysteine (NAC) and Morinda citrifolia extract versus antibiotic therapy in the prophylaxis of UTIs potentially associated with urological mini-invasive diagnostics procedures, in clinical model of the urodynamic investigation. Methods: 80 patients eligible for urodynamic examination, 42 men and 38 women, have been prospectively enrolled in the study and randomised in two groups (A and B) of 40 individuals. Patients of group A followed antibiotic therapy with Prulifloxacine, by mouth 400 mg/day for 5 days, while patients of the group B followed the association of mannose and NAC therapy, two vials/day for 7 days. Ten days after the urodynamic study, the patients were submitted to urine examination and urine culture. Results: The follow up assessment didn&apos;t show statistical significant difference between the two groups regarding the incidence of UTI. Conclusions: The association of mannose and NAC therapy resulted similar to the antibiotic therapy in preventing UTIs in patients submitted to urodynamic examination. This result leads to consider the possible use of these nutraceutical agents as a good alternative in the prophylaxis of the UTI afterwards urological procedures in urodynamics. © 2017, Edizioni Scripta Manent s.n.c. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :6&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85019219765&amp;doi=10.4081%2faiua.2017.1.45&amp;partnerID=40&amp;md5=4adac4e324dec89ae3e88726c1fcff3c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.4081/aiua.2017.1.45</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>222</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">222</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Paintsil, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departments of Pediatrics and Pharmacology, Yale School of Medicine, 333 Cedar Street, New Haven, CT 06520-8064, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Update on recent guidelines for the management of urinary tract infections in children: the shifting paradigm</style></title><secondary-title><style face="normal" font="default" size="100%">Current Opinion in Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Opinion in Pediatrics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">88-94</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">antibiotic prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">renal scars</style></keyword><keyword><style face="normal" font="default" size="100%">renal ultrasound</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">vesicoureteral reflux</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">PURPOSE OF REVIEW: Recent guidelines on the management of urinary tract infections (UTIs) in children have seen a shift from aggressive imaging studies and the use of prophylactic antibiotics to a more restrictive and targeted approach. This review focuses on new additions to the literature on management of UTI from January 2011 to September 2012. RECENT FINDINGS: The causal relationship between UTI-vesicoureteral reflux (VUR) and renal scarring has been challenged by several studies. Concerns about unnecessary exposure to ionizing radiation, invasiveness of some of the procedures, and risk of infection have also been raised. With improved prenatal ultrasound, a &apos;top-down&apos; approach to investigating febrile UTI in children using renal bladder ultrasound alone as an initial study has become popular. Several studies have reported that prophylactic antibiotics and imaging studies after first UTI can be reduced substantially without affecting the risk of recurrent UTI or renal scarring. SUMMARY: The use of targeted imaging approach in evaluating febrile UTI in children may lead to improved resource use and reduction of potential harmful procedures and interventions, without affecting outcomes of UTI in children. Providers using current guidelines should endeavor to collect practice-based evidence to validate and inform future guidelines. © 2013 Wolters Kluwer Health Lippincott Williams &amp; Wilkins.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :23&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84873092508&amp;doi=10.1097%2fMOP.0b013e32835c14cc&amp;partnerID=40&amp;md5=f793056418e9f745084832a7b18b82b2</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/MOP.0b013e32835c14cc</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>233</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">233</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pagonas, N.</style></author><author><style face="normal" font="default" size="100%">Hörstrup, J.</style></author><author><style face="normal" font="default" size="100%">Schmidt, D.</style></author><author><style face="normal" font="default" size="100%">Benz, P.</style></author><author><style face="normal" font="default" size="100%">Schindler, R.</style></author><author><style face="normal" font="default" size="100%">Reinke, P.</style></author><author><style face="normal" font="default" size="100%">Van Der Giet, M.</style></author><author><style face="normal" font="default" size="100%">Zidek, W.</style></author><author><style face="normal" font="default" size="100%">Westhoff, T. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Charité-Campus Benjamin Franklin, Department of Nephrology, Hindenburgdamm 30, 12200 Berlin, Germany&#xD;Department of Nephrology, Charité-Campus Virchow Klinikum, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prophylaxis of recurrent urinary tract infection after renal transplantation by cranberry juice and L-methionine</style></title><secondary-title><style face="normal" font="default" size="100%">Transplantation Proceedings</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Transplantation Proceedings</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3017-3021</style></pages><volume><style face="normal" font="default" size="100%">44</style></volume><number><style face="normal" font="default" size="100%">10</style></number><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Recurrent urinary tract infections (UTIs) increase mortality and reduce graft survival after renal transplantation. Strategies to prevent recurrent UTIs include L-methionine, cranberry juice, and antibiotics. Data on the efficacy of cranberry and L-methionine, however, are controversial in the general population; there are few data in renal transplant recipients. Methods: We performed a retrospective analysis of 82 transplant recipients with recurrent UTIs, who underwent prophylaxis with cranberry juice (2 × 50 mL/d, n = 39, 47.6%), or L-methionine (3 × 500 mg/d, n = 25, 30.5%), or both modalities (n = 18, 21.9%). Thirty patients without prophylaxis served as controls. We analyzed symptoms, pyuria/nitrituria, and incidence of UTI events during 1 year before versus after initiation of prophylaxis. Results: Prophylaxis highly significantly decreased the annual UTI incidence by 58.3% (P &lt;.001) in the study population with no change in the control group (P =.85); in addition, 53.7% of symptomatic patients reported relief of symptoms and pyuria/nitrituria disappeared in 42.4% of the dipstick-positive patients (P &lt;.001 each). Cranberry reduced the annual number of UTI episodes by 63.9% from 3.6 ± 1.4 to 1.3 ± 1.3/year (P &lt;.001) and L-methionine by 48.7% from 3.9 ± 1.8 to 2.0 ± 1.3/year (P &lt;.001). Conclusion: Cranberry juice and L-methionine successfully reduced the incidence of UTI after renal transplantation. © 2012 Elsevier Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :12&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84870213624&amp;doi=10.1016%2fj.transproceed.2012.06.071&amp;partnerID=40&amp;md5=4bcd39349ef1358b82d4ae17fb34720e</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.transproceed.2012.06.071</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>18</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">18</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Paalanne, N.</style></author><author><style face="normal" font="default" size="100%">Husso, A.</style></author><author><style face="normal" font="default" size="100%">Salo, J.</style></author><author><style face="normal" font="default" size="100%">Pieviläinen, O.</style></author><author><style face="normal" font="default" size="100%">Tejesvi, M. V.</style></author><author><style face="normal" font="default" size="100%">Koivusaari, P.</style></author><author><style face="normal" font="default" size="100%">Pirttilä, A. M.</style></author><author><style face="normal" font="default" size="100%">Pokka, T.</style></author><author><style face="normal" font="default" size="100%">Mattila, S.</style></author><author><style face="normal" font="default" size="100%">Jyrkäs, J.</style></author><author><style face="normal" font="default" size="100%">Turpeinen, A.</style></author><author><style face="normal" font="default" size="100%">Uhari, M.</style></author><author><style face="normal" font="default" size="100%">Renko, M.</style></author><author><style face="normal" font="default" size="100%">Tapiainen, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics and Adolescence, Oulu University Hospital, Oulu, Finland&#xD;PEDEGO Research Unit and Medical Research Center Oulu, University of Oulu, Oulu, Finland&#xD;Ecology and Genetics, Faculty of Science, University of Oulu, Oulu, Finland&#xD;Chain Antimicrobials Ltd, Teknologiantie 2, Oulu, 90590, Finland&#xD;Research Unit in Sustainable Chemistry, University of Oulu, Oulu, Finland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Intestinal microbiome as a risk factor for urinary tract infections in children</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Clinical Microbiology and Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Clinical Microbiology and Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1881-1891</style></pages><volume><style face="normal" font="default" size="100%">37</style></volume><number><style face="normal" font="default" size="100%">10</style></number><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">As urinary tract infection (UTI) pathogens originate from the gut, we hypothesized that the gut environment reflected by intestinal microbiome influences the risk of UTI. Our prospective case-control study compared the intestinal microbiomes of 37 children with a febrile UTI with those of 69 healthy children. We sequenced the regions of the bacterial 16S rRNA gene and used the LefSe algorithm to calculate the size of the linear discriminant analysis (LDA) effect. We measured fecal lactoferrin and iron concentrations and quantitative PCR for Escherichia coli. At the phylum level, there were no significant differences. At the genus level, Enterobacter was more abundant in UTI patients with an LDA score &gt; 3 (log 10), while Peptostreptococcaceae were more abundant in healthy subjects with an LDA score &gt; 3 (log 10). In total, 20 OTUs with significantly different abundances were observed. Previous use of antimicrobials did not associate with intestinal microbiome. The relative abundance of E. coli was 1.9% in UTI patients and 0.5% in controls (95% CI of the difference—0.8 to 3.6%). The mean concentration of E.coli in quantitative PCR was 0.14 ng/μl in the patients and 0.08 ng/μl in the controls (95% CI of the difference—0.04 to 0.16). Fecal iron and lactoferrin concentrations were similar between the groups. At the family and genus level, we noted several differences in the intestinal microbiome between children with UTI and healthy children, which may imply that the gut environment is linked with the risk of UTI in children. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85049826253&amp;doi=10.1007%2fs10096-018-3322-7&amp;partnerID=40&amp;md5=63a4b331cf995e6c93315f7add09a4f9</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10096-018-3322-7</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>462</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">462</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ouwehand, A. C.</style></author><author><style face="normal" font="default" size="100%">Derrien, M.</style></author><author><style face="normal" font="default" size="100%">De Vos, W.</style></author><author><style face="normal" font="default" size="100%">Tiihonen, K.</style></author><author><style face="normal" font="default" size="100%">Rautonen, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Danisco Innovation, Sokeritehtaantie 20, FIN-02460 Kantvik, Finland&#xD;Department of Microbiology, Wageningen University, 6700 HB Wageningen, Netherlands</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prebiotics and other microbial substrates for gut functionality</style></title><secondary-title><style face="normal" font="default" size="100%">Current Opinion in Biotechnology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Opinion in Biotechnology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">212-217</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">The intestinal microbiota is of great importance to our health and wellbeing. Modulation of the intestinal microbiota by exogenous and endogenous substrates can be expected to improve various physiological functions of our body, not just those in the intestine. Recently, new targets such as immune function and areas outside the colon have been considered to be influenced by the intestinal microbiota. Novel approaches might include the application of prebiotics in different combinations or the provision of nutrients to different bacterial groups and to different parts of the intestine. © 2005 Elsevier Ltd. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :96&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-17044414554&amp;doi=10.1016%2fj.copbio.2005.01.007&amp;partnerID=40&amp;md5=d16d0065a18a1f028aa427ed3498562f</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.copbio.2005.01.007</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>520</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">520</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ouwehand, A.</style></author><author><style face="normal" font="default" size="100%">Vesterlund, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Turku, Dept. of Biochemistry/Food Chemistry, 20014 Turku, Finland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Health aspects of probiotics</style></title><secondary-title><style face="normal" font="default" size="100%">IDrugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">IDrugs</style></full-title></periodical><pages><style face="normal" font="default" size="100%">573-580</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bifidobacterium</style></keyword><keyword><style face="normal" font="default" size="100%">Intestinal microbiota</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">Prebiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">Intestinal microbiota contribute in many different ways to our health; disturbances in the activity and/or composition of these microbiota may negatively influence health. In order to maintain a healthy intestinal microbiota, prebiotics and probiotics can be used. Selected probiotic strains safely shorten the duration of rotavirus diarrhea, relieve symptoms of lactose maldigestion and elicit beneficial immune-modulating effects. Other beneficial health effects have also been attributed to probiotics; however, these have not been sufficiently substantiated. Additional research into the mechanisms of probiotics is required.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :31&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038355056&amp;partnerID=40&amp;md5=446ef5c2ab3bae6053cc903e284aea75</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>76</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">76</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Osamwonyi, B.</style></author><author><style face="normal" font="default" size="100%">Foley, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Lister Hospital, Stevenage, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Management of recurrent urinary tract infections in adults</style></title><secondary-title><style face="normal" font="default" size="100%">Surgery (United Kingdom)</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Surgery (United Kingdom)</style></full-title></periodical><pages><style face="normal" font="default" size="100%">299-305</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotics</style></keyword><keyword><style face="normal" font="default" size="100%">D-mannose</style></keyword><keyword><style face="normal" font="default" size="100%">immunomodulators</style></keyword><keyword><style face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">recurrent UTI</style></keyword><keyword><style face="normal" font="default" size="100%">uropathogenic</style></keyword><keyword><style face="normal" font="default" size="100%">vaginal oestrogens</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Many women will experience one or more urinary tract infection (UTI) during their life. The most unfortunate will have numerous. They can occur at all ages, and bring significant morbidity and disruption to daily activities. Men presenting with infections, and women with recurrent episodes require further investigation. A diagnosis of a UTI is often based on a typical spectrum of symptoms, with confirmatory urine cultures lagging a few days behind. Unfortunately, symptoms of a UTI may not be typical, and other conditions can manifest similarly. Treatment of UTI with antibiotics is usually required, but there is an increasing awareness of the need for antimicrobial stewardship to avoid the misuse and overuse of antibiotics, even as patients are increasingly reluctant to take them. For patients experiencing recurrent UTI, each recurring infection can be very burdensome yet investigations rarely demonstrate a reversible cause. There are a host of different interventions, both antibiotic and non-antibiotic that aim to reduce the likelihood of further infections, however these are not reliably effective, bring side effects of their own and are often proposed to this desperate population of patients on the back of weak evidence of efficacy. © 2017</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85019156880&amp;doi=10.1016%2fj.mpsur.2017.03.004&amp;partnerID=40&amp;md5=2f2e32cc0c765179eed1d3350bf5af9c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.mpsur.2017.03.004</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>166</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">166</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Olin, S. J.</style></author><author><style face="normal" font="default" size="100%">Bartges, J. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, 2407 River Drive, Knoxville, TN 37996, United States&#xD;Cornell University Veterinary Specialists, 880 Canal Street, Stamford, CT 06902, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary Tract Infections. Treatment/Comparative Therapeutics</style></title><secondary-title><style face="normal" font="default" size="100%">Veterinary Clinics of North America - Small Animal Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Veterinary Clinics of North America - Small Animal Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">721-746</style></pages><volume><style face="normal" font="default" size="100%">45</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Canine</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Feline</style></keyword><keyword><style face="normal" font="default" size="100%">Prostatitis</style></keyword><keyword><style face="normal" font="default" size="100%">Pyelonephritis</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Veterinary medicine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infection (UTI) occurs when there is compromise of host defense mechanisms and a virulent microbe adheres, multiplies, and persists in a portion of the urinary tract. Most commonly, UTI is caused by bacteria, but fungi and viruses are possible. Urine culture and sensitivity are the gold standards for diagnosis of bacterial UTI. Identifying the location of infection (eg, bladder, kidney, prostate) as well as comorbidities (eg, diabetes mellitus, immunosuppression) is essential to guide the diagnostic and therapeutic plan. Antimicrobial agents are the mainstay of therapy for bacterial UTI and selected ideally based on culture and sensitivity. © 2015 Elsevier Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :15&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84930380521&amp;doi=10.1016%2fj.cvsm.2015.02.005&amp;partnerID=40&amp;md5=ff78cb19ec6b768e788036973cb9c2e6</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.cvsm.2015.02.005</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>139</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">139</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Olin, S.</style></author><author><style face="normal" font="default" size="100%">Bartges, J. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Small Animal Clinical Sciences, University of Tennessee, Knoxville, TN, United States&#xD;Small Animal Clinical Sciences, Cornell University, Ithaca, NY, United States&#xD;Cornell University Veterinary Specialists, Stamford, CT, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary Tract Infection</style></title><secondary-title><style face="normal" font="default" size="100%">August&apos;s Consultations in Feline Internal Medicine</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">509-517</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84960814895&amp;doi=10.1016%2fB978-0-323-22652-3.00052-9&amp;partnerID=40&amp;md5=5e04ae63049774e4575c2ecd4238f73c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/B978-0-323-22652-3.00052-9</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>93</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">93</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Olby, N. J.</style></author><author><style face="normal" font="default" size="100%">Vaden, S. L.</style></author><author><style face="normal" font="default" size="100%">Williams, K.</style></author><author><style face="normal" font="default" size="100%">Griffith, E. H.</style></author><author><style face="normal" font="default" size="100%">Harris, T.</style></author><author><style face="normal" font="default" size="100%">Mariani, C. L.</style></author><author><style face="normal" font="default" size="100%">Muñana, K. R.</style></author><author><style face="normal" font="default" size="100%">Early, P. J.</style></author><author><style face="normal" font="default" size="100%">Platt, S. R.</style></author><author><style face="normal" font="default" size="100%">Boozer, L.</style></author><author><style face="normal" font="default" size="100%">Giovanella, C.</style></author><author><style face="normal" font="default" size="100%">Longshore, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">College of Veterinary Medicine, North Carolina State University, Raleigh, NC, United States&#xD;Comparative Medicine Institute, North Carolina State University, Raleigh, NC, United States&#xD;Department of Statistics, North Carolina State University, Raleigh, NC, United States&#xD;College of Veterinary Medicine, University of Georgia, Athens, GA, United States&#xD;Gulf Coast Veterinary Specialists, Houston, TX, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of Cranberry Extract on the Frequency of Bacteriuria in Dogs with Acute Thoracolumbar Disk Herniation: A Randomized Controlled Clinical Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Veterinary Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Veterinary Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">60-68</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Incontinence</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidins</style></keyword><keyword><style face="normal" font="default" size="100%">Spinal cord injury</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Dogs with spinal cord injury are at increased risk of developing bacteriuria due to increased residual urine volume. Cranberry extract inhibits binding of E. coli to uroepithelial cells, potentially reducing risk of bacteriuria. Hypothesis: Cranberry extract reduces risk of bacteriuria in dogs after acute TL-IVDH. Animals: Client-owned dogs with acute onset TL-IVDH causing nonambulatory status. Methods: Randomized, placebo-controlled, blinded, prospective clinical trial. Dogs with acute TL-IVDH were recruited 48 hours postoperatively and randomized to receive cranberry extract or placebo in a masked fashion. Urine cultures and neurological examinations were performed 2, 4, and 6 weeks postoperatively. The number of dogs with bacteriuria (all bacterial species) and bacteriuria (E. coli) were primary and secondary outcome measures and were evaluated using chi-squared test. Urine antiadhesion activity (AAA) was measured in a subset (N = 47) and examined in a secondary analysis evaluating additional risk factors for bacteriuria. Results: Bacteriuria was detected 17 times in 94 dogs (6 placebo, 11 cranberry, P =.12). There were 7 E. coli. positive cultures (1 placebo, 6 cranberry, P =.09). Dogs in both groups had positive urine AAA (14/21: placebo, 16/26: cranberry), and dogs with urine AAA had significantly fewer E. coli positive cultures (n = 1) than dogs without it (n = 4) (P =.047). Conclusions and Clinical Importance: This clinical trial did not show a benefit of oral cranberry extract but had low power. Cranberry extract supplementation did not impact urine AAA, but a possible association between urine AAA and lower risk of E. coli bacteriuria was identified. Other doses could be investigated. Copyright © 2016 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :5&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85006117381&amp;doi=10.1111%2fjvim.14613&amp;partnerID=40&amp;md5=431d0d94dc6e6b847746acc9dd265eac</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/jvim.14613</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>422</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">422</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ohnishi, R.</style></author><author><style face="normal" font="default" size="100%">Ito, H.</style></author><author><style face="normal" font="default" size="100%">Kasajima, N.</style></author><author><style face="normal" font="default" size="100%">Kaneda, M.</style></author><author><style face="normal" font="default" size="100%">Kariyama, R.</style></author><author><style face="normal" font="default" size="100%">Kumon, H.</style></author><author><style face="normal" font="default" size="100%">Hatano, T.</style></author><author><style face="normal" font="default" size="100%">Yoshida, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacognosy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Tsushima, Okayama 700-8530, Japan&#xD;School of Pharmacy, Shujitsu University, Nishigawara, Okayama 703-8516, Japan&#xD;Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Shikata, Okayama 700-8558, Japan&#xD;Matsuyama University, Bunkyo-cho, Matsuyama 790-8578, Japan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary excretion of anthocyanins in humans after cranberry juice ingestion</style></title><secondary-title><style face="normal" font="default" size="100%">Bioscience, Biotechnology and Biochemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bioscience, Biotechnology and Biochemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1681-1687</style></pages><volume><style face="normal" font="default" size="100%">70</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anthocyanins</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry juice</style></keyword><keyword><style face="normal" font="default" size="100%">HPLC-ESI/MS</style></keyword><keyword><style face="normal" font="default" size="100%">Human urine</style></keyword><keyword><style face="normal" font="default" size="100%">MS-MS</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry, which is rich in polyphenols, including anthocyanins and proanthocyanidins, has been found to have various effects beneficial to human health, including prevention of urinary tract infections. These effects have been associated with polyphenols in the fruit. We investigated the excretion of anthocyanins in human urine after ingestion of cranberry juice. Eleven healthy volunteers consumed 200 ml of cranberry juice containing 650.8 μg total anthocyanins. Urine samples were collected within 24 h before and after consumption. Six of 12 anthocyanins identified in cranberry were quantified in human urine by HPLC coupled with electrospray ionization and tandem mass spectrometry (HPLC-ESI-MS-MS). Among these, peonidin 3-O-galactoside, the second most plentiful anthocyanin in the juice, was found most abundantly in urine within 24 h, corresponding to 41.5 nmol (56.1% of total anthocyanins). The urinary levels of anthocyanins reached a maximum between 3 and 6 h after ingestion, and the recovery of total anthocyanins in the urine over 24 h was estimated to be 5.0% of the amount consumed. This study found high absorption and excretion of cranberry anthocyanins in human urine.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :55&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33746422949&amp;doi=10.1271%2fbbb.60023&amp;partnerID=40&amp;md5=f174a487150acfdcf441ab4cdc36693e</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1271/bbb.60023</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>511</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">511</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ofek, I.</style></author><author><style face="normal" font="default" size="100%">Hasty, D. L.</style></author><author><style face="normal" font="default" size="100%">Sharon, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Human Microbiology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel&#xD;Dept. of Anatomy and Neurobiology, University of Tennessee, Memphis, TN 38163, United States&#xD;Research Service (151), VA Medical Center, Memphis, TN 38104, United States&#xD;Department of Biological Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anti-adhesion therapy of bacterial diseases: Prospects and problems</style></title><secondary-title><style face="normal" font="default" size="100%">FEMS Immunology and Medical Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">FEMS Immunology and Medical Microbiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">181-191</style></pages><volume><style face="normal" font="default" size="100%">38</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Carbohydrate</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Fimbria</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">The alarming increase in drug-resistant bacteria makes a search for novel means of fighting bacterial infections imperative. An attractive approach is the use of agents that interfere with the ability of the bacteria to adhere to tissues of the host, since such adhesion is one of the initial stages of the infectious process. The validity of this approach has been unequivocally demonstrated in experiments performed in a wide variety of animals, from mice to monkeys, and recently also in humans. Here we review various approaches to anti-adhesion therapy, including the use of receptor and adhesin analogs, dietary constituents, sublethal concentrations of antibiotics and adhesin-based vaccines. Because anti-adhesive agents are not bactericidal, the propagation and spread of resistant strains is much less likely to occur than as a result of exposure to bactericidal agents, such as antibiotics. Anti-adhesive drugs, once developed, may, therefore, serve as a new means to fight infectious diseases. © 2003 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :236&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Short Survey</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0142042801&amp;doi=10.1016%2fS0928-8244%2803%2900228-1&amp;partnerID=40&amp;md5=f048bffec0f4af06df33f1f238e81116</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0928-8244(03)00228-1</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>599</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">599</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ofek, I.</style></author><author><style face="normal" font="default" size="100%">Goldhar, J.</style></author><author><style face="normal" font="default" size="100%">Zafriri, D.</style></author><author><style face="normal" font="default" size="100%">Lis, H.</style></author><author><style face="normal" font="default" size="100%">Adar, R.</style></author><author><style face="normal" font="default" size="100%">Sharon, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Tel Aviv University, Tel Aviv 69778, Israel&#xD;Weizmann Institute of Science, Rehovot 76100, Israel</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anti-escherichia coli adhesin activity of cranberry and blueberry juices</style></title><secondary-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1599</style></pages><volume><style face="normal" font="default" size="100%">324</style></volume><number><style face="normal" font="default" size="100%">22</style></number><dates><year><style face="normal" font="default" size="100%">1991</style></year></dates><abstract><style face="normal" font="default" size="100%">To the Editor: Cranberry juice is widely recommended, particularly in the United States, for the treatment of urinary tract infections. The beneficial effects of the juice have been attributed to its hippuric acid content, although there is no scientific basis for this hypothesis.1,2 Recently, a number of studies have suggested that its effects are due to antiadhesive agents.3 4 5 Adhesion of Escherichia coli, the most common bacteria causing urinary tract infections, to cells of the urinary and alimentary tracts enables them to withstand cleansing mechanisms and to overcome nutrient deprivation, resulting in growth advantages and enhanced toxicity.6 Some years ago … © 1991, Massachusetts Medical Society. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :178&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Letter</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025906440&amp;doi=10.1056%2fNEJM199105303242214&amp;partnerID=40&amp;md5=d54bf93874fe4850e363fdd67124e471</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1056/NEJM199105303242214</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>127</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">127</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Occhipinti, A.</style></author><author><style face="normal" font="default" size="100%">Germano, A.</style></author><author><style face="normal" font="default" size="100%">Maffei, M. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Life Sciences and Systems Biology, University of Turin, Via Quarello 15/A, Turin, Italy&#xD;Farmacia Antoniana, Viale Cesare Balbo, 3, San Gillio (TO), 10040, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevention of urinary tract infection with Oximacro®, a cranberry extract with a high content of a-type proanthocyanidins: A pre-clinical double-blind controlled study</style></title><secondary-title><style face="normal" font="default" size="100%">Urology Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Urology Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2640-2649</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Pharmacology</style></keyword><keyword><style face="normal" font="default" size="100%">Plant extracts</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention &amp; control</style></keyword><keyword><style face="normal" font="default" size="100%">Therapeutic use</style></keyword><keyword><style face="normal" font="default" size="100%">Urinalysis</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Purpose: Urinary tract infections (UTIs) are widespread and affect a large portion of the human population. Cranberry juices and extracts have been used for UTI prevention due to their content of bioactive proanthocyanidins (PACs), particularly of the A type (PAC-A). Controversial clinical results obtained with cranberry are often due to a lack of precise determination and authentication of the PAC-A content. This study used Oximacro® (Biosfered S.r.l., Turin, Italy), a cranberry extract with a high content of PAC-A, to prevent UTIs in female and male volunteers. Materials and Methods: The Oximacro® PACs content was assayed using the Brunswick Laboratories 4-dimethylaminocinnamaldehyde (BL-DMAC) method, and the dimer and trimer PACs-A and PACs-B percentages were determined via high-performance liquid chromatography/electrospray ionization tandem mass spectrometry (HPLC/ESI-MS/MS). A balanced group of female (ranging from 19 to over 51 years) and male volunteers (over 51 years) was divided into two groups. The experimental group received 1 capsule containing Oximacro® (36 mg PACs-A) twice per day (morning and evening) for 7 days, and the placebo group was given the same number of capsules with no PACs. Results: Analysis of Oximacro® revealed a high total PAC content (372.34 mg/g ± 2.3) and a high percentage of PAC-A dimers and trimers (86.72% ± 1.65). After 7 days of Oximacro® administration, a significant difference was found between the placebo and Oximacro® groups for both females (Mann-Whitney U-test = 875; P &lt; .001; n = 60) and males (Mann-Whitney U-test = 24; P = .016; n = 10). When the female and male age ranges were analysed separately, the female age range 31-35 showed only slightly significant differences between the placebo and Oximacro® groups (Mann-Whitney U-test = 20.5; P = .095; n = 10), whereas all other female age ranges showed highly significant differences between the placebo and Oximacro® groups (Mann-Whitney U-test = 25; P = .008; n = 10). Furthermore, colony forming unit/mL counts from the urine cultures showed a significant difference (P &lt; .001) between the experimental and the placebo groups (SD difference = 51688; df = 34, t = -10.27; Dunn-Sidak Adjusted P &lt; .001, Bonferroni Adjusted P &lt; .001). Conclusion: Careful determination of the total PAC content using the BL-DMAC method and the authentication of PACs-A with mass spectrometry in cranberry extracts are necessary to prepare effective doses for UTI prevention. A dose of 112 mg Oximacro® containing 36 mg PACs-A was found to be effective in preventing UTIs when used twice per day for 7 days.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :9&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84970016811&amp;partnerID=40&amp;md5=d00f4d68792b5d228c6ae8ff81c56cc2</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>617</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">617</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">O&apos;Grady, F.</style></author><author><style face="normal" font="default" size="100%">Cattell, W. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departments of Bacteriology and Medicine, St Bartholomew&apos;s Hospital, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">KINETICS OF URINARY TRACT INFECTION: II. The Bladder</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">156-162</style></pages><volume><style face="normal" font="default" size="100%">38</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">1966</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :66&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0013899821&amp;doi=10.1111%2fj.1464-410X.1966.tb09694.x&amp;partnerID=40&amp;md5=4721f90ec4840da0b35e3a16d6b85a4a</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1464-410X.1966.tb09694.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>129</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">129</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">O&apos;Brien, V. P.</style></author><author><style face="normal" font="default" size="100%">Hannan, T. J.</style></author><author><style face="normal" font="default" size="100%">Nielsen, H. V.</style></author><author><style face="normal" font="default" size="100%">Hultgren, S. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Molecular Microbiology, Center for Women&apos;s Infectious Disease Research, St. Louis, MO 63110, United States&#xD;Department of Pathology and Immunology, Washington University Medical School, St. Louis, MO 63110, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Drug and vaccine development for the treatment and prevention of urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Microbiology Spectrum</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Microbiology Spectrum</style></full-title></periodical><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTI) are among the most common bacterial infections in humans, affecting millions of people every year. UTI cause significant morbidity in women throughout their lifespan, in infant boys, in older men, in individuals with underlying urinary tract abnormalities, and in those that require long-term urethral catheterization, such as patients with spinal cord injuries or incapacitated individuals living in nursing homes. Serious sequelae include frequent recurrences, pyelonephritis with sepsis, renal damage in young children, pre-term birth, and complications of frequent antimicrobial use including high-level antibiotic resistance and Clostridium difficile colitis. Uropathogenic E. coli (UPEC) cause the vast majority of UTI, but less common pathogens such as Enterococcus faecalis and other enterococci frequently take advantage of an abnormal or catheterized urinary tract to cause opportunistic infections. While antibiotic therapy has historically been very successful in controlling UTI, the high rate of recurrence remains a major problem, and many individuals suffer from chronically recurring UTI, requiring long-term prophylactic antibiotic regimens to prevent recurrent UTI. Furthermore, the global emergence of multi-drug resistant UPEC in the past ten years spotlights the need for alternative therapeutic and preventative strategies to combat UTI, including anti-infective drug therapies and vaccines. In this chapter, we review recent advances in the field of UTI pathogenesis, with an emphasis on the identification of promising drug and vaccine targets. We then discuss the development of new UTI drugs and vaccines, highlighting the challenges these approaches face and the need for a greater understanding of urinary tract mucosal immunity. © 2016 American Society for Microbiology. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :16&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84992702916&amp;doi=10.1128%2fmicrobiolspec.UTI-0013-2012&amp;partnerID=40&amp;md5=89f0ece6dd364b7d8e0501dcb2051b26</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">Uti-0013-2012</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/microbiolspec.UTI-0013-2012</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>588</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">588</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nygaard, I.</style></author><author><style face="normal" font="default" size="100%">Linder, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Iowa, College of Medicine&#xD;University of Iowa, College of Law, Iowa City, United States&#xD;Department of Obstetrics and Gynecology, 2 BT-GH, University of Iowa, College of Medicine, Iowa City, IA 52242, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Thirst at work - an occupational hazard?</style></title><secondary-title><style face="normal" font="default" size="100%">International Urogynecology Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Urogynecology Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">340-343</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Behavioral factors</style></keyword><keyword><style face="normal" font="default" size="100%">Infrequent voiding syndrome</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Voiding pattern</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1997</style></year></dates><abstract><style face="normal" font="default" size="100%">Of 1492 teachers 791 (53%) responded to a survey addressing whether voiding habits at work or behavioral factors influenced by this occupation predisposed women to urinary tract infection. The mean number of voids during the work day was 2.7 ± 1.4; 24.5% voided infrequently (never or only once) and 26.5% voided four or more times during the work day; 15.8% had had a urinary tract infection in the preceding year. Half of the respondents made a conscious effort to drink less while working, to avoid needing to use the toilet. There was no association between the prevalence of urinary tract infection and the number of voids or infrequent voiding at work. Compared to women who drank the volume they desired at work, those who drank less had a 2.21-fold higher risk (95% CI 1.45-3.38) of urinary tract infection after controlling for being parous, voiding infrequently at work, and urge incontinence. Further study is warranted to determine whether modification of behavioral factors at work can reduce the incidence of urinary tract infections. If this association holds, public policy must be changed to allow workers more adequate access to toilet facilities.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :49&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031432333&amp;doi=10.1007%2fBF02765593&amp;partnerID=40&amp;md5=8a6da7d32e4e1c5119995aae9e696c06</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/BF02765593</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>358</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">358</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nowack, R.</style></author><author><style face="normal" font="default" size="100%">Schmitt, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centers for Nephrology/Dialysis, Lindau, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry juice for prophylaxis of urinary tract infections - Conclusions from clinical experience and research</style></title><secondary-title><style face="normal" font="default" size="100%">Phytomedicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Phytomedicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">653-667</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-adhesion</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry (Vaccinium macrocarpon Aiton)</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">p-fimbriae</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidines</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry juice (Vaccinium macrocarpon) is a widely used and recommended North-American folk remedy for prophylaxis of urinary tract infections (UTI). Clinical trials have documented its efficacy in women with recurrent UTI, but so far not in other groups of patients. The composition of effective cranberry products and its dosage in UTI prophylaxis have not been defined. Intriguing experimental research has identified an anti-adhesive mechanism of cranberry juice that prevents docking of bacteria on host tissues. This efficacy mechanism can be traced in patients&apos; urine following oral intake of cranberry products and appears to be due to proanthocyanidins with an A-type linkage of flavanols. The application of this anti-adhesion mechanism of cranberry-proanthocyandins is currently also investigated in other common diseases of bacterial pathogenesis, for example Helicobacter pylori-associated gastritis and dental caries/periodontal disease. The use of cranberry products appears to be safe and provide additional benefits by anti-oxidant and cholesterol-lowering activity. © 2008 Elsevier GmbH. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :37&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-48849105700&amp;doi=10.1016%2fj.phymed.2008.07.009&amp;partnerID=40&amp;md5=da1ed218d99efdfd377140c88b0e8f6a</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.phymed.2008.07.009</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>372</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">372</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nowack, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dialysezentrum Lindau, Friedrichshafener Str. 82, DE-88131 Lindau, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry as a pharmaceutical agent in treating bacterial infections: Current research findings</style></title><secondary-title><style face="normal" font="default" size="100%">Schweizerische Zeitschrift fur GanzheitsMedizin</style></secondary-title><short-title><style face="normal" font="default" size="100%">Cranberry als phyto-prophylaktikum bei bakteriellen infektionen: Neue forschungsergebnisse</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Schweizerische Zeitschrift fur GanzheitsMedizin</style></full-title></periodical><pages><style face="normal" font="default" size="100%">149-155</style></pages><volume><style face="normal" font="default" size="100%">20</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-46449128789&amp;partnerID=40&amp;md5=6e4b2ad5834c18b96fa9b6c2e175c14b</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>393</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">393</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nowack, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dialysis-Center Lindau, Lindau, Germany&#xD;Dialysis-Center Lindau, Friedrichshafener Strasse 82, 88131 Lindau, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry juice - A well-characterized folk-remedy against bacterial urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">Wiener Medizinische Wochenschrift</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Wiener Medizinische Wochenschrift</style></full-title></periodical><pages><style face="normal" font="default" size="100%">325-330</style></pages><volume><style face="normal" font="default" size="100%">157</style></volume><number><style face="normal" font="default" size="100%">13-14</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-adhesive effect</style></keyword><keyword><style face="normal" font="default" size="100%">Caries</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Gastritis</style></keyword><keyword><style face="normal" font="default" size="100%">Helicobacter pylori-associated</style></keyword><keyword><style face="normal" font="default" size="100%">Periodontal disease</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry (Vaccinium macrocarpon) is a North-American folk remedy for treating and preventing infection. Research has identified an anti-adhesive mechanism of cranberry-proanthocyanidins that inhibit docking of bacteria on tissues &quot;in vitro&quot;. This efficacy mechanism can be traced in the patient&apos;s urine following oral intake of cranberry juice. The efficacy of cranberry juice and extracts as a prophylactic agent against recurrent urinary infections is well documented in women. The anti-adhesion effect of cranberry-proanthocyandins can also be applied for treatment of other common diseases of bacterial pathogenesis, e. g. Helicobacter pylori-associated gastritis and dental caries/periodontal disease. © Springer-Verlag 2007.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :21&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-34548459904&amp;doi=10.1007%2fs10354-007-0432-8&amp;partnerID=40&amp;md5=c6d6a9f6131e0129998152b655a6a0d8</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10354-007-0432-8</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>416</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">416</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nowack, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dialysezentrum Lindau, Friedrichshafener Str. 82, 88131 Lindau, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry as a pharmaceutical agent in treating bacterial infections: Current research findings</style></title><secondary-title><style face="normal" font="default" size="100%">Zeitschrift fur Phytotherapie</style></secondary-title><short-title><style face="normal" font="default" size="100%">Cranberry als phyto-prophylaktikum bei bakteriellen infektionen: Neue forschungsergebnisse</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Zeitschrift fur Phytotherapie</style></full-title></periodical><pages><style face="normal" font="default" size="100%">163-171</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-adhesive effect</style></keyword><keyword><style face="normal" font="default" size="100%">Antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">Caries</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Ericaceae</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Helicobacter pylori</style></keyword><keyword><style face="normal" font="default" size="100%">Periodontal disease</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidins</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon Aiton</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">The author presents new research findings on the efficacy of cranberry (Vaccinium macrocarpon) as a pharmaceutical agent in treating recurrent urinary tract infection, Helicobacter pylori infection of the upper gastrointestinal tract as well as caries and periodontal disease. In vitro, the proanthocyanidins in cranberries inhibit the docking of bacteria on tissues. The efficacy mechanism can be traced in the patient&apos;s urine following an oral intake of cranberry juice. As was shown in evidence based studies, cranberry juice leads to the prevention of urinary tract infection in women. The author also empirically verifies the high anti-oxidative capacity of cranberry products.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33750564813&amp;doi=10.1055%2fs-2006-951586&amp;partnerID=40&amp;md5=f011ccd768ea414232142ab395f14ab5</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1055/s-2006-951586</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>536</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">536</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nowack, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Internist und Nephrologe, Dialysezentrum Lindau, Friedrichshafener Str. 82, 88131 Lindau, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">The American Cranberry (Vaccinium macrocarpon Aiton): Portrait of a herbal remedy</style></title><secondary-title><style face="normal" font="default" size="100%">Zeitschrift fur Phytotherapie</style></secondary-title><short-title><style face="normal" font="default" size="100%">Die Amerikanische Cranberry (Vaccinum macrocarpon Aiton)</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Zeitschrift fur Phytotherapie</style></full-title></periodical><pages><style face="normal" font="default" size="100%">40-46</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">American Cranberry (Vaccinium macrocarpon Aiton)</style></keyword><keyword><style face="normal" font="default" size="100%">Epicatechin</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidines</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">The American Cranberry (Vaccinium macrocarpon Aiton) is a folk remedy in North America. Cranberry juice has been used as prophylaxis against urinary tract infection, and there is now increasing evidence from controlled studies for its efficacy. Recent in vitro research suggests that oligomeric proanthocyanidines in cranberries interfere with bacterial adhesion and prevent bacterial invasion into the mucosa by this mechanism. There is evidence that antioxidants from cranberries modify LDL-cholesterol oxidation and preliminary research shows beneficial effects of these compounds in cancer models.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037285647&amp;partnerID=40&amp;md5=7c09ead815feb17fac92501272749545</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>392</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">392</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nova, E.</style></author><author><style face="normal" font="default" size="100%">Wärnberg, J.</style></author><author><style face="normal" font="default" size="100%">Gómez-Martínez, S.</style></author><author><style face="normal" font="default" size="100%">Díaz, L. E.</style></author><author><style face="normal" font="default" size="100%">Romeo, J.</style></author><author><style face="normal" font="default" size="100%">Marcos, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Immunonutrition Research Group, Dept. Metabolism and Nutrition, Instituto del Frio. Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain&#xD;Unit for Preventive Nutrition, Dept. of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default" size="100%">Immunomodulatory effects of probiotics in different stages of life</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Journal of Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S90-S95</style></pages><volume><style face="normal" font="default" size="100%">98</style></volume><number><style face="normal" font="default" size="100%">SUPPL. 1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Diseases with underlying immune mechanisms</style></keyword><keyword><style face="normal" font="default" size="100%">Immunomodulation</style></keyword><keyword><style face="normal" font="default" size="100%">Lifespan</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">The immunomodulatory properties of lactic acid bacteria (LAB) and foods containing them (e.g., fermented milks) is a topic currently under investigation. Individuals could potentially benefit from the inclusion of LAB in the diet at different times during the life cycle. One of the most accepted specific uses of probiotic bacteria is the prevention of atopic eczema in infants with family history of the disease who receive the probiotic bacteria early, through supplementation of the gestating mother and orally after birth. Immune enhancing effects have also been suggested to be beneficial in diarrhoea treatment, especially in children infected with rotavirus and in malnourished patients, infants and adolescents, whose capacity to produce IFN-γ can be increased after LAB-containing yoghurt intake. Regarding young people and adults, investigations have been conducted exploring the immunomodulation by LAB in subjects under stressful situations, in the prevention of urinary tract infections in fertile women and in the treatment of allergy. However, the beneficial effects of probiotics in these conditions remain controversial and the scientific evidence provided so far is not considered to be conclusive. The elderly population has been the focus of investigations aimed at identifying the capacity of probiotics to counteract the immunosenescence process by increasing phagocytic and natural killer (NK) cell activities and to protect against infection. The mechanisms involved in the different effects attributed to LAB remain to be clarified. Moreover, considering that the immunomodulatory properties are strain-specific, defining the optimal dose of a certain bacteria or combination of bacteria strains and the duration of treatment for a desired effect in a target population group is essential in order to substantiate health claims. © 2007 The Authors.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :49&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Conference Paper</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-35148893084&amp;doi=10.1017%2fS0007114507832983&amp;partnerID=40&amp;md5=e988342ddb1e8b7c1e0b769f13b613d6</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1017/S0007114507832983</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>257</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">257</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nosseir, S. B.</style></author><author><style face="normal" font="default" size="100%">Lind, L. R.</style></author><author><style face="normal" font="default" size="100%">Winkler, H. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Urogynecology: Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, North Shore-Long Island Jewish Health System, 865 Northern Boulevard, Great Neck, NY 11021, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent uncomplicated urinary tract infections in women: A review</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Women&apos;s Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Women&apos;s Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">347-354</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Recurrent urinary tract infections most often present with symptoms of irritative voiding. In most cases, they are caused by reinfection with a previously isolated organism. Patients with one or more symptoms of uncomplicated recurrent urinary tract infection should undergo thorough examination and screening for underlying comorbidities that increase susceptibility. When frequent reinfections, empiric treatment relapse, persistent infections, or risk factors for complicated infections are encountered, patients may benefit from urodynamics, cystoscopy, renal ultrasound, intravenous urogram, or voiding cystourethrogram to evaluate for anatomic, functional, or metabolic abnormalities affecting the urinary tract (e.g., stones, stricture, obstruction, vesicoureteral reflux, lesions, detrusor underactivity). These patients may benefit from culture-guided empiric treatment and further evaluation by urology, nephrology, or infectious disease specialists. In patients with a history of uncomplicated urinary tract infections, empiric treatment guided by local antimicrobial resistance may efficiently treat a suspected recurrence. After successful treatment of the acute infection, postcoital prophylaxis, continuous prophylaxis, or self-start empiric treatment may be selected based on frequency of recurrent infections, temporal relation to intercourse, and patient characteristics. Ancillary measures such as probiotics, cranberry products, or local estrogen replacement may also be considered. This article will review the current definition, epidemiology, pathogenesis, diagnosis, work-up, treatment, treatment side effects, and prevention of recurrent urinary tract infections in women. A suggested algorithm for evaluation and treatment based on current literature is provided. © Copyright 2012, Mary Ann Liebert, Inc. 2012.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :24&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84858116019&amp;doi=10.1089%2fjwh.2011.3056&amp;partnerID=40&amp;md5=46ea52c1ea3117ed4a346231bf8619a7</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1089/jwh.2011.3056</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>419</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">419</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nohynek, L. J.</style></author><author><style face="normal" font="default" size="100%">Alakomi, H. L.</style></author><author><style face="normal" font="default" size="100%">Kähkönen, M. P.</style></author><author><style face="normal" font="default" size="100%">Heinonen, M.</style></author><author><style face="normal" font="default" size="100%">Helander, I. M.</style></author><author><style face="normal" font="default" size="100%">Oksman-Caldentey, K. M.</style></author><author><style face="normal" font="default" size="100%">Puupponen-Pimiä, R. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">VTT Biotechnology, Tietotie 2, FIN-02044 VTT, Finland&#xD;University of Helsinki, Department of Applied Chemistry and Microbiology, Microbiology, FIN-00014 University of Helsinki, Finland&#xD;University of Helsinki, Department of Applied Chemistry and Microbiology, Food Chemistry, FIN-00014 University of Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Berry phenolics: Antimicrobial properties and mechanisms of action against severe human pathogens</style></title><secondary-title><style face="normal" font="default" size="100%">Nutrition and Cancer</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nutrition and Cancer</style></full-title></periodical><pages><style face="normal" font="default" size="100%">18-32</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">Antimicrobial activity and mechanisms of phenolic extracts of 12 Nordic berries were studied against selected human pathogenic microbes. The most sensitive bacteria on berry phenolics were Helicobacter pylori and Bacillus cereus. Campylobacter jejuni and Candida albicans were inhibited only with phenolic extracts of cloudberry, raspberry, and strawberry, which all were rich in ellagitannins. Cloudberry extract gave strong microbicidic effects on the basis of plate count with all studied strains. However, fluorescence staining of liquid cultures of virulent Salmonella showed viable cells not detectable by plate count adhering to cloudberry extract, whereas Staphylococcus aureus cells adhered to berry extracts were dead on the basis of their fluorescence and plate count. Phenolic extracts of cloudberry and raspberry disintegrated the outer membrane of examined Salmonella strains as indicated by 1-N-phenylnaphthylamine (NPN) uptake increase and analysis of liberation of [14C]galactose- lipopolysaccharide. Gallic acid effectively permeabilized the tested Salmonella strains, and significant increase in the NPN uptake was recorded. The stability of berry phenolics and their antimicrobial activity in berries stored frozen for a year were examined using Escherichia coli and nonvirulent Salmonella enterica sv. Typhimurium. The amount of phenolic compounds decreased in all berries, but their antimicrobial activity was not influenced accordingly. Cloudberry, in particular, showed constantly strong antimicrobial activity during the storage. Copyright © 2006, Lawrence Erlbaum Associates, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :248&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Conference Paper</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33746571435&amp;doi=10.1207%2fs15327914nc5401_4&amp;partnerID=40&amp;md5=3c0ace1bd75f95e1b0f2b7af8948295c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1207/s15327914nc5401_4</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>324</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">324</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nishiura, J. L.</style></author><author><style face="normal" font="default" size="100%">Heilberg, I. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Escola Paulista de Medicina da Universidade Federal de São Paulo (EPM-UNIFESP), Brazil</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Revista Brasileira de Medicina</style></secondary-title><short-title><style face="normal" font="default" size="100%">Infecção urinária</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Revista Brasileira de Medicina</style></full-title></periodical><pages><style face="normal" font="default" size="100%">5-12</style></pages><volume><style face="normal" font="default" size="100%">66</style></volume><number><style face="normal" font="default" size="100%">DECEMBER SPEC. IS</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">The urinary tract infection (UTI), one of the most frequent conditions in Health Services, possesses a variable spectrum of clinical presentation including cystitis, pyelonephritis and asymptomatic bacteriuria. The severity and recurrence of UTI is associated with genetic, hormonal and behavioral factors, in addition to the virulence of the invading microorganism. The authors revisit the subject shedding light on the differential diagnosis and present a recent review of the antimicrobial regimens prescribed for treatment and prevention according to the international newest guidelines. Alternative therapy is also commented. © Copyright Moreira Jr. Editora.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-77349122559&amp;partnerID=40&amp;md5=f1d4d25736611ca88be2f5033685b3e7</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>177</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">177</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nile, S. H.</style></author><author><style face="normal" font="default" size="100%">Park, S. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Molecular Biotechnology, College of Life and Environmental Sciences, Konkuk University, Seoul, South Korea</style></auth-address><titles><title><style face="normal" font="default" size="100%">Edible berries: Bioactive components and their effect on human health</style></title><secondary-title><style face="normal" font="default" size="100%">Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">134-144</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blackberries</style></keyword><keyword><style face="normal" font="default" size="100%">Blueberries</style></keyword><keyword><style face="normal" font="default" size="100%">Human health</style></keyword><keyword><style face="normal" font="default" size="100%">Phytochemicals</style></keyword><keyword><style face="normal" font="default" size="100%">Raspberries</style></keyword><keyword><style face="normal" font="default" size="100%">Strawberries</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">The importance of food consumption in relation to human health has increased consumer attention in nutraceutical components and foods, especially fruits and vegetables. Berries are a rich source of a wide variety of non-nutritive, nutritive, and bioactive compounds such as flavonoids, phenolics, anthocyanins, phenolic acids, stilbenes, and tannins, as well as nutritive compounds such as sugars, essential oils, carotenoids, vitamins, and minerals. Bioactive compounds from berries have potent antioxidant, anticancer, antimutagenic, antimicrobial, anti-inflammatory, and antineurodegenerative properties, both invitro and invivo. The following is a comprehensive and critical review on nutritional and non-nutritional bioactive compounds of berries including their absorption, metabolism, and biological activity in relation to their potential effect on human health. © 2014 Elsevier Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :200&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84891164536&amp;doi=10.1016%2fj.nut.2013.04.007&amp;partnerID=40&amp;md5=d7dfa3414dc3d189cf0810f11ec34d99</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.nut.2013.04.007</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>437</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">437</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nikpour, S.</style></author><author><style face="normal" font="default" size="100%">Tabrizian, L.</style></author><author><style face="normal" font="default" size="100%">Roodsari, D. M.</style></author><author><style face="normal" font="default" size="100%">Haghani, H.</style></author><author><style face="normal" font="default" size="100%">Hadjikazemi, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculty of Nursing and Midwifery, Iran University of Medical Sciences and Health Services, Tehran, Iran&#xD;College of Nursing and Midwifery, Iran University of Medical Science and Health Services, Rashid yasami st. Vali ASR Ave., Tehran, Iran&#xD;Iran University of Medical Sciences and Health Services, Tehran, Iran&#xD;Faculty of Management and Information, Iran University of Medical Sciences and Health Services, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="default" size="100%">Sexual behaviors and hygiene habits for Urinary Tract Infections (UTIs) among married women: A case-control study</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Scientific Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Scientific Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">287-293</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Dietary factors</style></keyword><keyword><style face="normal" font="default" size="100%">Married women</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Because urinary tract infections (UTIs) are caused by bacteria in the stool, dietary factors may affect the risk of contracting UTIs by altering the properties of the fecal bacterial flora. Objective: To determine dietary factors for UTIs among married women in a case-control setting. Methods: Two hundred married women from selected hospitals of Tehran (between 14-45 y) with positive urine culture were compared with 200 women age-matched women with negative urine culture. Data on the women&apos;s dietary were collected by questionnaire. In culture results and the relevant microorganisms the data was concluded from the laboratory test results. A risk profile for UTIs expressed in the form of adjusted odds ratios (ORs) with 95% CIs was modeled in logistic regression analysis for 200 case-control pairs with all relevant information. Results: Frequent consumption of daily number of glasses of water and tea consumed, of sour drinks, (especially lemon - juice) and the type of food consumed was associated with a decreased risk of recurrence of UTIs: the OR for UTI was 0.5 (95% CI: 0.3, 0.8) consumption of water and tea &gt;4glasses in day. A preference for consuming sour drinks gave an OR of 0.7 (95% CI: 0.39, 0.89). Consumption of yogurt (daily or every other day) gave an OR of 0.51 (95% CI: 0.27, 0.978). Conclusion: Dietary habits seem to be an important risk factor for UTIs recurrence in married women, and dietary guidance could be a first step toward prevention. © EuroJournals Publishing, Inc. 2006.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33748849415&amp;partnerID=40&amp;md5=9dc7f735f49bf8c9345c8d87c820192f</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>595</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">595</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nielsen, A. F.</style></author><author><style face="normal" font="default" size="100%">Walter, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Aalborg Hospital, 9000 Aalborg, Denmark</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epidemiology of infrequent voiding and associated symptoms</style></title><secondary-title><style face="normal" font="default" size="100%">Scandinavian Journal of Urology and Nephrology, Supplement</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Scandinavian Journal of Urology and Nephrology, Supplement</style></full-title></periodical><pages><style face="normal" font="default" size="100%">49-54</style></pages><number><style face="normal" font="default" size="100%">157</style></number><keywords><keyword><style face="normal" font="default" size="100%">infrequent voiding</style></keyword><keyword><style face="normal" font="default" size="100%">nocturnal voiding</style></keyword><keyword><style face="normal" font="default" size="100%">voiding habits</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1994</style></year></dates><abstract><style face="normal" font="default" size="100%">In an attempt to study the epidemiology of infrequent voiding and its associated symptoms, 1613 women aged 20-25, 30-35 or 40-45 years randomly selected among the ordinary female population in Northern Jutland in Denmark were sent a questionnaire. It was to be answered anonymously. The women were asked about voiding frequency, frequency of nocturnal voidings, urinary infections, problems in initiating voiding and urinary leaking symptoms. The response rate was 65.0%. Overall, 7.7% of the women in the 3 groups had a voiding frequency of 3 or less per day. We found that women aged 20-25 had a higher rate of this low voiding frequency than women in the two older groups, (p &lt; 0.001). Women aged 40-45 had a higher rate of urinary leaking symptoms than the two younger groups, (p &lt; 0.02). In all 3 groups, women who voided 3 times or less per day had significantly more urinary infections than those with 4 or more voidings per day, (p &lt; 0.01). The investigation has given some impression of the frequency of the infrequent voiding and the frequency of its associated symptoms.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :17&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028183085&amp;partnerID=40&amp;md5=93f6bfc4c753e29f426acfb8522ae412</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>377</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">377</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nicolle, L. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departments of Internal Medicine and Medical Microbiology, Health Sciences Centre, University of Manitoba, Room GG443 -, 820 Sherbrook Street, Winnipeg, Man. R3A 1R9, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Uncomplicated Urinary Tract Infection in Adults Including Uncomplicated Pyelonephritis</style></title><secondary-title><style face="normal" font="default" size="100%">Urologic Clinics of North America</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Urologic Clinics of North America</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-12</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">Acute uncomplicated urinary tract infection and acute pyelonephritis are very common infections affecting many women throughout their lives. The determinants of infection have been well described and current strategies to prevent recurrent infections are highly effective. While antimicrobial management is straightforward for most episodes, the evolution of antimicrobial susceptibility of E. coli in community-acquired infection requires continuing re-evaluation of appropriate empiric therapy. © 2008 Elsevier Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :150&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-36448951581&amp;doi=10.1016%2fj.ucl.2007.09.004&amp;partnerID=40&amp;md5=26d08a1eae11056183fd798dbb16d484</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ucl.2007.09.004</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>488</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">488</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nicolle, L. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, University of Manitoba, Health Sciences Centre, 820 Sherbrook St., Winnipeg, Man. R3A 1R9, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Current challenges in the management of urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical Outcomes Management</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Clinical Outcomes Management</style></full-title></periodical><pages><style face="normal" font="default" size="100%">385-395</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">6</style></number><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">• Objective: To review the management of patients with and at risk for urinary tract infection (UTI). • Methods: Qualitative assessment of the literature. • Results: UTI is a common bacterial infection in adults. It presents as acute infection in otherwise well women or as complicated infection in individuals with functional or structural abnormalities of the genitourinary tract and in men. Management of UTI requires an understanding of characteristic features of presentation, laboratory diagnosis, natural history, and outcomes of therapy in different patient populations. Clinicians need to have knowledge of appropriate use of urine culture, approaches to empiric antimicrobial treatment, and population-specific factors that affect the duration of antimicrobial therapy, likelihood of recurrence, need for genitourinary investigations, and management of recurrent infection. Patients should not be screened for asymptomatic bacteriuria, except for pregnant women and individuals who are to undergo invasive procedures of the genitourinary tract with a high probability of mucosal bleeding. • Conclusion: Understanding relevant differences in distinct populations is key to successful management of UTI.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-4644282975&amp;partnerID=40&amp;md5=858b46160420d0063cd4e2dd1c1759ff</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>289</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">289</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Neto, C. C.</style></author><author><style face="normal" font="default" size="100%">Vinson, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemistry and Biochemistry, University of Massachusetts-Dartmouth, North Dartmouth, MA, United States&#xD;Department of Chemistry, University of Scranton, Scranton, PA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry</style></title><secondary-title><style face="normal" font="default" size="100%">Herbal Medicine: Biomolecular and Clinical Aspects: Second Edition</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">107-130</style></pages><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :6&#xD;Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054250513&amp;partnerID=40&amp;md5=9787aa669134eac83b45721d106d2c24</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>202</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">202</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nantz, M. P.</style></author><author><style face="normal" font="default" size="100%">Rowe, C. A.</style></author><author><style face="normal" font="default" size="100%">Muller, C.</style></author><author><style face="normal" font="default" size="100%">Creasy, R.</style></author><author><style face="normal" font="default" size="100%">Colee, J.</style></author><author><style face="normal" font="default" size="100%">Khoo, C.</style></author><author><style face="normal" font="default" size="100%">Percival, S. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Food Science and Human Nutrition, University of Florida, Box 110370, Gainesville, FL 32611, United States&#xD;Department of Statistics, University of Florida, Gainesville, FL 32611, United States&#xD;Ocean Spray Cranberries, Inc., Lakeville, MA 02349, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Consumption of cranberry polyphenols enhances human γδ-T cell proliferation and reduces the number of symptoms associated with colds and influenza: A randomized, placebo-controlled intervention study</style></title><secondary-title><style face="normal" font="default" size="100%">Nutrition Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nutrition Journal</style></full-title></periodical><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">γδ-T cell</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Immunity</style></keyword><keyword><style face="normal" font="default" size="100%">NK cell</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Our main objective was to evaluate the ability of cranberry phytochemicals to modify immunity, specifically γδ-T cell proliferation, after daily consumption of a cranberry beverage, and its effect on health outcomes related to cold and influenza symptoms. Methods. The study was a randomized, double-blind, placebo-controlled, parallel intervention. Subjects drank a low calorie cranberry beverage (450 ml) made with a juice-derived, powdered cranberry fraction (n = 22) or a placebo beverage (n = 23), daily, for 10 wk. PBMC were cultured for six days with autologous serum and PHA-L stimulation. Cold and influenza symptoms were self-reported. Results: The proliferation index of γδ-T cells in culture was almost five times higher after 10 wk of cranberry beverage consumption (p &lt;0.001). In the cranberry beverage group, the incidence of illness was not reduced, however significantly fewer symptoms of illness were reported (p = 0.031). Conclusions: Consumption of the cranberry beverage modified the ex vivo proliferation of γδ-T cells. As these cells are located in the epithelium and serve as a first line of defense, improving their function may be related to reducing the number of symptoms associated with a cold and flu. Trial registration. ClinicalTrials.gov Identifier: NCT01398150. © 2013 Nantz et al.; licensee BioMed Central Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :20&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84889996252&amp;doi=10.1186%2f1475-2891-12-161&amp;partnerID=40&amp;md5=4cf256bc01ffe897deeb66ac7caf802d</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">161</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/1475-2891-12-161</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>362</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">362</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Najm, W.</style></author><author><style face="normal" font="default" size="100%">Lie, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Predoctoral Education, Department of Family Medicine, University of California, 101 City Dr. South, Bldg. 200, Suite 512, Irvine, CA 92868, United States&#xD;Faculty Development, University of California, Irvine School of Medicine, 101 City Dr. South, Bldg. 200, Suite 512, Irvine, CA 92868, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dietary Supplements Commonly Used for Prevention</style></title><secondary-title><style face="normal" font="default" size="100%">Primary Care - Clinics in Office Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Primary Care - Clinics in Office Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">749-767</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Benefit</style></keyword><keyword><style face="normal" font="default" size="100%">Complementary &amp; alternative medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence</style></keyword><keyword><style face="normal" font="default" size="100%">Harm</style></keyword><keyword><style face="normal" font="default" size="100%">Herbals</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">The use of complimentary and alternative medicine is on the rise. This article reviews some of the commonly used herbal supplements and others focusing mainly on disease prevention. A summary table of medical conditions is provided, and when possible, a summary of efficacy and safety is provided to facilitate decision making. © 2008 Elsevier Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :13&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-53349129570&amp;doi=10.1016%2fj.pop.2008.07.010&amp;partnerID=40&amp;md5=c602aa45cf27beb7b5cd26852ecf226b</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.pop.2008.07.010</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>236</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">236</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Naber, K. G.</style></author><author><style face="normal" font="default" size="100%">Garau, J.</style></author><author><style face="normal" font="default" size="100%">Wullt, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Urology Department, Technical University of Munich, Germany&#xD;University of Barcelona, Germany&#xD;Department of Medicine, Universitari Mutua de Terrassa, Barcelona, Spain&#xD;Department of Urology, Lund University Hospital, Lund, Sweden</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent uncomplicated urinary tract infections: Summary of presentations given at a satellite symposium at the European Association of Urology, Paris, 25 February 2012</style></title><secondary-title><style face="normal" font="default" size="100%">European Urological Review</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Urological Review</style></full-title></periodical><pages><style face="normal" font="default" size="100%">74-80</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment guidelines</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Recurrent uncomplicated urinary tract infections (rUTIs) are very common and impose a substantial disease burden. Acute episodes can be successfully treated with antibiotics but recurrence occurs in about 20-30 % of adult women within 3-4 months. Historically, antibiotics have been used as prophylaxis against rUTIs but the rise in antibiotic resistance has led to the search for alternative strategies. Such strategies include the use of probiotics and oestradiol, use of immunoactive products and use of plant extracts such as cranberry products, although data to support the efficacy of the latter are inconclusive. The immunoprophylaxis approach involves oral treatment with an extract from 18 uropathogenic strains of Escherichia coli (OM-89, Uro-Vaxom®). OM-89 stimulates the innate and adaptive immune responses against UTI pathogens. Its efficacy and safety has been proven in several clinical trials. Recent guidelines published by the European Association of Urology (EAU) recommend the use of these alternative approaches, in particular OM-89, to prevent recurrence of rUTIs. © Touch Briefings 2012.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871840677&amp;partnerID=40&amp;md5=289c4f6d549079dadeee92fc866db5a5</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>95</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">95</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nabavi, S. F.</style></author><author><style face="normal" font="default" size="100%">Sureda, A.</style></author><author><style face="normal" font="default" size="100%">Daglia, M.</style></author><author><style face="normal" font="default" size="100%">Izadi, M.</style></author><author><style face="normal" font="default" size="100%">Nabavi, S. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran&#xD;Research Group on Community Nutrition and Oxidative Stress, University of Balearic Islands and CIBEROBN (Physiopathology of Obesity and Nutrition), Palma de Mallorca, Balearic Islands, E-07122, Spain&#xD;Department of Drug Sciences, Medicinal Chemistry and Pharmaceutical Technology Section, University of Pavia, Italy&#xD;Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry for urinary tract infection: From bench to bedside</style></title><secondary-title><style face="normal" font="default" size="100%">Current Topics in Medicinal Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Topics in Medicinal Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">331-339</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Antimicrobial effect</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections are common infectious diseases which can occur in any part of the urinary tract such as bladder, kidney, ureters, and urethra. They are commonly caused by bacteria that enter through the urethra. Urinary tract infections commonly develop in the bladder and spread to renal tissues. Up to now, there are different antimicrobial agents which have beneficial role on urinary tract infections. However, most of them cause different adverse effects and therefore, much attention has been paid to the search for effective therapeutic agents with negligible adverse effects. Cranberry is known as one of the most important edible plants, which possesses potent antimicrobial effects against the bacteria responsible for urinary tract infections. Growing evidence has shown that cranberry suppresses urinary tract infections and eradicates the bacteria. Therefore, the aim of this study is to critically review the available literature regarding the antimicrobial activities of cranberry against urinary tract infection microorganisms. In addition, we discuss etiology, epidemiology, risk factors, and current drugs of urinary tract infections to provide a more complete picture of this disease. © 2017 Bentham Science Publishers.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85011977074&amp;doi=10.2174%2f1568026616666160829161031&amp;partnerID=40&amp;md5=44de082916ed48c59533bc46bc96eb49</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2174/1568026616666160829161031</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>103</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">103</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mydock-McGrane, L.</style></author><author><style face="normal" font="default" size="100%">Cusumano, Z.</style></author><author><style face="normal" font="default" size="100%">Han, Z.</style></author><author><style face="normal" font="default" size="100%">Binkley, J.</style></author><author><style face="normal" font="default" size="100%">Kostakioti, M.</style></author><author><style face="normal" font="default" size="100%">Hannan, T.</style></author><author><style face="normal" font="default" size="100%">Pinkner, J. S.</style></author><author><style face="normal" font="default" size="100%">Klein, R.</style></author><author><style face="normal" font="default" size="100%">Kalas, V.</style></author><author><style face="normal" font="default" size="100%">Crowley, J.</style></author><author><style face="normal" font="default" size="100%">Rath, N. P.</style></author><author><style face="normal" font="default" size="100%">Hultgren, S. J.</style></author><author><style face="normal" font="default" size="100%">Janetka, J. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Fimbrion Therapeutics, Inc., Saint Louis, MO 63108, United States&#xD;Departments of Biochemistry and Molecular Biophysics and Chemistry, Washington University, School of Medicine, Saint Louis, MO 63110, United States&#xD;Department of Molecular Microbiology, Washington University, School of Medicine, Saint Louis, MO 63110, United States&#xD;Center for Women&apos;s Infectious Disease Research, Washington University, School of Medicine, Saint Louis, MO 63110, United States&#xD;Department of Chemistry and Biochemistry, University of Missouri, Saint Louis, MO 63121, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antivirulence C-Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Medicinal Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Medicinal Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">9390-9408</style></pages><volume><style face="normal" font="default" size="100%">59</style></volume><number><style face="normal" font="default" size="100%">20</style></number><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Gram-negative uropathogenic Escherichia coli (UPEC) bacteria are a causative pathogen of urinary tract infections (UTIs). Previously developed antivirulence inhibitors of the type 1 pilus adhesin, FimH, demonstrated oral activity in animal models of UTI but were found to have limited compound exposure due to the metabolic instability of the O-glycosidic bond (O-mannosides). Herein, we disclose that compounds having the O-glycosidic bond replaced with carbon linkages had improved stability and inhibitory activity against FimH. We report on the design, synthesis, and in vivo evaluation of this promising new class of carbon-linked C-mannosides that show improved pharmacokinetic (PK) properties relative to O-mannosides. Interestingly, we found that FimH binding is stereospecifically modulated by hydroxyl substitution on the methylene linker, where the R-hydroxy isomer has a 60-fold increase in potency. This new class of C-mannoside antagonists have significantly increased compound exposure and, as a result, enhanced efficacy in mouse models of acute and chronic UTI. © 2016 American Chemical Society.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :19&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84994045694&amp;doi=10.1021%2facs.jmedchem.6b00948&amp;partnerID=40&amp;md5=fa904b1b555d196f5e72fadd27791d0c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/acs.jmedchem.6b00948</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>75</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">75</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Muller, A. E.</style></author><author><style face="normal" font="default" size="100%">Verhaegh, E. M.</style></author><author><style face="normal" font="default" size="100%">Harbarth, S.</style></author><author><style face="normal" font="default" size="100%">Mouton, J. W.</style></author><author><style face="normal" font="default" size="100%">Huttner, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medical Centre Haaglanden-Bronovo, The Hague, Netherlands&#xD;Laboratory of Medical Microbiology and Immunology, St Elisabeth Hospital, Tilburg, Netherlands&#xD;Infection Control Programme, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland&#xD;Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, Netherlands</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nitrofurantoin&apos;s efficacy and safety as prophylaxis for urinary tract infections: a systematic review of the literature and meta-analysis of controlled trials</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Microbiology and Infection</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Microbiology and Infection</style></full-title></periodical><pages><style face="normal" font="default" size="100%">355-362</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Meta-analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Nitrofurantoin</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Toxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Objectives Nitrofurantoin has been used for the prevention of urinary tract infection (UTI) for over 60 years. We conducted a systematic review and meta-analysis to assess its efficacy and safety in the prophylaxis of UTI. Methods We performed a systematic review of all controlled trials in humans assessing nitrofurantoin for UTI prophylaxis published from 1946 to 2015. We further reviewed population-level cohort studies evaluating nitrofurantoin&apos;s toxicity. Meta-analyses assessing efficacy and adverse events were conducted on controlled trials. Results Twenty-six controlled trials including 3052 patients fulfilled entry criteria for the systematic review and meta-analysis on efficacy and toxicity, and 16 population-level cohort studies were identified for review of toxicity. Overall quality was poor, with all studies at increased risk for various biases. When compared with no prophylaxis, nitrofurantoin is effective in the prevention of UTI (risk ratio 0.38 in favour of nitrofurantoin, 95% CI 0.30–0.48). Its prophylactic efficacy is superior to that of methenamine hippurate and comparable to that of other antibacterials. Compared with patients receiving other antibacterials, those receiving nitrofurantoin had an increased risk of 2.24 (95% CI 1.77–2.83) for a non-severe adverse effect. In all controlled trials, only one patient experienced a severe adverse effect (interstitial pneumonia). Cohort studies reported severe adverse effect frequencies of 0.02–1.5 per 1000 nitrofurantoin users. Conclusions Nitrofurantoin is effective in the prevention of UTI. Its use may be associated with increased non-severe adverse effects; severe adverse effects occur infrequently. The risk of severe toxicity seems to increase with the duration of nitrofurantoin prophylaxis. © 2016 European Society of Clinical Microbiology and Infectious Diseases</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :9&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84994715844&amp;doi=10.1016%2fj.cmi.2016.08.003&amp;partnerID=40&amp;md5=2d6d0caff24e7d96f2e2e57da599daf3</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.cmi.2016.08.003</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>192</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">192</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mukherjee, M.</style></author><author><style face="normal" font="default" size="100%">Bandyopadhyay, P.</style></author><author><style face="normal" font="default" size="100%">Kundu, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Periodontics and Oral Implantology, Dr. R. Ahmed Dental College and Hospital, Kolkata, West Bengal, India</style></auth-address><titles><title><style face="normal" font="default" size="100%">Exploring the role of cranberry polyphenols in periodontits: A brief review</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Indian Society of Periodontology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Indian Society of Periodontology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">136-139</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">periodontitis</style></keyword><keyword><style face="normal" font="default" size="100%">proanthocyanidins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry juice polyphenols have gained importance over the past decade due to their promising health benefits. The bioactive component, proanthocyanidins is mainly responsible for its protective effect. A lot has been said about its role in urinary tract infection and other systemic diseases, but little is known about its oral benefits. An extensive search was carried out in the PubMed database using the terms &quot;cranberry polyphenols&quot; and &quot;periodontitis&quot; together. The institute library was also thoroughly scrutinized for all relevant information. Thus, a paper was formulated, the aim of which was to review the role of high molecular weight cranberry fraction on oral tissues and periodontal diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84899705042&amp;doi=10.4103%2f0972-124X.131301&amp;partnerID=40&amp;md5=44ab5b955ff653a91d0476015966f1b2</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.4103/0972-124X.131301</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>16</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">16</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moskowitz, D.</style></author><author><style face="normal" font="default" size="100%">Lee, U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Urology and Renal Transplantation, Virginia Mason Medical Center, Seattle, WA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Patient Distress in Women with Recurrent Urinary Tract Infections: How Can Physicians Better Meet Patients Needs?</style></title><secondary-title><style face="normal" font="default" size="100%">Current Urology Reports</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Urology Reports</style></full-title></periodical><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Patient satisfaction</style></keyword><keyword><style face="normal" font="default" size="100%">Quality of life</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Purpose of Review: Recurrent urinary tract infections are a common condition that can impact patients’ quality of life. The purpose of this review is to summarize and analyze the literature regarding the distress that these infections can cause to patients and provide guidance to clinicians on how to improve care of these patients. Recent Findings: The current literature on patient perspectives in urinary tract infections shows an emotional symptom experience that is not consistent with the typical symptoms expected by clinicians. The infections can impact all aspects of quality of life, including social, emotional, and financial domains. Summary: Women with recurrent urinary tract infections experience a significant amount of distress. They have a strong desire for validation of their experiences by their physicians. Clinicians can best serve these patients by understanding the true impact of their condition and creating treatment strategies that include shared decision making to meet patients’ goals. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055072327&amp;doi=10.1007%2fs11934-018-0849-1&amp;partnerID=40&amp;md5=f5d4404c59b71a5b5a2644c095162a03</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">97</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s11934-018-0849-1</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>97</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">97</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mortaş, H.</style></author><author><style face="normal" font="default" size="100%">Sanlıer, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Gazi University, Faculty of Health Sciences, Nutrition and Dietetics Department, Ankara, 06500, Turkey</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nutritional evaluation of commonly consumed berries: composition and health effects</style></title><secondary-title><style face="normal" font="default" size="100%">Fruits</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Fruits</style></full-title></periodical><pages><style face="normal" font="default" size="100%">5-23</style></pages><volume><style face="normal" font="default" size="100%">72</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antioxidant activity</style></keyword><keyword><style face="normal" font="default" size="100%">Blackberry (Rubus spp.)</style></keyword><keyword><style face="normal" font="default" size="100%">Blackcurrant (Ribes nigrum)</style></keyword><keyword><style face="normal" font="default" size="100%">Blueberry (Vaccinium corymbosum)</style></keyword><keyword><style face="normal" font="default" size="100%">Chokeberry (Aronia spp.)</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry (Vaccinium macrocarpon)</style></keyword><keyword><style face="normal" font="default" size="100%">Lingonberry (Vaccinium vitis-idaea)</style></keyword><keyword><style face="normal" font="default" size="100%">Nutritional value</style></keyword><keyword><style face="normal" font="default" size="100%">Phenolics</style></keyword><keyword><style face="normal" font="default" size="100%">Raspberry (Rubus spp.)</style></keyword><keyword><style face="normal" font="default" size="100%">Strawberry (Fragaria × ananassa)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Introduction – It is well known that berries have beneficial effects on health, owing to their content of phenolic molecules, such as anthocyanin, quercetin and phenolic acid, as well as their content of vitamins, minerals and fiber. There is a gradually increasing body of evidence suggesting that these bioactive molecules have antioxidant, anti-inflammatory, antimicrobial, anticarcinogenic, antimutagenic and neuroprotective effects. Owing to their antioxidant effects, berry consumption brings positive effects against cardiovascular diseases, obesity, ageing and neurodegenerative diseases. Specific objectives – This paper was aimed to highlight natural compounds and health effects of the berries; some mechanisms explored by experimental studies, and to outline human intervention trial. Thus, this review could be useful to develop consumption recommendations and following research in health outcomes. © ISHS 2017</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041016776&amp;doi=10.17660%2fth2017%2f72.1.1&amp;partnerID=40&amp;md5=06d1c5dbc14af6e1b5843a376ba931c7</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.17660/th2017/72.1.1</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>230</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">230</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Morán, E.</style></author><author><style face="normal" font="default" size="100%">Budía, A.</style></author><author><style face="normal" font="default" size="100%">Broseta, E.</style></author><author><style face="normal" font="default" size="100%">Boronat, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Servicio de Urología, Hospital Universitario y Politécnico la Fe, Valencia, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Phytotherapy in urology. Current scientific evidence of its application in urolithiasis, chronic pelvic pain, erectile dysfunction and urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Actas Urologicas Espanolas</style></secondary-title><short-title><style face="normal" font="default" size="100%">Fitoterapia en urología. Evidencia científica actual de su aplicación en urolitiasis, dolor pélvico crónico, disfunción eréctil e infecciones urinarias</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Actas Urologicas Espanolas</style></full-title></periodical><pages><style face="normal" font="default" size="100%">174-180</style></pages><volume><style face="normal" font="default" size="100%">37</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Chronic prostatitis</style></keyword><keyword><style face="normal" font="default" size="100%">Erectile disfuncion</style></keyword><keyword><style face="normal" font="default" size="100%">Phytotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary infection</style></keyword><keyword><style face="normal" font="default" size="100%">Urolithiasis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: To assess the usefulness of phytotherapy in urolitiasis, urinary tract infections, erectile dysfunction (ED) and chronic prostatitis/chronic pelvic pain (CP/CPP). Acquisition of the evidence: Systematic review of the evidence published until January 2011 using the following scientific terms:phytotherapy, urinary lithiasis, Chronic prostatitis, chronic pelvic pain, erectile dysfunction, urinary tract infection, cystitis and the scientific names of compounds following the rules of the International Code of Botanical Nomenclature. The databases used were Medline and The Cochrane Library.We included articles published until January 2011 written in English and Spanish. We included studies in Vitro/in vivo on animal models or human beings. Exclusion criteria were literature not in English and Spanish or articles with serious methodological flaws. Synthesis of the evidence: We included 86 articles selecting 40 that met the inclusion criteria. In Urolitiasis there are few works in humans. The phytate has its main use as prevention and in reducing the growth of residual fragments after extracorporeal shock wave lithotripsy (ESWL). In CP/CPP the only compound that has shown effectiveness was the extract of pollen in a field of multimodal treatment. In DE ther is no evidence for the use of herbal medicine.Most of the works have limitations in the design or low sample size. In urinary tract infections most of the products are diuretics.There is only evidence for the cranberry as prevention in young or pregnant women. It must not be used as a treatment for urinary tract infections. Conclusions: Phytotherapy is usefull in repeat urinary tract infections and the CP/CPP. It has some role in the urolitiasis and lacks useful in the DE. © 2012 AEU.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Short Survey</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84875218477&amp;doi=10.1016%2fj.acuro.2012.07.004&amp;partnerID=40&amp;md5=4b90611fcea20caa945627782e8c7b25</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.acuro.2012.07.004</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>279</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">279</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Montini, G.</style></author><author><style face="normal" font="default" size="100%">Tullus, K.</style></author><author><style face="normal" font="default" size="100%">Hewitt, I.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Azienda Ospedaliero-Universitaria Sant&apos;Orsola-Malpighi, Via Massarenti 11, Padiglione 13, 40138 Bologna, Italy&#xD;Department of Pediatric Nephrology, Great Ormond Street Hospital, London, United Kingdom&#xD;Princess Margaret Hospital for Children, Perth, WA, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Febrile urinary tract infections in children</style></title><secondary-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">239-250</style></pages><volume><style face="normal" font="default" size="100%">365</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :148&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79960574552&amp;doi=10.1056%2fNEJMra1007755&amp;partnerID=40&amp;md5=226e1278b019931d9888422fef9ccd31</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1056/NEJMra1007755</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>453</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">453</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Monroy-Torres, R.</style></author><author><style face="normal" font="default" size="100%">Macías, A. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Facultad de Medicina, Universidad de Guanajuato, 20 de Enero 929, 37320 León, Gto., Mexico&#xD;Hospital General Regional de León, León, Mexico</style></auth-address><titles><title><style face="normal" font="default" size="100%">¿Does cranberry juice have bacteriostatic activity?</style></title><secondary-title><style face="normal" font="default" size="100%">Revista de Investigacion Clinica</style></secondary-title><short-title><style face="normal" font="default" size="100%">¿Es bacteriostático el jugo de arándano?</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Revista de Investigacion Clinica</style></full-title></periodical><pages><style face="normal" font="default" size="100%">442-446</style></pages><volume><style face="normal" font="default" size="100%">57</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bacteriostatic</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">Background. Cranberry juice is used to prevent urinary infections but it is not known if it inhibits bacterial growth in urine or in bacteriologic broth. Objective. Determining if cranberry juice has bacteriostatic properties. Methods. The urine of 20 female university students was studied before and after drinking cranberry juice. Both specimens were submitted to pH determination and inoculated with a control strain of Escherichia coli. After 1 and 2 hours of incubation with the inoculum, the urine specimens were plated on agar to determine their bacterial counts. Additionally, the growth of 10 E. coli strains were studied in broths with serial dilutions of juice. Results. No inhibitory effect on bacterial growth was observed in urine after drinking cranberry juice. After 1 and two hours of incubation with the E. coli inoculum, control urine grew an average 132.2 and 153 × 103 colony-forming units/mL, respectively. After 1 and two hours of incubation with the inoculum, post-intervention urine grew an average 141.4 and 170.6 × 103 CFU/mL, respectively (p &amp;gt; 0.05). Against expectations, an increment was observed in urinary pH after drinking the juice (average pH in controls, 5.8 vs. 6.2 in post-intervention specimens; p = 0.043). In vitro analysis did not find a negative trend of E. coli growth in broths with higher concentrations of juice. Conclusions. Cranberry juice was not associated with bacteriostatic properties and its ingestion was not followed by a drop in urinary pH, which suggests that these are not its potential beneficial effects for the management and the prevention of urinary tract infections.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :12&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-24044468674&amp;partnerID=40&amp;md5=3d4393b45dfedf469306dc42d3d8091d</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>446</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">446</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Monroy-Torres, R.</style></author><author><style face="normal" font="default" size="100%">Macías, A. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Facultad de Medicina de la Universidad de Guanajuato, 20 de Enero 929, 37320 León, Gto., Mexico</style></auth-address><titles><title><style face="normal" font="default" size="100%">Commentary response [3]</style></title><secondary-title><style face="normal" font="default" size="100%">Revista de Investigacion Clinica</style></secondary-title><short-title><style face="normal" font="default" size="100%">Carta al editor</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Revista de Investigacion Clinica</style></full-title></periodical><pages><style face="normal" font="default" size="100%">823-824</style></pages><volume><style face="normal" font="default" size="100%">57</style></volume><number><style face="normal" font="default" size="100%">6</style></number><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Letter</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33646191705&amp;partnerID=40&amp;md5=3006016fd42b442e0585cca6a607241a</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>503</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">503</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Molldrem, K. L.</style></author><author><style face="normal" font="default" size="100%">Tanumihardjo, S. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Intgd. Grad. Prog. in Nutr. Sci., University of Wisconsin-Madison, Madison, WI 53706, United States&#xD;UW-Madison, 1415 Linden Drive, Madison, WI 53706, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lutein supplements are not bioavailable in the Mongolian gerbil while consuming a diet with or without cranberries</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal for Vitamin and Nutrition Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal for Vitamin and Nutrition Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">153-160</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Carotenoids</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberries</style></keyword><keyword><style face="normal" font="default" size="100%">Functional foods</style></keyword><keyword><style face="normal" font="default" size="100%">Lutein</style></keyword><keyword><style face="normal" font="default" size="100%">Mongolian gerbils</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Lutein is a carotenoid that may be involved in the prevention of macular degeneration and is available as supplements. Cranberries are a potential &quot;functional food&quot; due to anti-adhesion and antioxidant properties. This study was designed to determine the bioavailability of lutein supplements in Mongolian gerbils, as prior studies have focused on β-carotene, and to investigate any interactions between a lutein supplement and a diet containing cranberries. Gerbils (n = 28) were divided into treatment groups: lutein + cranberry; lutein + control; cottonseed oil + cranberry; and cottonseed oil + control. The lutein supplement (50 pg lutein in oil) was delivered orally for 14 days, and then blood, livers, and eyes were collected. Samples were analyzed by high-performance liquid chromatography (HPLC) and total antioxidant status was determined. Serum and liver were analyzed for lutein, retinol, and α-tocopherol. Serum lutein concentrations were extremely low in all four groups. Serum total antioxidants did not differ (p &gt; 0.2) among diet groups. Serum retinol concentrations were significantly lower in the cranberry groups (p = 0.0024). In conclusion, gerbils are able to thrive on a high cranberry diet. However, this study showed that lutein as a daily supplement in oil, is not bioavailable in Mongolian gerbils.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :16&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Conference Paper</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-2942707847&amp;doi=10.1024%2f0300-9831.74.2.153&amp;partnerID=40&amp;md5=931c9739c645fdc59c01945e4ddd9741</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1024/0300-9831.74.2.153</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>238</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">238</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Minodier, P.</style></author><author><style face="normal" font="default" size="100%">Bréaud, J.</style></author><author><style face="normal" font="default" size="100%">Bérard, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Urgences enfants, CHU Nord, Chemin des Bourrelly, 13015 Marseille, France&#xD;Urologie pédiatrique, Hôpitaux pédiatriques universitaires de Nice, 57, avenue de la Californie, 06200 Nice, France&#xD;Néphrologie pédiatrique, Hôpitaux pédiatriques universitaires de Nice, 57, avenue de la Californie, 06200 Nice, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">E. coli acute pyelonephritis: Prophylaxis</style></title><secondary-title><style face="normal" font="default" size="100%">Archives de Pediatrie</style></secondary-title><short-title><style face="normal" font="default" size="100%">Pyélonéphrites à E. coli : Stratégies prophylactiques</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archives de Pediatrie</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S117-S123</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">SUPPL. 3</style></number><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">The aim of the prevention of recurrent urinary tract infections in children is to reduce renal scarring, that is associated with hypertension or end-stage renal failure decades latter. However, heterogeneity of the studies prevents clear recommendations. Recent American Academy of Pediatrics meta-analysis failed to demonstrate any effectiveness of antibioprophylaxis in the prevention of recurrent febrile urinary tract infections in infants less than 2 years of age, whatever the presence or the grade of vesicoureteral reflux. Moreover, adverse events of cotrimoxazole, which is the sole antibioprophylaxis available in France, are questionable. Long term low doses of oral cephalosporins or cotrimoxazole are known to select resistant enterobacteriae, producing extended-spectrum beta-lactamases (ESBL) especially. To date, antibioprophylaxis should be discussed with urologists depending on the patient. Other preventive measures as cranberries or pre/ probiotics, are inconclusive. Surgery (or circumcision) depends on the associated uropathy. Dysfunctional elimination syndrome is frequent and has to be recognized and treated. © 2012 Elsevier Masson SAS.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84869746010&amp;doi=10.1016%2fS0929-693X%2812%2971284-8&amp;partnerID=40&amp;md5=d261fd7b8605a19e3e49261ac6204bcc</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0929-693X(12)71284-8</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>464</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">464</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Milo, G.</style></author><author><style face="normal" font="default" size="100%">Katchman, E. A.</style></author><author><style face="normal" font="default" size="100%">Paul, M.</style></author><author><style face="normal" font="default" size="100%">Christiaens, T.</style></author><author><style face="normal" font="default" size="100%">Baerheim, A.</style></author><author><style face="normal" font="default" size="100%">Leibovici, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine E, Rabin Medical Center, Beilinson Campus, Petah-Tiqva, Israel.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Duration of antibacterial treatment for uncomplicated urinary tract infection in women</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane database of systematic reviews (Online)</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane database of systematic reviews (Online)</style></full-title></periodical><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">BACKGROUND: Uncomplicated urinary tract infection (UTI) is a common disease, occurring frequently in young sexually active women. In the past, seven day antibiotic therapy was recommended while the current practice is to treat uncomplicated UTI for three days. OBJECTIVES: TO compare the efficacy and safety of three-day antibiotic therapy to multi-day therapy (five days or longer) on relief of symptoms and bacteriuria at short-term and long-term follow-up. SEARCH STRATEGY: The Cochrane Library (Issue 1, 2004), the Cochrane Renal Group&apos;s Register of trials (July 2003), EMBASE (January 1980 to August 2003), and MEDLINE (January 1966 to August 2003) were searched. We scanned references of all included studies and contacted the first or corresponding author of included trials and the pharmaceutical companies. SELECTION CRITERIA: Randomised controlled trials comparing three-days oral antibiotic therapy with multi-day therapy (five days and longer) for uncomplicated cystitis in 18 to 65 years old non-pregnant women without signs of upper UTI. DATA COLLECTION AND ANALYSIS: Data concerning bacteriological and symptomatic failure rates, occurrence of pyelonephritis and adverse effects were extracted independently by two reviewers. Relative risk (RR) and their 95% confidence intervals (CI) were estimated. Outcomes were also extracted by intention-to-treat analysis whenever possible. MAIN RESULTS: Thirty-two trials (9605 patients) were included. For symptomatic failure rates, no difference between three-day and 5-10 day antibiotic regimen was seen short-term (RR 1.06, 95% CI 0.88 to 1.28) and long-term follow-up (RR 1.09, 95% CI 0.94 to 1.27). Comparison of the bacteriological failure rates showed that three-day therapy was less effective than 5-10 day therapy for the short-term follow-up, however this difference was observed only in the subgroup of trials that used the same antibiotic in the two treatment arms (RR 1.37, 95% CI 1.07 to 1.74, P = 0.01). This difference was more significant at long-term follow-up (RR 1.43, 95% CI 1.19 to 1.73, P = 0.0002). Adverse effects were significantly more common in the 5-10 day treatment group (RR 0.83, 95% CI 0.74 to 0.93, P = 0.0010). Results were consistent for subgroup and sensitivity analyses. AUTHORS&apos; CONCLUSIONS: Three days of antibiotic therapy is similar to 5-10 days in achieving symptomatic cure during uncomplicated UTI treatment, while the longer treatment is more effective in obtaining bacteriological cure. In spite of the higher rate of adverse effects, treatment for 5-10 days could be considered for treatment of women in whom eradication of bacteriuria is important.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :72&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-21844444136&amp;partnerID=40&amp;md5=0d75f68095e91816593d717d6140c6e4</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>535</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">535</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Millán Rodríguez, F.</style></author><author><style face="normal" font="default" size="100%">Rousaud Baron, F.</style></author><author><style face="normal" font="default" size="100%">Rousaud Barón, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Servicio de Urología, Fundación Puigvert, C/ Cartagena, 340-350, 08025 Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Model study of the treatment of recurrent cystitis in women by means of AM3 (Inmunoferon®)</style></title><secondary-title><style face="normal" font="default" size="100%">Actas Urologicas Espanolas</style></secondary-title><short-title><style face="normal" font="default" size="100%">Estudio piloto del tratamiento coadyuvante de la cistitis recidivante de la mujer mediante AM3 (Inmunoferon®)</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Actas Urologicas Espanolas</style></full-title></periodical><pages><style face="normal" font="default" size="100%">196-201</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">AM3</style></keyword><keyword><style face="normal" font="default" size="100%">Inmunoferon®</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent cystitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">OBJECTIVES: The aim is to evaluate the effectiveness of AM3 (Inmunoferon®) in the treatment of the recurrent cystitis in women in order to know the rate of good results, previously to design a clinical trial. MATERIAL AND METHODS: Twenty-four women who had been diagnosed of two cystitis episodes in the previous 6 months without cure by antibiotic treatment were admitted to the study. Standard antibiotic treatment and 3 daily grammes of AM3 was given for 9 months. Infection and irritative symptoms during micturition rate were evaluated at the inclusion date and afterwards, at the first, third, sixth and nineth month. RESULTS: Nineteen patients finished the study. The infection rate decreased from 100% at the inclusion date to 26% in the first month and then it became stable about 50%. Irritative symptoms during micturition decreased from 46% at the inclusion date to a rate lower than 10% in the 4 controls running. CONCLUSION: AM3 reduced evident urinary infection in a 50% and irritative symptoms during micturition in a 90%. Control clinical trials are needed to confirm the AM3 effects on this pathology.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038287745&amp;partnerID=40&amp;md5=edccc55d5207756df6f26763a3b5b128</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>215</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">215</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Milart, P.</style></author><author><style face="normal" font="default" size="100%">Woźniakowska, E.</style></author><author><style face="normal" font="default" size="100%">Woźniak, S.</style></author><author><style face="normal" font="default" size="100%">Palacz, T.</style></author><author><style face="normal" font="default" size="100%">Czuczwar, P.</style></author><author><style face="normal" font="default" size="100%">Wrona, W.</style></author><author><style face="normal" font="default" size="100%">Szkodziak, P.</style></author><author><style face="normal" font="default" size="100%">Paszkowski, M.</style></author><author><style face="normal" font="default" size="100%">Paszkowski, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">III Katedra i Klinika Ginekologii, Uniwersytetu Medycznego, ul. Jaczewskiego 8, 20-094 Lublin, Poland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections in the menopausal period: Optimal management</style></title><secondary-title><style face="normal" font="default" size="100%">Przeglad Menopauzalny</style></secondary-title><short-title><style face="normal" font="default" size="100%">Infekcje układu moczowego w okresie menopauzy - Prawidłowe postȩpowanie</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Przeglad Menopauzalny</style></full-title></periodical><pages><style face="normal" font="default" size="100%">23-28</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Menopause</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTI) are among the most common infectious diseases in women. They are observed particularly frequently in two groups of patients at different life stages, i.e., in young and sexually active women, and in postmenopausal women. This paper summarizes the current state of knowledge in the field of treatment of postmenopausal UTI. Uncomplicated cystitis is a complex illness of multifactorial etiology, and various risk factors have to be considered during woman&apos;s lifespan. In the postmenopause, well-known UTI risk factors are post-voiding residual urine, reduced urinary flow, urinary incontinence and pelvic floor dysfunction. Behavioral risk factors should also be considered. The drop of estrogens concentration typical of menopause may suggest the auxiliary management option in cases of UTI in this age group. On the basis of recent literature review, the following conclusions seem to be justified: • The great majority of uncomplicated urinary tract infections in women are caused by Escherichia coli, independent of the patient&apos;s hormonal status. • Fosfomycin, nitrofurantoin, ciprofloxacin and amox-clavulanate are most commonly recommended in empirical therapy of UTI in postmenopausal women. In many cases ultra-short and short protocols are preferable because of better compliance and tolerability. • Systemic menopausal hormonal therapy does not provide effective prophylaxis of cystitis in menopausal women. • Asymptomatic bacteriuria in postmenopausal women usually does not require any therapy. • Adherence inhibition to urothelial cells and protection against biofilm formation are the key mechanisms of the antiuroseptic treatment especially with respect to the risk of recurrent UTIs.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84877268546&amp;doi=10.5114%2fpm.2013.33417&amp;partnerID=40&amp;md5=274812c5197b49f4b8932ee5aa155075</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.5114/pm.2013.33417</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>610</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">610</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Michaels, E. K.</style></author><author><style face="normal" font="default" size="100%">Chmiel, J. S.</style></author><author><style face="normal" font="default" size="100%">Plotkin, B. J.</style></author><author><style face="normal" font="default" size="100%">Schaeffer, A. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Northwestern University Medical School, Chicago, Illinois, United States&#xD;Department of Community Health and Preventive Medicine, Cancer Center Biometry Section, Northwestern University Medical School, Chicago, Illinois, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of D-mannose and D-glucose on Escherichia coli bacteriuria in rats</style></title><secondary-title><style face="normal" font="default" size="100%">Urological Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Urological Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">97-102</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adherence</style></keyword><keyword><style face="normal" font="default" size="100%">D-mannose</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Rats</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1983</style></year></dates><abstract><style face="normal" font="default" size="100%">The effect of D-mannose and D-glucose on bacteriuria due to Escherichia coli with mannose-sensitive adhesins was investigated in adult male Sprague-Dawley rats undergoing diuresis. Inocula of 105, 107, or 108 bacteria in 0.1 ml of normal saline or 2.5% or 10% D-mannose or D-glucose were injected intravesically and urine was cultured 1, 3, 5, 7 and 9 days later. The levels of bacteriuria on days 1 and 5 were significantly lower in rats inoculated with 105E. coli and 10% D-mannose than in controls (p&amp;lt;0.05 and 0.01 respectively) and the percentages of rats with &amp;lt; 100 bacteria/ml were higher on days 1 and 3 (p=0.05 and 0.02 respectively). Bacteriuria was significantly lower in rats inoculated with 107 bacteria and 10% D-mannose than in controls on days 5 and 7 (p&amp;lt;0.01 for each day) and the percentage of rats with &amp;lt;100 bacteria/ml was higher on day 7 (p=0.01). D-glucose reduced bacteriuria significantly only with a concentration of 10% after instillation of 105E. coli (p&amp;lt;0.05, day 1). The results indicate that D-mannose and D-glucose can significantly reduce bacteriuria within 1 day and that their efficacy is dependent upon the concentration of both saccharide and bacteria. © 1983 Springer-Verlag.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :16&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0020614670&amp;doi=10.1007%2fBF00256954&amp;partnerID=40&amp;md5=9292d65960f3883c0d65ebb5909b80f0</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/BF00256954</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>217</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">217</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Michael Allan, G.</style></author><author><style face="normal" font="default" size="100%">Nicolle, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Family Medicine, University of Alberta, Edmonton, Canada&#xD;Department of Internal Medicine and Medical Microbiology, University of Manitoba, Winnipeg, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry for preventing urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">Canadian Family Physician</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Canadian Family Physician</style></full-title></periodical><pages><style face="normal" font="default" size="100%">367</style></pages><volume><style face="normal" font="default" size="100%">59</style></volume><number><style face="normal" font="default" size="100%">4</style></number><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Note</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84876210713&amp;partnerID=40&amp;md5=043da84aa0a36f890fd63dd8ee827c9c</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>195</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">195</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Micali, S.</style></author><author><style face="normal" font="default" size="100%">Isgro, G.</style></author><author><style face="normal" font="default" size="100%">Bianchi, G.</style></author><author><style face="normal" font="default" size="100%">Miceli, N.</style></author><author><style face="normal" font="default" size="100%">Calapai, G.</style></author><author><style face="normal" font="default" size="100%">Navarra, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, University of Modena and Reggio Emilia, Modena, Italy&#xD;Department of Drug Sciences and Health Products, University of Messina, Messina, Italy&#xD;Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy&#xD;IRCCS Centro Neurolesi Bonino-Pulejo, Messina, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry and Recurrent Cystitis: More than Marketing?</style></title><secondary-title><style face="normal" font="default" size="100%">Critical Reviews in Food Science and Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Critical Reviews in Food Science and Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1063-1075</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">phytotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">proanthiocyanidine</style></keyword><keyword><style face="normal" font="default" size="100%">recurrent cystitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Epidemiologic studies indicate that millions of people suffer from recurrent cystitis, a pathology requiring antibiotic prophylaxis and entailing high social costs. Cranberry is a traditional folk remedy for cystitis and, which, in the form of a variety of products and formulations has over several decades undergone extensive evaluation for the management of urinary tract infections (UTI). The aim of this retrospective study is to summarize and review the most relevant and recent preclinical and clinical studies on cranberries for the treatment of UTIs. The scientific literature selected for this review was identified by searches of Medline via PubMed. A variety of recent experimental evidence has shed light on the mechanism underlying the anti-adhesive properties of proanthrocyanidins, their structure-activity relationships, and pharmacokinetics. Analysis of clinical studies and evaluation of the cranberry efficacy/safety ratio in the prevention of UTIs strongly support the use of cranberry in the prophylaxis of recurrent UTIs in young and middle-aged women. However, evidence of its clinical use among other patients remains controversial. © 2014 Copyright Taylor and Francis Group, LLC.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :27&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84893625419&amp;doi=10.1080%2f10408398.2011.625574&amp;partnerID=40&amp;md5=efb2998f8e72a3bb563628081e4c6b35</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/10408398.2011.625574</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>56</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">56</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Miao, M.</style></author><author><style face="normal" font="default" size="100%">Liu, Y. X.</style></author><author><style face="normal" font="default" size="100%">Hu, M. M.</style></author><author><style face="normal" font="default" size="100%">Yue, T. L.</style></author><author><style face="normal" font="default" size="100%">Yuan, Y. H.</style></author><author><style face="normal" font="default" size="100%">Cai, R.</style></author><author><style face="normal" font="default" size="100%">Wang, Z. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">College of Food Science and Engineering, Laboratory of Quality &amp; Safety Risk Assessment for Agro-products (YangLing), Ministry of Agriculture, National Engineering Research Center of Agriculture Integration Test (Yangling), Northwest A&amp;F University, Yangling, Shaanxi 712100, China</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antimicrobial Activity of Polyphenols from Black Chokeberry</style></title><secondary-title><style face="normal" font="default" size="100%">Modern Food Science and Technology</style></secondary-title><short-title><style face="normal" font="default" size="100%">黑果腺肋花楸多酚的抑菌活性研究</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Modern Food Science and Technology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">56-60</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antimicrobial activity</style></keyword><keyword><style face="normal" font="default" size="100%">Black chokeberry</style></keyword><keyword><style face="normal" font="default" size="100%">Minimum inhibitory concentration (MIC)</style></keyword><keyword><style face="normal" font="default" size="100%">Polyphenols</style></keyword><keyword><style face="normal" font="default" size="100%">Stability</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">The antimicrobial activity and antibacterial stability of polyphenols from black chokeberry on five kinds of bacteria and two kinds of fungi were investigated in this study. The bacteriostatic activity of polyphenols from black chokeberry was determined according to the diameter of bacteriostasis zone by double-layer plate perforating method. The minimum inhibitory concentrations (MICs) of polyphenols from black chokeberry against five bacteria were determined by spectrophotometry method. The effects of salt concentration, temperature and UV irradiation on the antibacterial stability of polyphenols from black chokeberry were investigated by using Alicyclobacillus and Bacillus subtilis as indicator bacteria. The results showed that the polyphenols from black chokeberry had good antibacterial activities against five kinds of bacteria, such as Alicyclobacillus and Bacillus subtilis, but no antibacterial effect on the two kinds of fungi. The MIC of polyphenols from black chokeberry against Alicyclobacillus (DSM 3922, AAT-92) and Enterobacter cloacae (20051) was 0.40 g/L, and the MICs of polyphenols from black chokeberry against Bacillus subtilis (10034) and Enterobacter aerogenes (10017) were 0.05 g/L and 0.10 g/L, respectively. With the increase of NaCl concentration, the antimicorbial activity of polyphenols from black chokeberry decreased significantly. After the heat treatment, the antibacterial activity of polyphenols from black chokeberry decreased slightly, and the antibacterial activity did not change after UV treatment. © 2017, Editorial Board of Modern Food Science and Technology. All right reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055640957&amp;doi=10.13982%2fj.mfst.1673-9078.2017.12.009&amp;partnerID=40&amp;md5=9aabe2ecf12aca64f462cfd10deac750</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.13982/j.mfst.1673-9078.2017.12.009</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>292</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">292</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Meyer, A. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universität Wien, Institut für Ernährungswissenschaften, Althanstraße 14, 1090 Wien, Austria</style></auth-address><titles><title><style face="normal" font="default" size="100%">Health-promoting properties of the American cranberry (Vaccinium macrocarpon) and products thereof: Urinary tract infections and other aspects</style></title><secondary-title><style face="normal" font="default" size="100%">Ernahrung</style></secondary-title><short-title><style face="normal" font="default" size="100%">Gesundheitsfördernde effekte der Amerikanischen Kranbeere (Vaccinium macrocarpon) und daraus hergestellter produkte: Harnwegsinfektionen und weitere aspekte</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Ernahrung</style></full-title></periodical><pages><style face="normal" font="default" size="100%">111-114</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bioactive plant compounds</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberries</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidines</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">The preventive effects of American cranberries (Vaccinium macrocarpon) on urinary tract infections are well established. The main active agents are proanthocyanidines, polyphenolic compounds that are abundant in cranberries. They contain the less common A-type molecules that hinder bacterial adhesion. Moreover, these and other related compounds such as anthocyanins and flavanoids are important antioxidants and thus, could contribute to the prevention of cardiovascular diseases and cancer as has been suggested by a number of studies. Considering the limited availability of fresh berries and their tartness, cranberry extracts in capsules can facilitate regular consumption.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84859649111&amp;partnerID=40&amp;md5=ef6dcfc6437252835d7a8b781185f7cf</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>13</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">13</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mehta, I.</style></author><author><style face="normal" font="default" size="100%">Zimmern, P.</style></author><author><style face="normal" font="default" size="100%">Reitzer, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biological Sciences, UT Dallas, Richardson, TX 75080, United States&#xD;Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390-9110, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Enzymatic assay of Dmannose from urine</style></title><secondary-title><style face="normal" font="default" size="100%">Bioanalysis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bioanalysis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1947-1954</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">23</style></number><keywords><keyword><style face="normal" font="default" size="100%">enzymatic analysis</style></keyword><keyword><style face="normal" font="default" size="100%">mannose</style></keyword><keyword><style face="normal" font="default" size="100%">methodology</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">urine</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Aim: Urinary tract infections (UTIs) are increasingly antibiotic resistant, and alternate or adjunct therapies are urgently needed. Several studies suggest that D mannose ingestion and a hypothesized increase in urinary Dmannose reduce UTI frequency. Our goal was to develop a reliable assay for urinary Dmannose, which is needed to assess the effects of supplemental Dmannose on urinary Dmannose and UTIs. Results: We developed an enzymatic assay for Dmannose in urine. Hexoses in urine were phosphorylated, sequentially isomerized and oxidized, and the increases in reduced NADPH were measured in a spectrophotometer. Urinary mannose from ten volunteers was well above the detection limit and ranged from 8 to 700 μM. Conclusion: A rapid, reliable, and sensitive assay was developed, readily detected urinary Dmannose, and is adaptable to highthroughput analysis. If urinary Dmannose is shown to correlate with susceptibility to UTIs, then the assay could assess susceptibility to UTIs and direct mannose therapy. © 2018 2018 Newlands Press.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058138445&amp;doi=10.4155%2fbio-2018-0121&amp;partnerID=40&amp;md5=7b008187b169efc5fe77f8ac3b0d1272</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.4155/bio-2018-0121</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>452</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">452</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McMurdo, M. E. T.</style></author><author><style face="normal" font="default" size="100%">Bissett, L. Y.</style></author><author><style face="normal" font="default" size="100%">Price, R. J. G.</style></author><author><style face="normal" font="default" size="100%">Phillips, G.</style></author><author><style face="normal" font="default" size="100%">Crombie, I. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Section of Ageing and Health, Division of Medicine and Therapeutics, University of Dundee, Dundee DD1 9SY, United Kingdom&#xD;Department of Medical Microbiology, Section of Public Health, University of Dundee, Dundee DD1 9SY, United Kingdom&#xD;Division of Community Health Sciences, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Does ingestion of cranberry juice reduce symptomatic urinary tract infections in older people in hospital? A double-blind, placebo-controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Age and Ageing</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Age and Ageing</style></full-title></periodical><pages><style face="normal" font="default" size="100%">256-261</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry juice</style></keyword><keyword><style face="normal" font="default" size="100%">Elderly</style></keyword><keyword><style face="normal" font="default" size="100%">Hospital</style></keyword><keyword><style face="normal" font="default" size="100%">Randomised clinical trial</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Cranberry juice is often given to older people in hospital to prevent urinary tract infection (UTI), although there is little evidence to support its use. Objective: To assess whether cranberry juice ingestion is effective in reducing UTIs in older people in hospital. Design: Randomised, placebo-controlled, double-blind trial. Setting: Medicine for the Elderly assessment and rehabilitation hospital wards. Subjects: 376 older patients in hospital. Methods: Participants were randomised to daily ingestion of 300 ml of cranberry juice or matching placebo beverage. The primary outcome was time to onset of first UTI. Secondary outcomes were adherence to beverage drinking, courses of antibiotics prescribed, and organisms responsible for UTIs. Results: A total of 21/376 (5.6%) participants developed a symptomatic UTI: 14/189 in the placebo group and 7/187 in the cranberry juice group. These between-group differences were not significant, relative risk (RR) 0.51 [95% CI 0.21-1.22, P=0.122). Although there were significantly fewer infections with Escherichia coli in the cranberry group (13 versus 4) RR 0.31 [95% CI 0.10-0.94, P=0.027], this should be interpreted with caution as it was a secondary outcome. Conclusion: Despite having the largest sample size of any clinical trial yet to have examined the effect of cranberry juice ingestion, the actual infection rate observed was lower than anticipated, making the study underpowered. This study has confirmed the acceptability of cranberry juice to older people. Larger trials are now required to determine whether it is effective in reducing UTIs in older hospital patients. © The Author 2005. Published by Oxford University Press on behalf of the British Geriatrics Society.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :79&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-19044399866&amp;doi=10.1093%2fageing%2fafi101&amp;partnerID=40&amp;md5=3dfb0b6f25bc0698262d9dad7fc9ab84</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/ageing/afi101</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>344</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">344</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McMurdo, M. E. T.</style></author><author><style face="normal" font="default" size="100%">Argo, I.</style></author><author><style face="normal" font="default" size="100%">Phillips, G.</style></author><author><style face="normal" font="default" size="100%">Daly, F.</style></author><author><style face="normal" font="default" size="100%">Davey, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Medicine and Therapeutics, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, United Kingdom&#xD;Department of Medical Microbiology NHS Tayside, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, United Kingdom&#xD;Division of Community Health Sciences, Ninewells Hospital and Medical School, University of Dundee, Mackenzie Building, Dundee DD1 9SY, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? A randomized controlled trial in older women</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Antimicrobial Chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Antimicrobial Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">389-395</style></pages><volume><style face="normal" font="default" size="100%">63</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary infections</style></keyword><keyword><style face="normal" font="default" size="100%">UTIs</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Objectives: To compare the effectiveness of cranberry extract with low-dose trimethoprim in the prevention of recurrent urinary tract infections (UTIs) in older women. Patients and methods: One hundred and thirty-seven women with two or more antibiotic-treated UTIs in the previous 12 months were randomized to receive either 500 mg of cranberry extract or 100 mg of trimethoprim for 6 months. Trial registration: ISRCTN80031108. Results: Thirty-nine of 137 participants (28%) had an antibiotic-treated UTI (25 in the cranberry group and 14 in the trimethoprim group); difference in proportions relative risk 1.616 (95% CI: 0.93, 2.79) P=0.084. The time to first recurrence of UTI was not significantly different between the groups (P=0.100). The median time to recurrence of UTI was 84.5 days for the cranberry group and 91 days for the trimethoprim group (U=166, P=0.479). There were 17/137 (12%) withdrawals from the study, 6/69 (9%) from the cranberry group and 11/68 (16%) from the trimethoprim group (P=0.205), with a relative risk of withdrawal from the cranberry group of 0.54 (95% CI: 0.19, 1.37). Conclusions: Trimethoprim had a very limited advantage over cranberry extract in the prevention of recurrent UTIs in older women and had more adverse effects. Our findings will allow older women with recurrent UTIs to weigh up with their clinicians the inherent attractions of a cheap, natural product like cranberry extract whose use does not carry the risk of antimicrobial resistance or super-infection with Clostridium difficile or fungi. © The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :93&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-58849110888&amp;doi=10.1093%2fjac%2fdkn489&amp;partnerID=40&amp;md5=b8da170f83ab55f26e064fb3eca4b458</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/jac/dkn489</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>500</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">500</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McLaughlin, S. P.</style></author><author><style face="normal" font="default" size="100%">Carson, C. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Urology, Department of Surgery, Univ. of North Carolina Hospitals, Chapel Hill, NC 27599-7235, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections in women</style></title><secondary-title><style face="normal" font="default" size="100%">Medical Clinics of North America</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Medical Clinics of North America</style></full-title></periodical><pages><style face="normal" font="default" size="100%">417-429</style></pages><volume><style face="normal" font="default" size="100%">88</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections in female patients are exceedingly common. One third of all women with an initial UTI demonstrate recurrence, and one third of those recurrences are in the first 6 months. The potential morbidity of RUTIs is high, especially in infants, the elderly, and pregnant patients. Uropathogenic bacteria reside in the rectal vault, colonize the vagina, and then ascend per the urethra into the bladder. These bacteria avidly adhere to uroepithelial cells using pili and can further ascend to the kidneys. Empiric treatment of an initial uncomplicated UTI is acceptable, but recurrences warrant a urine culture and possible radiographic evaluation. Fluoroquinolones are now first-line medications for UTIs, except in geographic areas where resistance to TMP-SMX is still low. Response to therapy should govern the need for additional treatment. Certain motivated patients with three or more UTIs per year should be considered for prophylaxis therapy.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :34&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-1242314714&amp;doi=10.1016%2fS0025-7125%2803%2900148-2&amp;partnerID=40&amp;md5=73141b8443671a216b38858d49014f90</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0025-7125(03)00148-2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>143</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">143</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McKibben, M. J.</style></author><author><style face="normal" font="default" size="100%">Seed, P.</style></author><author><style face="normal" font="default" size="100%">Ross, S. S.</style></author><author><style face="normal" font="default" size="100%">Borawski, K. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States&#xD;Division of Infectious Disease, Department of Pediatrics, Duke University Medical Center, Durham, NC, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary Tract Infection and Neurogenic Bladder</style></title><secondary-title><style face="normal" font="default" size="100%">Urologic Clinics of North America</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Urologic Clinics of North America</style></full-title></periodical><pages><style face="normal" font="default" size="100%">527-536</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotic prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Antimicrobial resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial interference</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenic bladder</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Spina bifida</style></keyword><keyword><style face="normal" font="default" size="100%">Spinal cord injury</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTIs) are frequent, recurrent, and lifelong for patients with neurogenic bladder and present challenges in diagnosis and treatment. Patients often present without classic symptoms of UTI but with abdominal or back pain, increased spasticity, and urinary incontinence. Failure to recognize and treat infections can quickly lead to life-threatening autonomic dysreflexia or sepsis, whereas overtreatment contributes to antibiotic resistance, thus limiting future treatment options. Multiple prevention methods are used but evidence-based practices are few. Prevention and treatment of symptomatic UTI requires a multimodal approach that focuses on bladder management as well as accurate diagnosis and appropriate antibiotic treatment. © 2015 Elsevier Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :12&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84945444787&amp;doi=10.1016%2fj.ucl.2015.05.006&amp;partnerID=40&amp;md5=a00721903bc8f1ee93a913b58933bc9d</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ucl.2015.05.006</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>510</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">510</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McHarg, T.</style></author><author><style face="normal" font="default" size="100%">Rodgers, A.</style></author><author><style face="normal" font="default" size="100%">Charlton, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Nutrition and Dietetics Division, Department of Medicine, Cape Town, South Africa&#xD;Department of Chemistry, University of Cape Town, Cape Town, South Africa&#xD;Department of Chemistry, University of Cape Town, Cape Town 7701, South Africa</style></auth-address><titles><title><style face="normal" font="default" size="100%">Influence of cranberry juice on the urinary risk factors for calcium oxalate kidney stone formation</style></title><secondary-title><style face="normal" font="default" size="100%">BJU International</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BJU International</style></full-title></periodical><pages><style face="normal" font="default" size="100%">765-768</style></pages><volume><style face="normal" font="default" size="100%">92</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Calcium oxalate</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry juice</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney stones</style></keyword><keyword><style face="normal" font="default" size="100%">Oxalate</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary risk factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To investigate the potential influence of cranberry juice on urinary biochemical and physicochemical risk factors associated with the formation of calcium oxalate kidney stones, as this product might affect the chemical composition of urine. SUBJECTS AND METHODS: Urinary variables were assessed in a randomized cross-over trial in 20 South African men (students) with no previous history of kidney stones. The first group of 10 subjects drank 500 ml of cranberry juice diluted with 1500 ml tap water for 2 weeks, white the second group drank 2000 mL of tap water for the same period. This was followed by a 2-week &apos;washout&apos; period before the two groups crossed over. During the experimental phase subjects kept a 3-day food diary to assess their dietary and fluid intakes; 24-h urine samples were collected at baseline and on day 14 of the trial periods, and analysed using modern laboratory techniques. Urine analysis data were used to calculate the relative urinary supersaturations of calcium oxalate, uric acid and calcium phosphate. Data were assessed statistically by analysis of variance. RESULTS The ingestion of cranberry juice significantly and uniquely altered three key urinary risk factors. Oxalate and phosphate excretion decreased while citrate excretion increased. In addition, there was a decrease in the relative supersaturation of calcium oxalate, which tended to be significantly lower than that induced by water alone. CONCLUSION: Cranberry juice has antilithogenic properties and, as such, deserves consideration as a conservative therapeutic protocol in managing calcium oxalate urolithiasis.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :67&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0345689563&amp;doi=10.1046%2fj.1464-410X.2003.04472.x&amp;partnerID=40&amp;md5=ddc8d9df2c8d8fb5b77acb0a2e28248c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1046/j.1464-410X.2003.04472.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>530</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">530</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">McEwen, L. N.</style></author><author><style face="normal" font="default" size="100%">Farjo, R.</style></author><author><style face="normal" font="default" size="100%">Foxman, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Epidemiology, Univ. of MI School of Public Health, Ann Arbor, MI, United States&#xD;Department of Epidemiology, 109 Observatory St., Ann Arbor, MI 48109-2029, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antibiotic prescribing for cystitis: How well does it match published guidelines?</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Epidemiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Epidemiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">479-483</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotic Resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Drug Therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">PURPOSE: Cystitis is one of the most common bacterial infections seen by physicians in outpatient settings. Published clinical guidelines by the Infectious Disease Society of America and other organizations have been established to enable effective treatment, while attempting to decrease cost and limit antibiotic resistance. METHODS: Insurance claims data for employees and dependents of a single Midwest corporation, with Preferred Provider Organization coverage, diagnosed with cystitis between 1996 and 1999 were matched to prescription drug claims for those who filled an antibiotic prescription within 3 days of diagnosis. RESULTS: For acute and recurrent cystitis physicians prescribed trimethoprim-sulfamethoxazole 37% and 18% respectively. The other most common antibiotics prescribed were the broad-spectrum flouroquinolones, and nitrofurantoin. The mean duration for these prescriptions was 10 days regardless of whether the infection was acute or recurrent. CONCLUSIONS: The first line recommended antibiotic, trimethoprim-sulfamethoxazole, was prescribed in 37% of acute infections, and for considerably longer than the suggested 3-day course of therapy. Steps should be taken to educate physicians and patients on the choice and dosage of antibiotics for cystitis to minimize emergence of antibiotic resistance. © 2003 Elsevier Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :26&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037485612&amp;doi=10.1016%2fS1047-2797%2803%2900009-7&amp;partnerID=40&amp;md5=c4a23049f7c04caa5fc59b678630d540</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S1047-2797(03)00009-7</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>542</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">542</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mazzulli, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Mount Sinai Hospital, Department of Microbiology, University of Toronto, Toronto, Ont., Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Resistance trends in urinary tract pathogens and impact on management</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1720-1722</style></pages><volume><style face="normal" font="default" size="100%">168</style></volume><number><style face="normal" font="default" size="100%">4 II</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bacteria, antibiotics, drug resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><abstract><style face="normal" font="default" size="100%">Purpose: The prevalence of antimicrobial resistance among urinary tract pathogens is reviewed and its clinical impact on management is determined. Materials and Methods: A Medline search supplemented with references quoted in bibliographies of articles on urinary tract infections, epidemiology of antimicrobial resistance among uropathogens and clinical outcomes in urinary tract infections was conducted. Results: Although some geographic variation is noted in resistance rates among urinary tract Escherichia coli isolates, rates were highest for ampicillin (39% to 45%) and trimethoprim-sulfamethoxazole (14% to 31.4%) and lowest for nitrofurantoin (1.8% to 16%) and fluoroquinolones (0.7% to 10%). Resistance rates also varied based on patient age. A few studies suggested that antimicrobial resistance impacts clinical and bacteriological outcome but the results are limited by the small number of patients. A randomized trial in women with acute uncomplicated pyelonephritis indicated that those treated with trimethoprim-sulfamethoxazole had a clinical and bacteriological success rate that was significantly lower in those patients treated with this drug when the infecting organism was resistant compared to those in whom the organism was susceptible to trimethoprim-sulfamethoxazole. Conclusions: Resistance rates among common uropathogens continue to evolve and appear to be increasing to many commonly used agents. Continued surveillance of resistance rates among uropathogens is needed to ensure that appropriate recommendations can be made for treatment of infected patients. Further studies addressing the clinical and bacteriological outcomes of patients infected with a resistant pathogen are needed.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :71&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Conference Paper</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036784223&amp;partnerID=40&amp;md5=0ea387ddaf07dc6a1f402f41c12290a8</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>243</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">243</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mazutti, K.</style></author><author><style face="normal" font="default" size="100%">Alberton, G. C.</style></author><author><style face="normal" font="default" size="100%">Ferreira, F. M.</style></author><author><style face="normal" font="default" size="100%">Lunardon, I.</style></author><author><style face="normal" font="default" size="100%">Zotti, E.</style></author><author><style face="normal" font="default" size="100%">Weber, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">UFPR, Brazil&#xD;PUC-PR Campus Toledo, Brazil&#xD;PUC-PR Campus São José dos Pinhais, Brazil</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of cranberry extract in the treatment of urinary tract infections in sows</style></title><secondary-title><style face="normal" font="default" size="100%">Archives of Veterinary Science</style></secondary-title><short-title><style face="normal" font="default" size="100%">Efeito do extrato de oxicoco no tratamento de infecções do trato urinário em porcas</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archives of Veterinary Science</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-9</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bacterial count</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Ph</style></keyword><keyword><style face="normal" font="default" size="100%">Urinalysis</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary acidifiers</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">The experiment consisted in assessing the effectiveness of a commercial product based on cranberry extracts (pHD® - Biomin LTDA) in the treatment of urinary tract infections (UTI) in sows. Were used 42 sows, with gestational ages ranging between 50 and 70 days, either suffering from UTI or not. Healthy animals were differentiated from affected animals by urinalysis and urine culture. The experiment was composed of sows with UTI that received the cranberry extract product in the diet for a period of 14 days; sows negative for UTI (negative controls) and sows positive for UTI (positive controls). The former two groups did not receive the cranberry extract product in the diet. Urine samples were collected on days zero, seven and 14 after initiation of treatment. Complete urinalysis of these samples, urine specific gravity, pH, bacterial count and bacterial isolation were performed. E. coli was the most frequent isolated agent (90,62%). The results showed that the commercial product made with cranberry extract was effective in promoting a reduction of urinary pH, but did not interfere in any other parameters observed.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84865362357&amp;partnerID=40&amp;md5=399ebd4d868a7e7ced922a880227153f</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>126</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">126</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Matulay, J. T.</style></author><author><style face="normal" font="default" size="100%">Mlynarczyk, C. M.</style></author><author><style face="normal" font="default" size="100%">Cooper, K. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Columbia University Medical Center, 161 Fort Washington Ave 11th Floor, New York, NY 10032, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary Tract Infections in Women: Pathogenesis, Diagnosis, and Management</style></title><secondary-title><style face="normal" font="default" size="100%">Current Bladder Dysfunction Reports</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Bladder Dysfunction Reports</style></full-title></periodical><pages><style face="normal" font="default" size="100%">53-60</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotic use in UTIs</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTIs) in women represent one of the most common disease entities in both the ambulatory and hospital setting. Nearly 60 % of all women will experience at least one UTI in their lifetime leading to billions of dollars of healthcare spending. There are several important factors on both a pathogen and host level that support bacterial colonization with ultimate progression to infection in otherwise healthy patients. In an era of increasing healthcare costs and limited face-to-face evaluation time, establishing the correct diagnosis can prove challenging and leads to misguided and sometimes excessive treatment. Ultimately, a stronger focus on preventative strategies may help to reduce the impact of uncomplicated UTIs on women. © 2016, Springer Science+Business Media New York.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84961639833&amp;doi=10.1007%2fs11884-016-0351-x&amp;partnerID=40&amp;md5=b25603e8cde859358a142c36f5ba40cb</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s11884-016-0351-x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>565</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">565</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Matsumoto, H.</style></author><author><style face="normal" font="default" size="100%">Inaba, H.</style></author><author><style face="normal" font="default" size="100%">Kishi, M.</style></author><author><style face="normal" font="default" size="100%">Tominaga, S.</style></author><author><style face="normal" font="default" size="100%">Hirayama, M.</style></author><author><style face="normal" font="default" size="100%">Tsuda, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Bioscience Laboratories, Meiji Seika Kaisha, Ltd., 5-3-1 Chiyoda, Sakado-shi, Saitama 350-0289, Japan&#xD;Tokaigakuen Women&apos;s College, 2-901 Nakahira, Tenpaku-ku, Nagoya 468-8514, Japan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Orally administered delphinidin 3-rutinoside and cyanidin 3-rutinoside are directly absorbed in rats and humans and appear in the blood as the intact forms</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1546-1551</style></pages><volume><style face="normal" font="default" size="100%">49</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Absorption</style></keyword><keyword><style face="normal" font="default" size="100%">Anthocyanins</style></keyword><keyword><style face="normal" font="default" size="100%">Black currant</style></keyword><keyword><style face="normal" font="default" size="100%">Cyanidin 3-glucoside</style></keyword><keyword><style face="normal" font="default" size="100%">Cyanidin 3-rutinoside</style></keyword><keyword><style face="normal" font="default" size="100%">Delphinidin 3-glucoside</style></keyword><keyword><style face="normal" font="default" size="100%">Delphinidin 3-rutinoside</style></keyword><keyword><style face="normal" font="default" size="100%">Excretion</style></keyword><keyword><style face="normal" font="default" size="100%">Human</style></keyword><keyword><style face="normal" font="default" size="100%">Rat</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2001</style></year></dates><abstract><style face="normal" font="default" size="100%">Four components of black currant anthocyanins (BCA), delphinidin 3-O-β-rutinoside (D3R), cyanidin 3-O-β-rutinoside (C3R), delphinidin 3-O-β-glucoside (D3G), and cyanidin 3-O-β-glucoside (C3G), were found to be directly absorbed and distributed to the blood and excreted into urine as the glycosylated forms. In a rat study, following oral administration of purified D3R, C3R, and C3G (800 μmol/kg of body weight), the anthocyanins were detected in the plasma and the Cmax values were 580 ± 410, 850 ± 120, and 840 ± 190 nmol/L, respectively, 0.5-2.0 h after administration. In a human study, when a mixtue of BCA [6.24 μmol (3.58 mg) consisting of 2.75 μmol (1.68 mg) of D3R, 2.08 μmol (1.24 mg) of C3R, 1.04 μmol (0.488 mg) of D3G, and 0.37 μmol (0.165 mg) of C3G/kg of body weight)] was orally ingested by eight volunteers, D3R, C3R, D3G, and C3G were detected in the plasma and urine. The plasma Cmax values were 73.4 ± 35.0, 46.3 ± 22.5, 22.7 ± 12.4, and 5.0 ± 3.7 nmol/L, respectively, 1.25-1.75 h after intake, and the cumulative excretion of the four compounds in urine in the period 0-8 h after intake was 0.11 ± 0.05% of the dose ingested. These results indicate that 3-O-β-rutinosyl anthocyanins were directly absorbed and distributed to the blood.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :249&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034833602&amp;doi=10.1021%2fjf001246q&amp;partnerID=40&amp;md5=47d187d865ce8e71a44883333dadfc2e</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/jf001246q</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>493</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">493</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Matheu, V.</style></author><author><style face="normal" font="default" size="100%">Baeza, M. L.</style></author><author><style face="normal" font="default" size="100%">Zubeldia, J. M.</style></author><author><style face="normal" font="default" size="100%">Barrios, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medical Inflammation Research MIR, Lund University, Lund, Sweden&#xD;Allergy Service, Hospital Gregorio Maranon, Madrid, Spain&#xD;Immunology Section, Hospital Universitario de Canarias, Canarias, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Allergy to lingonberry: A case report</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical and Molecular Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical and Molecular Allergy</style></full-title></periodical><volume><style face="normal" font="default" size="100%">2</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Food allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Lingonberry</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Past few years cranberry/lingonberry products have been incorporated as healthy products to the US and European market as prophylaxis of recurrent urinary tract infections in young women as well as in chronic infections in elderly which because of there are many biological activities attributed to the that fruit is a very popular additive to the new diets. To the best of our knowledge, this is the first case of allergy to lingonberry. We speculate that previous exposure to lingonberry products could be sensitising. The symptoms, timing of the episode, positive skin test, IgE-ELISA and western-blot strongly support the role of lingonberry as the causative agent. © 2004 Matheu et al; licensee BioMed Central Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-4243196970&amp;doi=10.1186%2f1476-7961-2-2&amp;partnerID=40&amp;md5=4241a2fcb4ddce861e2b313a1eb951b0</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">2</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/1476-7961-2-2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>331</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">331</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mathers, M. J.</style></author><author><style face="normal" font="default" size="100%">Von Rundstedt, F.</style></author><author><style face="normal" font="default" size="100%">Brandt, A. S.</style></author><author><style face="normal" font="default" size="100%">König, M.</style></author><author><style face="normal" font="default" size="100%">Lazica, D. A.</style></author><author><style face="normal" font="default" size="100%">Roth, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Urologische Gemeinschaftspraxis Remscheid, Kooperationspraxis der Klinik für Urologie und Kinderurologie, Klinikum Wuppertal, Universität Witten/Herdecke, Fastenrathstraße 1, 42853 Remscheid&#xD;Klinik für Urologie und Kinderurologie, Klinikum Wuppertal, Universität Witten/Herdecke, Wuppertal, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Myth or truth. Cranberry juice for prophylaxis and treatment of recurrent urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">Urologe - Ausgabe A</style></secondary-title><short-title><style face="normal" font="default" size="100%">Mythos oder wahrheit? &quot;cranberry-saft&quot; in der prophylaxe und behandlung von rezidivierenden harnweginfektionen</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Urologe - Ausgabe A</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1203-1209</style></pages><volume><style face="normal" font="default" size="100%">48</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Mechanism of action</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Recurrent urinary tract infections are a frequent problem in urological practice. Longterm antibiotic prophylaxis can cause resistance of some intestinal bacteria, and after therapy is stopped, infections often resume. In controlled studies, general recommendations for prophylaxis were shown to inhibit reinfection. One of these recommendations is the consumption of cranberries. A review of the literature in PubMed as well as the recently published Cochrane database systematic review confirmed that daily consumption of cranberries prevents recurrent urinary tract infections. In vitro studies have shown that binding of the P fimbriae of Escherichia coli to the uroepithelial tissue can be inhibited in the presence of proanthocyanidins, the active ingredient of cranberries. In clinical studies, the evidence is not so pronounced. Many other bacteria have fimbriae, but only a few subpopulations have P fimbriae. P fimbriae are frequent in E. coli, so this adhesion can be prevented. However, in a subanalysis of randomized and controlled studies, it was shown that women with recurrent urinary tract infections might profit from consuming cranberries. © Springer Medizin Verlag 2009.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-70449529865&amp;doi=10.1007%2fs00120-009-2051-z&amp;partnerID=40&amp;md5=7039b6ef1b3b634a4c696938e3712a73</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00120-009-2051-z</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>188</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">188</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Massini, L. A.</style></author><author><style face="normal" font="default" size="100%">Han, H.</style></author><author><style face="normal" font="default" size="100%">Seifter, J.</style></author><author><style face="normal" font="default" size="100%">Dwyer, J. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Tufts University, Frances Stern Nutrition Center Master of Science, Dietetic Internship Program, Boston, MA, United States&#xD;Friedman School of Nutrition Science and Policy, Tufts University, Tufts Medical Center, Boston, MA, United States&#xD;Harvard Vanguard Medical Associates, Boston, MA, United States&#xD;Renal Medical Stud. Education, Harvard University Medical School, Brigham and Womens Hospital, Boston, MA, United States&#xD;School of Nutrition Science and Policy, Department of Public Health and Family Medicine, Tufts University School of Medicine, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Diet and kidney stones: Myths and realities</style></title><secondary-title><style face="normal" font="default" size="100%">Nutrition Today</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nutrition Today</style></full-title></periodical><pages><style face="normal" font="default" size="100%">32-38</style></pages><volume><style face="normal" font="default" size="100%">49</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Nephrolithiasis, or kidney stones, is the presence of renal calculi caused by a disruption in the balance between salt solubility and precipitation in the kidneys, usually because of dehydration or certain genetic predispositions. The lifetime prevalence of kidney stones in the United States is 12% among men and 7% among women. There are many myths regarding the relationship between diet and risk of various types of kidney stones, which are addressed in this article. Conclusions are as follows: All individuals should avoid very high or very low total intakes of calcium. Stone formers should optimize fluid intake to increase urine volume and decrease stone risk. All individuals should aim for the dietary reference intake (DRI) for vitamin C, and those prone to oxalate stones should avoid excessive dietary supplementation. Eating amounts of protein near the DRI does not increase risk of stone recurrence, even if protein is from animal sources. Consumption of fruits and vegetables (at least 5 servings/day) may decrease risk for kidney stones. Follow the dietary recommendations that accompany kidney stone medications to maximize their efficacy. Strive for the DRIs for magnesium and potassium because they appear to be protective against kidney stones. Hyperuricosuric patients can reduce their uric acid excretion and increase their urinary pH by reducing purine intake. © 2014 Wolters Kluwer Health Lippincott Williams and Wilkins. Unauthorized reproduction of this article is prohibited. © 2014 Wolters Kluwer Health Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this article is prohibited.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84894146516&amp;doi=10.1097%2fNT.0000000000000014&amp;partnerID=40&amp;md5=314b7a3c3440ebe29fa7f175dda6961f</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/NT.0000000000000014</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>133</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">133</key></foreign-keys><ref-type name="Conference Proceedings">10</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Marzuke, A. B.</style></author><author><style face="normal" font="default" size="100%">Wan Kamarul Zaman, W. S.</style></author><author><style face="normal" font="default" size="100%">Shahbuddin, M.</style></author><author><style face="normal" font="default" size="100%">Aung, S. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biomedical Engineering, University of Malaya, Kuala Lumpur, Malaysia&#xD;Department of Biotechnology Engineering, Kulliyyah of Engineering, International Islamic University Malaysia, Gombak, Selangor, Malaysia&#xD;Department of Restorative Dentistry, University of Malaya, Kuala Lumpur, Malaysia</style></auth-address><titles><title><style face="normal" font="default" size="100%">The effects of KGM, mannose and co-supplementation of KGM and mannose on mammalian cells cultured at inside and outside incubator conditions</style></title><secondary-title><style face="normal" font="default" size="100%">IFMBE Proceedings</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">208-211</style></pages><volume><style face="normal" font="default" size="100%">56</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Breast cancer cells (MCF-7)</style></keyword><keyword><style face="normal" font="default" size="100%">Cellular viability and proliferation</style></keyword><keyword><style face="normal" font="default" size="100%">D-mannose</style></keyword><keyword><style face="normal" font="default" size="100%">Keratinocyte cell line (HaCaT)</style></keyword><keyword><style face="normal" font="default" size="100%">Konjac Glucomannan</style></keyword><keyword><style face="normal" font="default" size="100%">Mammalian cells</style></keyword><keyword><style face="normal" font="default" size="100%">Stem cells from human extracted deciduous tooth (SHED)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Mammalian cells including cancer cells, stem cells and cell lines are important in the application of cells for therapies and research activities. They require the cells to be transported from the laboratory or surgery theater to the bedside, making it a challenge to be exposed at outside, shear stress condition and differences especially in the tropical climate countries. In this research, Konjac Glucomannan (KGM) and D-mannose were examined for their potential use in the delivery of cells when subjected to differences in and outside incubator conditions. The objective of this work was to examine the risk and effects of different type of sugar supplementation in the transportation of cells. In this study, we used mammalian cells; stem cells from human extracted deciduous tooth (SHED), human keratinocyte cell lines (HaCaT) and human breast cancer (MCF-7). We hypothesized that the supplementations of KGM and D-mannose in the culture medium will act as protective agents to the cells due to their unique biological properties interacting via carbohydrate-protein interactions. Experiments were conducted in laboratory conditions to compare the effect of these sugars on the viability of different type of cells when placed at inside and outside incubator condition for 24, 48 and 72 hours. Evaluation of cellular viability and proliferation showed that co-supplementation of KGM and D-mannose inhibited the viability of MCF-7 at both inside and outside incubator conditions while supplementation of these sugars to other cells cultured at outside incubator condition did improve cellular viability and morphology compared to the cells cultured at inside the incubator, elucidating the potential benefit of sugar glycobiology in cellular transportation. © International Federation for Medical and Biological Engineering 2016.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Conference Paper</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84952801905&amp;doi=10.1007%2f978-981-10-0266-3_43&amp;partnerID=40&amp;md5=800b16c546219a7fbf66b5198f85b01d</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/978-981-10-0266-3_43</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>99</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">99</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martel, P.</style></author><author><style face="normal" font="default" size="100%">M&apos;Baya, O.</style></author><author><style face="normal" font="default" size="100%">Senn, L.</style></author><author><style face="normal" font="default" size="100%">Jichlinski, P.</style></author><author><style face="normal" font="default" size="100%">Cerantola, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Service d&apos;Urologie, CHUV, Lausanne, 1011, Switzerland&#xD;Service de Médecine Préventive Hospitalière, CHUV, Lausanne, 1011, Switzerland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Assessment and treatment of genitourinary infections</style></title><secondary-title><style face="normal" font="default" size="100%">Revue Medicale Suisse</style></secondary-title><short-title><style face="normal" font="default" size="100%">Bilan et traitements des infections urogénitales</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Revue Medicale Suisse</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2054-2059</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">541</style></number><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Antibiotics are most commonly prescribed for urinary bacterial infections. The purpose of this article is to review the most common infections of the genitourinary tract and to guide the choice of the most appropriate treatment. This choice depends also on the patients general state, local associated conditions and can range from obser vation to an emergency hospitalisation. Primary care physicians remain in the first line to take care of these patients but the urologists or the infectious disease specialists can provide some help in complex situations.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85012048751&amp;partnerID=40&amp;md5=0051b9acb90301c55e41c50ebe05e3a0</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>150</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">150</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Marquardt, P.</style></author><author><style face="normal" font="default" size="100%">Kaft, K.</style></author><author><style face="normal" font="default" size="100%">Nieber, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institut für Pharmazie, Universität Leipzig, Brüderstr. 34, Leipzig, 04193, Germany&#xD;Kooperation Phytopharmaka, Plittersdorfer Str. 2, Bonn, 53173, Germany&#xD;Lehrstuhl für Naturheilkunde, Universitätsmedizin Rostock, Rostock, 18057, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Clinical trials with herbal medicinal products in children: a literature analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Wiener Medizinische Wochenschrift</style></secondary-title><short-title><style face="normal" font="default" size="100%">Klinische Studien mit pflanzlichen Arzneimitteln bei Kindern – eine Literaturrecherche</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Wiener Medizinische Wochenschrift</style></full-title></periodical><pages><style face="normal" font="default" size="100%">236-242</style></pages><volume><style face="normal" font="default" size="100%">165</style></volume><number><style face="normal" font="default" size="100%">11-12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Age groups</style></keyword><keyword><style face="normal" font="default" size="100%">Children</style></keyword><keyword><style face="normal" font="default" size="100%">Clinical trials</style></keyword><keyword><style face="normal" font="default" size="100%">Herbal medicinal products</style></keyword><keyword><style face="normal" font="default" size="100%">Literature search</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Herbal medicinal products have been used since several decades for the health care of children. Nevertheless, well-controlled clinical studies with herbal medicinal products for children are rare. The authors’ objective therefore was to evaluate clinical trials with herbal medicinal products in children, based on a literature search in PubMed and Web of Science. A total of 133 trials were identified. 90 studies were randomized, 32.2 % were randomized and double-blinded. Most studies were performed in China, in the age group 6–12 years, and in children with respiratory diseases, most often herbal medicinal products with Hedera helix were tested. The analysis revealed that studies on herbal medicinal products were feasible in children. Although clinical trials have been found, this literature search have limitations and did not cover all studies performed. However, only few clinical trials of high quality were identified. Further studies therefore are urgently needed to support the good empirical findings. © 2015, Springer-Verlag Wien.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84938975120&amp;doi=10.1007%2fs10354-015-0373-6&amp;partnerID=40&amp;md5=752190c29366b5d136c3477ea740369b</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10354-015-0373-6</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>584</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">584</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mårild, S.</style></author><author><style face="normal" font="default" size="100%">Jodal, U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, Göteborg University, Göteborg, Sweden&#xD;Department of Paediatrics, Sahlgrenska University Hospital East, S-416 85 Göteborg, Sweden</style></auth-address><titles><title><style face="normal" font="default" size="100%">Incidence rate of first-time symptomatic urinary tract infection in children under 6 years of age</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Paediatrica, International Journal of Paediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Paediatrica, International Journal of Paediatrics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">549-552</style></pages><volume><style face="normal" font="default" size="100%">87</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Children</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence rate</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year></dates><abstract><style face="normal" font="default" size="100%">A retrospective population-based study was performed to describe the incidence rate of first time symptomatic urinary tract infection in children under 6 y of age. A total number of 299 children was identified during the 20-month study period in a population of 20 000 girls and 21 000 boys. The cumulative incidence rate during the first 6 y of life was 6.6% for girls and 1.8% for boys. The annual incidence rate in girls of urinary tract infection/1000 at risk was between 9 and 14 for each of the six 1-y age intervals. In girls, the proportion of febrile urinary tract infection was high during the infant year, while girls older than 2 y most often had non- febrile infection. For infant boys, the incidence rate and the proportion of febrile urinary tract infection were comparable to that of girls, while after the first year of life urinary infection of any kind was rare, with an incidence rate of 1-2/1000 at risk.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :163&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031804754&amp;doi=10.1080%2f08035259850158272&amp;partnerID=40&amp;md5=f6b5457aefcd241c29876682e0c8dbf6</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/08035259850158272</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>61</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">61</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Marcon, J.</style></author><author><style face="normal" font="default" size="100%">Stief, C. G.</style></author><author><style face="normal" font="default" size="100%">Magistro, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Urologische Klinik und Poliklinik, Klinikum der Universität München – Campus Großhadern, Ludwig-Maximilians-Universität München, Marchioninistr. 15, München, 81377, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections: What has been confirmed in therapy?</style></title><secondary-title><style face="normal" font="default" size="100%">Internist</style></secondary-title><short-title><style face="normal" font="default" size="100%">Harnwegsinfektionen: Was ist gesichert in der Therapie?</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Internist</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1242-1249</style></pages><volume><style face="normal" font="default" size="100%">58</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Drug resistance, bacterial</style></keyword><keyword><style face="normal" font="default" size="100%">Menopause</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection, prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection, recurrence</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTIs) affect approximately 150 million people worldwide per year, causing annual health costs of over three billion dollars just in the USA. Every second woman experiences at least one UTI in her lifetime, with every one in four experiencing recurrence. Uncomplicated infections like single or recurrent cystitis and pyelonephritis can be distinguished from complicated disease. UTIs in men can spread to the male glands, causing prostatitis and epididymitis. Antibiotic therapy is the standard procedure for UTIs. However, the extensive and sometimes irrational use of antibiotics for the treatment of infections has led to an increase in the incidence of multiresistant pathogens in recent years. Therefore, preventive nonantibiotic approaches are of great interest. This article provides an overview of the current management of urological infections as well as an outline of nonantibiotic preventive treatment modalities. © 2017, Springer Medizin Verlag GmbH.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85031909428&amp;doi=10.1007%2fs00108-017-0340-y&amp;partnerID=40&amp;md5=deb6395848244f4d0652a96978e203e7</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00108-017-0340-y</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>66</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">66</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Marchiori, D.</style></author><author><style face="normal" font="default" size="100%">Zanello, P. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Villa Erbosa Hospital, San Donato University and Research Group, Arcoveggio Street 52, Bologna, 40100, Italy&#xD;Department of Microbiology and Virology of Parma, Parma, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of N-acetylcysteine, D-mannose and morinda citrifolia to treat recurrent cystitis in breast cancer survivals</style></title><secondary-title><style face="normal" font="default" size="100%">In Vivo</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">In Vivo</style></full-title></periodical><pages><style face="normal" font="default" size="100%">931-936</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Breast cancer</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">D-mannose</style></keyword><keyword><style face="normal" font="default" size="100%">N-acetylcysteine</style></keyword><keyword><style face="normal" font="default" size="100%">Vaginal atrophy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Background/Aim: Breast cancer survivors in adjuvant therapy, frequently experience the estrogen deficiency with genitourinary symptoms mostly represented by recurrent bacterial cystitis. The objective of the present study was to evaluate the effectiveness of N-acetylcysteine, D-mannose and Morinda citrifolia fruit extract (NDM), when associated to antibiotic therapy, in reducing the persistence of recurrent cystitis in this risk population. Patients and Methods: Sixty breast cancer survived women with recurrent cystitis were retrospectively examined. Group 1, comprised of 40 patients treated with antibiotic therapy associated with NDM lasting for six months, Group 2 comprised of 20 patients treated with antibiotics alone. Results: The use of NDM in combination with antibiotic therapy showed a significant reduction in positive urine cultures, compared to antibiotics alone. Subjects of Group 1 rather than those of Group 2, showed improvement in symptoms score of urgency, frequency, urge incontinence, recurrent cystitis, bladder and urethral pain. Conclusion: In breast cancer survived women affected by genitourinary discomfort, the combination of NDM and antibiotic therapy showed a greater efficacy in reducing urinary tract infections and urinary discomfort with respect to antibiotic use only.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85029526910&amp;doi=10.21873%2finvivo.11149&amp;partnerID=40&amp;md5=b714d2a9d6c9c5f012694079d3ac4505</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.21873/invivo.11149</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>537</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">537</key></foreign-keys><ref-type name="Book">6</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mantle, F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Complementary and Alternative Medicine for Child and Adolescent Care: A Practical Guide for Healthcare Professionals</style></title><secondary-title><style face="normal" font="default" size="100%">Complementary and Alternative Medicine for Child and Adolescent Care: A Practical Guide for Healthcare Professionals</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1-228</style></pages><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">Children&apos;s health, psychological and social needs are qualitatively and quantitatively different from those of adults and the author has for this reason addressed not only medical conditions but also psycho-social development problems. This is a well-referenced and evidence-based book is an essential companion for all healthcare professionals who treat children and young adults. © 2004 Elsevier Ltd All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Book</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84902718661&amp;doi=10.1016%2fB978-0-7506-5175-2.X5001-5&amp;partnerID=40&amp;md5=fc9b834a000403e0ff49e7704265bef7</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/B978-0-7506-5175-2.X5001-5</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>189</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">189</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mansour, A.</style></author><author><style face="normal" font="default" size="100%">Hariri, E.</style></author><author><style face="normal" font="default" size="100%">Shelh, S.</style></author><author><style face="normal" font="default" size="100%">Irani, R.</style></author><author><style face="normal" font="default" size="100%">Mroueh, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Medicine, Lebanese American University, Byblos, 1401, Lebanon&#xD;School of Pharmacy, Lebanese American University, Byblos, 1401, Lebanon&#xD;Clinic Dr. Ralph Irani for Alternative Medicine, Beirut, 1202, Lebanon&#xD;Pharmaceutical Science Department, School of Pharmacy, Lebanese American University, Byblos, 1401, Lebanon</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficient and cost-effective alternative treatment for recurrent urinary tract infections and interstitial cystitis in women: A two-case report</style></title><secondary-title><style face="normal" font="default" size="100%">Case Reports in Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Case Reports in Medicine</style></full-title></periodical><volume><style face="normal" font="default" size="100%">2014</style></volume><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTIs) are among the most common bacterial infections affecting women. UTIs are primarily caused by Escherichia coli, which increases the likelihood of a recurrent infection. We encountered two cases of recurrent UTIs (rUTIs) with a positive E. coli culture, not improving with antibiotics due to the development of antibiotic resistance. An alternative therapeutic regimen based on parsley and garlic, L-arginine, probiotics, and cranberry tablets has been given. This regimen showed a significant health improvement and symptoms relief without recurrence for more than 12 months. In conclusion, the case supports the concept of using alternative medicine in treating rUTI and as a prophylaxis or in patients who had developed antibiotic resistance. © 2014 Anthony Mansour et al.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84949635922&amp;doi=10.1155%2f2014%2f698758&amp;partnerID=40&amp;md5=fc035ba43e522b1b45574263d567448a</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">698758</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1155/2014/698758</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>466</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">466</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Manach, C.</style></author><author><style face="normal" font="default" size="100%">Williamson, G.</style></author><author><style face="normal" font="default" size="100%">Morand, C.</style></author><author><style face="normal" font="default" size="100%">Scalbert, A.</style></author><author><style face="normal" font="default" size="100%">Rémésy, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unité des Maladies Métaboliques et Micronutriments, INRA, Saint-Genès Champanelle, France.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies</style></title><secondary-title><style face="normal" font="default" size="100%">The American journal of clinical nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">The American journal of clinical nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">230S-242S</style></pages><volume><style face="normal" font="default" size="100%">81</style></volume><number><style face="normal" font="default" size="100%">1 Suppl</style></number><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">Polyphenols are abundant micronutrients in our diet, and evidence for their role in the prevention of degenerative diseases is emerging. Bioavailability differs greatly from one polyphenol to another, so that the most abundant polyphenols in our diet are not necessarily those leading to the highest concentrations of active metabolites in target tissues. Mean values for the maximal plasma concentration, the time to reach the maximal plasma concentration, the area under the plasma concentration-time curve, the elimination half-life, and the relative urinary excretion were calculated for 18 major polyphenols. We used data from 97 studies that investigated the kinetics and extent of polyphenol absorption among adults, after ingestion of a single dose of polyphenol provided as pure compound, plant extract, or whole food/beverage. The metabolites present in blood, resulting from digestive and hepatic activity, usually differ from the native compounds. The nature of the known metabolites is described when data are available. The plasma concentrations of total metabolites ranged from 0 to 4 mumol/L with an intake of 50 mg aglycone equivalents, and the relative urinary excretion ranged from 0.3% to 43% of the ingested dose, depending on the polyphenol. Gallic acid and isoflavones are the most well-absorbed polyphenols, followed by catechins, flavanones, and quercetin glucosides, but with different kinetics. The least well-absorbed polyphenols are the proanthocyanidins, the galloylated tea catechins, and the anthocyanins. Data are still too limited for assessment of hydroxycinnamic acids and other polyphenols. These data may be useful for the design and interpretation of intervention studies investigating the health effects of polyphenols.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2431&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-13844281685&amp;partnerID=40&amp;md5=6162043cef0f8b6af551683e7996d87c</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>551</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">551</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Malinverni, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Département de Méd., Hôpital des Cadolles, CH-2000 Neuchâtel, Switzerland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections and antibiotic resistance</style></title><secondary-title><style face="normal" font="default" size="100%">Therapeutische Umschau</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Therapeutische Umschau</style></full-title></periodical><pages><style face="normal" font="default" size="100%">31-35</style></pages><volume><style face="normal" font="default" size="100%">59</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTI) are diseases which differ considerably regarding pathogenesis, natural history and management. Complicated UTI as well as uncomplicated acute pyelonephritis in women are managed with pretherapy urine and, possibly, blood culture. This is not the case, however, with the most frequent UTI, acute uncomplicated cystitis in women. Empirical management strategies, without pretherapy culture, are well established and widely used. The treatment of choice is trimethoprim-sulfamethoxazole (TMP-SMZ) and fluoroquinolones. E. coli cause the vast majority of these infections, and resistance to TMP-SMZ has been observed to increase considerably during the last decade. Data from Europe and Switzerland regarding resistance of etiologic agents causing acute uncomplicated cystitis are very limited. Indeed, these empirical management strategies have resulted in poor microbiological information, since only selected groups of women with UTI undergo urine culture. Data derived from laboratory isolates usually lack the necessary clinical and epidemiological correlations. Preliminary data allow some estimates of the clinical and microbiological success rates when treating TMP-SMZ resistant uropathogens with TMP-SMZ. TMP-SMZ should probably no longer be used if the prevalence of TMP-SMZ resistance among uropathogens causing acute uncomplicated cystitis is 20% or higher. In these cases, a fluoroquinolone during three days, amoxicillin-clavulanate during three to five days or nitrofurantoin during seven days should be given empirically. Non-antibiotic means of preventing UTI, such as increasing colonization resistance with lactobacilli, or the use of vaccines which provide inhibition of adherence of uropathogens to uroepithelial cells, show very promising experimental results. In order to survey and correct the value of our empirical strategies, more appropriate data on antimicrobial resistance and risk factors in the community are needed. This data can only be produced by a strong collaboration effort with networks of general practioners.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036007182&amp;doi=10.1024%2f0040-5930.59.1.31&amp;partnerID=40&amp;md5=d2867fe695331167de084b2069faa9d3</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1024/0040-5930.59.1.31</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>39</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">39</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maki, K. C.</style></author><author><style face="normal" font="default" size="100%">Nieman, K. M.</style></author><author><style face="normal" font="default" size="100%">Schild, A. L.</style></author><author><style face="normal" font="default" size="100%">Kaspar, K. L.</style></author><author><style face="normal" font="default" size="100%">Khoo, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Midwest Biomedical Research/Center for Metabolic and Cardiovascular Health, Glen Ellyn, IL, United States&#xD;Ocean Spray Cranberries, Lakeville-Middleboro, MA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Effect of Cranberry Juice Consumption on the Recurrence of Urinary Tract Infection: Relationship to Baseline Risk Factors</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American College of Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American College of Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">121-126</style></pages><volume><style face="normal" font="default" size="100%">37</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">predictors</style></keyword><keyword><style face="normal" font="default" size="100%">propensity</style></keyword><keyword><style face="normal" font="default" size="100%">recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: The objective of this study was to assess relationships between clinical predictors of urinary tract infection (UTI) and effects of cranberry juice consumption on recurrence in a post hoc analysis of a 24-week, randomized, double-blind, placebo-controlled, multicenter clinical trial in women with a recent history of UTI. Methods: Participants consumed a cranberry (n = 185) or placebo (n = 188) beverage (240 mL) daily. Odds ratios (OR) from 20 candidate predictor variables were evaluated in univariate analyses to assess clinical UTI incidence relationships in the placebo group. A multivariate logistic regression model was developed. The effects of cranberry juice consumption were evaluated in subsets categorized by the likelihood of a UTI event based on the prediction model. Results: In the placebo group, the final multivariate regression model identified four variables associated with the odds for having ≥ 1 UTI: intercourse frequency ≥ 1 time during the prior 4 weeks (OR: 2.36; 95% confidence interval [CI]: 0.98, 5.71; p = 0.057), use of vasectomy or hormonal methods for contraception (OR: 2.58; 95% CI: 1.20, 5.58; p = 0.016), most recent UTI &lt; 90 days prior to screening (OR: 2.28; 95% CI; 1.12, 4.67; p = 0.024), and living in France compared with the United States (OR: 0.17; 95% CI: 0.04, 0.79; p = 0.024). Three propensity categories were investigated (24-week probability &lt; 10%, 10%–21%, and &gt; 21%). Incidence rate ratios for the cranberry vs placebo groups were 0.76 (95% CI: 0.22, 2.60; p = 0.663) for those with &lt; 10% probability, 0.73 (95% CI: 0.35, 1.53; p = 0.064) for those with 10% to 21% probability, and 0.58 (95% CI: 0.35, 0.97; p = 0.039) for those with &gt; 21% probability. Conclusions: Results suggest that clinical predictors identify women with low and high risk of clinical UTI recurrence, which may be useful for design of clinical studies evaluating preventive therapies. © 2018 American College of Nutrition.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85033402571&amp;doi=10.1080%2f07315724.2017.1370398&amp;partnerID=40&amp;md5=e216a2a4db8b341ea45524b256a284aa</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/07315724.2017.1370398</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>114</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">114</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maki, K. C.</style></author><author><style face="normal" font="default" size="100%">Kaspar, K. L.</style></author><author><style face="normal" font="default" size="100%">Khoo, C.</style></author><author><style face="normal" font="default" size="100%">Derrig, L. H.</style></author><author><style face="normal" font="default" size="100%">Schild, A. L.</style></author><author><style face="normal" font="default" size="100%">Gupta, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Biofortis Clinical Research, Addison, IL, United States&#xD;MB Clinical Research, Glen Ellyn, IL, United States&#xD;Ocean Spray Cranberries, Lakeville-Middleboro, MA, United States&#xD;Department of Medicine, Boston University, School of Medicine, Boston, MA, United States&#xD;VA Boston Healthcare System, Boston, MA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Consumption of a cranberry juice beverage lowered the number of clinical urinary tract infection episodes in women with a recent history of urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Clinical Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Clinical Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1434-1442</style></pages><volume><style face="normal" font="default" size="100%">103</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteria</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidin</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Women</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Urinary tract infections (UTIs) are among the most common bacterial infections and are often treated with antibiotics. Concerns about multidrug-resistant uropathogens have pointed to the need for safe and effective UTI-prevention strategies such as cranberry consumption. Objective: We assessed the effects of the consumption of a cranberry beverage on episodes of clinical UTIs. Design: In this randomized, double-blind, placebo-controlled, multicenter clinical trial, women with a history of a recent UTI were assigned to consume one 240-mL serving of cranberry beverage/d (n = 185) or a placebo (n = 188) beverage for 24 wk. The primary outcome was the clinical UTI incidence density, which was defined as the total number of clinical UTI events (including multiple events per subject when applicable) per unit of observation time. Results: The dates of the random assignment of the first subject and the last subject&apos;s final visit were February 2013 and March 2015, respectively. The mean age was 40.9 y, and characteristics were similar in both groups. Compliance with study product consumption was 98%, and 86% of subjects completed the treatment period in both groups. There were 39 investigator-diagnosed episodes of clinical UTI in the cranberry group compared with 67 episodes in the placebo group (antibiotic use-adjusted incidence rate ratio: 0.61; 95% CI: 0.41, 0.91; P = 0.016). Clinical UTI with pyuria was also significantly reduced (incidence rate ratio: 0.63; 95% CI: 0.40, 0.97; P = 0.037). One clinical UTI event was prevented for every 3.2 womanyears (95% CI: 2.0, 13.1 woman-years) of the cranberry intervention. The time to UTI with culture positivity did not differ significantly between groups (HR: 0.97; 95% CI: 0.56, 1.67; P = 0.914). Conclusion: The consumption of a cranberry juice beverage lowered the number of clinical UTI episodes in women with a recent history of UTI. This study was registered at clinicaltrials.gov as NCT01776021. © 2016 American Society for Nutrition.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :20&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84973099667&amp;doi=10.3945%2fajcn.116.130542&amp;partnerID=40&amp;md5=d21e4a1d1e33469421567a3dc40bb124</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3945/ajcn.116.130542</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>27</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">27</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Majeed, M.</style></author><author><style face="normal" font="default" size="100%">Nagabhushanam, K.</style></author><author><style face="normal" font="default" size="100%">Arumugam, S.</style></author><author><style face="normal" font="default" size="100%">Natarajan, S.</style></author><author><style face="normal" font="default" size="100%">Majeed, S.</style></author><author><style face="normal" font="default" size="100%">Pande, A.</style></author><author><style face="normal" font="default" size="100%">Beede, K.</style></author><author><style face="normal" font="default" size="100%">Ali, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sami Labs Limited, 19/1, 19/2, First Main, Second Phase, Peenya Industrial Area, Bangalore, Karnataka 560 058, India&#xD;Sabinsa Corporation, 20 Lake Drive, East Windsor, NJ 08520, United States&#xD;Sabinsa Corporation, 750 Innovation Circle, Payson, UT 84651, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry seed fibre: a promising prebiotic fibre and its fermentation by the probiotic Bacillus coagulans MTCC 5856</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Food Science and Technology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Food Science and Technology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1640-1647</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bacillus coagulans</style></keyword><keyword><style face="normal" font="default" size="100%">cranberry seed fibre</style></keyword><keyword><style face="normal" font="default" size="100%">prebiotic</style></keyword><keyword><style face="normal" font="default" size="100%">probiotic</style></keyword><keyword><style face="normal" font="default" size="100%">short-chain fatty acids</style></keyword><keyword><style face="normal" font="default" size="100%">synbiotic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry, a versatile fruit, is known for nutritional as well as medicinal properties due to the presence of bioactive compounds. However, cranberry fruit has not been fully explored for its prebiotic potential. Therefore, this study was conducted to evaluate prebiotic potential of cranberry seed fibre (CSF) and also evaluate its fermentability by the probiotic strain Bacillus coagulans MTCC 5856. The resistance to gastric acid and porcine pancreatic enzymatic (PPE) hydrolysis of CSF was investigated using an in vitro model. It was found that CSF was resistant to gastric acid and also nondigestible to PPE hydrolysis. CSF as sole nutrition source was evaluated for the fermentability by B. coagulans MTCC 5856. A significant amount of short-chain fatty acids was produced by the B. coagulans MTCC 5856 while fermenting cranberry fibres anaerobically. CSF supported the growth of B. coagulans MTCC 5856 and also inhibited the growth of E. coli ATCC 25922 when cocultured in an anaerobic environment. CSF from the cranberry fruit exhibited prebiotic potential and also found to be fermentable by B. coagulans MTCC 5856. This study provided the scientific evidence of CSF as a prebiotic fibre and also its suitability with the probiotic B. coagulans MTCC 5856 for an ideal synbiotic preparation. © 2018 The Authors. International Journal of Food Science &amp; Technology published by John Wiley &amp; Sons Ltd on behalf of Institute of Food, Science and Technology (IFSTTF)</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042086353&amp;doi=10.1111%2fijfs.13747&amp;partnerID=40&amp;md5=fafedd2c3232c843661144e7d18f7ff5</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/ijfs.13747</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>343</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">343</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maharaj, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Otago, Wellington, New Zealand&#xD;Wellington Women&apos;s Hospital, Wellington, New Zealand</style></auth-address><titles><title><style face="normal" font="default" size="100%">Complications of infections in pregnancy</style></title><secondary-title><style face="normal" font="default" size="100%">Infectious Pregnancy Complications</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1-82</style></pages><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Epidemiological reports estimate that 7.7 million perinatal deaths occur annuallyworldwide, including 4.3 million that take place in late pregnancy, while the remainingneonates die in the first weeks of life. Reports attribute the majority of theseconsequences to infections of the fetus in utero. Infections during pregnancy affect themother, and often some infections may be transmitted to the fetus in utero, during theintrapartum period or, postnatally, with potentially serious consequences. Manyinfections have been linked to increased risks of premature delivery and low birthweight, and associated morbidity and mortality of both mother and child. Acute orchronic specific infectious diseases may be contracted during the course of pregnancy,and conception may occur in women already subject to an infection. The coexistence ofpregnancy may aggravate the risk to maternal life in cases of the more serious of thesediseases. In pregnancy most infections are no more common, nor more serious than in anon-pregnant population of women of similar age. The effects on pregnancy depend onthe degree of pyrexia, its duration, and the stage of fetal development when it occurs.Mild exposures during the preimplantation period, and more severe exposures duringembryonic and fetal development often result in miscarriage, premature labor, growthrestriction, or stillbirth. Hyperthermia may also cause a wide range of fetal structural andfunctional defects, with the central nervous system (CNS) being most at risk. While thereis a greater incidence of neonatal morbidity and mortality with transmitted infections, notall maternal infections lead to transmission to the fetus, nor does transmission to the fetuslead to disease or sequelae. During the puerperium, parturient women are particularlysusceptible to serious infections of the genital tract and childbed fever remains one of themost important causes of maternal death. Infections in pregnancy may be viral, bacterialor protozoal, affecting both mother and fetus. Some of the infections cause fevers, whileothers may not; this chapter will concentrate on infections resulting in maternal pyrexia,and some other infections which may not result in maternal pyrexia, but have importantimplications for the pregnancy and the fetus. © 2009 by Nova Science Publishers, Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84895217652&amp;partnerID=40&amp;md5=d93dc5d460965c2ee0314376b809ff2a</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>153</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">153</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mahady, G. B.</style></author><author><style face="normal" font="default" size="100%">Escalante, G.</style></author><author><style face="normal" font="default" size="100%">Mikkilineni, P.</style></author><author><style face="normal" font="default" size="100%">Mahady, L. J.</style></author><author><style face="normal" font="default" size="100%">Lawal, T. O.</style></author><author><style face="normal" font="default" size="100%">Adeniyi, B. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, United States&#xD;The Barrow Neurological Institute and Arizona State niversity, Phoenix, AZ, United States&#xD;Department of Pharmaceutical Microbiology, University of Ibadan, Ibadan, Nigeria</style></auth-address><titles><title><style face="normal" font="default" size="100%">Phytotherapies for infectious diseases: Are these really useful?</style></title><secondary-title><style face="normal" font="default" size="100%">Phytotherapies: Efficacy, Safety, and Regulation</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">483-503</style></pages><keywords><keyword><style face="normal" font="default" size="100%">Antimicrobial agent</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry juice</style></keyword><keyword><style face="normal" font="default" size="100%">Ginger</style></keyword><keyword><style face="normal" font="default" size="100%">Infectious diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Phytotherapies</style></keyword><keyword><style face="normal" font="default" size="100%">Plant-based medicines</style></keyword><keyword><style face="normal" font="default" size="100%">Turmeric</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections (UTIs)</style></keyword><keyword><style face="normal" font="default" size="100%">Zoonosis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Since the 1930s, natural products have played a significant role in the discovery of new classes and novel antibiotic drugs; and in fact, most antibacterial drugs were derived directly from natural products or discovered using a natural product lead. In addition to bacterial and fungal sources of natural antimicrobial agents, traditional plant-based medicines have been used for centuries in most countries worldwide for the treatment of diseases, including infectious diseases. During the eighteenth century, cranberry juice was commonly employed throughout Europe and New England for the treatment of urinary tract infections (UTIs). Turmeric is reported to have antibacterial effects against many Gram-positive bacteria and Gram-negative bacteria such as H.pylori. Ginger root has also been reported to have antimicrobial activities against a wide range of bacteria and fungi. Reducing pathogen carriage in foods to prevent zoonosis transmission to humans is an important part of reducing the rate of infectious diseases. © 2015 John Wiley &amp; Sons, Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85016376498&amp;doi=10.1002%2f9781119006039.ch19&amp;partnerID=40&amp;md5=136dcd0ae9f63a0e3696d789da6dd9ec</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/9781119006039.ch19</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>77</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">77</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Magistro, G.</style></author><author><style face="normal" font="default" size="100%">Marcon, J.</style></author><author><style face="normal" font="default" size="100%">Schubert, S.</style></author><author><style face="normal" font="default" size="100%">Gratzke, C.</style></author><author><style face="normal" font="default" size="100%">Stief, C. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Urologische Klinik und Poliklinik der Universität München, Campus Großhadern, Ludwig-Maximilians-Universität München, Marchioninistr. 15, München, 81377, Germany&#xD;Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie, Ludwig-Maximilians-Universität München, München, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pathogenesis of urinary tract infections: An update</style></title><secondary-title><style face="normal" font="default" size="100%">Urologe</style></secondary-title><short-title><style face="normal" font="default" size="100%">Pathogenese der Harnwegsinfektion: Ein Update</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Urologe</style></full-title></periodical><pages><style face="normal" font="default" size="100%">720-727</style></pages><volume><style face="normal" font="default" size="100%">56</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">Intracellular bacterial communities</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract</style></keyword><keyword><style face="normal" font="default" size="100%">Virulence factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections are among the most common bacterial infections worldwide. The management has become a public health concern of socioeconomic importance. Every second woman will experience at least one episode in her lifetime. Due to the emergence of multiresistant pathogens and the developmental void, treatment has become more challenging over the years. Deciphering the complex molecular interaction between host and pathogen is necessary to identify potent treatment targets for future approaches. The objective of this review is to present novel aspects on the pathogenesis of urinary tract infections and its relevance for clinical practice. © 2017, Springer Medizin Verlag GmbH.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018265525&amp;doi=10.1007%2fs00120-017-0391-7&amp;partnerID=40&amp;md5=07307ad49f5fedd3a401bedb3a369a6f</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00120-017-0391-7</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>123</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">123</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Magistro, G.</style></author><author><style face="normal" font="default" size="100%">Marcon, J.</style></author><author><style face="normal" font="default" size="100%">Beck, V.</style></author><author><style face="normal" font="default" size="100%">Herlemann, A.</style></author><author><style face="normal" font="default" size="100%">Stief, C. G.</style></author><author><style face="normal" font="default" size="100%">Gratzke, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Urologische Klinik und Poliklinik, Universität München, Ludwig-Maximilians-Universität München, Germany&#xD;Campus Grohadern Klinikum der, Ludwig-Maximilians-Universität (LMU) München, Urologische Klinik und Poliklinik, Marchioninistrae 15, München, 81377, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Current Aspects on the Pathogenesis of Urinary Tract Infections</style></title><secondary-title><style face="normal" font="default" size="100%">Aktuelle Urologie</style></secondary-title><short-title><style face="normal" font="default" size="100%">Aktuelle Aspekte zur Pathogenese der Harnwegsinfektion</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Aktuelle Urologie</style></full-title></periodical><pages><style face="normal" font="default" size="100%">203-209</style></pages><volume><style face="normal" font="default" size="100%">47</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">intracellular bacterial communities (IBC)</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">uropathogenic Escherichia coli (UPEC)</style></keyword><keyword><style face="normal" font="default" size="100%">virulence factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections are among the most common bacterial infectious diseases worldwide. Every second woman will experience at least one urinary tract infection in her lifetime. The administration of antibiotics has been a safe and efficient treatment modality so far. However, due to the emergence of multi-resistant pathogens and the developmental void of new antimicrobial drugs, the therapy of infections mighty become more challenging in the near future. So, knowledge of the complex host-pathogen interaction is of great importance. Common phenotypes observed in clinical practice suggest basic principles, which are relevant for the development of novel antimicrobial strategies. With invading pathogens forming intracellular bacterial communities they evade host response and provide a nidus for recurrent infection. A plethora of virulence factors allow uropathogenic bacteria to colonize and to establish infections in the urinary tract. In response, host responses seem to address specific virulence mechanisms that are essential to pathogenicity. Deciphering the molecular mechanisms underlying the complex host-pathogen interaction is critical to devise novel treatment options. © Georg Thieme Verlag KG Stuttgart, New York.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84973497861&amp;doi=10.1055%2fs-0042-101215&amp;partnerID=40&amp;md5=3f955f5337943e55155165529561558b</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1055/s-0042-101215</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>369</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">369</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Magariños, H. L. E.</style></author><author><style face="normal" font="default" size="100%">Sahr, C.</style></author><author><style face="normal" font="default" size="100%">Selaive, S. D. C.</style></author><author><style face="normal" font="default" size="100%">Costa, M. E.</style></author><author><style face="normal" font="default" size="100%">Figuerola, F. E.</style></author><author><style face="normal" font="default" size="100%">Pizarro, O. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Food Science and Technology, Faculty of Agropecuarian Sciences Southern University of Chile, Valdivia, Chile</style></auth-address><titles><title><style face="normal" font="default" size="100%">In vitro inhibitory effect of cranberry (Vaccinium macrocarpum Ait.) juice on pathogenic microorganisms</style></title><secondary-title><style face="normal" font="default" size="100%">Applied Biochemistry and Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Applied Biochemistry and Microbiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">300-304</style></pages><volume><style face="normal" font="default" size="100%">44</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">The purpose of this study was to determine the inhibitory effects of cranberry juice on pathogenic microorganisms. The microorganisms analyzed were Escherichia coli from patients with urinary infections, Salmonella spp., Listeria monocytogenes, Pseudomona aeruginosa, and Staphylococcus aureus. The disc method was used to determine the sensitivity of bacteria to cranberry juice (CJ, both concentrated and diluted). A lawn of 106 cfu/ml was grown on agar surfaces in Petri dishes and on Whatman discs that had been previously saturated with CJ and CJ : water. 1 : 1 to 1 : 50 juice solutions had been placed on the discs, which were cultured and incubated. The results indicated that S. aureus was more susceptible to cranberry juice inhibition than the other microorganisms. L. monocytogenes was the most resistant to the inhibitory action of cranberry juice, showing a significant difference from the inhibition of P. aeruginosa, uropathogenic E. coli, Salmonella spp., and S. aureus. This study also demonstrated that the inhibitory activity of cranberry juice for E. coli took place up to a dilution of 1 : 20. © 2008 MAIK Nauka.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :5&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-43749099270&amp;doi=10.1134%2fS0003683808030137&amp;partnerID=40&amp;md5=5091b8ce365529b8e213d77f9aabaedc</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1134/S0003683808030137</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>376</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">376</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Magariños, H.</style></author><author><style face="normal" font="default" size="100%">Cartes, P.</style></author><author><style face="normal" font="default" size="100%">Fraser, B.</style></author><author><style face="normal" font="default" size="100%">Selaive, S.</style></author><author><style face="normal" font="default" size="100%">Costa, M.</style></author><author><style face="normal" font="default" size="100%">Figuerola, F.</style></author><author><style face="normal" font="default" size="100%">Pizarro, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Instituto de Ciencia Y Tecnología de Los Alimentos, Facultad de Ciencias Agrarias, Universidad Austral de Chile, Casilla 47, Valdivia, Chile</style></auth-address><titles><title><style face="normal" font="default" size="100%">Viability of probiotic micro-organisms (Lactobacillus casei Shirota and Bifidobacterium animalis subspp. lactis) in a milk-based dessert with cranberry sauce</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Dairy Technology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Dairy Technology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">96-101</style></pages><volume><style face="normal" font="default" size="100%">61</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bifidobacterium animalis subspp. lactis</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus casei Shirota</style></keyword><keyword><style face="normal" font="default" size="100%">Micro-organism viability</style></keyword><keyword><style face="normal" font="default" size="100%">Milk-based dessert</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">The objective of this study was to evaluate the survival of two probiotic micro-organisms, Lactobacillus casei Shirota and Bifidobacterium animalis subspp. lactis, in a milk-based dessert (2.7% fat) with cranberry sauce added. B. lactis had a final concentration of 1.99 × 106 cfu/g after 21 days of study, with a logarithmic decrease of 8.87%. On other hand, L. casei Shirota had a final concentration of 2.05 × 107 cfu/g at the end of the same period, a logarithmic decrease of 8.41%. Statistical analysis showed that significant differences existed between both micro-organisms and over various storage times, the more viable micro-organism being L. casei Shirota, which decreased less than one logarithmic cycle after 21 days. © 2008 Society of Dairy Technology.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :11&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-39449094547&amp;doi=10.1111%2fj.1471-0307.2008.00365.x&amp;partnerID=40&amp;md5=308f2e4d4c84685b646bf000821e5276</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1471-0307.2008.00365.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>522</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">522</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">MacLennon, W. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">26 Caiystone Avenue, Edinburgh EH10 6SG, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections in older patients</style></title><secondary-title><style face="normal" font="default" size="100%">Reviews in Clinical Gerontology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Reviews in Clinical Gerontology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">119-127</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-2442507714&amp;doi=10.1017%2fS0959259803013236&amp;partnerID=40&amp;md5=ad4abeae45712c7f453c31e3c07a01e4</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1017/S0959259803013236</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>550</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">550</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Macfarlane, G. T.</style></author><author><style face="normal" font="default" size="100%">Cummings, J. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Dundee, MRC Microbiol./Gut Biology Grp., Ninewells Hospital Medical School, Dundee DD1 9SY, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Probiotics, infection and immunity</style></title><secondary-title><style face="normal" font="default" size="100%">Current Opinion in Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Opinion in Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">501-506</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bifidobacteria</style></keyword><keyword><style face="normal" font="default" size="100%">Diarrhoea</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal tract</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammatory bowel disease</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacilli</style></keyword><keyword><style face="normal" font="default" size="100%">Mucosal immunity</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><abstract><style face="normal" font="default" size="100%">Purpose of review: Taking live bacteria by mouth to improve health (probiotics) is not intuitively rational yet it is a practice with a long history. As interest in the effects on health of the intestinal flora has developed, along with major advances in the technology for studying it, so has come a new interest in establishing the true benefits of probiotic therapy. This review summarizes the most recent contributions to this rapidly developing area. Recent findings: Probiotic bacteria, mainly bifidobacteria and lactobacilli for historical reasons, can prevent or ameliorate some diseases. Many empirical studies have been done, but work to develop the ideal characteristics of probiotics lags behind. Current literature covers survival of probiotics in the gut, mucosal adherence, antibacterial/pathogen mechanisms, effects on immune function and clinical studies. Summary: Probiotic bacteria are effective in preventing and reducing the severity of acute diarrhoea in children. They are also useful in antibiotic associated diarrhoea but not for elimination of Helicobacter pylori. In inflammatory bowel disease, especially ulcerative colitis, probiotics offer a safe alternative to current therapy. Probiotics have been used to prevent urogenital tract infection with benefit and, perhaps more intriguingly, to reduce atopy in children. Probiotics do not invariably work and study of mechanisms is urgently needed.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :137&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036791162&amp;doi=10.1097%2f00001432-200210000-00008&amp;partnerID=40&amp;md5=c045bddf8b38c73bd7f6446872e0526b</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/00001432-200210000-00008</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>473</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">473</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lynch, D. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Continuum Ctr. for Hlth. and Healing, Beth Israel Medical Center, New York, NY, United States&#xD;Northampton Wellness Associates, Northampton, MA, United States&#xD;Georgetown University, School of Medicine, Washington, DC, United States&#xD;York (Pa.) Hospital, United States&#xD;Northampton Wellness Associates, 395 Pleasant St., Northampton, MA 01060, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry for prevention of urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">American Family Physician</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Family Physician</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2175-2177</style></pages><volume><style face="normal" font="default" size="100%">70</style></volume><number><style face="normal" font="default" size="100%">11</style></number><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Traditionally, cranberry has been used for the treatment and prophylaxis of urinary tract infections, Research suggests that its mechanism of action is preventing bacterial adherence to host cell surface membranes. Systematic reviews have concluded that no reliable evidence supports the use of cranberry in the treatment or prophylaxis of urinary tract infections; however, more recent, randomized controlled trials demonstrate evidence of cranberry&apos;s utility in urinary tract infection prophylaxis. Supporting studies in humans are lacking for other clinical uses of cranberry. Cranberry is a safe, well-tolerated herbal supplement that does not have significant drug interactions. Copyright © 2004 American Academy of Family Physicians.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :33&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-10244235234&amp;partnerID=40&amp;md5=9a90ef6a91681088c1a6d8f6aeb36df3</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>65</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">65</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Luís, Â</style></author><author><style face="normal" font="default" size="100%">Domingues, F.</style></author><author><style face="normal" font="default" size="100%">Pereira, L.</style></author><author><style face="normal" font="default" size="100%">Luís, Â</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centro de Investigação em Ciências da Saúde, Universidade da Beira Interior, Covilhã, Portugal&#xD;Centro de Matemática e Aplicações (LP), Universidade da Beira Interior, Covilhã, Portugal</style></auth-address><titles><title><style face="normal" font="default" size="100%">Can Cranberries Contribute to Reduce the Incidence of Urinary Tract Infections? A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Clinical Trials</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">614-621</style></pages><volume><style face="normal" font="default" size="100%">198</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">disease susceptibility</style></keyword><keyword><style face="normal" font="default" size="100%">fruit and vegetable juices</style></keyword><keyword><style face="normal" font="default" size="100%">proanthocyanidins</style></keyword><keyword><style face="normal" font="default" size="100%">study publication bias</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Purpose We sought to clarify the association between cranberry intake and the prevention of urinary tract infections. Materials and Methods This systematic review, which complies with the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analysis) statement, was done as a meta-analysis and trial sequential analysis of clinical trials. Results The findings clearly showed the potential use of cranberries for the clinical condition of urinary tract infection. Cranberry products significantly reduced the incidence of urinary tract infections as indicated by the weighted risk ratio (0.6750, 95% CI 0.5516–0.7965, p &lt;0.0001). The results of subgroup analysis demonstrated that patients at some risk for urinary tract infections were more susceptible to the effects of cranberry ingestion. Conclusions The results of the current study could be used by physicians to recommend cranberry ingestion to decrease the incidence of urinary tract infections, particularly in individuals with recurrent urinary tract infections. This would also reduce the administration of antibiotics, which could be beneficial since antibiotics can lead to the worldwide emergence of antibiotic resistant microorganisms. © 2017 American Urological Association Education and Research, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :11&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021838356&amp;doi=10.1016%2fj.juro.2017.03.078&amp;partnerID=40&amp;md5=e503214d273d56cbb6c926f7b1f3b2fc</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.juro.2017.03.078</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>467</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">467</key></foreign-keys><ref-type name="Book">6</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Low Dog, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Women&apos;s Health in Complementary and Integrative Medicine</style></title><secondary-title><style face="normal" font="default" size="100%">Women&apos;s Health in Complementary and Integrative Medicine</style></secondary-title></titles><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">&quot;Women&apos;s Health in Complementary and Integrative Medicine is a new resource that takes an evidence-based approach to complementary and integrative medicine in women&apos;s health - examining when, how, and for whom these therapies can be effective.&quot;--BOOK JACKET.Title Summary field provided by Blackwell North America, Inc. All Rights Reserved This book covers the most common areas of concern in women&apos;s health. It provides a truly integrative approach, showing when, how, and for whom complementary/integrative therapies can benefit women in continuity with their regular medical care. This is an evidence-based, clinically-oriented book that presents the background and range of complementary and alternative therapies related to common medical conditions and functional complaints and disorders. It summarizes and analyzes scientific studies on the safety and efficacy of these therapies for various women&apos;s health conditions. Each chapter includes a description of commonly used treatments, discussions of safety issues (including adverse effects and drug interactions), a comprehensive summary and methodological assessment of clinical trials on the subject (with animal and in vitro data included as appropriate), and advice on counseling patients. Provides a clear review of the scientific evidence relating complementary and integrative medicine to the care of women. Offers a roadmap to the options in the treatment of women with complementary and integrative medicine - expanding the clinician&apos;s practice, whatever their specialty, with realistic possibilities. Features comprehensive coverage of safety issues. Written by leading experts in the field. Sidebars within each chapter provide at-a-glance advice for patients and practitioners. Includes key coverage of non-gynecologic issues such as nutrition, headache, depression, cancer, and heart disease. Offers comprehensive coverage of commonly used treatments and related safety issues, such as possible adverse effects and drug interactions, plus a helpful appendix on Botanical Products. A focused table of contents makes it easy to find the right treatment for each patient based on their condition. Features advice on talking with patients about self-treatments they may have read about in books or on the Internet. © 2005 Elsevier Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :7&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Book</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85013983314&amp;doi=10.1016%2fB978-0-443-06639-9.X5001-1&amp;partnerID=40&amp;md5=dedd1d5d32e3cfdaea96d9ab80c4b16a</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/B978-0-443-06639-9.X5001-1</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>121</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">121</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lovisa, H. L.</style></author><author><style face="normal" font="default" size="100%">Dorota, K.</style></author><author><style face="normal" font="default" size="100%">Elin, S.</style></author><author><style face="normal" font="default" size="100%">Mikael, B.</style></author><author><style face="normal" font="default" size="100%">Merichel, P.</style></author><author><style face="normal" font="default" size="100%">Charlotta, T.</style></author><author><style face="normal" font="default" size="100%">Cecilia, H.</style></author><author><style face="normal" font="default" size="100%">Frida, F.</style></author><author><style face="normal" font="default" size="100%">Karin, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Experimental Medical Science, Lund University, BMC C11, Lund, SE-221 84, Sweden&#xD;ImaGene-IT, Medicon-Village Lund, Sweden&#xD;Astra-Zeneca RandD, Mölndal, Sweden&#xD;Department of Chemistry, Center for Analysis and Synthesis, Lund University, Lund, Sweden&#xD;Food for Health Science Centre, Lund University, Medicon-Village Lund, Sweden</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lingonberries alter the gut microbiota and prevent low-grade inflammation in high-fat diet fed mice</style></title><secondary-title><style face="normal" font="default" size="100%">Food and Nutrition Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Food and Nutrition Research</style></full-title></periodical><volume><style face="normal" font="default" size="100%">60</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Akkermansia</style></keyword><keyword><style face="normal" font="default" size="100%">Berries</style></keyword><keyword><style face="normal" font="default" size="100%">Hepatic steatosis</style></keyword><keyword><style face="normal" font="default" size="100%">High-fat diet</style></keyword><keyword><style face="normal" font="default" size="100%">LBP</style></keyword><keyword><style face="normal" font="default" size="100%">Metabolic endotoxemia</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: The gut microbiota plays an important role in the development of obesity and obesity-associated impairments such as low-grade inflammation. Lingonberries have been shown to prevent diet-induced obesity and low-grade inflammation. However, it is not known whether the effect of lingonberry supplementation is related to modifications of the gut microbiota. The aim of the present study was to describe whether consumption of different batches of lingonberries alters the composition of the gut microbiota, which could be relevant for the protective effect against high fat (HF)-induced metabolic alterations. Methods: Three groups of C57BL/6J mice were fed HF diet with or without a supplement of 20% lingonberries from two different batches (Lingon1 and Lingon2) during 11 weeks. The composition and functionality of the cecal microbiota were assessed by 16S rRNA sequencing and PICRUSt. In addition, parameters related to obesity, insulin sensitivity, hepatic steatosis, inflammation and gut barrier function were examined. Results: HF-induced obesity was only prevented by the Lingon1 diet, whereas both batches of lingonberries reduced plasma levels of markers of inflammation and endotoxemia (SAA and LBP) as well as modified the composition and functionality of the gut microbiota, compared to the HF control group. The relative abundance of Akkermansia and Faecalibacterium, genera associated with healthy gut mucosa and antiinflammation, was found to increase in response to lingonberry intake. Conclusions: Our results show that supplementation with lingonberries to an HF diet prevents low-grade inflammation and is associated with significant changes of the microbiota composition. Notably, the antiinflammatory properties of lingonberries seem to be independent of effects on body weight gain. © 2016 Lovisa Heyman-Lindén et al.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :12&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84979223171&amp;doi=10.3402%2ffnr.v60.29993&amp;partnerID=40&amp;md5=e0112ed5bc526f19217ca6072d0169fa</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">29993</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.3402/fnr.v60.29993</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>346</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">346</key></foreign-keys><ref-type name="Book">6</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Loo, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, Department of Pediatric Anesthesiology, Stanford Medical Center, Palo Alto, CA, United States&#xD;Neurodevelopmental Program, Department of Pediatrics, Santa Clara County Valley Medical Center, San Jose, CA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Integrative Medicine for Children</style></title><secondary-title><style face="normal" font="default" size="100%">Integrative Medicine for Children</style></secondary-title></titles><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Whether you initiate alternative therapies for children, or simply need to respond when asked for information or advice, it&apos;s crucial to have the most current, evidence-based information so that you can safely and effectively integrate CAM therapies with conventional treatment. This innovative and reliable reference is the ideal resource to have at hand. With its focus on integrating conventional medicine with the best complementary therapies for children, it familiarizes you with the scientific evidence and rationales for various CAM therapies, and clearly describes how to use them, in conjunction with conventional medicine. You&apos;ll find the information you need to distinguish among those therapies with good evidence, those that are safe but not yet proven to be effective, and those contraindicated for certain conditions. Covers a wide range of complementary and alternative therapies, focusing on those most often utilized with children: mind-body approaches (hypnosis, mind/body, probiotics, spirituality); manual therapies (chiropractic, massage, osteopathy, psychological); lifestyle approaches (nutrition, Qigong); alternative systems (homeopathy, naturopathy); energy medicine (acupuncture, aromatherapy, herbal, laser, magnets); and biological agents (Chinese and Western herbs and probiotics). 57 of the most common pediatric conditions are comprehensively discussed, first with a focus on conventional diagnostic and treatment information, then with authoritative information on the most effective and evidence-based CAM therapies available for treatment of the condition. Presents an integrative approach, combining conventional and alternative therapies. Helps you answer questions relevant to today&apos;s patients, such as giving echinacea for a cold, the use of acupuncture to treat ADHD, and which alternative therapies may be used to avoid side effects of conventional medication. © 2009 Elsevier Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Book</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85013966141&amp;doi=10.1016%2fB978-1-4160-2299-2.X0071-0&amp;partnerID=40&amp;md5=6f4c9a42c7e9e93e8af4a6fe2bcee700</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/B978-1-4160-2299-2.X0071-0</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>107</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">107</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Loke, I.</style></author><author><style face="normal" font="default" size="100%">Kolarich, D.</style></author><author><style face="normal" font="default" size="100%">Packer, N. H.</style></author><author><style face="normal" font="default" size="100%">Thaysen-Andersen, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemistry and Biomolecular Sciences, Macquarie University, Sydney, NSW 2109, Australia&#xD;Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Potsdam, 14424, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Emerging roles of protein mannosylation in inflammation and infection</style></title><secondary-title><style face="normal" font="default" size="100%">Molecular Aspects of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Molecular Aspects of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">31-55</style></pages><volume><style face="normal" font="default" size="100%">51</style></volume><keywords><keyword><style face="normal" font="default" size="100%">C-type lectin</style></keyword><keyword><style face="normal" font="default" size="100%">Glycoprotein</style></keyword><keyword><style face="normal" font="default" size="100%">Infection</style></keyword><keyword><style face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style face="normal" font="default" size="100%">Mannose</style></keyword><keyword><style face="normal" font="default" size="100%">Paucimannosylation</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Proteins are frequently modified by complex carbohydrates (glycans) that play central roles in maintaining the structural and functional integrity of cells and tissues in humans and lower organisms. Mannose forms an essential building block of protein glycosylation, and its functional involvement as components of larger and diverse α-mannosidic glycoepitopes in important intra- and intercellular glycoimmunological processes is gaining recognition. With a focus on the mannose-rich asparagine (N-linked) glycosylation type, this review summarises the increasing volume of literature covering human and non-human protein mannosylation, including their structures, biosynthesis and spatiotemporal expression. The review also covers their known interactions with specialised host and microbial mannose-recognising C-type lectin receptors (mrCLRs) and antibodies (mrAbs) during inflammation and pathogen infection. Advances in molecular mapping technologies have recently revealed novel immuno-centric mannose-terminating truncated N-glycans, termed paucimannosylation, on human proteins. The cellular presentation of α-mannosidic glycoepitopes on N-glycoproteins appears tightly regulated; α-mannose determinants are relative rare glycoepitopes in physiological extracellular environments, but may be actively secreted or leaked from cells to transmit potent signals when required. Simultaneously, our understanding of the molecular basis on the recognition of mannosidic epitopes by mrCLRs including DC-SIGN, mannose receptor, mannose binding lectin and mrAb is rapidly advancing, together with the functional implications of these interactions in facilitating an effective immune response during physiological and pathophysiological conditions. Ultimately, deciphering these complex mannose-based receptor–ligand interactions at the detailed molecular level will significantly advance our understanding of immunological disorders and infectious diseases, promoting the development of future therapeutics to improve patient clinical outcomes. © 2016 Elsevier Ltd</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :14&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84963971188&amp;doi=10.1016%2fj.mam.2016.04.004&amp;partnerID=40&amp;md5=4ed276ea7d69e90c714f2a8e2c467751</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.mam.2016.04.004</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>81</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">81</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Locke, A. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Family and Preventative Medicine, Office of Wellness and Integrative Health, University of Utah, Salt Lake City, UT, United States&#xD;Department of Family Medicine, University of Michigan, Ann Arbor, MI, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary Tract Infection (UTI)</style></title><secondary-title><style face="normal" font="default" size="100%">Integrative Medicine: Fourth Edition</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">211-217.e2</style></pages><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054159278&amp;doi=10.1016%2fB978-0-323-35868-2.00022-0&amp;partnerID=40&amp;md5=ff17a04805f28ccc3c9739f64af78067</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/B978-0-323-35868-2.00022-0</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>398</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">398</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Strauss, J.</style></author><author><style face="normal" font="default" size="100%">Camesano, T. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemical Engineering, Worcester Polytechnic Institute, 100 Institute Road, Worcester, MA 01609, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Thermodynamic investigation of Staphylococcus epidermidis interactions with protein-coated substrata</style></title><secondary-title><style face="normal" font="default" size="100%">Langmuir</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Langmuir</style></full-title></periodical><pages><style face="normal" font="default" size="100%">7134-7142</style></pages><volume><style face="normal" font="default" size="100%">23</style></volume><number><style face="normal" font="default" size="100%">13</style></number><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">We evaluated self-assembled monolayers (SAMs) as potential coatings to prevent bacterial adhesion to biomaterials. Bacterial retention experiments were conducted on SAMs, some of which were coated with the model proteins fetal bovine serum (FBS) and fibronectin (FN). A thermodynamic approach was applied to calculate the Gibbs free energy changes of adhesion (ΔG adh) of Staphylococcus epidermidis interacting with the substrates. When only nonspecific interactions controlled bacterial attachment, such as for the non-protein-coated substrates or the FBS substrates, the correlation between the thermodynamic predictions and measured values of bacterial retention was strong. However, when FN was adsorbed to the surfaces, the thermodynamic modeling underestimated bacterial adhesion, presumably since specific interactions between proteins of S. epidermidis and FN led to stronger attachment. Bacterial viability on the substrates was correlated with thermodynamic properties. For example, although bacteria attached more to surfaces having negative ΔG adh values, these cells experienced the greatest loss of viability, presumably since strongly attached bacteria were unable to divide and grow. When the AG adh values were decoupled into their components, we saw that acid-base interactions due to hydrogen bonding dominated the interactions of bacteria and proteins with each other and with the substrates in aqueous media. Finally, we discuss concerns regarding the use of the thermodynamic model to predict bacterial adhesion behavior in biomaterials systems. © 2007 American Chemical Society.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :30&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-34547367562&amp;doi=10.1021%2fla700575u&amp;partnerID=40&amp;md5=ad3520be11f4803de359fa20b41b0680</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/la700575u</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>366</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">366</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Gallardo-Moreno, A. M.</style></author><author><style face="normal" font="default" size="100%">Pinzon-Arango, P. A.</style></author><author><style face="normal" font="default" size="100%">Reynolds, Y.</style></author><author><style face="normal" font="default" size="100%">Rodriguez, G.</style></author><author><style face="normal" font="default" size="100%">Camesano, T. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemical Engineering, Worcester Polytechnic Institute, Worcester, MA 01609, United States&#xD;Department of Applied Physics, University of Extremadura, Avda. Elvass/n, 06710, Badajoz, Spain&#xD;Department of Biomedical Engineering, Worcester Polytechnic Institute, Worcester, MA 01609, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry changes the physicochemical surface properties of E. coli and adhesion with uroepithelial cells</style></title><secondary-title><style face="normal" font="default" size="100%">Colloids and Surfaces B: Biointerfaces</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Colloids and Surfaces B: Biointerfaces</style></full-title></periodical><pages><style face="normal" font="default" size="100%">35-42</style></pages><volume><style face="normal" font="default" size="100%">65</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Atomic force microscopy</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial adhesion</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Interfacial free energy</style></keyword><keyword><style face="normal" font="default" size="100%">Natural products</style></keyword><keyword><style face="normal" font="default" size="100%">Thermodynamic model</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberries have been suggested to decrease the attachment of bacteria to uroepithelial cells (UC), thus preventing urinary tract infections, although the mechanisms are not well understood. A thermodynamic approach was used to calculate the Gibbs free energy of adhesion changes (ΔGadh) for bacteria-UC interactions, based on measuring contact angles with three probe liquids. Interfacial tensions and ΔGadh values were calculated for Escherichia coli HB101pDC1 (P-fimbriated) and HB101 (non-fimbriated) exposed to cranberry juice (0-27 wt.%). HB101pDC1 can form strong bonds with the Gal-Gal disaccharide receptor on uroepithelial cells, while HB101-UC interactions are only non-specific. For HB101 interacting with UC, ΔGadh was always negative, suggesting favorable adhesion, and the values were insensitive to cranberry juice concentration. For the HB101pDC1-UC system, ΔGadh became positive at 27 wt.% cranberry juice, suggesting that adhesion was unfavorable. Acid-base (AB) interactions dominated the interfacial tensions, compared to Lifshitz-van der Waals (LW) interactions. Exposure to cranberry juice increased the AB component of the interfacial tension of HB101pDC1. LW interactions were small and insensitive to cranberry juice concentration. The number of bacteria attached to UC was quantified in batch adhesion assays and quantitatively correlated with ΔGadh. Since the thermodynamic approach should not agree with the experimental results when specific interactions are present, such as HB101pDC-UC ligand-receptor bonds, our results may suggest that cranberry juice disrupts bacterial ligand-UC receptor binding. These results help form the mechanistic explanation of how cranberry products can be used to prevent bacterial attachment to host tissue, and may lead to the development of better therapies based on natural products. © 2008 Elsevier B.V. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :56&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-44749088877&amp;doi=10.1016%2fj.colsurfb.2008.02.012&amp;partnerID=40&amp;md5=0a2042a399975857a6b8be68be66c8b5</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.colsurfb.2008.02.012</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>433</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">433</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Black, M. A.</style></author><author><style face="normal" font="default" size="100%">Caron, L.</style></author><author><style face="normal" font="default" size="100%">Camesano, T. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemical Engineering, Worcester Polytechnic Institute, Worcester, MA 01609, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Role of cranberry juice on molecular-scale surface characteristics and adhesion behavior of Escherichia coli</style></title><secondary-title><style face="normal" font="default" size="100%">Biotechnology and Bioengineering</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biotechnology and Bioengineering</style></full-title></periodical><pages><style face="normal" font="default" size="100%">297-305</style></pages><volume><style face="normal" font="default" size="100%">93</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Atomic force microscopy</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial adhesion</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry juice has long been believed to benefit the prevention and treatment of urinary tract infections (UTIs). As the first step in the development of infection, bacterial adhesion is of great research interest, yet few studies have addressed molecular level adhesion in this context. P-fimbriated Escherichia coli play a major role in the development of a serious type of UTI, acute pyelonephritis. Experiments were conducted to investigate the molecular-scale effects of cranberry juice on two E. coli strains: HB101, which has no fimbriae, and the mutant HB101pDC1 which expresses P-fimbriae. Atomic force microscopy (AFM) was used to investigate both bacterial surface characteristics and adhesion forces between a probe surface (silicon nitride) and the bacteria, providing a direct evaluation of bacterial adhesion and interaction forces. Cranberry juice affected bacterial surface polymer and adhesion behavior after a short exposure period (&lt;3 h). Cranberry juice affected the P-fimbriated bacteria by decreasing the adhesion forces between the bacterium and tip and by altering the conformation of the surface macromolecules on E. coli HB101pDC1. The equilibrium length of polymer (P-fimbriae) on this bacterium decreased from ∼148 to ∼48 nm upon being exposed to cranberry juice. Highly acidic conditions were not necessary for the prevention of bacterial adhesion, since neutralization of cranberry juice solutions to pH = 7.0 allowed us to observe differences in adhesion between the E. coli strains. Our results demonstrate molecular-level changes in the surfaces of P-fimbriated E. coli upon exposure to neutralized cranberry juice. © 2005 Wiley Periodicals, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :118&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33645556038&amp;doi=10.1002%2fbit.20675&amp;partnerID=40&amp;md5=cf7467be2bff948a70ac8abe2cce23a9</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/bit.20675</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>119</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">119</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Liska, D. J.</style></author><author><style face="normal" font="default" size="100%">Kern, H. J.</style></author><author><style face="normal" font="default" size="100%">Maki, K. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Biofortis Innovation Services, Addison, IL, United States&#xD;Midwest Center for Metabolic and Cardiovascular Research, Chicago, IL, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberries and urinary tract infections: How can the same evidence lead to conflicting advice?</style></title><secondary-title><style face="normal" font="default" size="100%">Advances in Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Advances in Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">498-506</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Meta-analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">Women</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry has been used traditionally to prevent urinary tract infections (UTIs), primarily among generally healthy women prone to recurrent UTIs. Results from a number of published clinical studies have supported this benefit; however, meta-analyses on cranberry and UTI prevention have reported conflicting conclusions. This article explores the methodological differences that contributed to these disparate findings. Despite similar research questions, the meta-analyses varied in the studies that were included, as well as the data that were extracted. In the 2 most comprehensive systematic reviews, heterogeneity was handled differently, leading to an I2 of 65% in one and 43% in the other. Most notably, the populations influencing the conclusions varied. In one analysis, populations with pathological/physiological conditions contributed 75.6% of the total weight to the summary risk estimate (RR: 0.86; 95% CI: 0.71, 1.04); another weighted the evidence relatively equally across UTI populations (RR: 0.62; 95% CI: 0.49, 0.80); and a third included only women with recurrent UTIs (RR: 0.53; 95% CI: 0.33, 0.83). Because women with recurrent UTIs are the group to whom most recommendations regarding cranberry consumption is directed, inclusion of other groups in the efficacy assessment could influence clinical practice quality. Therefore, conclusions on cranberry and UTIs should consider differences in results across various populations studied when interpreting results from meta-analyses. © 2016 American Society for Nutrition.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :10&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84971411291&amp;doi=10.3945%2fan.115.011197&amp;partnerID=40&amp;md5=87d47801321a26d5b270e9a67d7c536f</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3945/an.115.011197</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>33</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">33</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Linsenmeyer, T. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Kessler Institute for Rehabilitation, West Orange, NJ, United States&#xD;Department of Surgery (Division of Urology), Rutgers–New Jersey Medical School, Newark, NJ, United States&#xD;Department of Physical Medicine &amp; Rehabilitation, Rutgers–New Jersey Medical School, Newark, NJ, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Catheter-associated urinary tract infections in persons with neurogenic bladders</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Spinal Cord Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Spinal Cord Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">132-141</style></pages><volume><style face="normal" font="default" size="100%">41</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Catheter associated UTI (CAUTI)</style></keyword><keyword><style face="normal" font="default" size="100%">Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenic bladder</style></keyword><keyword><style face="normal" font="default" size="100%">SCI</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary catheters</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">This review is based on the author&apos;s Donald Munro Lecture given at the annual conference of the Academy of Spinal Cord Injury Professionals in New Orleans, LA. Indwelling catheters play an important role in bladder management following SCI for many individuals with neurogenic bladders. There is an increased risk of UTI compared to other types of bladder management with indwelling urethral catheters but not SP catheters. To minimize the risk of symptomatic UTI, the following steps are essential: prevent bladder wall distention and resulting ischemia, maintain colonization with “good” bacteria, and prevent bladder stones. For individuals with recurrent symptomatic UTIs, try to change the environment, prevent bladder over distention, and make sure the bladder is “quiet” by using strategies such as adequate dosages of anticholinergics, onabotulinum toxin A, and preventing catheter blockage. Bacterial colonization of the bladder is common. However, bacterial colonization may have a positive effect by inhibition of colonization of pathogenic bacteria. Judicious use of antibiotics is important since antibiotics hasten the evolution of more resistant organisms. Potential prevention and treatment strategies include killing the offending organisms, changing the environment (such as urinary acidification), and modifying virulence factors and the bacterial microbiome. © 2018, © The Academy of Spinal Cord Injury Professionals, Inc. 2018.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041138329&amp;doi=10.1080%2f10790268.2017.1415419&amp;partnerID=40&amp;md5=26f0b1e443ece2b3e48341b5ba366626</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/10790268.2017.1415419</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>201</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">201</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lin, S. C.</style></author><author><style face="normal" font="default" size="100%">Wang, C. C.</style></author><author><style face="normal" font="default" size="100%">Shih, S. C.</style></author><author><style face="normal" font="default" size="100%">Tjung, J. J.</style></author><author><style face="normal" font="default" size="100%">Tsou, M. T.</style></author><author><style face="normal" font="default" size="100%">Lin, C. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Nursing, Mackay Memorial Hospital, Taipei, Taiwan&#xD;Department of Nursing, Mackay Medical College, Taipei, Taiwan&#xD;Telehealth and Homecare Center, Department of Nursing, Mackay Memorial Hospital, Taipei, Taiwan&#xD;Department of Internal Medicine, Health Evaluation Center, Mackay Memorial Hospital, Taipei, Taiwan&#xD;Mackay Junior College of Medicine, Nursing, and Management, Taipei, Taiwan&#xD;Department of Family Medicine, Mackay Memorial Hospital, Taipei, Taiwan&#xD;Division of Nephrology, Department of Internal Medicine, Mackay Memorial Hospital, 92 Chung Shan North Road, Taipei, 104, Taiwan&#xD;Institute of Biotechnology, National Taipei University of Technology, Taipei, Taiwan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevention of asymptomatic bacteriuria with cranberries and Roselle juice in home-care patients with long-term urinary catheterization</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Gerontology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Gerontology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">152-156</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry juice</style></keyword><keyword><style face="normal" font="default" size="100%">Home care</style></keyword><keyword><style face="normal" font="default" size="100%">Roselle juice</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: This research investigated the effect of drinking Roselle tea and cranberry juice in preventing asymptomatic bacteriuria in home care patients with long-term indwelling catheter. Methods: The research participants were divided into three groups: Roselle tea group, cranberry juice group, and control group. Urinalysis, urine culture, and biochemical blood tests were performed for all patients. The research lasted for 6 months, and the aforementioned three tests were conducted prior to, 3 months after, and 6 months after the research had started. We compared the effect of drinking cranberry juice and Roselle tea in reducing urinary tract infection. Results: The results of the urinalysis, urine culture, and biochemical blood tests in the three groups did not show any significant difference. Furthermore, Roselle tea and cranberry juice did not effectively reduce urinary tract infection as compared with the control group in patients with long-term indwelling catheter. Conclusion: Based on our results, neither Roselle tea nor cranberry juice was able to reduce the frequency of asymptomatic bacteriuria. It is inferred that cranberry juice or Roselle tea can only be used in ordinary day health care for the urinary tract. Copyright © 2014, Taiwan Society of Geriatric Emergency &amp; Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84922380273&amp;doi=10.1016%2fj.ijge.2014.03.004&amp;partnerID=40&amp;md5=4b25a0cdc5bb13fbf201cf36b9c9b4d9</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ijge.2014.03.004</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>338</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">338</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Li, M.</style></author><author><style face="normal" font="default" size="100%">Andrew, M. A.</style></author><author><style face="normal" font="default" size="100%">Wang, J.</style></author><author><style face="normal" font="default" size="100%">Salinger, D. H.</style></author><author><style face="normal" font="default" size="100%">Vicini, P.</style></author><author><style face="normal" font="default" size="100%">Grady, R. W.</style></author><author><style face="normal" font="default" size="100%">Phillips, B.</style></author><author><style face="normal" font="default" size="100%">Shen, D. D.</style></author><author><style face="normal" font="default" size="100%">Anderson, G. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmaceutics, University of Washington, Seattle, WA 98105, United States&#xD;Department of Bioengineering, University of Washington, Seattle, WA 98105, United States&#xD;Applied Physics Laboratory, University of Washington, Seattle, WA 98105, United States&#xD;Department of Urology, School of Medicine, University of Washington, Seattle, WA 981954, United States&#xD;Pharmacokinetics Laboratory, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 981095, United States&#xD;Department of Pharmacy, Health Science Complex H-361A, University of Washington, Box 357630, Seattle, WA 98195, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of cranberry juice on pharmacokinetics of β-lactam antibiotics following oral administration</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2725-2732</style></pages><volume><style face="normal" font="default" size="100%">53</style></volume><number><style face="normal" font="default" size="100%">7</style></number><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry juice consumption is often recommended along with low-dose oral antibiotics for prophylaxis for recurrent urinary tract infection (UTI). Because multiple membrane transporters are involved in the intestinal absorption and renal excretion of β-lactam antibiotics, we evaluated the potential risk of pharmacokinetic interactions between cranberry juice and the β-lactams amoxicillin (amoxicilline) and cefaclor. The amoxicillin-cranberry juice interaction was investigated in 18 healthy women who received on four separate occasions a single oral test dose of amoxicillin at 500 mg and 2 g with or without cranberry juice cocktail (8 oz) according to a crossover design. A parallel cefaclor-cranberry juice interaction study was also conducted in which 500 mg cefaclor was administered with or without cranberry juice cocktail (12 oz). Data were analyzed by noncompartmental methods and nonlinear mixed-effects compartmental modeling. We conclude that the concurrent use of cranberry juice has no significant effect on the extent of oral absorption or the renal clearance of amoxicillin and cefaclor. However, delays in the absorption of amoxicillin and cefaclor were observed. These results suggest that the use of cranberry juice at usual quantities as prophylaxis for UTI is not likely to alter the pharmacokinetics of these two oral antibiotics. Copyright © 2009, American Society for Microbiology. All Rights Reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :13&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-67649978676&amp;doi=10.1128%2fAAC.00774-08&amp;partnerID=40&amp;md5=99ee6bbc10e440b83f7114b2bd947d31</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/AAC.00774-08</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>456</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">456</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leitão, D. P. S.</style></author><author><style face="normal" font="default" size="100%">Polizello, A. C. M.</style></author><author><style face="normal" font="default" size="100%">Ito, I. Y.</style></author><author><style face="normal" font="default" size="100%">Spadaro, A. C. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departamento de &apos;Fisica e Quimica, Fac. Cie. Farmaceut. Ribeirao Preto, Universidade de São Paulo, Ribeirao Preto, Sao Paulo, Brazil&#xD;Depto. de Anal. Clin., Toxicol./B., Fac. Cie. Farmaceut. Ribeirao Preto, Universidade de São Paulo, Ribeirao Preto, Sao Paulo, Brazil&#xD;Departamento de Fisica e Quimica, Fac. Cie. Farmaceut. Riheirao Preto, Universidade de São Paulo, Avenue do Café, s/n, CEP 14040-903, Ribeirao Preio, SP, Brazil</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antibacterial screening of anthocyanic and proanthocyanic fractions from cranberry juice</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Medicinal Food</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Medicinal Food</style></full-title></periodical><pages><style face="normal" font="default" size="100%">36-40</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anthocyanin</style></keyword><keyword><style face="normal" font="default" size="100%">Antibacterial activity</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidin</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">The effect of anthocyanin- and proanthocyanidin-rich fractions isolated from cranberry juice was studied for their antibacterial activity against nine bacterial strains. Activity was assessed by the agar diffusion assay. Staphylococcus aureus ATCC 6538 was the only strain to exhibit some susceptibility to four out of 10 anthocyanin-rich fractions tested. A variable susceptibility of S. aureus, Enterococcus faecalis ATCC 10541, and Micrococcus luteus ATCC 9341 to proanthocyanidin-rich fractions was also observed. Streptococcus mutons strains as well as Escherichia coli ATCC 10538 and Pseudomonas aeruginosa ATCC 27853 were not susceptible to any of the cranberry juice samples or fractions at the tested concentrations. There was no clear correlation between Gram-positive or Gram-negative bacterial susceptibility to cranberry juice. In this work, the role of cranberry juice anthocyanic and proanthocyanic fractions upon bacterial viability is discussed.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :42&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-18144364304&amp;doi=10.1089%2fjmf.2005.8.36&amp;partnerID=40&amp;md5=23080ab0278a306e6c97fc2423975441</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1089/jmf.2005.8.36</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>48</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">48</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, S. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, St. Vincent&apos;s Hospital, The Catholic University of Korea, Suwon, South Korea</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recent advances in managing lower urinary tract infections [version 1; referees: 2 approved]</style></title><secondary-title><style face="normal" font="default" size="100%">F1000Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">F1000Research</style></full-title></periodical><volume><style face="normal" font="default" size="100%">7</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Antimicrobial resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTIs) are among the most common bacterial infections. Traditionally, all symptomatic UTIs are tested and treated. The use of antibiotics has resulted in an antibiotic resistance crisis, and we have limited options for managing UTIs. Currently, we live in the era of antimicrobial resistance and may live in other eras like the era of the microbiome. New insights might provide an opportunity to prevent the overuse and misuse of antibiotics and could enable the development of innovate managing strategies. © 2018 Lee SJ.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059501535&amp;doi=10.12688%2ff1000research.16245.1&amp;partnerID=40&amp;md5=44d162466efc6e01ba89a9fbf5ac37e6</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">1964</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.12688/f1000research.16245.1</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>323</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">323</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, N. S.</style></author><author><style face="normal" font="default" size="100%">Lee, S. J.</style></author><author><style face="normal" font="default" size="100%">Cho, Y. H.</style></author><author><style face="normal" font="default" size="100%">Han, C. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, College of Medicine, Catholic University of Korea, Seoul, South Korea</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antimicrobial effect of Lactobacillus in a rat model of Escherichia coli urinary tract infection: A preliminary study</style></title><secondary-title><style face="normal" font="default" size="100%">Korean Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Korean Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1253-1257</style></pages><volume><style face="normal" font="default" size="100%">50</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Lactobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Purpose: Urinary tract infection (UTI) is one of the most common infectious diseases. There are reports that loss or destruction of normal urinary flora such as Lactobacillus increases UTI, and in more recent reports, human urinary epithelial cells have been found to competitively block uropathogen conjugation. We investigated the blocking effect of the Lactobacillus rhamnosus in a rat model of UTI caused by Escherichia coli. Materials and Methods: Thirty-two adult female Sprague-Dawley rats weighing 250 to 350 g (Samtako BioKorea, Osan, South Korea) were randomly divided into 4 groups (Group I, control group; Group II, Lactobacillus group; Group III, E. coli group; Group IV, E. coli and Lactobacillus group). After 3 weeks, the urine and bladder were cultured for microbiological study and the bladder was examined histopathologically. Results: Microbiological culture of urine demonstrated no significant differences in the four groups, but there were significantly fewer bacteria in group IV than in group III (p&lt;0.05). The bacterial growth of the bladder tissue showed the same result. Histological exam of the bladder of group IV showed decreased infiltration of leukocytes and less submucosal edema than in group III. Conclusions: We were able to confirm the blocking effect of L. rhamnosus on E. coli growth. More studies are needed to further identify the therapeutic effect of Lactobacillus and to determine the optimal lactobacilli species, dose, and method of administration. ©The Korean Urological Association, 2009.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-74249091706&amp;doi=10.4111%2fkju.2009.50.12.1253&amp;partnerID=40&amp;md5=89de75ae5acef6ae5655fb43c0ce5db3</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.4111/kju.2009.50.12.1253</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>410</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">410</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">PCTs</style></auth-address><titles><title><style face="normal" font="default" size="100%">Treating UTI in the primary care setting</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Community Nursing</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Community Nursing</style></full-title></periodical><pages><style face="normal" font="default" size="100%">4-9</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Continence</style></keyword><keyword><style face="normal" font="default" size="100%">Evidence</style></keyword><keyword><style face="normal" font="default" size="100%">Research</style></keyword><keyword><style face="normal" font="default" size="100%">UTI</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">Louise Lee reviews three research articles on the treatment of urinary tract infection (UTI) in a primary care setting. ©PTM Publishers Limited.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33846647499&amp;partnerID=40&amp;md5=823d91b8bdd0135c09b59f3980ef44c3</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>227</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">227</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lee, H. A.</style></author><author><style face="normal" font="default" size="100%">King, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Complementary therapy strategies: Myths, facts, and lifestyle</style></title><secondary-title><style face="normal" font="default" size="100%">Urinary Tract Infection: Clinical Perspectives on Urinary Tract Infection</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">59-72</style></pages><keywords><keyword><style face="normal" font="default" size="100%">Complementary therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Contraception</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry juice</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Sexual intercourse</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">The objective of this chapter is to consider widely held popular beliefs surrounding UTIs and to see whether they stand up when scrutinized by medical research. A great deal has been written on the subject of cranberry juice and its role in the treatment and prevention of UTIs. Cranberry juice can help prevent recurrent UTIs in women, but there is no evidence that it is effective in treating UTIs. Cranberry products work by inhibiting pathogenic adherence to the uroepithelium and probably not through acidificationof the urine as was previously thought. Uva ursi (bearberry) can be used to treat UTIs affecting the lower tract, but should not be used for long-term prophylaxis as prolongedexposure to metabolites may be carcinogenic. There is some weak evidence to suggest that probiotics and some vitamins (e.g., vitamin C) can help prevent UTIs. In addition to this, there is an association between frequency of sexual intercourse and UTIs, but not between number of partners and UTIs. Bubble bath probably does not increase the risk of UTIs, whereas condom use and contraceptive diaphragm use are associated with higher rates of UTI, although this should not discourage the use of safe sex. © Springer-Verlag London 2013.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84956678011&amp;doi=10.1007%2f978-1-4471-4709-1_7&amp;partnerID=40&amp;md5=ce72246937cfc304ae3ef40c02e8461c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/978-1-4471-4709-1_7</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>546</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">546</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leahy, M.</style></author><author><style face="normal" font="default" size="100%">Speroni, J.</style></author><author><style face="normal" font="default" size="100%">Starr, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Ocean Spray Cranberries, Inc., One Ocean Spray Drive, Lakeville, MA 02349, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Latest developments in cranberry health research</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmaceutical Biology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pharmaceutical Biology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">50-54</style></pages><volume><style face="normal" font="default" size="100%">40</style></volume><number><style face="normal" font="default" size="100%">SUPPL.</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-adhesion</style></keyword><keyword><style face="normal" font="default" size="100%">Antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">E. coli</style></keyword><keyword><style face="normal" font="default" size="100%">H. pylori</style></keyword><keyword><style face="normal" font="default" size="100%">LDL cholesterol</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract health benefits have long been ascribed to the American cranberry, Vaccinium macrocarpon, through folklore. Now, a growing body of science supports this association. Current research suggests that this benefit is due to components in cranberry preventing the adhesion of certain bacteria in the urinary tract. Cranberry&apos;s relatively unique A-type proanthocyanidins were identified as the components that prevented the adhesion of P-fimbriated E. coli to uroepithelial cells using bioassay-directed fractionation techniques. Very recently, using an animal model, in vivo evidence was obtained suggesting that cranberry proanthocyanidins were absorbed and elicited this specific anti-adherence activity in urine. Recent preliminary research suggests that cranberry&apos;s microbial anti-adhesion effect may extend into the gastrointestinal tract, which may contribute to both the urinary tract health benefit as well as preventing attachment of H. pylori, the bacteria responsible for many peptic ulcers. Diets high in fruits, vegetables, and grains contribute to improving health status in a number of ways. Oxidative stress may play a role in the development of many chronic diseases, including cardiovascular diseases. Ex vivo testing indicates that cranberry flavonoids inhibit the oxidation of human LDL cholesterol, with proanthocyanidins the most active flavonoid fraction. Additionally, a diet rich in cranberry juice powder significantly reduced the total and LDL cholesterol in hypercholesteremic pigs. Cranberry appears to be a relatively unique fruit in that it may provide benefits both through microbial anti-adhesion and possibly through antioxidant mechanisms.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :23&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Conference Paper</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036261015&amp;doi=10.1076%2fphbi.40.7.50.9172&amp;partnerID=40&amp;md5=e45a8f268f7d83365b1dcb7fe2886bc0</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1076/phbi.40.7.50.9172</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>479</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">479</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Le, J.</style></author><author><style face="normal" font="default" size="100%">Briggs, G. G.</style></author><author><style face="normal" font="default" size="100%">McKeown, A.</style></author><author><style face="normal" font="default" size="100%">Bustillo, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacy Practice, College of Pharmacy, W. University of Health Sciences, Pomona, CA, United States&#xD;Perinatal Support Services, Women&apos;s Hospital, Long Beach Memorial Medical Center, Long Beach, CA, United States&#xD;Department of Obstetrics/Gynecology, University of California, Irvine Medical Center, Irvine, CA, United States&#xD;Department of Obstetrics/Gynecology, Orange Coast Memorial Medical Center, Fountain Valley, CA, United States&#xD;College of Pharmacy, W. University of Health Sciences, 309 E. Second St., Pomona, CA 91766-1854, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections during pregnancy</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Pharmacotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Pharmacotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1692-1701</style></pages><volume><style face="normal" font="default" size="100%">38</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Gestation</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Pyelonephritis</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">OBJECTIVE: To provide a comprehensive review of urinary tract infections (UTIs) during pregnancy. All aspects of UTIs, including epidemiology, pathogenesis, resistance, clinical features, diagnosis, treatment, and prevention, were reviewed. DATA SOURCES: MEDLINE (1966-August 2003) and Cochrane Library searches were performed using the key search terms urinary tract infection, pyelonephritis, cystitis, asymptomatic bacteriuria, and resistance. STUDY SELECTION AND DATA EXTRACTION: All article abstracts were evaluated for relevance. Only articles pertaining to pregnancy were included. The majority of published literature were review articles; the number of original clinical studies was limited. DATA SYNTHESIS: UTIs are the most common bacterial infections during pregnancy. They are characterized by the presence of significant bacteria anywhere along the urinary tract. Pyelonephritis is the most common severe bacterial infection that can lead to perinatal and maternal complications including premature delivery, infants with low birth weight, fetal mortality, preeclampsia, pregnancy-induced hypertension, anemia, thrombocytopenia, and transient renal insufficiency. Enterobacteriaceae account for 90% of UTIs. The common antibiotics used are nitrofurantoin, cefazolin, cephalexin, ceftriaxone, and gentamicin. CONCLUSIONS: Therapeutic management of UTIs in pregnancy requires proper diagnostic workup and thorough understanding of antimicrobial agents to optimize maternal outcome, ensure safety to the fetus, and prevent complications that lead to significant morbidity and mortality in both the fetus and the mother.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :60&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-4644310403&amp;doi=10.1345%2faph.1D630&amp;partnerID=40&amp;md5=39bf71adfcbebd7607bf2c52986860e4</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1345/aph.1D630</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>385</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">385</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lavigne, J. P.</style></author><author><style face="normal" font="default" size="100%">Bourg, G.</style></author><author><style face="normal" font="default" size="100%">Combescure, C.</style></author><author><style face="normal" font="default" size="100%">Botto, H.</style></author><author><style face="normal" font="default" size="100%">Sotto, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institut National de la Santéet de la Recherche Médicale, ESPRI 26, Universitéde Montpellier 1, Avenue Kennedy, 30908 Nîmes Cedex 02, France&#xD;Département de l&apos;Information Médicale, Groupe Hospitalo-Universitaire de Carémeau, Nîmes, France&#xD;Service d&apos;Urologie, Hôpital Foch, Suresnes, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">In-vitro and in-vivo evidence of dose-dependent decrease of uropathogenic Escherichia coli virulence after consumption of commercial Vaccinium macrocarpon (cranberry) capsules</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Microbiology and Infection</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Microbiology and Infection</style></full-title></periodical><pages><style face="normal" font="default" size="100%">350-355</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adherence</style></keyword><keyword><style face="normal" font="default" size="100%">Caenorhabditis elegans</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">This study evaluated the antibacterial efficacy of the consumption of cranberry capsules vs. placebo in the urine of healthy volunteers. A first double-blind, randomised, crossover trial involved eight volunteers who had followed three regimens, with or without cranberry, with a wash-out period of at least 6days between each regimen. Twelve hours after consumption of cranberry or placebo hard capsules, the first urine of the morning was collected. Different Escherichia coli strains were cultured in the urine samples. Urinary antibacterial adhesion activity was measured in.vitro using the human T24 epithelial cell-line, and in.vivo using the Caenorhabditis elegans killing model. With the in-vitro model, 108 mg of cranberry induced a significant reduction in bacterial adherence to T24 cells as compared with placebo (p &lt; 0.001). A significant dose-dependent decrease in bacterial adherence in vitro was noted after the consumption of 108 and 36 mg of cranberry (p &lt; 0.001). The in-vivo model confirmed that E. coli strains had a reduced ability to kill C. elegans after growth in the urine of patients who consumed cranberry capsules. Overall, these in-vivo and in-vitro studies suggested that consumption of cranberry juice represents an interesting new strategy to prevent recurrent urinary tract infection. © 2008 European Society of Clinical Microbiology and Infectious Diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :61&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-40549111308&amp;doi=10.1111%2fj.1469-0691.2007.01917.x&amp;partnerID=40&amp;md5=1ab06423ce5c12fc35e9a855be1e8949</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1469-0691.2007.01917.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>388</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">388</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lavigne, J. P.</style></author><author><style face="normal" font="default" size="100%">Bourg, G.</style></author><author><style face="normal" font="default" size="100%">Botto, H.</style></author><author><style face="normal" font="default" size="100%">Sotto, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institut national de la santé et de la recherche médicale, ESPRI 26, Université de Montpellier-I, avenue Kennedy, 30908 Nîmes cedex 02, France&#xD;Laboratoire de bactériologie, de virologie et de parasitologie, CHU de Nîmes, groupe hospitalo-universitaire de Carémeau, place Professeur-Robert-Debré, 30029 Nîmes cedex 09, France&#xD;Service d&apos;urologie, hôpital Foch, Suresnes, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry (Vaccinium macrocarpon) and urinary tract infections: study model and review of literature</style></title><secondary-title><style face="normal" font="default" size="100%">Pathologie Biologie</style></secondary-title><short-title><style face="normal" font="default" size="100%">Cranberry (Vaccinium macrocarpon) et infections urinaires : étude et revue de la littérature</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pathologie Biologie</style></full-title></periodical><pages><style face="normal" font="default" size="100%">460-464</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><number><style face="normal" font="default" size="100%">8-9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-adhesion</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial virulence</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberries (Vaccinium macrocarpon) have long been the focus of interest for their beneficial effects in preventing urinary tract infections. Among cranberry compounds, a group of proanthocyanidins (PACs) with A-type linkages were isolated which exhibit bacterial anti-adhesion activity against uropathogenic Escherichia coli strains. These PAC inhibit P-fimbriae synthesis and induce a bacterial deformation. This activity was demonstrated on both antibiotic susceptible and resistant bacteria. This review focused on the last discoveries in the knowledge of cranberry effects. © 2007 Elsevier Masson SAS. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :11&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-35548995495&amp;doi=10.1016%2fj.patbio.2007.07.005&amp;partnerID=40&amp;md5=3d9fcd7d4801384b58fbea48137a9a57</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.patbio.2007.07.005</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>30</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">30</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lashkar, M. O.</style></author><author><style face="normal" font="default" size="100%">Nahata, M. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">King Abdulaziz University, Jeddah, Saudi Arabia&#xD;The Ohio State University, Columbus, OH, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antimicrobial Pharmacotherapy Management of Urinary Tract Infections in Pediatric Patients</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Pharmacy Technology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Pharmacy Technology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">62-81</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">disease management</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword><keyword><style face="normal" font="default" size="100%">prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: To discuss the risk factors, microbial resistance rates, and pharmacotherapy, including antimicrobial choices and medication dosage regimens, for urinary tract infections (UTIs) in pediatric patients. Data Sources: A MEDLINE literature search (1985 to December 2017) was performed using the following keywords and associated medical subject headings: urinary tract infection, antimicrobial, treatment, and children. Study Selection and Data Extraction: Search was conducted to identify clinical trials, systematic reviews, and guidelines. Search was filtered to include studies with age range between birth and 18 years and published in English. Additional references were identified from selected review articles. Data Synthesis: In total, 27 studies investigating microbial resistance, 31 studies assessing antimicrobial efficacy, 34 studies describing prophylaxis, and 6 systematic reviews were included. The resistance patterns differed across age groups and affected the choice of empirical therapy. If pyelonephritis is suspected, empiric antimicrobials should have high urinary and sufficient parenchymal concentrations. Nitrofurantoin has low microbial resistance rates and can generally be used empirically for treating uncomplicated cystitis in children &gt;1 month of age. Trimethoprim-sulfamethoxazole resistance has increased and should be avoided unless local susceptibility data are available. Certain patients with recurrent UTIs or renal abnormalities may require antimicrobial prophylaxis, which may be associated with adverse effects, such as intolerability or an increased risk of microbial resistance. Conclusion: The resistance pattern of uropathogens should be considered prior to initiating therapy. Controlled trials with large samples are needed to compare the treatment duration of various antimicrobial regimens and the specific role of prophylactic antimicrobials. © 2018, © The Author(s) 2018.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042478822&amp;doi=10.1177%2f8755122518755402&amp;partnerID=40&amp;md5=a713427a0d26c9ea86be92619f66d292</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/8755122518755402</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>357</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">357</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Larmo, P.</style></author><author><style face="normal" font="default" size="100%">Alin, J.</style></author><author><style face="normal" font="default" size="100%">Salminen, E.</style></author><author><style face="normal" font="default" size="100%">Kallio, H.</style></author><author><style face="normal" font="default" size="100%">Tahvonen, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Functional Foods Forum, University of Turku, Turku, Finland&#xD;Department of Biochemistry and Food Chemistry, University of Turku, Turku, Finland&#xD;Department of Biostatistics, University of Turku, Turku, Finland&#xD;Department of Radiotherapy and Oncology, Turku University Hospital, Turku, Finland&#xD;Functional Foods Forum/EPANET, University of Turku, Seinäjoki, Finland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of sea buckthorn berries on infections and inflammation: A double-blind, randomized, placebo-controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Clinical Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Clinical Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1123-1130</style></pages><volume><style face="normal" font="default" size="100%">62</style></volume><number><style face="normal" font="default" size="100%">9</style></number><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: To study the effect of sea buckthorn berries on the number and duration of common cold (CC) infections. As secondary objectives the effects on digestive and urinary tract infections (DTI, UTI), and serum C-reactive protein (CRP) concentrations were also investigated. Subjects: A total of 254 healthy volunteers were randomly assigned to receive sea buckthorn or placebo product during the study, which 233 of them completed. Results: There were no significant differences in the number or duration of CC or DTI between groups (CC: relative risks (sea buckthorn vs placebo) for the number and duration were 1.15 (95% CI 0.90-1.48) and 1.05 (95% CI 0.87-1.27), respectively). In the sea buckthorn group, as compared to the placebo, the serum CRP concentrations decreased significantly (difference in median change -0.059mg/l, P=0.039). The number of UTI was too small to draw solid conclusions, but the results indicate the subject merits further investigation. Conclusion: Sea buckthorn berries did not prevent CC or DTI. However, a reductive effect on CRP, a marker of inflammation, and a risk factor for cardiovascular diseases, was detected.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :33&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-51549120555&amp;doi=10.1038%2fsj.ejcn.1602831&amp;partnerID=40&amp;md5=8324a775f0eaf73505e77f7858921abd</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/sj.ejcn.1602831</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>266</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">266</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Laghari, A. H.</style></author><author><style face="normal" font="default" size="100%">Shah, A. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Biochemistry, University of Sindh, Jamshoro, Sindh, Pakistan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Multiple drug resistant (MDR) strains of escherichia coli isolated from urinary tract infection, a predictor of female childhood protein deficiency in southern sindh, Pakistan</style></title><secondary-title><style face="normal" font="default" size="100%">Pakistan Journal of Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pakistan Journal of Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">47-50</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Multiple drug resistant (MDR)</style></keyword><keyword><style face="normal" font="default" size="100%">Protein deficiency</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">A cross-sectional study to examine a current phenomenon of great concern among the medical communities in developing countries is rising multi-drug resistant organisms and the challenges of curing the infections in children. In this study, we evaluated the multi drug resistant strains of Escherichia coli (E. coli) isolated from urinary tract infection in children in southern sindh, Pakistan. Multi-drugs strains of E. coli in Urinary Tract Infection (UTI) with protein malnutrition, Iron deficiency anemia and Vitamin B12 and Folic Acid deficiency anemia was conducted among female children in southern sindh, Pakistan. A total of 150 female children aged up to 5 years were studied. The data were collected using structured questionnaires, anthropometric measurements and laboratory analysis of blood and Urine samples. The results showed that 47.4% of the female children were infected with multi-drugs resistance Escherichia coli, while 18.3% had significantly underweight, stunting and wasting respectively. Urinary tract infection with multi-drugs resistance strains Escherichia coli was statistically identified as a strong predictor of significant wasting in this study population. © Asian Network for Scientific Information, 2012.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-82855167347&amp;doi=10.3923%2fpjn.2012.47.50&amp;partnerID=40&amp;md5=d1be4e5ec413ad097f7804fc06f742a9</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3923/pjn.2012.47.50</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>220</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">220</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Laghari, A. H.</style></author><author><style face="normal" font="default" size="100%">Samoo, A. H.</style></author><author><style face="normal" font="default" size="100%">Qureshi, K. A.</style></author><author><style face="normal" font="default" size="100%">Shaikh, G. S.</style></author><author><style face="normal" font="default" size="100%">Shah, A. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry, GMMMC, Sukkur, Pakistan&#xD;Department of Physiology, GMMMC, Sukkur, Pakistan&#xD;Department of Pathology, GMMMC, Sukkur, Pakistan&#xD;Department of Biochemistry, CMC, Larkana, Pakistan&#xD;Department of Biochemistry, University of Sindh, Jamshoro, Pakistan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Isolation of E - Coli in UTI cases with malnutrition in children of distant rural area of Sukkur, Sindh</style></title><secondary-title><style face="normal" font="default" size="100%">Medical Forum Monthly</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Medical Forum Monthly</style></full-title></periodical><pages><style face="normal" font="default" size="100%">18-21</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">E - Coli infection</style></keyword><keyword><style face="normal" font="default" size="100%">Iron deficiency anaemia</style></keyword><keyword><style face="normal" font="default" size="100%">Protein malnutrition</style></keyword><keyword><style face="normal" font="default" size="100%">UTI</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Introduction: A cross-sectional study of isolation of Escherichia coli in urine culture of children and its correlation to childhood malnutrition induce microcytic hypochromic anaemia (I.D.A). Study Design: Cross Sectional Study Place and Duration of Study: This study was carried out at the Biochemistry Department, GMMMC, Sukkur from 01.12.2011 to 31.05.2013. Materials and Methods: Study was carry out among the children under 05 (five) years of age. Number of children included in this study was 150. Structured questionnaire were use to obtain the required data. Laboratory investigation of blood, urine samples was performing by standard methods and anthropometric data also collected. Results: The results showed that Escherichia coli positive children are 64.0%, 60.5% Childs has extremely low body weight, 43.6% shows stunting and 21.7% was wasting. Conclusion: This study showed that there is correlation between Urinary tract infection and malnutrition. So, energy yielding nutrients containing 8-10 essential amino acids, fates and minerals may be supplemented to less privileged patients of remote rural area of sukkur to enhance immune status.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84879906252&amp;partnerID=40&amp;md5=68e8ae13c2d8f6a143109876b2a85759</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>287</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">287</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kylli, P.</style></author><author><style face="normal" font="default" size="100%">Nohynek, L.</style></author><author><style face="normal" font="default" size="100%">Puupponen-Pimiä, R.</style></author><author><style face="normal" font="default" size="100%">Westerlund-Wikström, B.</style></author><author><style face="normal" font="default" size="100%">Leppänen, T.</style></author><author><style face="normal" font="default" size="100%">Welling, J.</style></author><author><style face="normal" font="default" size="100%">Moilanen, E.</style></author><author><style face="normal" font="default" size="100%">Heinonen, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Food and Environmental Sciences, University of Helsinki, P.O. Box 27, 00014 Helsinki, Finland&#xD;VTT Technical Research Centre of Finland, P.O. Box 1000, 02044 VTT, Finland&#xD;Department of Biosciences, University of Helsinki, P.O. Box 56, 00014 Helsinki, Finland&#xD;Immunopharmacology Research Group, University of Tampere School of Medicine and Medical Research Fund, Tampere University Hospital, 33014 Tampere, Finland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lingonberry (Vaccinium vitis-idaea) and European cranberry (Vaccinium microcarpon) proanthocyanidins: Isolation, identification, and bioactivities</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3373-3384</style></pages><volume><style face="normal" font="default" size="100%">59</style></volume><number><style face="normal" font="default" size="100%">7</style></number><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">European, small-fruited cranberries (Vaccinium microcarpon) and lingonberries (Vaccinium vitis-idaea) were characterized for their phenolic compounds and tested for antioxidant, antimicrobial, antiadhesive, and antiinflammatory effects. The main phenolic compounds in both lingonberries and cranberries were proanthocyanidins comprising 63-71% of the total phenolic content, but anthocyanins, hydroxycinnamic acids, hydroxybenzoic acids, and flavonols were also found. Proanthocyanidins are polymeric phenolic compounds consisting mainly of catechin, epicatechin, gallocatechin, and epigallocatechin units. In the present study, proanthocyanidins were divided into three groups: dimers and trimers, oligomers (mDP 4-10), and polymers (mDP &gt; 10). Catechin, epicatechin, A-type dimers and trimers were found to be the terminal units of isolated proanthocyanidin fractions. Inhibitions of lipid oxidation in liposomes were over 70% and in emulsions over 85%, and in most cases the oligomeric or polymeric fraction was the most effective. Polymeric proanthocyanidin extracts of lingonberries and cranberries were strongly antimicrobial against Staphylococcus aureus, whereas they had no effect on other bacterial strains such as Salmonella enterica sv. Typhimurium, Lactobacillus rhamnosus and Escherichia coli. Polymeric fraction of cranberries and oligomeric fractions of both lingonberries and cranberries showed an inhibitory effect on hemagglutination of E. coli, which expresses the M hemagglutin. Cranberry phenolic extract inhibited LPS-induced NO production in a dose-dependent manner, but it had no major effect on iNOS of COX-2 expression. At a concentration of 100 μg/mL cranberry phenolic extract inhibited LPS-induced IL-6, IL-1β and TNF-α production. Lingonberry phenolics had no significant effect on IL-1β production but inhibited IL-6 and TNF-α production at a concentration of 100 μg/mL similarly to cranberry phenolic extract. In conclusion the phenolics, notably proanthocyanidins (oligomers and polymers), in both lingonberries and cranberries exert multiple bioactivities that may be exploited in food development. © 2011 American Chemical Society.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :53&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79953837760&amp;doi=10.1021%2fjf104621e&amp;partnerID=40&amp;md5=450520fc7982677becf7dc366ef6bc27</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/jf104621e</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>353</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">353</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kulling, S. E.</style></author><author><style face="normal" font="default" size="100%">Rawel, H. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Food Chemistry, Institute of Nutritional Science, University of Potsdam, Nuthetal (OT Bergholz-Rehbrücke), Germany&#xD;University of Potsdam, Institute of Nutritional Science, Department of Food Chemistry, Arthur-Scheunert-Allee 114-116, 14558 Nuthetal (OT Bergholz-Rehbrücke), Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Chokeberry (Aronia melanocarpa) - A review on the characteristic components and potential health effects</style></title><secondary-title><style face="normal" font="default" size="100%">Planta Medica</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Planta Medica</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1625-1634</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">13</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anthocyanins</style></keyword><keyword><style face="normal" font="default" size="100%">Aronia melanocarpa</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular disease</style></keyword><keyword><style face="normal" font="default" size="100%">Chokeberry</style></keyword><keyword><style face="normal" font="default" size="100%">Colon cancer</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes</style></keyword><keyword><style face="normal" font="default" size="100%">Procyanidins</style></keyword><keyword><style face="normal" font="default" size="100%">Rosaceae</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">The intention of this review is to contribute to a better understanding of the potentials of the nutritional contribution of Aroma berries (Aronia melanocarpa). The paper gives a short background to their botanical classification and cultivation practice, going in detail to describe the chemical composition of the berries. The emphasis is laid thereby upon the phenolic constituents. The paper finally gives a short resume of their beneficial effects in biological systems in vitro, in animals, and in humans, thus underlining their medicinal potential.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :211&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-56249107261&amp;doi=10.1055%2fs-0028-1088306&amp;partnerID=40&amp;md5=69d60e62b6b7e08e71beed46e87098f0</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1055/s-0028-1088306</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>539</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">539</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Krieger, J. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Univ. of Washington Sch. of Medicine, Seattle, WA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections: What&apos;s new?</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2351-2358</style></pages><volume><style face="normal" font="default" size="100%">168</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Drug resistance, microbial</style></keyword><keyword><style face="normal" font="default" size="100%">Immunization</style></keyword><keyword><style face="normal" font="default" size="100%">Pyelonephritis</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">Virulence</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><abstract><style face="normal" font="default" size="100%">Purpose: This review provides practicing urologists with important basic information about urinary tract infections (UTIs) that can be applied to everyday clinical problems. Materials and Methods: A review is presented of provocative and controversial concepts in the current literature. Results: Bacterial virulence mechanisms are critical for overcoming the normal host defenses. Increasing antimicrobial resistance of uropathogens has led to reconsideration of traditional treatment recommendations in many areas. For effective patient management the first issue is to define complicating urological factors. Managing complicated urinary tract infections, particularly in urology, is determined by clinical experience to define the pertinent anatomy and to determine the optimal interventions. New clinical data are summarized on UTIs in long-term care patients, behavioral risks for UTI in healthy women and anatomical differences associated with an increased risk for UTI. The rationale is presented for UTI prophylaxis using cranberry juice, immunization and bacterial interference. Current treatment trends for UTI include empiric therapy (without urine culture and sensitivity testing), short-course therapy, patient-administered (self-start) therapy and outpatient therapy for uncomplicated pyelonephritis. Conclusions: Recommendations for treating patients with UTIs have changed based on basic science and clinical experience.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :62&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036896473&amp;doi=10.1016%2fS0022-5347%2805%2964145-6&amp;partnerID=40&amp;md5=13f2712684a195209ce67ab6c01c424a</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0022-5347(05)64145-6</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>285</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">285</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kreft, S.</style></author><author><style face="normal" font="default" size="100%">Lunder, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Fakulteta za Farmacijo, Univerza v Ljubljani, Slovenia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Herbal medicinal products for the treatment of the urogenital infection</style></title><secondary-title><style face="normal" font="default" size="100%">Farmacevtski Vestnik</style></secondary-title><short-title><style face="normal" font="default" size="100%">Rastlinski pripravki pri infekcijah urogenitalnega trakta</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Farmacevtski Vestnik</style></full-title></periodical><pages><style face="normal" font="default" size="100%">87-95</style></pages><volume><style face="normal" font="default" size="100%">62</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">Urogenital infections can be treated with medicinal plants with direct antibacterial activity (Arctostaphylos uvae-ursi), plants that prevent the binding of bacteria to the mucosa (cranberry), and medicinal plants acting as diuretic (birch, nettle). Due to inconclusive clinical studies European Medicines Agency has not confirmed well-established use of any diuretic plants, only their traditional use was confirmed. This paper presents the state of research of individual plants.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79959658791&amp;partnerID=40&amp;md5=cd57ed8064a98e01e7f99de694d4a51e</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>47</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">47</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kranz, J.</style></author><author><style face="normal" font="default" size="100%">Schmidt, S.</style></author><author><style face="normal" font="default" size="100%">Schneidewind, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology and Paediatric Urology, St. Antonius Hospital, Eschweiler, Germany&#xD;UroEvidence@Deutsche Gesellschaft für Urologie, Berlin and St.-Antonius Hospital, Germany&#xD;Department of Haematology/Oncology, University Medicine Greifswald, Greifswald, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Current Evidence on Nonantibiotic Prevention of Recurrent Urinary Tract Infections</style></title><secondary-title><style face="normal" font="default" size="100%">European Urology Focus</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Urology Focus</style></full-title></periodical><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Clinicians should be aware of the limited evidence on nonantibiotic prophylactic treatment for recurrent urinary tract infections. Owing to the rising antibiotic resistance rates worldwide, nonantibiotic prevention strategies should be considered for patient care. Further research is necessary to evaluate nonantibiotic treatment strategies using a robust randomised controlled trial methodology to contribute to a strong evidence basis. © 2018 European Association of Urology</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019&#xD;Article in Press</style></notes><work-type><style face="normal" font="default" size="100%">Article in Press</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054148382&amp;doi=10.1016%2fj.euf.2018.09.006&amp;partnerID=40&amp;md5=66950d6340147584011e489e928666d7</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.euf.2018.09.006</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>31</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">31</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kranz, J.</style></author><author><style face="normal" font="default" size="100%">Schmidt, S.</style></author><author><style face="normal" font="default" size="100%">Lebert, C.</style></author><author><style face="normal" font="default" size="100%">Schneidewind, L.</style></author><author><style face="normal" font="default" size="100%">Mandraka, F.</style></author><author><style face="normal" font="default" size="100%">Kunze, M.</style></author><author><style face="normal" font="default" size="100%">Helbig, S.</style></author><author><style face="normal" font="default" size="100%">Vahlensieck, W.</style></author><author><style face="normal" font="default" size="100%">Naber, K.</style></author><author><style face="normal" font="default" size="100%">Schmiemann, G.</style></author><author><style face="normal" font="default" size="100%">Wagenlehner, F. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Paediatric Urology, St. Antonius Hospital, Eschweiler, Germany&#xD;Gesellschaft Für Urologie, Berlin, Germany&#xD;Pharmacy Klinikum Nürnberg, Nürnberg, Germany&#xD;Klinik Für Innere Medizin C, Hämatologie Onkologie Universitätsmedizin Greifswald, Greifswald, Germany&#xD;Department of Obstetrics and Gynecology, Medical Center, University of Freiburg, Freiburg, Germany&#xD;Department of Infectious Diseases, Laboratory Dr. Wisplinghoff, Cologne, Germany&#xD;Division of Infectious Diseases, University Hospital Carl Gustav Carus, Dresden, Germany&#xD;Department of Urology, Kurpark-Klinik, Bad Nauheim, Germany&#xD;Technical University of Munich, Munich, Germany&#xD;Department for Health Services, Research Institute for Public Health and Nursing Science, Bremen University, Bremen, Germany&#xD;Clinic of Urology, Pediatric Urology and Andrology, Justus Liebig University, Giessen, DE-35392, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention</style></title><secondary-title><style face="normal" font="default" size="100%">Urologia Internationalis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Urologia Internationalis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">271-278</style></pages><volume><style face="normal" font="default" size="100%">100</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Clinical guideline</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Pyelonephritis</style></keyword><keyword><style face="normal" font="default" size="100%">Systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: We aimed to update the 2010 evidence- and consensus-based national clinical guideline on the diagnosis and management of uncomplicated urinary tract infections (UTIs) in adult patients. Results are published in 2 parts. Part 1 covers methods, the definition of patient groups, and diagnostics. This second publication focuses on treatment of acute episodes of cystitis and pyelonephritis as well as on prophylaxis of recurrent UTIs. Materials and Methods: An interdisciplinary group consisting of 17 representatives of 12 medical societies and a patient representative was formed. Systematic literature searches were conducted in MEDLINE, EMBASE, and the Cochrane Library to identify literature published in 2010-2015. Results: For the treatment of acute uncomplicated cystitis (AUC), fosfomycin-trometamol, nitrofurantoin, nitroxoline, pivmecillinam, and trimethoprim (depending on the local rate of resistance) are all equally recommended. Cotrimoxazole, fluoroquinolones, and cephalosporins are not recommended as antibiotics of first choice, for concern of an unfavorable impact on the microbiome. Mild to moderate uncomplicated pyelonephritis should be treated with oral cefpodoxime, ceftibuten, ciprofloxacin, or levofloxacin. For AUC with mild to moderate symptoms, instead of antibiotics symptomatic treatment alone may be considered depending on patient preference after discussing adverse events and outcomes. Primarily non-antibiotic options are recommended for prophylaxis of recurrent urinary tract infection. Conclusion: In accordance with the global antibiotic stewardship initiative and considering new insights in scientific research, we updated our German clinical UTI guideline to promote a responsible antibiotic use and to give clear hands-on recommendations for the diagnosis and management of UTIs in adults in Germany for healthcare providers and patients. © 2018 S. Karger AG, Basel.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :6&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044087094&amp;doi=10.1159%2f000487645&amp;partnerID=40&amp;md5=0e74786fddd41c8429bdcb930823b114</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1159/000487645</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>71</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">71</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kranz, J.</style></author><author><style face="normal" font="default" size="100%">Schmidt, S.</style></author><author><style face="normal" font="default" size="100%">Lebert, C.</style></author><author><style face="normal" font="default" size="100%">Fünfstück, R.</style></author><author><style face="normal" font="default" size="100%">Helbig, S.</style></author><author><style face="normal" font="default" size="100%">Hofmann, W.</style></author><author><style face="normal" font="default" size="100%">Hummers, E.</style></author><author><style face="normal" font="default" size="100%">Kunze, M.</style></author><author><style face="normal" font="default" size="100%">Kniehl, E.</style></author><author><style face="normal" font="default" size="100%">Naber, K.</style></author><author><style face="normal" font="default" size="100%">Mandraka, F.</style></author><author><style face="normal" font="default" size="100%">Mündner-Hensen, B.</style></author><author><style face="normal" font="default" size="100%">Schneidewind, L.</style></author><author><style face="normal" font="default" size="100%">Sester, U.</style></author><author><style face="normal" font="default" size="100%">Vahlensieck, W.</style></author><author><style face="normal" font="default" size="100%">Schmiemann, G.</style></author><author><style face="normal" font="default" size="100%">Wagenlehner, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Klinik für Urologie und Kinderurologie, St. Antonius-Hospital, Akademisches Lehrkrankenhaus der RWTH Aachen, Eschweiler, Germany&#xD;UroEvidence at Deutsche Gesellschaft für Urologie, Berlin, Germany&#xD;Apotheke Klinikum Nürnberg, Germany&#xD;Sophien- und Hufeland-Klinikum GmbH, Henry-van-de-Velde-Strasse 2, Weimar, 99425, Germany&#xD;Klinische Infektiologie, Universitätsklinikum Carl Gustav Carus, Dresden, Germany&#xD;Department Klinische Chemie, Städtisches Klinikum München, Germany&#xD;Institut für Allgemeinmedizin, Universitätsmedizin Göttingen, Germany&#xD;Klinik für Frauenheilkunde, Universitätsklinikum Freiburg, Germany&#xD;Abteilung für Mikrobiologie und Krankenhaushygiene, Städtisches Klinikum Karlsruhe, Germany&#xD;Urologische Klinik, Technische Universität, München, Germany&#xD;Klinische Infektiologie, Labor Dr. Wisplinghoff, Köln, Germany&#xD;ICA-Deutschland E.V., Förderverein InterstitielleZystitis (ICA), Euskirchen, Germany&#xD;Klinik für Innere Medizin C, Hämatologie/Onkologie, Universitätsmedizin Greifswald, Germany&#xD;Innere Medizin IV, Universitätsklinikum des Saarlandes, Bad Homburg, Germany&#xD;Fachklinik für Urologie, Kurparkklinik, Bad Nauheim, Germany&#xD;Institut für Public Health und Pflegeforschung, Versorgungsforschung, Universität Bremen, Germany&#xD;Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie, Universitätsklinikum Giessen und Marburg GmbH, Justus-Liebig-Universität Giessen, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Interdisciplinary AWMF S3 guidelines: Epidemiology, diagnosis, treatment, prevention and management of uncomplicated, bacterial, community-acquired urinary tract infections in adult patients</style></title><secondary-title><style face="normal" font="default" size="100%">Nieren- und Hochdruckkrankheiten</style></secondary-title><short-title><style face="normal" font="default" size="100%">Interdisziplinäre AWMF S3-Leitlinie: Epidemiologie, Diagnostik, Therapie, Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nieren- und Hochdruckkrankheiten</style></full-title></periodical><pages><style face="normal" font="default" size="100%">334-385</style></pages><volume><style face="normal" font="default" size="100%">46</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Asymptomatic bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Interdisciplinary S3 guideline</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Pyelonephritis</style></keyword><keyword><style face="normal" font="default" size="100%">Therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85033492845&amp;doi=10.5414%2fNHX1862&amp;partnerID=40&amp;md5=f3729d39f0addbdff0fa073462d215db</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.5414/NHX1862</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>180</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">180</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kranjčec, B.</style></author><author><style face="normal" font="default" size="100%">Papeš, D.</style></author><author><style face="normal" font="default" size="100%">Altarac, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Biochemistry, Zabok General Hospital, Zabok, Croatia&#xD;Department of Pediatric Surgery and Urology, Clinical Hospital Center Zagreb, Zagreb, Croatia&#xD;Department of Surgery and Urology, Zabok General Hospital, 49210 Zabok, Croatia</style></auth-address><titles><title><style face="normal" font="default" size="100%">D-mannose powder for prophylaxis of recurrent urinary tract infections in women: A randomized clinical trial</style></title><secondary-title><style face="normal" font="default" size="100%">World Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">World Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">79-84</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">d-mannose</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Purpose: To test whether d-mannose powder is effective for recurrent urinary tract infection (UTI) prevention. Materials and methods: After initial antibiotic treatment of acute cystitis, 308 women with history of recurrent UTI and no other significant comorbidities were randomly allocated to three groups. The first group (n = 103) received prophylaxis with 2 g of d-mannose powder in 200 ml of water daily for 6 months, the second (n = 103) received 50 mg Nitrofurantoin daily, and the third (n = 102) did not receive prophylaxis. Results: Overall 98 patients (31.8 %) had recurrent UTI: 15 (14.6) in the d-mannose group, 21 (20.4) in Nitrofurantoin group, and 62 (60.8) in no prophylaxis group, with the rate significantly higher in no prophylaxis group compared to active groups (P &lt; 0.001). Patients in d-mannose group and Nitrofurantoin group had a significantly lower risk of recurrent UTI episode during prophylactic therapy compared to patients in no prophylaxis group (RR 0.239 and 0.335, P &lt; 0.0001). In active groups, 17.9 % of patients reported side effects but they were mild and did not require stopping the prophylaxis. Patients in d-mannose group had a significantly lower risk of side effects compared to patients in Nitrofurantoin group (RR 0.276, P &lt; 0.0001), but the clinical importance of this finding is low because Nitrofurantoin was well tolerated. Conclusions: In our study, d-mannose powder had significantly reduced the risk of recurrent UTI which was no different than in Nitrofurantoin group. More studies will be needed to validate the results of this study, but initial findings show that d-mannose may be useful for UTI prevention. © 2013 Springer-Verlag Berlin Heidelberg.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :95&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84893657349&amp;doi=10.1007%2fs00345-013-1091-6&amp;partnerID=40&amp;md5=13f898bb2f17cf15634cdf8a3868bbd6</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00345-013-1091-6</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>98</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">98</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Krämer, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Berufsfachschule für Pharmazeutisch-technische Assistenten in München Arzneimittelkunde, Botanik und Drogenkunde, Chemie und Gefahrstoffkunde, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">It must not always be an antibiotic! The updated guidelines on the treatment of uncomplicated urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Deutsche Apotheker Zeitung</style></secondary-title><short-title><style face="normal" font="default" size="100%">Es muss nicht immer ein Antibiotikum sein!: Die aktualisierte Leitlinie zur Behandlung unkomplizierter Harnwegsinfekte</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Deutsche Apotheker Zeitung</style></full-title></periodical><volume><style face="normal" font="default" size="100%">157</style></volume><number><style face="normal" font="default" size="100%">43</style></number><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85034797599&amp;partnerID=40&amp;md5=36b0a36feb361cc04175e42da30ed9f0</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>223</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">223</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Krachler, A. M.</style></author><author><style face="normal" font="default" size="100%">Orth, K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Microbiology and infection, University of Birmingham, Birmingham, United Kingdom&#xD;Department of Molecular Biology, UT Southwestern Medical Center, Dallas, TX, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Targeting the bacteria-host interface strategies in anti-adhesion therapy</style></title><secondary-title><style face="normal" font="default" size="100%">Virulence</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Virulence</style></full-title></periodical><pages><style face="normal" font="default" size="100%">284-294</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-adhesion treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-adhesive</style></keyword><keyword><style face="normal" font="default" size="100%">Antimicrobial therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial adhesion</style></keyword><keyword><style face="normal" font="default" size="100%">Host-pathogen interactions</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Bacterial infections are a major cause of morbidity and mortality worldwide and are increasingly problematic to treat due to the rise in antibiotic-resistant strains. it becomes more and more challenging to develop new antimicrobials that are able to withstand the ever-increasing repertoire of bacterial resistance mechanisms. This necessitates the development of alternative approaches to prevent and treat bacterial infections. One of the first steps during bacterial infection is adhesion of the pathogen to host cells. A pathogen&apos;s ability to colonize and invade host tissues strictly depends on this process. Thus, interference with adhesion (anti-adhesion therapy) is an efficient way to prevent or treat bacterial infections. As a basis to present different strategies to interfere with pathogen adhesion, this review briefly introduces general concepts of bacterial attachment to host cells. we further discuss advantages and disadvantages of anti-adhesion treatments and issues that are in need of improvement so as to make anti-adhesion compounds a more broadly applicable alternative to conventional antimicrobials. © 2013 Landes Bioscience.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :78&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84878105446&amp;doi=10.4161%2fviru.24606&amp;partnerID=40&amp;md5=42e6ada139cf2b3b68658c0e8e527bbf</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.4161/viru.24606</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>440</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">440</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kowalczyk, E.</style></author><author><style face="normal" font="default" size="100%">Fijałkowski, P.</style></author><author><style face="normal" font="default" size="100%">Kura, M.</style></author><author><style face="normal" font="default" size="100%">Krzesiński, P.</style></author><author><style face="normal" font="default" size="100%">Błaszczyk, J.</style></author><author><style face="normal" font="default" size="100%">Kowalski, J.</style></author><author><style face="normal" font="default" size="100%">Śmigielski, J.</style></author><author><style face="normal" font="default" size="100%">Rutkowski, M.</style></author><author><style face="normal" font="default" size="100%">Kopff, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Zakład Fizjologii Człowieka i Biofizyki, Uniwersytetu Medycznego, Łodz, Poland&#xD;Katedra Rehabilitacji Kardiologicznej, Uniwersytetu Medycznego, Łodz, Poland&#xD;Zaktad Chemii i Biochemii Klinicznej, Uniwersytetu Medycznego, Łodz, Poland&#xD;Zakład Fizjologii Cztowieka i Biofizyki, Uniwersytetu Medycznego w Łodzi, Plac J. Hallera 1, 90-647 Łódź, Poland</style></auth-address><titles><title><style face="normal" font="default" size="100%">The influence of anthocyanins from Aronia melanocarpa on selected parameters of oxidative stress and microelements contents in men with hipercholesterolaemia</style></title><secondary-title><style face="normal" font="default" size="100%">Polski Merkuriusz Lekarski</style></secondary-title><short-title><style face="normal" font="default" size="100%">Wpływ antocyjanin z aronii czarnoowocowej na wybrane parametry stresu oksydacyjnego i zawartość mikroelementów u mȩżczyzn z hipercholesterolemia̧</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Polski Merkuriusz Lekarski</style></full-title></periodical><pages><style face="normal" font="default" size="100%">651-653</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">113</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anthocyanins</style></keyword><keyword><style face="normal" font="default" size="100%">Hipercholesterolaemia</style></keyword><keyword><style face="normal" font="default" size="100%">Microelements</style></keyword><keyword><style face="normal" font="default" size="100%">Oxidative-antioxidative balance</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">The aim of the study. Our investigations was to estimate the influence of Aronia anthocyanins (Aronox by Agropharm) on selected parameters of oxidative and antioxidative balance as well as on the concentration of selected metals in red blood cells in men with hipercholesterolaemia. Material and methods. 16 men aged 27 ± 6.4 years old with blood cholesterol concentration on the level of 205-250 mg/dl took 240 mg of anthocyanins a day for 30 days. Before and after the period of anthocyanins administration a blood sample was taken and following parameters were estimated: lead, aluminium, cooper and zinc concentration in erythrocytes with the method of atomic emission spectrometry with induced coupling plasma (AES-ICP), concentration of substances reacting with thiobarbituric acid (TBARS) and superoxide dismutase, glutathione peroxidase and catalase activities in hemolysate. Conclusion. 30 days long administration of 240 mg of anthocyanins a day, caused a substantial increase of glutathione peroxidase and catalase activities. The lead, aluminium and cooper concentration was decreased while zinc concentration in red blood cells was increased.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :35&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-28544445685&amp;partnerID=40&amp;md5=435147e2c92c8a7bb1a398f3df557e73</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>49</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">49</key></foreign-keys><ref-type name="Conference Proceedings">10</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Korneeva, O.</style></author><author><style face="normal" font="default" size="100%">Anokhina, E.</style></author><author><style face="normal" font="default" size="100%">Shuvayeva, G.</style></author><author><style face="normal" font="default" size="100%">Isuva, M.</style></author><author><style face="normal" font="default" size="100%">Startseva, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Voronezh State University of Engineering Technologies, Russian Federation&#xD;Voronezh State Medical University named after N.N. Burdenko of the Ministry of Health of the Russian Federation, Russian Federation</style></auth-address><titles><title><style face="normal" font="default" size="100%">Production of mannose-containing hydrolysates and investigation of their ability to normalize the microflora composition of the gastrointestinal tract of poultry</style></title><secondary-title><style face="normal" font="default" size="100%">International Multidisciplinary Scientific GeoConference Surveying Geology and Mining Ecology Management, SGEM</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">475-482</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><edition><style face="normal" font="default" size="100%">6.2</style></edition><keywords><keyword><style face="normal" font="default" size="100%">Mannose-containing hydrolysates</style></keyword><keyword><style face="normal" font="default" size="100%">Prebiotic</style></keyword><keyword><style face="normal" font="default" size="100%">β-mannanase</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">One of the ways to maintain the normal gastrointestinal tract microflora of poultry is to use prebiotic supplements in their feed. Among the prebiotics used in poultry farming, there are additives based on mannooligosaccharides from the cell walls of the yeast Saccharomyces cerevisiae. There are no similar domestic prebiotic drugs available, which determines the necessity and relevance of their development. For the production of mannose-containing hydrolysates, there was studied the process of hydrolysis of mannans of plant raw materials under the influence of the enzyme preparation of Trichoderma harzianum β-mannanase. The production of mannose-containing hydrolysates with the maximum degree of mannans splitting was provided by the dosage of the 15 U/g substrate enzyme and the duration of the process for 4 hours. Qualitative and quantitative analysis of the produced hydrolysates revealed the presence of mannose, mannobiose, mannotriose, mannotetrose, mannohexoses in the amount of, in mg/ ml: 29.1, 22.1, 42.2, 19.1 and 4.3, respectively. Studying the prebiotic properties of mannose-containing hydrolysates in vitro showed that the maximum accumulation of Bifidobacterium bifidum biomass on medium with these carbohydrates was observed by the 42nd h of cultivation and correlated with the accumulation of organic acids in the medium. Mannose-containing hydrolysates stimulated the development of B. bifidum to a greater extent than mannose and did not rank below to the known commercial prebiotic-inulin. The study of the effect of mannose-containing hydrolysates in the amount from 0.1 to 1% to the feed weight on the gastrointestinal microflora of chickens with experimental dysbiosis showed that an increase in the number of bifidobacteria and lactic acid bacteria was observed already on the 5th day of the experiment in all the doses tested. Complete normalization of the gastrointestinal microflora composition of poultry was observed when mannose-containing hydrolysates were introduced in the amount of 1% to the feed weight on the 10th day. © SGEM2018. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Conference Paper</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058892564&amp;doi=10.5593%2fsgem2018%2f6.2%2fS25.063&amp;partnerID=40&amp;md5=6fe7851dba7dcd154a37e8c63da2cef2</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.5593/sgem2018/6.2/S25.063</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>491</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">491</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kontiokari, T.</style></author><author><style face="normal" font="default" size="100%">Nuutinen, M.</style></author><author><style face="normal" font="default" size="100%">Uhari, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, University of Oulu, P.O. Box 5000, 90014 Oulu, Finland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dietary factors affecting susceptibility to urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">Pediatric Nephrology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pediatric Nephrology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">378-383</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Berry fruits</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">Milk</style></keyword><keyword><style face="normal" font="default" size="100%">Nutrition</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infection (UTI) is usually an ascending infection caused by bacteria derived from stools. Since the bacterial composition of stools is dependent on the diet, it is likely that the risk of UTI will change with changes in the diet. Most data describing diet as a risk factor for UTI come from epidemiological and interventional trials. It has been shown in a case-control setting that frequent consumption of fresh berry or fruit juices and fermented milk products containing probiotic bacteria decreases the risk for UTI recurrence in women. Several interventional trials have found Vaccinium berry products to provide protection from UTI recurrence. Probiotics have not been able to prevent UTI in interventional trials. However, the lack of an effect may be related to too low a dose or to the use of non-optimal products in these trials. Limited data are available on the effects of nutrition on UTI in children. However, there is no reason to expect that children would be different from adults in this respect. In this review, we discuss the dietary factors affecting the susceptibility to UTI. © IPNA 2004.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :15&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-1842789445&amp;doi=10.1007%2fs00467-003-1410-z&amp;partnerID=40&amp;md5=ea0e29a7d633783797e640779abf824f</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00467-003-1410-z</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>523</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">523</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kontiokari, T.</style></author><author><style face="normal" font="default" size="100%">Laitinen, J.</style></author><author><style face="normal" font="default" size="100%">Järvi, L.</style></author><author><style face="normal" font="default" size="100%">Pokka, T.</style></author><author><style face="normal" font="default" size="100%">Sundqvist, K.</style></author><author><style face="normal" font="default" size="100%">Uhari, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, University of Oulu, PO Box 5000, FIN-90014 Oulu, Finland&#xD;Oulu Regl. Inst. of Occup. Health, Oulu, Finland&#xD;Finnish Student Health Service, Oulu, Finland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dietary factors protecting women from urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Clinical Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Clinical Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">600-604</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Berry</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Fruit</style></keyword><keyword><style face="normal" font="default" size="100%">Juice</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacilli</style></keyword><keyword><style face="normal" font="default" size="100%">Milk</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Women</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Because urinary tract infections (UTIs) are caused by bacteria in the stool, dietary factors may affect the risk of contracting a UTI by altering the properties of the fecal bacterial flora. Objective: We studied dietary and other risk factors for UTI in fertile women in a case-control setting. Design: One hundred thirty-nine women from a health center for university students or from the staff of a university hospital (mean age: 30.5 y) with a diagnosis of an acute UTI were compared with 185 age-matched women with no episodes of UTIs during the past 5 y. Data on the women&apos;s dietary and other lifestyle habits were collected by questionnaire. A risk profile for UTI expressed in the form of adjusted odds ratios (ORs) with 95% CIs was modeled in logistic regression analysis for 107 case-control pairs with all relevant information. Results: Frequent consumption of fresh juices, especially berry juices, and fermented milk products containing probiotic bacteria was associated with a decreased risk of recurrence of UTI: the OR for UTI was 0.66 (95% CI: 0.48, 0.92) per 2 dL juice. A preference for berry juice over other juices gave an OR of 0.28 (95% CI: 0.14, 0.56). Consumption of fermented milk products ≥ 3 times/wk gave an OR of 0.21 (95% CI: 0.06, 0.66) relative to consumption &lt; 1 time/wk. Intercourse frequency was associated with an increased risk of UTI (OR for ≥ 3 times/wk compared with &lt; 1 time/wk: 2.7; 95% CI: 1.16, 6.2). Conclusion: Dietary habits seem to be an important risk factor for UTI recurrence in fertile women, and dietary guidance could be a first step toward prevention.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :68&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037369601&amp;partnerID=40&amp;md5=e1bd119de9492ba1579a75748f42da04</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>319</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">319</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kokotkiewicz, A.</style></author><author><style face="normal" font="default" size="100%">Jaremicz, Z.</style></author><author><style face="normal" font="default" size="100%">Luczkiewicz, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmacognosy, Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Aronia plants: a review of traditional use, biological activities, and perspectives for modern medicine</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of medicinal food</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Medicinal Food</style></full-title></periodical><pages><style face="normal" font="default" size="100%">255-269</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><abstract><style face="normal" font="default" size="100%">The Aronia genus (Rosaceae family, Maloideae subfamily) includes two species of native North American shrubs: Aronia melanocarpa (Michx.) Ell. (black chokeberry) and Aronia arbutifolia (L.) Pers. (red chokeberry). The fruits of A. melanocarpa have been traditionally used by Potawatomi Native Americans to cure colds. In the first half of the 20(th) century, cultivars of black chokeberry were introduced to the Soviet Union and other European countries, providing fruits used by food industry. At present, it is used mainly for juice, jam, and wine production, as well as an ornamental plant. Among other substances, the berries of A. melanocarpa contain anthocyanins and procyanidins, possessing strong antioxidative potential. Numerous health-promoting activities-namely, antioxidative, antimutagenic, anticancer, cardioprotective, hepatoprotective, gastroprotective, antidiabetic, anti-inflammatory, antibacterial, antiviral, radioprotective, and immunomodulatory-have been demonstrated for black chokeberry extracts by both in vitro and in in vivo studies. The presented review summarizes the information concerning botany, cultivation, chemical composition, and pharmacological activities of Aronia plants.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :121&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-77958187553&amp;doi=10.1089%2fjmf.2009.0062&amp;partnerID=40&amp;md5=6e7996ccdfd61042dcc49a21c8c41f09</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1089/jmf.2009.0062</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>315</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">315</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kodner, C. M.</style></author><author><style face="normal" font="default" size="100%">Thomas Gupton, E. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Louisville, School of Medicine, Louisville, KY, United States&#xD;Primary Care Medical Center, Murray, KY, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent urinary tract infections in women: Diagnosis and management</style></title><secondary-title><style face="normal" font="default" size="100%">American Family Physician</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Family Physician</style></full-title></periodical><pages><style face="normal" font="default" size="100%">638-643</style></pages><volume><style face="normal" font="default" size="100%">82</style></volume><number><style face="normal" font="default" size="100%">6</style></number><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><abstract><style face="normal" font="default" size="100%">Recurrent urinary tract infections, presenting as dysuria or irritative voiding symptoms, are most commonly caused by reinfection with the original bacterial isolate in young, otherwise healthy women with no anatomic or functional abnormalities of the urinary tract. Frequency of sexual intercourse is the strongest predictor of recurrent urinary tract infections in patients presenting with recurrent dysuria. In those who have comorbid conditions or other predisposing factors, recurrent complicated urinary tract infections represent a risk for ascending infection or urosepsis. Escherichia coli is the most common organism in all patient groups, but Klebsiella, Pseudomonas, Proteus, and other organisms are more common in patients with certain risk factors for complicated urinary tract infections. A positive urine culture with greater than 102 colony-forming units per mL is the standard for diagnosing urinary tract infections in symptomatic patients, although culture is often unnecessary for diagnosing typical symptomatic infection. Women with recurrent symptomatic urinary tract infections can be treated with continuous or postcoital prophylactic antibiotics; other treatment options include self-started antibiotics, cranberry products, and behavioral modification. Patients at risk of complicated urinary tract infections are best managed with broad-spectrum antibiotics initially, urine culture to guide subsequent therapy, and renal imaging studies if structural abnormalities are suspected. © 2010 American Academy of Family Physicians.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :44&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-78049393051&amp;partnerID=40&amp;md5=a2102a144d2e78f8f0bac63774ec8c4b</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>194</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">194</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koder, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Javni Zavod Gorenjske Lekarne, Gosposvetska ulica 12, Kran, 4000, Slovenia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract inflammation and urinary stones treatment - A community pharmacist&apos;s view</style></title><secondary-title><style face="normal" font="default" size="100%">Farmacevtski Vestnik</style></secondary-title><short-title><style face="normal" font="default" size="100%">Pogled lekarniškega farmacevta na zdravljenje vnetij sečil ter pojav sečnih kamnov</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Farmacevtski Vestnik</style></full-title></periodical><pages><style face="normal" font="default" size="100%">282-293</style></pages><volume><style face="normal" font="default" size="100%">65</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antimicrobial treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary stones</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">The most common cause for urinary tract inflammation is bacterial urinary tract infection which arises when bacteria invades the urinary tract and the balance between defense capability of the body and virulence ability of patogenic organism is disturbed. Classification of bacterial infection into uncomplicated and complicated infections is fundamental when treating a patient and deciding on treatment. In everyday practice, community pharmacists mostly encounter simple urinary tract infections which are typical for younger, otherwise healthy women. There are several risk factors for complicated urinary tract infection. One of them are urinary stones which present an obstacle for normal urine excretion. In the article, special emphasis is given to the urinary tract infection and guidelines for treatment of some more problematic groups of people: pregnant women, the elderly, diabetics, and children. From the public health perspective it is alarming that the most frequent urinary tract pathogen E. coli is developing resistence to the majority of antimicrobial medicines. In addition to counselling about correct and safe use of the antimicrobial medicines, counselling about self-medication and prophylaxis, an important role of a community pharmacist is also dealing with bacterial resistance. © 2014, Slovenian Pharmaceutical Society. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84930016500&amp;partnerID=40&amp;md5=714056a65adbd28eb800f559cf8e273c</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>334</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">334</key></foreign-keys><ref-type name="Serial">57</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Knight, S. D.</style></author><author><style face="normal" font="default" size="100%">Bouckaert, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Swedish University of Agricultural Sciences, Department of Molecular Biology, Uppsala Biomedical Center, PO Box 590, 75124 Uppsala, Sweden&#xD;Vrije Universiteit Brussel, Ultrastructure Laboratory, Pleinlaan 2, B1050 Brussels, Belgium&#xD;VIB, Department of Molecular and Cellular Interactions, Belgium</style></auth-address><titles><title><style face="normal" font="default" size="100%">Structure, function, and assembly of type 1 fimbriae</style></title><secondary-title><style face="normal" font="default" size="100%">Topics in Current Chemistry</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">67-107</style></pages><volume><style face="normal" font="default" size="100%">288</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Assembly</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial adhesion</style></keyword><keyword><style face="normal" font="default" size="100%">Chaperone/usher pathway</style></keyword><keyword><style face="normal" font="default" size="100%">Fimbriae/pili</style></keyword><keyword><style face="normal" font="default" size="100%">Lectin</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Bacterial infections constitute a major global health problem, acutely accentuated by he rapid spread of antibiotic resistant bacterial strains. The widespread need for acteria o attach - adhere - to target cells before they can initiat ean infection may be ed to dvantage by targeting the bacterial adhesion tools such as pili and fimbriae for velopment of novel anti-bacterial vaccines and drugs. Type 1 fimbriae are widely pressed by Escherichia coli and are used by uropathogenic strains to mediate tachment to specific niches in the urinary tract. These fimbriae belong to a class of brillar adhesion organelles assembled through the chaperone/usher pathway, one of e erminal branches of the general secretion pathway in Gram-negative bacteria. Our derstanding of the assembly, structure and function of these structures has evolved gnificantly over the last decade. Here, we summarize current understanding of the nction and biogenesis of fibrillar adhesion organelles, and provide some examples of cent progress towards interfering with bacterial adhesion as a means to prevent fection. © Springer-Verlag Berlin Heidelberg 2009.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :50&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-68949145300&amp;doi=10.1007%2f128_2008_13&amp;partnerID=40&amp;md5=6ad8203b8fd99e6ce042cc3ac6828bc3</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/128_2008_13</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>249</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">249</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Klinth, J. E.</style></author><author><style face="normal" font="default" size="100%">Castelain, M.</style></author><author><style face="normal" font="default" size="100%">Uhlin, B. E.</style></author><author><style face="normal" font="default" size="100%">Axner, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Physics, Umeå University, Umeå, Sweden&#xD;Department of Molecular Biology, Umeå University, Umeå, Sweden&#xD;Umeå Centre for Microbial Research (UCMR), Umeå University, Umeå, Sweden&#xD;Laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå University, Umeå, Sweden&#xD;Laboratoire d&apos;Ingénierie des Systèmes Biologiques et Procédés, INRA UMR792 - CNRS UMR5504, INSA Toulouse, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">The influence of pH on the specific adhesion of P piliated Escherichia coli</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS ONE</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">PLoS ONE</style></full-title></periodical><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">6</style></number><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Adhesion to host tissues is an initiating step in a majority of bacterial infections. In the case of Gram-negative bacteria this adhesion is often mediated by a specific interaction between an adhesin, positioned at the distal end of bacterial pili, and its receptor on the surface of the host tissue. Furthermore, the rod of the pilus, and particularly its biomechanical properties, is believed to be crucial for the ability of bacteria to withstand external forces caused by, for example, (in the case of urinary tract infections) urinary rinsing flows by redistributing the force to several pili. In this work, the adhesion properties of P-piliated E. coli and their dependence of pH have been investigated in a broad pH range by both the surface plasmon resonance technique and force measuring optical tweezers. We demonstrate that P piliated bacteria have an adhesion ability throughout the entire physiologically relevant pH range (pH 4.5 - 8). We also show that pH has a higher impact on the binding rate than on the binding stability or the biomechanical properties of pili; the binding rate was found to have a maximum around pH 5 while the binding stability was found to have a broader distribution over pH and be significant over the entire physiologically relevant pH range. Force measurements on a single organelle level show that the biomechanical properties of P pili are not significantly affected by pH. © 2012 Klinth et al.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :10&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84861914686&amp;doi=10.1371%2fjournal.pone.0038548&amp;partnerID=40&amp;md5=72de89cb97fd313ce4e3b8008aa087d4</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">e38548</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1371/journal.pone.0038548</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>506</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">506</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Klepser, T. B.</style></author><author><style face="normal" font="default" size="100%">Berryhill, B.</style></author><author><style face="normal" font="default" size="100%">Dixon, K.</style></author><author><style face="normal" font="default" size="100%">McGinnis, M. M.</style></author><author><style face="normal" font="default" size="100%">Mulholland, S.</style></author><author><style face="normal" font="default" size="100%">Pomeroy, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Ferris State Univ. Coll. of Pharmacy, Big Rapids, MI, United States&#xD;Spectrum Health, Grand Rapids, MI, United States&#xD;Ferris State University, K. Ctr. Med. Studs.-MI State Univ., 1000 Oakland Drive, Kalamazoo, MI 49008, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation of Dietary Supplements with Claims of Antimicrobial Activity</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Infectious Disease Pharmacotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Infectious Disease Pharmacotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-29</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antimicrobial</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Interaction</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">This article reviews four dietary supplements that have purported uses of antimicrobial activity. The four dietary supplements are cranberry, echinacea, garlic, and tea tree oil. Safety and efficacy are evaluated for each dietary supplement. © 2003 by The Haworth Press, Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-1442305208&amp;doi=10.1300%2fJ100v06n03_01&amp;partnerID=40&amp;md5=03f8e428dc688e4c87d82ba4b08bb7d2</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1300/J100v06n03_01</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>509</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">509</key></foreign-keys><ref-type name="Serial">57</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kinsel, J. F.</style></author><author><style face="normal" font="default" size="100%">Straus, S. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Natl. Ctr. Complement./Alt. Med., National Institutes of Health, Bethesda, MD 20892, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Complementary and Alternative Therapeutics: Rigorous Research is Needed to Support Claims</style></title><secondary-title><style face="normal" font="default" size="100%">Annual Review of Pharmacology and Toxicology</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">463-484</style></pages><volume><style face="normal" font="default" size="100%">43</style></volume><keywords><keyword><style face="normal" font="default" size="100%">CAM</style></keyword><keyword><style face="normal" font="default" size="100%">Dietary supplements</style></keyword><keyword><style face="normal" font="default" size="100%">Drug development</style></keyword><keyword><style face="normal" font="default" size="100%">Natural products</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">The establishment of the National Center for Complementary and Alternative Medicine (NCCAM) in 1998 as a part of the National Institutes of Health was catalyzed by the increasing interest and use of complementary and alternative medicine (CAM) modalities by the public. This article presents an overview of CAM, summarizes similarities and differences between the regulatory requirements for drugs and CAM/botanical products, identifies several challenges and opportunities for conducting research to demonstrate the safety and efficacy of CAM therapeutics, and highlights the role of NCCAM in supporting and stimulating research in this area.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :37&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0042352218&amp;doi=10.1146%2fannurev.pharmtox.43.100901.135757&amp;partnerID=40&amp;md5=cf2d49ec46cc990f769cfba0183530c6</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1146/annurev.pharmtox.43.100901.135757</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>613</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">613</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kinney, A. B.</style></author><author><style face="normal" font="default" size="100%">Blount, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Nursing, University of Virginia Medical Center, Charlottesville, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of cranberry juice on urinary pH</style></title><secondary-title><style face="normal" font="default" size="100%">Nursing Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nursing Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">287-290</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><number><style face="normal" font="default" size="100%">5</style></number><dates><year><style face="normal" font="default" size="100%">1979</style></year></dates><abstract><style face="normal" font="default" size="100%">Twenty-one female and 19 male subjects who had normal physical and laboratory examinations were randomly assigned into four groups of 10 subjects each. Each group was then randomly assigned a number (150,180, 210, 240) which determined the amount of cranberry juice, in milliliters. members of that group would ingest with each meal during the experimental phase of the study. The study took place over a 12-day period. A one-group before-and-after design was used, with each subject serving as his or her own control. Diet was controlled; menus on days 1 through 6 were repeated on days 7 through 12 with the addition of cranberry juice at each meal. Subjects used nitrazine pH tape to measure the pH of midstream urine at each voiding. There were significant (.01 level) differences in mean urinary pH between each control group and its corresponding experimental group. Anticipated problems with increased number of bowel movements, weight gain, increased voiding frequency, and subject pH measurement inaccuracy did not occur. © Lippincott-Raven Publishers.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :54&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0018523799&amp;partnerID=40&amp;md5=d745a606ae3a33005e8ad4f231d1c591</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>409</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">409</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, S. H.</style></author><author><style face="normal" font="default" size="100%">Han, C. H.</style></author><author><style face="normal" font="default" size="100%">Kang, S. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, The Catholic University of Korea College of Medicine, Seoul, South Korea</style></auth-address><titles><title><style face="normal" font="default" size="100%">Protective effects of cranberry on infection-induced oxidative renal damage in a vesicoureteral reflux rabbit model</style></title><secondary-title><style face="normal" font="default" size="100%">Korean Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Korean Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">536-541</style></pages><volume><style face="normal" font="default" size="100%">48</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Injury</style></keyword><keyword><style face="normal" font="default" size="100%">Kidney</style></keyword><keyword><style face="normal" font="default" size="100%">Reactive oxygen species</style></keyword><keyword><style face="normal" font="default" size="100%">Vesico-ureteral reflux</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">Purpose: We evaluated the protective effects of cranberry, which is known as a fruit with anti-oxidative effects, on infection-induced oxidative renal damage with using a rabbit vesico-ureteral reflux (VUR) model. Materials and methods: New Zealand male rabbits were divided into 5 groups (the control group, VUR group, E. coli group, cranberry group and melatonin group). VUR was created and confirmed at 2 weeks after the operation. Infection was induced by intravesical. instillation of an E. coli suspension. Cranberry powder was supplied with the feed. Melatonin was injected into the peritoneal cavity. The rabbit kidneys were obtained 3 weeks after the operation. Histopathologic examination was performed to evaluate for inflammation, fibrosis and the tubular change. The oxidative renal damage was evaluated by measuring malondialdehyde (MDA) in the renal tissue. Results: Grossly, the refluxing kidney was larger than the contralateral normal kidney and the refluxing ureter was dilated and tortuous. The microscopic observation of the kidneys from the E. coli group showed apparent periglomerular mononuclear cell infiltration, tubular dilatation and atrophy, and interstitial fibrosis. The kidneys from the reflux group, cranberry group and melatonin group showed mild mononuclear cell infiltration without interstitial fibrosis. The MDA level in the kidneys of the E. coli group was significantly higher than that in the control, cranberry and melatonin groups (p &lt; 0.05). The MDA level in the cranberry and melatonin groups didn&apos;t significantly differ from that in the sterile group. Conclusions: This study demonstrates that cranberry has an anti-inflammatory effect due to an anti-oxidative function and it may prevent infection-induced oxidative renal damage. But application of cranberry in children with VUR needs more clinical studies.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-34249861833&amp;doi=10.4111%2fkju.2007.48.5.536&amp;partnerID=40&amp;md5=f1e6211977de932a7f784cd2f747f8df</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.4111/kju.2007.48.5.536</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>25</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">25</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, H. W.</style></author><author><style face="normal" font="default" size="100%">Rhee, M. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, South Korea</style></auth-address><titles><title><style face="normal" font="default" size="100%">Response surface modeling of reductions in uropathogenic Escherichia coli biofilms on silicone by cranberry extract, caprylic acid, and thymol</style></title><secondary-title><style face="normal" font="default" size="100%">Biofouling</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biofouling</style></full-title></periodical><pages><style face="normal" font="default" size="100%">710-717</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antimicrobial mixtures</style></keyword><keyword><style face="normal" font="default" size="100%">biofilm eradication</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">natural products</style></keyword><keyword><style face="normal" font="default" size="100%">optimization modeling</style></keyword><keyword><style face="normal" font="default" size="100%">uropathogenic</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">A response surface methodology was used to build a model to predict reductions in uropathogenic Escherichia coli biofilms in response to three compounds: cranberry extract [CB] at 3.0–9.0%, and caprylic acid [CAR] and thymol [TM] at 0.01%–0.05%. The predictive model for microbial reduction had a high regression coefficient (R2 = 0.9988), and the accuracy of the model was verified (R2 = 0.9527). Values of CAR, TM, and the quadratic term CAR2 were the most significant (P &amp;lt; 0.0001) for bacterial reduction. Interactions between CB and CAR, and TM and CB, also affected bacterial reduction. The optimum conditions (a 5.8 log10 reduction) determined by ridge analysis were 8.3% CB +0.04% CAR +0.04% TM at 37 °C for 1 min. The model could be used to predict the most cost-efficient amounts of antimicrobial agents for anti-urinary tract infection products such as catheter lock solution and antimicrobial coatings for catheters. © 2018, © 2018 Informa UK Limited, trading as Taylor &amp; Francis Group.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053238062&amp;doi=10.1080%2f08927014.2018.1488969&amp;partnerID=40&amp;md5=5f4c4450ce9d0b21c580bda1f312fae0</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/08927014.2018.1488969</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>91</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">91</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, H. M.</style></author><author><style face="normal" font="default" size="100%">Choi, Y. S.</style></author><author><style face="normal" font="default" size="100%">Lee, D. S.</style></author><author><style face="normal" font="default" size="100%">Kim, Y. H.</style></author><author><style face="normal" font="default" size="100%">Bae, H. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Bio-Energy Research Center, Chonnam National University, Gwangju, 61186, South Korea&#xD;Department of Agricultural Biology, RDA, National Academy of Agriculture SciencesWanju 55365, South Korea&#xD;College of Life and Resource Science, Dankook University, Cheonan, 31116, South Korea&#xD;Department of Bioenergy Science and Technology, Chonnam National University, Gwangju, 61186, South Korea</style></auth-address><titles><title><style face="normal" font="default" size="100%">Production of bio-sugar and bioethanol from coffee residue (CR) by acid-chlorite pretreatment</style></title><secondary-title><style face="normal" font="default" size="100%">Bioresource Technology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Bioresource Technology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">194-201</style></pages><volume><style face="normal" font="default" size="100%">236</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Acid-chlorite pretreatment</style></keyword><keyword><style face="normal" font="default" size="100%">Bio-sugar</style></keyword><keyword><style face="normal" font="default" size="100%">Bioethanol</style></keyword><keyword><style face="normal" font="default" size="100%">Coffee residue</style></keyword><keyword><style face="normal" font="default" size="100%">Simultaneous saccharification and fermentation (SSF)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Nowadays, coffee residue (CR) after roasting is recognized as one of the most useful resources in the world for producing the biofuel and bio-materials. In this study, we evaluated the potential of bio-sugar and bioethanol production from acid-chlorite treated CR. Notably, CR treated three times with acid-chlorite after organic solvent extraction (OSE-3), showed the high monosaccharide content, and the efficient sugar conversion yield compared to the other pretreatment conditions. The OSE-3 (6% substrate loading, w/v) can produce bio-sugar (0.568 g/g OSE-3). Also, simultaneous saccharification and fermentation (SSF) produced ethanol (0.266 g/g OSE-3), and showed an ethanol conversion yield of 73.8% after a 72-h reaction period. These results suggest that acid-chlorite pretreatment can improve the bio-sugar and bioethanol production of CR by removing the phenolic and brown compounds. © 2017 Elsevier Ltd</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85017451032&amp;doi=10.1016%2fj.biortech.2017.03.143&amp;partnerID=40&amp;md5=6e67b2638980c038e47da29beab56f36</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.biortech.2017.03.143</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>268</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">268</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kim, B. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Inje University, College of Medicine, Busan, South Korea</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevention of recurrent urinary tract infections in women</style></title><secondary-title><style face="normal" font="default" size="100%">Infection and Chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infection and Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">343-356</style></pages><volume><style face="normal" font="default" size="100%">44</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-bacterial agents</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention and control</style></keyword><keyword><style face="normal" font="default" size="100%">Pyelonephritis</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infection (UTI) is one of the most common bacterial infections affecting women. One in four of these women will develop a recurrence. Recurrent UTIs are common among otherwise healthy women with anatomically and physiologically normal urinary tracts. These conditions have a significant effect on their quality of life and have a considerable economic impact due to health care costs. This article will review risk factors predisposing pre- and postmenopausal women to recurrent UTIs, and discuss antimicrobial prophylaxis and other non-antimicrobial preventive measures, including modification of behavioral factors, estrogen, and cranberry products. © 2012 by The Korean Society of Infectious Diseases | Korean Society for Chemotherapy.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872854583&amp;doi=10.3947%2fic.2012.44.5.343&amp;partnerID=40&amp;md5=e4cee7129dcd00db7747def64e9190d4</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3947/ic.2012.44.5.343</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>128</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">128</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Khairnar, M. R.</style></author><author><style face="normal" font="default" size="100%">Shimpi, P. V.</style></author><author><style face="normal" font="default" size="100%">Wadgave, U.</style></author><author><style face="normal" font="default" size="100%">Patil, S.</style></author><author><style face="normal" font="default" size="100%">Deshmukh, M. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Public Health Dentistry, Bharati Vidyapeeth Deemed University Dental College and Hospital, Sangli, Maharashtra, India&#xD;Department of Physiology, Lokamanya Tilak Municipal Medical College and Government Hospital, Sion, Mumbai, Maharashtra, India&#xD;Department of Periodontics, Bharati Vidyapeeth Deemed University Dental College and Hospital, Sangli, Maharashtra, India&#xD;Department of Public Health Dentistry, Swargiya Dadasaheb Kalmegh Smruti Dental College and Hospital, Nagpur, Maharshtra, India</style></auth-address><titles><title><style face="normal" font="default" size="100%">Potential systemic and oral health effects of cranberry: A review</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Research in Ayurveda and Pharmacy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Research in Ayurveda and Pharmacy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">136-140</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Anti-adhesive</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-bacterial</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-cancer</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Oral health</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Past few decades have witnessed a drastic resurgence towards herbal medicines. Amongst them, cranberries have attracted numerous researchers owing to their phytochemical content. The unique combination of phytochemicals found in cranberry fruit may produce synergistic health benefits. Recent in vitro and animal studies have demonstrated potential health effects of cranberry consumption; however in vivo data only partially supports this. This mixed outcome may be the result of variations in forms, dosage, regimens, patient compliance, etc. The present article is an attempt to review the existing research on the health effects of cranberry.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85043639955&amp;doi=10.7897%2f2277-4343.074171&amp;partnerID=40&amp;md5=fd5e8b92ab8a21e478168e8cb4221519</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.7897/2277-4343.074171</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>9</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">9</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kavouras, S. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Hydration Science Lab, College of Health Solutions, Arizona State University, Arizona Biomedical Collaborate, Suite 133, 435 N 5th St, Phoenix, AZ 85004, United States&#xD;Division of Endocrinology, University of Arkansas for Medical Sciences, Little Rock, AR, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hydration, dehydration, underhydration, optimal hydration: are we barking up the wrong tree?</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Nutrition</style></full-title></periodical><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019&#xD;Article in Press</style></notes><work-type><style face="normal" font="default" size="100%">Article in Press</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059702880&amp;doi=10.1007%2fs00394-018-01889-z&amp;partnerID=40&amp;md5=7c5c78bb224da997fe143e5e21e031e8</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00394-018-01889-z</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>69</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">69</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kardum, N.</style></author><author><style face="normal" font="default" size="100%">Konic Ristic, A.</style></author><author><style face="normal" font="default" size="100%">Zec, M.</style></author><author><style face="normal" font="default" size="100%">Kojadinovic, M.</style></author><author><style face="normal" font="default" size="100%">Petrovic-Oggiano, G.</style></author><author><style face="normal" font="default" size="100%">Zekovic, M.</style></author><author><style face="normal" font="default" size="100%">Kroon, P. A.</style></author><author><style face="normal" font="default" size="100%">Glibetić, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre of Research Excellence in Nutrition and Metabolism, Institute for Medical Research, University of Belgrade, Belgrade, Serbia&#xD;Food and Health Programme, Institute of Food Research, Norwich Research Park, Norwich, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Design, formulation and sensory evaluation of a polyphenol-rich food placebo: an example of aronia juice for food intervention studies</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Food Sciences and Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Food Sciences and Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">742-749</style></pages><volume><style face="normal" font="default" size="100%">68</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">anthocyanins</style></keyword><keyword><style face="normal" font="default" size="100%">Aronia melanocarpa</style></keyword><keyword><style face="normal" font="default" size="100%">bioactives</style></keyword><keyword><style face="normal" font="default" size="100%">functional food</style></keyword><keyword><style face="normal" font="default" size="100%">platelet function</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Products suitable for use as controls in food interventions designed to demonstrate the role of minor components are largely lacking. In the present study, we aimed to develop a formulation to be used as a placebo in a clinical trial designed to assess the effects of aronia juice polyphenols on platelet function. Three formulations with the same nutrient composition as aronia juice were prepared by mixing various nutrients, artificial colours and flavours with water. The similarity of formulations to aronia juice in terms of taste, colour, smell and texture was assessed by six food panellists. The final placebo was tested for its impact on platelet function, biochemical and anthropometric parameters in a 4-week long study. No significant changes in platelet function, or in several cardiovascular and safety markers were recorded. Formulation suitable for use as a placebo for dietary intervention studies using aronia juice has been developed and demonstrated to be well tolerated in humans. © 2017 Informa UK Limited, trading as Taylor &amp; Francis Group.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85011690499&amp;doi=10.1080%2f09637486.2017.1283682&amp;partnerID=40&amp;md5=cb20a0a5953dcf9b53351ca858911c7e</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/09637486.2017.1283682</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>52</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">52</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kamolvit, W.</style></author><author><style face="normal" font="default" size="100%">Nilsén, V.</style></author><author><style face="normal" font="default" size="100%">Zambrana, S.</style></author><author><style face="normal" font="default" size="100%">Mohanty, S.</style></author><author><style face="normal" font="default" size="100%">Gonzales, E.</style></author><author><style face="normal" font="default" size="100%">Östenson, C. G.</style></author><author><style face="normal" font="default" size="100%">Brauner, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology, Tumor and Cell Biology, Division of Clinical Microbiology, Karolinska Institutet, Karolinska University Hospital, Stockholm, 17176, Sweden&#xD;Department of Molecular Medicine and Surgery, Karolinska Institutet and Karolinska University Hospital, Stockholm, 17176, Sweden&#xD;Area de Farmacologia, Instituto de Investigaciones Farmaco Bioquimicas, Facultad de Ciencias Farmacéuticas y Bioquimicas, Universidad Mayor de San Andres, La Paz, Bolivia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lupinus mutabilis edible beans protect against bacterial infection in uroepithelial cells</style></title><secondary-title><style face="normal" font="default" size="100%">Evidence-based Complementary and Alternative Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Evidence-based Complementary and Alternative Medicine</style></full-title></periodical><volume><style face="normal" font="default" size="100%">2018</style></volume><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Lupinus mutabilis is a South American herb with edible beans, known to reduce serum glucose levels in diabetic patients. Furthermore, L. mutabilis contains phytochemicals known to decrease bacterial load. Based on the increased urinary tract infections experienced among patients with diabetes, we investigated the effect of L. mutabilis on bladder epithelial cells in the protection of E. coli infection during normal and high glucose concentrations. We did not observe any direct antibacterial effect by L. mutabilis extract. Instead we observed an influence on the host cells, with indirect impact on bacteria and their possibility of causing infection. L. mutabilis extract decreased adhesion to bladder epithelial cells of uropathogenic bacteria, including drug-resistant strains. Moreover, uroplakin1a, involved in adhesion, was downregulated while the antimicrobial peptide RNase 7 was upregulated in L. mutabilis treated cells irrespectively of glucose concentration. This supports an early effect fighting bacteria. Additionally, L. mutabilis prevented bacterial biofilm formation, which is used by bacteria to evade the immune system and antibiotics. In summary, L. mutabilis protects against bacterial infection in uroepithelial cells by preventing adhesion through alteration of the cell surface, increasing antimicrobial peptide expression, and reducing biofilm formation. Together, this promotes bacterial clearance, suggesting that L. mutabilis as extract or as a dietary item can contribute to the prevention of urinary tract infections, which is of importance in an era of increasing antibiotic resistance. © 2018 Witchuda Kamolvit et al.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059457929&amp;doi=10.1155%2f2018%2f1098015&amp;partnerID=40&amp;md5=e902c861b6b7955ff7da4bac8ba1a497</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">1098015</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1155/2018/1098015</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>232</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">232</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kamiya, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Infectious Diseases, Kyorin University School of Medicine, Mitaka, Tokyo 181-8611, Japan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Probiotics and prebiotics in infections</style></title><secondary-title><style face="normal" font="default" size="100%">Probiotics and Prebiotics in Food, Nutrition and Health</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">354-376</style></pages><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Probiotics are known to have beneficial effects on their hosts once consumed, and many investigations have examined the application of probiotics in a medical context. The diseases targeted by probiotic therapy were mainly infectious diseases such as Clostridium difficile infection (antibiotic-associated diarrhea:AAD, pseudomembranous colitis:PMC), rotavirus infection, traveler’s diarrhea, etc. In addition to intestinal infections, other studies have also reported positive clinical effects in a broad range of infectious diseases including opportunistic infection, postoperative infection, urinary tract infection and respiratory tract infection (Gerritsen et al. 2011, Quigley 2010). © 2014 by Taylor &amp; Francis Group, LLC.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055200037&amp;partnerID=40&amp;md5=1006d98b3554cc83a2f78a437df1615a</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>408</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">408</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kahlon, T. S.</style></author><author><style face="normal" font="default" size="100%">Smith, G. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Western Regional Research Center, USDA-ARS, 800 Buchanan St, Albany, CA 94710, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">In vitro binding of bile acids by blueberries (Vaccinium spp.), plums (Prunus spp.), prunes (Prunus spp.), strawberries (Fragaria X ananassa), cherries (Malpighia punicifolia), cranberries (Vaccinium macrocarpon) and apples (Malus sylvestris)</style></title><secondary-title><style face="normal" font="default" size="100%">Food Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Food Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1182-1187</style></pages><volume><style face="normal" font="default" size="100%">100</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Apples</style></keyword><keyword><style face="normal" font="default" size="100%">Bile acid binding</style></keyword><keyword><style face="normal" font="default" size="100%">Blueberries</style></keyword><keyword><style face="normal" font="default" size="100%">Cherries</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberries</style></keyword><keyword><style face="normal" font="default" size="100%">Plums</style></keyword><keyword><style face="normal" font="default" size="100%">Prunes</style></keyword><keyword><style face="normal" font="default" size="100%">Strawberries</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">The in vitro binding of bile acids by blueberries (Vaccinium spp.), plums (Prunus spp.), prunes (Prunus spp.), strawberries (Fragaria X ananassa), cherries (Malpighia punicifolia) cranberries (Vaccinium macrocarpon) and apples (Malus sylvestris) was determined using a mixture of bile acids secreted in human bile at a duodenal physiological pH of 6.3. Six treatments and two blank incubations were conducted to testing various fresh raw fruits on an equal dry matter basis. Considering cholestyramine (bile acid binding, cholesterol lowering drug) as 100% bound, the relative in vitro bile acid binding on dry matter (DM), total dietary fiber (TDF) and total polysaccharides (PCH) basis was for blueberries 7%, 47% and 25%; plums 6%, 53% and 50%; prunes 5%, 50% and 14%; strawberries 5%, 23% and 15%; cherries 5%, 37% and 5%; cranberries 4%, 12% and 7%; and apple 1%, 7% and 5%, respectively. Bile acid binding on DM basis for blueberries was significantly (P ≤ 0.05) higher than all the fruits tested. The bile acid binding for plums was similar to that for prunes and strawberries and significantly higher than cherries, cranberries and apples. Binding values for cherries and cranberries were significantly higher than those for apples. These results point to the relative health promoting potential of blueberries &gt; plums = prunes = strawberries = cherries = cranberries &gt; apples as indicated by their bile acid binding on DM basis. The variability in bile acid binding between the fruits tested maybe related to their phytonutrients (antioxidants, polyphenols, hydroxycinnamic acids, flavonoids, anthocyanins, flavonols, proanthocyanidins, catechins), structure, hydrophobicity of undigested fractions, anionic or cationic nature of the metabolites produced during digestion or their interaction with active binding sites. Inclusion of blueberries, plums, prunes, strawberries, cherries and cranberries in our daily diet as health promoting fruits should be encouraged. Animal studies are planned to validate in vitro bile acid binding of fruits observed herein to their potential of atherosclerosis amelioration (lipid and lipoprotein lowering) and cancer prevention (excretion of toxic metabolites).</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :51&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33745934046&amp;doi=10.1016%2fj.foodchem.2005.10.066&amp;partnerID=40&amp;md5=9655da6c06fca5b5d8af26ea3912a1f6</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.foodchem.2005.10.066</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>8</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">8</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jurikova, T.</style></author><author><style face="normal" font="default" size="100%">Skrovankova, S.</style></author><author><style face="normal" font="default" size="100%">Mlcek, J.</style></author><author><style face="normal" font="default" size="100%">Balla, S.</style></author><author><style face="normal" font="default" size="100%">Snopek, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for teacher training, Faculty of Central European Studies, Constantine the Philosopher University in Nitra, Nitra, SK-949 74, Slovakia&#xD;Department of Food Analysis and Chemistry, Faculty of Technology, Tomas Bata University in Zlín, Zlín, CZ-760 01, Czech Republic</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bioactive compounds, antioxidant activity, and biological effects of European cranberry (vaccinium oxycoccos)</style></title><secondary-title><style face="normal" font="default" size="100%">Molecules</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Molecules</style></full-title></periodical><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antioxidant effect</style></keyword><keyword><style face="normal" font="default" size="100%">Biological activities</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Polyphenols</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium oxycoccos</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2019</style></year></dates><abstract><style face="normal" font="default" size="100%">Lesser known fruits or underutilized fruit species are recently of great research interest due to the presence of phytochemicals that manifest many biological effects. European cranberry, Vaccinium oxycoccos fruit, as an important representative of this group, is a valuable source of antioxidants and other biologically active substances, similar to American cranberry (V. macrocarpon) which is well known and studied. European cranberry fruit is rich especially in polyphenolic compounds anthocyanins (12.4-207.3 mg/100 g fw), proanthocyanins (1.5-5.3 mg/100 g fw), and flavonols, especially quercetin (0.52-15.4 mg/100 g fw), which mostly contribute to the antioxidant activity of the fruit. Small cranberry is also important due to its various biological effects such as urinary tract protection (proanthocyanidins), antibacterial and antifungal properties (quercetin, proanthocyanidins, anthocyanins), cardioprotective (proanthocyanidins) and anticancer activities (proanthocyanidins), and utilization in food (juice drinks, jams, jellies, sauces, additive to meat products) and pharmacological industries, and in folk medicine. © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058907920&amp;doi=10.3390%2fmolecules24010024&amp;partnerID=40&amp;md5=9242f47f13ad78c11c3a0dccba6967d6</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">24010024</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/molecules24010024</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>74</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">74</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jurikova, T.</style></author><author><style face="normal" font="default" size="100%">Mlcek, J.</style></author><author><style face="normal" font="default" size="100%">Skrovankova, S.</style></author><author><style face="normal" font="default" size="100%">Sumczynski, D.</style></author><author><style face="normal" font="default" size="100%">Sochor, J.</style></author><author><style face="normal" font="default" size="100%">Hlavacova, I.</style></author><author><style face="normal" font="default" size="100%">Snopek, L.</style></author><author><style face="normal" font="default" size="100%">Orsavova, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute for Teacher Training, Faculty of Central European Studies, Constantine the Philosopher University in Nitra, Drazovska 4, Nitra, SK-949 74, Slovakia&#xD;Department of Food Analysis and Chemistry, Faculty of Technology, Tomas Bata University in Zlín, nám. T. G. Masaryka 5555, Zlín, CZ-760 01, Czech Republic&#xD;Department of Viticulture and Enology, Faculty of Horticulture, Mendel University in Brno, Valticka 337, Lednice, CZ-691 44, Czech Republic&#xD;Language Centre, Faculty of Humanities, Tomas Bata University in Zlín, nám. T. G. Masaryka 5555, Zlín, CZ-760 01, Czech Republic</style></auth-address><titles><title><style face="normal" font="default" size="100%">Fruits of black chokeberry aronia melanocarpa in the prevention of chronic diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Molecules</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Molecules</style></full-title></periodical><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aronia melanocarpa</style></keyword><keyword><style face="normal" font="default" size="100%">Bioactive compounds</style></keyword><keyword><style face="normal" font="default" size="100%">Black chokeberry</style></keyword><keyword><style face="normal" font="default" size="100%">Chronic diseases</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">In recent years, growing attention has been focused on the utilization of natural sources of antioxidants in the prevention of chronic diseases. Black chokeberry (Aronia melanocarpa) represents a lesser known fruit species utilized mainly as juices, purees, jams, jellies and wine, as important food colorants or nutritional supplements. The fruit is valued as a great source of antioxidants, especially polyphenols, such as phenolic acids (neochlorogenic and chlorogenic acids) and flavonoids (anthocyanins, proanthocyanidins, flavanols and flavonols), particularly cyanidin-3-galactoside and cyanidin-3-arabinoside, as well as (-)-epicatechin units. The berries of A. melanocarpa, due to the presence and the high content of these bioactive components, exhibit a wide range of positive effects, such as strong antioxidant activity and potential medicinal and therapeutic benefits (gastroprotective, hepatoprotective, antiproliferative or anti-inflammatory activities). They could be also contributory toward the prevention of chronic diseases including metabolic disorders, diabetes and cardiovascular diseases, because of supportive impacts on lipid profiles, fasting plasma glucose and blood pressure levels. © 2017 by the authors.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :10&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020703544&amp;doi=10.3390%2fmolecules22060944&amp;partnerID=40&amp;md5=36a5b7819f63586b1662a7f3cd7722d3</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">944</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/molecules22060944</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>156</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">156</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Joseph, N. M.</style></author><author><style face="normal" font="default" size="100%">Bhanupriya, B.</style></author><author><style face="normal" font="default" size="100%">Shewade, D. G.</style></author><author><style face="normal" font="default" size="100%">Harish, B. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology, JIPMER, Pondicherry, India&#xD;Department of Pharmacy, JIPMER, Pondicherry, India&#xD;Department of Pharmacology, JIPMER, Pondicherry, India</style></auth-address><titles><title><style face="normal" font="default" size="100%">Relationship between antimicrobial consumption and the incidence of antimicrobial resistance in Escherichia coli and Klebsiella pneumoniae isolates</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical and Diagnostic Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Clinical and Diagnostic Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">DC08-DC12</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antimicrobial drug resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Daily defined doses</style></keyword><keyword><style face="normal" font="default" size="100%">Drug utilization</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Klebsiella pneumoniae</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Introduction: Gram negative organisms are one of the major causes of nosocomial diseases. Development of resistance to antibiotics by these organisms increases their risk in clinical treatment of patients. It also affects morbidity and mortality hence needs to be monitored and controlled. Aim: The aim of the present study was to analyse the correlation between consumption of parenteral antibiotics and the rates of antimicrobial resistance among the Escherichia coli and Klebsiella pneumoniae isolates collected during Dec 2010 - Jun 2013 from JIPMER hospital. Materials and Methods: Consumption data of parenteral antibiotics in J01 category of Anatomical Therapeutic Chemical (ATC) in JIPMER was obtained and expressed in Defined Daily Doses (DDD) per 1000 inhabitants. Valid consumption and resistance data during the period Dec 2010 to Jun 2013 were obtained at 6 month intervals and were correlated to draw a relationship between antimicrobial consumption and its impact on drug resistance for Escherichia coli and Klebsiella pneumoniae. Results: Escherichia coli isolates showed high resistance for increased use of gentamycin and ciprofloxacin. Increase in antibiotic consumption increases the resistance for Escherichia coli except for amikacin. Among the Klebsiella isolates, meropenem and gentamycin showed high correlations followed by ceftazidime, amikacin, ceftriaxone and ciprofloxacin. Conclusion: In summary, a statistically significant association was noticed between consumption of the studied antimicrobials and resistance of Escherichia coli isolates, except for amikacin and ceftazidime. In the case of Klebsiella pneumoniae, there was a statistically significant association between the resistance rates and consumption of gentamycin, ceftazidime and meropenem. Further, a linear relationship was noted between antimicrobial consumption and resistant isolates of Escherichia coli and Klebsiella pneumoniae, except for Escherichia coli resistance to amikacin. © 2015, Journal of Clinical and Diagnostic Research. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :12&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84922261861&amp;doi=10.7860%2fJCDR%2f2015%2f11029.5537&amp;partnerID=40&amp;md5=e4aff9470c1c453c16bb7e6a155fda96</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.7860/JCDR/2015/11029.5537</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>526</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">526</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jones, A. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">3109 Olton Road C/Box 5006, Plainview, TX 79072, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">The next step in infectious disease: Taming bacteria</style></title><secondary-title><style face="normal" font="default" size="100%">Medical Hypotheses</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Medical Hypotheses</style></full-title></periodical><pages><style face="normal" font="default" size="100%">171-174</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">Except for immunization programs our warfare with bacteria has always been a frontal assault with antibiotics. In this warfare we win battles, but with every new battle the enemy gets stronger. We need other options. Recent experience suggests two alternatives. First, public health measures designed to control the spread of infectious disease are associated with the selection of less virulent strains of microorganisms. Second, the same selection pressures obtained by public health measures outside the body are brought into play when we inhibit the adherence of bacteria within the body. Two recent studies using food sugars known to inhibit bacterial adherence show long-term benefits best explained by the previously observed decreases in bacterial virulence, following chronic exposure to the respective substances. Cranberry juice selects for less uropathogenic strains of Escherichia coli and xylitol for less caries producing Streptococcus mutans. The ability of these substances to reduce bacterial adherence in the human host has been known for some time, but poorly utilized. Their in vitro ability to decrease virulence has been reported but not clinically studied. © 2002 Elsevier Science Ltd. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :7&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037321084&amp;doi=10.1016%2fS0306-9877%2802%2900352-3&amp;partnerID=40&amp;md5=bf4c5df05b1c2995b7222cc2578e1acb</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0306-9877(02)00352-3</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>499</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">499</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Johnston, S. L.</style></author><author><style face="normal" font="default" size="100%">Farrell, S. A.</style></author><author><style face="normal" font="default" size="100%">Bouchard, C.</style></author><author><style face="normal" font="default" size="100%">Beckerson, L. A.</style></author><author><style face="normal" font="default" size="100%">Comeau, M.</style></author><author><style face="normal" font="default" size="100%">Lefebvre, G.</style></author><author><style face="normal" font="default" size="100%">Papaioannou, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Kingston, ON, Canada&#xD;Halifax, NS, United Kingdom&#xD;Quebec, QC, Canada&#xD;Toronto, ON, Canada&#xD;Montreal, QC, Canada&#xD;Hamilton, ON, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Detection and Management of Vaginal Atrophy. These guidelines have been reviewed by the joint committee of Clinical Practice Gynaecology and Urogynaecology and approved by the Executive and Council of the Society of Obstetricians and Gynaecologists of Canada</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Obstetrics and Gynaecology Canada</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Obstetrics and Gynaecology Canada</style></full-title></periodical><pages><style face="normal" font="default" size="100%">503-508</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Administration, intravaginal</style></keyword><keyword><style face="normal" font="default" size="100%">Atrophy</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">Vaginal creams</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: To support the practitioner in the diagnosis of vaginal atrophy and in the management of the related symptoms.Options: The modalities of evaluation range from basic pelvic examination, examination of the vulva, and laboratory tests.Outcomes: A comprehensive approach to the detection of vaginal atrophy and a discussion of available therapeutic and non-therapeutic options.Evidence: Published opinions of experts, supplemented by evidence from clinical trials, where appropriate.Values: The quality of the evidence is rated using the criteria described by the Canadian Task Force on the Periodic Health Examination.Benefits, Harms, and Costs: Diagnosis of vaginal atrophy is often a challenge because women are unwilling to report symptoms, which have the potential to significantly decrease their quality of life. Increased clinical suspicion is the first step in the diagnosis of vaginal atrophy, which will prompt the initiation of safe therapies with proven efficacy.Recommendations:1Health-care providers should routinely assess postmenopausal women for the symptoms and signs of vaginal atrophy, a common condition that exerts significant negative effects on quality of life. (III-C)2Regular sexual activity should be encouraged to maintain vaginal health. (II-2B)3Women experiencing recurrent urinary tract infections should be instructed that consumption of pure cranberry-lingonber-ry juice, rather than cranberry drink, will decrease their risk of urinary tract infections. (I-A)4Vaginal moisturizers applied on a regular basis have an efficacy equivalent to local hormone replacement for the treatment of local urogenital symptoms such as vaginal itching, irritation, and dyspareunia, and should be offered to women wishing to avoid use of hormone replacement therapy. (I-A)5Women experiencing vaginal atrophy can be offered any of the following effective vaginal estrogen replacement therapies: conjugated equine estrogen cream (I-A), a sustained-release intravaginal estradiol ring (I-A), or a low-dose estradiol tablet (l-A).6Although systemic absorption of estrogen can occur with local preparations, there is insufficient data to recommend annual endometrial surveillance in asymptomatic women using local estrogens. (III-C)7For menopausal women experiencing recurrent urinary tract infections and who have no contraindication to local hormone replacement, vaginal estrogen therapy should be offered. (I-A)Validation: These guidelines have been reviewed by the joint committee of Clinical Practice Gynaecology and Urogynaecology and approved by the Executive and Council of the Society of Obstetricians and Gynaecologists of Canada.Sponsor: The Society of Obstetricians and Gynaecologists of Canada. © 2004 .</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :80&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-3242659275&amp;doi=10.1016%2fS1701-2163%2816%2930662-4&amp;partnerID=40&amp;md5=1c822f15acf227c70176c4fa2c97f962</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S1701-2163(16)30662-4</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>436</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">436</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Johnson-White, B.</style></author><author><style face="normal" font="default" size="100%">Buquo, L.</style></author><author><style face="normal" font="default" size="100%">Zeinali, M.</style></author><author><style face="normal" font="default" size="100%">Ligler, F. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Bio/Molecular Science and Engineering, Naval Research Laboratory, Washington, DC 20375-5348, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevention of nonspecific bacterial cell adhesion in immunoassays by use of cranberry juice</style></title><secondary-title><style face="normal" font="default" size="100%">Analytical Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Analytical Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">853-857</style></pages><volume><style face="normal" font="default" size="100%">78</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">The ability of Vaccinum macrocarpon, the North American cranberry, to prevent bacterial adhesion has been used to advantage in the prevention of urinary tract infections and has recently been described for the prevention of adhesion of bacteria responsible for oral infections and stomach ulcers. This report documents the ability of cranberry juice to reduce nonspecific adhesion of bacteria to the borosilicate glass microscope slides used in an immunoarray biosensor format. Nonspecific binding of analytes in the array sensor leads to high background signals that cause increased detection limits and false positives. Reduction in background-to-signal ratios can be seen as the juice concentration is increased from 0 to 50% of the sample. This impact cannot be duplicated with grape, orange, apple, or white cranberry juice. Sugar content and pH have been eliminated as the agents in the juice responsible for the anti-adhesive activity. © 2006 American Chemical Society.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :35&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-32444445043&amp;doi=10.1021%2fac051700v&amp;partnerID=40&amp;md5=f57d5c0c7d56004f26f53ca2d60c39aa</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/ac051700v</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>575</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">575</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Johnson, J. R.</style></author><author><style face="normal" font="default" size="100%">Stell, A. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">VA Medical Center, Department of Medicine, University of Minnesota, Minneapolis, MS, United States&#xD;University of Minnesota, Department of Medicine, Infectious Diseases (111F), 1 Veterans Dr., Minneapolis, MN 55417, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">261-272</style></pages><volume><style face="normal" font="default" size="100%">181</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2000</style></year></dates><abstract><style face="normal" font="default" size="100%">Among 75 urosepsis isolates of Escherichia coli, 29 virulence factor (VF) genes were detected by use of a novel polymerase chain reaction (PCR) assay. Compared with probe hybridization, the PCR assay&apos;s specificity was 100% and sensitivity 97.1%. fyuA (yersiniabactin: overall prevalence, 93%), tra T (serum resistance, 68%), and a pathogenicity-associated island marker (71%) occurred in most strains from both compromised and noncompromised hosts. Present in &lt;20% of strains each were sfaS, focG (F1C fimbriae), afaldra, bmaE (M fimbriae), gafD (G fimbriae), cnf1, cdtB (cytolethal distending toxin), cvaC (colicin V), and ibeA (invasion of brain endothelium). Different VFs were variously confined to virulence-associated phylogenetic group B2 (as defined by multilocus enzyme electrophoresis); concentrated in group B2, but with spread beyond; or concentrated outside of group B2. These findings provide novel insights into the VFs of extraintestinal pathogenic E. coli and demonstrate the new PCR assay&apos;s utility for molecular epidemiological studies.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :774&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033963533&amp;doi=10.1086%2f315217&amp;partnerID=40&amp;md5=97dc7b5a36b4b8999fcba1ee0bd5d703</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/315217</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>349</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">349</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Johnson, B. J.</style></author><author><style face="normal" font="default" size="100%">Lin, B.</style></author><author><style face="normal" font="default" size="100%">Dinderman, M. A.</style></author><author><style face="normal" font="default" size="100%">Rubin, R. A.</style></author><author><style face="normal" font="default" size="100%">Malanoski, A. P.</style></author><author><style face="normal" font="default" size="100%">Ligler, F. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Bio/Molecular Science and Engineering, Naval Research Laboratory, 4555 Overlook Ave SW, Code 6900, Washington, DC 20375, United States&#xD;8620 Portafino Place, Whittier, CA 90603, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of cranberry on Escherichia coli cellular surface characteristics</style></title><secondary-title><style face="normal" font="default" size="100%">Biochemical and Biophysical Research Communications</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Biochemical and Biophysical Research Communications</style></full-title></periodical><pages><style face="normal" font="default" size="100%">992-994</style></pages><volume><style face="normal" font="default" size="100%">377</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-adhesive</style></keyword><keyword><style face="normal" font="default" size="100%">Antibacterial</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyandin</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">The anti-adhesive effects of cranberry have been attributed to both interactions of its components with the surface of bacterial cells and to inhibition of p-fimbriae expression. Previous reports also suggested that the presence of cranberry juice changed the Gram stain characteristics of Escherichia coli. Here, we show that the morphology of E. coli is changed when grown in the presence of juice or extract from Vaccinium macrocarpon (cranberry). Gene expression analysis indicates the down regulation of flagellar basal body rod and motor proteins. Consistent with this finding and previous reports, the SEM images indicate a decrease in the visible p-fimbriae. The iodine used in Gram-staining protocols was found to interact differently with the bacterial membrane when cells were cultured in spiked media. Slight alterations in the Gram stain protocol demonstrated that culturing in the presence of cranberry juice does not change the Gram stain characteristics contradicting other reports.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :20&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-56049127891&amp;doi=10.1016%2fj.bbrc.2008.10.098&amp;partnerID=40&amp;md5=ba2cc85d69d2b1f9645ebf0087067941</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.bbrc.2008.10.098</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>226</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">226</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jiménez-Pacheco, A.</style></author><author><style face="normal" font="default" size="100%">Jiménez-Pacheco, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Servicio de Urología, Hospital Santa Ana, Granada, Spain&#xD;Servicio de Rehabilitación, Centro Traumatológico y de Rehabilitación, Hospital Universitario Virgen de las Nieves, Granada, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Probiotics as an alternative to prevent recurrent urinary tract infections in women</style></title><secondary-title><style face="normal" font="default" size="100%">Revista Medica de Chile</style></secondary-title><short-title><style face="normal" font="default" size="100%">El uso de probióticos como alternativa en la prevención de las infecciones urinarias recurrentes en mujeres</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Revista Medica de Chile</style></full-title></periodical><volume><style face="normal" font="default" size="100%">141</style></volume><number><style face="normal" font="default" size="100%">6</style></number><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Letter</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84884680477&amp;doi=10.4067%2fS0034-98872013000600020&amp;partnerID=40&amp;md5=663bdf1ce5aabed621e72c3c31d4b9fe</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.4067/S0034-98872013000600020</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>235</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">235</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jepson, R. G.</style></author><author><style face="normal" font="default" size="100%">Williams, G.</style></author><author><style face="normal" font="default" size="100%">Craig, J. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Nursing and Midwifery, University of Stirling, Stirling, UK.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberries for preventing urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane database of systematic reviews (Online)</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane database of systematic reviews (Online)</style></full-title></periodical><volume><style face="normal" font="default" size="100%">10</style></volume><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberries have been used widely for several decades for the prevention and treatment of urinary tract infections (UTIs). This is the third update of our review first published in 1998 and updated in 2004 and 2008. To assess the effectiveness of cranberry products in preventing UTIs in susceptible populations. We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL in The Cochrane Library) and the Internet. We contacted companies involved with the promotion and distribution of cranberry preparations and checked reference lists of review articles and relevant studies.Date of search: July 2012 All randomised controlled trials (RCTs) or quasi-RCTs of cranberry products for the prevention of UTIs. Two authors independently assessed and extracted data. Information was collected on methods, participants, interventions and outcomes (incidence of symptomatic UTIs, positive culture results, side effects, adherence to therapy). Risk ratios (RR) were calculated where appropriate, otherwise a narrative synthesis was undertaken. Quality was assessed using the Cochrane risk of bias assessment tool. This updated review includes a total of 24 studies (six cross-over studies, 11 parallel group studies with two arms; five with three arms, and two studies with a factorial design) with a total of 4473 participants. Ten studies were included in the 2008 update, and 14 studies have been added to this update. Thirteen studies (2380 participants) evaluated only cranberry juice/concentrate; nine studies (1032 participants) evaluated only cranberry tablets/capsules; one study compared cranberry juice and tablets; and one study compared cranberry capsules and tablets. The comparison/control arms were placebo, no treatment, water, methenamine hippurate, antibiotics, or lactobacillus. Eleven studies were not included in the meta-analyses because either the design was a cross-over study and data were not reported separately for the first phase, or there was a lack of relevant data. Data included in the meta-analyses showed that, compared with placebo, water or not treatment, cranberry products did not significantly reduce the occurrence of symptomatic UTI overall (RR 0.86, 95% CI 0.71 to 1.04) or for any the subgroups: women with recurrent UTIs (RR 0.74, 95% CI 0.42 to 1.31); older people (RR 0.75, 95% CI 0.39 to 1.44); pregnant women (RR 1.04, 95% CI 0.97 to 1.17); children with recurrent UTI (RR 0.48, 95% CI 0.19 to 1.22); cancer patients (RR 1.15 95% CI 0.75 to 1.77); or people with neuropathic bladder or spinal injury (RR 0.95, 95% CI: 0.75 to 1.20). Overall heterogeneity was moderate (I2 = 55%). The effectiveness of cranberry was not significantly different to antibiotics for women (RR 1.31, 95% CI 0.85, 2.02) and children (RR 0.69 95% CI 0.32 to 1.51). There was no significant difference between gastrointestinal adverse effects from cranberry product compared to those of placebo/no treatment (RR 0.83, 95% CI 0.31 to 2.27). Many studies reported low compliance and high withdrawal/dropout problems which they attributed to palatability/acceptability of the products, primarily the cranberry juice. Most studies of other cranberry products (tablets and capsules) did not report how much of the &apos;active&apos; ingredient the product contained, and therefore the products may not have had enough potency to be effective. Prior to the current update it appeared there was some evidence that cranberry juice may decrease the number of symptomatic UTIs over a 12 month period, particularly for women with recurrent UTIs. The addition of 14 further studies suggests that cranberry juice is less effective than previously indicated. Although some of small studies demonstrated a small benefit for women with recurrent UTIs, there were no statistically significant differences when the results of a much larger study were included. Cranberry products were not significantly different to antibiotics for preventing UTIs in three small studies. Given the large number of dropouts/withdrawals from studies (mainly attributed to the acceptability of consuming cranberry products particularly juice, over long periods), and the evidence that the benefit for preventing UTI is small, cranberry juice cannot currently be recommended for the prevention of UTIs. Other preparations (such as powders) need to be quantified using standardised methods to ensure the potency, and contain enough of the &apos;active&apos; ingredient, before being evaluated in clinical studies or recommended for use.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :204&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871911679&amp;partnerID=40&amp;md5=2623150efb5b31288c9f33220cde33b6</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>383</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">383</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jepson, R. G.</style></author><author><style face="normal" font="default" size="100%">Craig, J. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Nursing and Midwifery, University of Stirling, Stirling FK9 4LA, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberries for preventing urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane Database of Systematic Reviews</style></full-title></periodical><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">*Beverages</style></keyword><keyword><style face="normal" font="default" size="100%">*Phytotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">*Vaccinium macrocarpon</style></keyword><keyword><style face="normal" font="default" size="100%">Cross-over studies</style></keyword><keyword><style face="normal" font="default" size="100%">Humans</style></keyword><keyword><style face="normal" font="default" size="100%">Randomized controlled trials as topic</style></keyword><keyword><style face="normal" font="default" size="100%">Sex factors</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections [*prevention &amp; control]</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Cranberries have been used widely for several decades for the prevention and treatment of urinary tract infections (UTIs). Objectives: To assess the effectiveness of cranberry products in preventing UTIs in susceptible populations. Search strategy: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL in The Cochrane Library) and the Internet. We contacted companies involved with the promotion and distribution of cranberry preparations and checked reference lists of review articles and relevant studies. Date of last search: January 2007. Selection criteria: All randomised controlled trials (RCTs) or quasi-RCTs of cranberry products for the prevention of UTIs in all populations. Data collection and analysis: Two authors independently assessed and extracted information. Information was collected on methods, participants, interventions and outcomes (UTIs - symptomatic and asymptomatic, side effects, adherence to therapy). Relative risk (RR) were calculated where appropriate, otherwise a narrative synthesis was undertaken. Quality was assessed using the Cochrane criteria. Main results: Ten studies (n = 1049, five cross-over, five parallel group) were included. Cranberry/cranberry- lingonberry juice versus placebo, juice or water was evaluated in seven studies, and cranberries tablets versus placebo in four studies (one study evaluated both juice and tablets). Cranberry products significantly reduced the incidence of UTIs at 12 months (RR 0.65, 95% CI 0.46 to 0.90) compared with placebo/control. Cranberry products were more effective reducing the incidence of UTIs in women with recurrent UTIs, than elderly men and women or people requiring catheterisation. Six studies were not included in the meta-analyses due to methodological issues or lack of available data. However, only one reported a significant result for the outcome of symptomatic UTIs. Side effects were common in all studies, and dropouts/withdrawals in several of the studies were high. Authors&apos; conclusions: There is some evidence that cranberry juice may decrease the number of symptomatic UTIs over a 12 month period, particularly for women with recurrent UTIs. It&apos;s effectiveness for other groups is less certain. The large number of dropouts/withdrawals indicates that cranberry juice may not be acceptable over long periods of time. It is not clear what is the optimum dosage or method of administration (e.g. juice, tablets or capsules). Further properly designed studies with relevant outcomes are needed. Copyright © 2008 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :215&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-43649101092&amp;doi=10.1002%2f14651858.CD001321.pub4&amp;partnerID=40&amp;md5=f3a7004882ee9ddf815b7f6e7240dff8</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">Cd001321</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/14651858.CD001321.pub4</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>399</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">399</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jepson, R. G.</style></author><author><style face="normal" font="default" size="100%">Craig, J. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Nursing and Midwifery, University of Stirling, Stirling, United Kingdom&#xD;School of Public Health, University of Sydney, Sydney, NSW, Australia&#xD;Department of Nephrology, Children&apos;s Hospital at Westmead, Westmead, NSW, Australia&#xD;Department of Nursing and Midwifery, University of Stirling, Stirling FK9 4LA, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">A systematic review of the evidence for cranberries and blueberries in UTI prevention</style></title><secondary-title><style face="normal" font="default" size="100%">Molecular Nutrition and Food Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Molecular Nutrition and Food Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">738-745</style></pages><volume><style face="normal" font="default" size="100%">51</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Blueberry</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">In this review we assess the effectiveness of cranberry and blueberry products in preventing symptomatic urinary tract infections (UTIs). Selection criteria were randomised or quasi-randomised controlled trials of cranberry or blueberry juice/products for the prevention of symptomatic UTIs. A comprehensive search was undertaken in November 2006 whereupon two reviewers independently assessed and extracted data. Quality was assessed using Cochrane criteria. Relative risks (RR) were calculated where appropriate; otherwise a narrative synthesis was undertaken. No relevant trials of blueberry products were identified. Nine trials of cranberry products met the inclusion criteria. In four good quality randomised controlled trials (RCTs), cranberry products significantly reduced the incidence of symptomatic UTIs in 12 months (overall RR 0.65, 95% CI: 0.46-0.90) compared with placebo/ control. Five trials were not included in the meta-analyses due to the lack of appropriate data. However, only one reported a significant result. Side effects were common, and losses to followup/withdrawals in several of the trials were high (&gt;40%). There is some evidence from four good quality RCTs that cranberry juice may decrease the number of symptomatic UTIs over a 12-month period, particularly in women with recurrent UTIs. It is uncertain whether it is effective in other susceptible groups. © 2007 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :75&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-34447519188&amp;doi=10.1002%2fmnfr.200600275&amp;partnerID=40&amp;md5=dbfec489ed12ceb97f93f83e8453ff4d</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/mnfr.200600275</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>540</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">540</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jensen, H. D.</style></author><author><style face="normal" font="default" size="100%">Krogfelt, K. A.</style></author><author><style face="normal" font="default" size="100%">Cornett, C.</style></author><author><style face="normal" font="default" size="100%">Hansen, S. H.</style></author><author><style face="normal" font="default" size="100%">Christensen, S. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicinal Chemistry, Royal Danish School of Pharmacy, Universitetsparken 2, DK-2100 Copenhagen Ø, Denmark&#xD;Department of Gastro-Intestinal Infections, Statens Serum Institut, Copenhagen, Denmark&#xD;Department of Analytical and Pharmaceutical Chemistry, Royal Danish School of Pharmacy, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hydrophilic carboxylic acids and iridoid glycosides in the juice of American and European cranberries (Vaccinium macrocarpon and V. oxycoccos), lingonberries (V. vitis-idaea), and blueberries (V. myrtillus)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">6871-6874</style></pages><volume><style face="normal" font="default" size="100%">50</style></volume><number><style face="normal" font="default" size="100%">23</style></number><keywords><keyword><style face="normal" font="default" size="100%">American cranberry (Vaccinium macrocarpon)</style></keyword><keyword><style face="normal" font="default" size="100%">Blueberry (Vaccinium myrtillus)</style></keyword><keyword><style face="normal" font="default" size="100%">Citric acid</style></keyword><keyword><style face="normal" font="default" size="100%">European cranberry (Vaccinium oxycoccus)</style></keyword><keyword><style face="normal" font="default" size="100%">HPLC</style></keyword><keyword><style face="normal" font="default" size="100%">Iridoid glucosides</style></keyword><keyword><style face="normal" font="default" size="100%">Lingonberry (Vaccinium vitis-idaea)</style></keyword><keyword><style face="normal" font="default" size="100%">Malic acid</style></keyword><keyword><style face="normal" font="default" size="100%">Monotropein</style></keyword><keyword><style face="normal" font="default" size="100%">Quinic acid</style></keyword><keyword><style face="normal" font="default" size="100%">Shikimic acid</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><abstract><style face="normal" font="default" size="100%">Analysis of the hydrophilic fraction of cranberry juice by reversed-phase HPLC using an Aqua LUNA column with diode array or MS detection revealed the presence of quinic acid, malic acid, shikimic acid, and citric acid. For the first time, two iridoid glucosides were found in the juice. The two iridoid glucosides were shown to be monotropein and 6,7-dihydromonotropein by MS and NMR spectroscopy. A fast reversed-phase HPLC method for quantification of the hydrophilic carboxylic acids was developed and used for analyses of cranberry, lingonberry, and blueberry juices. The level of hydrophilic carboxylic acids in cranberries was 2.67-3.57% (w/v), in lingonberries 2.27-3.05%, and in blueberries 0.35-0.75%. In lingonberries both iridoid glucosides were present, whereas only monotropein was present in blueberries.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :49&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037032297&amp;doi=10.1021%2fjf0205110&amp;partnerID=40&amp;md5=7390090e82595f440ed783b85643892d</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/jf0205110</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>356</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">356</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jensen, G. S.</style></author><author><style face="normal" font="default" size="100%">Wu, X.</style></author><author><style face="normal" font="default" size="100%">Patterson, K. M.</style></author><author><style face="normal" font="default" size="100%">Barnes, J.</style></author><author><style face="normal" font="default" size="100%">Carter, S. G.</style></author><author><style face="normal" font="default" size="100%">Scherwitz, L.</style></author><author><style face="normal" font="default" size="100%">Beaman, R.</style></author><author><style face="normal" font="default" size="100%">Endres, J. R.</style></author><author><style face="normal" font="default" size="100%">Schauss, A. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Holger NIS Inc., 601 13th Avenue N.E., Calgary, AB T2E 1C7, Canada&#xD;Department of Physiology and Biophysics, Arkansas Children&apos;s Nutrition Center, University of Arkansas for Medical Sciences, Little Rock, AR 72202, United States&#xD;NIS Labs, 1437 Esplanade, Klamath Falls, OR 97601, United States&#xD;Natural and Medicinal Products Research, AIBMR Life Sciences, 4117 South Meridian, Puyallup, WA 98373, United States&#xD;Beaman&apos;s Wellness Center, 1903B Austin Street, Klamath Falls, OR 97603, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">In vitro and in vivo antioxidant and anti-inflammatory capacities of an antioxidant-rich fruit and berry juice blend. Results of a pilot and randomized, double-blinded, placebo-controlled, crossover study</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">8326-8333</style></pages><volume><style face="normal" font="default" size="100%">56</style></volume><number><style face="normal" font="default" size="100%">18</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acai</style></keyword><keyword><style face="normal" font="default" size="100%">Anti-inflammatory</style></keyword><keyword><style face="normal" font="default" size="100%">Antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">Cell-based antioxidant protection assay (CAP-e)</style></keyword><keyword><style face="normal" font="default" size="100%">Euterpe oleracear</style></keyword><keyword><style face="normal" font="default" size="100%">Fruit juice</style></keyword><keyword><style face="normal" font="default" size="100%">Lipid peroxidation</style></keyword><keyword><style face="normal" font="default" size="100%">Oxygen radical absorbance capacity (ORAC) assay</style></keyword><keyword><style face="normal" font="default" size="100%">Thiobarbituric acid reactive substances assay (TBARS)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">This study investigated the in vitro and in vivo antioxidant and anti-inflammatory properties of a juice blend (JB), MonaVie Active, containing a mixture of fruits and berries with known antioxidant activity, including açai, a palm fruit, as the predominant ingredient. The phytochemical antioxidants in the JB are primarily in the form of anthocyanins, predominantly cyanidin 3-rutoside, cyanidin 3-diglycoside, and cyanidin 3-glucoside. The cell-based antioxidant protection of erythrocytes (CAP-e) assay demonstrated that antioxidants in the JB penetrated and protected cells from oxidative damage (p &lt; 0.001), whereas polymorphonuclear cells showed reduced formation of reactive oxygen species (p &lt; 0.003) and reduced migration toward three different pro-inflammatory chemoattractants: fmlp (p &lt; 0.001), leukotriene B4 (p &lt; 0.05), and IL-8 (p &lt; 0.03). A randomized, double-blinded, placebo-controlled, crossover trial with 12 healthy subjects examined the JB&apos;s antioxidant activity in vivo. Blood samples at baseline, 1 h, and 2 h following consumption of the JB or placebo were tested for antioxidant capacity using several antioxidant assays and the TBARS assay, a measure of lipid peroxidation. A within subject comparison showed an increase in serum antioxidants at 1 h (p &lt; 0.03) and 2 h (p &lt; 0.015), as well as inhibition of lipid peroxidation at 2 h (p &lt; 0.01) postconsumption. © 2008 American Chemical Society.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :135&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-53649084506&amp;doi=10.1021%2fjf8016157&amp;partnerID=40&amp;md5=6142b9549f7db97387dc39aa97bfd311</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/jf8016157</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>333</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">333</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jansen, F. H.</style></author><author><style face="normal" font="default" size="100%">Van Haarst, E. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Aios Urologie, Diakonessenhuis, Utrecht, Netherlands&#xD;Uroloog, Sint Lucas Andreas Ziekenhuis, Amsterdam, Netherlands&#xD;Diakonessenhuis Utrecht, Afdeling Chirurgie, Postbus 80250, 3508 TC Utrecht, Netherlands</style></auth-address><titles><title><style face="normal" font="default" size="100%">Non-antibiotic prophylactic to prevent recurrent urinay tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Nederlands Tijdschrift voor Urologie</style></secondary-title><short-title><style face="normal" font="default" size="100%">Niet-antibiotische profylaxe bij recidiverende urineweginfecties</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nederlands Tijdschrift voor Urologie</style></full-title></periodical><pages><style face="normal" font="default" size="100%">125-129</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">D-mannose</style></keyword><keyword><style face="normal" font="default" size="100%">Estrogen</style></keyword><keyword><style face="normal" font="default" size="100%">Non-antibiotic prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">Vitamin C</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Goal: We conducted a literature study to clarify which non-antibiotic prophylactic measures are able to prevent recurrent urinary tract infections (RUTIs) in healthy women. Design: Literature study. Methods: The databases of Pub. Med, Medline and Cochrane were searched with relevant keywords between 1965-2005. Results: There is no proof that increasing the daily fluid intake does prevent RUTIs. Twice daily use of cranberry juice or capsules is able to reduce the number of symptomatic infections, especially in case of E.coli related infections. There is no proof of such an effect from D-mannose. In postmenopausal women, local vaginal application of estrogen significantly reduces the number of RUTIs. The use of probiotics, aimed to restore the dominance of Lactobacillus in the vaginal flora, has poorly been studied and showed insufficient evidence for a preventive role. Methenamine is able to decrease the number of RUTIs, particularly when used for short-term prophylaxis. The use of vitamin C does not adequately prevent RUTIs. Although several studies have showed promising results investigating the possibilities of vaccination to prevent RUTIs no commercial vaccines are currently available. Conclusions: Cranberries, methenamine and local estrogen suppletion in postmenopausal women are effective strategies to prevent RUTIs. In contrast, there is insufficient evidence for a preventive role of an increased fluid intake, vitamin C, probiotics and D-mannose. Vaccination strategies are promising but commercial vaccines are currently lacking.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349324344&amp;partnerID=40&amp;md5=5466d9585445777fca39d4e11587c212</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>299</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">299</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Janda, J.</style></author><author><style face="normal" font="default" size="100%">Sládková, E.</style></author><author><style face="normal" font="default" size="100%">Zůnová, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pediatrická Klinika UK 2. LF, FN Motol, V Úvalu 84, 150 06 Praha 5, Czech Republic&#xD;Dětská Klinika FN, Plzeň, Czech Republic</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infection in children and adolescents, recent data on etiology, diagnostics and therapy</style></title><secondary-title><style face="normal" font="default" size="100%">Cesko-Slovenska Pediatrie</style></secondary-title><short-title><style face="normal" font="default" size="100%">Infekce močových cest u dětí a dorostu, novější údaje o etiologii, diagnostice a léčbě</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cesko-Slovenska Pediatrie</style></full-title></periodical><pages><style face="normal" font="default" size="100%">706-714</style></pages><volume><style face="normal" font="default" size="100%">65</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Examination methods</style></keyword><keyword><style face="normal" font="default" size="100%">Pyelonephritic cicatrices</style></keyword><keyword><style face="normal" font="default" size="100%">Pyelonephritis</style></keyword><keyword><style face="normal" font="default" size="100%">Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Vesicourethral reflux</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTI) are the second most common cause of morbidity in children, only respiratory infection reveals a higher rate. Infants and toddlers are at highest risk of permanent damage of the renal parenchyma, particularly in inadequately treated urinary infection. Primary care pediatricians should take in account the possibility of acute pyelonephritis, firstly in children with high fever without symptoms of respiratory problems. In cases of suspected acute pyelonephritis, the child should be admitted to a hospital for intensive antibacterial therapy, during the first 2-3 days application i.v. This review summarizes the new insights, particularly concerning the modern investigative methods and their impact on the treatment. Approach to examinations of children with UTI has been changed during the last decades showing some news reflecting the impact of &quot;evidence based medicine&quot; studies and progress of the diagnostic techniques. Besides the classical treatment with antibiotics and chemotherapeutics the authors assess critically also the use of cranberries, E. coli extracts and use of probiotics.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-78651291915&amp;partnerID=40&amp;md5=2b6fb820ffb787c7986f6fccfd9c7d09</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>172</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">172</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jahromi, M. S.</style></author><author><style face="normal" font="default" size="100%">Mure, A.</style></author><author><style face="normal" font="default" size="100%">Gomez, C. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Miami Miller School of Medicine, 816 NW 11th St., Apt. 508, Miami, FL 33136, United States&#xD;Department of Urology, University of Miami Miller School of Medicine, 1400 NW 10th Ave, Suite 501, Miami, FL 33136, United States&#xD;Department of Urology, University of Miami Miller School of Medicine, 1400 NW 10th Ave, Suite 505, Miami, FL 33136, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">UTIs in Patients with Neurogenic Bladder</style></title><secondary-title><style face="normal" font="default" size="100%">Current Urology Reports</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Urology Reports</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-7</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Clean intermittent catheterization</style></keyword><keyword><style face="normal" font="default" size="100%">Multiple sclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenic bladder</style></keyword><keyword><style face="normal" font="default" size="100%">Spinal cord injury</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">UTI prophylaxis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTI) remain one of the most prevalent and frustrating morbidities for neurogenic bladder patients, and death attributed to urosepsis in the spinal cord injury (SCI) patient is higher when compared to the general population. Risk factors include urinary stasis, high bladder pressures, bladder stones, and catheter use. While classic symptoms of UTI include dysuria, increased frequency and urgency, neurogenic bladder patients present differently with increased spasticity, autonomic dysreflexia, urinary incontinence, and vague pains. Multiple modalities have been assessed for prevention including catheter type, oral supplements, bladder irrigation, detrusor injections and prophylactic antimicrobials. Of these, bladder inoculation with E. coli HU2117, irrigation with iAluRil®, detrusor injections, and weekly prophylaxis with alternating antibiotics appear to have a positive reduction in UTI but require further study. Ultimately, treatment for symptomatic UTI should account for the varied flora and possible antibiotic resistances including relying on urine cultures to guide antibiotic therapy. © 2014, Springer Science+Business Media New York.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :16&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84957440408&amp;doi=10.1007%2fs11934-014-0433-2&amp;partnerID=40&amp;md5=e43a3d31b82351f706315815982d1cb3</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">433</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s11934-014-0433-2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>170</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">170</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jafari, M.</style></author><author><style face="normal" font="default" size="100%">Orenstein, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of California IrvineCA, United States&#xD;University of California Los AngelesCA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Women and herbal medicine</style></title><secondary-title><style face="normal" font="default" size="100%">Women&apos;s Health and Wellness Across the Lifespan</style></secondary-title></titles><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84975076495&amp;partnerID=40&amp;md5=af48302f3b869ab1c8b839c3edcc054c</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>216</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">216</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jaakola, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biology, University of Oulu, Oulu, Finland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Phenylpropanoid Metabolism and Biosynthesis of Anthocyanins</style></title><secondary-title><style face="normal" font="default" size="100%">The Molecular Biology and Biochemistry of Fruit Ripening</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">117-134</style></pages><keywords><keyword><style face="normal" font="default" size="100%">Anthocyanins</style></keyword><keyword><style face="normal" font="default" size="100%">Cinnamic acids</style></keyword><keyword><style face="normal" font="default" size="100%">Coumarins</style></keyword><keyword><style face="normal" font="default" size="100%">Flavonols</style></keyword><keyword><style face="normal" font="default" size="100%">Lignans</style></keyword><keyword><style face="normal" font="default" size="100%">Lignin</style></keyword><keyword><style face="normal" font="default" size="100%">Monolignols</style></keyword><keyword><style face="normal" font="default" size="100%">Phenylpropanoid biosynthesis</style></keyword><keyword><style face="normal" font="default" size="100%">Phenylpropanoid metabolism</style></keyword><keyword><style face="normal" font="default" size="100%">Stilbenoids</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Fruit phenylpropanoids form an important part of the recommended human diet. Phenylpropanoids constitute the majority of the secondary metabolites in fruits. Several thousand phenylpropanoid compounds have been described in plants, of which those belonging to classes of hydroxycinnamic acids, flavonols, anthocyanins and flavan-3-ols are highly abundant in fruits. The recent advances in understanding the regulation of phenylpropanoid biosynthesis have opened new possibilities to modify the qualitative and the quantitative composition of these compounds in fruits, both with traditional and modern breeding and cultivation technologies. Monolignols are source materials for biosynthesis of lignans and lignin. The biosynthesis of coumarins and stilbenoids are discussed in the chapter. The simultaneous accumulation of new information on health benefits of specific phenylpropanoid compounds or groups for human health and the factors that modulate the biosynthesis of the same compounds in plants will give guidelines for the future fruit breeding work. © 2013 John Wiley &amp; Sons, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84889342194&amp;doi=10.1002%2f9781118593714.ch5&amp;partnerID=40&amp;md5=cf37db20dab0edf4b2caea83ef5ef46f</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/9781118593714.ch5</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>265</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">265</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Iswaldi, I.</style></author><author><style face="normal" font="default" size="100%">Gómez-Caravaca, A. M.</style></author><author><style face="normal" font="default" size="100%">Arráez-Román, D.</style></author><author><style face="normal" font="default" size="100%">Uberos, J.</style></author><author><style face="normal" font="default" size="100%">Lardón, M.</style></author><author><style face="normal" font="default" size="100%">Segura-Carretero, A.</style></author><author><style face="normal" font="default" size="100%">Fernández-Gutiérrez, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Analytical Chemistry, Faculty of Sciences, University of Granada, Avenida Fuentenueva s/n, 18071 Granada, Spain&#xD;Research and Development Functional Food Centre (CIDAF), Health Science Technological Park, Avenida del Conocimiento 3, 18100 Granada, Spain&#xD;UGC Pediatría, Hospital Clínico San Cecilio Granada, 18012 Granada, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Characterization by high-performance liquid chromatography with diode-array detection coupled to time-of-flight mass spectrometry of the phenolic fraction in a cranberry syrup used to prevent urinary tract diseases, together with a study of its antibacterial activity</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Pharmaceutical and Biomedical Analysis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Pharmaceutical and Biomedical Analysis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">34-41</style></pages><volume><style face="normal" font="default" size="100%">58</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-adhesion activity</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry syrup</style></keyword><keyword><style face="normal" font="default" size="100%">High-performance liquid chromatography (HPLC)</style></keyword><keyword><style face="normal" font="default" size="100%">Mass spectrometry (MS)</style></keyword><keyword><style face="normal" font="default" size="100%">Phenolic compounds</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">The phenolic fraction of a commercial cranberry syrup, which is purported to have good properties for the prevention of urinary diseases, has been thoroughly characterized using HPLC-DAD-TOF-MS. A study of its antibacterial activity has also been carried out. For this purpose a new HPLC-DAD-TOF-MS method using negative and positive ionization modes was developed and it was thus possible to identify 34 different compounds, nine of which have been tentatively characterized for the first time in cranberry syrup. It is also important to highlight that different coumarins in this matrix were also determined, which, to our knowledge, have not been found previously in the cranberry. The phenolic fraction obtained by HPLC-DAD was found to be 5.47. mg/mL. Catechin and procyanidins belonging to flavanols were the family of compounds found at the highest concentrations (2.37. mg/mL); flavonols were at a concentration of 1.91. mg/mL and phenolic-acid derivatives were found at the lowest concentration (0.15. mg/mL). With regard to antibacterial activity, the incubation of Escherichia coli with cranberry syrup was found to reduce surface hydrophobicity as a function of the concentration of the extract. © 2011 Elsevier B.V.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :30&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-80255131062&amp;doi=10.1016%2fj.jpba.2011.09.027&amp;partnerID=40&amp;md5=7a1861ac79c479189254f64389412a57</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jpba.2011.09.027</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>306</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">306</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Inglese, S.</style></author><author><style face="normal" font="default" size="100%">Guaschino, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dipartimento di Ginecologia e Ostetricia, IRCS Burlo Garofolo, Università degli Studi di Trieste, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dystrophies in premenopausal and postmenopausal women</style></title><secondary-title><style face="normal" font="default" size="100%">Giornale Italiano di Ostetricia e Ginecologia</style></secondary-title><short-title><style face="normal" font="default" size="100%">Distrofie peri- e postmenopausali</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Giornale Italiano di Ostetricia e Ginecologia</style></full-title></periodical><pages><style face="normal" font="default" size="100%">200-208</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">4</style></number><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-77957834328&amp;partnerID=40&amp;md5=4eed457d1002628602b1b6dee6852544</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>590</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">590</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ikäheimo, R.</style></author><author><style face="normal" font="default" size="100%">Siitonen, A.</style></author><author><style face="normal" font="default" size="100%">Heiskanen, T.</style></author><author><style face="normal" font="default" size="100%">Kärkkäinen, U.</style></author><author><style face="normal" font="default" size="100%">Kuosmanen, P.</style></author><author><style face="normal" font="default" size="100%">Lipponen, P.</style></author><author><style face="normal" font="default" size="100%">Mäkelä, P. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Kuopio University Hospital, FIN-70211 Kuopio, Finland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrence of urinary tract infection in a primary care setting: Analysis of a 1-year follow-up of 179 women</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">91-99</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">1996</style></year></dates><abstract><style face="normal" font="default" size="100%">In a prospective study, 179 adult women (age range, 17-82 years) were followed up for 12 months after an index episode of community-acquired cystitis caused by Escherichia coli. Episodes of symptomatic urinary tract infection (UTI) were recorded, and urinary isolates were compared with the index episode isolate; 147 UTI episodes were detected during the follow-up. Of these episodes, 131 were classified as recurrences occurring at least 1 month after the index episode; 44% of the patients had recurrences. A history of UTI increased the risk of recurrence; only 11.8% of the 17 patients without previous episodes of UTI had at least one recurrence, while 47.5% of those with previous episodes had at least one recurrence (OR, 6.8; univariate logistic regression). E. coli caused 78% of the recurrent episodes. Phenotypic and genotypic analysis of E. coli strains showed that one-third of the recurrences were caused by the index episode strain, which could persist and cause recurrences throughout the 1-year follow-up period. The prevalence of adhesins or other identified virulence factors for UTI among the recurrence strains was identical to that among the index episode strains. The presence of these factors did not affect the risk of recurrence but did increase the likelihood that the index episode strain would persist and cause recurrent episodes of UTI.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :204&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030034932&amp;partnerID=40&amp;md5=a322d4082e7179d3b9ed9b8b7ce10dd4</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>148</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">148</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hwang, Y. R.</style></author><author><style face="normal" font="default" size="100%">Hwang, E. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Nutrition and Culinary Science, Hankyong National University, Anseong, Gyeonggi, 42601, South Korea</style></auth-address><titles><title><style face="normal" font="default" size="100%">Quality characteristics and antioxidant activity of sulgidduk prepared by addition of aronia powder (aronia melanocarpa)</style></title><secondary-title><style face="normal" font="default" size="100%">Korean Journal of Food Science and Technology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Korean Journal of Food Science and Technology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">452-459</style></pages><volume><style face="normal" font="default" size="100%">47</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antioxidant activity</style></keyword><keyword><style face="normal" font="default" size="100%">Aronia powder</style></keyword><keyword><style face="normal" font="default" size="100%">Quality characteristics</style></keyword><keyword><style face="normal" font="default" size="100%">Sensory evaluation</style></keyword><keyword><style face="normal" font="default" size="100%">Sulgidduk</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">The effects of aronia powder on the rheological and sensory characteristics of Sulgidduk were investigated. The moisture content of Sulgidduk ranged from 40.86 to 44.40%; however, addition of aronia powder to Sulgidduk tended to decrease its moisture content. With regard to the rheological properties, the addition of aronia powder decreased the hardness, springiness, adhesiveness, cohesiveness, chewiness, gumminess, and brittleness of Sulgidduk. Chromaticity determination revealed a decrease in L and b values, while the a value increased with the increasing amounts of aronia powder. Total polyphenol, total flavonoid and total anthocyanin contents increased with the increasing amounts of aronia powder. Antioxidant activity, measured by DPPH and ABTS radical scavenging activities, was significantly higher than that of the control, and increased proportionally with the amount of aronia powder. During 4 day storage, the growth of total aerobic colony and coliform content significantly decreased with increasing levels of aronia powder in Sulgidduk. Sensory evaluation demonstrated the best score in color, taste and overall acceptance when aronia powder was added at 5% of rice powder. These results suggest that 5% aronia powder can be added for the preparation of Sulgidduk. © The Korean Society of Food Science and Technology.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84950241745&amp;doi=10.9721%2fKJFST.2015.47.4.452&amp;partnerID=40&amp;md5=6c3e888ebf5d1a73cf72657b76b07b47</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.9721/KJFST.2015.47.4.452</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>298</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">298</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huttunen, S.</style></author><author><style face="normal" font="default" size="100%">Toivanen, M.</style></author><author><style face="normal" font="default" size="100%">Arkko, S.</style></author><author><style face="normal" font="default" size="100%">Ruponen, M.</style></author><author><style face="normal" font="default" size="100%">Tikkanen-Kaukanen, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Public Health and Clinical Nutrition, Kuopio Campus, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland&#xD;School of Pharmacy, Kuopio Campus, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inhibition activity of wild berry juice fractions against streptococcus pneumoniae binding to human bronchial cells</style></title><secondary-title><style face="normal" font="default" size="100%">Phytotherapy Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Phytotherapy Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">122-127</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">antiadhesion</style></keyword><keyword><style face="normal" font="default" size="100%">antimicrobial</style></keyword><keyword><style face="normal" font="default" size="100%">berries</style></keyword><keyword><style face="normal" font="default" size="100%">Calu-3</style></keyword><keyword><style face="normal" font="default" size="100%">Streptococcus pneumoniae</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">Bacterial adhesion to the cell surface is a crucial step before infection can take place. Inhibition of bacterial binding offers a novel preventive approach against infections. Cranberry (Vaccinium macrocarpon Ait.) juice has been found to have antiadhesive activity against different bacteria. Streptococcus pneumoniae is an important pathogen and the most common cause for pneumonia, meningitis, and otitis media. In this study the inhibitory activity of cranberry (Vaccinium oxycoccos L.), bilberry (Vaccinium myrtillus L.) and crowberry (Empetrum nigrum and Empetrum hermaphroditum L.) juice fractions against pneumococcal binding was tested using human bronchial cells (Calu-3) as an adhesion model. In addition, the antimicrobial activity of the berry juice fractions was tested. It was found that the studied berry juice fractions had antiadhesion activity and cranberry juice was the most active. The adhesion inhibition activity of cranberry juice was nearly 90% at a concentration of 8.7 mg/g of soluble solids. The antimicrobial activity of the studied berry juice fractions was found to be remarkable; pneumococcal growth was inhibited totally at a concentration of ∼86 mg/g. Both antiadhesion and antimicrobial activities were reduced after solid-phase extraction of the berry juices, which may suggest molecular synergistic effects of the berry juice molecules against S. pneumoniae. The findings indicate that cranberry, bilberry and crowberry juices have potential against pneumococcal infections. © 2010 John Wiley &amp; Sons, Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :17&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-78650662307&amp;doi=10.1002%2fptr.3240&amp;partnerID=40&amp;md5=412d62cbbe20b2cd85707bcca56b1d6a</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/ptr.3240</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>543</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">543</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hummers-Pradier, E.</style></author><author><style face="normal" font="default" size="100%">Kochen, M. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of General Practice, University of Göttingen, Humboldtalle 38, 37073 Göttingen, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections in adult general practice patients</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of General Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Journal of General Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">752-761</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">482</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Optimal treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTIs) are symptomatic infections of the urinary tract, mainly caused by the bacterium Escherichia coli. One in two women suffers from a UTI at least once in her life. The young and sexually active are particularly affected, but it is also seen in elderly, postmenopausal women. The likelihood of recurrence is high. Diagnosis is made with regard to typical complaints and the presence of leucocytes and nitrites in the urine. A culture is unnecessary in most cases. Uncomplicated UTI should be distinguished from complicated UTI, which has a risk of severe illness. The treatment of choice - short-t erm therapy with trimethoprim or nitrofurantoin - is successful in over 80% of the cases. Co-trimoxazol, fluoroquinolones or cephalosporins are not considered first-choice drugs. There are indications that general practitioners&apos; (GPs&apos;) management of UTI is not always optimal, specifically concerning diagnostic tests, the application of second-choice antibiotics, and the length of prescribed treatment courses. Many points relevant to GPs require further research, such as epidemiology and resistance of urinary pathogens in the community and natural history of UTI, as well as optimal management in elderly or complicated patients and men.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :53&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036769898&amp;partnerID=40&amp;md5=8734aaa16f6451e977f55f11aa45dbe2</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>489</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">489</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huang, S. M.</style></author><author><style face="normal" font="default" size="100%">Lesko, L. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Off. Clin. Pharmacol./Biopharmaceut., Ctr. for Drug Eval. and Res. (CDER), Food and Drug Administration, Rockville, MD 20850, United States&#xD;Off. Clin. Pharmacol./Biopharmaceut., Ctr. for Drug Eval. and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20850, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: What have we learned?</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Clinical Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Clinical Pharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">559-569</style></pages><volume><style face="normal" font="default" size="100%">44</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Drug development</style></keyword><keyword><style face="normal" font="default" size="100%">Drug-dietary supplement interaction</style></keyword><keyword><style face="normal" font="default" size="100%">Drug-drug interaction</style></keyword><keyword><style face="normal" font="default" size="100%">Drug-juice interaction</style></keyword><keyword><style face="normal" font="default" size="100%">Exposure-response relationship</style></keyword><keyword><style face="normal" font="default" size="100%">Labeling</style></keyword><keyword><style face="normal" font="default" size="100%">Risk management</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Serious drug-drug interactions have contributed to recent U.S. market withdrawals and also recent nonapprovals of a few new molecular entities. Many of these interactions involved the inhibition or induction of metabolizing enzymes and efflux transporters, resulting in altered systemic exposure and adverse drug reactions or loss of efficacy. In addition to drug-drug interactions, drug-dietary supplement and drug-citrus fruit interactions, among others, could also cause adverse drug reactions or loss of efficacy and are important issues to consider in the evaluation of new drug candidates. This commentary reviews (1) the current understanding of the mechanistic basis of these interactions, (2) issues to consider in the interpretation of study results, and (3) recent labeling examples to illustrate the translation of study results to information useful for patients and health care providers.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :116&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-2442700486&amp;doi=10.1177%2f0091270004265367&amp;partnerID=40&amp;md5=53d568dee60f7ad7679a02ebf3d5be0f</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/0091270004265367</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>19</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">19</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Huang, J.</style></author><author><style face="normal" font="default" size="100%">Yu, L.</style></author><author><style face="normal" font="default" size="100%">Zhang, W.</style></author><author><style face="normal" font="default" size="100%">Zhang, T.</style></author><author><style face="normal" font="default" size="100%">Guang, C.</style></author><author><style face="normal" font="default" size="100%">Mu, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, China&#xD;International Joint Laboratory on Food Safety, Jiangnan University, Wuxi, China</style></auth-address><titles><title><style face="normal" font="default" size="100%">Production of d-mannose from d-glucose by co-expression of d-glucose isomerase and d-lyxose isomerase in Escherichia coli</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the Science of Food and Agriculture</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the Science of Food and Agriculture</style></full-title></periodical><pages><style face="normal" font="default" size="100%">4895-4902</style></pages><volume><style face="normal" font="default" size="100%">98</style></volume><number><style face="normal" font="default" size="100%">13</style></number><keywords><keyword><style face="normal" font="default" size="100%">co-expression</style></keyword><keyword><style face="normal" font="default" size="100%">d-glucose isomerase</style></keyword><keyword><style face="normal" font="default" size="100%">d-lyxose isomerase</style></keyword><keyword><style face="normal" font="default" size="100%">d-mannose</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">BACKGROUND: d-Mannose is not only the epimer of d-glucose at the C-2 position, but also the aldose isomer of d-fructose. Because of its physiological properties and health benefits, d-mannose has attracted public interest. It has been confirmed that d-mannose has broad applications in food, cosmetics, and pharmaceutical industries. According to the Izumoring strategy, d-glucose isomerase (d-GI) and d-lyxose isomerase (d-LI) play important roles in the conversions of d-fructose from d-glucose and of d-mannose from d-fructose respectively. In this study, a one-step enzyme process of d-mannose production from d-glucose has been constructed by co-expression of the d-GI from Acidothermus cellulolyticus and d-LI from Thermosediminibacter oceani in Escherichia coli BL21(DE3) cells. RESULTS: The co-expression system exhibits maximum activity at pH 6.5 and 65 °C with Co2+ supplement. It is relatively thermostable at less than 65 °C. When the reaction reaches equilibrium, the ratio of d-glucose, d-fructose, and d-mannose is approximately 34 : 49.6 : 16.4. By using this co-expression system, about 60.0 g L−1 d-mannose is obtained from 400 g L−1 d-glucose in 8 h. CONCLUSION: This co-expression of d-GI and d-LI system provides a novel and efficient approach for d-mannose production. © 2018 Society of Chemical Industry. © 2018 Society of Chemical Industry</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052519430&amp;doi=10.1002%2fjsfa.9021&amp;partnerID=40&amp;md5=137b213b79f2db7f35b2d789e328ca1b</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/jsfa.9021</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>111</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">111</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hu, X.</style></author><author><style face="normal" font="default" size="100%">Shi, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, P.</style></author><author><style face="normal" font="default" size="100%">Miao, M.</style></author><author><style face="normal" font="default" size="100%">Zhang, T.</style></author><author><style face="normal" font="default" size="100%">Jiang, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">State Key Laboratory of Food Science and Technology, Jiangnan Univ, 1800 Lihu Ave, Wuxi, Jiangsu 214122, China&#xD;Synergetic Innovation Center of Food Safety and Nutrition, Jiangnan Univ, 1800 Lihu Avenue, Wuxi, Jiangsu 214122, China&#xD;College of Food Science and Technology, Nanjing Agricultural Univ, 1 Weigang, Nanjing, Jiangsu 210095, China</style></auth-address><titles><title><style face="normal" font="default" size="100%">d-Mannose: Properties, Production, and Applications: An Overview</style></title><secondary-title><style face="normal" font="default" size="100%">Comprehensive Reviews in Food Science and Food Safety</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Comprehensive Reviews in Food Science and Food Safety</style></full-title></periodical><pages><style face="normal" font="default" size="100%">773-785</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">applications</style></keyword><keyword><style face="normal" font="default" size="100%">bioprocessing</style></keyword><keyword><style face="normal" font="default" size="100%">characteristics</style></keyword><keyword><style face="normal" font="default" size="100%">d-mannose</style></keyword><keyword><style face="normal" font="default" size="100%">functionality</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">d-Mannose is a C-2 epimer of d-glucose, which is a natural monosaccharide. It can be obtained from both plants and microorganisms. Chemical synthesis and biotransformation of d-mannose from d-fructose or d-glucose by using d-mannose isomerases, d-lyxose isomerases, and cellobiose 2-epimerase were intensively studied. d-Mannose is an important component of polysaccharides and glycoproteins. It has been widely used in the food, pharmaceutical, and poultry industries, acting as the source of dietary supplements, starting material for the synthesis of drugs and blocking colonization in animal feeds. d-Mannose is a glyconutrient with high research value in basic science because of its structure and function. This article presents a review of current studies on sources, characteristics, production, and application of d-mannose. © 2016 Institute of Food Technologists®</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :17&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84971222266&amp;doi=10.1111%2f1541-4337.12211&amp;partnerID=40&amp;md5=192f31ebce04357750b5c54ffb007458</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/1541-4337.12211</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>32</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">32</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hsu, D.</style></author><author><style face="normal" font="default" size="100%">Melzer, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Infectious Diseases Department, Royal London Hospital, Barts Health NHS Trust, London, E1 1BB, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Strategy to reduce E. coli bacteraemia based on cohort data from a London teaching hospital</style></title><secondary-title><style face="normal" font="default" size="100%">Postgraduate Medical Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Postgraduate Medical Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">212-215</style></pages><volume><style face="normal" font="default" size="100%">94</style></volume><number><style face="normal" font="default" size="100%">1110</style></number><keywords><keyword><style face="normal" font="default" size="100%">bacteraemia</style></keyword><keyword><style face="normal" font="default" size="100%">E. Coli</style></keyword><keyword><style face="normal" font="default" size="100%">reduction</style></keyword><keyword><style face="normal" font="default" size="100%">strategy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Background and aim In 2017, National Health Service Improvement set a 10% reduction target for Escherichia coli bacteraemia by 2018, followed by a 50% reduction in healthcare-associated Gram-negative bacteraemias by 2022. We analysed consecutive cases of E. coli bacteraemia and devised a strategy to achieve these targets. Methods From December 2012 to November 2013, demographic, clinical and microbiological data were prospectively collected on all patients with bacteraemia at the Royal London Hospital in East London, UK. Results There were 594 significant bacteraemic episodes and 207 (34.8%) were E. coli. Twenty-four (11.6%) of the E. coli isolates were extended spectrum beta-lactamase producers, 22 (10.6%) gentamicin resistant and 2 (1.0%) amikacin resistant. The three most common sites of infection were pyelonephritis 105 (56.7%), catheter-associated urinary tract infection 22 (10.6%), and other medical devices and procedures that cause bacteraemia 32 (15.5%). In the pyelonephritis group, trimethoprim resistance in urinary isolates was 16/47 (34.0%) compared with 3/47 (6.4%) for nitrofurantoin. Twelve months postbacteraemia, recurrent bacteraemia rates were 10/105 (9.5%). There were 44 medical device-associated E. coli bacteraemias, and 22 (50%) were urinary catheter associated. There were 10 patients with E. coli bacteraemia caused by procedures, seven genitourinary or biliary tract instrumentation and three postgastrointestinal surgery. Conclusion E. coli bacteraemias related to urosepsis could have been prevented by better empirical treatment and targeted prophylaxis. Urinary catheter quality improvement programmes should contribute to a further reduction. For patients undergoing high-risk urinary or biliary tract procedures or device manipulation, we advocate single-dose amikacin prophylaxis. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044824433&amp;doi=10.1136%2fpostgradmedj-2017-135454&amp;partnerID=40&amp;md5=7b097d366aa324ba7c508bf3a09cebbf</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/postgradmedj-2017-135454</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>352</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">352</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hsieh, M. H.</style></author><author><style face="normal" font="default" size="100%">Versalovic, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Pediatric Urology, Texas Children&apos;s Hospital, Scott Department of Urology, Houston, TX, United States&#xD;Department of Pathology, Texas Children&apos;s Hospital, Baylor College of Medicine, Houston, TX, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Human Microbiome and Probiotics: Implications for Pediatrics</style></title><secondary-title><style face="normal" font="default" size="100%">Current Problems in Pediatric and Adolescent Health Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Problems in Pediatric and Adolescent Health Care</style></full-title></periodical><pages><style face="normal" font="default" size="100%">309-327</style></pages><volume><style face="normal" font="default" size="100%">38</style></volume><number><style face="normal" font="default" size="100%">10</style></number><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">Advances in the science of probiotics in the 21st century will be fueled by human microbiome research and functional genomics of beneficial microbes. These indigenous microbes or &quot;old friends&quot; facilitate digestion, absorption of vitamins, development of robust immune responses, and suppression of pathogens. Two primary pipelines will serve as development strategies for new probiotics in human medicine. First, identification of genes responsible for key probiotic functions will enable derivation of genetically modified organisms, or so-called &quot;designer strains,&quot; that will represent improved engineered alternatives to natural probiotic strains for specific biomedical applications. Second, candidate probiotic strains isolated from natural sources (human, animal, or food) can be compared systematically by functional genomics and systems biology. Optimal or &quot;ideal&quot; natural probiotics can then be selected for specific probiotics applications in medicine. Many additional laboratory and clinical studies must be performed in the future to clarify mechanisms of probiosis and matching of specific probiotics or synbiotics with specific disease phenotypes in children. In summary, humans have utilized beneficial bacteria via the diet throughout human history. Investigator-initiated research and mega-science as in the Human Microbiome Project will drive accelerated development of probiotics for prevention and treatment of many pediatric disorders now and in the future. © 2008 Mosby, Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :11&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-55149083135&amp;doi=10.1016%2fj.cppeds.2008.09.001&amp;partnerID=40&amp;md5=eb28cfb0ef87d97a21f3c10de3d5230c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.cppeds.2008.09.001</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>582</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">582</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Howell, A. B.</style></author><author><style face="normal" font="default" size="100%">Vorsa, N.</style></author><author><style face="normal" font="default" size="100%">Marderosian, A. D.</style></author><author><style face="normal" font="default" size="100%">Foo, L. Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Rutgers University, Chatsworth, NJ 08019, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inhibition of the adherence of P-fimbriated Escherichia coli to uroepithelial-cell surfaces by proanthocyanidin extracts from cranberries [6]</style></title><secondary-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1085-1086</style></pages><volume><style face="normal" font="default" size="100%">339</style></volume><number><style face="normal" font="default" size="100%">15</style></number><dates><year><style face="normal" font="default" size="100%">1998</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :302&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Letter</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032497537&amp;doi=10.1056%2fNEJM199810083391516&amp;partnerID=40&amp;md5=3e76c0af1220b3781738717debd71fbf</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1056/NEJM199810083391516</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>465</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">465</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Howell, A. B.</style></author><author><style face="normal" font="default" size="100%">Reed, J. D.</style></author><author><style face="normal" font="default" size="100%">Krueger, C. G.</style></author><author><style face="normal" font="default" size="100%">Winterbottom, R.</style></author><author><style face="normal" font="default" size="100%">Cunningham, D. G.</style></author><author><style face="normal" font="default" size="100%">Leahy, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Marucci Center for Blueberry Cranberry Research, Rutgers University, Chatsworth, NJ 08019, United States&#xD;Department of Animal Sciences, University of Wisconsin, Madison, WI 53706, United States&#xD;Ocean Spray Cranberries, Inc., Lakeville-Middleboro, MA 02349, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity</style></title><secondary-title><style face="normal" font="default" size="100%">Phytochemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Phytochemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2281-2291</style></pages><volume><style face="normal" font="default" size="100%">66</style></volume><number><style face="normal" font="default" size="100%">18 SPEC. ISS.</style></number><keywords><keyword><style face="normal" font="default" size="100%">A-type linkage</style></keyword><keyword><style face="normal" font="default" size="100%">Bacterial adhesion</style></keyword><keyword><style face="normal" font="default" size="100%">Condensed tannin</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Ericaceae</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidin</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon Ait</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">Clinical, epidemiological and mechanistic studies support the role of cranberry (Vaccinium macrocarpon Ait.) in maintaining urinary tract health. Cranberry proanthocyanidins contain A-type linkages and have been associated with preventing adhesion of P-fimbriated uropathogenic Escherichia coli to uroepithelial cells. It is not known if the presence of the A-type linkage is a prerequisite for anti-adhesion activity. Other commercial sources of proanthocyanidins with all B-type linkages have not previously been screened for this activity. The goals of this study were to compare the in vitro anti-adhesion activity of A-linked proanthocyanidins from cranberry juice cocktail with the anti-adhesion activities of B-linked proanthocyanidins from commercial grape and apple juices, green tea and dark chocolate, and determine if anti-adhesion activity is detectable in human urine following consumption of single servings of each commercial food product. Structural heterogeneity and presence of the A-type linkage in cranberry proanthocyanidins was confirmed utilizing MALDI-TOF/MS and DI/ESI MS, as was the presence of all B-type linkages in the proanthocyanidins from the other commercial products. The isolated A-type proanthocyanidins from cranberry juice cocktail elicited in vitro anti-adhesion activity at 60 μg/ml, the B-type proanthocyanidins from grape exhibited minor activity at 1200 μg/ml, while other B-type proanthocyanidins were not active. Anti-adhesion activity in human urine was detected following cranberry juice cocktail consumption, but not after consumption of the non-cranberry food products. Results suggest that presence of the A-type linkage in cranberry proanthocyanidins may enhance both in vitro and urinary bacterial anti-adhesion activities and aid in maintaining urinary tract health. © 2005 Elsevier Ltd. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :290&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-24344440795&amp;doi=10.1016%2fj.phytochem.2005.05.022&amp;partnerID=40&amp;md5=653f53c0e4a6290f799a9d8b90772602</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.phytochem.2005.05.022</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>544</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">544</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Howell, A. B.</style></author><author><style face="normal" font="default" size="100%">Foxman, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Marucci Center for Blueberry and Cranberry Research, Rutgers University, Chatsworth, NJ, United States&#xD;Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry juice and adhesion of antibiotic-resistant uropathogens</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Medical Association</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Medical Association</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3082-3083</style></pages><volume><style face="normal" font="default" size="100%">287</style></volume><number><style face="normal" font="default" size="100%">23</style></number><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :103&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Letter</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037134828&amp;doi=10.1001%2fjama.287.23.3082&amp;partnerID=40&amp;md5=a1c555538b20944b10545ba682b59db9</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jama.287.23.3082</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>313</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">313</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Howell, A. B.</style></author><author><style face="normal" font="default" size="100%">Botto, H.</style></author><author><style face="normal" font="default" size="100%">Combescure, C.</style></author><author><style face="normal" font="default" size="100%">Blanc-Potard, A. B.</style></author><author><style face="normal" font="default" size="100%">Gausa, L.</style></author><author><style face="normal" font="default" size="100%">Matsumoto, T.</style></author><author><style face="normal" font="default" size="100%">Tenke, P.</style></author><author><style face="normal" font="default" size="100%">Sotto, A.</style></author><author><style face="normal" font="default" size="100%">Lavigne, J. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Marucci Center for Blueberry and Cranberry Research and Extension, Rutgers, The State University of New Jersey, Chatsworth, NJ, United States&#xD;Service d&apos;Urologie, Hôpital Foch, Suresnes, France&#xD;Faculté de Médecine, Université de Genève, Genève, Switzerland&#xD;Institut National de la Santé et de la Recherche Médicale, Université Montpellier 1, Espri26, Nîmes, France&#xD;Fundació Puigvert, Barcelona, Spain&#xD;Department of Urology, Graduate School of Medical Sciences, Kyushu University, Kitakyushu, Japan&#xD;Department of Urology, South-Pest Hospital, Budapest, Hungary&#xD;Laboratoire de Bactériologie, Virologie, Parasitologie, University Hospital Carémeau, Nîmes, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: A multicentric randomized double blind study</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMC Infectious Diseases</style></full-title></periodical><volume><style face="normal" font="default" size="100%">10</style></volume><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Ingestion of cranberry (Vaccinium macrocarpon Ait.) has traditionally been utilized for prevention of urinary tract infections. The proanthocyanidins (PACs) in cranberry, in particular the A-type linkages have been implicated as important inhibitors of primarily P-fimbriated E. coli adhesion to uroepithelial cells. Additional experiments were required to investigate the persistence in urine samples over a broader time period, to determine the most effective dose per day and to determine if the urinary anti-adhesion effect following cranberry is detected within volunteers of different origins.Methods: Two separate bioassays (a mannose-resistant hemagglutination assay and an original new human T24 epithelial cell-line assay) have assessed the ex-vivo urinary bacterial anti-adhesion activity on urines samples collected from 32 volunteers from Japan, Hungary, Spain and France in a randomized, double-blind versus placebo study. An in vivo Caenorhabditis elegans model was used to evaluate the influence of cranberry regimen on the virulence of E. coli strain.Results: The results indicated a significant bacterial anti-adhesion activity in urine samples collected from volunteers that consumed cranberry powder compared to placebo (p &lt; 0.001). This inhibition was clearly dose-dependent, prolonged (until 24 h with 72 mg of PAC) and increasing with the amount of PAC equivalents consumed in each cranberry powder regimen. An in vivo Caenorhabditis elegans model showed that cranberry acted against bacterial virulence: E. coli strain presented a reduced ability to kill worms after a growth in urines samples of patients who took cranberry capsules. This effect is particularly important with the regimen of 72 mg of PAC.Conclusions: Administration of PAC-standardized cranberry powder at dosages containing 72 mg of PAC per day may offer some protection against bacterial adhesion and virulence in the urinary tract. This effect may offer a nyctohemeral protection. © 2010 Howell et al; licensee BioMed Central Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :130&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-77950644517&amp;doi=10.1186%2f1471-2334-10-94&amp;partnerID=40&amp;md5=2d9785e4954400b6180620a6a2638d41</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">94</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/1471-2334-10-94</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>400</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">400</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Howell, A. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Marucci Center for Blueberry and Cranberry Research and Extension, Rutgers, the State University of New Jersey, New Jersey, United States&#xD;Marucci Center for Blueberry Cranberry Research and Extension, Rutgers University, 125A Lake Oswego Rd, Chatsworth, NJ 08019, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bioactive compounds in cranberries and their role in prevention of urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Molecular Nutrition and Food Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Molecular Nutrition and Food Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">732-737</style></pages><volume><style face="normal" font="default" size="100%">51</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antiadhesion</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidin</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry (Vaccinium macrocarpon Ait.) ingestion has long been associated with prevention of urinary tract infections. The beneficial mechanism was historically thought to be due to the fruit acids causing a bacteriostatic effect in the urine. However, recently, a group of proanthocyanidins (PACs) with A-type linkages were isolated from cranberry which exhibit bacterial antiadhesion activity against both antibiotic susceptible and resistant strains of uropathogenic P-fimbriated Escherichia coli bacteria. The link between cranberry ingestion and maintenance of urinary tract health as well as the structural diversity, pharmacokinetics, quantification, and bacterial antiadhesion bioactivity of the A-linked cranberry PACs are reviewed. © 2007 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :164&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-34447530882&amp;doi=10.1002%2fmnfr.200700038&amp;partnerID=40&amp;md5=47b940e5af0c131e63547d771eb9837e</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/mnfr.200700038</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>374</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">374</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Horn, B.</style></author><author><style face="normal" font="default" size="100%">Yu, W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Eastern Center for Complementary Medicine</style></auth-address><titles><title><style face="normal" font="default" size="100%">Herbal strategies in the treatment of urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Alternative Therapies in Womens Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Alternative Therapies in Womens Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">17-21</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-42149184681&amp;partnerID=40&amp;md5=342310ed80972570e443491118a88355</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>589</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">589</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hooton, T. M.</style></author><author><style face="normal" font="default" size="100%">Scholes, D.</style></author><author><style face="normal" font="default" size="100%">Hughes, J. P.</style></author><author><style face="normal" font="default" size="100%">Winter, C.</style></author><author><style face="normal" font="default" size="100%">Roberts, P. L.</style></author><author><style face="normal" font="default" size="100%">Stapleton, A. E.</style></author><author><style face="normal" font="default" size="100%">Stergachis, A.</style></author><author><style face="normal" font="default" size="100%">Stamm, W. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, University of Washington, School of Medicine, Seattle, WA, United States&#xD;Department of Biostatistics, University of Washington, School of Medicine, Seattle, WA, United States&#xD;Department of Epidemiology, University of Washington, School of Medicine, Seattle, WA, United States&#xD;Department of Pharmacy, University of Washington, School of Medicine, Seattle, WA, United States&#xD;Center for Health Studies, Grp. Hlth. Coop. of Puget Sound, Seattle, WA, United States&#xD;Harborview Med. Ctr. Madison Clinic, 1001 Broadway, Seattle, WA 98122, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">A prospective study of risk factors for symptomatic urinary tract infection in young women</style></title><secondary-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">468-474</style></pages><volume><style face="normal" font="default" size="100%">335</style></volume><number><style face="normal" font="default" size="100%">7</style></number><dates><year><style face="normal" font="default" size="100%">1996</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Although acute urinary tract infections are common in young women, the associated risk factors have not been defined prospectively. Methods: We recruited sexually active young women who were starting a new method of contraception at a university health center or a health maintenance organization (HMO) and monitored them for six months for symptomatic urinary tract infections. Daily diaries and serial interviews were used to collect data on potential risk factors. Results: Among 796 women, the incidence of urinary tract infections per person-year was 0.7 in the university cohort (mean age, 23 years; n = 348) and 0.5 in the HMO cohort (mean age, 29; n = 448). In both cohorts, there were strong dose-response relations between the risk of infection and both recent use of a diaphragm with spermicide (respective relative risks for one, three, and five days of use in the past week, 1.42, 2.83, and 5.68 in the university cohort, P&lt;0.001; and 1.29, 2.14, and 3.54 in the HMO cohort, P = 0.04) and recent sexual intercourse (respective relative risks for one, three, and five days with intercourse in the past week, 1.37, 2.56, and 4.81 in the university cohort, P&lt;0.001; and 1.24, 1.91, and 2.96 in the HMO cohort, P = 0.002). The risk of acute infection was also associated with a history of recurrent infection (relative risk, 5.58 in the university cohort and 2.10 in the HMO cohort) but not with cervical-cap use, ABO-blood-group nonsecretor phenotype, or delayed postcoital voiding. Conclusions: Among sexually active young women the incidence of symptomatic urinary tract infection is high, and the risk is strongly and independently associated with recent sexual intercourse, recent use of a diaphragm with spermicide, and a history of recurrent urinary tract infections.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :451&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029739053&amp;doi=10.1056%2fNEJM199608153350703&amp;partnerID=40&amp;md5=aff10972ed33c41c49873864a74367d3</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1056/NEJM199608153350703</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>229</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">229</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hooton, T. M.</style></author><author><style face="normal" font="default" size="100%">Roberts, P. L.</style></author><author><style face="normal" font="default" size="100%">Cox, M. E.</style></author><author><style face="normal" font="default" size="100%">Stapleton, A. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, School of Medicine, University of Miami, Miami, FL, United States&#xD;Department of Medicine, School of Medicine, University of Washington, Seattle, WA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Voided midstream urine culture and acute cystitis in premenopausal women</style></title><secondary-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1883-1891</style></pages><volume><style face="normal" font="default" size="100%">369</style></volume><number><style face="normal" font="default" size="100%">20</style></number><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">BACKGROUND: The cause of acute uncomplicated cystitis is determined on the basis of cultures of voided midstream urine, but few data guide the interpretation of such results, especially when gram-positive bacteria grow. METHODS: Women from 18 to 49 years of age with symptoms of cystitis provided specimens of midstream urine, after which we collected urine by means of a urethral catheter for culture (catheter urine). We compared microbial species and colony counts in the paired specimens. The primary outcome was a comparison of positive predictive values and negative predictive values of organisms grown in midstream urine, with the presence or absence of the organism in catheter urine used as the reference. RESULTS: The analysis of 236 episodes of cystitis in 226 women yielded 202 paired specimens of midstream urine and catheter urine that could be evaluated. Cultures were positive for uropathogens in 142 catheter specimens (70%), 4 of which had more than one uropathogen, and in 157 midstream specimens (78%). The presence of Escherichia coli in midstream urine was highly predictive of bladder bacteriuria even at very low counts, with a positive predictive value of 102 colony-forming units (CFU) per milliliter of 93% (Spearman&apos;s r=0.944). In contrast, in midstream urine, enterococci (in 10% of cultures) and group B streptococci (in 12% of cultures) were not predictive of bladder bacteriuria at any colony count (Spearman&apos;s r=0.322 for enterococci and 0.272 for group B streptococci). Among 41 episodes in which enterococcus, group B streptococci, or both were found in midstream urine, E. coli grew from catheter urine cultures in 61%. CONCLUSIONS: Cultures of voided midstream urine in healthy premenopausal women with acute uncomplicated cystitis accurately showed evidence of bladder E. coli but not of enterococci or group B streptococci, which are often isolated with E. coli but appear to rarely cause cystitis by themselves. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases.) Copyright © 2013 Massachusetts Medical Society.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :95&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84887465769&amp;doi=10.1056%2fNEJMoa1302186&amp;partnerID=40&amp;md5=42c29d0dbe278d1b43b015e61db35704</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1056/NEJMoa1302186</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>256</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">256</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hooton, T. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, University of Miami, Miller School of Medicine, 1120 NW 14th St., Miami, FL 33136, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Uncomplicated urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1028-1037</style></pages><volume><style face="normal" font="default" size="100%">366</style></volume><number><style face="normal" font="default" size="100%">11</style></number><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :266&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84858227303&amp;doi=10.1056%2fNEJMcp1104429&amp;partnerID=40&amp;md5=008018b9bf8a297feb9d3cae0d7042f2</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1056/NEJMcp1104429</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>512</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">512</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoepelman, A. I. M.</style></author><author><style face="normal" font="default" size="100%">Meiland, R.</style></author><author><style face="normal" font="default" size="100%">Geerlings, S. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Div. Acute Med./Infectious Diseases, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, Netherlands&#xD;Department of Internal Medicine, Free University Medical Center, Amsterdam, Netherlands&#xD;Academic Medical Center, Amsterdam, Netherlands</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Antimicrobial Agents</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Antimicrobial Agents</style></full-title></periodical><pages><style face="normal" font="default" size="100%">35-43</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">SUPPL. 2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Asymptomatic bacteruria</style></keyword><keyword><style face="normal" font="default" size="100%">Diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">Pathogenesis</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTIs) are more common and tend to have a more complicated course in patients with diabetes mellitus (DM). The mechanisms, which potentially contribute to the increased prevalence of both asymptomatic and symptomatic bacteriuriai in these patients are defects in the local urinary cytokine secretions and an increased adherence of the microorganisms to the uroepithelial cells. The need for treatment of asymptomatic bacteriuria remains controversial. No evidence is available on the optimal treatment of acute cystitis and pyelonephritis in patients with DM. Because of the frequent (asymptomatic) upper tract involvement and the possible serious complications, many experts recommend a 7-14-day oral antimicrobial regimen for bacterial cystitis in these patients, with an antimicrobial agent that achieves high levels both in the urine and in urinary tract tissues. Current data suggest that shorter regimens will lead to failure also in uncomplicated UTI in women. The recommended treatment of acute pyelonephritis does not differ from that in nondiabetic patients. Clinical trials specifically dealing with the treatment of UTIs in diabetic patients, comparing the optimal duration and choice of antimicrobial agent, are needed. Besides that, new approaches to preventive strategies must prove their value in this specific patient group. © 2003 Published by Elsevier B.V. and the International Society of Chemotherapy.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :86&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0141758350&amp;doi=10.1016%2fS0924-8579%2803%2900234-6&amp;partnerID=40&amp;md5=c8f33fee88e6bd5549dcccfa69a5b5fb</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0924-8579(03)00234-6</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>167</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">167</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hodson, E. M.</style></author><author><style face="normal" font="default" size="100%">Craig, J. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Kidney Research, The Children’s Hospital at Westmead, Westmead, Sydney, NSW, Australia&#xD;Sydney School of Public Health, University of Sydney, Sydney, NSW, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections in children</style></title><secondary-title><style face="normal" font="default" size="100%">Pediatric Nephrology, Seventh Edition</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1695-1714</style></pages><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infection (UTI) is an acute illness usually accompanied by fever, with or without other constitutional symptoms, and local symptoms of loin pain and bladder irritation. UTI is responsible for significant morbidity. In the USA alone, children diagnosed with UTI account for 500,000 visits to emergency departments each year [1]. A retrospective analysis of the Healthcare Cost and Utilization Project Kids’ Inpatient Database in the USA identified that about 10 % of these children, or 50,000, were admitted, representing about 1.8 % of all pediatric admissions [1]. Total hospital charges exceeded $520 million. © Springer-Verlag Berlin Heidelberg 2009, 2016.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84957643940&amp;doi=10.1007%2f978-3-662-43596-0_49&amp;partnerID=40&amp;md5=183cb446bd6e59c853cb229091263c84</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/978-3-662-43596-0_49</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>242</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">242</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hisano, M.</style></author><author><style face="normal" font="default" size="100%">Bruschini, H.</style></author><author><style face="normal" font="default" size="100%">Nicodemo, A. C.</style></author><author><style face="normal" font="default" size="100%">Srougi, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Faculdade de Medicina da Universidade de São Paulo, Laboratory of Medical Investigation, Department of Urology (LIM55), São Paulo/SP, Brazil&#xD;Hospital das Clínicas da Faculdade de Medicina, Universidade de São Paulo, Department of Infectious and Parasitic Diseases, São Paulo/SP, Brazil</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberries and lower urinary tract infection prevention</style></title><secondary-title><style face="normal" font="default" size="100%">Clinics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">661-667</style></pages><volume><style face="normal" font="default" size="100%">67</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Lower urinary tract infections are very common diseases. Recurrent urinary tract infections remain challenging to treat because the main treatment option is long-term antibiotic prophylaxis; however, this poses a risk for the emergence of bacterial resistance. Some options to avoid this risk are available, including the use of cranberry products. This article reviews the key methods in using cranberries as a preventive measure for lower urinary tract infections, including in vitro studies and clinical trials. © 2012 CLINICS.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :29&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84866328418&amp;doi=10.6061%2fclinics%2f2012%2806%2918&amp;partnerID=40&amp;md5=9b2098dc95648c1d69146375a5441d72</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.6061/clinics/2012(06)18</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>295</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">295</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hilbert, D. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Femeris Women&apos;s Health Research Center, Medical Diagnostic Laboratories, Hamilton NJ, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Uropathogenic Escherichia Coli: The pre-eminent urinary tract infection pathogen</style></title><secondary-title><style face="normal" font="default" size="100%">E. coli Infections: Causes, Treatment and Prevention</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1-66</style></pages><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">Community-acquired urinary tract infections (UTIs) are a major health problem, largely affecting women. In the United States, 11% of women suffer a UTI each year, and 60% of women experience at least one UTI during their lifetime. Recurrence is common, with 44% of patients suffering another infection within 1 year. Most infections remain confined to the bladder and cause painful and urgent urination (cystitis), although some patients are colonized asymptomatically. In a subset of infections, the pathogen ascends to the kidneys, resulting in pyelonephritis, a serious and life-threatening condition. Uropathogenic Escherichia coli (UPEC) is responsible for &gt;80% of community-acquired UTIs. UPEC originate in the gastrointestinal (GI) tract and are transmitted to the urinary tract via colonization of the vagina and periurethral area. UPEC utilizes a number of virulence factors to colonize the urinary tract, including fimbriae to adhere to and invade the bladder epithelium, siderophores to scavenge iron, and toxins to modify host cell signaling. These virulence factors are required to overcome the formidable innate immune defenses of the bladder. Toll-like Receptors (TLRs), especially TLR4, sense UPEC and trigger a multifaceted response to combat the infection, including secretion of chemokines to recruit neutrophils, antimicrobial peptide (AMP) secretion and exfoliation of the bladder epithelium. The sequencing of UPEC genomes has revealed a highly mosaic structure with numerous pathogenicity islands (PAIs) integrated at multiple sites in the genome. In addition, comparative genomics has revealed a close relationship between UPEC and other pathogenic E. coli, including strains that cause avian colibacillosis and neonatal meningitis. Although most UTIs can be treated with standard antimicrobial therapy, resistance to these agents is rising. The search for new therapies has led to both the innovation of novel molecules to inhibit UPEC adherence as well as the revisiting of older agents such as fosfomycin. Prevention of UTIs has focused on cranberry consumption and the use of probiotics to prevent vaginal colonization by UPEC. Lastly, progress has been made on development of a vaccine to prevent UTIs. In summary, UTIs caused by E. coli are a major health problem, with researchers using a multidisciplinary approach to improve prevention and therapy. © 2011 by Nova Science Publishers, Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84892851786&amp;partnerID=40&amp;md5=245f31c25163fbf6a25f985913957b69</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>294</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">294</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hidalgo, G.</style></author><author><style face="normal" font="default" size="100%">Ponton, A.</style></author><author><style face="normal" font="default" size="100%">Fatisson, J.</style></author><author><style face="normal" font="default" size="100%">O&apos;May, C.</style></author><author><style face="normal" font="default" size="100%">Asadishad, B.</style></author><author><style face="normal" font="default" size="100%">Schinner, T.</style></author><author><style face="normal" font="default" size="100%">Tufenkji, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemical Engineering, McGill University, 3610 University Street, Montreal QC H3A 2B2, Canada&#xD;McGill University and Génome Québec Innovation Centre, 740 Dr. Penfield Avenue, Montreal, QC H3A 1E4, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Induction of a state of iron limitation in Uropathogenic Escherichia coli CFT073 by Cranberry-derived proanthocyanidins as revealed by microarray analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Applied and Environmental Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Applied and Environmental Microbiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1532-1535</style></pages><volume><style face="normal" font="default" size="100%">77</style></volume><number><style face="normal" font="default" size="100%">4</style></number><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">Transcriptional profiles of uropathogenic Escherichia coli CFT073 exposed to cranberry-derived proanthocyanidins (PACs) were determined. Our results indicate that bacteria grown on media supplemented with PACs were iron deprived. To our knowledge, this is the first time that PACs have been shown to induce a state of iron limitation in this bacterium. © 2011, American Society for Microbiology.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :12&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79953192544&amp;doi=10.1128%2fAEM.02201-10&amp;partnerID=40&amp;md5=4d86489ae9220a2ec75cf02fae440be7</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/AEM.02201-10</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>361</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">361</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hess, M. J.</style></author><author><style face="normal" font="default" size="100%">Hess, P. E.</style></author><author><style face="normal" font="default" size="100%">Sullivan, M. R.</style></author><author><style face="normal" font="default" size="100%">Nee, M.</style></author><author><style face="normal" font="default" size="100%">Yalla, S. V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Spinal Cord Injury, VA Boston Health Care System, West Roxbury, MA, United States&#xD;Department of Anesthesiology, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United States&#xD;Department of Urology, VA Boston Health Care System, West Roxbury, MA, United States&#xD;Department of Spinal Cord Injury, VA Boston Health Care System, Building 2, 1400 VFW Parkway, West Roxbury, MA 02132, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation of cranberry tablets for the prevention of urinary tract infections in spinal cord injured patients with neurogenic bladder</style></title><secondary-title><style face="normal" font="default" size="100%">Spinal Cord</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Spinal Cord</style></full-title></periodical><pages><style face="normal" font="default" size="100%">622-626</style></pages><volume><style face="normal" font="default" size="100%">46</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenic bladder</style></keyword><keyword><style face="normal" font="default" size="100%">Spinal cord injury</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">Study Design: Randomized, double blind, placebo-controlled trial with a crossover design. Objective: To evaluate cranberry tablets for the prevention of urinary tract infection (UTI) in spinal cord injured (SCI) patients. Setting: Spinal Cord Injury Unit of a Veterans Administration Hospital, MA, USA. Methods: Subjects with spinal cord injury and documentation of neurogenic bladder were randomized to receive 6 months of cranberry extract tablet or placebo, followed by the alternate preparation for an additional 6 months. The primary outcome was the incidence of UTI. Results: Forty-seven subjects completed the trial. We found a reduction in the likelihood of UTI and symptoms for any month while receiving the cranberry tablet (P&amp;lt;0.05 for all). During the cranberry period, 6 subjects had 7 UTI, compared with 16 subjects and 21 UTI in the placebo period (P&amp;lt;0.05 for both number of subjects and incidence). The frequency of UTI was reduced to 0.3 UTI per year vs 1.0 UTI per year while receiving placebo. Subjects with a glomerular filtration rate (GFR) greater than 75 ml min -1 received the most benefit. Conclusion: Cranberry extract tablets should be considered for the prevention of UTI in SCI patients with neurogenic bladder. Patients with a high GFR may receive the most benefit. Sponsorship: Spinal Cord Research Foundation, sponsored by the Paralyzed Veterans of America. © 2008 International Spinal Cord Society All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :63&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-51349104866&amp;doi=10.1038%2fsc.2008.25&amp;partnerID=40&amp;md5=932a9703786ca0e9c1db4e59ea5478f0</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/sc.2008.25</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>42</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">42</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Henze, T.</style></author><author><style face="normal" font="default" size="100%">Feneberg, W.</style></author><author><style face="normal" font="default" size="100%">Flachenecker, P.</style></author><author><style face="normal" font="default" size="100%">Seidel, D.</style></author><author><style face="normal" font="default" size="100%">Albrecht, H.</style></author><author><style face="normal" font="default" size="100%">Starck, M.</style></author><author><style face="normal" font="default" size="100%">Meuth, S. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Praxisgemeinschaft für Neurologie, Psychiatrie, Psychotherapie, Günzstr. 1, Regensburg, 93059, Germany&#xD;Department für Neurologie und Institut für Translationale Neurologie, Klinik für Allgemeine Neurologie, Universitätsklinikum, Münster, Germany&#xD;Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gemeinnützige GmbH, Berg, Germany&#xD;Neurologisches Rehabilitationszentrum Quellenhof, Bad Wildbad, Germany&#xD;Bocholt, Germany&#xD;Praxis für Neurologie, München, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">What is new in symptomatic MS treatment: Part 3—bladder dysfunction</style></title><secondary-title><style face="normal" font="default" size="100%">Nervenarzt</style></secondary-title><short-title><style face="normal" font="default" size="100%">Neues zur symptomatischen MS-Therapie: Teil 3 – Blasenfunktionsstörungen</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nervenarzt</style></full-title></periodical><pages><style face="normal" font="default" size="100%">184-192</style></pages><volume><style face="normal" font="default" size="100%">89</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bladder dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">Multiple sclerosis</style></keyword><keyword><style face="normal" font="default" size="100%">Review</style></keyword><keyword><style face="normal" font="default" size="100%">Symptomatic treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Vegetative nervous system</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">The symptomatic treatment of multiple sclerosis (MS) nowadays is of similar importance as immunotherapy within a comprehensive concept of therapy of this chronic disease, since it contributes considerably to the reduction of disabilities in activities of daily living as well as social and occupational life. Moreover, symptomatic treatment is of great importance for amelioration of quality of life. Since our last survey of symptomatic MS treatment in 2004 and publication of the guidelines of the German Neurological Society and the Klinisches Kompetenznetz Multiple Sklerose (KKNMS) in 2014 several developments within the topics of mobility, bladder and sexual function, vision, fatigue, cognition and rehabilitation took place. These new findings together with further aspects of disease measures and overall treatment strategies of the respective symptoms, as well as treatment goals are introduced in a series of six individual contributions. Here, the symptoms of bladder dysfunction will be discussed. © 2017, Springer Medizin Verlag GmbH.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85032484302&amp;doi=10.1007%2fs00115-017-0440-x&amp;partnerID=40&amp;md5=4f0f5122670f56ab9aca070356712b88</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00115-017-0440-x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>59</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">59</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Helbig, S.</style></author><author><style face="normal" font="default" size="100%">Mandraka, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universitätsklinikum Carl Gustav Carus An der TU Dresden, Zentralbereich Klinische Infektiologie, Technischen Universität Dresden, Fetscherstr. 74, Dresden, 01307, Germany&#xD;Labor Dr. Wisplinghoff, Klinische Infektiologie, Köln, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Update on Uncomplicated Urinary Tract Infections - New Guideline 2017</style></title><secondary-title><style face="normal" font="default" size="100%">Deutsche Medizinische Wochenschrift</style></secondary-title><short-title><style face="normal" font="default" size="100%">Update unkomplizierte Harnwegsinfektionen - Die neue Leitlinie 2017</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Deutsche Medizinische Wochenschrift</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1814-1819</style></pages><volume><style face="normal" font="default" size="100%">142</style></volume><number><style face="normal" font="default" size="100%">24</style></number><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85037148485&amp;doi=10.1055%2fs-0043-112243&amp;partnerID=40&amp;md5=37b93a962a6a867605a04349a2dbab7c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1055/s-0043-112243</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>403</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">403</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Heinonen, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Helsinki, Department of Applied Chemistry and Microbiology, Food Chemistry, Helsinki, Finland&#xD;University of Helsinki, Department of Applied Chemistry and Microbiology, 00014 Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antioxidant activity and antimicrobial effect of berry phenolics - A Finnish perspective</style></title><secondary-title><style face="normal" font="default" size="100%">Molecular Nutrition and Food Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Molecular Nutrition and Food Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">684-691</style></pages><volume><style face="normal" font="default" size="100%">51</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antimicrobial effect</style></keyword><keyword><style face="normal" font="default" size="100%">Antioxidants</style></keyword><keyword><style face="normal" font="default" size="100%">Berries</style></keyword><keyword><style face="normal" font="default" size="100%">Bioactivities</style></keyword><keyword><style face="normal" font="default" size="100%">Phenolics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">In Finland, berries are part of the traditional diet significantly contributing to the intake of flavonoids and other phenolic compounds. Compositional data on phenolic compounds in berries has been rapidly accumulating and included in the national food composition database. Among the different bioactive substances in berries, phenolic compounds including flavonoids, tannins, and phenolic acids have received considerable interest due to their effects in food and health. A great amount of in vitro evidence exists showing that berry phenolics are powerful antioxidants. However, the antioxidant effect of berry phenolics is strongly dependent on the choice of berry raw material, as the antioxidant activity differs between the different phenolic constituents, including anthocyanins, ellagitannins, and proanthocyanidins. In foods, the antioxidant effect is also influenced by the structure of food. Tannin-containing berries exhibit antimicrobial properties against pathogenic bacteria, thus offering many new applications for food industry. Much of the interest in berry phenolics has focused on cranberries and both cultivated and wild blueberries, although also other berries including black currants, cloudberries, lingonberries, and red raspberries posses promising bioactivities that may have relevance to human health. Antioxidant activity of berry phenolics, in addition to other mechanisms, may contribute to human health, but the possible relationship remains yet to be scientifically substantiated. © 2007 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :196&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-34447514349&amp;doi=10.1002%2fmnfr.200700006&amp;partnerID=40&amp;md5=b3606c15b16d71b0b9e40d021024c381</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/mnfr.200700006</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>360</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">360</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Head, K. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Thorne Research, Inc.&#xD;Thorne Research, PO Box 25, Dover, ID 83825, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Natural approaches to prevention and treatment of infections of the lower urinary tract</style></title><secondary-title><style face="normal" font="default" size="100%">Alternative Medicine Review</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Alternative Medicine Review</style></full-title></periodical><pages><style face="normal" font="default" size="100%">227-244</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">Infections of the lower urinary tract are common occurrences in young women, during pregnancy, and in peri- and postmenopausal women. Because of the chronic nature of urinary tract infections (UTIs) and the potential for antibiotic resistance, a natural approach to prevention and treatment is desirable. Clinical research suggests the best natural options for long-term prevention include cranberry, mannose, and probiotics. Botanicals that can be effective at the first sign of an infection and for short-term prophylaxis include berberine and uva ursi. Estriol cream and vitamins A and C have also been shown to prevent UTIs, while potassium salts can alkalinize the urine and reduce dysuria.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :24&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-53549124994&amp;partnerID=40&amp;md5=26488c26c2341e3d883ea5eff0aeea84</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>370</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">370</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hatakka, K.</style></author><author><style face="normal" font="default" size="100%">Saxelin, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Valio R and D, P.O. Box 30, FIN-00039 Valio Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Probiotics in intestinal and non-intestinal infectious diseases - Clinical evidence</style></title><secondary-title><style face="normal" font="default" size="100%">Current Pharmaceutical Design</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Pharmaceutical Design</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1351-1367</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">14</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bifidobacterium</style></keyword><keyword><style face="normal" font="default" size="100%">Gastrointestinal</style></keyword><keyword><style face="normal" font="default" size="100%">Infection</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">Oral</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Respiratory</style></keyword><keyword><style face="normal" font="default" size="100%">Urogenital</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">There is increasing evidence that certain probiotic strains can be useful in improving human health. The use of probiotics has received attention as a natural way of restoring body&apos;s normal microbiota, and an alternative and inexpensive way of preventing or treating infectious diseases without side effects. The best-documented clinical application of probiotics comes from trials on the treatment of gastrointestinal infections, mainly infectious diarrhoea. The enhancement of local as well as systemic immune responses by probiotics also offers now opportunities for probiotics in preventing infections at distal mucosal surfaces, such as those in the oral cavity, respiratory and urogenital tracts. The underlying mechanisms of probiotics are still unclear, but may include strengthening of the non-immunological gut barrier, interference with pathogen adhesion and growth inhibition, and the enhancement of the local mucosal immune system in the gut, as well as of the systemic immune response. © 2008 Bentham Science Publishers Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :39&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-47249143768&amp;doi=10.2174%2f138161208784480162&amp;partnerID=40&amp;md5=290dff4933dfaefec6e0a3d5ef629550</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2174/138161208784480162</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>142</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">142</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Harbarth, S.</style></author><author><style face="normal" font="default" size="100%">Balkhy, H. H.</style></author><author><style face="normal" font="default" size="100%">Goossens, H.</style></author><author><style face="normal" font="default" size="100%">Jarlier, V.</style></author><author><style face="normal" font="default" size="100%">Kluytmans, J.</style></author><author><style face="normal" font="default" size="100%">Laxminarayan, R.</style></author><author><style face="normal" font="default" size="100%">Saam, M.</style></author><author><style face="normal" font="default" size="100%">Van Belkum, A.</style></author><author><style face="normal" font="default" size="100%">Pittet, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Geneva University Hospitals and Faculty of Medicine, Infection Control Programme and WHO Collaborating Centre on Patient Safety, Rue Gabrielle-Perret-Gentil 4, Geneva, Switzerland&#xD;King Saud bin Abdulaziz University for Health Sciences, College of Medicine, Riyadh, Saudi Arabia&#xD;University of Antwerp, Department of Medical Microbiology, Vaccine and Infectious Disease Institute, Wilrijk, Belgium&#xD;Université Pierre et Marie Curie-Paris 6, Laboratory of Bacteriology-Hygiene, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris, France&#xD;University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, Netherlands&#xD;Center for Disease Dynamics, Economics and Policy (CDDEP), Washington, DC, United States&#xD;Communication in Science, Rue des Maraîchers 8, Geneva, Switzerland&#xD;BioMérieux, Microbiology R and D Department, La Balme Les Grottes, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antimicrobial resistance: One world, one fight!</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrobial Resistance and Infection Control</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrobial Resistance and Infection Control</style></full-title></periodical><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Animal health</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic stewardship</style></keyword><keyword><style face="normal" font="default" size="100%">Antimicrobial conservation</style></keyword><keyword><style face="normal" font="default" size="100%">Antimicrobial resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Global health</style></keyword><keyword><style face="normal" font="default" size="100%">Hand hygiene</style></keyword><keyword><style face="normal" font="default" size="100%">Infection control</style></keyword><keyword><style face="normal" font="default" size="100%">One health</style></keyword><keyword><style face="normal" font="default" size="100%">Surveillance networks</style></keyword><keyword><style face="normal" font="default" size="100%">World healthcare-associated infections resistance forum</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">The lack of new antibiotic classes calls for a cautious use of existing agents. Yet, every 10 min, almost two tons of antibiotics are used around the world, all too often without any prescription or control. The use, overuse and misuse of antibiotics select for resistance in numerous species of bacteria which then renders antimicrobial treatment ineffective. Almost all countries face increased antimicrobial resistance (AMR), not only in humans but also in livestock and along the food chain. The spread of AMR is fueled by growing human and animal populations, uncontrolled contamination of fresh water supplies, and increases in international travel, migration and trade. In this context of global concern, 68 international experts attending the fifth edition of the World HAI Resistance Forum in June 2015 shared their successes and failures in the global fight against AMR. They underlined the need for a &quot;One Health&quot; approach requiring research, surveillance, and interventions across human, veterinary, agricultural and environmental sectors. This strategy involves concerted actions on several fronts. Improved education and increased public awareness are a well-understood priority. Surveillance systems monitoring infections need to be expanded to include antimicrobial use, as well as the emergence and spread of AMR within clinical and environmental samples. Adherence to practices to prevent and control the spread of infections is mandatory to reduce the requirement of antimicrobials in general care and agriculture. Antibiotics need to be banned as growth promoters for farm animals in countries where it has not yet been done. Antimicrobial stewardship programmes in animal husbandry have proved to be efficient for minimising AMR, without compromising productivity. Regarding the use of antibiotics in humans, new tools to provide highly specific diagnoses of pathogens can decrease diagnostic uncertainty and improve clinical management. Finally, infection prevention and control measures - some of them as simple as hand hygiene - are essential and should be extended beyond healthcare settings. Aside from regulatory actions, all people can assist in AMR reduction by limiting antibiotic use for minor illnesses. Together, we can all work to reduce the burden of AMR. © 2015 Harbarth et al.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :24&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85006208810&amp;doi=10.1186%2fs13756-015-0091-2&amp;partnerID=40&amp;md5=ac1838ef601f6aa665df484f5fd6909d</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">49</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/s13756-015-0091-2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>585</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">585</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Guyot, S.</style></author><author><style face="normal" font="default" size="100%">Marnet, N.</style></author><author><style face="normal" font="default" size="100%">Laraba, D.</style></author><author><style face="normal" font="default" size="100%">Sanoner, P.</style></author><author><style face="normal" font="default" size="100%">Drilleau, J. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratoire de Recherches Cidricoles, Biotransformation Fruits et Legumes, Inst. Natl. de la Rech. Agronomique, B.P. 29, 35650 Le Rheu, France&#xD;Laboratoire de Biotechnologies, Institut des Sciences de la Nature, Université de Constantine, Constantine, Algeria</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reversed-Phase HPLC following Thiolysis for Quantitative Estimation and Characterization of the Four Main Classes of Phenolic Compounds in Different Tissue Zones of a French Cider Apple Variety (Malus domestica Var. Kermerrien)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1698-1705</style></pages><volume><style face="normal" font="default" size="100%">46</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Apple</style></keyword><keyword><style face="normal" font="default" size="100%">Cider</style></keyword><keyword><style face="normal" font="default" size="100%">HPLC</style></keyword><keyword><style face="normal" font="default" size="100%">Phenolics</style></keyword><keyword><style face="normal" font="default" size="100%">Procyanidins</style></keyword><keyword><style face="normal" font="default" size="100%">Thiolysis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year></dates><abstract><style face="normal" font="default" size="100%">Phenolic compounds, which are present in the epidermis zone, parenchyma zone, core zone, and seeds of fruit (Malus domestica var. Kermerrien), were extracted from freeze-dried material by three successive solvent extractions. The dry methanol extract and the dry aqueous acetone extracts were analyzed using reversed-phase HPLC coupled with diode array detection following thiolysis to quantify phenolic compounds according to their classes (hydroxycinnamic acid derivatives, flavan-3-ols, flavonols, and dihydrochalcones). The method is suitable for the determination of the relative proportions of the different classes of polyphenols and provided information on the constitutive units and the average degree of polymerization of oligomeric and polymeric procyanidin structures. Results showed that procyanidins are the predominant phenolic constituents in cider apple fruits, much of them corresponding to highly polymerized structures.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :258&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0001171808&amp;partnerID=40&amp;md5=dad90ed827b491b7d4813c2a053b5a8b</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>116</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">116</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gupta, P.</style></author><author><style face="normal" font="default" size="100%">Song, B.</style></author><author><style face="normal" font="default" size="100%">Neto, C.</style></author><author><style face="normal" font="default" size="100%">Camesano, T. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemical Engineering, Worcester Polytechnic Institute, Worcester, MA 01609, United States&#xD;Department of Chemistry and Biochemistry, University of Massachusetts-Dartmouth, North Dartmouth, MA 02747, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Atomic force microscopy-guided fractionation reveals the influence of cranberry phytochemicals on adhesion of Escherichia coli</style></title><secondary-title><style face="normal" font="default" size="100%">Food and Function</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Food and Function</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2655-2666</style></pages><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">6</style></number><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry juice has been long used to prevent infections because of its effect on the adhesion of the bacteria to the host surface. Proanthocyanidins (PACs) comprise of one of the major classes of phytochemicals found in cranberry, which have been extensively studied and found effective in combating adhesion of pathogenic bacteria. The role of other cranberry constituents in impacting bacterial adhesion haven&apos;t been studied very well. In this study, cranberry juice fractions were prepared, characterized and tested for their effect on the surface adhesion of the pathogenic clinical bacterial strain E. Coli B78 and non-pathogenic control E. Coli HB101. The preparations tested included crude cranberry juice extract (CCE); three fractions containing flavonoid classes including proanthocyanidins, anthocyanins and flavonols; selected sub-fractions, and commercially available flavonol glycoside, quercetin-3-O-galactoside. Atomic force microscopy (AFM) was used to quantify the adhesion forces between the bacterial surface and the AFM probe after the treatment with the cranberry fractions. Adhesion forces of the non-pathogenic, non fimbriated lab strain HB101 are small (average force 0.19 nN) and do not change with cranberry treatments, whereas the adhesion forces of the pathogenic, Dr adhesion E. Coli strain B78 (average force of 0.42 nN) show a significant decrease when treated with cranberry juice extract or fractions (average force of 0.31 nN, 0.37 nN and 0.39 nN with CCE, Fraction 7 and Fraction 4 respectively). In particular, the fractions that contained flavonols in addition to PACs were more efficient at lowering the force of adhesion (average force of 0.31 nN-0.18 nN between different sub-fractions containing flavonols and PACs). The sub-fractions containing flavonol glycosides (from juice, fruit and commercial quercetin) all resulted in reduced adhesion of the pathogenic bacteria to the model probe. This strongly suggests the anti adhesive role of other classes of cranberry compounds in conjunction with already known PACs and may have implications for development of alternative anti bacterial treatments. © 2016 The Royal Society of Chemistry.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :5&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84975466623&amp;doi=10.1039%2fc6fo00109b&amp;partnerID=40&amp;md5=c88f1ac18154ee5f2a6334e59f28b383</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1039/c6fo00109b</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>579</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">579</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gupta, K.</style></author><author><style face="normal" font="default" size="100%">Stamm, W. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Div. of Allerg. and Infect. Diseases, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pathogenesis and management of recurrent urinary tract infections in women</style></title><secondary-title><style face="normal" font="default" size="100%">World Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">World Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">415-420</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">6</style></number><dates><year><style face="normal" font="default" size="100%">1999</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :46&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033253082&amp;doi=10.1007%2fs003450050168&amp;partnerID=40&amp;md5=934227ab93855eda58d8eb9e5b61d17d</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s003450050168</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>578</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">578</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gupta, K.</style></author><author><style face="normal" font="default" size="100%">Scholes, D.</style></author><author><style face="normal" font="default" size="100%">Stamm, W. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Div. of Allerg. and Infect. Diseases, Univ. of Washington Sch. of Medicine, Seattle, WA, United States&#xD;Center for Health Studies, Grp. Hlth. Coop. of Puget Sound, Seattle, WA, United States&#xD;Div. of Allerg. and Infect. Diseases, University of Washington, Box 356523, 1959 NE Pacific St, Seattle, WA 98195, United States&#xD;Procter and Gamble Inc., Cincinnati, OH, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Medical Association</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Medical Association</style></full-title></periodical><pages><style face="normal" font="default" size="100%">736-738</style></pages><volume><style face="normal" font="default" size="100%">281</style></volume><number><style face="normal" font="default" size="100%">8</style></number><dates><year><style face="normal" font="default" size="100%">1999</style></year></dates><abstract><style face="normal" font="default" size="100%">Context: Guidelines for the management of acute uncomplicated cystitis in women that recommend empirical therapy in properly selected patients rely on the predictability of the agents causing cystitis and knowledge of their antimicrobial susceptibility patterns. Objective: To assess the prevalence of and trends in antimicrobial resistance among uropathogens causing well- defined episodes of acute uncomplicated cystitis in a large population of women. Design: Cross-sectional survey of antimicrobial susceptibilities of urine isolates collected during a 5-year period (January, May, and September 1992-1996). Setting: Health maintenance organization. Patients: Women aged 18 to 50 years with an outpatient diagnosis of acute cystitis. Main Outcome Measures: Proportion of uropathogens demonstrating in vitro resistance to selected antimicrobials; trends in resistance over the 5-year study period. Results: Escherichia coli and Staphylococcus saprophyticus were the most common uropathogens, accounting for 90% of the 4342 urine isolates studied. The prevalence of resistance among E coli and all isolates combined was more than 20% for ampicillin, cephalothin, and sulfamethoxazole in each year studied. The prevalence of resistance to trimethoprim and trimethoprim- sulfamethoxazole rose from more than 9% in 1992 to more than 18% in 1996 among E coli, and from 8% to 16% among all isolates combined. There was a statistically significant increasing linear trend in the prevalence of resistance from 1992 to 1996 among E coli and all isolates combined to ampicillin (P&lt;.002), and to cephalothin, trimethoprim, and trimethoprim- sulfamethoxazole (P&lt;.001). In contrast, the prevalence of resistance to nitrofurantoin, gentamicin, and ciprofloxacin hydrochloride was 0% to 2% among E coli and less than 10% among all isolates combined, and did not change significantly during the 5-year period. Conclusions: While the prevalence of resistance to trimethoprim-sulfamethoxazole, ampicillin, and cephalothin increased significantly among uropathogens causing acute cystitis, resistance to nitrofurantoin and ciprofloxacin remained infrequent. These in vitro susceptibility patterns should be considered along with other factors, such as efficacy, cost, and cost-effectiveness in selecting empirical therapy for acute uncomplicated cystitis in women.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :428&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033599264&amp;doi=10.1001%2fjama.281.8.736&amp;partnerID=40&amp;md5=dae3ae9c0e6ce08fc2e08ef79d30cfb8</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jama.281.8.736</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>567</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">567</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gupta, K.</style></author><author><style face="normal" font="default" size="100%">Hooton, T. M.</style></author><author><style face="normal" font="default" size="100%">Roberts, P. L.</style></author><author><style face="normal" font="default" size="100%">Stamm, W. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Division of Allergy Diseases, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">9-16</style></pages><volume><style face="normal" font="default" size="100%">135</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2001</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Recurrent urinary tract infections (UTIs) are a common outpatient problem, resulting in frequent office visits and often requiring the use of prophylactic antimicrobial agents. Patient-initiated treatment of recurrent UTIs may decrease antimicrobial use and improve patient convenience. Objective: To determine the safety and feasibility of patient-initiated treatment of recurrent UTIs. Design: Uncontrolled, prospective clinical trial. Setting: University-based primary health care clinic. Participants: Women at least 18 years of age with a history of recurrent UTIs and no recent pregnancy, hypertension, diabetes, or renal disease. Intervention: After self-diagnosing UTI on the basis of symptoms, participating women initiated therapy with ofloxacin or levofloxacin. Measurements: Accuracy of self-diagnosis determined by evidence of a definite (culture-positive) or probable (sterile pyuria and no alternative diagnosis) UTI on pretherapy urinalysis and culture. Women with a self-diagnosis of UTI that was not microbiologically confirmed were evaluated for alternative diagnoses. Post-therapy interviews and urine cultures were used to assess clinical and microbiological cure rates, adverse events, and patient satisfaction. Results: 88 of 172 women self-diagnosed a total of 172 UTIs. Laboratory evaluation showed a uropathogen in 144 cases (84%), sterile pyuria in 19 cases (11%), and no pyuria or bacteriuria in 9 cases (5%). Clinical and microbiological cures occurred in 92% and 96%, respectively, of culture-confirmed episodes. No serious adverse events occurred. Conclusion: Adherent women can accurately self-diagnose and self-treat recurrent UTIs.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :156&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035800050&amp;doi=10.7326%2f0003-4819-135-1-200107030-00004&amp;partnerID=40&amp;md5=fa0e3a0dfb36927f9d4b8b88d45e5ae1</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.7326/0003-4819-135-1-200107030-00004</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>291</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">291</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gupta, K.</style></author><author><style face="normal" font="default" size="100%">Hooton, T. M.</style></author><author><style face="normal" font="default" size="100%">Naber, K. G.</style></author><author><style face="normal" font="default" size="100%">Wullt, B.</style></author><author><style face="normal" font="default" size="100%">Colgan, R.</style></author><author><style face="normal" font="default" size="100%">Miller, L. G.</style></author><author><style face="normal" font="default" size="100%">Moran, G. J.</style></author><author><style face="normal" font="default" size="100%">Nicolle, L. E.</style></author><author><style face="normal" font="default" size="100%">Raz, R.</style></author><author><style face="normal" font="default" size="100%">Schaeffer, A. J.</style></author><author><style face="normal" font="default" size="100%">Soper, D. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Veterans Affairs Boston Health Care System and Boston University, School of Medicine, Boston, MA, United States&#xD;Department of Medicine, University of Miami Miller, School of Medicine, Miami, FL, United States&#xD;Department of Family and Community Medicine, University of Maryland, Baltimore, MD, United States&#xD;Division of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, United States&#xD;Department of Emergency Medicine, Division of Infectious Diseases Olive, View-UCLA Medical Center, Slymar, CA, United States&#xD;Deptartment of Urology, Northwestern University, Chicago, IL, United States&#xD;Department of Obstetrics and Gynecology and Medicine, Medical University of South Carolina, Charleston, SC, United States&#xD;Department of Internal Medicine, University of Manitoba, Winnipeg, Canada&#xD;Technical University of Munich, Munich, Germany&#xD;Lund University Hospital, Lund, Sweden&#xD;Infectious Diseases Unit, Ha&apos;Emek Medical Center, Afula, and Rappaport Faculty of Medicine, Technion, Haifa, Israel</style></auth-address><titles><title><style face="normal" font="default" size="100%">International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e103-e120</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">5</style></number><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">A Panel of International Experts was convened by the Infectious Diseases Society of America (IDSA) in collaboration with the European Society for Microbiology and Infectious Diseases (ESCMID) to update the 1999 Uncomplicated Urinary Tract Infection Guidelines by the IDSA. Co-sponsoring organizations include the American Congress of Obstetricians and Gynecologists, American Urological Association, Association of Medical Microbiology and Infectious Diseases-Canada, and the Society for Academic Emergency Medicine. The focus of this work is treatment of women with acute uncomplicated cystitis and pyelonephritis, diagnoses limited in these guidelines to premenopausal, non-pregnant women with no known urological abnormalities or co-morbidities. The issues of in vitro resistance prevalence and the ecological adverse effects of antimicrobial therapy (collateral damage) were considered as important factors in making optimal treatment choices and thus are reflected in the rankings of recommendations. © The Author 2011.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :993&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79951831698&amp;doi=10.1093%2fcid%2fciq257&amp;partnerID=40&amp;md5=62ff5c4acaa9e7dc6cf8b4abcbfa4f33</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/cid/ciq257</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>63</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">63</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gupta, K.</style></author><author><style face="normal" font="default" size="100%">Grigoryan, L.</style></author><author><style face="normal" font="default" size="100%">Trautner, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">VA Boston Healthcare System, Boston University School of Medicine, Boston, MA, United States&#xD;Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, TX, United States&#xD;Houston VA Health Services Research, Development Center of Excellence, Baylor College of Medicine, Houston, TX, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">In the clinic® urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">ITC49-ITC64</style></pages><volume><style face="normal" font="default" size="100%">167</style></volume><number><style face="normal" font="default" size="100%">7</style></number><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :8&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Note</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85030462480&amp;doi=10.7326%2fAITC201710030&amp;partnerID=40&amp;md5=caa533a7f15d15ef24f13b61b07e1e45</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.7326/AITC201710030</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>402</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">402</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gupta, K.</style></author><author><style face="normal" font="default" size="100%">Chou, M. Y.</style></author><author><style face="normal" font="default" size="100%">Howell, A.</style></author><author><style face="normal" font="default" size="100%">Wobbe, C.</style></author><author><style face="normal" font="default" size="100%">Grady, R.</style></author><author><style face="normal" font="default" size="100%">Stapleton, A. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Section of Infectious Diseases, Yale University School of Medicine, West Haven, CT, United States&#xD;Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, United States&#xD;Department of Urology, Children&apos;s Hospital, Regional Medical Center, Seattle, WA, United States&#xD;Marucci Center for Blueberry and Cranberry Research, Rutgers University, Chatsworth, NJ, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry Products Inhibit Adherence of P-Fimbriated Escherichia Coli to Primary Cultured Bladder and Vaginal Epithelial Cells</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2357-2360</style></pages><volume><style face="normal" font="default" size="100%">177</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">bladder</style></keyword><keyword><style face="normal" font="default" size="100%">cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">vagina</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">Purpose: Cranberry proanthocyanidins have been identified as possible inhibitors of Escherichia coli adherence to uroepithelial cells. However, little is known about the dose range of this effect. Furthermore, it has not been studied directly in the urogenital system. To address these issues we tested the effect of a cranberry powder and proanthocyanidin extract on adherence of a P-fimbriated uropathogenic E. coli isolate to 2 new urogenital model systems, namely primary cultured bladder epithelial cells and vaginal epithelial cells. Materials and Methods: E. coli IA2 was pre-incubated with a commercially available cranberry powder (9 mg proanthocyanidin per gm) or with increasing concentrations of proanthocyanidin extract. Adherence of E. coli IA2 to primary cultured bladder epithelial cells or vaginal epithelial cells was measured before and after exposure to these products. Results: Cranberry powder decreased mean adherence of E. coli IA2 to vaginal epithelial cells from 18.6 to 1.8 bacteria per cell (p &lt;0.001). Mean adherence of E. coli to primary cultured bladder epithelial cells was decreased by exposure to 50 μg/ml proanthocyanidin extract from 6.9 to 1.6 bacteria per cell (p &lt;0.001). Inhibition of adherence of E. coli by proanthocyanidin extract occurred in linear, dose dependent fashion over a proanthocyanidin concentration range of 75 to 5 μg/ml. Conclusions: Cranberry products can inhibit E. coli adherence to biologically relevant model systems of primary cultured bladder and vaginal epithelial cells. This effect occurs in a dose dependent relationship. These findings provide further mechanistic evidence and biological plausibility for the role of cranberry products for preventing urinary tract infection. © 2007 American Urological Association.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :119&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-34248354400&amp;doi=10.1016%2fj.juro.2007.01.114&amp;partnerID=40&amp;md5=4894c0383edfed0f4369edbf99de347b</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.juro.2007.01.114</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>187</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">187</key></foreign-keys><ref-type name="Book">6</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Guo, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Nutrition and Food Sciences Department, University of Vermont, Burlington, VT, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Functional foods: Principles and technology</style></title><secondary-title><style face="normal" font="default" size="100%">Functional Foods: Principles and Technology</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1-358</style></pages><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">The subject of functional foods is one of the hottest topics in food science and nutrition. This trend will continue for a long time. I have been teaching Functional Foods-Principles and Technology at University of Vermont since 2000. The course is getting more and more popular on the campus. Students in my classroom keep asking to have a textbook for study and for future reference. Although there are a number of books on functional foods available on the market, none of them are written for classrooms. In 2005, I decided to take a one-half year sabbatical leave to write a textbook for my class (I now realize that six months was not sufficient to complete this task). The structure of the book is based on my lecture notes. This textbook consists of nine chapters and laboratory manuals as an appendix. Chapter 1 describes the definition, history, and global aspects of functional foods. Chapters 2, 3, 4, 5 and 6 deal with some of the foundations of functional foodsantioxidants, dietary fiber, pre- and probiotics, functional fatty acids, and vitamins and minerals, respectively. Chapter 7 discusses the chemistry and health benefits of soybeans and soy products. Chapter 8 deals with aspects of biochemistry and formulation of sports drinks. The last chapter (9) discusses human milk chemistry and infant formula formulation. © 2009 Woodhead Publishing Limited. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Book</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84902752261&amp;doi=10.1533%2f9781845696078&amp;partnerID=40&amp;md5=f4ae6dc2b688289c61197aa1c3b69aea</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1533/9781845696078</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>46</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">46</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Guo, L.</style></author><author><style face="normal" font="default" size="100%">Hou, Y.</style></author><author><style face="normal" font="default" size="100%">Song, L.</style></author><author><style face="normal" font="default" size="100%">Zhu, S.</style></author><author><style face="normal" font="default" size="100%">Lin, F.</style></author><author><style face="normal" font="default" size="100%">Bai, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Orthodontics School of Stomatology, Capital Medical University, Beijing, China&#xD;Department of Orthodontics, Peking University School of Stomatology, Third Dental Center, Beijing, China&#xD;Department of Stomatology, Fifth People&apos;s Hospital of Shanghai, Fudan University, Shanghai, China&#xD;Laboratory of Tissue Regeneration and Immunology, Department of Periodontics, Beijing Key Laboratory of Tooth Regeneration and Function Reconstruction, School of Stomatology, Capital Medical University, Beijing, China</style></auth-address><titles><title><style face="normal" font="default" size="100%">D-Mannose enhanced immunomodulation of periodontal ligament stem cells via inhibiting IL-6 secretion</style></title><secondary-title><style face="normal" font="default" size="100%">Stem Cells International</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Stem Cells International</style></full-title></periodical><volume><style face="normal" font="default" size="100%">2018</style></volume><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Periodontal ligament stem cell- (PDLSC-) mediated periodontal tissue regeneration has recently been proposed for the new therapeutic method to regenerate lost alveolar bone and periodontal ligament. It was reported that both autogenic and allogeneic PDLSCs could reconstruct damaged periodontal tissues but the regeneration effects were not consistent. The effective methods to improve the properties of PDLSCs should be further considered. In this study, we investigated if D-mannose could affect the immunomodulatory properties of hPDLSCs. After being pretreated with D-mannose, hPDLSCs could inhibit T cell proliferation and affect T cell differentiation into Treg cells. We found that less IL-6 could be detected in D-mannose-pretreated hPDLSCs. In the D-mannose pretreatment group, induced Treg cell number would decrease if increased IL-6 levels could be detected. Our data uncovered a previously unrecognized function of D-mannose to regulate the immunomodulatory function of PDLSCs and that IL-6 might play a key role in this process. The results provided a property method to improve PDLSC-based periodontal regeneration. © 2018 Lijia Guo et al.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058980097&amp;doi=10.1155%2f2018%2f7168231&amp;partnerID=40&amp;md5=54a9f50ec2870d27bde742cf0f1fc5b5</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">7168231</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1155/2018/7168231</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>339</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">339</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Guay, D. R. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, United States&#xD;HealthPartners Geriatrics, HealthPartners Inc., Minneapolis, MN, United States&#xD;College of Pharmacy, University of Minnesota, Weaver-Densford Hall 7-148, 308 Harvard Street SE, Minneapolis, MN 55455, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry and urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drugs</style></full-title></periodical><pages><style face="normal" font="default" size="100%">775-807</style></pages><volume><style face="normal" font="default" size="100%">69</style></volume><number><style face="normal" font="default" size="100%">7</style></number><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infection (UTI) refers to the presence of clinical signs and symptoms arising from the genitourinary tract plus the presence of one or more micro-organisms in the urine exceeding a threshold value for significance (ranges from 102 to 103 colony-forming unitsmL). Infections are localized to the bladder (cystitis), renal parenchyma (pyelonephritis) or prostate (acute or chronic bacterial prostatitis). Single UTI episodes are very common, especially in adult women where there is a 50-fold predominance compared with adult men. In addition, recurrent UTIs are also common, occurring in up to one-third of women after first-episode UTIs. Recurrences requiring intervention are usually defined as two or more episodes over 6 months or three or more episodes over 1 year (this definition applies only to young women with acute uncomplicated UTIs).A cornerstone of prevention of UTI recurrence has been the use of low-dose once-daily or post-coital antimicrobials; however, much interest has surrounded non-antimicrobial-based approaches undergoing investigation such as use of probiotics, vaccines, oligosaccharide inhibitors of bacterial adherence and colonization, and bacterial interference with immunoreactive extracts of Escherichia coli. Local (intravaginal) estrogen therapy has had mixed results to date.Cranberry products in a variety of formulations have also undergone extensive evaluation over several decades in the management of UTIs. At present, there is no evidence that cranberry can be used to treat UTIs. Hence, the focus has been on its use as a preventative strategy. Cranberry has been effective in vitro and in vivo in animals for the prevention of UTI. Cranberry appears to work by inhibiting the adhesion of type I and P-fimbriated uropathogens (e.g. uropathogenic E. coli) to the uroepithelium, thus impairing colonization and subsequent infection. The isolation of the component(s) of cranberry with this activity has been a daunting task, considering the hundreds of compounds found in the fruit and its juice derivatives. Reasonable evidence suggests that the anthocyanidinproanthocyanidin moieties are potent antiadhesion compounds. However, problems still exist with standardization of cranberry products, which makes it extremely difficult to compare products or extrapolate results. Unfortunately, most clinical trials have had design deficiencies and none have evaluated specific key cranberry-derived compounds considered likely to be active moieties (e.g. proanthocyanidins). In general, the preventive efficacy of cranberry has been variable and modest at best. Meta-analyses have established that recurrence rates over 1 year are reduced approximately 35 in young to middle-aged women. The efficacy of cranberry in other groups (i.e. elderly, paediatric patients, those with neurogenic bladder, those with chronic indwelling urinary catheters) is questionable. Withdrawal rates have been quite high (up to 55), suggesting that these products may not be acceptable over long periods. Adverse events include gastrointestinal intolerance, weight gain (due to the excessive calorie load) and drug-cranberry interactions (due to the inhibitory effect of flavonoids on cytochrome P450-mediated drug metabolism). The findings of the Cochrane Collaboration support the potential use of cranberry products in the prophylaxis of recurrent UTIs in young and middle-aged women. However, in light of the heterogeneity of clinical study designs and the lack of consensus regarding the dosage regimen and formulation to use, cranberry products cannot be recommended for the prophylaxis of recurrent UTIs at this time. © 2009 Adis Data Information BV. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :128&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-66149152188&amp;doi=10.2165%2f00003495-200969070-00002&amp;partnerID=40&amp;md5=d5df5093f20854aaa3e60bbd27b19754</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2165/00003495-200969070-00002</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>86</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">86</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gu, J.</style></author><author><style face="normal" font="default" size="100%">Liang, D.</style></author><author><style face="normal" font="default" size="100%">Pierzynski, J. A.</style></author><author><style face="normal" font="default" size="100%">Zheng, L.</style></author><author><style face="normal" font="default" size="100%">Ye, Y.</style></author><author><style face="normal" font="default" size="100%">Zhang, J.</style></author><author><style face="normal" font="default" size="100%">Ajani, J. A.</style></author><author><style face="normal" font="default" size="100%">Wu, X.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States&#xD;Department of Oncology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200092, China&#xD;Department of Pharmaceutical Sciences, Texas Southern University, Houston, TX 77004, United States&#xD;College of Life Sciences and Bioengineering, School of Science, Beijing Jiaotong University, Beijing, 100044, China&#xD;Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">D-mannose: A novel prognostic biomarker for patients with esophageal adenocarcinoma</style></title><secondary-title><style face="normal" font="default" size="100%">Carcinogenesis</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Carcinogenesis</style></full-title></periodical><pages><style face="normal" font="default" size="100%">162-167</style></pages><volume><style face="normal" font="default" size="100%">38</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Metabolomic profiling is a promising approach to identify new biomarkers for cancer prognosis. However, the role of circulating metabolites as prognostic indicators in esophageal adenocarcinoma (EAC) has not been well explored. In this study, we aimed to evaluate the prognostic value of three serum metabolites, d-mannose, l-proline (LP), and 3-hydroxybutyrate (BHBA), which were significantly different between EAC patients and controls, identified through a global and targeted metabolite profiling. We measured the levels of d-mannose, LP, and BHBA in pretreatment serum from 159 EAC patients, using liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) methods. A multivariable Cox model was used to estimate the hazard ratios (HRs) and 95% confidence intervals (95% CIs) for the association of these metabolites with recurrence and overall survival. We found that serum levels of d-mannose were significantly associated with recurrence and overall survival in EAC patients, whereas levels of LP and BHBA were not. Compared with patients with a low (first tertile) level of d-mannose, those with a high (second plus third tertiles) level had 49% reduced risk of recurrence (HR = 0.51; 95% CI: 0.29-0.91; P = 0.02), and 56% reduced risk of death (HR = 0.44; 95% CI: 0.25-0.77, P &lt; 0.01). The significant association of high d-mannose levels with better prognosis was consistent among patients with early-stage and advancedstage EAC. Our results suggest that serum level of d-mannose may be used as a novel prognostic biomarker for patients with EAC. Further studies in independent populations are warranted to confirm our findings. © The Author 2017.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85019689745&amp;doi=10.1093%2fcarcin%2fbgw207&amp;partnerID=40&amp;md5=5da20c9d8c80145da139d5d20cdd1c4c</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">bgw207</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/carcin/bgw207</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>205</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">205</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Grin, P. M.</style></author><author><style face="normal" font="default" size="100%">Kowalewska, P. M.</style></author><author><style face="normal" font="default" size="100%">Alhazzani, W.</style></author><author><style face="normal" font="default" size="100%">Fox-Robichaud, A. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, McMaster University, Hamilton, ON, Canada&#xD;Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada&#xD;Medical Sciences Graduate Program, McMaster University, Hamilton, ON, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lactobacillus for preventing recurrent urinary tract infections in women: Meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Canadian Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Canadian Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">6607-6614</style></pages><volume><style face="normal" font="default" size="100%">20</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">Meta-analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Introduction: Urinary tract infections (UTIs) are the most common infections affecting women, and often recur. Lactobacillus probiotics could potentially replace low dose, long term antibiotics as a safer prophylactic for recurrent UTI (rUTI). This systematic review and metaanalysis was performed to compile the results of existing randomized clinical trials (RCTs) to determine the efficacy of probiotic Lactobacillus species in preventing rUTI. Materials and methods: MEDLINE and EMBASE were searched from inception to July 2012 for RCTs using a Lactobacillus prophylactic against rUTI in premenopausal adult women. A random-effects model meta-analysis was performed using a pooled risk ratio, comparing incidence of rUTI in patients receiving Lactobacillus to control. Results: Data from 294 patients across five studies were included. There was no statistically significant difference in the risk for rUTI in patients receiving Lactobacillus versus controls, as indicated by the pooled risk ratio of 0.85 (95% confidence interval of 0.58-1.25, p = 0.41). A sensitivity analysis was performed, excluding studies using ineffective strains and studies testing for safety. Data from 127 patients in two studies were included. A statistically significant decrease in rUTI was found in patients given Lactobacillus, denoted by the pooled risk ratio of 0.51 (95% confidence interval 0.26-0.99, p = 0.05) with no statistical heterogeneity (I2 = 0%). Conclusion: Probiotic strains of Lactobacillus are safe and effective in preventing rUTI in adult women. However, more RCTs are required before a definitive recommendation can be made since the patient population contributing data to this meta-analysis was small. © The Canadian Journal Of Urology ™.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :48&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84880708778&amp;partnerID=40&amp;md5=f3b30ce76664e1181cd4a2164687599c</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>461</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">461</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Griebling, T. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Center on Aging, University of Kansas, Kansas City, KS, United States&#xD;Department of Urology, Mailstop 3016, University of Kansas, 3901 Rainbow Blvd., Kansas City, KS 66160, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urologic diseases in America project: Trends in resource use for urinary tract infections in men</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1288-1294</style></pages><volume><style face="normal" font="default" size="100%">173</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Economics, medical</style></keyword><keyword><style face="normal" font="default" size="100%">Epidemiology</style></keyword><keyword><style face="normal" font="default" size="100%">Health services</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">Purpose: Various types of urinary tract infection (UTI) occur in men. In this study we examined health care use trends, including epidemiological and economic factors, for UTI in men in the United States. Materials and Methods: The analytical methods used to generate these results have been described previously. Results: Approximately 20% of all UTIs occur in men. Between 1988 and 1994 the overall lifetime prevalence of UTI was estimated to be 13,689/100,000 men. Orchitis rates, particularly in older men, are generally higher than those of cystitis or pyelonephritis. Approximately 10% of all inpatient care of men with UTI is for orchitis (12 to 14/100,000 population). Rates of outpatient hospital and physician office care for male UTI have increased in the last decade. Rates for emergency room care for UTI in elderly men (85 to 94 years old) were almost twice those in men younger than 85 years. The adjusted mean health care expenditure for privately insured men with UTI was $5,544 in 1999 compared to $2,715 for men without UTI. Total annual health care expenditures for men and women with UTI were $5,544 and $5,407, respectively. Mean time lost from work was slightly higher for men. Based on composite data overall medical expenditures for men with UTI in the United States were estimated to be approximately $1.028 billion in 2000. Conclusions: Health care use and economic data on UTIs in men revealed a number of intriguing trends. These results raise various important questions for future research. Copyright © 2005 by American Urological Association.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :93&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-15044357706&amp;doi=10.1097%2f01.ju.0000155595.98120.8e&amp;partnerID=40&amp;md5=24bff6a45f3eb8ff33427c02e6d3263d</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/01.ju.0000155595.98120.8e</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>447</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">447</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Greenberg, J. A.</style></author><author><style face="normal" font="default" size="100%">Newmann, S. J.</style></author><author><style face="normal" font="default" size="100%">Howell, A. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Brigham and Women&apos;s Hospital, Boston, MA, United States&#xD;Harvard Medical School, Boston, MA, United States&#xD;Massachusetts General Hospital, Boston, MA, United States&#xD;Rutgers University, Marucci Center for Blueberry Cranberry Research, Chatsworth, NJ, United States&#xD;1153 Centre Street, Boston, MA 02130, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Consumption of sweetened dried cranberries versus unsweetened raisins for inhibition of uropathogenic Escherichia coli adhesion in human urine: A pilot study</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Alternative and Complementary Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Alternative and Complementary Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">875-878</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">5</style></number><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">Objectives: The aim of this study was to determine whether consumption of sweetened dried cranberries elicits urinary anti-adherence properties against Escherichia coli as previously demonstrated with cranberry juice and/or sweetened cranberry juice cocktail, compared to unsweetened raisins. Design: Uropathogenic E. coli isolates were obtained from five women with culture-confirmed urinary tract infections (UTIs). Four urine samples were collected from each subject. The first urine sample was collected before any study intervention. The second urine sample was collected 2-5 hours after consumption of one box (42.5 g) of raisins. The third urine sample was collected 5-7 days later. The final urine sample was collected 2-5 hours after consumption of approximately 42.5 g of dried cranberries. Materials and methods: E. coli isolates were incubated separately in each of the four urine samples collected from the five subjects. Bacteria were harvested from the urine and tested for the ability to prevent adhesion of P-fimbriated E. coli bacteria using a mannose-resistant hemagglutination assay with human red blood cells (A1, Rh+). Results: Of the urine samples collected after dried cranberry consumption, one demonstrated 50% antiadherence activity, two demonstrated 25% activity, and two did not show any increased activity. None of the control urine samples and none of the postraisin consumption samples demonstrated any inhibitory activity. Conclusions: Data from this pilot study on only five subjects suggest that consumption of a single serving of sweetened dried cranberries may elicit bacterial antiadhesion activity in human urine, whereas consumption of a single serving of raisins does not. Further studies are needed to verify the antiadhesion effect of sweetened dried cranberries. In addition, dose-response and pharmacokinetics of the active compounds in the dried cranberries need to be determined. If clinical research is positive, dried cranberries could potentially be a viable alternative to cranberry juice consumption for prevention of UTIs. © Mary Ann Liebert, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :42&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-28544435742&amp;doi=10.1089%2facm.2005.11.875&amp;partnerID=40&amp;md5=eac471f6ea92fa4ba5a723f2a51e2aeb</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1089/acm.2005.11.875</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>484</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">484</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Greenberg, J. A.</style></author><author><style face="normal" font="default" size="100%">Newman, S. J.</style></author><author><style face="normal" font="default" size="100%">Morgan, M. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dept. Obstet., Gynecol./Repro. Biol., Brigham and Women&apos;s Hospital, Harvard Medical School, Boston, MA, United States&#xD;Research Department, Amer. Coll. of Obstet. and Gynecol., Washington, DC, United States&#xD;1153 Centre Street, Boston, MA 02130, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberries and urinary-tract health: A knowledge assessment of American College of Obstetricians and Gynecologists Fellows [4]</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Alternative and Complementary Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Alternative and Complementary Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">603-605</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">4</style></number><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Letter</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-4444222501&amp;doi=10.1089%2f1075553041829299&amp;partnerID=40&amp;md5=82fc0641d35d4f134bdb68b877421759</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1089/1075553041829299</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>171</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">171</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Graziottin, A.</style></author><author><style face="normal" font="default" size="100%">Zanello, R. P.</style></author><author><style face="normal" font="default" size="100%">D&apos;Errico, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centro di Ginecologia e Sessuologia Medica, Ospedale San Raffaele Resnati, Milano, Italy&#xD;Dipartimento di Scienze Biomediche, Biotecnologiche e Traslazionali, Unità di Microbiologia e Virologia, Università degli Studi di Parma, Parma, Italy&#xD;Divisione di Ostetricia e Ginecologia, Ospedale Civile di Vigevano, Pavia, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent cystits and vaginitis: Role of Biofilms and persister cells. from pathophysiology to new therapeutic strategies</style></title><secondary-title><style face="normal" font="default" size="100%">Minerva Ginecologica</style></secondary-title><short-title><style face="normal" font="default" size="100%">Cistiti e vaginiti reddivanti: ruolo dei biofilm e delle persister cells. Dalla fisiopatologia a nuove strategie terapeutiche</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Minerva Ginecol</style></full-title><abbr-1><style face="normal" font="default" size="100%">Minerva ginecologica</style></abbr-1></periodical><pages><style face="normal" font="default" size="100%">497-512</style></pages><volume><style face="normal" font="default" size="100%">66</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Pelvis</style></keyword><keyword><style face="normal" font="default" size="100%">Vaginitis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Recurrent vaginitis and cystitis are a daily challenge for the woman and the physician. The recurrence worsens the symptoms&apos; severity, increases comorbidities, both pelvic (provoked vestibulodynia, bladder pain syndrome, levator ani hyperactivity, introitai dyspareunia, obstructive constipation, chronic pelvic pain) and cerebral (neuroinflammation and depression), increases health costs, worsens the quality of life. Antibiotics increase the risk of bacterial resistences and devastate the ecosystems: intestinal, vaginal and mucocutaneous. Pathogenic biofilms are the (still) neglected etiology of recurrences. Biofilms are structured communities of bacteria and yeasts, protected by a self-produced polymeric matrix adherent to a living or inert structures, such as medical devices. Biofims can be intra or extracellular. Pathogens live in a resting state in the deep biofilm layers as &quot;persister cells&quot;, resistant to antibiotics and host defences and ready to re-attack the host. The paper updates the evidence on biofilms and introduces new non-antibiotic strategies of preventing and modulating recurrent vaginitis and cystitis.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84946709298&amp;partnerID=40&amp;md5=ef9a7df2d8e0ddd6e239e7509936912c</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>498</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">498</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Grant, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Surgery, William Harvey Hospital Ashford, 7 Military Road, Rye, East Sussex TN31 7NX, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Warfarin and cranberry juice: An interaction?</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Heart Valve Disease</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Heart Valve Disease</style></full-title></periodical><pages><style face="normal" font="default" size="100%">25-26</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Herein, the case is reported of a persistently elevated INR consequent to an interaction between warfarin and cranberry juice in a patient with a prosthetic mitral valve. The elevation in INR was noted two weeks after the patient began to drink cranberry juice. Subsequent symptoms included postoperative bleeding problems. The bleeding was thought due to a biologically plausible interaction between the drug and the juice. It was concluded that patients taking warfarin should limit their cranberry juice intake. © Copyright by ICR Publishers 2004.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :51&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-4344651322&amp;partnerID=40&amp;md5=b793bc19c1f95f7462ea5a393bd079f5</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>241</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">241</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Grady, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, University of Washington School of Medicine, Seattle Children&apos;s Hospital, Seattle, WA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Editorial comment</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1587</style></pages><volume><style face="normal" font="default" size="100%">188</style></volume><number><style face="normal" font="default" size="100%">4 SUPPL.</style></number><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Note</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84866091814&amp;doi=10.1016%2fj.juro.2012.02.2596&amp;partnerID=40&amp;md5=5829f12976ba527b63949b5500c7edc5</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.juro.2012.02.2596</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>55</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">55</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Grady, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, University of California San Francisco, United States&#xD;University of California San Francisco, San Francisco VA Medical Center, Medicine, 550 16th St, Box 0558, San Francisco, CA 94158, United States&#xD;Deputy Edit., JAMA Internal Medicine, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Drinking More Water for Prevention of Recurrent Cystitis</style></title><secondary-title><style face="normal" font="default" size="100%">JAMA Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">JAMA Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1515</style></pages><volume><style face="normal" font="default" size="100%">178</style></volume><number><style face="normal" font="default" size="100%">11</style></number><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Note</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054152167&amp;doi=10.1001%2fjamainternmed.2018.4195&amp;partnerID=40&amp;md5=3f1418e179482c726d967891e63d486d</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jamainternmed.2018.4195</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>340</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">340</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gouin, S. G.</style></author><author><style face="normal" font="default" size="100%">Wellens, A.</style></author><author><style face="normal" font="default" size="100%">Bouckaert, J.</style></author><author><style face="normal" font="default" size="100%">Kovensky, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Chemistry, Institut de Chimie de Picardie, Université de Picardie Jules Verne, 33 Rue Saint Leu, 80039 Amiens Cedex, France&#xD;Department of Molecular and Cellular Interactions, VIB, Belgium&#xD;Structural Biology Brussels, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium</style></auth-address><titles><title><style face="normal" font="default" size="100%">Synthetic multimeric heptyl mannosides as potent antiadhesives of uropathogenic Escherichia coli</style></title><secondary-title><style face="normal" font="default" size="100%">ChemMedChem</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">ChemMedChem</style></full-title></periodical><pages><style face="normal" font="default" size="100%">749-755</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antiadhesive drugs</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Click chemistry</style></keyword><keyword><style face="normal" font="default" size="100%">E. coli</style></keyword><keyword><style face="normal" font="default" size="100%">Multivalency</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections caused by uropathogenic Escherichia coli presents a serious communal and nosocomial health problem initiated by bacterial adhesion to the bladder cells. E. coli expresses fimbriae with a mannose-binding adhesin, FimH, at the tip. Heptyl α-D-mannoside (HM) is a nanomolar inhibitor of this lectin, preventing adhesion of type 1-piliated E. coli and reducing bacteria levels in a murine cystitis model. Herein, we described the synthesis of multimeric heptyl-mannosides with valencies ranging from one to four by copper-catalyzed azide alkyne cycloaddition (CuAAC). Biological evaluation of the multivalent compounds revealed an increase in potency compared to HM. Inhibition of bladder cell binding highlighted a promising tetravalent derivative with inhibitory concentrations 6000-and 64-fold lower than mannose and HM respectively. © 2009 Wiley-VCH Verlag GmbH &amp; Co. KGaA.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :58&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-67651121957&amp;doi=10.1002%2fcmdc.200900034&amp;partnerID=40&amp;md5=a52de02af7b432d3a5fdc60d2da6f5b3</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/cmdc.200900034</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>106</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">106</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gouin, S. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">LUNAM Université, CEISAM, UMR CNRS 6230, 2, rue de la Houssinière, Nantes Cedex 3, 44322, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">Repurposing Escherichia coli antiadhesives in Crohn&apos;s disease</style></title><secondary-title><style face="normal" font="default" size="100%">Future Medicinal Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Future Medicinal Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1903-1906</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">16</style></number><keywords><keyword><style face="normal" font="default" size="100%">antiadhesives</style></keyword><keyword><style face="normal" font="default" size="100%">Crohn&apos;s disease</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">FimH antagonists</style></keyword><keyword><style face="normal" font="default" size="100%">Mannosides</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84989821165&amp;doi=10.4155%2ffmc-2016-0134&amp;partnerID=40&amp;md5=f7160fdb61b02804a5e0bec71a8b1242</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.4155/fmc-2016-0134</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>332</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">332</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gottesman, B. S.</style></author><author><style face="normal" font="default" size="100%">Carmeli, Y.</style></author><author><style face="normal" font="default" size="100%">Shitrit, P.</style></author><author><style face="normal" font="default" size="100%">Chowers, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Infectious Diseases Unit, Meir Medical Center, Kfar Saba, Israel&#xD;Sackler Medical School, Tel Aviv University, Israel&#xD;Division of Epidemiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel&#xD;Infectious Diseases Unit, Meir Medical Center, 59 Tsharnichovski St., Kfar Saba 44281, Israel</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">869-875</style></pages><volume><style face="normal" font="default" size="100%">49</style></volume><number><style face="normal" font="default" size="100%">6</style></number><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Background. Decreased antimicrobial susceptibility after increased antibiotic use is a known phenomenon. Restoration of susceptibility once antimicrobial use is decreased is not self-evident. Our objective was to evaluate, in a community setting, the impact of quinolone restriction on the antimicrobial resistance of E. coli urine isolates. Methods. We conducted a retrospective, quasi-experimental ecological study to assess the proportion of quinolone-susceptible E. coli urine isolates in the periods before, during, and after a nationwide restriction on ciprofloxacin use was implemented. We used an interrupted time interval analysis for outcome evaluation. Results. We found a significant decline in quinolone consumption, measured as defined daily doses (DDDs) per month, between the preintervention and intervention periods (point estimate, -1827.3 DDDs per month; 95% confidence interval [CI], -2248.8 to -1405.9 DDDs per month; P &lt; .001). This decline resulted in a significant decrease in E. coli nonsusceptibility to quinolones, from a mean of 12% in the preintervention period to a mean of 9% in the intervention period (odds ratio, 1.35; P = .014). The improved susceptibility pattern reversed immediately when quinolone consumption rose. Moreover, a highly significant inverse relationship was found between the level of quinolone use (regardless of intervention period) and the susceptibility of E. coli urine isolates to quinolone (odds ratio, 1.70; 95% CI, 1.26-2.28). During the months of highest quinolone use (8321 DDDs per month), the proportion of nonsusceptibility was 14%, whereas during the months of lowest quinolone use (4027 DDDs per month), the proportion of nonsusceptibility was 9%. An average decrease in resistance of 1.16% was observed for each decrease of 1000 DDDs. Conclusion. Reducing quinolone consumption can lead to an immediate increase in the susceptibility of E. coli urine isolates to quinolones. © 2009 by the Infectious Diseases Society of America. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :71&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-70049084153&amp;doi=10.1086%2f605530&amp;partnerID=40&amp;md5=0a1cdee14ef53d191e3372ba12970593</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/605530</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>198</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">198</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gordon, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Radiotherapy, School of Health and Social Work, University of Hertfordshire, College Lane, Hatfield, Hertfordshire AL10 9AB, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry in radiotherapy: Dispelling the myths. A review of the literature</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Radiotherapy in Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Radiotherapy in Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">98-105</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">radiation cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">radiotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Background Therapeutic radiographers routinely offer advice to patients regarding treatment-related side effects. Cranberry has long been used as a natural remedy for several health complaints and has more recently been suggested as having a role in the treatment and prophylaxis of urinary tract infection (UTI) and symptoms. Purpose The aim of this review was to investigate whether there is a place for cranberry as part of the management of radiation cystitis caused by radiotherapy treatment of pelvic cancers, in order to aid therapeutic radiographers in tailoring their advice regarding pelvic side effects. Materials and methods A structured search was carried out using PubMed, CINAHL, Scopus and Cochrane Library databases. A total of 25 articles were selected for review. Results Themes of mechanism of action of cranberry, composition of cranberry products, cranberry and UTI, use of cranberry in radiotherapy and further issues to consider were identified and explored. Conclusion A lack of high-quality data was identified in the literature reviewed and no firm evidence was found to support the continued recommendation of cranberry as part of management of radiation induced urinary tract side effects. Well-designed randomised controlled trials are required before further recommendations regarding the use of cranberry in radiotherapy are made. Copyright © 2013 Cambridge University Press.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84896473075&amp;doi=10.1017%2fS1460396913000320&amp;partnerID=40&amp;md5=9b7b57c264a9697a92c939f3b92f5ef1</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1017/S1460396913000320</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>254</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">254</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Goldman, R. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">BC Children&apos;s Hospital, Department of Pediatrics, Ambulatory Care Bldg, 4480 Oak St, Vancouver, BC V6H 3V4, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry juice for urinary tract infection in children</style></title><secondary-title><style face="normal" font="default" size="100%">Canadian Family Physician</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Canadian Family Physician</style></full-title></periodical><pages><style face="normal" font="default" size="100%">398-400</style></pages><volume><style face="normal" font="default" size="100%">58</style></volume><number><style face="normal" font="default" size="100%">4</style></number><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Question: Several children in my clinic are recovering from urinary tract infections (UTI). A mother of one of the children asked me if I recommended cranberry juice for children to prevent future episodes of UTI. She was given cranberry juice after she suffered from a UTI several months ago. Answer: Cranberry juice has been shown to be effective in preventing adhesion of bacteria such as Escherichia coli to the bladder epithelium. Current evidence supports the use of cranberry juice for prevention of UTI in adult women, but no such evidence exists at this time for the prevention of UTI in children. While cranberry juice is very safe for most children, its acidity reduces palatability among children. The dose of cranberry juice to prevent UTI in children has also yet to be determined.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :8&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84860273350&amp;partnerID=40&amp;md5=0c4f174cde78871e03d73cdb9a6bcadd</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>183</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">183</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Goetz, L. L.</style></author><author><style face="normal" font="default" size="100%">Klausner, A. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Veterans Affairs, Hunter Holmes McGuire VA Medical Center, 1201 Broad Rock Boulevard, Richmond, VA 23249, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Strategies for prevention of urinary tract infections in neurogenic bladder dysfunction</style></title><secondary-title><style face="normal" font="default" size="100%">Physical Medicine and Rehabilitation Clinics of North America</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Physical Medicine and Rehabilitation Clinics of North America</style></full-title></periodical><pages><style face="normal" font="default" size="100%">605-618</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Catheter-associated urinary tract infection (CAUTI)</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenic bladder</style></keyword><keyword><style face="normal" font="default" size="100%">Spinal cord injuries</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">In this article, the problem of urinary tract infections (UTIs) after spinal cord injury and disorders is defined, the relationship of bladder management to UTIs is discussed, and mechanical and medical strategies for UTI prevention in spinal cord injury and disorders are described. © 2014 .</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :9&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84904674363&amp;doi=10.1016%2fj.pmr.2014.04.002&amp;partnerID=40&amp;md5=c49c6f43f5df31997909397affeac602</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.pmr.2014.04.002</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>94</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">94</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Goetz, L. L.</style></author><author><style face="normal" font="default" size="100%">Droste, L.</style></author><author><style face="normal" font="default" size="100%">Klausner, A. P.</style></author><author><style face="normal" font="default" size="100%">Newman, D. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Physical Medicine and Rehabilitation, Virginia Commonwealth University, Richmond, VA 23284-0667, United States&#xD;Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, VA 23224, United States&#xD;Division of Urology, Department of Surgery, Virginia Commonwealth University, Richmond, VA 23298-0118, United States&#xD;Division of Urology, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Catheters used for intermittent catheterization</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Application of Urologic Catheters, Devices and Products</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">47-77</style></pages><keywords><keyword><style face="normal" font="default" size="100%">Catheter-associated urinary tract infection (CAUTI)</style></keyword><keyword><style face="normal" font="default" size="100%">Clean intermittent catheterization</style></keyword><keyword><style face="normal" font="default" size="100%">Intermittent catheterization</style></keyword><keyword><style face="normal" font="default" size="100%">Intermittent self-catheterization</style></keyword><keyword><style face="normal" font="default" size="100%">Urethral catheterization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Bladder emptying is controlled by the autonomic nervous system and micturition centers in the brain. Any disruption of the nerve pathways can lead to difficulty emptying the bladder (Nazarko. Br J Community Nurs 17(9):408-12, 2012 and Newman DK, Wein. Managing and treating urinary incontinence. 2Nd ed. Baltimore, MD: Health Professions Press; 2009). Intermittent catheterization is the insertion of a tube several times a day to drain the bladder. Re-catheterization occurs on a scheduled basis to mimic bladder function of filling and emptying. Intermittent catheterization is a preferred bladder management technique for persons with urinary retention, bladder obstruction, catheterizable channel following a urinary diversion, neurogenic lower urinary tract dysfunction from disorders that cause a loss of sensation requiring assisted bladder emptying. Individual sterile single-use catheters and catheter included kits, usually with self-contained collection bags may be used. Newer catheter materials, designed for ease and comfort, have helped to improve the quality of life of those who depend on intermittent catheterization for bladder management. Patient choice and ease of use are major considerations in the process of catheter selection. Other important factors include patient lifestyle, hand function, and caregiver abilities. Prevention of catheter-associated urinary tract infection requires an understanding of multiple factors related to neuroanatomy, bladder function, management approaches, and medical options. © Springer International Publishing AG 2018.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042513437&amp;doi=10.1007%2f978-3-319-14821-2_2&amp;partnerID=40&amp;md5=04ab08f84a92ad0fd135401bcfb95632</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/978-3-319-14821-2_2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>191</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">191</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Glover, M.</style></author><author><style face="normal" font="default" size="100%">Moreira, C. G.</style></author><author><style face="normal" font="default" size="100%">Sperandio, V.</style></author><author><style face="normal" font="default" size="100%">Zimmern, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">UT Southwestern Medical Center, Dallas, TX, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent urinary tract infections in healthy and nonpregnant women</style></title><secondary-title><style face="normal" font="default" size="100%">Urological Science</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Urological Science</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-8</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Intracellular bacterial communities</style></keyword><keyword><style face="normal" font="default" size="100%">Postmenopausal women</style></keyword><keyword><style face="normal" font="default" size="100%">Quiescent intracellular reservoir</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">Reinfection</style></keyword><keyword><style face="normal" font="default" size="100%">Risk factors for urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Recurrent urinary tract infections (RUTI) are prevalent and pose significant clinical challenges. Although the term RUTI has long been vaguely defined, a consensus definition has emerged in recent years. The exact etiology behind RUTI remains under debate, with valid arguments for both ascending reinfections as well as persistent infection inside the bladder. These persistent infections exist in the form of quiescent intracellular reservoirs in the mouse model and may represent a novel concept to explain UTI recurrence in humans. Manageable risk factors such as behavioral patterns alongside nonmanageable risk factors including genetic susceptibility are growing fields of investigation. Acute UTI have been studied through two model bacterial strains: Escherichia coli UTI89 and CFT073. However, the clinical relevance to RUTI of these two strains has not been firmly established. Current treatment strategies for RUTI are limited and remain dominated by antibiotic usage despite variable efficacy. The majority of studies in humans have focused on younger groups of women with little information available about the postmenopausal population despite a heightened risk of RUTI in this age group. © 2014.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :11&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84896543995&amp;doi=10.1016%2fj.urols.2013.11.007&amp;partnerID=40&amp;md5=f437789a20709f6c71f7deabe01c50f0</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.urols.2013.11.007</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>273</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">273</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gilbart, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Touch Briefings, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent uncomplicated urinary tract infections-the place of immuno-prophylaxis</style></title><secondary-title><style face="normal" font="default" size="100%">European Urological Review</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Urological Review</style></full-title></periodical><pages><style face="normal" font="default" size="100%">114-119</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Clinical evidence</style></keyword><keyword><style face="normal" font="default" size="100%">Guidelines</style></keyword><keyword><style face="normal" font="default" size="100%">Immunoprophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Immunostimulant treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Mode of action</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">Recurrent uncomplicated urinary tract infections (UTIs), especially cystitis in women, are very common and impose a substantial disease burden in populations worldwide. While acute episodes can be successfully treated with antibiotics, they often fail to preventrecurrence; pathogenic bacteria re-establish and symptoms reappear within a few months. The intractable nature of some UTIs and the alarming development of antibiotic resistance have stimulated efforts to identify non-antibiotic and more effective treatments that provide a better solution. Such alternatives are diverse and include probiotics, cranberry juice and hormonal therapies, but these have shown limited efficacy. Another approach, immuno-active prophylaxis with Uro-Vaxom®, has been more widely studied and its use is supported by an extensive body of clinical evidence. In this treatment, patients receive oral capsules containing an extract from multiple pathogenic Escherichia coli strains (Uro-Vaxom ®). Mechanism of action studies show that Uro-Vaxom effectively stimulates both innate and adaptive immune responses against UTI pathogens. In a series of large clinical trials and in regular clinical use, Uro-Vaxom has proven to be a highly effective and well-tolerated approach to treating recurrent UTIs. In a larger example of these trials, Uro-Vaxom reduced the frequency of UTI recurrences by 34%, the duration of recurrences by 49% and significantly reduced the consumption of antibiotics compared with placebo. These positive results led the European Association of Urology guidelines to recommend its use for prevention of recurrent UTI. ©Touch briefings 2011.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871828868&amp;partnerID=40&amp;md5=9b8ab3eaf28be53c95c7116b8eed1730</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>145</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">145</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Giessing, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universitätsklinik für Urologie, Heinrich Heine-Universitätsklinikum Düsseldorf, Moorenstraße 5, Düsseldorf, 40225, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urological follow-up and development of cancer after renal transplantation</style></title><secondary-title><style face="normal" font="default" size="100%">Urologe</style></secondary-title><short-title><style face="normal" font="default" size="100%">Urologische Nachsorge und Entwicklung von Malignomen nach Nierentransplantation</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Urologe</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1393-1401</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Immunosuppression</style></keyword><keyword><style face="normal" font="default" size="100%">Neoplasms</style></keyword><keyword><style face="normal" font="default" size="100%">Urethral stricture</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary bladder dysfunction</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: The number of renal transplant recipients is rising, as well as graft and recipient survival. The mainstay of urological follow-up is to ensure urine transport and voiding function; also, the diagnosis and treatment of urological malignancies following renal transplantats is growing in importance. As urological malignancies are one of the three most common tumors following renal transplantation (RT), meticulous and regular urological evaluation is a central part of follow-up care after RT. Recommendations: Urological evaluation following RT must ensure correct urine transport and voiding function. Transplant ureter strictures, relevant ureteral reflux and voiding dysfuntion (e.g., neurologic dysfunction, benign prostate hypeplasia) must be excluded or treated. Urinary tract infection (UTI), which can be life threatening in the immunosuppressed transplant recipient, must be diagnosed and treated consequently and for an adequate period of time. Prophylaxis of UTIs is indicated in patients with recurrent symptomatic UTI as well as in the initial 6 months following renal transplantation. Asymptomatic bacteriuria must not necessarily be treated. The incidence of urological malignancies like renal cell carcinoma, urothelial cancer of the bladder, and penile carcinoma is increased following RT, while the incidence of prostate and testis cancer is the same as in the nontransplant population. Surgical and nonsurgical treatment options do not differ from the normal population. Adaptation, cessation, or switching of the immunosuppressive regimen in case of urologic malignancy must be decided on the individual recipient basis. © 2015, Springer-Verlag Berlin Heidelberg.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84944065057&amp;doi=10.1007%2fs00120-015-3910-4&amp;partnerID=40&amp;md5=4dbcd7d1ff8f1179cb869635058265c1</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00120-015-3910-4</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>581</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">581</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gibson, G. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Microbiology Department, Institute of Food Research, Reading, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Dietary modulation of the human gut microflora using prebiotics</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Journal of Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S209-S212</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">SUPPL. 2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Fermentation</style></keyword><keyword><style face="normal" font="default" size="100%">Gut flora</style></keyword><keyword><style face="normal" font="default" size="100%">Prebiotics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year></dates><abstract><style face="normal" font="default" size="100%">The human colonic flora has both beneficial and pathogenic potentials with respect to host health. There is now much interest in manipulation of the microbiota composition in order to improve the potentially beneficial aspects. The prebiotic approach dictates that non-viable food components are specifically fermented in the colon by indigenous bacteria thought to be of positive value, e.g. bifidobacteria, lactobacilli. Any food ingredient that enters the large intestine is a candidate prebiotic. However, to be effective, selectivity of the fermentation is essential. Most current attention and success has been derived using non-digestible oligosaccharides. Types primarily being looked at include those which contain fructose, xylose, soya, galactose, glucose and mannose. In particular, fructose-containing oligosaccharides, which occur naturally in a variety of plants such as onion, asparagus, chicory, banana and artichoke, fulfil the prebiotic criteria. Various data have shown that fructo-oligosaccharides (FOS) are specifically fermented by bifidobacteria. During controlled feeding studies, ingestion of these prebiotics causes bifidobacteria to become numerically dominant in faeces. Recent studies have indicated that a FOS dose of 4 g/d is prebiotic. To exploit this concept more fully, there is a need for assessments of (a) improved determination of the gut microbiota composition and activity; (b) the use of molecular methodologies to assess accurately prebiotic identities and develop efficient bacterial probing strategies; (c) the prebiotic potential of raw and processed foods; and (d) the health consequences of dietary modulation.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :228&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Conference Paper</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031770742&amp;partnerID=40&amp;md5=7dd257c31bd6f0b5f2b219f5e261485c</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>286</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">286</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ghazarian, H.</style></author><author><style face="normal" font="default" size="100%">Idoni, B.</style></author><author><style face="normal" font="default" size="100%">Oppenheimer, S. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Biology and Center for Cancer and Developmental Biology, California State University Northridge, 18111 Nordhoff Street, Northridge, CA 91330-8303, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">A glycobiology review: Carbohydrates, lectins and implications in cancer therapeutics</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Histochemica</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Histochemica</style></full-title></periodical><pages><style face="normal" font="default" size="100%">236-247</style></pages><volume><style face="normal" font="default" size="100%">113</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cancer glycans</style></keyword><keyword><style face="normal" font="default" size="100%">Cancer therapeutics</style></keyword><keyword><style face="normal" font="default" size="100%">Carbohydrates</style></keyword><keyword><style face="normal" font="default" size="100%">Glycobiology review</style></keyword><keyword><style face="normal" font="default" size="100%">Lectins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">This review is intended for general readers who would like a basic foundation in carbohydrate structure and function, lectin biology, and the implications of glycobiology in human health and disease, particularly in cancer therapeutics. These topics are among the hundreds included in the field of glycobiology and are treated here because they form the cornerstone of glycobiology or the focus of many advances in this rapidly expanding field. © 2010 Elsevier GmbH.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :179&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79952008246&amp;doi=10.1016%2fj.acthis.2010.02.004&amp;partnerID=40&amp;md5=3fb20fd42580cf928ac067d98564d5f0</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.acthis.2010.02.004</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>560</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">560</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ghazanfar, S.</style></author><author><style face="normal" font="default" size="100%">Camire, M. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dept. of Food Science, Univ. of Maine, 5735 Hitchner Hall, Orono, ME 04469-5735, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Influence of health attitudes on the acceptability of cranberry juice</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Food Science</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Food Science</style></full-title></periodical><pages><style face="normal" font="default" size="100%">3497-3501</style></pages><volume><style face="normal" font="default" size="100%">67</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Consumer</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Hedonic</style></keyword><keyword><style face="normal" font="default" size="100%">Nutrition</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><abstract><style face="normal" font="default" size="100%">Although cranberry juice cocktail contains only 27 to 31% cranberry juice, higher concentrations of cranberry may appeal to health-conscious consumers. Fifty women rated blends containing 27, 34, 41, 54, and 100% cranberry juice for body, sweetness, tartness, and overall acceptability and completed the Multidimensional Health Locus of Control (MHLC) Scales questionnaire. One week later, subjects received information on health benefits of cranberries and re-evaluated samples labeled with the percentage cranberry juice. MHLC scores did not affect the ratings of the samples. Mean ratings for all attributes were not different between 27 and 34% juices. Hedonic ratings for tartness and overall acceptability of the 41% blend increased during the 2nd session.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036867365&amp;doi=10.1111%2fj.1365-2621.2002.tb09612.x&amp;partnerID=40&amp;md5=f5a11e5975f305556b7944ff600d5ca3</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1365-2621.2002.tb09612.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>318</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">318</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ghanghro, A. B.</style></author><author><style face="normal" font="default" size="100%">Laghari, A. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Biochemistry, University of Sindh, Jamshoro, Sindh, Pakistan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary Tract infection as a predictor of childhood malnutrition in southern Sindh, Pakistan</style></title><secondary-title><style face="normal" font="default" size="100%">Pakistan Journal of Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pakistan Journal of Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">819-821</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Iron deficiency anaemia</style></keyword><keyword><style face="normal" font="default" size="100%">Malnutrition</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><abstract><style face="normal" font="default" size="100%">A cross-sectional study to examine the association of urinary tract infection (UTI) with protein- energy malnutrition and microcytic hypochromic anemia (Iron deficiency anemia) was conducted among children in southern sindh Pakistan. A total of 150 children aged up to 5 years were studied. The data were collected using structured questionnaires, anthropometric measurements and laboratory analysis of blood and Urine samples. The results showed that 31.6% of the children were infected with Escherichia coli, while 56.5, 41.3 and 15.1% had significant underweight, stunting and wasting, respectively. Urinary tract infection with Escherichia coli was statistically identified as a strong predictor of significant wasting in this study population. © Asian Network for Scientific Information, 2010.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-78649558115&amp;doi=10.3923%2fpjn.2010.819.821&amp;partnerID=40&amp;md5=f585865f6d9816245df7626d3a440c2c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3923/pjn.2010.819.821</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>468</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">468</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gettman, M. T.</style></author><author><style face="normal" font="default" size="100%">Ogan, K.</style></author><author><style face="normal" font="default" size="100%">Brinkley, L. J.</style></author><author><style face="normal" font="default" size="100%">Adams-Huet, B.</style></author><author><style face="normal" font="default" size="100%">Pak, C. Y. C.</style></author><author><style face="normal" font="default" size="100%">Pearle, M. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Mayo Clinic, Rochester, MN, United States&#xD;Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, United States&#xD;Jane and Charles Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, TX, United States&#xD;Department of Urology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9110, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of cranberry juice consumption on urinary stone risk factors</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">590-594</style></pages><volume><style face="normal" font="default" size="100%">174</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Kidney calculi</style></keyword><keyword><style face="normal" font="default" size="100%">Oxalates</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">Purpose: We evaluated the effect of cranberry juice on urinary stone risk factors. Materials and Methods: A total of 12 normal subjects and 12 calcium oxalate stone formers underwent 2, 7-day phases of study in random order while on a controlled metabolic diet. Subjects ingested 1 l of cranberry juice (CBJ) daily in 1 phase and 1 l of deionized water in the other phase. On the last 2 days of each phase 2, 24-hour urine collections and blood samples were obtained for stone risk factors and serum chemistries. Results: No significant differences were found between normal subjects and stone formers in response to CBJ and, therefore, the groups were combined. CBJ significantly increased urinary calcium (from 154 to 177 mg per day, p =0.0008) and urinary oxalate (from 26.4 to 29.2 mg per day, p =0.04), thereby increasing urinary saturation of calcium oxalate by 18%. Urinary citrate was unchanged and urinary magnesium increased slightly. Urinary pH decreased (from 5.97 to 5.67, p =0.0005), and urinary ammonium, titratable acidity and net acid excretion increased during CBJ ingestion. Urinary uric acid decreased (from 544 to 442 mg per day, p &lt;0.0001) as did serum uric acid. Thus, the urinary saturation of brushite and monosodium urate was reduced by CBJ but the amount of undissociated uric acid increased. Conclusions: CBJ exerts a mixed effect on urinary stone forming propensity. It reduces urinary pH likely by providing an acid load and decreases urinary uric acid perhaps by retarding urate synthesis. Overall CBJ increases the risk of calcium oxalate and uric acid stone formation but decreases the risk of brushite stones. Copyright © 2005 by American Urological Association.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :66&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-22144439393&amp;doi=10.1097%2f01.ju.0000165168.68054.f8&amp;partnerID=40&amp;md5=c9f2f5aba86d13c32106198c13b51bc2</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/01.ju.0000165168.68054.f8</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>519</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">519</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Geissbühler, V.</style></author><author><style face="normal" font="default" size="100%">Eberhard, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Leitende Arztin Frauenklinik, Kantonsspital, CH-8501 Frauenfeld, Switzerland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Conservative treatment of urinary incontinence and other urinary tract dysfunction</style></title><secondary-title><style face="normal" font="default" size="100%">Therapeutische Umschau</style></secondary-title><short-title><style face="normal" font="default" size="100%">Konservative therapie von harninkontinenz und blasenbeschwerden der frau</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Therapeutische Umschau</style></full-title></periodical><pages><style face="normal" font="default" size="100%">268-274</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">5</style></number><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary incontinence and urogenital disorders are increasing. This is bothersome and impinges on the patient&apos;s quality of life. Early recognition, allowing early diagnosis, effective therapy as well as long-term prophylaxis are important. For diagnosis that quickly leads to a therapeutic decision, the anamnesis should specifically cover this area. Additionally, clinical examination, urinalysis including residual urine determination and cystoscopy for evaluating the bladder wall and a coughing test with a full bladder should be performed - all investigations easily done in the gynecologists&apos;s office. After diagnosis, treatment planning takes place. Urinary incontinence and urogenital complaints often have several pathologic causes. To improve success, various treatment possibilities should be optimally combined. Conservative therapy basics include: drinking and miction training, pelvic floor training including training aids and electrostimulation, pessaries, pharmaceutical therapies, estrogen as well as a thorough prophylaxis and treatment of infection. The primary treatment must be followed up with long-term prophylaxis. The most important requirements for a successful conservative therapy include knowing the various treatment basics, their uses, understanding and having the patience to follow through with an involved and time-intensive treatment plan. This work provides an overview of the various conservative treatments and their successful combinations.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037910272&amp;partnerID=40&amp;md5=ef47696ba09ae57c2125dbbdfb383e41</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>175</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">175</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Geerlings, S. E.</style></author><author><style face="normal" font="default" size="100%">Beerepoot, M. A. J.</style></author><author><style face="normal" font="default" size="100%">Prins, J. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division Infectious Diseases, Department of Internal Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevention of recurrent urinary tract infections in women. Antimicrobial and nonantimicrobial strategies</style></title><secondary-title><style face="normal" font="default" size="100%">Infectious Disease Clinics of North America</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infectious Disease Clinics of North America</style></full-title></periodical><pages><style face="normal" font="default" size="100%">135-147</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antimicrobial prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberries</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacilli</style></keyword><keyword><style face="normal" font="default" size="100%">Methenamine</style></keyword><keyword><style face="normal" font="default" size="100%">Non-antimicrobial strategies</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :23&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84895074747&amp;doi=10.1016%2fj.idc.2013.10.001&amp;partnerID=40&amp;md5=d2e72e9f4c018a33a40f3832bc4c5e53</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.idc.2013.10.001</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>193</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">193</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gardner, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The health properties of cranberry juice</style></title><secondary-title><style face="normal" font="default" size="100%">Nutrition Bulletin</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nutrition Bulletin</style></full-title></periodical><pages><style face="normal" font="default" size="100%">223-230</style></pages><volume><style face="normal" font="default" size="100%">39</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84900550273&amp;doi=10.1111%2fnbu.12093&amp;partnerID=40&amp;md5=487e5ea7f93711b3906f851cafbe2af7</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/nbu.12093</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>290</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">290</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Garat Barredo, J. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Unidad de Urología Pediátrica, Fundació Puigvert, Cartagena, 340, 08025 Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Treatment of pediatric urinary infections with North American red cranberry concentrated extract</style></title><secondary-title><style face="normal" font="default" size="100%">Acta Pediatrica Espanola</style></secondary-title><short-title><style face="normal" font="default" size="100%">Tratamiento de las infecciones urinarias en pediatría con extracto de arándano rojo americano</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Acta Pediatrica Espanola</style></full-title></periodical><pages><style face="normal" font="default" size="100%">117-120</style></pages><volume><style face="normal" font="default" size="100%">69</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Observational study</style></keyword><keyword><style face="normal" font="default" size="100%">Phytotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">Introduction: In our search for alternatives to antibiotic chemoprophylaxis to prevent pediatric urinary infections, we have started to use a concentrated extract of North American red cranberries containing 118 mg of proanthocyanidins, the before mentioned inhibit the adherence of P-fimbriated Escherichia coli to the urinary tract wall. Objectives: To observe the effectiveness and tolerance of a concentrated extract of cranberries in children with frequent urinary tract infections. Material and methods: We selected groups of patients with frequently recurrent urinary infections, with no malformative systemic pathologies and either neuropathic bladder, lithiasis or renal failure. The observational study was conducted over one year in 62 children from 5 to 17 years old. Results: The results were quite satisfactory: 100% prevention of acute pyelonephritis, and 92% absence of symptomatic infections. Conclusions: We have been able to confirm the high effectiveness of the product, the absence of adverse effects, an excellent acceptance by the parents and patients regarding a long-term treatment, and a very low rate of dropouts. Prospective double-blind randomized and placebo-controlled trials will be required in order to issue recommendations supported by a high degree of evidence.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79955703346&amp;partnerID=40&amp;md5=dd60ea5c8bc5afe358726faeae990f67</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>130</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">130</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ganyecz, M.</style></author><author><style face="normal" font="default" size="100%">Köves, B.</style></author><author><style face="normal" font="default" size="100%">Tenke, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Jahn Ferenc Dél-pesti Kórház, Urológia Osztály, Hungary&#xD;Jahn Ferenc South-pest Hospital, Department of Urology, Királyhágó tér 1. 2/10, Budapest, H-1126, Hungary</style></auth-address><titles><title><style face="normal" font="default" size="100%">Possibilites of modern, evidence based prevention of recurrent cystitis</style></title><secondary-title><style face="normal" font="default" size="100%">Lege Artis Medicinae</style></secondary-title><short-title><style face="normal" font="default" size="100%">Visszatéro hólyaghurut bizonyítékokon alapuló korszeru megelozési lehetoségei</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lege Artis Medicinae</style></full-title></periodical><pages><style face="normal" font="default" size="100%">101-106</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotic prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Disease prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Recurrent cystitis is a very common disease in women; every second women experiences at least one episode of acute cystitis during their lifetime, and in 20% of the cases it develops to recurrent cystitis. The disease also has a significant negative impact on quality of life. In 60% percent of the cases mild-severe depression can be shown, which can be reduced by 30-40% with the properly chosen prophylaxis. Therefore the up-to-date knowledge of the evidence based recommendations on disease management is mandatory to all clinicans dealing with this patient group. In case of a recurrent urinary tract infection treatment of the actual episode is not enough. Rather, emphasis has to be placed on appropriate prevention strategy. Alway non-antimicrobial methods has to be preferred as first choice, antibiotic prophylaxis should be considered only when the nonantimicrobials have been unsuccessful. In this review the authors summarise the evidence based management options of recurrent urinary tract infections in detail, based on the guideline recommendations of the European Association of Urology.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84990868205&amp;partnerID=40&amp;md5=65cdce683f82405c5d867c3c9e732135</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>269</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">269</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gallis, C.</style></author><author><style face="normal" font="default" size="100%">Di Stefano, M.</style></author><author><style face="normal" font="default" size="100%">Moutsatsou, P.</style></author><author><style face="normal" font="default" size="100%">Sarjala, T.</style></author><author><style face="normal" font="default" size="100%">Virtanen, V.</style></author><author><style face="normal" font="default" size="100%">Holmbom, B.</style></author><author><style face="normal" font="default" size="100%">Buhagiar, J. A.</style></author><author><style face="normal" font="default" size="100%">Katalanos, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Forest Research Institute, Thessaloniki, Greece&#xD;Journal L&apos;Erborista Tecniche Nuove, Milan, Italy&#xD;Department of Biological Chemistry, Medical School, University of Athens, Athens, Greece&#xD;Finnish Forest Research Institute, Parkano, Finland&#xD;Laboratory of Biotechnology, University of Oulu, Sotkamo, Finland&#xD;Process Chemistry Centre, Åbo Akademi University, Åbo, Finland&#xD;Department of Biology, Argotti Botanic Gardens, University of Malta, Msida, Malta&#xD;Department of Forests, Ministry of Agriculture, Natural Resources and Environment, Nicosia, Cyprus</style></auth-address><titles><title><style face="normal" font="default" size="100%">Forest products with health-promoting and medicinal properties</style></title><secondary-title><style face="normal" font="default" size="100%">Forests, Trees and Human Health</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">41-76</style></pages><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">Forests are a rich renewable source of health-promoting and -medicinal products. Not only the trees but also berries, nuts and mushrooms in forests contain a multitude of natural bioactive compounds which can be used in -health-promoting products and medicines. In addition to the main structural -components that trees contain, namely cellulose, hemicelluloses and lignin, -thousands of -bioactive -compounds have been identified. Forest products have always had a key role in -traditional medicine which continues to be of great importance, -especially in developing countries. In the industrialized countries, the pharmaceutical -industry is again increasingly looking at plant-derived natural drugs. Plant-derived compounds help to build a bridge between the traditional medical drugs in developing countries and the modern pharmaceuticals in the developed countries. Plant-derived bioactive compounds serve especially as -preventive agents helping to maintain health. © 2011 Springer Science+Business Media B.V.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84855648762&amp;doi=10.1007%2f978-90-481-9806-1_3&amp;partnerID=40&amp;md5=d082f0e99d7e9379a97289942f61ef61</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/978-90-481-9806-1_3</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>57</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">57</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fu, Z.</style></author><author><style face="normal" font="default" size="100%">Liska, D.</style></author><author><style face="normal" font="default" size="100%">Talan, D.</style></author><author><style face="normal" font="default" size="100%">Chung, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, United States&#xD;Nutrition Science and Biostatistics, Biofortis Research, Addison, IL, United States&#xD;University of California, Los Angeles School of Medicine, UCLA-Olive View Medical Center, Sylmar, CA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry reduces the risk of urinary tract infection recurrence in otherwise healthy women: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2282-2288</style></pages><volume><style face="normal" font="default" size="100%">147</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Meta-analysis</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidin</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Cranberry (Vaccinium spp.) has been advocated for treatment of urinary tract infection (UTI); however, its efficacy is controversial. Women have a 50% risk of UTI over their lifetime, and ;20-30% experience a subsequent UTI recurrence. Objective: We conducted this meta-analysis to assess the effect of cranberry on the risk of UTI recurrence in otherwise healthy women. Methods: Literature published before January 2011 was obtained from 2 published systematic reviews, and we conducted updated searches in EMBASE and MEDLINE (through July 2017). We included randomized controlled trials that were conducted in generally healthy nonpregnant women aged ≥18 y with a history of UTI, compared cranberry intervention to a placebo or control, and reported the outcome as the number of participants experiencing a UTI. Two researchers conducted abstract and full-text screenings, data extractions, and risk of bias assessments independently, and discrepancies were resolved by group consensus. Meta-analyses were performed by using Stata SE software (version 13). We employed a fixed-effect model using the Mantel-Haenszel method to estimate the summary risk if the heterogeneity was low to moderate (I2 &amp;lt; 50%). Otherwise, we applied a random-effects model using the DerSimonian- Laird method. Results: We identified 7 randomized controlled trials conducted in healthy women at risk of UTI (n = 1498 participants). Results of the meta-analysis showed that cranberry reduced the risk of UTI by 26% (pooled risk ratio: 0.74; 95% CI: 0.55, 0.98; I2 = 54%). Risk of bias indicated that 2 studies had high loss to follow-up or selective outcome reporting. Overall, the studies were relatively small, with only 2 having &amp;gt; 300 participants. Conclusion: These results suggest that cranberry may be effective in preventing UTI recurrence in generally healthy women; however, larger high-quality studies are needed to confirm these findings. © 2017 American Society for Nutrition.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85036526221&amp;doi=10.3945%2fjn.117.254961&amp;partnerID=40&amp;md5=b50c85be2ff72dede4f12cd3e2e44918</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3945/jn.117.254961</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>614</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">614</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Friedman, S. A.</style></author><author><style face="normal" font="default" size="100%">Gladstone, J. L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The effects of hydration and bladder incubation time on urine colony counts</style></title><secondary-title><style face="normal" font="default" size="100%">The Journal of urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">The Journal of urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">428-432</style></pages><volume><style face="normal" font="default" size="100%">105</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">1971</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :6&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0015024876&amp;doi=10.1016%2fS0022-5347%2817%2961542-8&amp;partnerID=40&amp;md5=cab3041f8e0fc915122086c732cd5bfc</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0022-5347(17)61542-8</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>439</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">439</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">French, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Family Practice, College of Human Medicine, Michigan State University, East Lansing, MI, United States&#xD;B101 Clinical Center, College of Human Medicine, Michigan State University, East Lansing, MI 48824, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infection in women</style></title><secondary-title><style face="normal" font="default" size="100%">Advanced Studies in Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Advanced Studies in Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">24-29</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">PURPOSE: To review the epidemiology, diagnosis, and treatment of urinary tract infection (UTI) in women. EPIDEMIOLOGY: UTI is the most commonly diagnosed bacterial infection in women. Uncomplicated cystitis rarely leads to major morbidity or mortality, but economic costs and impact on quality of life are considerable. Populations at increased risk of complications include older women, pregnant women, and women who have diabetes, are immunocompromised, or have anatomic or functional disorders of the urinary tract. REVIEW SUMMARY: A presumptive diagnosis of uncomplicated UTI can be made based on history alone, or with limited diagnostic testing such as dipstick urinalysis. Culture should be obtained if the patient has risk factors for complicated disease, presumed treatment failure, or frequent recurrences. A 3-day course of trimethoprim-sulfamethoxazole has been recommended as the preferred initial treatment for uncomplicated UTI as long as resistance to the drug remains sufficiently low. Other options for first-line treatment include ofloxacin, nitrofurantoin macrocrystals, and cephalexin. Women with frequent recurrences may use continuous prophylaxis, postcoital prophylaxis, or self-treatment of recurrent episodes. Cranberry juice or pills reduce recurrences. In postmenopausal women intravaginal estrogen can reduce recurrences. TYPE OF AVAILABLE EVIDENCE: Meta-analyses, controlled trials, cohort studies, case-control studies, and nationally recognized and foreign treatment guidelines. GRADE OF AVAILABLE EVIDENCE: Fair to good. CONCLUSION: Diagnosis of UTI based on suggestive history alone is safe but leads to over-treatment. In regard to treatment, there is concern about emerging antibiotic resistance. Future research should include head-to-head trials of inexpensive generic antibiotics for the treatment of UTIs.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-32344443881&amp;partnerID=40&amp;md5=7035caf29d64c18a7027438ad3f68bd6</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>363</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">363</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Frank, U.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institut für Umweltmedizin und Krankenhaushygiene, Breisacher Str. 115b, 79106 Freiburg im Breisgau, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections: Plant antibiotics for the prevention of urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Deutsche Apotheker Zeitung</style></secondary-title><short-title><style face="normal" font="default" size="100%">Harnwegsinfektionen: Pflanzliche antibiotika zur prophylaxe von harnwegsinfekten</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Deutsche Apotheker Zeitung</style></full-title></periodical><pages><style face="normal" font="default" size="100%">60-61</style></pages><volume><style face="normal" font="default" size="100%">148</style></volume><number><style face="normal" font="default" size="100%">33</style></number><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Letter</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-53549121176&amp;partnerID=40&amp;md5=fe0b3146ae7a8298b31f0e0718138f7a</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>573</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">573</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Foxman, B.</style></author><author><style face="normal" font="default" size="100%">Gillespie, B.</style></author><author><style face="normal" font="default" size="100%">Koopman, J.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Palin, K.</style></author><author><style face="normal" font="default" size="100%">Tallman, P.</style></author><author><style face="normal" font="default" size="100%">Marsh, J. V.</style></author><author><style face="normal" font="default" size="100%">Spear, S.</style></author><author><style face="normal" font="default" size="100%">Sobel, J. D.</style></author><author><style face="normal" font="default" size="100%">Marty, M. J.</style></author><author><style face="normal" font="default" size="100%">Marrs, C. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Epidemiology, Univ. of Michigan Sch. of Pub. Hlth., Ann Arbor, MI, United States&#xD;Ctr. for Stat. Consult. and Research, University of Michigan, Ann Arbor, MI, United States&#xD;Department of Biology, Bates College, Lewiston, ME, United States&#xD;Department of Pediatrics, University of Wisconsin, Madison, WI, United States&#xD;Division of Infectious Diseases, Wayne State University, Detroit, MI, United States&#xD;Department of Epidemiology, 109 Observatory Street, Ann Arbor, MI 48109-2029, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Risk factors for second urinary tract infection among college women</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Epidemiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Epidemiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1194-1205</style></pages><volume><style face="normal" font="default" size="100%">151</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Risk factors</style></keyword><keyword><style face="normal" font="default" size="100%">Sex behavior</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">Women</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2000</style></year></dates><abstract><style face="normal" font="default" size="100%">To better understand the etiology of recurrent urinary tract infection (UTI), the authors followed a cohort of 285 female college students with first UTI for 6 months or until second UTI. A first UTI due to Escherichia coli was followed by a second UTI three times more often than was a non-E, coli first UTI (24 vs. 8%; p = 0.02). In a logistic regression analysis limited to the 224 women from the University of Michigan Health Service and the University of Texas at Austin Health Service from September 1992 to December 1994, with a first UTI due to E. coli, vaginal intercourse increased the risk of a second UTI with both a different (odds ratio (OR) = 1.60, 95% confidence interval (CI): 1.19, 2.15) and the same (OR = 1.37, 95% CI: 0.91, 2.07) uropathogen, as did using a diaphragm, cervical cap, and/or spermicide (same uropathogen: OR = 1.53, 95% CI: 0.95, 2.47; different uropathogen: OR = 1.77, 95% Ch 1.22, 2.58). Condom use decreased the risk of a second UTI caused by a different uropathogen (OR = 0.68, 95% CI 0.48, 0.99) but had no effect on a second UTI caused by the same E. coli (OR = 0.99; 95% CI: 0.66, 1.50). Type or duration of treatment was not associated with a second UTI. Although the risk of second UTI is strongly influenced by sexual behavior, women with a first UTI caused by E. coli are more likely than are those with a non-E, coli first UTI to have a second UTI within 6 months.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :179&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-17444443238&amp;doi=10.1093%2foxfordjournals.aje.a010170&amp;partnerID=40&amp;md5=f855e054ef794bfda314290473ff68c5</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/oxfordjournals.aje.a010170</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>282</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">282</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Foxman, B.</style></author><author><style face="normal" font="default" size="100%">Elgersma, K.</style></author><author><style face="normal" font="default" size="100%">Wen, A.</style></author><author><style face="normal" font="default" size="100%">Buxton, M.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Barbosa-Cesnik, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Molecular and Clinical Epidemiology of Infectious Diseases, Department of Epidemiology, University of Michigan School of Public Health, 1415 Washington Heights, Ann Arbor, MI 48109-2029, United States&#xD;Department of Ecology and Evolutionary Biology, University of Michigan, United States&#xD;Department of Environmental Health Sciences, University of Michigan School of Public Health, Ann Arbor, MI, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reply to Eells et al</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1394-1395</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">11</style></number><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Letter</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79957494470&amp;doi=10.1093%2fcid%2fcir194&amp;partnerID=40&amp;md5=442dc16f4d3726fdabb955b99d4c33e6</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/cid/cir194</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>532</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">532</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Foxman, B.</style></author><author><style face="normal" font="default" size="100%">Brown, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Epidemiology, Ctr. Molec./Clin. Epidemiol. I. D., Univ. of Michigan Sch. of Pub. Hlth., 109 Observatory Street, Ann Arbor, MI 48109-2029, United States&#xD;Department of Internal Medicine, Wayne State University, School of Medicine, 3990 John R, Detroit, MI 48201, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Epidemiology of urinary tract infections: Transmission and risk factors, incidence, and costs</style></title><secondary-title><style face="normal" font="default" size="100%">Infectious Disease Clinics of North America</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infectious Disease Clinics of North America</style></full-title></periodical><pages><style face="normal" font="default" size="100%">227-241</style></pages><volume><style face="normal" font="default" size="100%">17</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">Uropathogenic E coli have special features that allow them to take advantage of the bladder environment. There UPEC can grow to substantial numbers in pure culture that are shed frequently into the environment and have a high probability of transmission to other hosts. A better understanding of the transmission system and the host and bacterial factors influencing transmission is essential for the identification of effective prevention strategies. Although the risk of severe morbidity among otherwise healthy populations is low, the incidence is high. Further, the potential impact of antibiotic treatment on the emergence of increasingly antibiotic-resistant UPEC (the resistant mechanisms that may be transmitted to other bowel inhabitants) is high. The benefits of successfully preventing UTI are substantial.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :250&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038270674&amp;doi=10.1016%2fS0891-5520%2803%2900005-9&amp;partnerID=40&amp;md5=8a84c7979bc2bef9ba69741918039f0f</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0891-5520(03)00005-9</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>570</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">570</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Foxman, B.</style></author><author><style face="normal" font="default" size="100%">Barlow, R.</style></author><author><style face="normal" font="default" size="100%">D&apos;Arcy, H.</style></author><author><style face="normal" font="default" size="100%">Gillespie, B.</style></author><author><style face="normal" font="default" size="100%">Sobel, J. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Epidemiology, University of Michigan, School of Public Health, Ann Arbor, MI, United States&#xD;Center for Statistical Consultation and Research, University of Michigan, Ann Arbor, MI, United States&#xD;Division of Infectious Diseases, Wayne State University, Detroit, MI, United States&#xD;Department of Epidemiology, 109 Observatory Street, Ann Arbor, MI 48109-2029, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infection: Self-reported incidence and associated costs</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Epidemiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Epidemiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">509-515</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">8</style></number><keywords><keyword><style face="normal" font="default" size="100%">Costs</style></keyword><keyword><style face="normal" font="default" size="100%">Incidence</style></keyword><keyword><style face="normal" font="default" size="100%">Risk</style></keyword><keyword><style face="normal" font="default" size="100%">Survey</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary Tract Infection</style></keyword><keyword><style face="normal" font="default" size="100%">Women</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2000</style></year></dates><abstract><style face="normal" font="default" size="100%">PURPOSE: To estimate the annual incidence, cumulative probability of presumed urinary tract infection (UTI) by age, and the social costs. METHODS: Analysis of a random digit dialing survey of 2000 women in the United States. RESULTS: 10.8 percent (95% CI: 9.4, 12.1%) of women aged 18 and older reported at least one presumed UTI during the past 12 months, with the majority of the cases occurring among women with a history of two or more UTI episodes in their life. We estimate that by age 24, one-third of women will have at least one physician-diagnosed UTI that was treated with prescription medication. Overall, an estimated 11.3 million women in the United States had at least one presumed UTI treated with antibiotics in 1995. We estimate the annual cost of UTI cases with prescriptions to be $1.6 billion in 1995. If the costs occurring after 1995 are discounted at 5% annually, the total cost over 20 years has a present value of $25.5 billion. CONCLUSION: If a vaccine were developed that would prevent either initial or recurrent UTI the net benefits to society would be substantial, even at a developmental cost of one billion dollars. (C) 2000 Elsevier Science Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :473&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033665053&amp;doi=10.1016%2fS1047-2797%2800%2900072-7&amp;partnerID=40&amp;md5=cbe65c64a5be25176f81bab1eb603b7d</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S1047-2797(00)00072-7</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>601</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">601</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Foxman, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Epidemiology, School of Public Health, University of Michigan, 109 Observatory Street, Ann Arbor, MI 48103, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurring urinary tract infection: Incidence and risk factors</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Public Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">American Journal of Public Health</style></full-title></periodical><pages><style face="normal" font="default" size="100%">331-333</style></pages><volume><style face="normal" font="default" size="100%">80</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">1990</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infection (UTI) is a common infection among young women, with a high recurrence rate. This study documents the six-month incidence of second UTI among a cohort of women with one initial UTI and the factors associated with recurrence. Among the cohort of 113 women, 30 (26.6 percent) experienced at least one culture-confirmed recurrence within the six months following initial infection. The presence of hematuria and urgency as symptoms of initial infection were the strongest predictors of second infection. Behavioral factors associated with initial infection (frequency of sexual intercourse, diaphragm use, and voiding after sexual intercourse) did not distinguish between women who would and would not experience a second UTI during the six-month follow-up period.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :226&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025100976&amp;doi=10.2105%2fAJPH.80.3.331&amp;partnerID=40&amp;md5=6441d0ed74bc01f91a8ce758bc03b67d</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2105/AJPH.80.3.331</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>574</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">574</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Foo, L. Y.</style></author><author><style face="normal" font="default" size="100%">Lu, Y.</style></author><author><style face="normal" font="default" size="100%">Howell, A. B.</style></author><author><style face="normal" font="default" size="100%">Vorsa, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Industrial Research, P.O. Box 31-310, Lower Hutt, New Zealand&#xD;Blueberry Cranberry Research Center, Rutgers University, Chatsworth, NJ 08019, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">The structure of cranberry proanthocyanidins which inhibit adherence of uropathogenic P-fimbriated Escherichia coli in vitro</style></title><secondary-title><style face="normal" font="default" size="100%">Phytochemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Phytochemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">173-181</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">A-type</style></keyword><keyword><style face="normal" font="default" size="100%">Adherence inhibitors</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Ericaceae</style></keyword><keyword><style face="normal" font="default" size="100%">ES-MS</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">MALDI-TOF</style></keyword><keyword><style face="normal" font="default" size="100%">Phloroglucinol adducts</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidin</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2000</style></year></dates><abstract><style face="normal" font="default" size="100%">Ethyl acetate extracts of Sephadex LH20-purified proanthocyanidins of American cranberry (Vaccinium macrocarpon Ait.) exhibited potent biological activity by inhibiting adherence of uropathogenic isolates of P-fimbriated Escherichia coli bacteria to cellular surfaces containing α-Gal(1 → 4)β- Gal receptor sequences similar to those on epithelial cells in the urinary tract. The chemical structures of the proanthocyanidins were determined by 13C NMR, electrospray mass spectrometry, matrix-assisted laser absorption time-of-flight mass spectrometry and by acid catalyzed degradation with phloroglucinol. The proanthocyanidin molecules consisted predominantly of epicatechin units with mainly DP of 4 and 5 containing at least one A-type linkage. The procyanidin A2 was the most common terminating unit occurring about four times as frequently as the epicatechin monomer. (C) 2000 Elsevier Science Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :311&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0001585772&amp;doi=10.1016%2fS0031-9422%2899%2900573-7&amp;partnerID=40&amp;md5=dcef0718ed91093ba68470c939f4ca8a</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0031-9422(99)00573-7</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>572</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">572</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Foo, L. Y.</style></author><author><style face="normal" font="default" size="100%">Lu, Y.</style></author><author><style face="normal" font="default" size="100%">Howell, A. B.</style></author><author><style face="normal" font="default" size="100%">Vorsa, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Industrial Research, Gracefield Research Center, PO Box 31-310, Lower Hutt, New Zealand&#xD;Philip E. Marucci Center for Blueberry and Cranberry Research, Rutgers University, Chatsworth, NJ 08019, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">A-type proanthocyanidin trimers from cranberry that inhibit adherence of uropathogenic P-fimbriated Escherichia coli</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Natural Products</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Natural Products</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1225-1228</style></pages><volume><style face="normal" font="default" size="100%">63</style></volume><number><style face="normal" font="default" size="100%">9</style></number><dates><year><style face="normal" font="default" size="100%">2000</style></year></dates><abstract><style face="normal" font="default" size="100%">Three proanthocyanidin trimers possessing A-type interflavanoid linkages, epicatechin-(4β→6)-epicatechin-(4β→8, 2β→O→7)-epicatechin (4), epicatechin-(4β→8, 2β→O→7)-epicatechin-(4β→8)-epicatechin (5), and epicatechin-(4β→8)-epicatechin-(4β→8, 2β→O→7)-epicatechin (6), were isolated from the ripe fruits of Vaccinium macrocarpon (cranberry) and prevented adherence of P-fimbriated Escherichia coli isolates from the urinary tract to cellular surfaces containing α-Gal(1→4)β-Gal receptor sequences similar to those on uroepithelial cells. The structure of 4 was elucidated by a combination of spectroscopic methods and acid-catalyzed degradation with phloroglucinol. Also isolated were the weakly active epicatechin-(4β→8, 2β→O→7)-epicatechin (procyanidin A2) (3) and the inactive monomer epicatechin (1) and the inactive dimer epicatechin-(4β→8)-epicatechin (procyanidin B2) (2).</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :323&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033802087&amp;doi=10.1021%2fnp000128u&amp;partnerID=40&amp;md5=91381195383c38fbc64b70f9acdfcbf6</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/np000128u</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>481</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">481</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Finer, G.</style></author><author><style face="normal" font="default" size="100%">Landau, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, Soroka University Medical Centre, Ben-Gurion University of the Negev, Beer-Sheva, Israel&#xD;Department of Paediatrics, Soroka University Medical Centre, PO Box 151, Beer-Sheva, 84101 I., Israel</style></auth-address><titles><title><style face="normal" font="default" size="100%">Pathogenesis of urinary tract infections with normal female anatomy</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lancet Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">631-635</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">10</style></number><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Recurrent urinary tract infections (UTIs) are common among girls and young women who are healthy and have anatomically normal urinary tracts. These infections are a main source of morbidity and health-care costs in this population. The interaction between specific infecting bacteria and urinary tract epithelium characteristics underlies the pathogenesis of this disease. Several pathogen-related factors predispose people to recurrent UTI, including periurethral bacterial colonisation and Escherichia coli virulence. Host behavioural risk factors include voiding dysfunction, high intercourse frequency, and oral contraceptive and spermicide use. The role of vesicoureteral reflux in recurrent childhood UTI is probably overestimated in the medical literature and is important only in a small group of children with high-grade reflux. Family pedigree analysis suggests a familial genetic predisposition for UTI among young females. Animal models show the multigenic nature of recurrent UTI. Putative candidate genes for the disease include ABH blood groups, interleukin-8 receptor (CXCR1), the human leucocyte antigen locus, toll-like receptors, tumour necrosis factor, and Tamm-Horsfall protein.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :72&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-4644226097&amp;doi=10.1016%2fS1473-3099%2804%2901147-8&amp;partnerID=40&amp;md5=456b2eb7166ad0335c36a0a85e9f7271</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S1473-3099(04)01147-8</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>449</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">449</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Finch, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Royal Hospital for Neuro-disability, London, United Kingdom&#xD;Royal Hospital for Neurodisability, West Hill, London SW15 3SW, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nutrition and hydration for the vegetative state and minimally conscious state patient</style></title><secondary-title><style face="normal" font="default" size="100%">Neuropsychological Rehabilitation</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Neuropsychological Rehabilitation</style></full-title></periodical><pages><style face="normal" font="default" size="100%">537-547</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">3-4</style></number><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">This paper presents nutritional issues particular to patients in the vegetative state (VS) or minimally conscious state (MCS). It assumes that such patients would be tube fed and it examines suitable ways of assessing and monitoring their nutrition. It covers problems frequently encountered such as undernourishment, high fluid requirements, bowel management, and vomiting. It also looks at the practicalities of long-term tube feeding. Once medical stability has been achieved, feeding these patients is almost always successful with the patient&apos;s body weight restored to being within normal limits. © 2005 Psychology Press Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Conference Paper</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-24344502309&amp;doi=10.1080%2f09602010443000542&amp;partnerID=40&amp;md5=a8bd1ac33b12f64cc970d253f72d1757</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/09602010443000542</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>518</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">518</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fihn, S. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">NW Hlth. Serv. Res./Devmt. Ctr. E., VA Puget Sound Health Care System, University of Washington, Seattle, WA, United States&#xD;NW Hlth. Serv. Res./Devmt. Ctr. E., VA Puget Sound Health Care System, 1660 S. Columbian Way, Seattle, WA 98108, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Acute uncomplicated urinary tract infection in women</style></title><secondary-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">259-266</style></pages><volume><style face="normal" font="default" size="100%">349</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :205&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038825532&amp;doi=10.1056%2fNEJMcp030027&amp;partnerID=40&amp;md5=b435bcff9afd167577d899fb81063a5b</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1056/NEJMcp030027</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>151</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">151</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ferreira-Pêgo, C.</style></author><author><style face="normal" font="default" size="100%">Guelinckx, I.</style></author><author><style face="normal" font="default" size="100%">Moreno, L. A.</style></author><author><style face="normal" font="default" size="100%">Kavouras, S. A.</style></author><author><style face="normal" font="default" size="100%">Gandy, J.</style></author><author><style face="normal" font="default" size="100%">Martinez, H.</style></author><author><style face="normal" font="default" size="100%">Bardosono, S.</style></author><author><style face="normal" font="default" size="100%">Abdollahi, M.</style></author><author><style face="normal" font="default" size="100%">Nasseri, E.</style></author><author><style face="normal" font="default" size="100%">Jarosz, A.</style></author><author><style face="normal" font="default" size="100%">Babio, N.</style></author><author><style face="normal" font="default" size="100%">Salas-Salvadó, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Human Nutrition Unit, Biochemistry and Biotechnology Department, Hospital Universitari de Sant Joan de Reus, Institut d’Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, C/Sant Llorenç, 21, Reus, 43201, Spain&#xD;Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERobn), Institute of Health Carlos III, Madrid, Spain&#xD;Department of Hydration and Health, Danone Nutricia Research, Palaiseau, France&#xD;Growth, Exercise, NUtrition and Development (GENUD) Research Group, Universidad de Zaragoza, Saragossa, Spain&#xD;Department of Health, Human Performance and Recreation, University of Arkansas, Fayetteville, AR, United States&#xD;British Dietetic Association, Birmingham, United Kingdom&#xD;School of Life and Medical Services, University of Hertfordshire, Hatfield, United Kingdom&#xD;RAND Corporation, Santa Monica, CA, United States&#xD;Hospital Infantil de México Federico Gómez, Mexico City, Mexico&#xD;Department of Nutrition, University of Indonesia, Jakarta, Indonesia&#xD;Department of Nutrition Research, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran&#xD;National Food and Nutrition Institute, Warsaw, Poland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Total fluid intake and its determinants: cross-sectional surveys among adults in 13 countries worldwide</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">35-43</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Adult population</style></keyword><keyword><style face="normal" font="default" size="100%">Beverages</style></keyword><keyword><style face="normal" font="default" size="100%">EFSA adequate intake</style></keyword><keyword><style face="normal" font="default" size="100%">Fluid intake</style></keyword><keyword><style face="normal" font="default" size="100%">Liq.In7</style></keyword><keyword><style face="normal" font="default" size="100%">Water</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Purpose: To evaluate the total fluid intake from drinking water and beverages in adult populations from different countries and assess the percentage of individuals complying with the European Food Safety Agency (EFSA) adequate intake (AI) of water from fluids. Methods: A total of 16,276 adults (7580 men and 8696 women) aged between 18 and 70 years (mean age 39.8 years) were randomly recruited from 13 different countries from three continents. Information about the total daily fluid intake (sum of drinking water and beverages) was collected using a 24-h fluid-specific record over seven consecutive days. Results: Important differences in total fluid intake between countries were found; however, few differences between men and women were reported in most of the countries. Less than 50 % of the women and approximately 60 % of the men do not comply with the EFSA AI of water from fluids. Women were more than twice as likely as men to meet these AI (OR 2.15; 95 % CI 2.02–2.29). The odds of meeting the AI of water from fluids were lower in individuals over 50 years (OR 0.88; 95 % CI 0.80–0.96). Nine percent of the total population consumed less than half of the AI, 40.5 % between 50 and 100 %, and 50.5 % more than the AI. Conclusions: There were considerable differences in total fluid intake between countries but not between genders. Only 40 % of men and 60 % of women comply with the EFSA AI of water from fluids. Men and elderly individuals had an increased risk of not complying with this reference value. © 2015, The Author(s).</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :35&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84931573964&amp;doi=10.1007%2fs00394-015-0943-9&amp;partnerID=40&amp;md5=9d501d10af90751888bf581a4edd9b93</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00394-015-0943-9</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>161</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">161</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernández-Puentes, V.</style></author><author><style face="normal" font="default" size="100%">Uberos, J.</style></author><author><style face="normal" font="default" size="100%">Rodríguez-Belmonte, R.</style></author><author><style face="normal" font="default" size="100%">Nogueras-Ocaña, M.</style></author><author><style face="normal" font="default" size="100%">Blanca-Jover, E.</style></author><author><style face="normal" font="default" size="100%">Narbona-López, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Servicio de Pediatría, Hospital Universitario San Cecilio, Granada, Spain&#xD;Servicio de Urología, Hospital Universitario San Cecilio, Granada, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy and safety profile of cranberry in infants and children with recurrent urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">Anales de Pediatria</style></secondary-title><short-title><style face="normal" font="default" size="100%">Eficacia y perfil de seguridad del arándano americano en lactantes y niños con infección urinaria recurrente</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Anales de Pediatria</style></full-title></periodical><pages><style face="normal" font="default" size="100%">397-403</style></pages><volume><style face="normal" font="default" size="100%">82</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotic prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Trimethoprim</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tractinfections</style></keyword><keyword><style face="normal" font="default" size="100%">Vesicoureteral reflux</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective Cranberry prophylaxis of recurrent urinary tract infection in infants has proven effective in the experimental model of the adult. There are few data on its efficacy, safety and recommended dose in the pediatric population. Methods A controlled, double-blind Phase III clinical trial was conducted on children older than 1 month of age to evaluate the efficacy and safety of cranberry in recurrent urinary tract infection. The assumption was of the non-inferiority of cranberry versus trimethoprim. Statistical analysis was performed using Kaplan Meier analysis. Results A total of 85 patients under 1 year of age and 107 over 1 year were recruited. Trimethoprim was prescribed to 75 patients and 117 received cranberry. The cumulative rate of urinary infection associated with cranberry prophylaxis in children under 1 year was 46% (95% CI; 23-70) in children and 17% (95% CI; 0-38) in girls, effectively at doses inferior to trimethoprim. In children over 1 year-old cranberry was not inferior to trimethoprim, with a cumulative rate of urine infection of 26% (95% CI; 12-41). The cranberry was well tolerated and with no new adverse effects. Conclusions Our study confirms that cranberry is safe and effective in the prophylaxis of recurrent urinary tract infection in infants and children. With the doses used, their efficiency is not less than that observed for trimethoprim among those over 1 year-old. (Clinical Trials Registry ISRCTN16968287). © 2014 Asociación Espãnola de Pediatría. Published by Elsevier España, S.L.U. All rights reser-ved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84930064280&amp;doi=10.1016%2fj.anpedi.2014.08.012&amp;partnerID=40&amp;md5=b3b853859485860db56e2e36bd1f3220</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.anpedi.2014.08.012</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>320</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">320</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fekete, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Temple University School of Medicine, Philadelphia, PA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary Tract Infections</style></title><secondary-title><style face="normal" font="default" size="100%">Evidence-Based Infectious Diseases: Second Edition</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">115-135</style></pages><keywords><keyword><style face="normal" font="default" size="100%">Asymptomatic bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">Combining clinical features and urine testing for pyuria and nitrates</style></keyword><keyword><style face="normal" font="default" size="100%">Noninvasive diagnostic tests - microscopic analysis of urinary sediment and urine culture</style></keyword><keyword><style face="normal" font="default" size="100%">Other diagnostic testing</style></keyword><keyword><style face="normal" font="default" size="100%">Therapy for ambulatory patients</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment guidelines - for telephone-based prescription strategies</style></keyword><keyword><style face="normal" font="default" size="100%">Two important gram-positive uropathogens - of ambulatory women</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections (UTI)</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections in men</style></keyword><keyword><style face="normal" font="default" size="100%">UTIs, common medical problem</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84891006457&amp;doi=10.1002%2f9781444301601.ch9&amp;partnerID=40&amp;md5=0ea2324cc8dac8000da507c4b55e8876</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/9781444301601.ch9</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>426</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">426</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fanos, V.</style></author><author><style face="normal" font="default" size="100%">Atzei, A.</style></author><author><style face="normal" font="default" size="100%">Zaffanello, M.</style></author><author><style face="normal" font="default" size="100%">Piras, A.</style></author><author><style face="normal" font="default" size="100%">Cataldi, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Patologia e Terapia Intensiva Neonatale, Università degli Studi di Cagliari, Italy&#xD;Clinica Pediatrica, Università degli Studi di Verona, Italy&#xD;Divisione di Neonatologia, Policlinico Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry and prevention of urinary tract infections in children</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">21-24</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">C. R. 3</style></number><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :7&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Conference Paper</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33745043301&amp;partnerID=40&amp;md5=78583af3d78eb6a9499fbb4461f6769d</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>478</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">478</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fanos, P. V.</style></author><author><style face="normal" font="default" size="100%">Cataldi, P. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Neonatal Intensive Care Unit, University of Cagliari, Cagliari, Italy&#xD;Neonatology Division, Policlinico a Gemelli, Sacred Heart University of Rome, Rome, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antibiotics or surgery for vesicoureteric reflux in children</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Lancet</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1720-1722</style></pages><volume><style face="normal" font="default" size="100%">364</style></volume><number><style face="normal" font="default" size="100%">9446</style></number><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Context 1-2% of children have vesicoureteric reflux (VUR). VUR occurs in 25-40% of children with acute pyelonephritis. VUR can lead to renal scarring, hypertension, and end-stage renal disease. The best form of treatment for children with VUR is debated: no treatment, long-term antibiotic prophylaxis, surgery, or a combination of antibiotic prophylaxis and surgery. In children with recurrent urinary tract infections (UTIs) and progressive renal damage, despite antibiotic prophylaxis, surgical correction of VUR, especially high-grade VUR, is generally recommended. Starting point Danielle Wheeler and colleagues recently did a meta-analysis of ten randomised controlled trials (964 children) to evaluate whether any intervention for VUR is better than no treatment (Cochrane Database Syst Rev 2004; 3: CD001532). The main endpoints were incidence of UTIs, new or progressive renal damage, renal growth, hypertension, and glomerular filtration rate. They concluded that it is uncertain whether the identification of children with VUR is associated with clinically important benefit. The additional benefit of surgery over antibiotics is small. Where next? New strategies for management will require a tailored diagnostic and therapeutic approach, including non-invasive or less invasive diagnostic procedures, and a less aggressive therapeutic approach. Whether the common practice of cystourethrography as a first-line investigation is warranted needs evaluation. The goal of paediatricians in the future, to prevent kidney damage, will probably be prevention of renal parenchymal injury and not necessarily the correction of ureterovesical junction anomalies. Because two main clinical pictures of VUR (diagnosed prenatally or postnatally with different age and sex distribution) can be identified, boys and girls will probably be managed differently. The factors responsible for congenital and acquired renal injury in children with VUR need to be studied.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :83&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Short Survey</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-7644233239&amp;doi=10.1016%2fS0140-6736%2804%2917359-5&amp;partnerID=40&amp;md5=592beb6851fb7046a6a3068249e56771</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0140-6736(04)17359-5</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>423</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">423</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Falagas, M. E.</style></author><author><style face="normal" font="default" size="100%">Betsi, G. I.</style></author><author><style face="normal" font="default" size="100%">Tokas, T.</style></author><author><style face="normal" font="default" size="100%">Athanasiou, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece&#xD;Department of Medicine, Tufts University School of Medicine, Boston, MA, United States&#xD;First Department of Obstetrics and Gynecology, Athens University School of Medicine, Athens, Greece&#xD;Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, Marousi, 151 23, Greece</style></auth-address><titles><title><style face="normal" font="default" size="100%">Probiotics for prevention of recurrent urinary tract infections in women: A review of the evidence from microbiological and clinical studies</style></title><secondary-title><style face="normal" font="default" size="100%">Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drugs</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1253-1261</style></pages><volume><style face="normal" font="default" size="100%">66</style></volume><number><style face="normal" font="default" size="100%">9</style></number><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">Recurrent urinary tract infections (UTIs) afflict a great number of women around the world. The use of probiotics, especially lactobacilli, has been considered for the prevention of UTIs. Since lactobacilli dominate the urogenital flora of healthy premenopausal women, it has been suggested that restoration of the urogenital flora, which is dominated by uropathogens, with lactobacilli may protect against UTIs. This review is based on a search of PubMed for relevant articles. Many in vitro studies, animal experiments, microbiological studies in healthy women, and clinical trials in women with UTIs have been carried out to assess the effectiveness and safety of probiotics for prophylaxis against uropathogens. Most of them had encouraging findings for some specific strains of lactobacilli. Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 (previously called L. fermentum RC-14) seemed to be the most effective among the studied lactobacilli for the prevention of UTIs. L. casei shirota and L. crispatus CTV-05 have also shown efficacy in some studies. L. rhamnosus GG did not appear to be quite as effective in the prevention of UTIs. The evidence from the available studies suggests that probiotics can be beneficial for preventing recurrent UTIs in women; they also have a good safety profile. However, further research is needed to confirm these results before the widespread use of probiotics for this indication can be recommended. © 2006 Adis Data Information BV. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :85&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33745929346&amp;doi=10.2165%2f00003495-200666090-00007&amp;partnerID=40&amp;md5=e1ab774995081f515fbf734331fb6c33</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2165/00003495-200666090-00007</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>260</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">260</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fagan, M.</style></author><author><style face="normal" font="default" size="100%">Mæhlen, M.</style></author><author><style face="normal" font="default" size="100%">Lindbæk, M.</style></author><author><style face="normal" font="default" size="100%">Berild, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of General Practice and Community Medicine, University of Oslo, Oslo, Norway&#xD;Department of Medical Genetics, Oslo University Hospital, Ullevål, Norway&#xD;Department of General Practice and Community Medicine, Antibiotic Centre for Primary Care, University of Oslo, Norway&#xD;Department of Infectious Disease, Oslo University Hospital, Oslo, Norway</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antibiotic prescribing in nursing homes in an area with low prevalence of antibiotic resistance: Compliance with national guidelines</style></title><secondary-title><style face="normal" font="default" size="100%">Scandinavian Journal of Primary Health Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Scandinavian Journal of Primary Health Care</style></full-title></periodical><pages><style face="normal" font="default" size="100%">10-15</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anti-bacterial agents</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">compliance</style></keyword><keyword><style face="normal" font="default" size="100%">geriatrics</style></keyword><keyword><style face="normal" font="default" size="100%">infection</style></keyword><keyword><style face="normal" font="default" size="100%">nursing homes</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective. To examine antibiotic prescribing in nursing homes and determine to what degree the prescribing was in accordance with the national guidelines for antibiotic prescribing. Design. Retrospective examination of patients&apos; records who were prescribed antibiotics in the period 1 March 2007 to 28 February 2008. Setting and patients. Patients residing in the nursing homes of Arendal, Norway. Main outcome measures. Choice of antibiotic in respect of the recommendations in the national guidelines for antibiotic prescribing. Results. A total of 714 antibiotic courses were prescribed to 327 patients yielding a prevalence of 6.6%. Compliant prescribing was 77% for urinary tract infections (UTI), 79% for respiratory tract infections (RTI), and 76% for skin and soft tissue infections (SSTI). Ciprofloxacin was responsible for 63% of non-compliant prescribing. On the respite wards there was a higher rate of total prescribing, non-compliant prescribing, and prescribing by physicians employed at the local hospital. Conclusion. Guidelines for antibiotic use must be implemented actively and efforts to improve antibiotic prescribing in nursing homes must be aimed at both nursing home and hospital physicians. © 2012 Informa Healthcare.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :16&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84857259744&amp;doi=10.3109%2f02813432.2011.629156&amp;partnerID=40&amp;md5=7748100a3d41952d8568ceb291edd2b4</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3109/02813432.2011.629156</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>247</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">247</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Esparza Olcina, M. J.</style></author><author><style face="normal" font="default" size="100%">Benito Herreros, A. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">CS Barcelona, Móstoles, Madrid, Spain&#xD;EAP Taco-La Laguna, Santa Cruz de Tenerife, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry preparations, safe but of doubtful efficacy for urinary tract infection in children</style></title><secondary-title><style face="normal" font="default" size="100%">Pediatria de Atencion Primaria</style></secondary-title><short-title><style face="normal" font="default" size="100%">Los preparados de arándano, inocuos pero de dudosa eficacia para la infección urinaria en niños</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pediatria de Atencion Primaria</style></full-title></periodical><pages><style face="normal" font="default" size="100%">265-273</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">55</style></number><keywords><keyword><style face="normal" font="default" size="100%">Urinary tract infections: prevention and control</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">This paper has the structure of a critical appraised topic; it sought to determine the use of cranberry extracts in urinary tract infection prevention in children. The steps of evidence based medicine were followed: presentation of a clinical scenario, structured clinical question, bibliographic research and critical appraisal of the selected studies retrieved. Finally, an answer for the clinical scenario is provided. Four studies were selected for the appraisal. The reviewed studies show discrepancies on the effectiveness of cranberry juice in the prevention of urinary tract infection recurrences. The best conducted study finds some effectiveness of cranberry juice in reducing total urinary infections in the sample but not in the number of children with recurrences. The validity of the results of the other three studies should be interpreted with caution due to methodological limitations. Cranberry products seem safe.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84868237750&amp;partnerID=40&amp;md5=a71931e08dbac282283540cab5608a0b</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>155</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">155</key></foreign-keys><ref-type name="Book">6</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Escott-Stump, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">East Carolina University, Greenville, NC, United States&#xD;Winterville, NC, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nutrition and diagnosis-related care: Eighth edition</style></title><secondary-title><style face="normal" font="default" size="100%">Nutrition and Diagnosis-Related Care: Eighth Edition</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1-1038</style></pages><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Prepare your students for effective practice with Nutrition and Diagnosis-Related Care, 8e. Written by well-known author and nutritionist Sylvia Escott-Stump, this best-selling book provides &quot;need to know,&quot; condition-specific, evidence-based medical nutrition therapy information for more than 360 diseases and disorders in a unique monograph-style format that makes information easy to find. Revised and updated throughout, the Eighth Edition features new information on the treatment of inflammation through nutrition therapy; new and updated coverage of autism and neurodegenerative and neuropsychiatric disorders; timely information for the dietician working in a collaborative, interdisciplinary care setting. © 2015 Wolters Kluwer. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Book</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84973098908&amp;partnerID=40&amp;md5=7700d089c39b37ec25903ccd274afe52</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>264</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">264</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ermel, G.</style></author><author><style face="normal" font="default" size="100%">Georgeault, S.</style></author><author><style face="normal" font="default" size="100%">Inisan, C.</style></author><author><style face="normal" font="default" size="100%">Besnard, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">UMR CNRS 6026 Cellular and Molecular Interactions-DUALS, Université de Rennes 1, 263 avenue du General Leclerc, 35042 Rennes Cedex, France&#xD;Diana Naturals, Antrain, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">Inhibition of adhesion of uropathogenic escherichia coli bacteria to uroepithelial cells by extracts from cranberry</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Medicinal Food</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Medicinal Food</style></full-title></periodical><pages><style face="normal" font="default" size="100%">126-134</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">adhesion</style></keyword><keyword><style face="normal" font="default" size="100%">cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">proanthocyanidins</style></keyword><keyword><style face="normal" font="default" size="100%">procyanidins</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry extract has been reported as a therapeutic agent, mainly in urinary tract infections due to its anti-adhesive capacity. In order to compare the effects of proanthocyanidin (procyanidin) (PAC)-standardized cranberry extracts and commercial PAC A2, we first investigated the presence of genes encoding known adhesins on 13 strains of uropathogenic strains coming from patients with cystisis. After this characterization, the anti-adhesive effects of PAC A2 were assayed on selected uropathogenic Escherichia coli strains before testing cranberry extracts. Before checking inhibitory effect on bacterial adhesion to cells, we showed that neither PAC A2 or three cranberry extracts (A, B, and C) specifically inhibited the growth and did not supply any potential nutrient to E. coli strains, including the unrelated control strain. PAC A2 exhibited an inhibitory effect on the adhesion of two selected uropathogenic strains of E. coli. This work also showed that a preliminary exposure of bacteria to PAC A2 significantly reduced the adhesion. This phenomenon has been also observed with a lesser impact when uroepithelial cells were pretreated with PAC A2. Moreover, the assays were more robust when bacteria were in fast growing conditions (exponential phase): the adhesion to uroepithelial cells was greater. Significant reduction of adhesion to urepithelial cells was observed: around 80% of inhibition of adhesion with the cranberry extracts at equivalent PAC concentration of 50 μg/mL. The effects of the different assayed extracts were not obviously different except for extract B, which inhibited approximately 55% of adhesion at an equivalent PAC concentration of 5 μg/mL. © 2012, Mary Ann Liebert, Inc. and Korean Society of Food Science and Nutrition.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :14&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84856292918&amp;doi=10.1089%2fjmf.2010.0312&amp;partnerID=40&amp;md5=b46a36db64aa2e3349dbc8422dab6773</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1089/jmf.2010.0312</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>485</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">485</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eriksen, H. M.</style></author><author><style face="normal" font="default" size="100%">Iversen, B. G.</style></author><author><style face="normal" font="default" size="100%">Aavitsland, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Norwegian Institute of Public Health, Postboks 4404, Nydalen 0403 Oslo, Norway&#xD;EPIET, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevalence of nosocomial infections and use of antibiotics in long-term care facilities in Norway, 2002 and 2003</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Hospital Infection</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Hospital Infection</style></full-title></periodical><pages><style face="normal" font="default" size="100%">316-320</style></pages><volume><style face="normal" font="default" size="100%">57</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Infections</style></keyword><keyword><style face="normal" font="default" size="100%">Long-term care facilities</style></keyword><keyword><style face="normal" font="default" size="100%">Norway</style></keyword><keyword><style face="normal" font="default" size="100%">Nosocomial</style></keyword><keyword><style face="normal" font="default" size="100%">Prevalence</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">There were 42 900 institution-beds in long-term care facilities for elderly persons in Norway in 2000. This is twice as many as in 1984. Of those living in an elderly people&apos;s care institution 77% were above 80 years. To determine the magnitude and distribution of nosocomial infections in such institutions, the Norwegian Institute of Public Health initiated a surveillance system. The system is based on two annual one-day prevalence surveys recording the four most common nosocomial infections: urinary tract infections, lower respiratory tract infections, surgical-site infections and skin infections, as well as antibiotic use. All long-term care facilities were invited to participate in the four surveys in 2002 and 2003. The total prevalence of the four recorded nosocomial infections varied between 6.6 and 7.3% in the four surveys. Nosocomial infections occurred most frequently in the urinary tract (50%), followed by infections of the skin (25%), of the lower respiratory tract (19%) and of surgical sites (5%). The prevalence of nosocomial infections was highest in rehabilitation and short-term wards, whereas the lowest prevalence was found in special units for persons with dementia. In all the surveys the prevalence of the four recorded nosocomial infections was higher than the prevalence of patients receiving antibiotics. The frequency of nosocomial infections in such facilities highlights the need for nosocomial infection surveillance in this population and a need to implement infection control measures, such as infection control programmes including surveillance of nosocomial infections. © 2004 The Hospital Infection Society. Published by Elsevier Ltd. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :65&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-3543132527&amp;doi=10.1016%2fj.jhin.2004.03.028&amp;partnerID=40&amp;md5=7acabf0605b43ed7b517de77beb1f398</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.jhin.2004.03.028</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>288</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">288</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Erdogan-Yildirim, Z.</style></author><author><style face="normal" font="default" size="100%">Burian, A.</style></author><author><style face="normal" font="default" size="100%">Manafi, M.</style></author><author><style face="normal" font="default" size="100%">Zeitlinger, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Clinical Pharmacology, Medical University of Vienna, Allgemeines Krankenhaus Wien, Wahringer Gurtel 18-20, 1090 Vienna, Austria&#xD;Institute of Hygiene and Applied Immunology, Medical University of Vienna, Kinderspitalgasse 15, 1090 Vienna, Austria</style></auth-address><titles><title><style face="normal" font="default" size="100%">Impact of pH on bacterial growth and activity of recent fluoroquinolones in pooled urine</style></title><secondary-title><style face="normal" font="default" size="100%">Research in Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Research in Microbiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">249-252</style></pages><volume><style face="normal" font="default" size="100%">162</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Ciprofloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">Levofloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">Loxifloxacin</style></keyword><keyword><style face="normal" font="default" size="100%">PH</style></keyword><keyword><style face="normal" font="default" size="100%">UTI</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">Acidification of urine is widely recommended for prevention and treatment of urinary tract infections. We set out to describe the effect of modification of pH on bacterial growth of relevant bacteria as well as on activity of modern fluoroquinolones in urine in vitro. Bacterial growth of Escherichia coli ATCC 25922 and Klebsiella oxytoca ATCC 700324 was determined in pooled human urine adjusted to pH levels between 5.0 and 8.0. Minimal inhibitory concentrations (MICs) and time-kill curves were performed for ciprofloxacin, levofloxacin and moxifloxacin in pH-adjusted urine and Mueller-Hinton Broth (MHB). Uptake of radioactive labeled [C14]-ciprofloxacin into bacterial cells was investigated at different pHs. While no difference in bacterial growth of E. coli and K. oxytoca was observed at pH values between 5.0 and 8.0, acidification of urine led to major impairment of antimicrobial activity of all tested fluoroquinolones, indicated by an up to 40-fold increase in MIC compared to MHB and nearly total neutralization of activity in time-kill experiments. The most probable mechanism behind this observation may have been reduced uptake of fluoroquinolones into bacterial cells, as indicated by bacterial uptake of [C14]-ciprofloxacin and a reversibility of the effect. The observed reduction in activity of modern fluoroquinolones confirms previous observations from older compounds. © 2011 Institut Pasteur.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :22&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79952898296&amp;doi=10.1016%2fj.resmic.2011.01.004&amp;partnerID=40&amp;md5=4abd27d6837b376202380532cec8c45e</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.resmic.2011.01.004</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>317</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">317</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Epp, A.</style></author><author><style face="normal" font="default" size="100%">Larochelle, A.</style></author><author><style face="normal" font="default" size="100%">Lovatsis, D.</style></author><author><style face="normal" font="default" size="100%">Walter, J. E.</style></author><author><style face="normal" font="default" size="100%">Easton, W.</style></author><author><style face="normal" font="default" size="100%">Farrell, S. A.</style></author><author><style face="normal" font="default" size="100%">Girouard, L.</style></author><author><style face="normal" font="default" size="100%">Gupta, C.</style></author><author><style face="normal" font="default" size="100%">Harvey, M. A.</style></author><author><style face="normal" font="default" size="100%">Robert, M.</style></author><author><style face="normal" font="default" size="100%">Ross, S.</style></author><author><style face="normal" font="default" size="100%">Schachter, J.</style></author><author><style face="normal" font="default" size="100%">Schulz, J. A.</style></author><author><style face="normal" font="default" size="100%">Wilkie, D.</style></author><author><style face="normal" font="default" size="100%">Ehman, W.</style></author><author><style face="normal" font="default" size="100%">Domb, S.</style></author><author><style face="normal" font="default" size="100%">Gagnon, A.</style></author><author><style face="normal" font="default" size="100%">Hughes, O.</style></author><author><style face="normal" font="default" size="100%">Konkin, J.</style></author><author><style face="normal" font="default" size="100%">Lynch, J.</style></author><author><style face="normal" font="default" size="100%">Marshall, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Saskatoon, SK, Canada&#xD;St. Lambert, QC, Canada&#xD;Toronto, ON, Canada&#xD;Westmount, QC, Canada&#xD;Halifax, NS, Canada&#xD;Winnipeg, MB, Canada&#xD;Kingston, ON, Canada&#xD;Calgary, AB, Canada&#xD;Ottawa, ON, Canada&#xD;Edmonton, AB, Canada&#xD;Vancouver, BC, Canada&#xD;Naniamo, BC, Canada&#xD;Blainville, QC, Canada&#xD;Lower Sackville, NS, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent Urinary Tract Infection</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Obstetrics and Gynaecology Canada</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Obstetrics and Gynaecology Canada</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1082-1090</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">11</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotic</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: To provide an update of the definition, epidemiology, clinical presentation, investigation, treatment, and prevention of recurrent urinary tract infections in women. Options: Continuous antibiotic prophylaxis, post-coital antibiotic prophylaxis, and acute self-treatment are all efficient alternatives to prevent recurrent urinary tract infection. Vaginal estrogen and cranberry juice can also be effective prophylaxis alternatives. Evidence: A search of PubMed and The Cochrane Library for articles published in English identified the most relevant literature. Results were restricted to systematic reviews, randomized control trials/controlled clinical trials, and observational studies. There were no date restrictions. Values: This update is the consensus of the Sub-Committee on Urogynaecology of the Society of Obstetricians and Gynaecologists of Canada. Recommendations were made according to the guidelines developed by the Canadian Task Force on Preventive Health Care (Table 1). Options: Recurrent urinary tract infections need careful investigation and can be efficiently treated and prevented. Different prophylaxis options can be selected according to each patient&apos;s characteristics. Recommandations: 1.Urinalysis and midstream urine culture and sensitivity should be performed with the first presentation of symptoms in order to establish a correct diagnosis of recurrent urinary tract infection. (III-L)2.Patients with persistent hematuria or persistent growth of bacteria aside from Escherichia coli should undergo cystoscopy and imaging of the upper urinary tract. (III-L)3.Sexually active women suffering from recurrent urinary tract infections and using spermicide should be encouraged to consider an alternative form of contraception. (II-2B)4.Prophylaxis for recurrent urinary tract infection should not be undertaken until a negative culture 1 to 2 weeks after treatment has confirmed eradication of the urinary tract infection. (III-L)5.Continuous daily antibiotic prophylaxis using cotrimoxazole, nitrofurantoin, cephalexin, trimethoprim, trimethoprim-sulfamethoxazole, or a quinolone during a 6-to 12-month period should be offered to women with ≥ 2 urinary tract infections in 6 months or ≥ 3 urinary tract infections in 12 months. (I-A)6.Women with recurrent urinary tract infection associated with sexual intercourse should be offered post-coital prophylaxis as an alternative to continuous therapy in order to minimize cost and side effects. (I-A)7.Acute self-treatment should be restricted to compliant and motivated patients in whom recurrent urinary tract infections have been clearly documented. (I-B)8.Vaginal estrogen should be offered to postmenopausal women who experience recurrent urinary tract infections. (I-A)9.Patients should be informed that cranberry products are effective in reducing recurrent urinary tract infections. (I-A)10.Acupuncture may be considered as an alternative in the prevention of recurrent urinary tract infections in women who are unresponsive to or intolerant of antibiotic prophylaxis. (I-B)11.Probiotics and vaccines cannot be offered as proven therapy for recurrent urinary tract infection. (II-2C)12.Pregnant women at risk of recurrent urinary tract infection should be offered continuous or post-coital prophylaxis with nitrofurantoin or cephalexin, except during the last 4 weeks of pregnancy. (II-1B). © 2010 Society of Obstetricians and Gynaecologists of Canada.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :56&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79952199897&amp;doi=10.1016%2fS1701-2163%2816%2934717-X&amp;partnerID=40&amp;md5=11b34d2625edce61db19f42e08ef67bf</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S1701-2163(16)34717-X</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>513</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">513</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Emody, L.</style></author><author><style face="normal" font="default" size="100%">Kerényi, M.</style></author><author><style face="normal" font="default" size="100%">Nagy, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dept. of Med. Microbiol./Immunology, Univ. Medical School of Pécs, Szigeti ut 12, H-7624 Pécs, Hungary</style></auth-address><titles><title><style face="normal" font="default" size="100%">Virulence factors of uropathogenic Escherichia coli</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Antimicrobial Agents</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Antimicrobial Agents</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S29-S33</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">SUPPL. 2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adhesion</style></keyword><keyword><style face="normal" font="default" size="100%">Cytotoxicity</style></keyword><keyword><style face="normal" font="default" size="100%">Fimbriae</style></keyword><keyword><style face="normal" font="default" size="100%">Virulence factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">Virulence factors of Escherichia coli are of two main types; those produced on the surface of the cell and those produced within the cell and then exported to the site of action. Those on the surface include different sorts of fimbriae that have a role in adhesion to the surface of host cells but may also have additional roles such as tissue invasion, biofilm formation or cytokine induction. The activities of cell wall components are discussed and several exported virulence factors are described that have anti host cell activities. Others virulence factors enable the bacteria to grow in an environment of iron restriction. © 2003 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :92&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0141869954&amp;doi=10.1016%2fS0924-8579%2803%2900236-X&amp;partnerID=40&amp;md5=856a6a5d8edaf0bd350c08c2696964c6</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0924-8579(03)00236-X</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>224</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">224</key></foreign-keys><ref-type name="Book">6</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Elmer, G. W.</style></author><author><style face="normal" font="default" size="100%">McFarland, L. V.</style></author><author><style face="normal" font="default" size="100%">McFarland, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Washington, Seattle, United States&#xD;Puget Sound Veterans Administration, Health Services Research and Development, Seattle, United States&#xD;Prosthetic Research Study, Seattle, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">The power of probiotics: Improving your health with beneficial microbes</style></title><secondary-title><style face="normal" font="default" size="100%">The Power of Probiotics: Improving Your Health with Beneficial Microbes</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1-237</style></pages><volume><style face="normal" font="default" size="100%">9781315821139</style></volume><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Get information you can trust to make the right decisions about probiotics The Power of Probiotics is a consumer-friendly guide to the selection and use of probiotics that have been proven effective in the prevention and treatment of human diseases. This jargon-free reference resource provides practical advice on how and when to use probiotics and how to select the best commercially available products, based on usefulness, quality, and safety, to lower the risk of disease and maintain a positive health image. The book offers objective information on evaluating product claims, making sense of regulations and labeling, and sorting through manufacturing and marketing issues. The Power of Probiotics presents an expert review of the scientific evidence for probiotics, illustrated with summary tables and diagrams for quick reference. Each chapter starts with a series of FAQs with clear and concise answers before moving into more in-depth analysis from the book’s authors, who combine more than 20 years of research from the patient clinic and the bench laboratory with extensive experience in writing and translating medical articles for consumer-oriented publications. This unique book presents definitions and descriptions of probiotics and a history of their uses, a review of medical conditions prevented and/or treated by probiotics, available products (with brand names), uses with other medications, and risks and side effects. The Power of Probiotics examines the treatment and/or prevention of: • allergies. • cancer • colds and flu • constipation • dental health • diarrhea • high cholesterol • indigestion • inflammatory bowel diseases • pseudomembranous colitis • stomach ulcers • stress • urinary tract infections • vaginal infections • weight loss • and much more! The Power of Probiotics is an essential resource for health-conscious consumers who are interested in natural alternatives to conventional medicines. Health professionals, educators, and students will also benefit from the book’s extensive references. © 2007 by The Haworth Press, Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Book</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84909379247&amp;doi=10.4324%2f9781315821139&amp;partnerID=40&amp;md5=a9dc14b0dcd4925843cb75e0cc516834</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.4324/9781315821139</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>571</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">571</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ellis, A. K.</style></author><author><style face="normal" font="default" size="100%">Verma, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Queen&apos;s University, Kingston, Ont., Canada&#xD;Kingston General Hospital, Department of Family Medicine, Queen&apos;s University, Kingston, Ont., Canada&#xD;Department of Family Medicine, Queen&apos;s University, 220 Bagot St, Kingston, Ont. K7L 3G2, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Quality of Life in Women with Urinary Tract Infections: Is Benign Disease a Misnomer?</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Board of Family Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Board of Family Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">392-397</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">6</style></number><dates><year><style face="normal" font="default" size="100%">2000</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: The objective of this study was to undertake an exploratory evaluation of quality-of-life indicators for women suffering from urinary tract infections. Methods: The RAND 36-Item Health Survey 1.0 (SF-36) was administered to 47 women with a diagnosed urinary tract infection who were being cared for in the Family Medicine Center, Student Health Services, or Urology Outpatient Clinic. A control population of 71 women was obtained from the female members of an undergraduate geography class, a community basketball league, and a local women&apos;s choir. Results: All subsections of the SF-36 quality-of-life indices were significantly decreased in the subject population compared with the control population (lower score indicates lower quality of life): patient general health perception (63-3 vs 78.9, P &lt; .001) physical functioning (76.6 vs 87.6, P = .012), role limitation owing to physical health (53.8 vs 93.0, P &lt; .001) and emotional health (67.4 vs 88.3, P &lt; .001), vitality (43.0 vs 64.9, P &lt; .001), emotional well-being (64.4 vs 80.2, P &lt; .001), pain (58.7 vs 91.5, P &lt; .001), and social functioning (60.4 vs 90.4. P &lt; .001). Conclusion: Suffering from an urinary tract infection has a detrimental influence on patient quality of life. The effect of urinary tract infections on women and their perception of quality of life have not been hitherto reported in the medical literature. The significant findings in this study call into question whether acute, non-life-threatening illness should be regarded as benign.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :53&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034321555&amp;partnerID=40&amp;md5=89f342c8501f2ab0eca1112288db591a</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>322</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">322</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eldridge, S.</style></author><author><style face="normal" font="default" size="100%">Kerry, S.</style></author><author><style face="normal" font="default" size="100%">Torgerson, D. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre for Health Sciences, Barts and the London School of Medicine and Dentistry, University of London, London E1 2AT, United Kingdom&#xD;Department of Community Health Sciences, St george&apos;s, University of London, London SW17 0RE, United Kingdom&#xD;York Trials Unit, Department of Health Sciences, University of York, York YO10 5DD, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bias in identifying and recruiting participants in cluster randomised trials: What can be done?</style></title><secondary-title><style face="normal" font="default" size="100%">BMJ (Online)</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMJ (Online)</style></full-title></periodical><pages><style face="normal" font="default" size="100%">36-39</style></pages><volume><style face="normal" font="default" size="100%">339</style></volume><number><style face="normal" font="default" size="100%">7736</style></number><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :49&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84879257038&amp;doi=10.1136%2fbmj.b4006&amp;partnerID=40&amp;md5=a3c10df14546524a25a3d39d9959331f</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">b4006</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/bmj.b4006</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>412</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">412</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ek, S.</style></author><author><style face="normal" font="default" size="100%">Kartimo, H.</style></author><author><style face="normal" font="default" size="100%">Mattila, S.</style></author><author><style face="normal" font="default" size="100%">Tolonen, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of Oulu, P.O. Box 3000, 90014 Oulu, Finland&#xD;Novamass Analytical Ltd., Kiviharjuntie 11, 90220 Oulu, Finland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Characterization of phenolic compounds from lingonberry (Vaccinium vitis-idaea)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">9834-9842</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">26</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anthocyanidins</style></keyword><keyword><style face="normal" font="default" size="100%">Catechins</style></keyword><keyword><style face="normal" font="default" size="100%">Flavonols</style></keyword><keyword><style face="normal" font="default" size="100%">Lingonberry</style></keyword><keyword><style face="normal" font="default" size="100%">Phenolics</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">Phenolic compounds from the lingonberry (Vaccinium vitis-idaea) were identified using LC-TOFMS, LC-MS/MS, and NMR experiments. The compounds were extracted from the plant material using methanol in an ultrasonicator and further isolated and purified using solid-phase extraction and preparative liquid chromatographic techniques. A total of 28 phenolic compounds were at least tentatively identified, including flavonols, anthocyanidins, catechins and their glycosides, and different caffeoyl and ferulic acid conjugates. This is apparently the first report of coumaroyl-hexose-hydroxyphenol, caffeoyl-hexose-hydroxyphenol, coumaroyl-hexose-hydroxyphenol, quercetin-3-O-α-arabinofuranoside, kaempferol-pentoside, and kaempferol-deoxyhexoside in the plant, and the flavonol acylglycosides quercetin-3-O-[4″-(3-hydroxy-3-methylglutaroyl)]-α-rhamnose and kaempferol-3-O-[4″-(3-hydroxy-3-methylglutaroyl)]-α-rhamnose are presented here for the first time ever. In addition, more detailed structure in comparison to earlier reports is described for some compounds previously known to exist in lingonberry. © 2006 American Chemical Society.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :80&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33846472702&amp;doi=10.1021%2fjf0623687&amp;partnerID=40&amp;md5=aa8fb6f64af6d07f4cdaf5cb8b8b31f3</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/jf0623687</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>209</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">209</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Egger, C.</style></author><author><style face="normal" font="default" size="100%">Oberhuber, C.</style></author><author><style face="normal" font="default" size="100%">Reider, N.</style></author><author><style face="normal" font="default" size="100%">Eisendle, K.</style></author><author><style face="normal" font="default" size="100%">Jahn-Schmid, B.</style></author><author><style face="normal" font="default" size="100%">Marsh, J.</style></author><author><style face="normal" font="default" size="100%">Focke, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institut für Pathophysiologie und Allergieforschung, Zentrum für Pathophysiologie, Infektiologie und Immunologie, Medizinische Universität Wien, Innrain 143, A-6020 Innsbruck, Austria&#xD;Universitätsklinik für Dermatologie und Venerologie, Medizinische Universität Innsbruck, Austria&#xD;Biomay AG, Wien, Austria&#xD;Institut für Pathophysiologie und Allergieforschung, Zentrum für Pathophysiologie, Infektiologie und Immunologie, Medizinische Universität Wien, Austria&#xD;Rothamsted Research, Harpenden, Hertfordshire, Großbritannien, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anaphylaxis to blueberry (Vaccinium myrtillus) -identification of a new lipid transfer protein</style></title><secondary-title><style face="normal" font="default" size="100%">Allergologie</style></secondary-title><short-title><style face="normal" font="default" size="100%">Anaphylaktische reaktion auf heidelbeere (vaccinium myrtillus) -identifizierung eines neuen lipidtransferproteins</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Allergologie</style></full-title></periodical><pages><style face="normal" font="default" size="100%">375-383</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">Allergy</style></keyword><keyword><style face="normal" font="default" size="100%">Bet v 1</style></keyword><keyword><style face="normal" font="default" size="100%">Blueberry</style></keyword><keyword><style face="normal" font="default" size="100%">Lipid transfer protein</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: A 29-year-old female presented with a first-time anaphylactic reaction. History revealed the intake of &quot;Schwarzbeernocken&quot;, a Tyrolean speciality containing blueberries, 1 hour prior to the onset of symptoms. We aimed to identify the culprit allergen. Methods: Serum from a blueberry allergic donor was studied for IgE reactivity to blueberry, mugwort (Artemisia vulgaris) and birch (Betula verrucosa) pollen extract in IgE immunoblot experiments. IgE inhibition experiments and N-terminal sequencing were performed to further identify the putative blueberry allergen. In addition, blueberry extract was evaluated for cross-reactive allergens with sera from a Bet v 1-and a monosensitized mugwort pollen-allergic patient. Results: Blueberries contain a 9 kDa allergen which cross-reacts with Pru p 3, the nonspecific lipid transfer protein from peach, and shows sequence homology with cabbage lipid transfer protein. No allergen homologous to Bet v 1 could be identified in blueberries. Conclusion: Blueberry lipid transfer protein represents a relevant food allergen which can cause severe anaphylactic reactions. However, blueberries apparently do not contain any Bet v 1-homologue. This protein family is found in many other foods and known as the most common cause of oral allergy syndrome in the Northern hemisphere. © 2013 Dustri-Verlag Dr. Karl Feistle.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84885126308&amp;doi=10.5414%2fALX01589&amp;partnerID=40&amp;md5=e5f7d87d2e76a9a5843bf86bca15134d</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.5414/ALX01589</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>181</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">181</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eells, S. J.</style></author><author><style face="normal" font="default" size="100%">Bharadwa, K.</style></author><author><style face="normal" font="default" size="100%">McKinnell, J. A.</style></author><author><style face="normal" font="default" size="100%">Miller, L. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Infectious Diseases, ID-CORE, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 W Carson St, Box 466, Torrance, CA 90502, United States&#xD;Harbor-University of California, Los Angeles (UCLA) Medical Center, Torrance, United States&#xD;David Geffen School of Medicine at UCLA, United States&#xD;Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent urinary tract infections among women: Comparative effectiveness of 5 prevention and management strategies using a markov chain monte carlo model</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">147-160</style></pages><volume><style face="normal" font="default" size="100%">58</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Management</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Background. Recurrent urinary tract infections (UTIs) are a common problem among women. However, comparative effectiveness strategies for managing recurrent UTIs are lacking.Methods. We performed a systematic literature review of management of women experiencing ≥3 UTIs per year. We then developed a Markov chain Monte Carlo model of recurrent UTI for each management strategy with ≥2 adequate trials published. We simulated a cohort that experienced 3 UTIs/year and a secondary cohort that experienced 8 UTIs/year. Model outcomes were treatment efficacy, patient and payer cost, and health-related quality of life.Results. Five strategies had ≥2 clinical trials published: (1) daily antibiotic (nitrofurantoin) prophylaxis; (2) daily estrogen prophylaxis; (3) daily cranberry prophylaxis; (4) acupuncture prophylaxis; and (5) symptomatic self-treatment. In the 3 UTIs/year model, nitrofurantoin prophylaxis was most effective, reducing the UTI rate to 0.4 UTIs/year, and the most expensive to the payer ($821/year). All other strategies resulted in payer cost savings but were less efficacious. Symptomatic self-treatment was the only strategy that resulted in patient cost savings, and was the most favorable strategy in term of cost per quality-adjusted life-year (QALY) gained.Conclusions. Daily antibiotic use is the most effective strategy for recurrent UTI prevention compared to daily cranberry pills, daily estrogen therapy, and acupuncture. Cost savings to payers and patients were seen for most regimens, and improvement in QALYs were seen with all. Our findings provide clinically meaningful data to guide the physician-patient partnership in determining a preferred method of prevention for this common clinical problem. © The Author 2013.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :15&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84891749772&amp;doi=10.1093%2fcid%2fcit646&amp;partnerID=40&amp;md5=c143eea2e01fc1f5ada7482eca8de8e6</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/cid/cit646</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>591</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">591</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eckford, S. D.</style></author><author><style face="normal" font="default" size="100%">Keane, D. P.</style></author><author><style face="normal" font="default" size="100%">Lamond, E.</style></author><author><style face="normal" font="default" size="100%">Jackson, S. R.</style></author><author><style face="normal" font="default" size="100%">Abrams, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Bristol Urological Institute, Southmead Hospital, Bristol, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hydration monitoring in the prevention of recurrent idiopathic urinary tract infections in pre‐menopausal women</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">90-93</style></pages><volume><style face="normal" font="default" size="100%">76</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">conductivity probe</style></keyword><keyword><style face="normal" font="default" size="100%">hydration monitoring</style></keyword><keyword><style face="normal" font="default" size="100%">Idiopathic urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">urethral flushing</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1995</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective To assess whether the use of simple hydration monitoring can encourage adequate hydration and reduce urinary osmolality and the incidence of urinary tract infections (UTIs) in a population of susceptible pre‐menopausal women with recurrent idiopathic urinary infections. Subjects and methods The study included 28 premenopausal women who had at least two idiopathic UTIs in the previous 6 months. Urinary osmolality was assessed by the patients at each void by a simple hand‐held probe, and the readings over 4 months compared. Monthly urine culture was compared between successive 4‐month periods in which the probe was or was not used. Results The study was completed by 17 women. There was a significant shift towards urine of lower osmolality over the 4‐month period using the probe (Pearson&apos;s χ2 &amp;lt; 0.001). Significantly fewer urinary tract infections developed during the 4 months using the probe (McNemar&apos;s χ2= 0.046). Conclusions The use of the osmolality probe encouraged the subject to maintain adequate hydration. The resulting augmentation of the natural urethral washout mechanism led to lower osmolality urine and a reduction in the incidence of UTIs. Copyright © 1995, Wiley Blackwell. All rights reserved</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :42&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029054241&amp;doi=10.1111%2fj.1464-410X.1995.tb07839.x&amp;partnerID=40&amp;md5=2c0311e7fa34719513dccf5531491bb9</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1464-410X.1995.tb07839.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>525</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">525</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ebringer, A.</style></author><author><style face="normal" font="default" size="100%">Rashid, T.</style></author><author><style face="normal" font="default" size="100%">Wilson, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Div. Life Sci., Infect./Immun. Grp., King&apos;s College London, London, United Kingdom&#xD;Department of Rheumatology, Middlesex Hospital, University College, London, United Kingdom&#xD;Div. Life Sci., Infect./Immun. Grp., King&apos;s College London, 150 Stamford Street, London SE1 8WA, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Rheumatoid arthritis: Proposal for the use of anti-microbial therapy in early cases</style></title><secondary-title><style face="normal" font="default" size="100%">Scandinavian Journal of Rheumatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Scandinavian Journal of Rheumatology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2-11</style></pages><volume><style face="normal" font="default" size="100%">32</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Diet</style></keyword><keyword><style face="normal" font="default" size="100%">Proteus urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">Rheumatoid arthritis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">Rheumatoid arthritis (RA) is a chronic disease, affecting women more than men, especially in those possessing the &quot;shared epitope&quot; (EQK/ RRAA) amino acid sequences present in HLA-DR1/4 molecules. Proteus mirabilis carries sequences showing molecular mimicry to the &quot;shared epitope&quot; and to type XI collagen of hyaline cartilage. Elevated levels of antibodies to P. mirabilis have been reported from 14 different countries involving 1375 RA patients and the microbe has been isolated from urine cultures of such patients. Our working hypothesis is that the disease develops as a result of repeated episodes of Proteus upper urinary tract infections. Prospective studies involving the trial of anti-Proteus measures in RA patients should be evaluated in the management of this disease. Antibiotics, high fluid intake, and fruit extracts, such as cranberry juice, have all been found to be effective in the treatment of urinary tract infections. Such measures could be used as possible additional adjuncts to the standard therapy with NSAIDs and DMARDs.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :33&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037260890&amp;doi=10.1080%2f03009740310000337&amp;partnerID=40&amp;md5=162a7eee4d0d289ecd98cbb5416e2ced</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/03009740310000337</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>541</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">541</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dwyer, P. L.</style></author><author><style face="normal" font="default" size="100%">O&apos;Reilly, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urogynaecology, Mercy Hosp. for Women/Roy. W. H., Melbourne, Vic., Australia&#xD;Department of Infectious Diseases, Box Hill Hospital, Melbourne, Vic., Australia&#xD;13 Brunswick Street, Fitzroy, Vic. 3065, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent urinary tract infection in the female</style></title><secondary-title><style face="normal" font="default" size="100%">Current Opinion in Obstetrics and Gynecology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Opinion in Obstetrics and Gynecology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">537-543</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aetiology</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrence</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment</style></keyword><keyword><style face="normal" font="default" size="100%">UTI</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><abstract><style face="normal" font="default" size="100%">Purpose of review: Recurrent urinary tract infection is a common problem and can affect women of all ages, particularly the elderly and pregnant women. Obstetricians and gynaecologists need to have up-to-date knowledge of the diagnosis, pathophysiology and management of this condition. Recent findings: The diagnosis of urinary tract infection is made on the basis of symptoms and bacteriuria of more than 103 bacteria per ml. Host and bacterial virulence factors are important in the pathogenesis of recurrent urinary tract infections. General host factors predisposing to recurrent infection are genetic factors, ageing, the menopause, urogenital dysfunction, sexual behaviour, and previous pelvic surgery. Urinary tract infection is common in pregnancy, and recent studies have suggested an association with mental retardation and developmental delay. Women with recurrent urinary tract infection in pregnancy should be considered for long-term antibiotic prophylaxis. Intravaginal oestrogens and cranberry juice have been found to be effective for prevention, although more research is required. Women with recurrent urinary tract infection should have at least a 3-day course of trimethoprim or cotrimoxazole, ora 5-day course of β-lactams or nitrofurantoin, with perhaps a 10-day course in the elderly. Women with frequent urinary tract infection (more than three episodes per year) should be offered prophylactic antibiotics, which can be patient-initiated, postcoital, or long-term low-dose therapy. In the future, vaccines against specific uropathogenic bacteria may be useful in urinary tract infection prophylaxis. Summary: More research is required, by all medical disciplines, on various aspects of urinary tract infection.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :59&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036823399&amp;doi=10.1097%2f00001703-200210000-00016&amp;partnerID=40&amp;md5=f9bd4f1f4e95d0218f7d2bc687ee0be3</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/00001703-200210000-00016</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>165</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">165</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Durham, S. H.</style></author><author><style face="normal" font="default" size="100%">Stamm, P. L.</style></author><author><style face="normal" font="default" size="100%">Eiland, L. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Auburn University Harrison School of Pharmacy, Auburn, AL, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry Products for the Prophylaxis of Urinary Tract Infections in Pediatric Patients</style></title><secondary-title><style face="normal" font="default" size="100%">Annals of Pharmacotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Annals of Pharmacotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1349-1356</style></pages><volume><style face="normal" font="default" size="100%">49</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">children</style></keyword><keyword><style face="normal" font="default" size="100%">cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">cranberry juice</style></keyword><keyword><style face="normal" font="default" size="100%">pediatrics</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: To evaluate the existing data regarding the use of cranberry products for the prevention of urinary tract infections (UTIs) in pediatric patients. Data Sources: A literature search of Medline databases from 1966 to June 2015 was conducted. Study Selection and Data Extraction: The databases were searched using the terms “pediatrics,” “children,” “cranberry,” “cranberry juice,” and “urinary tract infections.” The identified trials were then searched for additional references applicable to this topic. Data Synthesis: A total of 8 clinical trials were identified that examined the use of cranberry products, mostly juice, for the prevention of UTIs in children. Three trials examined the use in otherwise healthy children. Five trials examined the use in pediatric patients with underlying urogenital abnormalities of which 2 compared cranberry to antibiotics. In healthy pediatric patients, cranberry use was associated with a reduction in the overall number of UTIs and a decrease in the number of antibiotic days per year for UTI treatment. In patients with urogenital abnormalities, results were conflicting, with some studies showing no reduction in UTIs compared with placebo, but others demonstrating a significant reduction. However, cranberry products had similar efficacy when compared with both cefaclor and trimethoprim. All studies used a wide variety of doses and frequencies of cranberry, making specific product recommendations difficult. Conclusions: Cranberry appears effective for the prevention of UTIs in otherwise healthy children and is at least as effective as antibiotics in children with underlying urogenital abnormalities. However, recommendations for cranberry dosing and frequency cannot be confidently made at this time. Larger, well-designed trials are recommended. © 2015, © The Author(s) 2015.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :5&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84947256401&amp;doi=10.1177%2f1060028015606729&amp;partnerID=40&amp;md5=66ee97c2c7c2008d3d00bb788937456b</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1177/1060028015606729</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>90</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">90</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Duran, M. R.</style></author><author><style face="normal" font="default" size="100%">Sönnichsen, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institut für Allgemeinmedizin und Familienmedizin, Universität Witten, Herdecke, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberries for treatment and prophylaxis of urinary tract infections - Really helpful?</style></title><secondary-title><style face="normal" font="default" size="100%">Zeitschrift fur Allgemeinmedizin</style></secondary-title><short-title><style face="normal" font="default" size="100%">Cranberry zur therapie und prophylaxe von harnwegsinfekten - Was bringt es wirklich?</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Zeitschrift fur Allgemeinmedizin</style></full-title></periodical><pages><style face="normal" font="default" size="100%">439-442</style></pages><volume><style face="normal" font="default" size="100%">93</style></volume><number><style face="normal" font="default" size="100%">11</style></number><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Frage: Besonders zur Rezidivprophylaxe bei rezidivierenden Harnwegsinfekten werden immer wieder Cranberry-Produkte als natürliche, pflanzliche Heilmittel angepriesen. Gibt es Studien zu Wirkungen und Risiken dieser Therapie? Antwort: Die Studienlage zur Effektivität von Cranberry-Präparaten in der Behandlung oder Prophylaxe von Harnwegsinfektionen ist uneinheitlich. Während die Behandlung akuter Infektionen wenig erfolgversprechend ist, zeigt sich in der Prophylaxe ein positiver Trend in zahlreichen RCTs, der allerdings durch Qualitätsmängel der Studien und möglichen Publikationsbias relativiert wird. Allerdings konnte in mehreren RCTs auch kein eindeutiger Vorteil einer Antibiotikaprophylaxe gegenüber Cranberry nachgewiesen werden, und wenn, dann zum Preis von unerwünschten Wirkungen und Begünstigung von Resistenzbildung, während durch Cranberry kaum unerwünschte Wirkungen zu erwarten sind. Aus diesem Grunde erscheint ein Therapieversuch mit Cranberry durchaus gerechtfertigt, besonders wenn der Patient eine natürliche pflanzliche Behandlung einer dauerhaften Antibiotikaeinnahme vorzieht und den Geschmack von Cranberry toleriert. Question: Especially in the prevention of recurrent urinary tract infections (UTI) cranberry products are frequently recommended as a natural phytotherapeutic option. Are there studies providing evidence for benefits and harms of this treatment? Answer: Studies on the effectiveness of cranberry in treatment and prophylaxis of urinary tract infections show inconsistent results. While the treatment of acute infections is most likely unsuccessful, prophylactic therapy seems promising in a number of RCTs, although this positive trend is compromised by quality deficits of the studies and probable publication bias. On the other hand, studies comparing antibiotic prophylaxis with cranberry did not reveal a clear advantage of antibiotics, and if so at the price of adverse drug events and induction of bacterial resistance while cranberry rarely causes relevant adverse events. Therefore, a therapeutic attempt with cranberry seems well justified, especially if the patient prefers phytothera-peutic, non-antibiotic treatment and tolerates the taste of cranberry.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85034805306&amp;partnerID=40&amp;md5=913ce48aaf6a7cae43298a36471d2e31</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>555</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">555</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dupont, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Service de Néonatologie, Hôpital St Vincent de Paul, 82 avenue Denfert-Rochereau, 75014 Paris, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">Probiotics and prebiotics</style></title><secondary-title><style face="normal" font="default" size="100%">Medecine Therapeutique Pediatrie</style></secondary-title><short-title><style face="normal" font="default" size="100%">Probiotiques et prébiotiques</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Medecine Therapeutique Pediatrie</style></full-title></periodical><pages><style face="normal" font="default" size="100%">49-53</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036290850&amp;partnerID=40&amp;md5=7dff465519e2554e619c3a9c5b28d83e</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>554</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">554</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dunning, M.</style></author><author><style face="normal" font="default" size="100%">Stonehewer, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Urinary tract infections in small animals: Therapeutic options and management of problem cases</style></title><secondary-title><style face="normal" font="default" size="100%">In Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">In Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">518-527</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">9</style></number><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><abstract><style face="normal" font="default" size="100%">AN article in the last issue (September 2002, pp 418-432) discussed the aetiology and pathophysiology of urinary tract infections (UTIs) in dogs and cats and outlined an approach to the diagnostic work-up. This article describes the treatment options for UTIs and the strategies for long-term control as well as control in recurrent cases. It is important that underlying causes are determined (see previous article) and resolved, where possible, prior to the initiation of therapy. UTIs occurring secondarily to underlying conditions may not be appropriately managed by antibiotic therapy alone.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036799550&amp;doi=10.1136%2finpract.24.9.518&amp;partnerID=40&amp;md5=8d031c5a50d397b92d0a08626fb8f286</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/inpract.24.9.518</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>549</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">549</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dunne, C.</style></author><author><style face="normal" font="default" size="100%">Shanahan, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Cork Cancer Research Center, Department of Medicine, National University of Ireland, Cork, Ireland&#xD;Department of Medicine, Clinical Sciences Building, Cork University Hospital, Cork, Ireland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Role of probiotics in the treatment of intestinal infections and inflammation</style></title><secondary-title><style face="normal" font="default" size="100%">Current Opinion in Gastroenterology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Opinion in Gastroenterology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">40-45</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><abstract><style face="normal" font="default" size="100%">Despite the relative success of analogous approaches in soil, aquatic, and animal environments, the enhancement of human health through probiotic consumption has not been generally endorsed in modern medicine. Laboratory-based studies are elucidating the mechanisms that mediate the properties attributed to beneficial lactic acid bacteria and Saccharomyces species in vivo. This research is now providing fundamental evidence to support observations of adhesion of probiotic species to intestinal tissue, antimicrobial activities, and immunomodulation. Probiotics appear to have a promising future in the treatment of certain disorders. Rigorously performed, controlled, double-blinded trials will overcome doubts relating to efficacy in vivo and open avenues along which probiotic-based therapies will rapidly progress. As a result of our emerging understanding of microbial activities and gene expression in situ, novel strategies will combine complementary probiotic functionalities in the form of microbial consortia or genetically enhanced organisms. As scientific knowledge and biotechnologic proficiency advance at an accelerating pace, the requirement for informed legislation and for mechanisms of effectively delivering these therapies to the sites of their intended function may limit the applications of probiotics. © 2002 Lippincott Williams &amp; Wilkins, Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :22&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036140190&amp;doi=10.1097%2f00001574-200201000-00007&amp;partnerID=40&amp;md5=83b3046fc18e3fc57f26d49cc30172e3</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/00001574-200201000-00007</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>603</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">603</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dulawa, J.</style></author><author><style face="normal" font="default" size="100%">Jann, K.</style></author><author><style face="normal" font="default" size="100%">Thomsen, M.</style></author><author><style face="normal" font="default" size="100%">Rambausek, M.</style></author><author><style face="normal" font="default" size="100%">Ritz, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, University of Heidelberg, Freiburg, Germany&#xD;Max-Planck-Institut für Immunbiologie, Freiburg, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Tamm Horsfall glycoprotein interferes with bacterial adherence to human kidney cells</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Clinical Investigation</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Clinical Investigation</style></full-title></periodical><pages><style face="normal" font="default" size="100%">87-91</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">bacterial adherence</style></keyword><keyword><style face="normal" font="default" size="100%">diabetes mellitus</style></keyword><keyword><style face="normal" font="default" size="100%">pyelonephritis</style></keyword><keyword><style face="normal" font="default" size="100%">Tamm Horsfall glycoprotein</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1988</style></year></dates><abstract><style face="normal" font="default" size="100%">Abstract. The effect of Tamm Horsfall protein (THP) of 18 healthy subjects and 14 diabetics on adherence of Escherichia coli (06:K13) 2699 strain to human kidney cells (HUK) was studied. Adhesion of bacteria (without additions: 100 bacteria per cell) was reduced dose‐dependently by THP, half maximal inhibition occurring with 250 μg THP ml‐1. Maximal inhibition (– 84% at 1000 μg ml‐1) exceeded inhibition by alphamethyl‐mannoside (36% at 50 mM), was specific (not reproduced by other glycoproteins, e.g. ovalbumin, mucin or thyroglobulin) and reversible (abolished by washing THP off HUK cells). Anti‐adherence property of THP was not abolished by neuraminidase treatment. No significant difference of anti‐adherence activity of THP was found between controls and diabetics, despite altered carbohydrate composition of THP in diabetes. Copyright © 1988, Wiley Blackwell. All rights reserved</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :37&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023940041&amp;doi=10.1111%2fj.1365-2362.1988.tb01171.x&amp;partnerID=40&amp;md5=a0ad716c535fda7f23e39422221a50fe</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1365-2362.1988.tb01171.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>380</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">380</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dugoua, J. J.</style></author><author><style face="normal" font="default" size="100%">Seely, D.</style></author><author><style face="normal" font="default" size="100%">Perri, D.</style></author><author><style face="normal" font="default" size="100%">Mills, E.</style></author><author><style face="normal" font="default" size="100%">Koren, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Graduate Department of Pharmaceutical Sciences, Leslie Dan Facility of Pharmacy, University of Toronto&#xD;Motherisk Program, Hospital for Sick Children, Toronto, Canada&#xD;Department of Research and Clinical Epidemiology, Canadian College of Naturopathic Medicine&#xD;Institute of Medical Science, University of Toronto&#xD;Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada&#xD;Division of Clinical Pharmacology and Toxicology, University of Toronto, Toronto, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Safety and efficacy of cranberry (Vaccinium Macrocarpon) during pregnancy and lactation</style></title><secondary-title><style face="normal" font="default" size="100%">Canadian Journal of Clinical Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Canadian Journal of Clinical Pharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">e80-e86</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Breastfeeding</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Lactation</style></keyword><keyword><style face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style face="normal" font="default" size="100%">Systematic review</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: There is a lack of basic knowledge on the part of both clinicians and patients as to the indications for use and safety of herbs used during pregnancy and lactation. This is one article in a series that systematically reviews the evidence for herbs commonly used during pregnancy and lactation. Objectives: To systematically review the literature for evidence on the use, safety and pharmacology of cranberry, focusing on issues pertaining to pregnancy and lactation. Methods: We searched 7 electronic databases and compiled data according to the grade of evidence found. Results: There is no direct evidence of safety or harm to the mother or fetus as a result of consuming cranberry during pregnancy. Indirectly, there is good scientific evidence that cranberry may be of minimal risk, where a survey of 400 pregnant women did not uncover any adverse events when cranberry was regularly consumed. In lactation, the safety or harm of cranberry is unknown. Conclusions: Women experience urinary tract infections with greater frequency during pregnancy. Given the evidence to support the use of cranberry for urinary tract infections (UTIs) and its safety profile, cranberry supplementation as fruit or fruit juice may be a valuable therapeutic choice in the treatment of UTIs during pregnancy. ©2008 Canadian Society for Clinical Pharmacology. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :38&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-38549098501&amp;partnerID=40&amp;md5=4e7e6bd322c814d152829e2cef9da402</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>203</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">203</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Duffey, K. J.</style></author><author><style face="normal" font="default" size="100%">Sutherland, L. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Human Nutrition, Foods and Exercise, Virginia Tech, 223 Wallace Hall, 295 Campus Drive, Blacksburg, VA 24061, United States&#xD;LA Sutherland Consulting, LLC, 6 Mink Drive, Hanover, NH 03755, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Adult cranberry beverage consumers have healthier macronutrient intakes and measures of body composition compared to non-consumers: National health and nutrition examination survey (NHANES) 2005-2008</style></title><secondary-title><style face="normal" font="default" size="100%">Nutrients</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nutrients</style></full-title></periodical><pages><style face="normal" font="default" size="100%">4938-4949</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adults</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Flavonoids</style></keyword><keyword><style face="normal" font="default" size="100%">Obesity</style></keyword><keyword><style face="normal" font="default" size="100%">Sugar sweetened beverages</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Flavonoids, present in high levels in cranberries, are potent bioactives known for their health-promoting benefits, but cranberry beverages (CB) are not typically recommended as part of a healthy diet. We examine the association between CB consumption with macronutrient intake and weight status. Data for US adults (≥19 years, n = 10,891) were taken from the National Health and Nutrition Examination Survey (NHANES) Survey 2005-2008. Total CB consumption was measured over two non-consecutive 24-h dietary recalls. Linear and logistic regression models adjusting for important covariates were used to examine predicted differences between CB consumers and non-consumers on macronutrient and anthropometric outcomes. Results are weighted to be nationally representative. CB consumers (n = 581) were older (&amp;gt;50 year) non-Hispanic black females. They consumed an average 221 mL (7.5 oz) CB per day. In fully adjusted models CB consumers (vs. non-consumers) had higher carbohydrates and total sugars and lower percent energy from protein and total fat (all p &amp;lt; 0.001), but no difference in total energy. A significantly higher proportion of CB consumers were predicted to be normal weight (BMI &amp;lt; 25 kg/m2; p = 0.001) and had to have lower waist circumferences (p = 0.001). Although there was not a significant trend across level of CB intake, low and middle level CB consumers compared to non-consumers were more likely to be normal weight (p &amp;lt; 0.001) and less likely to be overweight/obese (BMI ≥ 25 kg/m2, p &amp;lt; 0.001). Despite having slightly higher daily macronutrient intakes, CB consumers have more desirable anthropometric measures compared to non-consumers. © 2013 by the authors; licensee MDPI, Basel, Switzerland.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84889565803&amp;doi=10.3390%2fnu5124938&amp;partnerID=40&amp;md5=0a9c1f2f2cedf45170f644e358f1dbc8</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/nu5124938</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>271</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">271</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Doležel, Z.</style></author><author><style face="normal" font="default" size="100%">Dostálková, D.</style></author><author><style face="normal" font="default" size="100%">Štarha, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pediatrická klinika, LF MU a FN Brno, Czech Republic</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infection - what is and what is not new</style></title><secondary-title><style face="normal" font="default" size="100%">Pediatrie pro Praxi</style></secondary-title><short-title><style face="normal" font="default" size="100%">Infekce močových cest - co je a co není zcela nové</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pediatrie pro Praxi</style></full-title></periodical><pages><style face="normal" font="default" size="100%">300-303</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Acute pyelonephritis</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">In recent years, added some new evidence relating to the issue of urinary tract infections (UTI). Critically, it is clear that so far only a part of this new knowledge found its use in routine clinical practice. Many problems are solved by the UTI in a number of ongoing studies and they can expect in the coming years will be to review some best practices. Constant attention is especially important to pediatricians acute pyelonephritis (AP), which are often the lowest in children aged nonspecific clinical symptoms and can sometimes be diagnosed late. Especially after repeated episodes of AP in the kidneys, then the scar tissue can cause chronic renal failure.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84860795984&amp;partnerID=40&amp;md5=bfd0f391c550d652788ada9a0824ba6d</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>185</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">185</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Disaanayake, D. M. B. T.</style></author><author><style face="normal" font="default" size="100%">Faoagali, J.</style></author><author><style face="normal" font="default" size="100%">Laroo, H.</style></author><author><style face="normal" font="default" size="100%">Hancock, G.</style></author><author><style face="normal" font="default" size="100%">Whitehouse, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pathology Queensland, Princess Alexandra Hospital, Brisbane, QLD 4102, Australia&#xD;Laroo Research, Ipswich, QLD, Australia&#xD;Wellness Focus Centre (WFC), Brisbane, QLD, Australia&#xD;School of Biomolecular and Physical Sciences, Griffith University, Brisbane, QLD 4111, Australia&#xD;Microbiology Department, University of Sri Jayewardenepura, Sri Jayewardenepura Kotte, Sri Lanka</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy of some colloidal silver preparations and silver salts against Proteus bacteria, one possible cause of rheumatoid arthritis</style></title><secondary-title><style face="normal" font="default" size="100%">Inflammopharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Inflammopharmacology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">73-77</style></pages><volume><style face="normal" font="default" size="100%">22</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Nanoparticulate silver</style></keyword><keyword><style face="normal" font="default" size="100%">Proteus</style></keyword><keyword><style face="normal" font="default" size="100%">Rheumatoid arthritis</style></keyword><keyword><style face="normal" font="default" size="100%">Silver antimicrobials</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">There has been increased interest in the role of anti-Proteus antibodies in the aetiology of rheumatoid arthritis (RA) and whether chemotherapeutic agents active against Proteus species might reduce the risk and/or exacerbations of RA. We examined the in vitro antibacterial effects of ten different silver preparations which were either ionic silver [Ag(I)] solutions or nanoparticulate silver (NPS) (Ag0) suspensions against ATCC and two wild (clinical) strains of Proteus. The data establish the low minimum inhibitory concentration and minimum bactericidal concentration of all the silver formulations tested against these four Proteus strains. In a pilot study, a potent NPS preparation ex vivo showed long-lasting anti-Proteus activity in a normal human volunteer. © 2014 Springer.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84896073188&amp;doi=10.1007%2fs10787-013-0198-0&amp;partnerID=40&amp;md5=20a07392df29aaeff7256649fb07463c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10787-013-0198-0</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>21</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">21</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dingjan, T.</style></author><author><style face="normal" font="default" size="100%">Gillon, É</style></author><author><style face="normal" font="default" size="100%">Imberty, A.</style></author><author><style face="normal" font="default" size="100%">Pérez, S.</style></author><author><style face="normal" font="default" size="100%">Titz, A.</style></author><author><style face="normal" font="default" size="100%">Ramsland, P. A.</style></author><author><style face="normal" font="default" size="100%">Yuriev, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia&#xD;University Grenoble Alpes, CNRS, CERMAV, Grenoble, 38000, France&#xD;University Grenoble Alpes, CNRS, DPM, Grenoble, 38000, France&#xD;Chemical Biology of Carbohydrates, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, Saarbrücken, D-66123, Germany&#xD;Deutsches Zentrum für Infektionsforschung (DZIF), Standort Hannover-Braunschweig, Germany&#xD;Department of Pharmacy, Saarland University, Saarbrücken, D-66123, Germany&#xD;School of Science, RMIT University, Bundoora, VIC 3083, Australia&#xD;Department of Surgery Austin Health, University of Melbourne, Heidelberg, VIC 3084, Australia&#xD;Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Melbourne, VIC 3004, Australia&#xD;Burnet Institute, Melbourne, VIC 3004, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Virtual Screening Against Carbohydrate-Binding Proteins: Evaluation and Application to Bacterial Burkholderia ambifaria Lectin</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Chemical Information and Modeling</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Chemical Information and Modeling</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1976-1989</style></pages><volume><style face="normal" font="default" size="100%">58</style></volume><number><style face="normal" font="default" size="100%">9</style></number><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Bacterial adhesion to human epithelia via lectins constitutes a therapeutic opportunity to prevent infection. Specifically, BambL (the lectin from Burkholderia ambifaria) is implicated in cystic fibrosis, where lectin-mediated bacterial adhesion to fucosylated lung epithelia is suspected to play an important role. We employed structure-based virtual screening to identify inhibitors of BambL-saccharide interaction with potential therapeutic value. To enable such discovery, a virtual screening protocol was iteratively developed via 194 retrospective screening protocols against 4 bacterial lectins (BambL, BC2L-A, FimH, and LecA) with known ligands. Specific attention was given to the rigorous evaluation of retrospective screening, including calculation of analytical errors for enrichment metrics. The developed virtual screening workflow used crystallographic constraints, pharmacophore filters, and a final manual selection step. The protocol was applied to BambL, predicting 15 active compounds from virtual libraries of approximately 7 million compounds. Experimental validation using fluorescence polarization confirmed micromolar inhibitory activity for two compounds, which were further characterized by isothermal titration calorimetry and surface plasmon resonance. Subsequent testing against LecB from Pseudomonas aeruginosa demonstrated binding specificity of one of the hit compounds. This report demonstrates the utility of virtual screening protocols, integrating ligand-based pharmacophore filtering and structure-based constraints, in the search for bacterial lectin inhibitors. © 2018 American Chemical Society.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052336278&amp;doi=10.1021%2facs.jcim.8b00185&amp;partnerID=40&amp;md5=c4f548d80a5a0bfbd3601f1aff74ac46</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/acs.jcim.8b00185</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>297</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">297</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dielubanza, E. J.</style></author><author><style face="normal" font="default" size="100%">Schaeffer, A. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Northwestern University, Feinberg School of Medicine, 303 East Chicago Avenue, Tarry 16-703, Chicago, IL 60611-3008, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections in women</style></title><secondary-title><style face="normal" font="default" size="100%">Medical Clinics of North America</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Medical Clinics of North America</style></full-title></periodical><pages><style face="normal" font="default" size="100%">27-41</style></pages><volume><style face="normal" font="default" size="100%">95</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Women</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infection (UTI) is the most common extraintestinal infectious disease entity in women worldwide, and perhaps one of the most formidable challenges in clinical practice given its high prevalence, frequent recurrence, and myriad associated morbidities in the setting of rapidly evolving antimicrobial resistance. Achieving timely symptom relief and infection control and preventing morbidity, growth of resistant organisms, and recurrent infection are often difficult. This article reviews epidemiology and pathogenesis of urinary tract infection in women; characterizes common patterns of infection, clinical red flags, and appropriate laboratory testing and imaging; explores emerging patterns of antimicrobial resistance; and reviews the updated guidelines for the treatment of uncomplicated UTI in women. © 2011.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :108&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-78649385067&amp;doi=10.1016%2fj.mcna.2010.08.023&amp;partnerID=40&amp;md5=cb24d8907ae16da3a4dfdc05d95e0d4e</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.mcna.2010.08.023</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>435</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">435</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Di Martino, P.</style></author><author><style face="normal" font="default" size="100%">Agniel, R.</style></author><author><style face="normal" font="default" size="100%">David, K.</style></author><author><style face="normal" font="default" size="100%">Templer, C.</style></author><author><style face="normal" font="default" size="100%">Gaillard, J. L.</style></author><author><style face="normal" font="default" size="100%">Denys, P.</style></author><author><style face="normal" font="default" size="100%">Botto, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratoire ERRMECe (EA1391), Université de Cergy-Pontoise, 2 Avenue A. Chauvin, 95302 Pontoise Cedex, France&#xD;Service de Médecine des Personnels, Université de Cergy-Pontoise, Pontoise, France&#xD;Laboratoire de Microbiologie, Hôpital Raymond Poincaré, Garches, France&#xD;Service de Médecine Physique et de Réadaptation, Hôpital Raymond Poincaré, Garches, France&#xD;Service d&apos;Urologie, Hôpital Foch, Garches, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reduction of Escherichia coli adherence to uroepithelial bladder cells after consumption of cranberry juice: A double-blind randomized placebo-controlled cross-over trial</style></title><secondary-title><style face="normal" font="default" size="100%">World Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">World Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">21-27</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adherence</style></keyword><keyword><style face="normal" font="default" size="100%">Colonization</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Pili</style></keyword><keyword><style face="normal" font="default" size="100%">Trial</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">To determine the efficacy of the consumption of cranberry juice versus placebo with regard to the presence of in vitro bacterial anti-adherence activity in the urine of healthy volunteers. Twenty healthy volunteers, 10 men and 10 women, were included. The study was a double-blind, randomized, placebo-controlled, and cross-over study. In addition to normal diet, each volunteer received at dinner a single dose of 750 ml of a total drink composed of: (1) 250 ml of the placebo and 500 ml of mineral water, or (2) 750 ml of the placebo, or (3) 250 ml of the cranberry juice and 500 ml of mineral water, or (4) 750 ml of the cranberry juice. Each volunteer took the four regimens successively in a randomly order, with a washout period of at least 6 days between every change in regimen. The first urine of the morning following cranberry or placebo consumption was collected and used to support bacterial growth. Six uropathogenic Escherichia coli strains (all expressing type 1 pili; three positive for the gene marker for P-fimbriae pap C and three negative for pap C), previously isolated from patients with symptomatic urinary tract infections, were grown in urine samples and tested for their ability to adhere to the T24 bladder cell line in vitro. There were no significant differences in the pH or specific gravity between the urine samples collected after cranberry or placebo consumption. We observed a dose dependent significant decrease in bacterial adherence associated with cranberry consumption. Adherence inhibition was observed independently from the presence of genes encoding type P pili and antibiotic resistance phenotypes. Cranberry juice consumption provides significant anti-adherence activity against different E. coli uropathogenic strains in the urine compared with placebo. © Springer-Verlag 2006.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :102&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33644541090&amp;doi=10.1007%2fs00345-005-0045-z&amp;partnerID=40&amp;md5=f725d4c802eabab3b324e9f695f9e31e</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00345-005-0045-z</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>457</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">457</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Devillard, E.</style></author><author><style face="normal" font="default" size="100%">Burton, J. P.</style></author><author><style face="normal" font="default" size="100%">Reid, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Canadian Research and Development Centre for Probiotics, Lawson Health Research Institute, London, Ont., Canada&#xD;Department of Microbiology and Immunology, University of Western Ontario, London, Ont., Canada&#xD;BLIS Technologies, Centre for Innovation, University of Otago, Dunedin, New Zealand&#xD;Canadian Research and Development Centre for Probiotics, Lawson Health Research Institute, 268 Grosvenor Street, London, Ont. N6A 4V2, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Complexity of vaginal microflora as analyzed by PCR denaturing gradient gel electrophoresis in a patient with recurrent bacterial vaginosis</style></title><secondary-title><style face="normal" font="default" size="100%">Infectious Disease in Obstetrics and Gynecology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infectious Disease in Obstetrics and Gynecology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">25-30</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bacterial vaginosis</style></keyword><keyword><style face="normal" font="default" size="100%">Diagnosis</style></keyword><keyword><style face="normal" font="default" size="100%">PCR-DGGE</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Vaginal microflora</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: Gardnerella vaginalis has long been the most common pathogen associated with bacterial vaginosis (BV). We aimed to test our hypothesis that symptoms and signs of BV do not necessarily indicate colonization by this organism, and often will not respond to standard metronidazole or clindamycin treatment. Methods: Using a relatively new molecular tool, PCR denaturing gradient gel electrophoresis (DGGE), the vaginal microflora of a woman with recalcitrant signs and symptoms of BV was investigated over a 6-week timeframe. Results: The vagina was colonized by pathogenic enterobacteriaceae, staphylococci and Candida albicans. The detection of the yeast by PCR-DGGE is particularly novel and enhances the ability of this tool to examine the true nature of the vaginal microflora. The patient had not responded to antifungal treatment, antibiotic therapy targeted at anaerobic Gram-negative pathogens such as Gardnerella, nor daily oral probiotic intake of Lactobacillus rhamnosus GG. The failure to find the GG strain in the vagina indicated it did not reach the site, and the low counts of lactobacilli demonstrated that therapy with this probiotic did not appear to influence the vaginal flora. Conclusions: BV is not well understood in terms of its causative organisms, and further studies appear warranted using non-culture, molecular methods. Only when the identities of infecting organisms are confirmed can effective therapy be devized. Such therapy may include the use of probiotic lactobacilli, but only using strains which confer a benefit on the vagina of pre- and postmenopausal women. © 2005 Taylor &amp; Francis Group Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :23&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-18744401362&amp;doi=10.1080%2f10647440400025504&amp;partnerID=40&amp;md5=0c74494fb54bc45be672c57b1f18ae3f</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1080/10647440400025504</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>144</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">144</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Detweiler, K.</style></author><author><style face="normal" font="default" size="100%">Mayers, D.</style></author><author><style face="normal" font="default" size="100%">Fletcher, S. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Touro University College of Osteopathic Medicine - California, 1310 Club Drive, Vallejo, CA 94592, United States&#xD;Kaiser Permanente Northern California, 401 Bicentennial Way, Santa Rosa, CA 95403, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bacteruria and Urinary Tract Infections in the Elderly</style></title><secondary-title><style face="normal" font="default" size="100%">Urologic Clinics of North America</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Urologic Clinics of North America</style></full-title></periodical><pages><style face="normal" font="default" size="100%">561-568</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Asymptomatic bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">Bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Pyuria</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Both urinary tract infection (UTI) and asymptomatic bacteriuria (ASB) are common problems among elderly adults and represent a significant health care burden. Despite their frequency, differentiating between ASB and true UTI remains controversial among health care providers. Several challenges exist in the evaluation of urinary symptoms in the elderly patient. Symptoms of UTI are variable; problems are encountered in the collection, testing, and interpretation of urine specimens; and results of urinalysis are often misinterpreted and mishandled. Multiple studies have shown no morbidity or mortality benefit to antibiotic therapy in either community or long-term care facility residents with ASB. © 2015 Elsevier Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :21&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84945460849&amp;doi=10.1016%2fj.ucl.2015.07.002&amp;partnerID=40&amp;md5=cc2c5087681135fb1c5c3316c133d1bc</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ucl.2015.07.002</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>276</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">276</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dessì, A.</style></author><author><style face="normal" font="default" size="100%">Atzei, A.</style></author><author><style face="normal" font="default" size="100%">Fanos, V.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Paediatrics, Neonatal Intensive Care Unit, Neonatal Pathology, Puericultura Institute and Neonatal Section, University of Cagliari, Italy&#xD;Department of Paediatrics, Neonatal Intensive Care Unit, Neonatal Pathology, Puericultura Institute and Neonatal Section, Azienda Ospedaliero Universitaria, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry in children: Prevention of recurrent urinary tract infections and review of the literature</style></title><secondary-title><style face="normal" font="default" size="100%">Brazilian Journal of Pharmacognosy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Brazilian Journal of Pharmacognosy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">807-813</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Children</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenic bladder</style></keyword><keyword><style face="normal" font="default" size="100%">Pediatrics</style></keyword><keyword><style face="normal" font="default" size="100%">UTI</style></keyword><keyword><style face="normal" font="default" size="100%">VUR</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTI) are common in childhood. In 30-50% of children with UTI the infections occur recurrently, especially in those with vesicoureteral reflux (VUR), neurogenic bladder (NB), previous cystitis or pyelonephritis and malformative uropathies. To reduce the likelihood of UTI, antibiotic prophylaxis has been regarded as the therapeutic standard for many years. However, the disadvantage of long-term antibiotic therapy is the potential for development of collateral effects and resistant organisms in the host. Such reasons have induced scientists to search for alternative modalities of UTI prevention and have contributed to determining the increasing desire for &quot;naturalness&quot; of the population and preventing excessive medication. The use of cranberry fulfils these needs by potentially replacing or enhancing traditional procedures. The purpose of this study was to assess the effectiveness of cranberry in preventing UTI in pediatric populations. We searched Pubmed, the Cochrane Central Register of Controlled Trials and Internet. Cranberry in patients with previous UTI was evaluated in three studies, cranberry in patients with VUR in three studies and four studies analyzed the efficacy of cranberry in children with NB. In seven of nine studies cranberry had a significant effect in preventing UTI.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-80053442634&amp;doi=10.1590%2fS0102-695X2011005000126&amp;partnerID=40&amp;md5=b86562071c61fb6d4f79b488d52ed1f0</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1590/S0102-695X2011005000126</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>415</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">415</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Desireddi, N. V.</style></author><author><style face="normal" font="default" size="100%">Schaeffer, A. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States&#xD;Department of Urology, Feinberg School of Medicine, Northwestern University Medical School, Chicago, IL, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary Tract Infections</style></title><secondary-title><style face="normal" font="default" size="100%">Multidisciplinary Management of Female Pelvic Floor Disorders</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">297-305</style></pages><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84882860309&amp;doi=10.1016%2fB978-0-443-07272-7.50030-1&amp;partnerID=40&amp;md5=3784793c5d7f5c9dd96934ce859b5364</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/B978-0-443-07272-7.50030-1</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>245</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">245</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Denev, P. N.</style></author><author><style face="normal" font="default" size="100%">Kratchanov, C. G.</style></author><author><style face="normal" font="default" size="100%">Ciz, M.</style></author><author><style face="normal" font="default" size="100%">Lojek, A.</style></author><author><style face="normal" font="default" size="100%">Kratchanova, M. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Biologically Active Substances, 139 Ruski Blvd, Plovdiv-4000, Bulgaria&#xD;Vitanea Ltd., 20 d-r G.M. Dimitrov str., Plovdiv-4000, Bulgaria&#xD;Inst. of Biophysics of the Academy of Sciences of the Czech Republic, Kralovopolska 135, 612 65 Brno, Switzerland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bioavailability and Antioxidant Activity of Black Chokeberry (Aronia melanocarpa) Polyphenols: In vitro and in vivo Evidences and Possible Mechanisms of Action: A Review</style></title><secondary-title><style face="normal" font="default" size="100%">Comprehensive Reviews in Food Science and Food Safety</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Comprehensive Reviews in Food Science and Food Safety</style></full-title></periodical><pages><style face="normal" font="default" size="100%">471-489</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antioxidant activity</style></keyword><keyword><style face="normal" font="default" size="100%">Aronia melanocarpa</style></keyword><keyword><style face="normal" font="default" size="100%">Bioavailability</style></keyword><keyword><style face="normal" font="default" size="100%">Chokeberry</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Black chokeberry (Aronia melanocarpa) is a distinctive berry with a high content of polyphenol compounds and possesses one of the highest in vitro antioxidant activities among fruits. The bioavailability of aronia polyphenols seems to be low, but there is ample evidence for chokeberry health benefits including antidiabetic, cardioprotective, hepatoprotective, antimutagenic, and anticarcinogenic effects. This review presents the available information for the bioavailability and antioxidant activity of chokeberry polyphenols and explains the possible mechanisms of action in vivo in the prevention and treatment of oxidative stress-related diseases. The review shows the available data for chokeberry antioxidant activity in vitro, in isolated cells and cell lines, and in vivo, in both human subjects and animals. It is evident that in vivo antioxidant action of chokeberry extends far beyond radical scavenging and includes suppression of reactive oxygen and nitrogen species formation, inhibition of prooxidant enzymes, restoration of antioxidant enzymes, and probably cellular signaling to regulate the level of antioxidant compounds and enzymes. The original contribution of this work is that it compiles the available information up to date and outlines the gaps and future directions in the assessment of chokeberry antioxidant action in vivo. © 2012 Institute of Food Technologists®.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :81&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84865571888&amp;doi=10.1111%2fj.1541-4337.2012.00198.x&amp;partnerID=40&amp;md5=716fe97dab02b44e8de4b5eed01dc517</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1541-4337.2012.00198.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>200</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">200</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">den Heijer, C. D. J.</style></author><author><style face="normal" font="default" size="100%">Stobberingh, E. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medical Microbiology, Maastricht University Medical Centre/CAPHRI, PO Box 5800, Maastricht, 6202AZ, Netherlands&#xD;National Institute for Public Health and the Environment, Centre for Infectious Disease Control Netherlands (CIb), Bilthoven, Netherlands</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antibiotic and non-antibiotic methods of prophylaxis for recurrent urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Urinary Tract Infections: Epidemiology, Pathogenesis and Prevention</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1-16</style></pages><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTIs) are one of the most common bacterial infections seen. Episodes of UTI can effectively be treated with antibiotics, often given on an empirical basis. For patients with recurrent UTIs, i.e., patients with at least 3 UTIs within a period of 12 months, antibiotic prophylaxis has been shown to reduce the number of UTI episodes. However, this poses a high selective antibiotic pressure on the bacteria causing the UTIs, i.e., the uropathogens, in this patient population. For this reason, several non-antibiotic alternatives for the prophylaxis of UTIs have been developed in order to reduce the antibiotic load to which uropathogens are exposed. In this chapter we review the current options, antibiotic as well as non-antibiotic alternatives, for the prevention of rUTIs. In summary, antibiotic alternatives to the continuous low-dose antibiotic prophylaxis, such as self-treatment and post-coital prophylaxis, show promising results, although these regimens will not be applicable to all women with rUTI. The effectiveness of most nonantibiotic alternatives remains inconclusive, mainly because of the lack of trials among human subjects or inconsistency in the type and dosage used in clinical trials. We opt for consensus on the specific regimen that needs evaluation for each non-antibiotic group, which makes powerful metaanalyses possible. Hereby, the actual value of specific non-antibiotic options could be assessed, increasing the chance of incorporating an effective non-antibiotic option in clinical guidelines. Subsequently, the substantial antibiotic use among women with rUTI will be lowered, resulting in a better control of antibiotic resistance. © 2014 by Nova Science Publishers, Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84948951092&amp;partnerID=40&amp;md5=fc8876134135b7ca9b7c916021b597ce</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>389</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">389</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Delehanty, J. B.</style></author><author><style face="normal" font="default" size="100%">Johnson, B. J.</style></author><author><style face="normal" font="default" size="100%">Hickey, T. E.</style></author><author><style face="normal" font="default" size="100%">Pons, T.</style></author><author><style face="normal" font="default" size="100%">Ligler, F. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Center for Bio/Molecular Science and Engineering, U.S. Naval Research Laboratory, Washington, DC 20375, United States&#xD;Division of Optical Sciences, U.S. Naval Research Laboratory, Washington, DC 20375, United States&#xD;Laboratoire de Spectroscopie en Lumière Polarisée, CNRS UPR A0005, ESPCI, 10 rue Vauquelin, 75231 Paris Cedex 05, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">Binding and neutralization of lipopolysaccharides by plant proanthocyanidins</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Natural Products</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Natural Products</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1718-1724</style></pages><volume><style face="normal" font="default" size="100%">70</style></volume><number><style face="normal" font="default" size="100%">11</style></number><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">Proanthocyanidins (PACs), polyphenolic metabolites that are widely distributed in higher plants, have been associated with potential positive health benefits including antibacterial, chemotherapeutic, and antiatherosclerotic activities. In this paper, we analyze the binding of PACs from cranberries, tea, and grapes to lipopolysaccharide (LPS), a major component of the outer membrane of Gram-negative bacteria and the cause of several human illnesses. We demonstrate that in the case of cranberries, the most potent LPS-binding activity is contained within a PAC fraction composed of polymers with an average degree of polymerization of 21. The PAC fraction modestly inhibits the binding of LPS to the surface of HEK 293 cells expressing the full complement of LPS receptors (TLR4/MD2 and CD 14), while it significantly abrogates the endocytosis of LPS. This PAC fraction also inhibits LPS-induced nuclear factor-κB activation in a manner that is not readily overcome by excess LPS. Such an effect is mediated through the inhibition of LPS interaction with TLR4/MD2 and the partial abrogation of LPS interaction with CD14. Importantly, PAC concentrations that mediate effective LPS neutralization elicit minimal in vitro cytotoxicity. Our results identify PACs as a new class of LPS-binding compound and suggest that they have potential utility in applications that necessitate either the purification and removal of LPS or the in vivo neutralization of LPS. © 2007 American Chemical Society and American Society of Pharmacognosy.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :34&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-37249080862&amp;doi=10.1021%2fnp0703601&amp;partnerID=40&amp;md5=ec80f92a60e6af5509a74448756e4413</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/np0703601</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>45</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">45</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Del Popolo, G.</style></author><author><style face="normal" font="default" size="100%">Nelli, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Neuro-Urology, Azienda Ospedaliero-Universitaria Careggi, L.go G. Alessandro Brambilla, 3, Firenze, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent bacterial symptomatic cystitis: A pilot study on a new natural option for treatment</style></title><secondary-title><style face="normal" font="default" size="100%">Archivio Italiano di Urologia e Andrologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archivio Italiano di Urologia e Andrologia</style></full-title></periodical><pages><style face="normal" font="default" size="100%">101-103</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bacterial cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">D-mannose</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenic bladder dysfunction, Lactobacillus acidophilus La-14</style></keyword><keyword><style face="normal" font="default" size="100%">Salicin</style></keyword><keyword><style face="normal" font="default" size="100%">UTI</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Objectives: The aim of our study was to explore the effectiveness of the combination of D-mannose, Salicin, and Lactobacillus acidophilus (La-14) in patients complaining recurrent symptomatic cystitis due to E. coli. Materials and methods: From July 2013 to September 2014, 85 consecutive subjects (68 women and 17 men) affected by recurrent symptomatic cystitis were enrolled. Of those, 46 (33 women and 13 men) suffered from neurogenic bladder. Overall 78 patients received an initial 5-days regimen consisting on a tid oral combination of 1000 mg of D-mannose plus 200 mg of dry willow extract (salicin) (attack phase), followed by bid 7-days with 700 mg of D-mannose plus 50 mg (1x109 CFU) of Lactobacillus acidophilus (La-14) (maintenance treatment). The maintenance treatment was repeated every 15 days for the next two months. Patients&apos; symptoms were evaluated through a 3-days bladder diary and a Visual Analogic Scale (VAS). Results: After treatment VAS scores decreased from 8.07 ± 1.70 to 4.74 ± 2.07 (p = 0.001) in non-neurological patients (group A) and from 7.21 ± 1.90 to 3.74 ± 3.12 (p = 0.001) in the neurological patients (group B). A significant reduction of daily frequency was noted in both groups: from 14 ± 3 to 7 ± 3 (p = 0.001) in group A and from 15 ± 3 to 8 ± 3 (p = 0.001) in group B. A reduction of incontinence episodes in Group A patients was observed, as well as in 12/39 Group B. Improvements were maintained during follow-up. Conclusion: This therapeutic approach combining D-Mannose with Salicin (acute treatment) and Lactobacillus acidophilus La-14 (maintaining treatment) seems to be effective in symptomatic bacterial UTIs. Further larger and randomized control trials (RCTs) are needed to confirm our results. © 2018 Edizioni Scripta Manent s.n.c. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054592786&amp;doi=10.4081%2faiua.2018.2.101&amp;partnerID=40&amp;md5=9a5a65735e71ff4c028a8cd1e09f7545</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.4081/aiua.2018.2.101</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>152</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">152</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">De Llano, D. G.</style></author><author><style face="normal" font="default" size="100%">Esteban-Fernández, A.</style></author><author><style face="normal" font="default" size="100%">Sánchez-Patán, F.</style></author><author><style face="normal" font="default" size="100%">Martín-Álvarez, P. J.</style></author><author><style face="normal" font="default" size="100%">Moreno-Arribas, M. V.</style></author><author><style face="normal" font="default" size="100%">Bartolomé, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institute of Food Science Research (CIAL), CSIC-UAM, C/Nicolás Cabrera 9, Madrid, 28049, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anti-adhesive activity of cranberry phenolic compounds and their microbial-derived metabolites against uropathogenic escherichia coli in bladder epithelial cell cultures</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Molecular Sciences</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Molecular Sciences</style></full-title></periodical><pages><style face="normal" font="default" size="100%">12119-12130</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Flavan-3-ols</style></keyword><keyword><style face="normal" font="default" size="100%">Phenolic metabolites</style></keyword><keyword><style face="normal" font="default" size="100%">T-24 cells</style></keyword><keyword><style face="normal" font="default" size="100%">UPEC</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Uropathogenic escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">UTI</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry consumption has shown prophylactic effects against urinary tract infections (UTI), although the mechanisms involved are not completely understood. In this paper, cranberry phenolic compounds and their potential microbial-derived metabolites (such as simple phenols and benzoic, phenylacetic and phenylpropionic acids) were tested for their capacity to inhibit the adherence of uropathogenic Escherichia coli (UPEC) ATCC®53503™ to T24 epithelial bladder cells. Catechol, benzoic acid, vanillic acid, phenylacetic acid and 3,4-dihydroxyphenylacetic acid showed anti-adhesive activity against UPEC in a concentration-dependent manner from 100-500 µM, whereas procyanidin A2, widely reported as an inhibitor of UPEC adherence on uroepithelium, was only statistically significant (p &lt; 0.05) at 500 µM (51.3% inhibition). The results proved for the first time the anti-adhesive activity of some cranberry-derived phenolic metabolites against UPEC in vitro, suggesting that their presence in the urine could reduce bacterial colonization and progression of UTI. © 2015 by the authors; licensee MDPI, Basel, Switzerland.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :24&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84930667805&amp;doi=10.3390%2fijms160612119&amp;partnerID=40&amp;md5=23ae29bf7ed96acfaeae30a1aaaccbcd</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/ijms160612119</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>184</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">184</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Davidson, E.</style></author><author><style face="normal" font="default" size="100%">Zimmermann, B. F.</style></author><author><style face="normal" font="default" size="100%">Jungfer, E.</style></author><author><style face="normal" font="default" size="100%">Chrubasik-Hausmann, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pain Relief Unit, Department of Anesthesia, Hadassah Hebrew University Hospital, Jerusalem, Israel&#xD;Department of Nutrition and Food Sciences - Food Chemistry, University of Bonn, Endenicher Allee 11-13, 53115 Bonn, Germany&#xD;Institut Prof. Dr. Kurz GmbH, Eupener Strasse 161, 50933 Köln, Germany&#xD;Institute of Forensic Medicine, University of Freiburg, Albertstr. 9, 79104 Freiburg, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevention of urinary tract infections with vaccinium products</style></title><secondary-title><style face="normal" font="default" size="100%">Phytotherapy Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Phytotherapy Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">465-470</style></pages><volume><style face="normal" font="default" size="100%">28</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">lingonberry</style></keyword><keyword><style face="normal" font="default" size="100%">prevention</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberries exert a dose-dependent inhibition of the adherence of E. coli fimbriae to uroepithelial cells. This was demonstrated in vitro but also ex vivo in vitro with urine from cranberry consumers. The active principle has not been identified in detail but type-A proanthocyanidins (PAC) play an important role in the mechanism of action. Since the three species, American cranberry (Vaccinium macrocarpon), European cranberry (Vaccinium oxycoccus) and/or lingonberry (Vaccinium vitis-idaea), have different patterns of type-A PACs, results from one species cannot be transferred to the others. It seems likely that most of the studies with monopreparations from V. macrocarpon were underdosed. Whereas photometric PAC quantification may overestimate the true content on co-active compounds, reversed phase high-performance liquid chromatograpy may underestimate them. Recent studies with PAC doses in the upper range (DMAC method) or declared type-A PAC content in the daily dose reveal a dose-dependent trend of clinical effectiveness, however, with a possible ceiling effect. In order to clarify this, future three-arm studies should investigate Vaccinium preparations with higher type-A PAC doses than previously used. We analysed two popular European vitis-idaea products, a mother juice and a proprietary extract. Both preparations may be appropriate to confirm the Vaccinium urinary tract infection-preventive effect beyond doubt. © 2013 John Wiley &amp; Sons, Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :8&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84895822589&amp;doi=10.1002%2fptr.5047&amp;partnerID=40&amp;md5=1938157106ee7cf513bfecb3cc8e4564</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/ptr.5047</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>275</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">275</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dason, S.</style></author><author><style face="normal" font="default" size="100%">Dason, J. T.</style></author><author><style face="normal" font="default" size="100%">Kapoor, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada&#xD;Department of Family Medicine, McMaster University, Hamilton, ON, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Guidelines for the diagnosis and management of recurrent urinary tract infection in women</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the Canadian Urological Association</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the Canadian Urological Association</style></full-title></periodical><pages><style face="normal" font="default" size="100%">316-322</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">5</style></number><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :62&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-80053931997&amp;doi=10.5489%2fcuaj.11214&amp;partnerID=40&amp;md5=ef20b15877c44198cebbd35d46c932b9</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.5489/cuaj.11214</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>239</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">239</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Darouiche, R. O.</style></author><author><style face="normal" font="default" size="100%">Hull, R. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Medical and Spinal Cord Injury Care Lines, Infectious Disease Section, Michael E. DeBakey Veterans Affairs Medical Center, United States&#xD;Department of Medicine, Baylor College of Medicine, 1333 Moursund Ave, Ste A221, Houston, TX 77030, United States&#xD;Department of Surgery, Baylor College of Medicine, 1333 Moursund Ave, Ste A221, Houston, TX 77030, United States&#xD;Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, 1333 Moursund Ave, Ste A221, Houston, TX 77030, United States&#xD;Department of Molecular Virology and Microbiology, Baylor College of Medicine, 1333 Moursund Ave, Ste A221, Houston, TX 77030, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Bacterial interference for prevention of urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1400-1407</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><number><style face="normal" font="default" size="100%">10</style></number><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :29&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84868029572&amp;doi=10.1093%2fcid%2fcis639&amp;partnerID=40&amp;md5=a20d6a7ae22f6ec1e19c8cf9f539d8ec</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/cid/cis639</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>350</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">350</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Darewicz, B.</style></author><author><style face="normal" font="default" size="100%">Skrodzka, M.</style></author><author><style face="normal" font="default" size="100%">Kudelski, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Klinika Urologii, Uniwersytetu Medyczny, ul. Skłodowskiej-Curie 24a, 15-276 Białystok, Poland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urological problems in postmenopausal women</style></title><secondary-title><style face="normal" font="default" size="100%">Przeglad Menopauzalny</style></secondary-title><short-title><style face="normal" font="default" size="100%">Problemy urologiczne kobiet okresu pomenopauzalnego</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Przeglad Menopauzalny</style></full-title></periodical><pages><style face="normal" font="default" size="100%">175-183</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">4</style></number><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">Menopausal transition in women is correlated with lower quality of life. Decreased oestrogen levels entail dysfunction of many organs and systems. This paper depicts urological problems in perimenopausal women. The authors delineate the influence of oestrogen levels on physiology and pathophysiology of the urinary tract. Risk factors and treatment options of urological dysfunctions (urinary incontinence, recurrent urinary tract infections, symptoms of urgency) in menopausal transition are characterized. Proper diagnostics and therapy of urogenital problems in climacteric women require cooperation between urologists and gynaecologists as well as broadened knowledge of patients and general practitioners.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-58049192364&amp;partnerID=40&amp;md5=8ece6232367cfbb095dff7dc9368122f</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>521</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">521</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dalbosco, V.</style></author><author><style face="normal" font="default" size="100%">Srougi, M.</style></author><author><style face="normal" font="default" size="100%">Dall&apos;Oglio, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Disciplina de Urologia, Universidade Federal de Sao Paulo, São Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Revista Brasileira de Medicina</style></secondary-title><short-title><style face="normal" font="default" size="100%">Infecções do trato urinário</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Revista Brasileira de Medicina</style></full-title></periodical><pages><style face="normal" font="default" size="100%">320-336</style></pages><volume><style face="normal" font="default" size="100%">60</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bacteriuria</style></keyword><keyword><style face="normal" font="default" size="100%">Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTI) are considered the most common bacterial infection, responsible for 80 in every 1000 clinical consultations. Fiftheen per cent of the deaths due renal failure result from a secondary lesion of the kidneys caused by local chronic infection. Although the UTIs occur very often in children up to 6 years old and in young women, the prevalence of these infections increases as age advances, becoming a disease of great importance in elderly adults. In the present study the authors discuss epidemiologic characteristics, pathogenic agents, and review important points in the clinical and manifestations diagnosis of the UTI, with practical remarks on its treatment.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0042631140&amp;partnerID=40&amp;md5=c6c25ff653f87d59168a8edcf44a3068</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>335</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">335</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Czaja, C. A.</style></author><author><style face="normal" font="default" size="100%">Stamm, W. E.</style></author><author><style face="normal" font="default" size="100%">Stapleton, A. E.</style></author><author><style face="normal" font="default" size="100%">Roberts, P. L.</style></author><author><style face="normal" font="default" size="100%">Hawn, T. R.</style></author><author><style face="normal" font="default" size="100%">Scholes, D.</style></author><author><style face="normal" font="default" size="100%">Samadpour, M.</style></author><author><style face="normal" font="default" size="100%">Hultgren, S. J.</style></author><author><style face="normal" font="default" size="100%">Hooton, T. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departments of Medicine, Seattle, WA, United States&#xD;Department of Epidemiology, University of Washington, Seattle, WA, United States&#xD;Center for Health Studies, Group Health Cooperative, Seattle, WA, United States&#xD;Institute for Environmental Health, Seattle, WA, United States&#xD;Department of Microbiology, Washington University, St Louis, MO, United States&#xD;Department of Medicine, University of Miami, Miami, FL, United States&#xD;Department of Medicine, University of Colorado, Denver, United States&#xD;Dept of Medicine, Div of Infectious Diseases, National Jewish Health, 1400 Jackson St, Rm G309, Denver, CO 80206, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prospective cohort study of microbial and inflammatory events immediately preceding escherichia coli recurrent urinary tract infection in women</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">528-536</style></pages><volume><style face="normal" font="default" size="100%">200</style></volume><number><style face="normal" font="default" size="100%">4</style></number><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Background. A prospective cohort study was conducted to characterize the temporal sequence of microbial and inflammatory events immediately preceding Escherichia coli recurrent urinary tract infection (rUTI). Methods. Women with acute cystitis and a history of UTI within the previous year self-collected periurethral and urine samples daily and recorded measurements of urine leukocyte esterase, symptoms, and sexual intercourse daily for 3 months. rUTI strains were characterized by pulsed-field gel electrophoresis and genomic virulence profiling. Urinary cytokine levels were measured. Results. There were 38 E. coli rUTIs in 29 of 104 women. The prevalence of periurethral rUTI strain carriage increased from 46% to 90% during the 14 days immediately preceding rUTI, with similar increases in same-strain bacteriuria (from 7% to 69%), leukocyte esterase (from 31% to 64%), and symptoms (from 3% to 43%), most notably 2-3 days before rUTI (P&lt;.05 for all comparisons). Intercourse with periurethral carriage of the rUTI strain also increased before rUTI (P = .008). Recurrent UTIs preceded by bacteriuria, pyuria, and symptoms were caused by strains less likely to have P fimbriae than other rUTI strains (P = .002). Conclusions. Among women with frequent rUTIs, the prevalences of periurethral rUTI strain carriage, bacteriuria, pyuria, and intercourse dramatically increase over the days preceding rUTI. A better understanding of the pathogenesis of rUTI will lead to better prevention strategies. © 2009 by the Infectious Diseases Society of America. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :64&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-69149091826&amp;doi=10.1086%2f600385&amp;partnerID=40&amp;md5=3ab6e0361441dab3aca0f0ea90354713</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1086/600385</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>406</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">406</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Czaja, C. A.</style></author><author><style face="normal" font="default" size="100%">Hooton, T. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Update on acute uncomplicated uriranry tract infection in women</style></title><secondary-title><style face="normal" font="default" size="100%">SENDROM</style></secondary-title><short-title><style face="normal" font="default" size="100%">Kadinlarda akut basit idrar yolu infeksiyonuna ili§kin bir güncelleme</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">SENDROM</style></full-title></periodical><pages><style face="normal" font="default" size="100%">64-68</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">UTI continues to be a common problem for otherwise healthy adult women. Treatment of UTI has become more difficult because of the rising levels of resistance to commonly used antibiotcs. Further research is needed to develop new antibiotic therapies and nonantibiotic prevention measures.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33947614252&amp;partnerID=40&amp;md5=68fb74a20e4eca92280253e1e4cb5ad1</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>438</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">438</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Czaja, C. A.</style></author><author><style face="normal" font="default" size="100%">Hooton, T. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Update on acute uncomplicated urinary tract infection in women</style></title><secondary-title><style face="normal" font="default" size="100%">Postgraduate Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Postgraduate Medicine</style></full-title></periodical><volume><style face="normal" font="default" size="100%">119</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">UTI continues to be a common problem for otherwise healthy adult women. Treatment of UTI has become more difficult because of the rising levels of resistance to commonly used antibiotics. Further research is needed to develop new antibiotic therapies and nonantibiotic prevention measures.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :19&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33746529236&amp;doi=10.3810%2fpgm.2006.06.1639&amp;partnerID=40&amp;md5=4820aa59d5cbc79c80c8637e3fb2b15d</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3810/pgm.2006.06.1639</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>135</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">135</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cusumano, Z. T.</style></author><author><style face="normal" font="default" size="100%">Klein, R. D.</style></author><author><style face="normal" font="default" size="100%">Hultgren, S. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO 63110, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Innovative solutions to sticky situations: Antiadhesive strategies for treating bacterial infections</style></title><secondary-title><style face="normal" font="default" size="100%">Microbiology Spectrum</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Microbiology Spectrum</style></full-title></periodical><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Bacterial adherence to host tissue is an essential process in pathogenesis, necessary for invasion and colonization and often required for the efficient delivery of toxins and other bacterial effectors. As existing treatment options for common bacterial infections dwindle, we find ourselves rapidly approaching a tipping point in our confrontation with antibiotic-resistant strains and in desperate need of new treatment options. Bacterial strains defective in adherence are typically avirulent and unable to cause infection in animal models. The importance of this initial binding event in the pathogenic cascade highlights its potential as a novel therapeutic target. This article seeks to highlight a variety of strategies being employed to treat and prevent infection by targeting the mechanisms of bacterial adhesion. Advancements in this area include the development of novel antivirulence therapies using small molecules, vaccines, and peptides to target a variety of bacterial infections. These therapies target bacterial adhesion through a number of mechanisms, including inhibition of pathogen receptor biogenesis, competition-based strategies with receptor and adhesin analogs, and the inhibition of binding through neutralizing antibodies. While this article is not an exhaustive description of every advancement in the field, we hope it will highlight several promising examples of the therapeutic potential of antiadhesive strategies. © 2016 American Society for Microbiology. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85011296003&amp;doi=10.1128%2fmicrobiolspec.VMBF-0023-2015&amp;partnerID=40&amp;md5=240993fedae13c3f6857d1e73c916bd4</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">Vmbf-0023-2015</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/microbiolspec.VMBF-0023-2015</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>234</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">234</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cozens, D.</style></author><author><style face="normal" font="default" size="100%">Read, R. C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Infection and Immunity, University of Sheffield, Royal Hallamshire Hospital, Sheffield, S10 3JF, United Kingdom&#xD;Department of Clinical and Experimental Sciences, University of Southampton, Southampton General Hosptal, Tremona road, Southampton, SO16 6YD, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Anti-adhesion methods as novel therapeutics for bacterial infections</style></title><secondary-title><style face="normal" font="default" size="100%">Expert Review of Anti-Infective Therapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Expert Review of Anti-Infective Therapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1457-1468</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">adhesins</style></keyword><keyword><style face="normal" font="default" size="100%">anti-adhesion therapy</style></keyword><keyword><style face="normal" font="default" size="100%">antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">bacterial adherence</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Anti-adhesion therapies for bacterial infections offer an alternative to antibiotics, with those therapies bacteria are not killed but are prevented from causing harm to a host by inhibiting adherence to host cells and tissues, a prerequisite for the majority of infectious diseases. The mechanisms of these potential therapeutic agents include inhibition of adhesins and their host receptors, vaccination with adhesins or analogs, use of probiotics and dietary supplements that interfere with receptor-adhesin interactions, subminimal inhibitory concentrations of antibiotics and manipulation of hydrophobic interactions. Once developed, these drugs will contribute to the arsenal for fighting infectious disease in the future, potentially subverting antibiotic resistance. © 2012 Expert Reviews Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :28&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871420688&amp;doi=10.1586%2feri.12.145&amp;partnerID=40&amp;md5=0be81763027391e99112f5da438e21aa</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1586/eri.12.145</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>199</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">199</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cox, L.</style></author><author><style face="normal" font="default" size="100%">Cameron, A. P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, University of Michigan, 1500 E. Medical Center Drive, 3875 Taubman Center, SPC 5330, Ann Arbor, MI 48109-5330, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Prevention of Urinary Tract Infection for Patients with Neurogenic Bladder</style></title><secondary-title><style face="normal" font="default" size="100%">Current Bladder Dysfunction Reports</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Bladder Dysfunction Reports</style></full-title></periodical><pages><style face="normal" font="default" size="100%">282-288</style></pages><volume><style face="normal" font="default" size="100%">9</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Complications</style></keyword><keyword><style face="normal" font="default" size="100%">Intermittent catheterization</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenic bladder</style></keyword><keyword><style face="normal" font="default" size="100%">Neuropathic bladder</style></keyword><keyword><style face="normal" font="default" size="100%">Spinal cord injury</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infection is a common problem among patients with neurogenic bladder dysfunction that can be costly and challenging to manage. Current literature on the topic of preventing urinary tract infections in this heterogeneous patient population is challenged by the difficulty in defining urinary tract infections and by the lack of long-term data from controlled randomized studies. New research suggests that intradetrusor injection of onabotulinumtoxin A may be a useful adjunct in preventing urinary tract infections, and further studies are needed to determine if probiotics, bacterial interference, and/or vaccines will prove to be of use in the population. © 2014, Springer Science+Business Media New York.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84911967557&amp;doi=10.1007%2fs11884-014-0257-4&amp;partnerID=40&amp;md5=ca292a6f3abde42eb730d10306f21f02</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s11884-014-0257-4</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>618</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">618</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cox, C. E.</style></author><author><style face="normal" font="default" size="100%">Hinman, F., Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Urology, Bowman Gray School of Medicine, Wake Forest College, Winston-Salem, NC, Division of Urology, University of California School of Medicine, San Francisco, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">Retention Catheterization and the Bladder Defense Mechanism</style></title><secondary-title><style face="normal" font="default" size="100%">JAMA: The Journal of the American Medical Association</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">JAMA: The Journal of the American Medical Association</style></full-title></periodical><pages><style face="normal" font="default" size="100%">171-174</style></pages><volume><style face="normal" font="default" size="100%">191</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">1965</style></year></dates><abstract><style face="normal" font="default" size="100%">A dichotomy of opinion exists regarding the incidence of infection after urinary instrumentation. Determinants of infection exist which explain these opposing viewpoints. That the condition of the urinary bladder is a major variable in the incidence of infection was demonstrated by a low incidence of retention catheter-induced infection in 80 patients with normal bladders. Further studies on the bladder indicated that the normal bladder is resistant to infection and that this resistance is a function of two bladder defense mechanisms: (1) voiding, and (2) intrinsic antibacterial activity. © 1965 American Medical Association. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :7&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-76549182645&amp;doi=10.1001%2fjama.1965.03080030015003&amp;partnerID=40&amp;md5=331b06dcd8a80713fd78831ecad6cc3b</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jama.1965.03080030015003</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>310</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">310</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Costelloe, C.</style></author><author><style face="normal" font="default" size="100%">Metcalfe, C.</style></author><author><style face="normal" font="default" size="100%">Lovering, A.</style></author><author><style face="normal" font="default" size="100%">Mant, D.</style></author><author><style face="normal" font="default" size="100%">Hay, A. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">NIHR National School for Primary Care Research, Department of Community Based Medicine, University of Bristol, Bristol BS8 2AA, United Kingdom&#xD;Department of Social Medicine, Canynge Hall, University of Bristol, Bristol BS8 2PS, United Kingdom&#xD;Department of Microbiology, Bristol Centre for Antimicrobial Research and Enterprise, Southmead Hospital, Bristol BS9 3HU, United Kingdom&#xD;Department of Primary Health Care, NIHR National School for Primary Care Research, Oxford University, Headington, Oxford OX3 7LF, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: Systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default" size="100%">BMJ (Online)</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMJ (Online)</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1120</style></pages><volume><style face="normal" font="default" size="100%">340</style></volume><number><style face="normal" font="default" size="100%">7756</style></number><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: To systematically review the literature and, where appropriate, meta-analyse studies investigating subsequent antibiotic resistance in individuals prescribed antibiotics in primary care. Design: Systematic review with meta-analysis. Data sources: Observational and experimental studies identified through Medline, Embase, and Cochrane searches. Review methods: Electronic searches using MeSH terms and text words identified 4373 papers. Two independent reviewers assessed quality of eligible studies and extracted data. Meta-analyses were conducted for studies presenting similar outcomes. Results: The review included 24 studies; 22 involved patients with symptomatic infection and two involved healthy volunteers; 19 were observational studies (of which two were prospective) and five were randomised trials. In five studies of urinary tract bacteria (14 348 participants), the pooled odds ratio (OR) for resistance was 2.5 (95% confidence interval 2.1 to 2.9) within 2 months of antibiotic treatment and 1.33 (1.2 to 1.5) within 12 months. In seven studies of respiratory tract bacteria (2605 participants), pooled ORs were 2.4 (1.4 to 3.9) and 2.4 (1.3 to 4.5) for the same periods, respectively. Studies reporting the quantity of antibiotic prescribed found that longer duration and multiple courses were associated with higher rates of resistance. Studies comparing the potential for different antibiotics to induce resistance showed no consistent effects. Only one prospective study reported changes in resistance over a long period; pooled ORs fell from 12.2 (6.8 to 22.1) at 1 week to 6.1 (2.8 to 13.4) at 1 month, 3.6 (2.2 to 6.0) at 2 months, and 2.2 (1.3 to 3.6) at 6 months. Conclusions: Individuals prescribed an antibiotic in primary care for a respiratory or urinary infection develop bacterial resistance to that antibiotic. The effect is greatest in the month immediately after treatment but may persist for up to 12 months. This effect not only increases the population carriage of organisms resistant to first line antibiotics, but also creates the conditions for increased use of second line antibiotics in the community.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :731&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-77953917693&amp;doi=10.1136%2fbmj.c2096&amp;partnerID=40&amp;md5=c9d98f84432a76b42b4de420f7c260f8</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">c2096</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/bmj.c2096</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>96</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">96</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Costantini, E.</style></author><author><style face="normal" font="default" size="100%">Giannitsas, K.</style></author><author><style face="normal" font="default" size="100%">Illiano, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Urology and Andrology Clinic, Department of Surgical and Biomedical Sciences, University of Perugia, Perugia, Italy&#xD;Urology Department, Patras University Hospital, Patras University, Patras, Greece</style></auth-address><titles><title><style face="normal" font="default" size="100%">The role of nonantibiotic treatment of community-acquired urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Current Opinion in Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Opinion in Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">120-126</style></pages><volume><style face="normal" font="default" size="100%">27</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Purpose of review: To summarize evidence on the efficacy of nonantibiotic treatments in the prevention of recurrent urinary tract infections (UTIs). The need for antibiotic-free regimens seems to be imperative given the worldwide rates of resistance of uropathogens to available antibiotics. Recent findings: In the recently published literature, cranberry products and probiotics are the focus of research. They both seem to be effective in preventing recurrent UTIs compared with placebo, but their benefit becomes less clear when they are compared with antibiotics. Summary: A number of nonantibiotic-containing alternatives are available for the prevention of recurrent UTIs. For the majority of these alternatives, contradictory results have been published. These can be, at least partially, explained by variation in doses administered and duration of treatment. Selection of patients more likely to benefit from these interventions seems to be a realistic approach from a clinical-practice perspective, as well a worthwhile focus for future research. © 2017 Wolters Kluwer Health, Inc. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85000868478&amp;doi=10.1097%2fMOU.0000000000000366&amp;partnerID=40&amp;md5=8ea7ba4eb890b81fdd80345d8b2f1bb4</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/MOU.0000000000000366</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>502</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">502</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cos, P.</style></author><author><style face="normal" font="default" size="100%">de Bruyne, T.</style></author><author><style face="normal" font="default" size="100%">Hermans, N.</style></author><author><style face="normal" font="default" size="100%">Apers, S.</style></author><author><style face="normal" font="default" size="100%">Vanden Berghe, D.</style></author><author><style face="normal" font="default" size="100%">Vlietinck, A. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dept. of Pharmaceutical Sciences, University of Antwerp, Universiteitsplein 1, B-2610 Antwerp, Belgium</style></auth-address><titles><title><style face="normal" font="default" size="100%">Proanthocyanidins in health care: Current and new trends</style></title><secondary-title><style face="normal" font="default" size="100%">Current Medicinal Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Medicinal Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1345-1359</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antioxidant</style></keyword><keyword><style face="normal" font="default" size="100%">Bioavailability</style></keyword><keyword><style face="normal" font="default" size="100%">Cancer</style></keyword><keyword><style face="normal" font="default" size="100%">Cardiovascular disease</style></keyword><keyword><style face="normal" font="default" size="100%">Condensed tannins</style></keyword><keyword><style face="normal" font="default" size="100%">Free radicals</style></keyword><keyword><style face="normal" font="default" size="100%">Polyphenols</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidins</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Polyphenolic compounds are widely distributed in higher plants and are an integral part of the human diet. Recent interest in these substances has been stimulated by their potential health benefits, which are believed to arise mainly from their antioxidant activity. In the past years, the antioxidant activity of flavonoids has been studied in detail. An important but often overlooked group of polyphenols is that of the proanthocyanidins. Therefore, the present review is focused mainly on the antioxidant activity of proanthocyanidins and its relevancy in vivo. The three most important mechanisms of their antioxidant action will be discussed, i.e. free radical scavenging activity, chelation of transition metals, and inhibition of enzymes. In addition, the protective role of proanthocyanidins against lipid peroxidation and peroxynitrite, as well as their antimicrobial properties will be discussed. To study the in vivo relevancy of the proanthocyanidin activities, the knowledge of their pharmacokinetic parameters is crucial. Although bioavailability and metabolism data on polyphenols in general and proanthocyanidins in particular are still largely unavailable, the first reports indicate that at least monomers and smaller oligomeric procyanidins are absorbed. There is also considerable scientific and public interest in the important role that antioxidants may play in health care, e.g. by acting as cancer chemopreventive and anti-inflammatory agents and by reducing risk of cardiovascular mortality. Each of these aspects will be discussed, with special attention to the role of proanthocyanidins on apoptosis, gene expression and transcription factors, such as NF-kappa B. © 2004 Bentham Science Publishers Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :249&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-2342597191&amp;doi=10.2174%2f0929867043365288&amp;partnerID=40&amp;md5=dbd727ea76bee123faffd8931eb37780</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.2174/0929867043365288</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>82</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">82</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Coddens, A.</style></author><author><style face="normal" font="default" size="100%">Loos, M.</style></author><author><style face="normal" font="default" size="100%">Vanrompay, D.</style></author><author><style face="normal" font="default" size="100%">Remon, J. P.</style></author><author><style face="normal" font="default" size="100%">Cox, E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratory of Veterinary Immunology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133Merelbeke 9820, Belgium&#xD;Laboratory for Immunology and Animal Biotechnology, Department of Animal Production, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, Ghent, B-9000, Belgium&#xD;Laboratory of Pharmaceutical Technology, Ghent University, Harelbekestraat 72, Gent, 9000, Belgium&#xD;Ablynx nv., Technologiepark 21, Zwijnaarde, 9052, Belgium&#xD;Delaval NV, Industriepark-Drongen 10, Gent, 9031, Belgium</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry extract inhibits in vitro adhesion of F4 and F18+ Escherichia coli to pig intestinal epithelium and reduces in vivo excretion of pigs orally challenged with F18+ verotoxigenic E. coli</style></title><secondary-title><style face="normal" font="default" size="100%">Veterinary Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Veterinary Microbiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">64-71</style></pages><volume><style face="normal" font="default" size="100%">202</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">F4+ and F18+ Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Pig</style></keyword><keyword><style face="normal" font="default" size="100%">Polyphenols</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">F4+ E. coli and F18+ E. coli infections are an important threat for pig industry worldwide. Antibiotics are commonly used to treat infected piglets, but the emerging development of resistance against antibiotics raises major concerns. Hence, alternative therapies to prevent pigs from F4+ E. coli and F18+ E. coli infections need to be developed. Since cranberry previously showed anti-adhesive activity against uropathogenic E. coli, we aimed to investigate whether cranberry extract could also inhibit binding of F4+ E. coli and F18+ E. coli to pig intestinal epithelium. Using the in vitro villus adhesion assay, we found that low concentrations of cranberry extract (20 μg or 100 μg/ml) have strong inhibitory activity on F4+ E. coli (75.3%, S.D. = 9.31 or 95.8%, S.D. = 2.56, respectively) and F18+ E. coli adherence (100% inhibition). This effect was not due to antimicrobial activity. Moreover, cranberry extract (10 mg or 100 mg) could also abolish in vivo binding of F4 and F18 fimbriae to the pig intestinal epithelium in ligated loop experiments. Finally, two challenge experiments with F18+ E. coli were performed to address the efficacy of in-feed or water supplemented cranberry extract. No effect could be observed in piglets that received cranberry extract only in feed (1 g/kg or 10 g/kg). However, supplementation of feed (10 g/kg) and drinking water (1 g/L) significantly decreased excretion and diarrhea. The decreased infection resulted in a decreased serum antibody response indicating reduced exposure to F18+ E. coli. © 2017 Elsevier B.V.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85011051988&amp;doi=10.1016%2fj.vetmic.2017.01.019&amp;partnerID=40&amp;md5=d092fcd3efc75140482c5191d87d2946</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.vetmic.2017.01.019</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>390</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">390</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cimolai, N.</style></author><author><style face="normal" font="default" size="100%">Cimolai, T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada&#xD;Department of Pathology and Laboratory Medicine, Children&apos;s and Women&apos;s Health Centre of British Columbia, Vancouver, BC V6H 3V4, Canada&#xD;Faculty of Science, University of Alberta, Edmonton, Alta., Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">The cranberry and the urinary tract</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Clinical Microbiology and Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Clinical Microbiology and Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">767-776</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">11</style></number><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry products have been heralded as natural treatments for urinary tract infections (UTIs) and have been widely used for this purpose. Current evidence favours an antibacterial role for the cranberry&apos;s natural polyphenols or tannins. Although limited species- and strain-specific direct inhibition has been determined in vitro, it has been suggested that a key mechanism of inhibition, especially for the abundant uropathogenic E. coli, relies on anti-adhesion properties. Many studies of prevention have been complicated due to the enrollment of patients who have had complicated urinary tracts, and outcomes have not been consistently favourable. In contrast, significant prevention has been shown for acute cystitis among high-risk young females. While reasonably well tolerated and deplete from side effects, further scientific work is required to better place the role of cranberry products in the management of UTIs. Progress in this area has set the stage for further hypothesis testing studies. © 2007 Springer-Verlag.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :21&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-35348907314&amp;doi=10.1007%2fs10096-007-0379-0&amp;partnerID=40&amp;md5=7139cc9dd77a3d970d38b95c0c728d49</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s10096-007-0379-0</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>212</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">212</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chrubasik, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Institut für Rechtsmedizin, Albertstr. 9, 79104 Freiburg i. Br., Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">What disappoints, the cranberry juice or the Cochrane review?</style></title><secondary-title><style face="normal" font="default" size="100%">Zeitschrift fur Phytotherapie</style></secondary-title><short-title><style face="normal" font="default" size="100%">Was enttäuscht, der Preiselbeersaft oder das Cochrane-Review?</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Zeitschrift fur Phytotherapie</style></full-title></periodical><pages><style face="normal" font="default" size="100%">173-175</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><number><style face="normal" font="default" size="100%">4</style></number><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Letter</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84885183927&amp;doi=10.1055%2fs-0032-1331500&amp;partnerID=40&amp;md5=dea853cab8385a7ad27b8f13f0b1e347</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1055/s-0032-1331500</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>559</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">559</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Christiansen, K.</style></author><author><style face="normal" font="default" size="100%">Carbon, C.</style></author><author><style face="normal" font="default" size="100%">Cars, O.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology and Infectious Diseases, Royal Perth Hospital, Perth, WA, Australia&#xD;Division of Infectious Diseases, CHUV Lausanne, Switzerland&#xD;Swedish Institute for Infectious Disease Control, Solna, Sweden</style></auth-address><titles><title><style face="normal" font="default" size="100%">Moving from recommendation to implementation and audit: Part 2. Review of interventions and audit</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Microbiology and Infection</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Microbiology and Infection</style></full-title></periodical><pages><style face="normal" font="default" size="100%">107-128</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">SUPPL. 2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antimicrobial resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Disease burden</style></keyword><keyword><style face="normal" font="default" size="100%">Interventions audit</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><abstract><style face="normal" font="default" size="100%">There are multiple interventions available that may help to control the development and spread of resistance to antimicrobial agents in bacteria implicated in community-acquired respiratory tract infections. Unfortunately, very few studies have assessed the effectiveness of these interventions using objective end-points, such as reduction in resistance rates and improvement in clinical outcomes. Most interventions are centered on reducing inappropriate or unnecessary use of antibiotics; others focus on reducing disease burden and bacterial colonization. With regard to antibiotic use, efforts should be concentrated at both the prescriber and consumer levels. Interventions that target prescribers include: provision of educational materials; strategies and tools to improve diagnosis; implementation of practice guidelines; personalized interactive sessions with feedback on the practice profile; and use of delayed prescription and alternative prescribing strategies. Optimal results are usually obtained when these interventions are combined with consumer education. Regulatory interventions (e.g. licensing regulations and controlled access to drugs), restrictions in the use of agents for growth promotion in animals, and use of nonantimicrobial therapies (e.g. probiotics) may help further to reduce inappropriate antibiotic use and thereby decrease the selective pressure for development of resistance. Infection-control strategies, public health measures, vaccination programs, and new antibiotics all have a role in minimizing the spread of resistant organisms. Ideally, resistance-control programs should include predefined criteria for success and integral audit processes based on objective end-points (antibiotic use, resistance trends, and health outcomes). Standardization of data collection is imperative so that the relative merits of various interventions can be compared. Effective implementation and audit of interventions is often difficult in developing countries owing to poor health-care infrastructures, lack of resources, poor education/training, and minimal regulatory controls on the supply and quality of antimicrobials. Substantial support from governments and health-care organizations across the globe is required to initiate and sustain effective intervention programs to control antimicrobial resistance.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :19&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036401366&amp;doi=10.1046%2fj.1469-0691.8.s.2.9.x&amp;partnerID=40&amp;md5=385068c1bd5d8818931ab23727b358c5</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1046/j.1469-0691.8.s.2.9.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>367</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">367</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chomarat, M.</style></author><author><style face="normal" font="default" size="100%">Maulin, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Groupement Hospitalier Sud, Centre Hospitalier Lyon-Sud, 165, chemin du Grand Revoyet, 69495 Pierre-Bénite Cedex, France&#xD;Médecin Infectiologue, Centre Hospitalier du Pays d&apos;Aix, avenue des Tamaris, 13000 Aix en Provence, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">Biologist and clinician dialogue on management and antibiotic therapy of urinary infections</style></title><secondary-title><style face="normal" font="default" size="100%">Feuillets de Biologie</style></secondary-title><short-title><style face="normal" font="default" size="100%">Dialogue entre le biologiste et le clinicien dans la prise en charge et l&apos;antibiothérapie des infections urinaires</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Feuillets de Biologie</style></full-title></periodical><pages><style face="normal" font="default" size="100%">25-31</style></pages><volume><style face="normal" font="default" size="100%">49</style></volume><number><style face="normal" font="default" size="100%">283</style></number><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-48749114677&amp;partnerID=40&amp;md5=159faf7699cb7e05375a644927478af0</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>38</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">38</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Choe, H. S.</style></author><author><style face="normal" font="default" size="100%">Lee, S. J.</style></author><author><style face="normal" font="default" size="100%">Yang, S. S.</style></author><author><style face="normal" font="default" size="100%">Hamasuna, R.</style></author><author><style face="normal" font="default" size="100%">Yamamoto, S.</style></author><author><style face="normal" font="default" size="100%">Cho, Y. H.</style></author><author><style face="normal" font="default" size="100%">Matsumoto, T.</style></author><author><style face="normal" font="default" size="100%">the Committee for Development of the, U. A. A. Aaus Guidelines for U. T. I.</style></author><author><style face="normal" font="default" size="100%">Sti,</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, St. Vincent&apos;s Hospital, The Catholic University of Korea, Suwon, South Korea&#xD;Department of Urology, Buddhist Tzu Chi University, Hualien, Taiwan&#xD;Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan&#xD;Department of Urology, Hyogo College of Medicine, Nishinomiya, Japan&#xD;Department of Urology, St. Mary&apos;s Hospital, The Catholic University of Korea, Seoul, South Korea</style></auth-address><titles><title><style face="normal" font="default" size="100%">Summary of the UAA-AAUS guidelines for urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">175-185</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">guideline</style></keyword><keyword><style face="normal" font="default" size="100%">sexually transmitted infection</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections, genital tract infections and sexually transmitted infections are the most prevalent infectious diseases, and the establishment of locally optimized guidelines is critical to provide appropriate treatment. The Urological Association of Asia has planned to develop the Asian guidelines for all urological fields, and the present urinary tract infections, genital tract infections and sexually transmitted infections guideline was the second project of the Urological Association of Asia guideline development, which was carried out by the Asian Association of Urinary Tract Infection and Sexually Transmitted Infection. The members have meticulously reviewed relevant references, retrieved via the PubMed and MEDLINE databases, published between 2009 through 2015. The information identified through the literature review of other resources was supplemented by the author. Levels of evidence and grades of recommendation for each management were made according to the relevant strategy. If the judgment was made on the basis of insufficient or inadequate evidence, the grade of recommendation was determined on the basis of committee discussions and resultant consensus statements. Here, we present a short English version of the original guideline, and overview its key clinical issues. © 2017 The Japanese Urological Association</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85035192436&amp;doi=10.1111%2fiju.13493&amp;partnerID=40&amp;md5=a5981a5f2905fc03a0bf57ff743693f5</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/iju.13493</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>138</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">138</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chethana, B. K.</style></author><author><style face="normal" font="default" size="100%">Lee, D.</style></author><author><style face="normal" font="default" size="100%">Mushrif, S. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Chemical and Biomedical Engineering, Nanyang Technological University, 62 Nanyang Drive, Singapore, 637459, Singapore</style></auth-address><titles><title><style face="normal" font="default" size="100%">First principles investigation into the metal catalysed 1,2 carbon shift reaction for the epimerization of sugars</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Molecular Catalysis A: Chemical</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Molecular Catalysis A: Chemical</style></full-title></periodical><pages><style face="normal" font="default" size="100%">66-73</style></pages><volume><style face="normal" font="default" size="100%">410</style></volume><keywords><keyword><style face="normal" font="default" size="100%">1,2 Carbon shift</style></keyword><keyword><style face="normal" font="default" size="100%">Density functional theory</style></keyword><keyword><style face="normal" font="default" size="100%">Epimerization</style></keyword><keyword><style face="normal" font="default" size="100%">Homogeneous catalysts</style></keyword><keyword><style face="normal" font="default" size="100%">Molybdate</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">We investigate the metal catalyzed intramolecular 1,2 carbon shift reaction, usually associated with the epimerization of sugars, using the density functional theory. Metals like molybdenum (Mo), tungsten (W) and vanadium (V), in their oxoanion complex forms (molybdate, tungstate, vanadate) are investigated. The experimentally observed difference in the activity of these metal complexes, in catalyzing 1,2 carbon shift in glucose, at different pH is explained. Formation of larger (polynuclear) metal oxoanions (&quot;metalates&quot;) at higher pH reduces the structural flexibility of the metal complex. Thus, upon binding with glucose, their ability to rearrange the carbon backbone in sugar molecules decreases, resulting in lower activity towards 1,2 carbon shift at higher pH. For example, the activation barrier for 1,2 carbon shift catalyzed by &quot;active&quot; di-nuclear molybdate (exists at pH 2.5-3.5) is 21.1 kcal/mol; whereas it is 26.8 kcal/mol for the tetra-nuclear molybdate (exists at pH 4-5.5). Bonding interaction analysis has been carried out to quantify the flexibility/rigidity of the metal oxoanion complexes. Comparison of catalytic activities of Mo, W and V (as dimetalate) showed that vanadate is more active than the popular molybdate complex and W is the least active of them all. The trend in the catalytic activities of these metals is explained on the basis of the participation of higher orbitals in the complexation of metal oxoanions with glucose. Additionally, the flexibility/rigidity of the metal complex is also shown to be a descriptor of its catalytic activity for the 1,2 carbon shift reaction. © 2015 Elsevier B.V.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :10&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84942082270&amp;doi=10.1016%2fj.molcata.2015.09.004&amp;partnerID=40&amp;md5=cd3f8b42356aabbfb9333eafbe3631c9</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">9620</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.molcata.2015.09.004</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>112</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">112</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, Y.</style></author><author><style face="normal" font="default" size="100%">Martynenko, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Engineering, Faculty of Agriculture, Dalhousie University, Truro, NS B2N 5E3, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of hydrothermodynamic (HTD) processing on physical and chemical qualities of American cranberry puree using response surface methodology (RSM)</style></title><secondary-title><style face="normal" font="default" size="100%">LWT - Food Science and Technology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">LWT - Food Science and Technology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">322-332</style></pages><volume><style face="normal" font="default" size="100%">70</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Antioxidant activity</style></keyword><keyword><style face="normal" font="default" size="100%">Bioactive compounds</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry puree</style></keyword><keyword><style face="normal" font="default" size="100%">Hydrothermodynamic</style></keyword><keyword><style face="normal" font="default" size="100%">Optimization</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">The effect of hydrothermodynamic (HTD) processing in the range of temperatures 70-95 °C and holding times 0-10 min on physical and chemical qualities of cranberry puree was investigated using response surface methodology (RSM). Analysis of variance (ANOVA) of pH, Brix, viscosity, particle size, anthocyanin content, PAC content, total phenolic content and antioxidant activities (DPPH, ABTS and FRAP assays) showed that fitted models obtained with RSM were adequate and accurate. Temperatures and holding time showed negative effect on the anthocyanin content, but positive effects on all the other responses, indicating that most bioactive compounds in cranberry were stable under HTD processing. The optimal combination of operating conditions was 91 °C and 6 min of holding time, which provided maximal overall desirability of the product at 0.676. Comparison with three commercially available cranberry juices showed that HTD processed cranberry puree contained 26.8-86.8% more anthocyanins, 51.6-91.6% higher content of PACs and 30.6-86.3% higher content of total phenolics. This study demonstrated a strong potential of HTD technology to produce a cranberry puree with better texture properties and higher nutritional value. © 2016 Elsevier Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :5&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84960499239&amp;doi=10.1016%2fj.lwt.2016.02.054&amp;partnerID=40&amp;md5=9ebadedbbb64b2c89fd6a6a5b79f0066</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.lwt.2016.02.054</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>606</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">606</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chan, R. C. Y.</style></author><author><style face="normal" font="default" size="100%">Reid, G.</style></author><author><style face="normal" font="default" size="100%">Irvin, R. T.</style></author><author><style face="normal" font="default" size="100%">Bruce, A. W.</style></author><author><style face="normal" font="default" size="100%">Costerton, J. W.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Urology, Toronto General Hospital, Toronto, Ont. M5G 1L7, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Competitive exclusion of uropathogens from human uroepithelial cells by Lactobacillus whole cells and cell wall fragments</style></title><secondary-title><style face="normal" font="default" size="100%">Infection and Immunity</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Infection and Immunity</style></full-title></periodical><pages><style face="normal" font="default" size="100%">84-89</style></pages><volume><style face="normal" font="default" size="100%">47</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">1985</style></year></dates><abstract><style face="normal" font="default" size="100%">Previous studies have shown that indigenous bacteria isolated from cervical, vaginal, and urethral surfaces of healthy women are able to adhere to human uroepithelial cells in vitro. Furthermore, these organisms were found to block the adherence of uropathogenic bacteria to uroepithelial cells from women with and without a history of urinary tract infections. In the present study, complete or partial inhibition of the adherence of gram-negative uropathogens was achieved by preincubating the uroepithelial cells with bacterial cell wall fragments isolated from a Lactobacillus strain. Competitive exclusion was most effective with whole viable cells and less effective with cell wall fragments obtained by sonication, extraction with sodium dodecyl sulfate, and treatment with sodium dodecyl sulfate and acid. Analysis of the Lactobacillus cell wall preparations suggested that lipoteichoic acid was responsible for the adherence of the Lactobacillus cells to uroepithelial cells but that steric hindrance was the major factor in preventing the adherence of uropathogens. This conclusion was also supported by blockage studies with reconstituted lipoteichoic acid-peptidoglycan, which was more effective at blocking adherence than lipoteichoic acid or peptidoglycan alone. The results suggest that the normal flora of the urinary tract may be used to protect against the attachment of uropathogens to the surfaces of uroepithelial cells. The long-term implications of these findings may lead to alternative methods for the management and prevention of recurrent urinary tract infections in females.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :161&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021970838&amp;partnerID=40&amp;md5=7c6982b064423cbc93a1f42f666e5b17</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>615</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">615</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cattell, W. R.</style></author><author><style face="normal" font="default" size="100%">Fry, I. K.</style></author><author><style face="normal" font="default" size="100%">Spiro, F. I.</style></author><author><style face="normal" font="default" size="100%">Sardeson, J. M.</style></author><author><style face="normal" font="default" size="100%">Sutcliffe, M. B.</style></author><author><style face="normal" font="default" size="100%">O&apos;Grady, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departments of Medicine, Diagnostic Radiology, and Bacteriology, Bartholomew&apos;s Hospital, London, ECI, United Kingdom&#xD;The Renal Unit, St Leonard&apos;S Hospital, London, NI, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">EFFECT OF DIURESIS AND FREQUENT MICTURITION ON THE BACTERIAL CONTENT OF INFECTED URINE: A MEASURE OF COMPETENCE OF INTRINSIC HYDROKINETIC CLEARANCE MECHANISMS</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">290-295</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">1970</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :13&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0014804245&amp;doi=10.1111%2fj.1464-410X.1970.tb11922.x&amp;partnerID=40&amp;md5=9e0cc364077ecf36e78d436b6f720d3f</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1464-410X.1970.tb11922.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>597</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">597</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Catão, R. M. R.</style></author><author><style face="normal" font="default" size="100%">Nunes, L. E.</style></author><author><style face="normal" font="default" size="100%">Viana, A. P. P.</style></author><author><style face="normal" font="default" size="100%">da Rocha, W. R. V.</style></author><author><style face="normal" font="default" size="100%">de Medeiros, A. C. D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Universidade Estadual da Paraíba - UEPB, Laboratório de Atividade Antimicrobiana, UEPB, Campina Grande, PB, Brazil&#xD;Universidade Estadual da Paraíba - UEPB, Laboratório de Desenvolvimento de Medicamentos, Campina Grande, PB, Brazil</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antibacterial activity and interactive effect in vitro of a cranberry product on Escherichia coli</style></title><secondary-title><style face="normal" font="default" size="100%">Revista de Ciencias Farmaceuticas Basica e Aplicada</style></secondary-title><short-title><style face="normal" font="default" size="100%">Atividade antibacteriana e efeito interativo in vitro de um produto a base de cranberry sobre Escherichia coli</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Revista de Ciencias Farmaceuticas Basica e Aplicada</style></full-title></periodical><pages><style face="normal" font="default" size="100%">723-729</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibacterial activity</style></keyword><keyword><style face="normal" font="default" size="100%">Interactive effect</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1993</style></year></dates><abstract><style face="normal" font="default" size="100%">Products derived from plants are being studied because often have substances with antimicrobial activity, mainly due to the increase in bacterial resistance to antimicrobial compounds. Vaccinium macrocarpon Aiton, known as cranberry, is a plant native to, quite widespread in North America for its therapeutic properties, particularly in the prevention and treatment of urinary infections. This study aimed to evaluate the antibacterial activity, the minimum inhibitory concentration (MIC) and the possible interactions between a cranberry product when in association with antimicrobial agents against strains of Escherichia coli. The sensitivity profile was performed by disk diffusion using discs (Multifar ®), and the assessments of antibacterial activity and the MIC were performed using sterile filter paper discs (Cefar ®), soaked in 30 μl of the solution of cranberry, tested in different concentrations. The study of interference of cranberry solution about the effectiveness of antimicrobials was accomplished by soaking the antibiotic discs in their respective concentrations, with cranberry solution 30μL [20 mg/mL] equivalent to 0.5 MIC. The results showed that cranberry solution presented activity for all strains regardless of resistance profile of these lineages and was able to provoke different interactive effects when associated to antimicrobials. These results prove the antibacterial potential of this fruit promising possible, for studies of development of new products, however, also show that in some situations, it may interfere on the effectiveness of antimicrobials for clinical use.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84939789452&amp;partnerID=40&amp;md5=5fb64fb7e0c6d121e5e83b4c5a405147</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>10</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">10</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Castle, A. C.</style></author><author><style face="normal" font="default" size="100%">Park, A.</style></author><author><style face="normal" font="default" size="100%">Mitchell, A. J.</style></author><author><style face="normal" font="default" size="100%">Bliss, D. Z.</style></author><author><style face="normal" font="default" size="100%">Gelfand, J. A.</style></author><author><style face="normal" font="default" size="100%">De, E. J. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, United States&#xD;Department of Urology, Massachusetts General Hospital, Boston, MA 02114, United States&#xD;Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Boston, MA 02129, United States&#xD;School of Nursing, University of Minnesota, Minneapolis, MN 55455, United States&#xD;Division of Infectious Disease, Massachusetts General Hospital, Boston, MA 02114, United States&#xD;Spaulding Rehabilitation Network, Massachusetts General Hospital, Boston, MA 02114, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Neurogenic Bladder: Recurrent Urinary Tract Infections—Beyond Antibiotics</style></title><secondary-title><style face="normal" font="default" size="100%">Current Bladder Dysfunction Reports</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Bladder Dysfunction Reports</style></full-title></periodical><pages><style face="normal" font="default" size="100%">191-200</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Catheter-associated UTI</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenic bladder</style></keyword><keyword><style face="normal" font="default" size="100%">Neurogenic UTI</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Purpose of Review: Our goal was to identify evidenced-based strategies to prevent and treat patients with neurogenic bladder who suffer from recurrent urinary tract infections. We focused on therapy beyond standard antibiotics to address a multitude of factors implicated in these complex infections. Recent Findings: Anatomic and functional components specific to neurogenic bladder contribute to the risk of infection and require close clinical monitoring. The host-pathogen interaction is one that allows for colonization of bacteria in the bladder. We recognize that bacteriuria in the neurogenic bladder population does not equate with infection. Local antibiotic treatment and oral supplements are often not adequate to eliminate infection nor prevent recurrent infection due to biofilms. However, novel medical therapies, such as photodynamic therapy, bacterial interference, and infrared laser therapy to augment local immune cells, are promising options to prevent and treat symptomatic infection. Summary: A combination approach including management of anatomic and functional factors with medical intervention can significantly improve frequency of urinary infection. Further study of non-antibiotic therapeutic strategies is much needed as we recognize the complexity of the urinary biomes and the limitations of antibiotic therapies. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059785954&amp;doi=10.1007%2fs11884-018-0481-4&amp;partnerID=40&amp;md5=0f0fef4bda9c58762e45a4b5ef9b1ad7</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s11884-018-0481-4</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>534</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">534</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Campbell, G.</style></author><author><style face="normal" font="default" size="100%">Pickles, T.</style></author><author><style face="normal" font="default" size="100%">D’yachkova, Y.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Vancouver Cancer Centre, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">A randomised trial of cranberry versus apple juice in the management of urinary symptoms during external beam radiation therapy for prostate cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Oncology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Oncology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">322-328</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry juice</style></keyword><keyword><style face="normal" font="default" size="100%">International Prostate Symptom Score (IPSS)</style></keyword><keyword><style face="normal" font="default" size="100%">Prostate cancer</style></keyword><keyword><style face="normal" font="default" size="100%">Radiation therapy</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">Aims: The aim of the study was to assess whether the oral intake of cranberry juice cocktail compared with apple juice was associated with a significant difference in urinary symptoms experienced during radical external beam radiation therapy (EBRT) for prostate carcinoma. Materials and methods: One hundred and twelve men with prostate cancer were randomised to either 354 ml cranberry juice or apple juice a day. Stratification was based on a history of a previous transurethral resection of prostate (TURP yes/no) and baseline International Prostate Symptom Score (IPSS &lt;6 or ≥6) of urinary symptoms. Results: The maximum IPSS (MRT) and the maximum change in IPSS from baseline (DRT) are used to report the results. We analysed the effects of juice allocation on DRT and MRT using analysis of covariates (ANCOVA). We observed no significant difference for DRT (P=0.39) or MRT (P=0.76) related to the consumption of cranberry compared with apple juice. However, we found a significant relationship between the history of a previous TURP and both DRT (P=0.01) and MRT (P=0.01). The history of a previous TURP was associated with lower values for both end points. Baseline IPSS was significant for DRT (P=0.004) and MRT (P≤0.001). We found a significant relationship between the baseline IPSS &lt;6 or ≥6 cut point on MRT (P≤0.001) but not on DRT (P=0.43). The use of neoadjuvant hormones had no significant effect on DRT (P=0.64) or MRT (P=0.76). The use of additional symptomatic medication during the study was not significantly different between the two arms. Conclusions: This study shows no significant difference in the urinary symptoms experienced during EBRT related to the consumption of cranberry juice compared with apple juice. © 2003 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :21&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0041409720&amp;doi=10.1016%2fS0936-6555%2803%2900161-4&amp;partnerID=40&amp;md5=131e42f360b887e1b7ae946480f2fce9</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0936-6555(03)00161-4</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>557</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">557</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Camire, M. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Food Science and Human Nutrition, University of Maine, Orono, ME, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Phytochemicals in the vaccinium family: Bilberries, blueberries, and cranberries</style></title><secondary-title><style face="normal" font="default" size="100%">Phytochemicals in Nutrition and Health</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">19-40</style></pages><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :18&#xD;Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33645336639&amp;partnerID=40&amp;md5=d755205d453e72613cb7875f9ac1f338</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>20</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">20</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cai, T.</style></author><author><style face="normal" font="default" size="100%">Tiscione, D.</style></author><author><style face="normal" font="default" size="100%">Cocci, A.</style></author><author><style face="normal" font="default" size="100%">Puglisi, M.</style></author><author><style face="normal" font="default" size="100%">Cito, G.</style></author><author><style face="normal" font="default" size="100%">Malossini, G.</style></author><author><style face="normal" font="default" size="100%">Palmieri, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Santa Chiara Regional Hospital, Trento, Italy&#xD;Department of Urology, University of Florence, Florence, Italy&#xD;Department of Urology, University of Naples, Federico II, Naples, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Hibiscus extract, vegetable proteases and Commiphora myrrha are useful to prevent symptomatic UTI episode in patients affected by recurrent uncomplicated urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Archivio Italiano di Urologia e Andrologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archivio Italiano di Urologia e Andrologia</style></full-title></periodical><pages><style face="normal" font="default" size="100%">203-207</style></pages><volume><style face="normal" font="default" size="100%">90</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotic stewardship</style></keyword><keyword><style face="normal" font="default" size="100%">Ellirose</style></keyword><keyword><style face="normal" font="default" size="100%">Myrliq</style></keyword><keyword><style face="normal" font="default" size="100%">Plant extracts</style></keyword><keyword><style face="normal" font="default" size="100%">Protelix</style></keyword><keyword><style face="normal" font="default" size="100%">Serrazimes</style></keyword><keyword><style face="normal" font="default" size="100%">Treatment</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: To evaluate the efficacy of a combination of Hibiscus extract, vegetable proteases and Commiphora myrrha extract in the prophylaxis of symptomatic episode in women affected by recurrent urinary tract infections (rUTIs). Materials and methods: In this phase II clinical trial, all patients with history and diagnosis of rUTI were enrolled. All patients underwent the following treatment schedule: 1 tablet in the morning and 1 tablet in the evening for 7 days and, then, 1 tablet in the evening for 10 days (1 cycle every each month, for 6 months) of a combination of Hibiscus extract, vegetable proteases and Commiphora myrrha extract. At the baseline, all patients underwent urologic visit with quality of life (QoL) questionnaires and mid-stream urine culture. After 3 and 6 months, all patients underwent urologic visit, urine culture and QoL questionnaires evaluation. Results: Fifty-five women were enrolled (mean age 49.3; range: 28-61). At the enrollment time, the most common pathogen was Escherichia coli (63.7%). The median number of UTI per 6 months was 5 (IQR: 4-9). At the end of the second follow-up evaluation, 25 women did not reported any symptomatic episode of UTI (49%), 18 reported less than 2 episodes (35.3%), while 8 reported more than 2 episodes (15.7%). However, at the first and second follow-up evaluation the clinical statistically significant improvement (QoL) was reported by 38/51 (74.5%) (p &lt; 0.001 from baseline) and 43/51 (84.3%) (p &lt; 0.001 from baseline) women, respectively. The median number of UTI decreased to 2 (IQR: 0-3). At the end of the follow-up period, 30/51 had sterile urine (58.8%), while 21/51 (41.2%) reported a transition from symptomatic UTI to asymptomatic bacteriuria. Conclusions: In conclusion, this treatment, in motivated patients, is able to prevent symptomatic UTI symptomatic episode and improve patient’s QoL. © 2018 Edizioni Scripta Manent s.n.c. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055617563&amp;doi=10.4081%2faiua.2018.3.203&amp;partnerID=40&amp;md5=05d3029e4d5827be8bd9e1eb6ad9c0c1</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.4081/aiua.2018.3.203</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>92</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">92</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cai, T.</style></author><author><style face="normal" font="default" size="100%">Tamanini, I.</style></author><author><style face="normal" font="default" size="100%">Kulchavenya, E.</style></author><author><style face="normal" font="default" size="100%">Perepanova, T.</style></author><author><style face="normal" font="default" size="100%">Köves, B.</style></author><author><style face="normal" font="default" size="100%">Wagenlehner, F. M. E.</style></author><author><style face="normal" font="default" size="100%">Tandogdu, Z.</style></author><author><style face="normal" font="default" size="100%">Bonkat, G.</style></author><author><style face="normal" font="default" size="100%">Bartoletti, R.</style></author><author><style face="normal" font="default" size="100%">Johansen, T. E. B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Santa Chiara Regional Hospital, Trento, Italy&#xD;TB Research Institute, Medical University, Novosibirsk, Russian Federation&#xD;N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology, National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, Russian Federation&#xD;Jahn Ferenc South Pest Teaching Hospital, Budapest, Hungary&#xD;Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie, Universitätsklinikum Giessen und Marburg GmbH, Justus-Liebig-Universität, Giessen, Germany&#xD;Northern Institute for Cancer Research, Newcastle University, Newcastle upon-Tyne, NE1 7RU, United Kingdom&#xD;Alta Uro AG, Merian Iselin Klinik, Center of Biomechanics and Calorimetry (COB), University Basel, Basel, Switzerland&#xD;Department Translational Research and New Technologies, University of Pisa, Pisa, Italy&#xD;Oslo University Hospital, Univeristy of Oslo, Oslo, Norway</style></auth-address><titles><title><style face="normal" font="default" size="100%">The role of nutraceuticals and phytotherapy in the management of urinary tract infections: What we need to know?</style></title><secondary-title><style face="normal" font="default" size="100%">Archivio Italiano di Urologia e Andrologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archivio Italiano di Urologia e Andrologia</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-6</style></pages><volume><style face="normal" font="default" size="100%">89</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Nutraceuticals</style></keyword><keyword><style face="normal" font="default" size="100%">Phytotherapy</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary Tract Infections (UTIs) are amongst the most common infectious diseases and carry a significant impact on patient quality of life and health care costs. Despite that, there is no well-established recommendation for a &quot;standard&quot; prophylactic antibiotic management to prevent UTI recurrences. The majority of patients undergoes long-term antibiotic treatment that severely impairs the normal microbiota and increases the risk of development of multidrug-resistant microorganisms. In this scenario, the use of phytotherapy to both alleviate symptoms related to UTI and decrease the rate of symptomatic recurrences is an attractive alternative. Several recently published papers report conflicting findings and cannot give confident recommendations for the everyday clinical practice. A new approach to the management of patients with recurrent UTI might be to use nutraceuticals or phytotherapy after an accurate assessment of the patient&apos;s risk factors. No single compound or mixture has been identified so far as the best preventive approach in patients with recurrent UTI. We reviewed our non-antibiotic approach to the management of recurrent UTI patients in order to clarify the evidence-base for the commonly used substances, understand their pharmacokinetics and pharmacodynamics in order to tailor the best way to improve patient&apos;s quality of life and reduce the rate of antibiotic resistance. Lack of a gold-standard recommendation and the risk of increasing antibiotic resistance is the reason why we need alternatives to antibiotics in the management of urinary tract infections (UTIs). A tailored approach according to bacterial characteristics and the patient risk factors profile is a promising option. © 2017, Edizioni Scripta Manent s.n.c. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85019242679&amp;doi=10.4081%2faiua.2017.1.1&amp;partnerID=40&amp;md5=b24d193a1ed0d3abeda87077540e1e68</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.4081/aiua.2017.1.1</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>325</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">325</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Čadková, I.</style></author><author><style face="normal" font="default" size="100%">Doudová, L.</style></author><author><style face="normal" font="default" size="100%">Nováčkova, M.</style></author><author><style face="normal" font="default" size="100%">Huvar, I.</style></author><author><style face="normal" font="default" size="100%">Chmel, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Gynekologicko-Porodnické Oddělení, Nemocnice Milosrdných Bratří, Brno, Czech Republic&#xD;Katedra Ekonometrie, Fakulta Ekonomiky a Managementu, Univerzita Obrany, Brno, Czech Republic&#xD;Gynekologicko-Porodnická Klinika, 2. LF a FN Motol, Praha, Czech Republic&#xD;Nemocnice Milosrdných Bratří, Polní 3, 639 00 Brno, Czech Republic</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effect of cranberry extract capsules taken during the perioperative period upon the post-surgical urinary infection in gynecology</style></title><secondary-title><style face="normal" font="default" size="100%">Ceska Gynekologie</style></secondary-title><short-title><style face="normal" font="default" size="100%">Perioperační podávání kapslí s brusinkovým extraktem v profylaxi uroinfekcí po gynekologických operacích</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Ceska Gynekologie</style></full-title></periodical><pages><style face="normal" font="default" size="100%">454-458</style></pages><volume><style face="normal" font="default" size="100%">74</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">CAUTI (catheter associated UTI)</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Hysterectomy</style></keyword><keyword><style face="normal" font="default" size="100%">UTI (urinary tract infection)</style></keyword><keyword><style face="normal" font="default" size="100%">Vaginal surgery</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: To evaluate the effect of cranberry extract capsules taken during the perioperative period upon the post-surgical urinary infection (UTI) in gynecology. Design: Clinical prospective pilot trial. Setting: Obstetrics and Gynecology Department, Merciful Brothers Hospital, Brno and Obstetrics and Gynecology Department, Charles University 2nd Medical Faculty and Teaching Hospital Motol, Prague. Materials and Methods: The cohort consisted of 286 women who underwent hysterectomy and/or anterior vaginal repair (with or without anti-incontinence operation) in the above hospitals in the period 1. 9. 2006 - 30. 6. 2007. 132 women from among the total were given cranberry extract capsules (equiv. 17 000 mg of fresh fruit) twice a day, 4 days before and 5 days after the surgery. The rest were the control group. The clinical state and the analysis of catheterized urine including bacteriology were determined on the day of surgery and on the 6th postoperative day. Cases with preoperative UTI and those with antibiotic therapy (due to other than urology indications) were excluded from the study. Thus the statistical analysis was made in the remaining 117 patients with prophylactic cranberry capsules and 139 controls. Results: There were 30.8% of positive cultured urines, 18.0% of pyuric specimens and 6.8% symptomatic urinary infections in the group of cranberry prophylaxis. Controls had significant bacteriuria in 27.3%, pyuria in 23.7% and symptomatic UTI in 5.0%. Differences were not statistically significant. Conclusion: The intake of cranberry extracts in the perioperative period (4 days before and 5 days after the surgery) did not affect the number of post-surgical UTIs.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-74349114965&amp;partnerID=40&amp;md5=fab25a2d724f184d136eed91666045bc</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>547</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">547</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cadieux, P.</style></author><author><style face="normal" font="default" size="100%">Burton, J.</style></author><author><style face="normal" font="default" size="100%">Gardiner, G.</style></author><author><style face="normal" font="default" size="100%">Braunstein, I.</style></author><author><style face="normal" font="default" size="100%">Bruce, A. W.</style></author><author><style face="normal" font="default" size="100%">Kang, C. Y.</style></author><author><style face="normal" font="default" size="100%">Reid, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Canadian Res./Devmt. Ctr. Probiotics, Lawson Health Research Institute, London, Ont., Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lactobacillus strains and vaginal ecology [3]</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Medical Association</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Medical Association</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1940-1941</style></pages><volume><style face="normal" font="default" size="100%">287</style></volume><number><style face="normal" font="default" size="100%">15</style></number><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :91&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Letter</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037123254&amp;doi=10.1001%2fjama.287.15.1940&amp;partnerID=40&amp;md5=b71570894c34961588791fa72b41f3e5</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jama.287.15.1940</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>208</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">208</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Burleigh, A. E.</style></author><author><style face="normal" font="default" size="100%">Benck, S. M.</style></author><author><style face="normal" font="default" size="100%">McAchran, S. E.</style></author><author><style face="normal" font="default" size="100%">Reed, J. D.</style></author><author><style face="normal" font="default" size="100%">Krueger, C. G.</style></author><author><style face="normal" font="default" size="100%">Hopkins, W. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI 53792, United States&#xD;Department of Urology, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison, WI 53792, United States&#xD;Department of Nutritional Sciences, University of Wisconsin-Madison, 256 Animal Science Bldg., 1675 Observatory Drive, Madison, WI 53706, United States&#xD;Department of Urology, University of Wisconsin, School of Medicine and Public Health, 1685 Highland Ave., Madison, WI 53705, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Consumption of sweetened, dried cranberries may reduce urinary tract infection incidence in susceptible women - A modified observational study</style></title><secondary-title><style face="normal" font="default" size="100%">Nutrition Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nutrition Journal</style></full-title></periodical><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">E. coli</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Urinary tract infections (UTIs) are one of the most common bacterial infections, and over 50% of women will have a UTI during their lifetimes. Antibiotics are used for prophylaxis of recurrent UTIs but can lead to emergence of drug-resistant bacteria. Therefore, it is reasonable to investigate nutritional strategies for prevention of UTIs. Cranberry juices and supplements have been used for UTI prophylaxis, but with variable efficacy. Because dried cranberries may contain a different spectrum of polyphenolics than juice, consuming berries may or may not be more beneficial than juice in decreasing the incidence of UTIs in susceptible women. The primary objectives of this study were to determine if consumption of sweetened, dried cranberries (SDC) decreases recurrent UTIs and whether this intervention would alter the heterogeneity, virulence factor (VF) profiles, or numbers of intestinal E. coli. Methods. Twenty women with recurrent UTIs were enrolled in the trial and consumed one serving of SDC daily for two weeks. Clinical efficacy was determined by two criteria, a decrease in the six-month UTI rates pre- and post-consumption and increased time until the first UTI since beginning the study. Strain heterogeneity and virulence factor profiles of intestinal E. coli isolated from rectal swabs were determined by DNA fingerprinting and muliplex PCR, respectively. The numbers of intestinal E. coli eluted from rectal swabs pre- and post-consumption were also quantified. Results: Over one-half of the patients did not experience a UTI within six months of SDC consumption, and the mean UTI rate per six months decreased significantly. Kaplan-Meier analysis of infection incidence in women consuming SDC compared to patients in a previous control group showed a significant reduction in time until first UTI within six months. The heterogeneity, VF profiles, and prevalence of intestinal E. coli strains were not significantly different after cranberry consumption. Conclusions: Results of this study indicate a beneficial effect from consuming SDC to reduce the number of UTIs in susceptible women. Because there were no changes in the heterogeneity or VF profiles of E. coli, additional studies are needed to determine the mechanism of action of SDC for reduction of UTIs. © 2013 Burleigh et al.; licensee BioMed Central Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :13&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84885526237&amp;doi=10.1186%2f1475-2891-12-139&amp;partnerID=40&amp;md5=a43fa387685ca7e1e03b67f64d437dcf</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">139</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1186/1475-2891-12-139</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>329</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">329</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Burkhardt-Sischka, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Birkenstr. 2, 71106 Magstadt</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry: Bacterial defense for urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">Deutsche Apotheker Zeitung</style></secondary-title><short-title><style face="normal" font="default" size="100%">Cranberry: Bakterienabwehr bei harnwegsinfekten</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Deutsche Apotheker Zeitung</style></full-title></periodical><pages><style face="normal" font="default" size="100%">127-129</style></pages><volume><style face="normal" font="default" size="100%">149</style></volume><number><style face="normal" font="default" size="100%">40</style></number><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Short Survey</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-70350348377&amp;partnerID=40&amp;md5=19ca22a5189903d691eff76c2895007f</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>255</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">255</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buonsenso, D.</style></author><author><style face="normal" font="default" size="100%">Cataldi, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Sacro Cuore Catholic University, Rome, Italy</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections in children: A review</style></title><secondary-title><style face="normal" font="default" size="100%">Minerva Pediatrica</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Minerva Pediatrica</style></full-title></periodical><pages><style face="normal" font="default" size="100%">145-157</style></pages><volume><style face="normal" font="default" size="100%">64</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Child</style></keyword><keyword><style face="normal" font="default" size="100%">Ultrasonography</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Febrile urinary tract infection is the most common serious bacterial infection in childhood, but the most appropriate evaluation of children with this condition is still unclear, overall regarding the best long-term management of children after a first UTI. Here we review current recommendations for the diagnosis, treatment, imaging evaluation and use of antibiotic prophylaxis in children with the first febrile urinary tract infection. Nevertheless, the development of a universally accepted diagnostic protocol remains elusive.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :8&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84861388741&amp;partnerID=40&amp;md5=5e4922f9cd49550358d0d934c24c36e6</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>83</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">83</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bukutu, C.</style></author><author><style face="normal" font="default" size="100%">Vohra, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pediatrics, University of Albert, Stollery Children&apos;s Hospital, 8B, 11111 Jasper Ave, Edmonton, AB T5K 0L4GBR, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Complementary and alternative treatments for renal diseases</style></title><secondary-title><style face="normal" font="default" size="100%">Pediatric Kidney Disease: Second Edition</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">1948-1974</style></pages><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055216981&amp;doi=10.1007%2f978-3-662-52972-0_73&amp;partnerID=40&amp;md5=7b4814149e9fc8c4694d40266f7f8eaf</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/978-3-662-52972-0_73</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>424</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">424</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bruyère, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Service d&apos;urologie, CHRU Bretonneau, 2, boulevard Tonnelle, 37044 Tours, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">Use of cranberry in chronic urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Medecine et Maladies Infectieuses</style></secondary-title><short-title><style face="normal" font="default" size="100%">Utilisation de la canneberge dans les infections urinaires récidivantes</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Medecine et Maladies Infectieuses</style></full-title></periodical><pages><style face="normal" font="default" size="100%">358-363</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><number><style face="normal" font="default" size="100%">7</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Urology</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: Chronic cystitis in women is frequent and difficult to treat. Up to now, an empirical prescription of antibiotics could decrease the frequency of acute episodes but with adverse effects and increasing risks of resistance. Studies have shown that cranberries should be used for that indication. We made a systematic review of literature to demonstrate how to use the cranberry. Results: Randomized studies confirmed that the proanthocyanidin contained in cranberries can eliminate Escherichia coli adhesion to the urothelium. Clinical studies showed that the incidence of acute cystitis decreased when treated by cranberries. On the other hand, patients with a neurogenic bladder and intermittent catheterization do not seem to benefit from the fruit. We did not find any study on postcoital use of cranberries. Various substances and doses were used in these studies and we could not conclude on best galenic presentation to prescribe. Conclusion: Cranberries can inhibit E. coli adhesion to the urothelium and could be useful to treat urinary infections. Clinical studies confirm the probable benefit of this fruit as a prophylactic treatment for female cystitis. Prescriptions modalities remain to be defined. © 2006 Elsevier SAS. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :7&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Short Survey</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33746781397&amp;doi=10.1016%2fj.medmal.2006.05.001&amp;partnerID=40&amp;md5=da2a6ecbb4bc0a2ed503165753f364c2</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.medmal.2006.05.001</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>583</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">583</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brumfitt, W.</style></author><author><style face="normal" font="default" size="100%">Hamilton-Miller, J. M. T.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Urinary Infection Clinic, Royal Free Hampstead NHS Trust, Roy. Free Hosp. School of Medicine, Pond Street, London NW3 2QG, United Kingdom&#xD;Department of Medical Microbiology, Royal Free Hospital, School of Medicine, Pond Street, London NW3 2QG, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Efficacy and safety profile of long-term nitrofurantoin in urinary infections: 18 years&apos; experience</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Antimicrobial Chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Antimicrobial Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">363-371</style></pages><volume><style face="normal" font="default" size="100%">42</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">1998</style></year></dates><abstract><style face="normal" font="default" size="100%">Case records from 219 female patients between 1975 and 1992 who were given long-term prophylaxis (1 year) with nitrofurantoin for the prevention of recurrent urinary infections have been reviewed. Patients&apos; age ranged from 9 to 89 years (median 31-35 years, mode 26-30 years); most (61%) were &lt; 40 years old. The median number of symptomatic episodes in the 12 months immediately before prophylaxis was six (mode 4, mean 6.9). 14.4% of the patients were allergic to an antibiotic, and 23.6% had an imaging abnormality. Three regimens were used: group A (43 patients), 50 mg microcrystalline nitrofurantoin, bd; group B (110 patients), 100 mg macrocrystalline nitrofurantoin (Macrodantin), od; group C (66 patients), 50 mg Macrodantin, od. There were no obvious differences in efficacy between the patient groups (173 assessable patients). The mean incidence of symptomatic episodes decreased 5.4-fold during prophylaxis. Four-fifths of the 43 breakthrough infections (mostly due to Escherichia coli), were caused by nitrofurantoin-sensitive strains. An important finding was that patients with an imaging abnormality responded as well as those with no such abnormalities. In 16% of patients, prophylaxis was not helpful, objectively or subjectively, for no obvious reasons. In most patients where prophylaxis was successful, clinical improvement was maintained for at least 6 months after the end of prophylaxis. Nausea was more common in group A (P &lt; 0.001), as were &apos;all adverse events&apos;. Of those in group A 25.6% stopped prematurely as a result of an adverse event of any type, compared with 13% of those taking Macrodantin (P &lt; 0.01). Older patients (&gt; 65 years) did not report more adverse events than younger patients. No adverse event was life-threatening. Faecal flora analysis showed neither overgrowth by nitrofurantoin-resistant bacteria nor elimination of sensitive coliforms. Thus, macrocrystalline nitrofurantoin 50 mg at bedtime is appropriate for use in the long-term (12 months) prophylaxis of recurrent urinary infections, in view of its efficacy and favourable safety and tolerability profile. Patients can be managed by their family doctor.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :81&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031664617&amp;doi=10.1093%2fjac%2f42.3.363&amp;partnerID=40&amp;md5=c69aaa63c18cfe6890e15fcf7bb59c45</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/jac/42.3.363</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>250</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">250</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brumbaugh, A. R.</style></author><author><style face="normal" font="default" size="100%">Mobley, H. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Preventing urinary tract infection: Progress toward an effective Escherichia coli vaccine</style></title><secondary-title><style face="normal" font="default" size="100%">Expert Review of Vaccines</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Expert Review of Vaccines</style></full-title></periodical><pages><style face="normal" font="default" size="100%">663-676</style></pages><volume><style face="normal" font="default" size="100%">11</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">ExPEC</style></keyword><keyword><style face="normal" font="default" size="100%">Extraintestinal pathogenic</style></keyword><keyword><style face="normal" font="default" size="100%">Immunization</style></keyword><keyword><style face="normal" font="default" size="100%">UPEC</style></keyword><keyword><style face="normal" font="default" size="100%">Uropathogenic</style></keyword><keyword><style face="normal" font="default" size="100%">UTI</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Uncomplicated urinary tract infections (UTIs) are common, with nearly half of all women experiencing at least one UTI in their lifetime. This high frequency of infection results in huge annual economic costs, decreased workforce productivity and high patient morbidity. At least 80% of these infections are caused by uropathogenic Escherichia coli (UPEC). UPEC can reside side by side with commensal strains in the gastrointestinal tract and gain access to the bladder via colonization of the urethra. Antibiotics represent the current standard treatment for UTI; however, even after treatment, patients frequently suffer from recurrent infection with the same or different strains. In addition, successful long-term treatment has been complicated by a rise in both the number of antibiotic-resistant strains and the prevalence of antibiotic-resistance mechanisms. As a result, preventative approaches to UTI, such as vaccination, have been sought. This review summarizes recent advances in UPEC vaccine development and outlines future directions for the field. © 2012 Expert Reviews Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :89&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84864917488&amp;doi=10.1586%2ferv.12.36&amp;partnerID=40&amp;md5=0bd93d286a9f67a84594c4cbb6807f92</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1586/erv.12.36</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>23</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">23</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brubaker, L.</style></author><author><style face="normal" font="default" size="100%">Carberry, C.</style></author><author><style face="normal" font="default" size="100%">Nardos, R.</style></author><author><style face="normal" font="default" size="100%">Carter-Brooks, C.</style></author><author><style face="normal" font="default" size="100%">Lowder, J. L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Reproductive Medicine, University of California San Diego, 9500 Gilman Drive, San Diego, CA 92093, United States&#xD;Division of Urogynecology and Reconstructive Pelvic Surgery, Department of Obstetrics and Gynecology, Alpert Medical School of Brown University, Providence, RI, United States&#xD;Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Oregon Health and Sciences University, Portland, OR, United States&#xD;Division of Urogynecology and Reconstructive Surgery, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA, United States&#xD;Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Washington University in St Louis, St Louis, MO, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">American Urogynecologic Society Best-Practice Statement: Recurrent Urinary Tract Infection in Adult Women</style></title><secondary-title><style face="normal" font="default" size="100%">Female Pelvic Medicine and Reconstructive Surgery</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Female Pelvic Medicine and Reconstructive Surgery</style></full-title></periodical><pages><style face="normal" font="default" size="100%">321-335</style></pages><volume><style face="normal" font="default" size="100%">24</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">recurrent UTI</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">UTI</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052909037&amp;doi=10.1097%2fSPV.0000000000000550&amp;partnerID=40&amp;md5=ae1a0588d740aef667c21b4ca32aa013</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/SPV.0000000000000550</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>293</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">293</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brown, P. N.</style></author><author><style face="normal" font="default" size="100%">Shipley, P. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of British Columbia Okanagan, 3333 University Way, Kelowna, BC V1V 1V7, Canada&#xD;British Columbia Institute of Technology, 3700 Willingdon Ave., Burnaby, BC V5G 3H2, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Determination of anthocyanins in cranberry fruit and cranberry fruit products by high-performance liquid chromatography with ultraviolet detection: Single-laboratory validation</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of AOAC International</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of AOAC International</style></full-title></periodical><pages><style face="normal" font="default" size="100%">459-466</style></pages><volume><style face="normal" font="default" size="100%">94</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">A single-laboratory validation study was conducted on an HPLC method for the detection and quantification of cyanidin-3-O-galactoside (C3Ga), cyanidin-3-O-glucoside (C3Gl), cyanidin-3-O-arabinoside (C3Ar), peonidin-3-O-galactoside (P3Ga), and peonidin-3-O-arabinoside (P3Ar) in cranberry fruit (Vaccinium macrocarpon Aiton) raw material and finished products. An extraction procedure using a combination of sonication and shaking with acidified methanol was optimized for all five anthocyanins in freeze-dried cranberry fruit and finished products (commercial extract powder, juice, and juice cocktail). Final extract solutions were analyzed by HPLC using a C18 RP column. Calibration curves for all anthocyanin concentrations had correlation coefficients (r2) of ≥99.8%. The method detection limits for C3Ga, C3Gl, C3Ar, P3Ga, and P3Ar were estimated to be 0.018, 0.016, 0.006, 0.013, and 0.011 μg/mL, respectively. Separation was achieved with a chromatographic run time of 35 min using a binary mobile phase with gradient elution. Quantitative determination performed in triplicate on four test materials on each of 3 days (n = 12) resulted in RSDr from 1.77 to 3.31%. Analytical range, as defined by the calibration curves, was 0.57-36.53 μg/mL for C3Ga, 0.15-9.83 μg/mL for C3Gl, 0.28-17.67 μg/mL for C3Ar, 1.01-64.71 μg/mL for P3Ga, and 0.42-27.14 μg/mL for P3Ar. For solid materials prepared by the described method, this translates to 0.06-3.65 mg/g for C3Ga, 0.02-0.98 mg/g for C3Gl, 0.03-1.77 mg/g for C3Ar, 0.10-6.47 mg/g for P3Ga, and 0.04-2.71 mg/g for P3Ar.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :29&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79953720571&amp;partnerID=40&amp;md5=c293854ee52373b93f7a7b1d60ec3401</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>125</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">125</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brown, E.</style></author><author><style face="normal" font="default" size="100%">Gill, C.</style></author><author><style face="normal" font="default" size="100%">Stewart, D.</style></author><author><style face="normal" font="default" size="100%">McDougall, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Environmental and Biochemical Sciences Group, Enhancing Crop Productivity and Utilisation Theme, James Hutton Institute, Invergowrie, Dundee, DD2 5DA, United Kingdom&#xD;Northern Ireland Centre for Food and Health, Centre for Molecular Biosciences, University of Ulster, Cromore Road, Coleraine, N. Ireland, United Kingdom&#xD;School of Life Sciences, Heriot-Watt University, Edinburgh, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lingonberries (Vaccinium vitis-idaea L) and blueberries (Vaccinium corymbosum) contain discrete epicatechin anthocyanin derivatives linked by ethyl bridges</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Berry Research</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Berry Research</style></full-title></periodical><pages><style face="normal" font="default" size="100%">13-23</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Anthocyanins</style></keyword><keyword><style face="normal" font="default" size="100%">berries</style></keyword><keyword><style face="normal" font="default" size="100%">LCMSn</style></keyword><keyword><style face="normal" font="default" size="100%">proanthocyanidins</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">BACKGROUND: Lingonberries have been associated with a range of potential bioactivities related to their polyphenol content and composition, in particular anthocyanin and proanthocyanidin derivatives. OBJECTIVES: The objective of this study was to examine the anthocyanin composition of extracts of lingonberry and related Vaccinium berries with respect to previously unidentified anthocyanin-like components. METHODS: Extracts were prepared from lingonberries, blueberries and a commercial cranberry juice product and examined by liquid chromatography mass spectroscopic techniques (LCMSn) before and after various fractionation steps. RESULTS: A range of discrete anthocyanin derivatives ethyl linked to (epi)catechin units were identified in lingonberry extracts using LC-MSn methods. Analogous derivatives were detected in similar blueberry extracts, and confirmed in cranberry juices. CONCLUSIONS: Through a combination of fractionation techniques and LCMSn analysis, this paper provides the first evidence that anthocyanin-epicatechin derivatives linked by ethyl bridges are present in lingonberries and in blueberries. These discrete components may be the smallest in a series of proanthocyanidin derivatives with terminal anthocyanins linked through ethyl groups which have previously been inferred in cranberries using mass spectrometric techniques. © 2016 - IOS Press and the authors. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :5&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84960963779&amp;doi=10.3233%2fJBR-150108&amp;partnerID=40&amp;md5=44892652df32faefd8563b6f3dd5403f</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3233/JBR-150108</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>558</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">558</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bronzwaer, S. L. A. M.</style></author><author><style face="normal" font="default" size="100%">Cars, O.</style></author><author><style face="normal" font="default" size="100%">Udo Buchholz, S. M.</style></author><author><style face="normal" font="default" size="100%">Goettsch, W.</style></author><author><style face="normal" font="default" size="100%">Veldhuijzen Jacob L Kool, I. K.</style></author><author><style face="normal" font="default" size="100%">Sprenger, M. J. W.</style></author><author><style face="normal" font="default" size="100%">Degener, J. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">National Institute of Public Health and the Environment, Bilthoven, Netherlands&#xD;Swedish Institute for Infectious Disease Control, Solna, Sweden&#xD;Nepi Foundation, Malmö, Sweden&#xD;Groningen University Hospital, Groningen, Netherlands</style></auth-address><titles><title><style face="normal" font="default" size="100%">A European study on the relationship between antimicrobial use and antimicrobial resistance</style></title><secondary-title><style face="normal" font="default" size="100%">Emerging Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Emerging Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">278-282</style></pages><volume><style face="normal" font="default" size="100%">8</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><abstract><style face="normal" font="default" size="100%">In Europe, antimicrobial resistance has been monitored since 1998 by the European Antimicrobial Resistance Surveillance System (EARSS). We examined the relationship between penicillin nonsusceptibility of invasive isolates of Streptococcus pneumoniae and antibiotic sales. Information was collected on 1998-99 resistance data for invasive isolates of S. pneumoniae to penicillin, based on surveillance data from EARSS and on outpatient sales during 1997 for beta-lactam antibiotics and macrolides. Our results show that in Europe antimicrobial resistance of S. pneumoniae to penicillin is correlated with use of beta-lactam antibiotics and macrolides.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :446&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036200188&amp;doi=10.3201%2feid0803.010192&amp;partnerID=40&amp;md5=bb63a3fe084ff9063c567f1ad70c2f8f</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3201/eid0803.010192</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>218</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">218</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bräunlich, M.</style></author><author><style face="normal" font="default" size="100%">Slimestad, R.</style></author><author><style face="normal" font="default" size="100%">Wangensteen, H.</style></author><author><style face="normal" font="default" size="100%">Brede, C.</style></author><author><style face="normal" font="default" size="100%">Malterud, K. E.</style></author><author><style face="normal" font="default" size="100%">Barsett, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">School of Pharmacy, Department of Pharmaceutical Chemistry, University of Oslo, P.O. Box 1068, Blindern, N-0316 Oslo, Norway&#xD;PlantChem, Særheim Research Center, N-4353 Klepp station, Norway&#xD;Department of Medical Biochemistry, Stavanger University Hospital, N-4068 Stavanger, Norway</style></auth-address><titles><title><style face="normal" font="default" size="100%">Extracts, anthocyanins and procyanidins from Aronia melanocarpa as radical scavengers and enzyme inhibitors</style></title><secondary-title><style face="normal" font="default" size="100%">Nutrients</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nutrients</style></full-title></periodical><pages><style face="normal" font="default" size="100%">663-678</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">15-lipoxygenase</style></keyword><keyword><style face="normal" font="default" size="100%">Anthocyanins</style></keyword><keyword><style face="normal" font="default" size="100%">Aronia melanocarpa</style></keyword><keyword><style face="normal" font="default" size="100%">DPPH</style></keyword><keyword><style face="normal" font="default" size="100%">Procyanidins</style></keyword><keyword><style face="normal" font="default" size="100%">Xanthine oxidase</style></keyword><keyword><style face="normal" font="default" size="100%">α-glucosidase</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Extracts, subfractions, isolated anthocyanins and isolated procyanidins B2, B5 and C1 from the berries and bark of Aronia melanocarpa were investigated for their antioxidant and enzyme inhibitory activities. Four different bioassays were used, namely scavenging of the diphenylpicrylhydrazyl (DPPH) radical, inhibition of 15-lipoxygenase (15-LO), inhibition of xanthine oxidase (XO) and inhibition of α-glucosidase. Among the anthocyanins, cyanidin 3-arabinoside possessed the strongest and cyanidin 3-xyloside the weakest radical scavenging and enzyme inhibitory activity. These effects seem to be influenced by the sugar units linked to the anthocyanidin. Subfractions enriched in procyanidins were found to be potent α-glucosidase inhibitors; they possessed high radical scavenging properties, strong inhibitory activity towards 15-LO and moderate inhibitory activity towards XO. Trimeric procyanidin C1 showed higher activity in the biological assays compared to the dimeric procyanidins B2 and B5. This study suggests that different polyphenolic compounds of A. melanocarpa can have beneficial effects in reducing blood glucose levels due to inhibition of α-glucosidase and may have a potential to alleviate oxidative stress. © 2013 by the authors; licensee MDPI, Basel, Switzerland.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :69&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84874823622&amp;doi=10.3390%2fnu5030663&amp;partnerID=40&amp;md5=5c59ca5f89d20d661fdc882f4ed32f1b</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/nu5030663</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>204</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">204</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Braunlich, M.</style></author><author><style face="normal" font="default" size="100%">Økstad, O. A.</style></author><author><style face="normal" font="default" size="100%">Slimestad, R.</style></author><author><style face="normal" font="default" size="100%">Wangensteen, H.</style></author><author><style face="normal" font="default" size="100%">Malterud, K. E.</style></author><author><style face="normal" font="default" size="100%">Barsett, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Pharmaceutical Chemistry, School of Pharmacy, University of Oslo, P.O. Box 1068, Blindern, Oslo N-0316, Norway&#xD;Laboratory for Microbial Dynamics and Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, P.O. Box 1068, Blindern, Oslo N-0316, Norway&#xD;PlantChem, Særheim Research Center, N-4353 Klepp Station, Norway</style></auth-address><titles><title><style face="normal" font="default" size="100%">Effects of aronia melanocarpa constituents on biofilm formation of escherichia coli and bacillus cereus</style></title><secondary-title><style face="normal" font="default" size="100%">Molecules</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Molecules</style></full-title></periodical><pages><style face="normal" font="default" size="100%">14989-14999</style></pages><volume><style face="normal" font="default" size="100%">18</style></volume><number><style face="normal" font="default" size="100%">12</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aronia melanocarpa</style></keyword><keyword><style face="normal" font="default" size="100%">Bacillus cereus</style></keyword><keyword><style face="normal" font="default" size="100%">Biofilm formation</style></keyword><keyword><style face="normal" font="default" size="100%">Escherichia coli</style></keyword><keyword><style face="normal" font="default" size="100%">Flavonoids</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Many bacteria growing on surfaces form biofilms. Adaptive and genetic changes of the microorganisms in this structure make them resistant to antimicrobial agents. Biofilm-forming organisms on medical devices can pose serious threats to human health. Thus, there is a need for novel prevention and treatment strategies. This study aimed to evaluate the ability of Aronia melanocarpa extracts, subfractions and compounds to prevent biofilm formation and to inhibit bacterial growth of Escherichia coli and Bacillus cereus in vitro. It was found that several aronia substances possessed anti-biofilm activity, however, they were not toxic to the species screened. This non-toxic inhibition may confer a lower potential for resistance development compared to conventional antimicrobials. © 2013 by the authors; licensee MDPI, Basel, Switzerland.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :8&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84890954157&amp;doi=10.3390%2fmolecules181214989&amp;partnerID=40&amp;md5=0b9df5074c15e0a4c14eef1eeba7d51a</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/molecules181214989</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>463</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">463</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bouckaert, J.</style></author><author><style face="normal" font="default" size="100%">Berglund, J.</style></author><author><style face="normal" font="default" size="100%">Schembri, M.</style></author><author><style face="normal" font="default" size="100%">De Genst, E.</style></author><author><style face="normal" font="default" size="100%">Cools, L.</style></author><author><style face="normal" font="default" size="100%">Wuhrer, M.</style></author><author><style face="normal" font="default" size="100%">Hung, C. S.</style></author><author><style face="normal" font="default" size="100%">Pinkner, J.</style></author><author><style face="normal" font="default" size="100%">Slättegård, R.</style></author><author><style face="normal" font="default" size="100%">Zavialov, A.</style></author><author><style face="normal" font="default" size="100%">Choudhury, D.</style></author><author><style face="normal" font="default" size="100%">Langermann, S.</style></author><author><style face="normal" font="default" size="100%">Hultgren, S. J.</style></author><author><style face="normal" font="default" size="100%">Wyns, L.</style></author><author><style face="normal" font="default" size="100%">Klemm, P.</style></author><author><style face="normal" font="default" size="100%">Oscarson, S.</style></author><author><style face="normal" font="default" size="100%">Knight, S. D.</style></author><author><style face="normal" font="default" size="100%">De Greve, H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Laboratorium voor Ultrastructuur, Vrije Universiteit Brussel (VUB), Vlaams Interuniv. Inst. Biotech., Pleinlaan 2, 1050 Brussels, Belgium&#xD;Department of Molecular Biology, Swed. Univ. of Agricultural Sciences, Uppsala Biomedical Center, PO Box 590, SE-751 24 Uppsala, Sweden&#xD;Sch. of Molec. and Microbial Sci., University of Queensland, Brisbane, QLD 4072, Australia&#xD;Biomolecular Mass Spectrometry Unit, Department of Parasitology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, Netherlands&#xD;Department of Molecular Microbiology, Box 8230, Washington Univ. School of Medicine, 660 S. Euclid Ave., St. Louis, MO 63110, United States&#xD;Department of Organic Chemistry, Arrhenius Laboratory, Stockholm University, SE-10691 Stockholm, Sweden&#xD;MedImmune, 35 W. Watkins Mill Road, Gaithersburg, MD 20878, United States&#xD;Microbial Adhesion Group, Technical University of Denmark, BioCentrum-DTU, DK-2800 Lyngby, Denmark&#xD;Centre for Biotechnology, Jawaharlal Nehru University, New Delhi 110067, India&#xD;PharmAthene, Inc., 175 Admiral Cochrane Drive, Annapolis, MD 21401, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin</style></title><secondary-title><style face="normal" font="default" size="100%">Molecular Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Molecular Microbiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">441-455</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">Mannose-binding type 1 pili are important virulence factors for the establishment of Escherichia coli urinary tract infections (UTIs). These infections are initiated by adhesion of uropathogenic E. coli to uroplakin receptors in the uroepithelium via the FimH adhesin located at the tips of type 1 pili. Blocking of bacterial adhesion is able to prevent infection. Here, we provide for the first time binding data of the molecular events underlying type 1 fimbrial adherence, by crystallographic analyses of the FimH receptor binding domains from a uropathogenic and a K-12 strain, and affinity measurements with mannose, common mono- and disaccharides, and a series of alkyl and aryl mannosides. Our results illustrate that the lectin domain of the FimH adhesin is a stable and functional entity and that an exogenous butyl α-D-mannoside, bound in the crystal structures, exhibits a significantly better affinity for FimH (Kd = 0.15 μM) than mannose (Kd = 2.3 μM). Exploration of the binding affinities of α-D-mannosides with longer alkyl tails revealed affinities up to 5 nM. Aryl mannosides and fructose can also bind with high affinities to the FimH lectin domain, with a 100-fold improvement and 15-fold reduction in affinity, respectively, compared with mannose. Taken together, these relative FimH affinities correlate exceptionally well with the relative concentrations of the same glycans needed for the inhibition of adherence of type 1 piliated E. coli. We foresee that our findings will spark new ideas and initiatives for the development of UTI vaccines and anti-adhesive drugs to prevent anticipated and recurrent UTIs.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :271&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-19944433174&amp;doi=10.1111%2fj.1365-2958.2004.04415.x&amp;partnerID=40&amp;md5=aff172576980aca503b73b31f9793cd2</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/j.1365-2958.2004.04415.x</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>515</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">515</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Botto, H.</style></author><author><style face="normal" font="default" size="100%">Aho, L. S.</style></author><author><style face="normal" font="default" size="100%">Boiteux, J. P.</style></author><author><style face="normal" font="default" size="100%">Brion, J. P.</style></author><author><style face="normal" font="default" size="100%">Brouqui, P.</style></author><author><style face="normal" font="default" size="100%">Chartier-Kastler, E.</style></author><author><style face="normal" font="default" size="100%">Dupon, M.</style></author><author><style face="normal" font="default" size="100%">Jehl, F.</style></author><author><style face="normal" font="default" size="100%">Jonquet, O.</style></author><author><style face="normal" font="default" size="100%">Legrain, S.</style></author><author><style face="normal" font="default" size="100%">Marmonier, A.</style></author><author><style face="normal" font="default" size="100%">Mimoz, O.</style></author><author><style face="normal" font="default" size="100%">Rothan-Tondeur, M.</style></author><author><style face="normal" font="default" size="100%">Rousselot, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Service d&apos;Urologie, Hôpital Foch, 40, rue Worth, 92151 Suresnes, France&#xD;Urology, Hôpital Foch, Suresnes, France&#xD;Hygiene, Hôpital d&apos;Enfants, Dijon, France&#xD;Urology, CHU Hôpital Montpied, Clermont-Ferrand, France&#xD;Infectiology, CHU, Grenoble, France&#xD;Infectiology, CHU, Hôpital Nord, Marseille, France&#xD;Urology, GH La Pitie-Salpetriere, Paris, France&#xD;Infectiology, GH Pellegrin, Bordeaux, France&#xD;Microbiology, CHU, Hôpital Civil, Strasbourg, France&#xD;Intensive Care, CHU, Hôpital Guy-de-Chauliac, Montpellier, France&#xD;Gériatry, Hôpital Bichat-Claude Bernard, Paris, France&#xD;CHU, Hôpital Charles-Foix, Paris, France&#xD;Urology, Clinique Saint-Germain, Brive-La-Gaillarde, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">Nosocomial urinary tract infection (NUTI) in adult patients</style></title><secondary-title><style face="normal" font="default" size="100%">Medecine et Maladies Infectieuses</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Medecine et Maladies Infectieuses</style></full-title></periodical><pages><style face="normal" font="default" size="100%">216s-244s</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">SUPPL. 4</style></number><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Conference Paper</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0141480942&amp;partnerID=40&amp;md5=03ee4482203f827bc55368dd13a91e0e</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>101</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">101</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Borowska, S.</style></author><author><style face="normal" font="default" size="100%">Brzóska, M. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Borowska and Brzóska are with Dept. of Toxicology, Medical Univ. of Bialystok, Bialystok, Poland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Chokeberries (Aronia melanocarpa) and Their Products as a Possible Means for the Prevention and Treatment of Noncommunicable Diseases and Unfavorable Health Effects Due to Exposure to Xenobiotics</style></title><secondary-title><style face="normal" font="default" size="100%">Comprehensive Reviews in Food Science and Food Safety</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Comprehensive Reviews in Food Science and Food Safety</style></full-title></periodical><pages><style face="normal" font="default" size="100%">982-1017</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Aronia melanocarpa berries (chokeberries)</style></keyword><keyword><style face="normal" font="default" size="100%">noncommunicable diseases</style></keyword><keyword><style face="normal" font="default" size="100%">polyphenolic compounds</style></keyword><keyword><style face="normal" font="default" size="100%">protection</style></keyword><keyword><style face="normal" font="default" size="100%">xenobiotics</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Aronia melanocarpa berries (chokeberries) constitute a very rich source of numerous substances exerting a beneficial impact on health, including mainly polyphenols (proanthocyanidins, anthocyanins, flavonoids, and phenolic acids), possessing antioxidative, anti-inflammatory, antiviral, anticancer, antiatherosclerotic, hypotensive, antiplatelet, and antidiabetic properties. Thus, the consumption of products made from chokeberries is of vital importance for health maintenance and protection. Nowadays, due to the growing prevalence of noncommunicable diseases and ubiquitous human exposure to numerous man-made and naturally occurring toxic substances, some of which are dangerous even at low amounts, it is very important to look for effective means of health protection. An important role in this regard may be played by A. melanocarpa berries; however, up to now the attention of scientists, nutritionists, and health practitioners has been focused mainly on the effectiveness of chokeberry products in the prevention and treatment of noncommunicable diseases, while only little attention has been paid to the possibility of their use to counteract the adverse health effects of exposure to xenobiotics. That is why in this review article the main interest has been focused on the possibility of using chokeberries in the protection against unfavorable health effects caused by the action of substances to which humans may be exposed environmentally and/or occupationally. The available experimental data indicate that not only the fruit but also the leaves of A. melanocarpa and their products may be effective means for prevention and treatment of the effects of toxic action of some xenobiotics in humans; however, further studies on this subject are necessary. © 2016 Institute of Food Technologists®</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :13&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84980041594&amp;doi=10.1111%2f1541-4337.12221&amp;partnerID=40&amp;md5=b95c5d0ea179ddf5ad437d7aa010f1ef</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1111/1541-4337.12221</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>619</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">619</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bodel, P. T.</style></author><author><style face="normal" font="default" size="100%">Cotran, R.</style></author><author><style face="normal" font="default" size="100%">Kass, E. H.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Mallory Institute of Pathology, Thorndike Memorial Laboratory, Second and Fourth (Harvard) Medical Services, Boston, MA, United States&#xD;Departments of Bacteriology and Immunology and Medicine, Harvard Medical School, Boston, MA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry juice and the antibacterial action of hippuric acid</style></title><secondary-title><style face="normal" font="default" size="100%">The Journal of Laboratory and Clinical Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">The Journal of Laboratory and Clinical Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">881-888</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">6</style></number><dates><year><style face="normal" font="default" size="100%">1959</style></year></dates><abstract><style face="normal" font="default" size="100%">Cranberry juice, given in maximal tolerable amounts to normal subjects, increases the acidity of the urine slightly and increases the hippuric acid content of the urine by several grams a day. Hippuric acid, in concentrations of 0.02 - 0.04 M, is bacteriostatic at pH 5.0 for the common pathogens of the urinary tract, and its activity decreases about fivefold as the pH is raised to 5.6. Only occasionally does cranberry juice contribute enough hippuric acid to the urine to achieve concentrations which are bacteriostatic at pH 5.O. Hippuric acid, in doses of 12 to 14 Gm. per day, usually lowers the pH of the urine to 5.2 or less, and is excreted in sufficient concentration to induce inhibition of bacterial growth in urine at this pH. The data suggest that the use of hippuric acid as a urinary antiseptic deserves further study. © 1959.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :78&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0000519589&amp;partnerID=40&amp;md5=9f7f9d80b80654eadf32222e2d581919</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>231</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">231</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Blumberg, J. B.</style></author><author><style face="normal" font="default" size="100%">Camesano, T. A.</style></author><author><style face="normal" font="default" size="100%">Cassidy, A.</style></author><author><style face="normal" font="default" size="100%">Kris-Etherton, P.</style></author><author><style face="normal" font="default" size="100%">Howell, A.</style></author><author><style face="normal" font="default" size="100%">Manach, C.</style></author><author><style face="normal" font="default" size="100%">Ostertag, L. M.</style></author><author><style face="normal" font="default" size="100%">Sies, H.</style></author><author><style face="normal" font="default" size="100%">Skulas-Ray, A.</style></author><author><style face="normal" font="default" size="100%">Vita, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, United States&#xD;Department of Chemical Engineering, Worcester Polytechnic Institute, Worcester, MA, United States&#xD;Department of Nutrition, Norwich Medical School, University of East Anglia, Norwich, United Kingdom&#xD;Department of Nutritional Sciences, Pennsylvania State University, University Park, PA, United States&#xD;Rutgers University, Marucci Center for Blueberry Cranberry Research, Chatsworth, NJ, United States&#xD;INRA, UMR1019 Nutrition Humaine, Centre de Recherche de Clermont-Ferrand/Theix, Saint-Genes-Champanelle, France&#xD;Heinrich-Heine-University Dusseldorf, Institute for Biochemistry and Molecular Biology I, Dusseldorf, Germany&#xD;Evans Department of Medicine, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberries and their bioactive constituents in human health</style></title><secondary-title><style face="normal" font="default" size="100%">Advances in Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Advances in Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">618-632</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">6</style></number><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Recent observational and clinical studies have raised interest in the potential health effects of cranberry consumption, an association that appears to be due to the phytochemical content of this fruit. The profile of cranberry bioactives is distinct from that of other berry fruit, being rich in A-type proanthocyanidins (PACs) in contrast to the B-type PACs present in most other fruit. Basic research has suggested a number of potential mechanisms of action of cranberry bioactives, although further molecular studies are necessary. Human studies on the health effects of cranberry products have focused principally on urinary tract and cardiovascular health, with some attention also directed to oral health and gastrointestinal epithelia. Evidence suggesting that cranberries may decrease the recurrence of urinary tract infections is important because a nutritional approach to this condition could lower the use of antibiotic treatment and the consequent development of resistance to these drugs. There is encouraging, but limited, evidence of a cardioprotective effect of cranberries mediated via actions on antioxidant capacity and lipoprotein profiles. The mixed outcomes from clinical studies with cranberry products could result from interventions testing a variety of products, often uncharacterized in their composition of bioactives, using different doses and regimens, as well as the absence of a biomarker for compliance to the protocol. Daily consumption of a variety of fruit is necessary to achieve a healthy dietary pattern, meet recommendations for micronutrient intake, and promote the intake of a diversity of phytochemicals. Berry fruit, including cranberries, represent a rich source of phenolic bioactives that may contribute to human health. © 2013 American Society for Nutrition.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :91&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84895162150&amp;doi=10.3945%2fan.113.004473&amp;partnerID=40&amp;md5=ad4db27b5c0017fc0a7fcfddbb783186</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3945/an.113.004473</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>620</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">620</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Blatherwick, N. R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">NEW HAVEN, CONN., United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">The specific role of foods in relation to the composition of the urine</style></title><secondary-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">409-450</style></pages><volume><style face="normal" font="default" size="100%">XIV</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">1914</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :58&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0000110157&amp;doi=10.1001%2farchinte.1914.00070150122008&amp;partnerID=40&amp;md5=772f7f73af25226ccb74e4ddf3981758</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/archinte.1914.00070150122008</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>312</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">312</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Blango, M. G.</style></author><author><style face="normal" font="default" size="100%">Mulvey, M. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pathology Department, Division of Cell Biology and Immunology, University of Utah, 15 North Medical Drive East, Salt Lake City, UT 84112-0565, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics</style></title><secondary-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antimicrobial Agents and Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1855-1863</style></pages><volume><style face="normal" font="default" size="100%">54</style></volume><number><style face="normal" font="default" size="100%">5</style></number><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><abstract><style face="normal" font="default" size="100%">Numerous antibiotics have proven to be effective at ameliorating the clinical symptoms of urinary tract infections (UTIs), but recurrent and chronic infections continue to plague many individuals. Most UTIs are caused by strains of uropathogenic Escherichia coli (UPEC), which can form both extra- and intracellular biofilm-like communities within the bladder. UPEC also persist inside host urothelial cells in a more quiescent state, sequestered within late endosomal compartments. Here, we tested a panel of 17 different antibiotics, representing seven distinct functional classes, for their effects on the survival of the reference UPEC isolate UTI89 within both biofilms and host bladder urothelial cells. All but one of the tested antibiotics prevented UTI89 growth in broth culture, and most were at least modestly effective against bacteria present within in vitro-grown biofilms. In contrast, only a few of the antibiotics, including nitrofurantoin and the fluoroquinolones ciprofloxacin and sparfloxacin, were able to eliminate intracellular bacteria in bladder cell culture-based assays. However, in a mouse UTI model system in which these antibiotics reached concentrations in the urine specimens that far exceeded minimal inhibitory doses, UPEC reservoirs in bladder tissues were not effectively eradicated. We conclude that the persistence of UPEC within the bladder, regardless of antibiotic treatments, is likely facilitated by a combination of biofilm formation, entry of UPEC into a quiescent or semiquiescent state within host cells, and the stalwart permeability barrier function associated with the bladder urothelium. Copyright © 2010, American Society for Microbiology. All Rights Reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :151&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-77951231961&amp;doi=10.1128%2fAAC.00014-10&amp;partnerID=40&amp;md5=ffca90691cd2365e9b13e5cf9d2e0a37</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1128/AAC.00014-10</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>548</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">548</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Biering-Sørensen, F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Clinic for Para- and Tetraplegia, Neuroscience Centre, Rigshospitalet TH2091, Blegdamsvej 9, DK-2100 Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infection in individuals with spinal cord lesion</style></title><secondary-title><style face="normal" font="default" size="100%">Current Opinion in Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Opinion in Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">45-49</style></pages><volume><style face="normal" font="default" size="100%">12</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infection is the most frequently reported secondary impairment in individuals with spinal cord lesion. The most prevalent risk indicator is an indwelling catheter. Hydrophilic catheters for clean intermittent catheterization may induce lower rates of bacteriuria and long-term urethral complications. Due to chronic bacterial infection within biofilms, an antibacterial treatment based on a urinary culture of bacteria in the urine and its antimicrobial susceptibility may fail to eradicate catheter-associated urinary tract infection. No commercially available drugs are sufficiently active against the bacteria in a mature biofilm. Biomaterials may be modified to decrease the formation of a biofilm. Silver alloy catheters are effective in preventing urinary tract infection when indwelling urinary catheterization is necessary. The risk of systemic argyria in long-term use needs to be evaluated. Suprapubic cystostomy drainage in patients with neurogenic bladder is preferred to an indwelling urethral catheter. In cases of recurring urinary tract infection in patients with a permanent urinary catheter, it may be beneficial to change the catheter every 1 or 2 weeks. There is some evidence that cranberry products may prevent urinary tract infection. In the future, bacterial interference and vaccination may be a possibility for prevention of urinary tract infection. © 2002 Lippincott Williams &amp; Wilkins.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :36&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036138019&amp;doi=10.1097%2f00042307-200201000-00009&amp;partnerID=40&amp;md5=4820177bb9176a3e9295600a70e54444</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/00042307-200201000-00009</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>492</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">492</key></foreign-keys><ref-type name="Serial">57</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Berman, J. D.</style></author><author><style face="normal" font="default" size="100%">Straus, S. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Natl. Ctr. Complementary A., National Institutes of Health, Bethesda, MD 20892, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Implementing a research agenda for complementary and alternative medicine</style></title><secondary-title><style face="normal" font="default" size="100%">Annual Review of Medicine</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">239-254</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Alternative medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Complementary medicine</style></keyword><keyword><style face="normal" font="default" size="100%">Research</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">Complementary and alternative medicine (CAM) consists of diverse clinical interventions that are practiced because of their popularity rather than the prior demonstration of safety and efficacy required for conventional agents. CAM therapies can be grouped into five categories: biologically based therapies, manipulative and body-based interventions, mind-body interventions, &quot;energy&quot; therapies, and alternative medical systems. The present evidence that individual CAM interventions are efficacious is largely anecdotal, but hundreds of small trials have yielded positive results. For a few modalities, existing data are either very encouraging or else sufficient to conclude that they are ineffective. CAM interventions are presumed to be safe, yet they may not be, particularly in the case of botanical agents with inherent toxicities, significant drug interactions, or potent adulterants. The public health questions regarding CAM can only be addressed through a research agenda that defines which interventions have favorable therapeutic indices. Implementation of this agenda involves adequate characterization and standardization of the product or practice, with rigorous investigation to demonstrate its safety, mechanism of action, and efficacy.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :50&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-1542299103&amp;doi=10.1146%2fannurev.med.55.091902.103657&amp;partnerID=40&amp;md5=3a135ca820ce7e62e23151e3c4873712</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1146/annurev.med.55.091902.103657</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>72</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">72</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bergamin, P. A.</style></author><author><style face="normal" font="default" size="100%">Kiosoglous, A. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Royal Brisbane and Women&apos;s HospitalQLD, Australia&#xD;Queen Elizabeth II Jubilee Hospital, Brisbane, Australia&#xD;School of Medicine, University of Queensland, Brisbane, Australia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Non-surgical management of recurrent urinary tract infections in women</style></title><secondary-title><style face="normal" font="default" size="100%">Translational Andrology and Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Translational Andrology and Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S142-S152</style></pages><volume><style face="normal" font="default" size="100%">6</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Non-antimicrobial</style></keyword><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections (UTIs)</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">One in three women will experience a clinically significant urinary tract infection (UTI) by age twenty-four and almost half will have at least one in their lifetime. Recurrent UTIs (rUTIs) are defined as having greater than two infections in a 6-month period, or three infections over twelve months, with complete resolution for at least two weeks. These may be due to relapse from incomplete treatment (persistence) or re-infection (new source). It may be difficult to distinguish between the two, where the same organism is cultured. There are several risk factors for rUTIs including an impairment of the body&apos;s immune system and virulence factors. Reversible or treatable causes are sought and excluded in the patient&apos;s initial review. Patient&apos;s with rUTI are often complex and difficult to manage. The long-term management options in women are multimodal and should focus on prevention of relapse and recurrence. Behavioural factors include adequate hydration, care with sexual hygiene, reducing one&apos;s body mass index (BMI) and post-void residual (PVR) volume. There are several non-antimicrobial options for rUTIs which have become a multi-billion-dollar business. Unfortunately, there are numerous studies which fail to show any major benefit or having conflicting data. Vaccines are currently being explored as a prevention strategy, delivered through injection, intra-nasal sprays, or vaginal suppositories, which are made from combinations of heat killed uro-pathogenic strains. There are no widely available vaccines at present due to limited clinical success. It is well established that appropriate antibiotic therapy results in higher rates of symptom relief and bacterial eradication in women with uncomplicated cystitis. There are several options for antimicrobial use which have been shown to be highly effective in reducing the risk of rUTI in women. The pain and discomfort of the UTI must be balanced with the cost and risk of developing resistance when using antimicrobials. Continuous prophylaxis, pre- and postcoital voiding, and self-starting are the three commonly accepted options for prophylaxis. The choice between these will depend upon patient preference, cultures and previous pattern of infection. Intra-vesical instillation of hyaluronic acid and chondroitin sulphate have been used for glycosaminoglycan (GAG) layer replenishment for many indications, including interstitial cystitis, overactive bladder syndrome, radiation cystitis and prevention of rUTI. At present, intra-vesical therapies are reserved for only those with the most unresponsive rUTIs. The principles of treating rUTI are to break the cycle and to treat any reversible causes. With our ever-expanding research knowledge, there are now many useful products that may be used for the successful treatment of rUTI. A management plan including a combination of a non-antimicrobial and selective antimicrobial regime for a minimum of six months should be considered. It is a prudent clinician that clearly defines this management plan, with reassurance of a finite period of therapy. © Translational Andrology and Urology.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :5&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85024912760&amp;doi=10.21037%2ftau.2017.06.09&amp;partnerID=40&amp;md5=90f25a413c69525fd4eceeb4c7fdd2df</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.21037/tau.2017.06.09</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>545</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">545</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bent, S.</style></author><author><style face="normal" font="default" size="100%">Nallamothu, B. K.</style></author><author><style face="normal" font="default" size="100%">Simel, D. L.</style></author><author><style face="normal" font="default" size="100%">Fihn, S. D.</style></author><author><style face="normal" font="default" size="100%">Saint, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University of California, San Francisco, General Internal Medicine Section, San Francisco VA Medical Center, United States&#xD;Department of Medicine, University of Michigan, Medical School, Ann Arbor, United States&#xD;Department of Medicine, Durham VA Medical Center, Duke University School of Medicine, Durham, NC, United States&#xD;Health Services Research and Development, Center of Excellence, VA Puget Sound Health Care System, Seattle, WA, United States&#xD;Department of Medicine, Ann Arbor VA Medical Center and Patient Safety Enhancement Program, University of Michigan Health System, Ann Arbor, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Does this woman have an acute uncomplicated urinary tract infection?</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of the American Medical Association</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of the American Medical Association</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2701-2710</style></pages><volume><style face="normal" font="default" size="100%">287</style></volume><number><style face="normal" font="default" size="100%">20</style></number><dates><year><style face="normal" font="default" size="100%">2002</style></year></dates><abstract><style face="normal" font="default" size="100%">Context: Symptoms suggestive of acute urinary tract infection (UTI) constitute one of the most common reasons for women to visit clinicians. Although the clinical encounter typically involves taking a history and performing a physical examination, the diagnostic accuracy of the clinical assessment for UTI remains uncertain. Objective: To review the accuracy and precision of history taking and physical examination for the diagnosis of UTI in women. Data Sources: We conducted a MEDLINE search for articles published from 1966 through September 2001 and manually reviewed bibliographies, 3 commonly used clinical skills textbooks, and contacted experts in the field. Study Selection: Studies were included if they contained original data on the accuracy or precision of history or physical examination for diagnosing acute uncomplicated UTI in women. One author initially screened titles and abstracts found by our search. Nine of 464 identified studies met inclusion criteria. Data Extraction: Two authors independently abstracted data from the included studies. Disagreements were resolved by discussion and consensus with a third author. Data Synthesis: Four symptoms and 1 sign significantly increased the probability of UTI: dysuria (summary positive likelihood ratio [LR], 1.5; 95% confidence interval [CI], 1.2-2.0), frequency (LR, 1.8; 95% CI, 1.1 -3.0), hematuria (LR, 2.0; 95% CI, 1.3-2.9), back pain (LR, 1.6; 95% CI, 1.2-2.1), and costovertebral angle tenderness (LR, 1.7; 95% CI, 1.1 -2.5). Four symptoms and 1 sign significantly decreased the probability of UTI: absence of dysuria (summary negative LR, 0.5; 95% CI, 0.3-0.7), absence of back pain (LR, 0.8; 95% CI, 0.7-0.9), history of vaginal discharge (LR, 0.3; 95% CI, 0.10.9), history of vaginal irritation (LR, 0.2; 95% CI, 0.1 -0.9), and vaginal discharge on examination (LR, 0.7; 95% CI, 0.5-0.9). Of all individual diagnostic signs and symptoms, the 2 most powerful were history of vaginal discharge and history of vaginal irritation, which significantly decreased the likelihood of UTI when present (LRs, 0.3 and 0.2, respectively). One study examined combinations of symptoms, and the resulting LRs were more powerful (24.6 for the combination of dysuria and frequency but no vaginal discharge or irritation). One study of patients with recurrent UTI found that self-diagnosis significantly increased the probability of UTI (LR, 4.0). Conclusions: In women who present with 1 or more symptoms of UTI, the probability of infection is approximately 50%. Specific combinations of symptoms (eg, dysuria and frequency without vaginal discharge or irritation) raise the probability of UTI to more than 90%, effectively ruling in the diagnosis based on history alone. In contrast, history taking, physical examination, and dipstick urinalysis are not able to reliably lower the posttest probability of disease to a level where a UTI can be ruled out when a patient presents with 1 or more symptoms.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :286&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037157095&amp;doi=10.1001%2fjama.287.20.2701&amp;partnerID=40&amp;md5=e54eada17afb891da7e46aa84957396a</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jama.287.20.2701</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>430</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">430</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Benoit, J. M.</style></author><author><style face="normal" font="default" size="100%">Berges, J. L.</style></author><author><style face="normal" font="default" size="100%">Falcou, M.</style></author><author><style face="normal" font="default" size="100%">Jeanjean, P.</style></author><author><style face="normal" font="default" size="100%">Jourfier, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">La Preste et Service d&apos;Urologie, CHU Rangueil, Toulouse, France&#xD;Biologiste, La Preste et Perpignan, France&#xD;Service d&apos;Urologie, CHU Rangueil, TSA 50032, 31059 Toulouse Cedex 9, France</style></auth-address><titles><title><style face="normal" font="default" size="100%">Ionic solutions and possibilities of prevention of recurrent cystitis</style></title><secondary-title><style face="normal" font="default" size="100%">Progres en Urologie</style></secondary-title><short-title><style face="normal" font="default" size="100%">Solutions ioniques et possibilités de prévention des cystites récidivantes</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Progres en Urologie</style></full-title></periodical><pages><style face="normal" font="default" size="100%">163-167</style></pages><volume><style face="normal" font="default" size="100%">16</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Adhesion</style></keyword><keyword><style face="normal" font="default" size="100%">Bladder</style></keyword><keyword><style face="normal" font="default" size="100%">Cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">Infection</style></keyword><keyword><style face="normal" font="default" size="100%">Ionic complex</style></keyword><keyword><style face="normal" font="default" size="100%">P-fimbriae</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: In view of the importance of the phenomenon of adhesion of bacteria to urothelial cells in the pathogenesis of urinary tract infections, the authors investigated the possibility of decreasing this adhesion by means of a complex ionic solution: La Preste mineral water. Subjects and Method: The in vitro adhesion of Escherichia coli P-fimbriae (Gal-Gal pili) to urothelial cells in women with recurrent cystitis was compared in neutral medium and in mineral water and the interaction of this same micro-organism with microparticles coated with Gal-Gal receptors was also studied in the same media. In vivo, urothelial cells of 13 women with a normal urological assessment, presenting recurrent cystitis and a high adhesion capacity, were tested three times a day in relation to the same micro-organism on the first and last day of their course of mineral water therapy. Results: In vitro, pretreatment of urothelial cells by mineral water induced decreased adhesion (p=0.001), while pretreatment of bacteria with the same mineral water had no effect. In vivo, adhesion was significantly (p=0.021) decreased 2 to 3 hours after ingestion of mineral water and a significant global reduction of adhesion (p=0.016) was observed between the first and last day of mineral water therapy. Conclusions : These data show a reduction of adhesion (type P) between Escherichia coli and urothelial cells in the presence of La Preste mineral water, due to an action on urothelial cells. These results indicate the probable role of sulphur and silica in this process, while modulation of adhesion by ions has only been demonstrated to date for calcium and magnesium.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33746721036&amp;partnerID=40&amp;md5=f2184046eda9bee13a72fb8245bc04e0</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>207</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">207</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Begcevic, I.</style></author><author><style face="normal" font="default" size="100%">Simundic, A. M.</style></author><author><style face="normal" font="default" size="100%">Nikolac, N.</style></author><author><style face="normal" font="default" size="100%">Dobrijevic, S.</style></author><author><style face="normal" font="default" size="100%">Rajkovic, M. G.</style></author><author><style face="normal" font="default" size="100%">Tesija-Kuna, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">University Department of Chemistry, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia&#xD;Department of Medical Biochemistry and Hematology, Faculty of Pharmacy and Biochemistry, University of Zagreb, Domagojeva 2, 10 000 Zagreb, Croatia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Can cranberry extract and vitamin C + Zn supplements affect the in vivo activity of paraoxonase 1, antioxidant potential, and lipid status?</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Laboratory</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Laboratory</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1053-1060</style></pages><volume><style face="normal" font="default" size="100%">59</style></volume><number><style face="normal" font="default" size="100%">9-10</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antioxidant supplement</style></keyword><keyword><style face="normal" font="default" size="100%">Lipid status</style></keyword><keyword><style face="normal" font="default" size="100%">Paraoxonase 1 activity</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2013</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: The modern way of life exposes us to substantial oxidative stress, putting the focus on the research of antioxidant effects of dietary supplements. Recent studies have shown that the effectiveness of particular vitamins and herbal preparations might have an effect on paraoxonase activity. Paraoxonase 1 is an HDL associated enzyme which prevents the oxidation of LDL. Several studies have shown the beneficial effect of some dietary components to the activity of paraoxonase. The aim of this study was to analyze the effects of cranberry extract and vitamin C and zinc preparations (vitamin C + Zn) on serum paraoxonase 1 activity, antioxidant status, and glucose and lipid concentration. Methods: The study included 31 healthy volunteers (median age 24 years). They were divided into 3 groups according to the intervention type and smoking status and exposed to commercially available preparations of the cranberry extract (2 g/day) and vitamin C + Zn (300 mg/day) during 4 weeks. Results: The results have shown that there is a significant increase in the activity of the paraoxonase 1 in non-smokers after the intervention with the cranberry extract as well as with vitamin C + Zn preparations. Also, total antioxidant status increased in the non-smokers subgroup after intervention with vitamin C + Zn. However, the lipid profile did not change significantly in response to antioxidant preparations. Conclusions: Our results show that antioxidant supplements can increase the antioxidant potential of an organism as well as paraoxonase 1 activity. This observation is pointing to the potential complementary role of dietary supplements in the primary prevention of atherosclerosis.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84886440133&amp;doi=10.7754%2fClin.Lab.2012.121005&amp;partnerID=40&amp;md5=2298aa25b6bfffe3b6914046bbb0b303</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.7754/Clin.Lab.2012.121005</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>531</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">531</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beetz, R.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Pediatric Clinic, University of Mainz, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Mild dehydration: A risk factor of urinary tract infection?</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Clinical Nutrition</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Journal of Clinical Nutrition</style></full-title></periodical><pages><style face="normal" font="default" size="100%">S52-S58</style></pages><volume><style face="normal" font="default" size="100%">57</style></volume><keywords><keyword><style face="normal" font="default" size="100%">Dehydration</style></keyword><keyword><style face="normal" font="default" size="100%">Fluid intake</style></keyword><keyword><style face="normal" font="default" size="100%">Host factors</style></keyword><keyword><style face="normal" font="default" size="100%">Hydration</style></keyword><keyword><style face="normal" font="default" size="100%">Urinay tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">Bacterial growth in the urinary tract is usually prevented by host factors including bacterial eradication by urinary and mucus flow, urothelial bactericidal activity, urinary secretory IgA, and blood group antigens in secretions which interfere with bacterial adherence. Bacterial eradication from the urinary tract is partially dependent on urine flow and voiding frequency. Therefore, it seems logical to postulate a connection between fluid intake and the risk of urinary tract infections (UTIs). However, experimental and clinical data on this subject are conflicting. Experimental studies concerning the effect of water intake on susceptibility and course of UTIs were predominantly performed in the 60 s and 70 s. Despite many open questions, there has been no continuous research in this field.Only few clinical studies producing contradictory results are available on the influence of fluid intake concerning the risk of UTI. One explanation for the inconsistency between the data might be the uncertainty about the exact amounts of fluid intake, which was mostly recorded in questionnaires. So far, there is no definitive evidence that the susceptibility for UTI is dependent on fluid intake. Nevertheless, adequate hydration is important and may improve the results of antimicrobial therapy in UTI. Results of experimental and clinical studies concerning urinary hydrodynamics are the basis for advice given by expert committees to patients with UTI to drink large volumes of fluid, void frequently, and completely empty the bladder. The combination of the behaviourally determined aspects of host defence and not simply increasing fluid intake is important in therapy and prophylaxis of UTI. © 2003 Nature Publishing Group. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :51&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0742306789&amp;doi=10.1038%2fsj.ejcn.1601902&amp;partnerID=40&amp;md5=76f97939b676969572e03ff7639186dd</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1038/sj.ejcn.1601902</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>432</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">432</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beerepoot, M. A. J.</style></author><author><style face="normal" font="default" size="100%">Ter Riet, G.</style></author><author><style face="normal" font="default" size="100%">Verbon, A.</style></author><author><style face="normal" font="default" size="100%">Nys, S.</style></author><author><style face="normal" font="default" size="100%">De Reijke, T. M.</style></author><author><style face="normal" font="default" size="100%">Geerlings, S. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Afd. Inwendige Geneeskunde, Academisch Medisch Centrum, Universiteit van Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands&#xD;Afd. Huisartsgeneeskunde, Academisch Medisch Centrum, Universiteit van Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands&#xD;Afd. Urologie, Academisch Medisch Centrum, Universiteit van Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands&#xD;Academisch Ziekenhuis Maastricht, Afd. Medische Microbiologie, Maastricht, Netherlands</style></auth-address><titles><title><style face="normal" font="default" size="100%">Non-antibiotic prophylaxis for recurrent urinary-tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Nederlands Tijdschrift voor Geneeskunde</style></secondary-title><short-title><style face="normal" font="default" size="100%">Niet-antibiotische profylaxe van recidiverende urineweginfecties</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Nederlands Tijdschrift voor Geneeskunde</style></full-title></periodical><pages><style face="normal" font="default" size="100%">541-544</style></pages><volume><style face="normal" font="default" size="100%">150</style></volume><number><style face="normal" font="default" size="100%">10</style></number><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary-tract infections (UTIs) occur frequently and hence have significant financial implications. Antibiotic prophylaxis can be considered in women with recurrent UTIs. However, frequent exposure to antibiotics can lead to antimicrobial resistance and side effects. The most important steps in the pathogenesis of UTIs are the colonisation and adherence of uropathogens. Lactobacilli impede intravaginal colonisation by competing with uropathogens. Cranberries interfere with the adherence of uropathogens to uroepithelial cells. Therefore, cranberries and lactobacilli are potential alternatives in the prophylaxis of UTIs. Randomised clinical trials comparing these compounds with long-term, low-dose antibiotics for the prevention of recurrent UTIs in women have not yet been conducted. Such a trial has recently been started in the Netherlands: the &apos;Non-antibiotic versus antibiotic prophylaxis for recurrent urinary-tract infections&apos; (NAPRUTI) study.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33644956354&amp;partnerID=40&amp;md5=b1b5bbee91f62ac4826ba47ec0da6d7f</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>278</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">278</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beerepoot, M. A. J.</style></author><author><style face="normal" font="default" size="100%">Ter Riet, G.</style></author><author><style face="normal" font="default" size="100%">Nys, S.</style></author><author><style face="normal" font="default" size="100%">Van Der Wal, W. M.</style></author><author><style face="normal" font="default" size="100%">De Borgie, C. A. J. M.</style></author><author><style face="normal" font="default" size="100%">De Reijke, T. M.</style></author><author><style face="normal" font="default" size="100%">Prins, J. M.</style></author><author><style face="normal" font="default" size="100%">Koeijers, J.</style></author><author><style face="normal" font="default" size="100%">Verbon, A.</style></author><author><style face="normal" font="default" size="100%">Stobberingh, E.</style></author><author><style face="normal" font="default" size="100%">Geerlings, S. E.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Infectious Diseases, Tropical Medicine and AIDS, Department of Internal Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands&#xD;Department of General Practice, Academic Medical Center, Amsterdam, Netherlands&#xD;Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, Netherlands&#xD;Department of Urology, Academic Medical Center, Amsterdam, Netherlands&#xD;Department of Medical Microbiology, Maastricht University Medical Center, Maastricht, Netherlands&#xD;Department of Infectious Diseases, Maastricht University Medical Center, Maastricht, Netherlands&#xD;Department of Biostatistics, Julius Center, University Medical Center Utrecht, Utrecht, Netherlands&#xD;Department of Infectious Diseases, Erasmus Medical Center, Rotterdam, Netherlands</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberries vs antibiotics to prevent urinary tract infections: A randomized double-blind noninferiority trial in premenopausal women</style></title><secondary-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Archives of Internal Medicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1270-1278</style></pages><volume><style face="normal" font="default" size="100%">171</style></volume><number><style face="normal" font="default" size="100%">14</style></number><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: The increasing prevalence of uropathogens resistant to antimicrobial agents has stimulated interest in cranberries to prevent recurrent urinary tract infections (UTIs). Methods: In a double-blind, double-dummy noninferiority trial, 221 premenopausal women with recurrent UTIs were randomized to 12-month prophylaxis use of trimethoprim-sulfamethoxazole (TMP-SMX), 480 mg once daily, or cranberry capsules, 500 mg twice daily. Primary end points were the mean number of symptomatic UTIs over 12 months, the proportion of patients with at least 1 symptomatic UTI, the median time to first UTI, and development of antibiotic resistance in indigenous Escherichia coli. Results: After 12 months, the mean number of patients with at least 1 symptomatic UTI was higher in the cranberry than in the TMP-SMX group (4.0 vs 1.8; P=.02), and the proportion of patients with at least 1 symptomatic UTI was higher in the cranberry than in the TMP-SMX group (78.2% vs 71.1%). Median time to the first symptomatic UTI was 4 months for the cranberry and 8 months for the TMP-SMX group. After 1 month, in the cranberry group, 23.7% of fecal and 28.1% of asymptomatic bacteriuria E coli isolates were TMP-SMX resistant, whereas in the TMP-SMX group, 86.3% of fecal and 90.5% of asymptomatic bacteriuria E coli isolates were TMP-SMX resistant. Similarly, we found increased resistance rates for trimethoprim, amoxicillin, and ciprofloxacin in these E coli isolates after 1 month in the TMP-SMX group. After discontinuation of TMP-SMX, resistance reached baseline levels after 3 months. Antibiotic resistance did not increase in the cranberry group. Cranberries and TMP-SMX were equally well tolerated. Conclusion: In premenopausal women, TMP-SMX, 480 mg once daily, is more effective than cranberry capsules, 500 mg twice daily, to prevent recurrent UTIs, at the expense of emerging antibiotic resistance. Trial Registration: isrctn.org Identifier: ISRCTN50717094. ©2011 American Medical Association. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :101&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79960956720&amp;doi=10.1001%2farchinternmed.2011.306&amp;partnerID=40&amp;md5=3b415013a0cc4aab8e0b37dbc3e2bc7c</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/archinternmed.2011.306</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>122</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">122</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Beerepoot, M.</style></author><author><style face="normal" font="default" size="100%">Geerlings, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Internal Medicine, Division of Infectious Diseases, Academic Medical Center, Meibergdreef 9, Amsterdam, 1105 AZ, Netherlands</style></auth-address><titles><title><style face="normal" font="default" size="100%">Non-antibiotic prophylaxis for urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Pathogens</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Pathogens</style></full-title></periodical><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Non-antibiotic strategies</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention and control</style></keyword><keyword><style face="normal" font="default" size="100%">Review</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">Increasing antimicrobial resistance has stimulated interest in non-antibiotic prophylaxis of recurrent urinary tract infections (UTIs). Well-known steps in the pathogenesis of UTIs are urogenital colonization and adherence of uropathogens to uroepithelial cell receptors. To prevent colonization in postmenopausal women, vaginal, but not oral, estrogens have been shown to restore the vagina lactobacilli flora, reduce vaginal colonization with Enterobacteriaceae, and reduce the number of UTIs compared to placebo. Different lactobacilli strains show different results in the prevention of recurrent UTIs. Intravaginal suppositories with Lactobacillus crispatus in premenopausal women and oral capsules with Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 in postmenopausal women are promising. Ascorbic acid (vitamin C) cannot be recommended for the prevention of UTIs. Cranberries are thought to contain proanthocyanidins that can inhibit adherence of P-fimbriated E. coli to the uroepithelial cell receptors. Cranberry products decreased UTI recurrences about 30%-40% in premenopausal women with recurrent UTIs, but are less effective than low-dose antimicrobial prophylaxis. However, the optimal dose of cranberry product has still to be determined. Initially OM-89, a vaccine with 18 heat-killed E. coli extracts, seemed promising, but this was not confirmed in a recently randomized trial. © 2016 by the authors; licensee MDPI, Basel, Switzerland.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :21&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85036502092&amp;doi=10.3390%2fpathogens5020036&amp;partnerID=40&amp;md5=fd4c1036ac2e7740db28c7434f05053f</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">36</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/pathogens5020036</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>53</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">53</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Becker, R.</style></author><author><style face="normal" font="default" size="100%">Szakiel, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Plant Biochemistry, Faculty of Biology, University of Warsaw, Miecznikowa 1, Warsaw, 02-096, Poland</style></auth-address><titles><title><style face="normal" font="default" size="100%">Phytochemical characteristics and potential therapeutic properties of blue honeysuckle Lonicera caerulea L. (Caprifoliaceae)</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Herbal Medicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Herbal Medicine</style></full-title></periodical><keywords><keyword><style face="normal" font="default" size="100%">Antioxidant properties</style></keyword><keyword><style face="normal" font="default" size="100%">Blue honeysuckle</style></keyword><keyword><style face="normal" font="default" size="100%">Edible honeysuckle</style></keyword><keyword><style face="normal" font="default" size="100%">Honeyberry</style></keyword><keyword><style face="normal" font="default" size="100%">Lonicera caerulea</style></keyword><keyword><style face="normal" font="default" size="100%">Polyphenols</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Lonicera caerulea, known as honeyberry, blue honeysuckle, sweet berry honeysuckle, edible honeysuckle, or haskap, is a perennial fruit-bearing plant belonging to the family Caprifoliaceae. Currently, the cultivation of this plant species is becoming increasingly popular due to the early ripening of the fruits, the plant´s exceptional resistance to frost, pests, and diseases, as well as for its potential health-promoting and therapeutic properties. Phytochemical analysis of blue honeysuckle constituents using methods such as colorimetry, LC–MS/MS and HPLC-ESI-MS have been carried out over the last two decades. According to the reported data, L. caerulea fruits are rich in phenolic compounds, their amount - with the level of flavonoids reaching 2 g per 100 g of dry fruit weight - is comparable to those of some blueberries (Vaccinium spp.), blackberries (Rubus spp.), and currants (Ribes spp.). Among phenolics acting as antioxidants, anthocyanins are particularly important for some health-promoting activities, e.g., heart disease prevention and in supporting the treatment of various eye diseases. In L. cearulea these compounds are represented mostly by derivatives of cyanidin and, in smaller quantities, peonidin and pelargonidin. Other reported properties of L. cearulea fruit involve antimicrobial, anti-inflammatory, anti-atherosclerotic, and anticarcinogenic activities, demonstrated in in vitro and some in vivo tests. Therefore, due to the high content of bioactive substances and their health-promoting properties, blue honeysuckle berries can be regarded and recommended as a valuable component of a healthy diet. © 2018 Elsevier GmbH</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019&#xD;Article in Press</style></notes><work-type><style face="normal" font="default" size="100%">Article in Press</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055637112&amp;doi=10.1016%2fj.hermed.2018.10.002&amp;partnerID=40&amp;md5=233d764621774dcc0cf14e28a323cd23</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.hermed.2018.10.002</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>258</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">258</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Baulies Romero, G.</style></author><author><style face="normal" font="default" size="100%">Torres Castella, R. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">ABS la Llagosta, Barcelona, Spain&#xD;ABS Ciutat Meridiana, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Update on phytotherapy and medicinal plants</style></title><secondary-title><style face="normal" font="default" size="100%">FMC Formacion Medica Continuada en Atencion Primaria</style></secondary-title><short-title><style face="normal" font="default" size="100%">Actualización en fitoterapia y plantas medicinales</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">FMC Formacion Medica Continuada en Atencion Primaria</style></full-title></periodical><pages><style face="normal" font="default" size="100%">149-160</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84858961495&amp;doi=10.1016%2fS1134-2072%2812%2970324-9&amp;partnerID=40&amp;md5=abc10a3dae037fe56bb1d93a024d2990</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S1134-2072(12)70324-9</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>117</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">117</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bauer, H. W.</style></author><author><style face="normal" font="default" size="100%">Bessler, W. G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Urologische Praxis Maximilianstrae, Ludwig-Maximilians-Universität München, Germany&#xD;Institut für Molekulare Medizin und Zellforschung, Universität Freiburg, Germany&#xD;Maximilianstrae 31, München, 80539, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Non-Antibiotic Strategies to Prevent the Recurrence of Uncomplicated Urinary Tract Infections in Women</style></title><secondary-title><style face="normal" font="default" size="100%">Aktuelle Urologie</style></secondary-title><short-title><style face="normal" font="default" size="100%">Nicht antibiotische Strategien zur Rezidivprophylaxe von unkomplizierten Harnwegsinfektionen der Frau</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Aktuelle Urologie</style></full-title></periodical><pages><style face="normal" font="default" size="100%">214-219</style></pages><volume><style face="normal" font="default" size="100%">47</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">cranberry extract</style></keyword><keyword><style face="normal" font="default" size="100%">immunostimulants</style></keyword><keyword><style face="normal" font="default" size="100%">local estrogen replacement</style></keyword><keyword><style face="normal" font="default" size="100%">probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">recurrent urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2016</style></year></dates><abstract><style face="normal" font="default" size="100%">The aim of all medical treatment is primum nihil nocere (First, do no harm). Restoring the integrity of intestinal microbiota and optimising the immune response in recurrent infections, especially in the urinary tract, are treatment alternatives which are closer to this target than the usual focus on antibiotic prevention of recurrence. In the future, antibiotics will continue to be recommended for the prevention of urinary tract infections on a case-by-case basis. However, the problems of an excessive use of antibiotics, e. g. resistance and long-term interference with intestinal microbiota, are forcing us to search for alternatives. The use of probiotics alone or in combination with immunotherapeutics, or the sole use of immunotherapeutics, are important treatment options, which are already routinely available in clinical practice. These therapies are focused on the pathomechanism of an infection and tackle the root cause of the problem. Phytotherapeutics or small molecules like mannose, which restricts the adherence of bacteria to the urothelium, are complementary approaches. The EAU guidelines recommend the following treatments for the long-term prevention of urinary tract infections: Oral and parenteral immunostimulants (StroVac®), local estrogen replacement and administration of Lactobacillus rhamnosus and Lactobacillus reuteri. © Georg Thieme Verlag KG Stuttgart, New York.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :2&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84965064169&amp;doi=10.1055%2fs-0042-101846&amp;partnerID=40&amp;md5=7dbeb39bc5e9530b05aee70239c2a7c9</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1055/s-0042-101846</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>564</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">564</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Battle, M.</style></author><author><style face="normal" font="default" size="100%">Martin, T.</style></author><author><style face="normal" font="default" size="100%">Fulton, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dept. of Health Care of the Elderly, Derriford Hospital, Plymouth PL6 8DH, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lactulose may help prevent urinary tract infections [6]</style></title><secondary-title><style face="normal" font="default" size="100%">British Medical Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">British Medical Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">936</style></pages><volume><style face="normal" font="default" size="100%">323</style></volume><number><style face="normal" font="default" size="100%">7318</style></number><dates><year><style face="normal" font="default" size="100%">2001</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Letter</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035922824&amp;partnerID=40&amp;md5=2ea6a5fe020acabd4fc492882039554b</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>158</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">158</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bastigkeit, M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Fachdozent für Pharmakologie, Medizinjournalist (DJV), Dorfstraße 83, Geschendorf, 23 815, Germany</style></auth-address><titles><title><style face="normal" font="default" size="100%">Herbal medicines against urinary tract infections - Traditional empiricism or pharmacological evidence?</style></title><secondary-title><style face="normal" font="default" size="100%">Medizinische Monatsschrift fur Pharmazeuten</style></secondary-title><short-title><style face="normal" font="default" size="100%">Phytopharmaka - Traditionelle Empirie oder pharmakologische Evidenz? Teil 3: Phytopharmaka bei Infektionen der Harnwege</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Medizinische Monatsschrift fur Pharmazeuten</style></full-title></periodical><pages><style face="normal" font="default" size="100%">42-47</style></pages><volume><style face="normal" font="default" size="100%">38</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Empirically, a variety of plants are used for uncomplicated urinary tract infections. The variety of phytopharmaceuticals with valid results is much smaller. There is a variety of observational studies about Cranberry, bearsgrape leaves, birch leaves and European goldenrod. This also justifies a recommendation in the pharmacy in a complementary medical treatment. Desireably, larger placebo-controlled studies, which proove the empirical healing, would provide more evidence. Children, pregnant women, men and patients with fever, severe cramps and blood in the urine should not medicate themselve. The patient should be referred to a doctor.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84921892668&amp;partnerID=40&amp;md5=8a8d92d0987ca57da7f30f276df8d3ad</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>529</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">529</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bass Iii, P. F.</style></author><author><style face="normal" font="default" size="100%">Jarvis, J. A. W.</style></author><author><style face="normal" font="default" size="100%">Mitchell, C. K.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Gen. Internal Medicine, University of Louisville, 500 South Preston Street, Louisville, KY 40292, United States&#xD;Univ. of Louisville Sch. of Medicine, Off. of Curriculum Devmt./Evaluation, Instructional Building, 500 South Preston Street, Louisville, KY 40292, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Primary Care - Clinics in Office Practice</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Primary Care - Clinics in Office Practice</style></full-title></periodical><pages><style face="normal" font="default" size="100%">41-61</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTIs) are a common infectious disease in primary care practice. This article reviews topics highlighting recent research, including UTIs in pregnancy and pediatric UTIs. The authors also discuss catheter-associated UTIs, given the large number of hospitalized patients undergoing catheterization and residents of long-term care facilities, in whom catheters are used frequently, and complicated UTIs.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :24&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037358828&amp;doi=10.1016%2fS0095-4543%2802%2900057-X&amp;partnerID=40&amp;md5=34231785b5ef02aa9aac4c304895f832</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0095-4543(02)00057-X</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>375</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">375</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Barrons, R.</style></author><author><style face="normal" font="default" size="100%">Tassone, D.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Wingate University School of Pharmacy, Wingate, NC, United States&#xD;Virginia Commonwealth University School of Pharmacy, Inova Fairfax Campus, Falls Church, VA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Use of Lactobacillus probiotics for bacterial genitourinary infections in women: A review</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Therapeutics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Therapeutics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">453-468</style></pages><volume><style face="normal" font="default" size="100%">30</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">bacterial vaginosis</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">vaginal colonization</style></keyword><keyword><style face="normal" font="default" size="100%">vaginal flora</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Lactobacilli are the dominant bacteria of the vaginal flora and possess antimicrobial properties that regulate other urogenital microbiota. Incomplete cure and recurrence of genitourinary infections lead to a shift in the local flora from a predominance of lactobacilli to coliform uropathogens. Use of Lactobacillus-containing probiotics to restore commensal vaginal flora has been proposed for the treatment and prophylaxis of bacterial urogenital infections. Objective: This review summarizes randomized controlled trials that have assessed the therapeutic efficacy and tolerability of lactobacilli in bacterial vaginosis (BV) and urinary tract infection (UTI). Methods: Relevant randomized controlled trials published in English were identified through a search of MEDLINE (through November 2007), ClinicalTrials.gov, and the Cochrane Database (second quarter 2007). The search terms included probiotics, Lactobacillus, lactobacilli, urinary, urogenic, bacterial vaginosis, vaginal, colonization, bacteremia, sepsis, pathogenic, taxonomy, diagnosis, and infections. Results: Eleven randomized controlled trials were identified that investigated the effects of lactobacilli in the treatment and prophylaxis of bacterial urogenital infections. In the 2 studies that reported a beneficial effect for probiotics in the treatment of BV, cure rates for lactobacilli at 30 days were 60% (P = 0.004) and 88% (P &lt; 0.005), more than double the effect of controls. One trial reported a 35% reduction in recurrent episodes of BV compared with placebo (P = 0.004). Among the 4 trials involving treatment of UTI, 1 reported a 73% reduction in episodes of recurrent UTI compared with the previous year (P = 0.001). Seven studies found no therapeutic effect of lactobacilli in the treatment or prophylaxis of BV or UTI. Only 2 of the identified trials attempted to validate the probiotic dosing strategy by obtaining quantitative evidence of local colonization with lactobacilli and had sufficient power to detect treatment effects, and only 1 trial addressed the stability of the probiotic product at the end of the study. Conclusions: Despite enhanced cure rates in some studies, concerns about product stability and limited documentation of strain-specific effects prevent recommendations for the use of Lactobacillus-containing probiotics in the treatment of BV. The results of studies of lactobacilli for the prophylaxis of UTI remain inconclusive as a result of small sample sizes and use of unvalidated dosing strategies. © 2008 Excerpta Medica Inc.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :129&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-41849150786&amp;doi=10.1016%2fj.clinthera.2008.03.013&amp;partnerID=40&amp;md5=35a6aba3dd569563c2dab4f6e29c4556</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.clinthera.2008.03.013</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>296</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">296</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Barbosa-Cesnik, C.</style></author><author><style face="normal" font="default" size="100%">Brown, M. B.</style></author><author><style face="normal" font="default" size="100%">Buxton, M.</style></author><author><style face="normal" font="default" size="100%">Zhang, L.</style></author><author><style face="normal" font="default" size="100%">Debusscher, J.</style></author><author><style face="normal" font="default" size="100%">Foxman, B.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Epidemiology, Center for Molecular and Clinical Epidemiology of Infectious Diseases, University of Michigan, Ann Arbor, MI, United States&#xD;Department of Biostatistics, University of Michigan, School of Public Health, Ann Arbor, MI, United States&#xD;Department of Environmental Health Sciences, University of Michigan, School of Public Health, Ann Arbor, MI, United States&#xD;Department of Pathology, University of Michigan, Ann Arbor, MI, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry juice fails to prevent recurrent urinary tract infection: Results from a randomized placebo-controlled trial</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Infectious Diseases</style></full-title></periodical><pages><style face="normal" font="default" size="100%">23-30</style></pages><volume><style face="normal" font="default" size="100%">52</style></volume><number><style face="normal" font="default" size="100%">1</style></number><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: A number of observational studies and a few small or open randomized clinical trials suggest that the American cranberry may decrease incidence of recurring urinary tract infection (UTI). Methods: We conducted a double-blind, placebo-controlled trial of the effects of cranberry on risk of recurring UTI among 319 college women presenting with an acute UTI. Participants were followed up until a second UTI or for 6 months, whichever came first. A UTI was defined on the basis of the combination of symptoms and a urine culture positive for a known uropathogen. The study was designed to detect a 2-fold difference between treated and placebo groups, as was detected in unblinded trials. We assumed 30% of participants would experience a UTI during the follow-up period. Results: Overall, the recurrence rate was 16.9% (95% confidence interval, 12.8%-21.0%), and the distribution of the recurrences was similar between study groups, with the active cranberry group presenting a slightly higher recurrence rate (20.0% vs 14.0%). The presence of urinary symptoms at 3 days, 1-2 weeks, and at ≥1 month was similar between study groups, with overall no marked differences. Conclusions: Among otherwise healthy college women with an acute UTI, those drinking 8 oz of 27% cranberry juice twice daily did not experience a decrease in the 6-month incidence of a second UTI, compared with those drinking a placebo. © The Author 2011.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :122&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79951655012&amp;doi=10.1093%2fcid%2fciq073&amp;partnerID=40&amp;md5=c5f0fa1d4d3745c00d100fda01ae2b9d</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1093/cid/ciq073</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>561</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">561</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ball, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dept. of Anaesthesia/Intensive Care, St George&apos;s Hospital Medical School, University of London, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry juice, fluid replacement and bad innervations</style></title><secondary-title><style face="normal" font="default" size="100%">Critical Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Critical Care</style></full-title></periodical><pages><style face="normal" font="default" size="100%">331-332</style></pages><volume><style face="normal" font="default" size="100%">5</style></volume><number><style face="normal" font="default" size="100%">6</style></number><dates><year><style face="normal" font="default" size="100%">2001</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035706059&amp;partnerID=40&amp;md5=f0c09235671ca2d98b1af9a0f64e2c83</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>405</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">405</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bailey, D. T.</style></author><author><style face="normal" font="default" size="100%">Dalton, C.</style></author><author><style face="normal" font="default" size="100%">Joseph Daugherty, F.</style></author><author><style face="normal" font="default" size="100%">Tempesta, M. S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Phenolics, LLC, 846 San Carlos Avenue, El Granada, CA 94018-2439, United States&#xD;Helios Integrated Medicine, PC, 4150 Darley Avenue, Boulder, CO 80305, United States&#xD;328 Overlook Lane, Boulder, CO 80302, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Can a concentrated cranberry extract prevent recurrent urinary tract infections in women? A pilot study</style></title><secondary-title><style face="normal" font="default" size="100%">Phytomedicine</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Phytomedicine</style></full-title></periodical><pages><style face="normal" font="default" size="100%">237-241</style></pages><volume><style face="normal" font="default" size="100%">14</style></volume><number><style face="normal" font="default" size="100%">4</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry extract</style></keyword><keyword><style face="normal" font="default" size="100%">Pilot study</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">Background: Urinary tract infections (UTIs) are extremely prevalent and despite treatment with antibiotics, reoccurrences are common causing frustration in the patient and the potential for developing antibiotic resistance. The use of cranberry products to prevent UTIs has recently become popular and more clinical studies are needed to explore this use. Objective: This open label pilot study examined the ability of a concentrated cranberry preparation to prevent UTIs in women with a history of recurrent infections. Subjects: Women between the ages of 25 and 70 years old were included with a history of a minimum of 6 UTIs in the proceeding year. Intervention: The women took one capsule twice daily for 12 weeks containing 200 mg of a concentrated cranberry extract standardized to 30% phenolics. Design: A questionnaire was used initially to determine the patient&apos;s medical history and they were asked at monthly intervals if any of the information had changed. All of the women in the study had urinalysis within 24 h before starting on the study preparation and once a month after that for 4 months. Subjects were followed-up approximately 2 years later. Results: All 12 subjects participated in the 12-week study and were available for follow up 2 years later. During the study none of the women had a UTI. No adverse events were reported. Two years later, eight of the women who continue to take cranberry, continue to be free from UTIs. Conclusion: A cranberry preparation with a high phenolic content may completely prevent UTIs in women who are subject to recurrent infections. © 2007 Elsevier GmbH. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :39&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33947147255&amp;doi=10.1016%2fj.phymed.2007.01.004&amp;partnerID=40&amp;md5=e9c58062d7e515852c2a548547159e24</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.phymed.2007.01.004</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>141</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">141</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aydin, A.</style></author><author><style face="normal" font="default" size="100%">Ahmed, K.</style></author><author><style face="normal" font="default" size="100%">Zaman, I.</style></author><author><style face="normal" font="default" size="100%">Khan, M. S.</style></author><author><style face="normal" font="default" size="100%">Dasgupta, P.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Guy’s and St. Thomas’ NHS Foundation Trust, King’s Health Partners, MRC Centre for Transplantation, King’s College London, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent urinary tract infections in women</style></title><secondary-title><style face="normal" font="default" size="100%">International Urogynecology Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Urogynecology Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">795-804</style></pages><volume><style face="normal" font="default" size="100%">26</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">Management</style></keyword><keyword><style face="normal" font="default" size="100%">Pathway</style></keyword><keyword><style face="normal" font="default" size="100%">Prevention</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent UTI</style></keyword><keyword><style face="normal" font="default" size="100%">Women</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Introduction and hypothesis: Recurrent urinary tract infections (UTIs) are more common in women and are frequently defined as ≥2 episodes in the last 6 months or ≥3 episodes in the last 12 months. In a primary care setting, 53 % of women above the age of 55 years and 36 % of younger women report a recurrence within 1 year. Thus, management and prevention of recurrent UTI is of utmost significance. This review aims to highlight the latest research in prevention strategies and suggest a management pathway. Methods: A search was conducted on MEDLINE, Embase and the Cochrane Database of Systematic Reviews databases for the latest systematic reviews and high-quality randomized controlled trials. Special emphasis was placed on the remit “recurrent” and strongly adhered to. Furthermore, a Google search was conducted for current guidelines on the management of UTIs. Results: Current prevention strategies include eliminating risk factors that increase the risk of acquiring recurrent UTI and continuous, post-coital and self-initiated antimicrobial prophylaxis. Other prospective preventative strategies, currently under trial, include use of vaccinations, D-mannose and lactobacillus (probiotics). Conclusion: Although risk factors should be identified and addressed accordingly, individualized antibiotic prophylaxis remains the most effective method of management. Non-antibiotic prevention strategies such as cranberry, vitamin C and methenamine salts lack strong evidence to be introduced as routine management options and as alternatives to antibiotics. Based on current evidence and guidelines, a management pathway is recommended. Emerging therapies require further evaluation before they can be recommended. © 2014, The International Urogynecological Association.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :22&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84929839148&amp;doi=10.1007%2fs00192-014-2569-5&amp;partnerID=40&amp;md5=1cba4ab1dfa9b4b94b8418e3109caa43</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1007/s00192-014-2569-5</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>157</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">157</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Awais, M.</style></author><author><style face="normal" font="default" size="100%">Rehman, A.</style></author><author><style face="normal" font="default" size="100%">Baloch, N. U. A.</style></author><author><style face="normal" font="default" size="100%">Khan, F.</style></author><author><style face="normal" font="default" size="100%">Khan, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Radiology, Aga Khan University Hospital, P.O. box 3500, Stadium Road, Karachi, Sindh, 74800, Pakistan&#xD;Department of Biological and Biomedical Sciences, Aga Khan University, P.O. box 3500, Stadium Road, Karachi, Sindh, 74800, Pakistan&#xD;Department of Surgery, Aga Khan University, P.O. box 3500, Stadium Road, Karachi, Sindh, 74800, Pakistan&#xD;Department of Pediatrics, Aga Khan University, P.O. box 3500, Stadium Road, Karachi, Sindh, 74800, Pakistan</style></auth-address><titles><title><style face="normal" font="default" size="100%">Evaluation and management of recurrent urinary tract infections in children: State of the art</style></title><secondary-title><style face="normal" font="default" size="100%">Expert Review of Anti-Infective Therapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Expert Review of Anti-Infective Therapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">209-231</style></pages><volume><style face="normal" font="default" size="100%">13</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">antibiotic prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">cystitis</style></keyword><keyword><style face="normal" font="default" size="100%">pyelonephritis</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract anomalies</style></keyword><keyword><style face="normal" font="default" size="100%">urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">vesicoureteral reflux</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2015</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections (UTIs) represent an important cause of febrile illness in young children and can lead to renal scarring and kidney failure. However, diagnosis and treatment of recurrent UTI in children is an area of some controversy. Guidelines from the American Academy of Pediatrics, National Institute for Health and Clinical Excellence and European Society of Paediatric Radiology differ from each other in terms of the diagnostic algorithm to be followed. Treatment of vesicoureteral reflux and antibiotic prophylaxis for prevention of recurrent UTI are also areas of considerable debate. In this review, we collate and appraise recently published literature in order to formulate evidence-based guidance for the diagnosis and treatment of recurrent UTI in children. © 2015 Informa UK, Ltd.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84937145272&amp;doi=10.1586%2f14787210.2015.991717&amp;partnerID=40&amp;md5=0fb114e06a4e9c7bb64b3fa34b39795d</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1586/14787210.2015.991717</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>594</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">594</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Avorn, J.</style></author><author><style face="normal" font="default" size="100%">Monane, M.</style></author><author><style face="normal" font="default" size="100%">Gurwitz, J. H.</style></author><author><style face="normal" font="default" size="100%">Glynn, R. J.</style></author><author><style face="normal" font="default" size="100%">Choodnovskiy, I.</style></author><author><style face="normal" font="default" size="100%">Lipsitz, L. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Analysis of Clinical Strategies, Gerontology Division, Division of Preventive Medicine, Department of Medicine, Brigham and Women&apos; Hospital and Harvard Medical School, United States&#xD;Hebrew Rehabilitation Center for Aged, Geriatric Research and Training Center, Harvard Medical School, Boston, Mass, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Reduction of Bacteriuria and Pyuria After Ingestion of Cranberry Juice</style></title><secondary-title><style face="normal" font="default" size="100%">JAMA: The Journal of the American Medical Association</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">JAMA: The Journal of the American Medical Association</style></full-title></periodical><pages><style face="normal" font="default" size="100%">751-754</style></pages><volume><style face="normal" font="default" size="100%">271</style></volume><number><style face="normal" font="default" size="100%">10</style></number><dates><year><style face="normal" font="default" size="100%">1994</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :432&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028258220&amp;doi=10.1001%2fjama.1994.03510340041031&amp;partnerID=40&amp;md5=73770af54c77a745d9b1950add08f7d2</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jama.1994.03510340041031</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>444</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">444</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ávila-Funes, J. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Centre de Recherche sur le Vieillissement, 1036 Belvédère sud., Sherbrooke, Que. J1H 4C4, Canada</style></auth-address><titles><title><style face="normal" font="default" size="100%">Comments to the manuscript: Does cranberry juice have bacteriostatistic activity? [2]</style></title><secondary-title><style face="normal" font="default" size="100%">Revista de Investigacion Clinica</style></secondary-title><short-title><style face="normal" font="default" size="100%">Carta al editor</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Revista de Investigacion Clinica</style></full-title></periodical><pages><style face="normal" font="default" size="100%">822</style></pages><volume><style face="normal" font="default" size="100%">57</style></volume><number><style face="normal" font="default" size="100%">6</style></number><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Letter</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33646191479&amp;partnerID=40&amp;md5=8e3407e0ca51e11bc311f66cb94f0818</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>44</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">44</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aragón, I. M.</style></author><author><style face="normal" font="default" size="100%">Herrera-Imbroda, B.</style></author><author><style face="normal" font="default" size="100%">Queipo-Ortuño, M. I.</style></author><author><style face="normal" font="default" size="100%">Castillo, E.</style></author><author><style face="normal" font="default" size="100%">Del Moral, J. S. G.</style></author><author><style face="normal" font="default" size="100%">Gómez-Millán, J.</style></author><author><style face="normal" font="default" size="100%">Yucel, G.</style></author><author><style face="normal" font="default" size="100%">Lara, M. F.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology, Virgen de la Victoria University Hospital, Malaga, Spain&#xD;Service of Endocrinology and Nutrition, Biomedical Research Institute, University of Malaga, Malaga, Spain&#xD;Biomedical Research Networking Center for Pathophysiology of Obesity and Nutrition, Madrid, Spain&#xD;Urology Unit, University Hospital Carlos Haya, Malaga, Spain&#xD;Department of Radiation Oncology, University Hospital Virgen de la Victoria, Malaga, Spain&#xD;Program in Epithelial Biology, School of Medicine, Stanford University, Stanford, CA, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">The Urinary Tract Microbiome in Health and Disease</style></title><secondary-title><style face="normal" font="default" size="100%">European Urology Focus</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">European Urology Focus</style></full-title></periodical><pages><style face="normal" font="default" size="100%">128-138</style></pages><volume><style face="normal" font="default" size="100%">4</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">16S rRNA sequencing</style></keyword><keyword><style face="normal" font="default" size="100%">Prebiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary microbiome</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract</style></keyword><keyword><style face="normal" font="default" size="100%">Urine culture</style></keyword><keyword><style face="normal" font="default" size="100%">Urologic disorders</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Context: The urinary tract, previously considered a sterile body niche, has emerged as the host of an array of bacteria in healthy individuals, revolutionizing the urology research field. Objective: To review the literature on microbiome implications in the urinary tract and the usefulness of probiotics/prebiotics and diet as treatment for urologic disorders. Evidence acquisition: A systematic review was conducted using PubMed and Medline from inception until July 2016. The initial search identified 1419 studies and 89 were included in this systematic review. Evidence synthesis: Specific bacterial communities have been found in the healthy urinary tract. Changes in this microbiome have been observed in certain urologic disorders such as urinary incontinence, urologic cancers, interstitial cystitis, neurogenic bladder dysfunction, sexually transmitted infections, and chronic prostatitis/chronic pelvic pain syndrome. The role of probiotics, prebiotics, and diet as treatment or preventive agents for urologic disorders requires further investigation. Conclusions: There is a microbiome associated with the healthy urinary tract that can change in urologic disorders. This represents a propitious context to identify new diagnostic, prognostic, and predictive microbiome-based biomarkers that could be used in clinical urology practice. In addition, probiotics, prebiotics, and diet modifications appear to represent an opportunity to regulate the urinary microbiome. Patient summary: We review the urinary microbiome of healthy individuals and its changes in relation to urinary disorders. The question to resolve is how we can modulate the microbiome to improve urinary tract health. The urinary tract has a specific microbiome that can change in urologic disorders. Changes in the specific urinary microbial communities point to the microbiome as a possible therapeutic target. How we can modulate the microbiome to improve urinary tract health remains a key question. Further investigations are required to provide new diagnostic, prognostic, and predictive microbiome-based biomarkers that could be used in clinical practice and translational research. © 2016 European Association of Urology</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :7&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85006789846&amp;doi=10.1016%2fj.euf.2016.11.001&amp;partnerID=40&amp;md5=7c2b76e194cc9558082e33fe945dd8f7</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.euf.2016.11.001</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>277</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">277</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Anthony, J. P.</style></author><author><style face="normal" font="default" size="100%">Fyfe, L.</style></author><author><style face="normal" font="default" size="100%">Stewart, D.</style></author><author><style face="normal" font="default" size="100%">McDougall, G. J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Dietetics, Nutrition and Biological Sciences, Queen Margaret University, Clerwood Terrace, Edinburgh EH12 8TS, United Kingdom&#xD;Scottish Parasite Diagnostic Laboratory, House on the Hill Reference Laboratories, Stobhill Hospital, Balornock Road, Glasgow G21 3UW, United Kingdom&#xD;Plant Products and Food Quality Programme, James Hutton Institute, Invergowrie, Dundee DD2 5DA, United Kingdom&#xD;Solus Scientific Solutions, Royal College Building, R4.19, University of Strathclyde, 204 George Street, Glasgow G1 1XW, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Differential effectiveness of berry polyphenols as anti-giardial agents</style></title><secondary-title><style face="normal" font="default" size="100%">Parasitology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Parasitology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1110-1116</style></pages><volume><style face="normal" font="default" size="100%">138</style></volume><number><style face="normal" font="default" size="100%">9</style></number><keywords><keyword><style face="normal" font="default" size="100%">berry</style></keyword><keyword><style face="normal" font="default" size="100%">ellagitannin</style></keyword><keyword><style face="normal" font="default" size="100%">Giardia duodenalis</style></keyword><keyword><style face="normal" font="default" size="100%">mortality</style></keyword><keyword><style face="normal" font="default" size="100%">polyphenol</style></keyword><keyword><style face="normal" font="default" size="100%">trophozoite</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2011</style></year></dates><abstract><style face="normal" font="default" size="100%">Following previous work on the anti-giardial effect of blueberry polyphenols, a range of polyphenol-rich extracts from berries and other fruits was screened for their ability to kill Giardia duodenalis, an intestinal parasite of humans. Polyphenol-rich extracts were prepared from berries using solid-phase extraction and applied to trophozoites of Giardia duodenalis grown in vitro. All berry extracts caused inhibition at 166 μg gallic acid equivalents (GAE)/ml phenol content but extracts from strawberry, arctic bramble, blackberry and cloudberry were as effective as the currently used drug, metronidazole, causing complete trophozoite mortality in vitro. Cloudberry extracts were found to be the most effective causing effectively complete trophozoite mortality at 66 μg GAE/ml. The polyphenol composition of the more effective berry extracts suggested that the presence of ellagitannins could be an important factor. However, the potency of cloudberry could be related to high ellagitannin content but also to the presence of substantial amounts of unconjugated p-coumaric acid and benzoic acid. These in vitro effects occur at concentrations easily achievable in the gut after berry ingestion and we discuss the likelihood that berry extracts could be effective anti-giardial agents in vivo. © 2011 Cambridge University Press. The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution-NonCommercial-ShareAlike licence &lt;http://creative commons.org/licenses/by-nc-sa/2.5/&gt;. The written permission of Cambridge University Press must be obtained for commercial re-use.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :7&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-80053059914&amp;doi=10.1017%2fS0031182011000825&amp;partnerID=40&amp;md5=84875af1b1a0bac928eb0b9989ab3d8b</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1017/S0031182011000825</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>496</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">496</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Andreu, A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Microbiology Service, Hospital Vall d&apos;Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain&#xD;Microbiology Service, Hospital Vall d&apos;Hebron, Pg. Vall d&apos;Hebron 119-129, 08035 Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Lactobacillus as a probiotic for preventing urogenital infections</style></title><secondary-title><style face="normal" font="default" size="100%">Reviews in Medical Microbiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Reviews in Medical Microbiology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-6</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bacterial vaginosis</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Vaginal candidiasis</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">The use of probiotics to control certain infections and to reestablish the human bacterial ecology is gaining acceptance as an alternative to conventional antibiotic therapy. This article discusses the role of Lactobacillus as a probiotic agent for the maintenance of vaginal microflora and the prevention of urogenital infections. Lactobacillus protects the vagina from colonization by pathogens by two main mechanisms: blocking their attachment to the vaginal epithelium and producing substances that inhibit their multiplication. Not all Lactobacillus strains express these properties with the same intensity; on the contrary, there are substantial differences among species and among strains from a single species. Some lactobacilli adhere avidly to vaginal epithelial cells, some block pathogen attachment to these cells, and others inhibit pathogen growth. Moreover, the same Lactobacillus strain can show different blocking and inhibiting activity against different pathogens. This demonstrates the importance of characterizing Lactobacillus strains prior to their use as probiotics in humans. To date only a small number of systematic clinical trials with well-characterized strains has been conducted and there are few conclusive results. Further large clinical studies are needed to define the role of Lactobacillus as a probiotic. The main indications for probiotic Lactobacillus use in urogenital tract infections would include recurrent urinary tract infection in healthy pre-menopausal and post-menopausal women, post-infection prophylaxis to re-establish the vaginal flora and prevent future episodes, bacterial vaginosis and recurrent vaginal candidiasis. © 2004 Lippincott Williams &amp; Wilkins.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :18&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-3242729201&amp;doi=10.1097%2f01.revmedmi.0000131423.90481.82&amp;partnerID=40&amp;md5=292441c2b1397f95530121bf53a692a3</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1097/01.revmedmi.0000131423.90481.82</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>267</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">267</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Andrašević, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Klinika za infektivne bolesti Dr. Fran Mihaljević, Zavod za urogenitalne infekcije, Mirogojska 8, 10000 Zagreb, Croatia</style></auth-address><titles><title><style face="normal" font="default" size="100%">Recurrent urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Medicus</style></secondary-title><short-title><style face="normal" font="default" size="100%">Rekurirajuće infekcije mokraćnog sustava</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Medicus</style></full-title></periodical><pages><style face="normal" font="default" size="100%">29-35</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Recurrent urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">Risk factors</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2012</style></year></dates><abstract><style face="normal" font="default" size="100%">Recurrent urinary tract infections (UTIs) are infections that occur at least twice every six months or three or more times per year. They are etiologically proven and mostly present as cystitis. Recurrent UTIs are an important public health problem due to their high incidence, morbidity rate and costs. These infections are most frequent among young and postmenopausal women. Predisposing factors include genetic, biological and behavioral factors. The choice of prophylactic method depends on a type of an infection. Apart from the antimicrobial prophylaxis, there are numerous alternative prophylactic remedies and there is also a possibility of preventing recurrence by immunostimulation. Therapy of recurrent UTIs is the same as that of sporadic episodes except that the sensitivity of previous isolates should be taken into consideration. Recurrent UTIs still present a substantial public health problem and an area of intensive research to further elucidate their pathogenesis and improve prevention.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84868246345&amp;partnerID=40&amp;md5=3a9b54791ca2b62f8883e4a6835f3788</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>311</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">311</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alfonso, F. N.</style></author><author><style face="normal" font="default" size="100%">Córcoles, M. N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Servicio de Ginecología, Hospital Universitario La Fe, Avda. Campanar, 21, 46009 Valencia, Spain&#xD;ETSIA Biotecnología, Universidad Politécnica, Valencia, Spain</style></auth-address><titles><title><style face="normal" font="default" size="100%">Cranberry (Vaccinium macrocarpon): Research findings and clinical evidence</style></title><secondary-title><style face="normal" font="default" size="100%">Revista de Fitoterapia</style></secondary-title><short-title><style face="normal" font="default" size="100%">Arándano americano (Vaccinium macrocarpon): Conclusiones de la investigación y de la evidencia clínica</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Revista de Fitoterapia</style></full-title></periodical><pages><style face="normal" font="default" size="100%">5-21</style></pages><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry</style></keyword><keyword><style face="normal" font="default" size="100%">Proanthocyanidin</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword><keyword><style face="normal" font="default" size="100%">Vaccinium macrocarpon</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><abstract><style face="normal" font="default" size="100%">This review explores possible relationship between metabolites of cranberry (fruit of Vaccinium macrocarpon) and its beneficial effect on human health. In vitro studies in E. coli have shown that Cranberry has anti bacterial adhesion effect due to its content of proanthocyanidin (PAC) type A, in a dose-dependent way. Many studies have shown its preventive effect in the development of urinary infections in different populations. Its apparent lack of risk during gestation, good tolerability and absence of significative interactions with drugs are allowing their widespread use. Preclinic studies suggest possible benefits of cranberry in antitumoral and antioxidative fields. Clinical assays link cranberry with the prevention of both gastric disease caused by H. pylori and periodontal disease. However, for these applications, additional studies are needed to explain the mechanisms and to confirm clinical expectatives.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-77958590284&amp;partnerID=40&amp;md5=5b3f696e1965a2df5c2ca872375f35bb</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>501</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">501</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Albert, X.</style></author><author><style face="normal" font="default" size="100%">Huertas, I.</style></author><author><style face="normal" font="default" size="100%">Pereiró, I. I.</style></author><author><style face="normal" font="default" size="100%">Sanfélix, J.</style></author><author><style face="normal" font="default" size="100%">Gosalbes, V.</style></author><author><style face="normal" font="default" size="100%">Perrota, C.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Health Center of Marco Merenciano, Conselleria de Sanidad, Marco Merenciano no 26, Valencia, Spain, 46025.</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antibiotics for preventing recurrent urinary tract infection in non-pregnant women</style></title><secondary-title><style face="normal" font="default" size="100%">Cochrane database of systematic reviews (Online)</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Cochrane database of systematic reviews (Online)</style></full-title></periodical><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2004</style></year></dates><abstract><style face="normal" font="default" size="100%">BACKGROUND: Urinary tract infection (UTI) is a common health care problem. Recurrent UTI (RUTI) in healthy non-pregnant women is defined as three or more episodes of UTI during a twelve month period. Long-term antibiotics have been proposed as a prevention strategy for RUTI. OBJECTIVES: To determine the efficacy (during and after) and safety of prophylactic antibiotics used to prevent uncomplicated RUTI in adult non-pregnant women. SEARCH STRATEGY: We searched MEDLINE (1966-April 2004), EMBASE (1980-January 2003), Cochrane Central Register of Controlled Trials( in The Cochrane Library Issue 1, 2004) and reference lists of retrieved articles SELECTION CRITERIA: Any published randomised controlled trial where antibiotics were used as prophylactic therapy in RUTI. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed trial quality and extracted data. Statistical analyses were performed using the random effects model and the results expressed as relative risk (RR) with 95% confidence intervals (CI). MAIN RESULTS: Nineteen studies involving 1120 women were eligible for inclusion. Antibiotic versus antibiotic (10 trials, 430 women): During active prophylaxis the rate range of microbiological recurrence patient-year (MRPY) was 0 to 0.9 person-year in the antibiotic group against 0.8 to 3.6 with placebo. The RR of having one microbiological recurrence (MR) was 0.21 (95% CI 0.13 to 0.34), favouring antibiotic and the NNT was 1.85. For clinical recurrences (CRPY) the RR was 0.15 (95% CI 0.08 to 0.28). The NNT was 1.85. The RR of having one MR after prophylaxis was 0.82 (95% CI 0.44 to 1.53). The RR for severe side effects was 1.58 (95% CI 0.47 to 5.28) and for other side effects the RR was 1.78 (CI 1.06 to 3.00) favouring placebo. Side effects included vaginal and oral candidiasis and gastrointestinal symptoms. Antibiotic versus antibiotic (eight trials, 513 women): These trials were not pooled. Weekly pefloxacin was more effective than monthly. The RR for MR was 0.31(95% CI 0.19 to 0.52). There was no significant difference in MR between continuous daily and postcoital ciprofloxacin. REVIEWERS&apos; CONCLUSIONS: Continuous antibiotic prophylaxis for 6-12 months reduced the rate of UTI during prophylaxis when compared to placebo. After prophylaxis two studies showed nodifference between groups. There were more adverse events in the antibiotic group. One RCT compared postcoital versus continuous daily ciprofloxacin and found no significant difference in rates of UTIs, suggesting that postcoital treatment could be offered to woman who have UTI associated with sexual intercourse.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :203&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-16544377676&amp;partnerID=40&amp;md5=0356a46295096dfd0c82c328e3e893b5</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>26</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">26</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ákos, L.</style></author><author><style face="normal" font="default" size="100%">Zita, K.</style></author><author><style face="normal" font="default" size="100%">Adrienn Mercédesz, V.</style></author><author><style face="normal" font="default" size="100%">Ákos, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Feldebrol Állatgyógyószati Központ, Kossuth út 66., Feldebro, H-3352, Hungary&#xD;Állatorvostudományi Egyetem, Gyógyszertani És Méregtani Tanszék, István u. 2, Budapest, H-1078, Hungary</style></auth-address><titles><title><style face="normal" font="default" size="100%">Aetiology and treatment of urinary tract infections in companion animals</style></title><secondary-title><style face="normal" font="default" size="100%">Magyar Allatorvosok Lapja</style></secondary-title><short-title><style face="normal" font="default" size="100%">A húgyúti ferto′zések kóroktana és korszeru′ gyógykezelése a kisállatgyógyászatban</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Magyar Allatorvosok Lapja</style></full-title></periodical><pages><style face="normal" font="default" size="100%">401-410</style></pages><volume><style face="normal" font="default" size="100%">140</style></volume><number><style face="normal" font="default" size="100%">7</style></number><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections are one of the most common infectious diseases in dogs and cats. Similarly to humans, E. coli is the most prevalent causative agent of bacterial urinary tract infections (UTl). Several other bacteria can also play a role in the pathogenesis of the disease, like the Enterococcus, Staphylococcus, Proteus and Klebsiella genuses. The authors present the use of amoxicillin and amoxicillin-clavulanic acid, as first line antibiotics and several other possibilities, like cephalexin, the potentiated sulphonamides, cefuroxime, cefovecin, enrofloxacin, marbofloxacin, pradofloxacin, amikacin, nitrofurantoin and fosfo-mycin as potential candidates for UTl treatment. The article emphasizes the importance of correct diagnosis and susceptibility tests to avoid unnecessary antibiotic usage and decrease the spread of resistant bacteria. Dosages and application routes are presented in details to prevent underdosing. In addition, the authors describe the special characteristics of cystitis, prostatitis and pyelonephritis treatment including their supporting therapy. Prostatitis and pyelonephritis are great challenges for practitioners taking into account their recurrent attributes and risk of development of resistance during the long treatment. Thus, susceptibility tests are essential in most of the cases.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85051757110&amp;partnerID=40&amp;md5=ad9af3ed8fa1032b1c5396f41a28dd3f</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>586</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">586</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ahuja, S.</style></author><author><style face="normal" font="default" size="100%">Kaack, B.</style></author><author><style face="normal" font="default" size="100%">Roberts, J.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Urology and Tulane, University Primate Center, Tulane University School of Medicine, New Orleans, LA, United States&#xD;Tulane Primate Research Center, 18703 Three Rivers Road, Covington, LA 70433, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Loss of fimbrial adhesion with the addition of Vaccinum macrocarpon to the growth medium of P-fimbriated Escherichia coli</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Urology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Urology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">559-562</style></pages><volume><style face="normal" font="default" size="100%">159</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Cranberry juice</style></keyword><keyword><style face="normal" font="default" size="100%">P-fimbriae</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">1998</style></year></dates><abstract><style face="normal" font="default" size="100%">Purpose: Vaccinium macrocarpon-the American cranberry-irreversibly inhibits the expression of P-fimbriae of E. coli. Further effects on the function and expression of P-fimbriae were studied by growing P-fimbriated E. coli in solid media laced with cranberry juice. Methods: Cranberry concentrate at pH 7.0 was added to CFA medium to a final concentration of 25%. E. coli strains JR1 and DS17 were plated on this medium with a plain CFA control and incubated at 37C. Cultures were tested for ability to agglutinate P-receptor specific beads. Bacteria were washed in PBS and agglutination retested. Cultures were also replated on plain CFA agar and rechecked for their ability to agglutinate. Transmission electron micrographs were performed on positive control and test bacteria. Results: For E. coli strain JR1, P-fimbrial agglutination was inhibited after the third plating. DS17 was fully inhibited after the second plating. Washing in PBS did not affect agglutination, but replating on CFA agar allowed agglutination to recur. Electron micrographic study of control populations confirmed fimbriae. Fully inhibited bacteria had a 100% reduction in expression of fimbriae. Additionally, inhibited bacteria showed cellular elongation. Conclusions: Cranberry juice irreversibly inhibits P-fimbriae. Electron micrographic evidence suggests that cranberry juice acts on the cell wall preventing proper attachment of the fimbrial subunits or as a genetic control preventing the expression of normal fimbrial subunits or both.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :94&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031964610&amp;doi=10.1016%2fS0022-5347%2801%2963983-1&amp;partnerID=40&amp;md5=9b6433a9ba4607657cb98b8112435b8d</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/S0022-5347(01)63983-1</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>80</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">80</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ahmed, H.</style></author><author><style face="normal" font="default" size="100%">Davies, F.</style></author><author><style face="normal" font="default" size="100%">Francis, N.</style></author><author><style face="normal" font="default" size="100%">Farewell, D.</style></author><author><style face="normal" font="default" size="100%">Butler, C.</style></author><author><style face="normal" font="default" size="100%">Paranjothy, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Division of Population Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom&#xD;Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom</style></auth-address><titles><title><style face="normal" font="default" size="100%">Long-term antibiotics for prevention of recurrent urinary tract infection in older adults: Systematic review and meta-analysis of randomised trials</style></title><secondary-title><style face="normal" font="default" size="100%">BMJ Open</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">BMJ Open</style></full-title></periodical><volume><style face="normal" font="default" size="100%">7</style></volume><number><style face="normal" font="default" size="100%">5</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotic prophylaxis</style></keyword><keyword><style face="normal" font="default" size="100%">Antibiotic resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: To address clinical uncertainties about the effectiveness and safety of long-term antibiotic therapy for preventing recurrent urinary tract infections (UTIs) in older adults. Design: Systematic review andmeta-analysis of randomised trials. Method: We searched Medline, Embase, The Cumulative Index to Nursing and Allied Health Literature(CINAHL), and the Cochrane Register of Controlled Trials from inception to August 2016. Eligible studies compared long-term antibiotic therapy with non-antibiotic therapy or placebo in men or women aged over 65, or in postmenopausal women, with recurrent UTIs. Results: We did not identify any studies that included older men. Three randomised controlled trials compared long-term antibiotics with vaginal oestrogens (n=150), oral lactobacilli (n=238) and D-mannose powder (n=94) in postmenopausal women. Long-term antibiotics reduced the risk of UTI recurrence by 24% (three trials, n=482; pooled risk ratio (RR) 0.76; 95% CI 0.61 to 0.95, number needed to treat=8.5). There was no statistically significant increase in risk of adverse events (mild adverse events: pooled RR 1.52; 95% CI 0.76 to 3.03; serious adverse events: pooled RR 0.90, 95% CI 0.31 to 2.66). One trial showed 90% of urinary and faecal Escherichia coli isolates were resistant to trimethoprim-sulfamethoxazole after 1 month of prophylaxis. Conclusions: Findings from three small trials with relatively short follow-up periods suggest long-term antibiotic therapy reduces the risk of recurrence in postmenopausal women with recurrent UTI. We did not identify any evidence to inform several clinically important scenarios including, benefits and harms in older men or frail care home residents, optimal duration of prophylaxis, recurrence rates once prophylaxis stops and effects on urinary antibiotic resistance. © 2017 Article author(s) (or their employer(s) unless otherwise stated in the text of the article). All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :5&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85019988067&amp;doi=10.1136%2fbmjopen-2016-015233&amp;partnerID=40&amp;md5=0f903c1b7020461d81c7fb3daaca1849</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">e015233</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/bmjopen-2016-015233</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>612</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">612</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Adatto, K.</style></author><author><style face="normal" font="default" size="100%">Galland, L.</style></author><author><style face="normal" font="default" size="100%">Doebele, K. G.</style></author><author><style face="normal" font="default" size="100%">Granowetter, L.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Departments of Sociology, United States&#xD;Family Medicine, United States&#xD;University Health Services, United States&#xD;State University of New York, Stony Brook, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Behavioral Factors and Urinary Tract Infection</style></title><secondary-title><style face="normal" font="default" size="100%">JAMA: The Journal of the American Medical Association</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">JAMA: The Journal of the American Medical Association</style></full-title></periodical><pages><style face="normal" font="default" size="100%">2525-2526</style></pages><volume><style face="normal" font="default" size="100%">241</style></volume><number><style face="normal" font="default" size="100%">23</style></number><dates><year><style face="normal" font="default" size="100%">1979</style></year></dates><abstract><style face="normal" font="default" size="100%">Voiding and sexual habits of 84 female university students with a history of recurrent urinary infection were compared with those of a control group. There was one highly significant difference between the two groups: 61% of the patients but only 11% of the controls gave a history of regular voluntary deferral of micturition for periods of one hour to longer than six hours. Sexual practices among patients and controls were remarkably similar. A behavioral regimen stressing regular, complete bladder emptying was shown to be effective in preventing reinfection in the patient group. Voluntary urinary retention may play a pathogenic role in women with recurrent urinary tract infection, and its correction may play an important part in the management of urinary tract infection. © 1979, American Medical Association. All rights reserved.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :51&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0018743618&amp;doi=10.1001%2fjama.1979.03290490031020&amp;partnerID=40&amp;md5=6e843de488c8003d8d61b7323994c0e2</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1001/jama.1979.03290490031020</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>308</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">308</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Acar, C.</style></author><author><style face="normal" font="default" size="100%">Gürocak, S.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Konya Asker Hastanesi, Üroloji Kliniǧi, Konya, Turkey&#xD;Üroloji AD, Gazi Üniversitesi Tip Fakültesi, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="default" size="100%">Current approaches and treatment alternatives in vesicouretheral reflux: Review</style></title><secondary-title><style face="normal" font="default" size="100%">Turkiye Klinikleri Pediatri</style></secondary-title><short-title><style face="normal" font="default" size="100%">Vezikoüreteral reflüde güncel yaklaşimlar ve tedavi alternatifleri</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Turkiye Klinikleri Pediatri</style></full-title></periodical><pages><style face="normal" font="default" size="100%">38-46</style></pages><volume><style face="normal" font="default" size="100%">19</style></volume><number><style face="normal" font="default" size="100%">1</style></number><keywords><keyword><style face="normal" font="default" size="100%">Therapy</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">Urination disorders</style></keyword><keyword><style face="normal" font="default" size="100%">Vesico-ureteral reflux</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2010</style></year></dates><abstract><style face="normal" font="default" size="100%">Vesicouretheral reflux (VUR) is the most common urological anomaly which causes acute pyelonephritis in childhood. The incidence of VUR is about 1-2% in children whereas VUR is present in 25-40% of children with acute pyelonephritis. In this respect, presence of VUR must be investigated especially after the first urinary tract infection (UTI) or acute pyelonephritis attack. Classically, UTI symptoms are seen in VUR. Hypertension, failure of renal functions, complications of pregnancy and chronic renal failure is long term complications. Videocystourethrography is the gold standard study in diagnosis of VUR. The main goal of treatment of children with VUR is treated with long term antibiotics and/or surgical procedures to prevent the renal damage due to UTI. Antibiotic proflaxis is recommended under 1 year regardless reflux grade, although VUR maintains in patients with high grade, bilateral VUR, presence of renal damage and dilateted ureter. Also, the evaluation and management of dysfunctional elimination syndromes (DES) has become integral part of the treatment of the every child with VUR. Surgical treatment is accepted the first choice in children above 1 year who has renal scar, uni or bilateral grade V reflux. Surgical procedures (intavesical and extravesical) are very successful in treatment of VUR. With the beginning of using dextranomer/hyalunoric acid colpomer endoscopic treatments recorded large advancement, therapy success as become comparable with open surgery. In addition, it is thought that the effective treatment against DES whether decreases the frequency of UTI in follow-up or increases success rate of surgical treatment. Copyright © 2010 by Türkiye Klinikleri.</style></abstract><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-77953792500&amp;partnerID=40&amp;md5=d88d53b0e9190bf5b5876a17da72e05b</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>387</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">387</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abu-Lail, L. I.</style></author><author><style face="normal" font="default" size="100%">Liu, Y.</style></author><author><style face="normal" font="default" size="100%">Atabek, A.</style></author><author><style face="normal" font="default" size="100%">Camesano, T. A.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Civil and Environmental Engineering, Life Sciences and Bioengineering Institute at Gateway Park, Worcester Polytechnic Institute, Worcester, MA 01609, United States&#xD;Department of Chemical Engineering, Life Sciences and Bioengineering Institute at Gateway Park, Worcester Polytechnic Institute, 100 Institute Rd, Worcester, MA 01609, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Quantifying the adhesion and interaction forces between Pseudomonas aeruginosa and natural organic matter</style></title><secondary-title><style face="normal" font="default" size="100%">Environmental Science and Technology</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Environmental Science and Technology</style></full-title></periodical><pages><style face="normal" font="default" size="100%">8031-8037</style></pages><volume><style face="normal" font="default" size="100%">41</style></volume><number><style face="normal" font="default" size="100%">23</style></number><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">Atomic force microscopy (AFM) was used to characterize interactions between natural organic matter (NOM), and glass or bacteria. Poly(methacrylic acid) (PMA), soil humic Acid (SHA), and Suwannee River humic Acid (SRHA), were adsorbed to silica AFM probes. Adhesion forces (Fadh) for the interaction of organic-probes and glass slides correlated with organic molecular weight (MW), but not with radius of the organic aggregate (R), charge density (Q), or zeta potential (ζ). Two Pseudomonas aeruginosa strains with different lipopolysaccharides (LPS) were chosen: PA01 (A+B +), whose LPS have common antigen (A-band) + 0-antigen (B-band); and mutant AK1401 (A+B-). Fadh between bacteria and organics correlated with organic MW, R, and Q, but not ζ. PA01 had lower Fadh with silica than NOM, which was attributed to negative charges from the B-band polymers causing electrostatic repulsion. AK1401 adhered stronger to silica than to the organics, perhaps because the absence of the B-band exposed underlying positively charged proteins. DLVO calculations could not explain the differences in the two bacteria or predict qualitative or quantitative trends in interaction forces in these systems. Molecular-level information from AFM studies can bring us closer to understanding the complex nature of bacterial-NOM interactions. © 2007 American Chemical Society.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :38&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-36849078685&amp;doi=10.1021%2fes071047o&amp;partnerID=40&amp;md5=ca4ee2cd274991c2273ebbddc5f35b46</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/es071047o</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>173</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">173</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abbo, L. M.</style></author><author><style face="normal" font="default" size="100%">Hooton, T. M.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Department of Medicine, Division of Infectious Diseases, University of Miami Miller School of Medicine, 1120 NW 14th Street, Suite 851, Miami, FL 33136, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Antimicrobial stewardship and urinary tract infections</style></title><secondary-title><style face="normal" font="default" size="100%">Antibiotics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Antibiotics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">174-192</style></pages><volume><style face="normal" font="default" size="100%">3</style></volume><number><style face="normal" font="default" size="100%">2</style></number><keywords><keyword><style face="normal" font="default" size="100%">Antibiotics</style></keyword><keyword><style face="normal" font="default" size="100%">Antimicrobial resistance</style></keyword><keyword><style face="normal" font="default" size="100%">Antimicrobial stewardship</style></keyword><keyword><style face="normal" font="default" size="100%">Appropriate</style></keyword><keyword><style face="normal" font="default" size="100%">Duration</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary tract infections</style></keyword><keyword><style face="normal" font="default" size="100%">UTI</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2014</style></year></dates><abstract><style face="normal" font="default" size="100%">Urinary tract infections are the most common bacterial infections encountered in ambulatory and long-term care settings in the United States. Urine samples are the largest single category of specimens received by most microbiology laboratories and many such cultures are collected from patients who have no or questionable urinary symptoms. Unfortunately, antimicrobials are often prescribed inappropriately in such patients. Antimicrobial use, whether appropriate or inappropriate, is associated with the selection for antimicrobial-resistant organisms colonizing or infecting the urinary tract. Infections caused by antimicrobial-resistant organisms are associated with higher rates of treatment failures, prolonged hospitalizations, increased costs and mortality. Antimicrobial stewardship consists of avoidance of antimicrobials when appropriate and, when antimicrobials are indicated, use of strategies to optimize the selection, dosing, route of administration, duration and timing of antimicrobial therapy to maximize clinical cure while limiting the unintended consequences of antimicrobial use, including toxicity and selection of resistant microorganisms. This article reviews successful antimicrobial stewardship strategies in the diagnosis and treatment of urinary tract infections. © 2014 by the authors; licensee MDPI, Basel, Switzerland.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :17&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85010652344&amp;doi=10.3390%2fantibiotics3020174&amp;partnerID=40&amp;md5=292f9f508af5213cff6b9c3671367977</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.3390/antibiotics3020174</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>347</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">347</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Abad, C. L.</style></author><author><style face="normal" font="default" size="100%">Safdar, N.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">H4/574 University of Wisconsin Hospital and Clinics, Madison, WI 53792, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">The role of Lactobacillus probiotics in the treatment or prevention of urogenital infections - A systematic review</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Chemotherapy</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Chemotherapy</style></full-title></periodical><pages><style face="normal" font="default" size="100%">243-252</style></pages><volume><style face="normal" font="default" size="100%">21</style></volume><number><style face="normal" font="default" size="100%">3</style></number><keywords><keyword><style face="normal" font="default" size="100%">Bacterial vaginosis</style></keyword><keyword><style face="normal" font="default" size="100%">Lactobacillus</style></keyword><keyword><style face="normal" font="default" size="100%">Probiotic</style></keyword><keyword><style face="normal" font="default" size="100%">Urinary infection</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">Probiotics are increasingly being used to treat and prevent urogenital infections. However, a critical assessment of their efficacy in major urogenital infections is lacking. We report the results of a systematic review to determine the efficacy of probiotics for prevention or treatment of three major urogenital infections: bacterial vaginosis, vulvovaginal candidiasis, and urinary tract infection. Using multiple computerized databases, we extracted data from clinical trials using a lactobacillus-containing preparation to either prevent or treat a urogenital infection. Of 25 included studies, 18 studies used lactobacillus preparations for treatment or prevention of urogenital infections and seven studies focused solely on vaginal colonization. Four studies included patients with vaginal candidiasis, five included patients with urinary tract infections, and eight included patients with bacterial vaginosis. One included several types of genitourinary infections. Overall, lactobacilli were beneficial for the treatment of patients with bacterial vaginosis. No clear benefit was seen for candidiasis or urinary tract infection. Studies were heterogenous, with some limited by a small population size. In conclusion, the use of certain lactobacillus strains such as L. rhamnosus GR-1 and L. reuteri for prevention and treatment of recurrent urogenital infection is promising, especially for recurrent bacterial vaginosis. Scant data on the use of probiotics for urinary tract infection and vulvovaginal candidiasis precludes definitive recommendations. Further research and larger studies on types of lactobacilli strains, dosage of lactobacilli, optimal route and vehicle of administration are needed. © E.S.I.F.T. srl.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :62&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-68349101909&amp;doi=10.1179%2fjoc.2009.21.3.243&amp;partnerID=40&amp;md5=d440ea93e623a99e9d216c4d61ae51a9</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1179/joc.2009.21.3.243</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>397</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">397</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aaby, K.</style></author><author><style face="normal" font="default" size="100%">Wrolstad, R. E.</style></author><author><style face="normal" font="default" size="100%">Ekeberg, D.</style></author><author><style face="normal" font="default" size="100%">Skrede, G.</style></author></authors></contributors><auth-address><style face="normal" font="default" size="100%">Matforsk AS, Norwegian Food Research Institute, Osloveien 1, N-1430 Aas, Norway&#xD;Department of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, P.O. Box 5003, N-1432 Aas, Norway&#xD;Department of Food Science and Technology, 100 Wiegand Hall, Oregon State University, Corvallis, OR 97331-6602, United States</style></auth-address><titles><title><style face="normal" font="default" size="100%">Polyphenol composition and antioxidant activity in strawberry purees; impact of achene level and storage</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Journal of Agricultural and Food Chemistry</style></full-title></periodical><pages><style face="normal" font="default" size="100%">5156-5166</style></pages><volume><style face="normal" font="default" size="100%">55</style></volume><number><style face="normal" font="default" size="100%">13</style></number><keywords><keyword><style face="normal" font="default" size="100%">Achenes</style></keyword><keyword><style face="normal" font="default" size="100%">Anthocyanins</style></keyword><keyword><style face="normal" font="default" size="100%">Antioxidant activity</style></keyword><keyword><style face="normal" font="default" size="100%">Ascorbic acid</style></keyword><keyword><style face="normal" font="default" size="100%">Ellagic acid</style></keyword><keyword><style face="normal" font="default" size="100%">Ellagitannins</style></keyword><keyword><style face="normal" font="default" size="100%">Fragaria x ananassa</style></keyword><keyword><style face="normal" font="default" size="100%">FRAP</style></keyword><keyword><style face="normal" font="default" size="100%">HPLC</style></keyword><keyword><style face="normal" font="default" size="100%">MS</style></keyword><keyword><style face="normal" font="default" size="100%">ORAC</style></keyword><keyword><style face="normal" font="default" size="100%">Phenolic compounds</style></keyword><keyword><style face="normal" font="default" size="100%">Puree</style></keyword><keyword><style face="normal" font="default" size="100%">Storage</style></keyword><keyword><style face="normal" font="default" size="100%">Strawberry</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2007</style></year></dates><abstract><style face="normal" font="default" size="100%">In this study the impact of achenes on polyphenolic compounds, ascorbic acids, and antioxidant activities in strawberry purees at production and after storage at 6 and 22°C for 8 and 16 weeks was investigated. Strawberry purees were made from flesh, berry, and achene-enriched homogenate and contained 0, 1.2, and 2.9% achenes, respectively. At production, strawberry purees made from flesh contained more anthocyanins, p-coumaroyl glycosides, and ascorbic acids, whereas increasing achene levels caused increasing levels of ellagic acid derivatives, proanthocyanidins, flavonols, total phenolics (TP), and antioxidant activities. In addition, the anthocyanins, TP, and ferric reducing ability power (FRAP) in purees with more achenes were better retained during storage. Ascorbic acids and anthocyanins declined rapidly during storage, whereas other polyphenols and antioxidant activities were more stable; that is, the contributions from anthocyanins and ascorbic acids to TP and antioxidant activities decreased. The findings that achenes contributed significantly to polyphenol content and stability of strawberry purees may be interesting in a nutritional and, thus, commercial, perspective. © 2007 American Chemical Society.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :114&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-34447297837&amp;doi=10.1021%2fjf070467u&amp;partnerID=40&amp;md5=7e021b881ea2b18b1e8a76d246272045</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/jf070467u</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>11</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">11</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Study results show increased hydration can prevent recurrent cystitis</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Pharmacist</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Clinical Pharmacist</style></full-title></periodical><volume><style face="normal" font="default" size="100%">10</style></volume><number><style face="normal" font="default" size="100%">12</style></number><dates><year><style face="normal" font="default" size="100%">2018</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058533343&amp;doi=10.1211%2fCP.2018.20205727&amp;partnerID=40&amp;md5=381d3d6d71cc3000cb0b3f22c8e721f4</style></url></related-urls></urls><custom7><style face="normal" font="default" size="100%">20205727</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1211/CP.2018.20205727</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>379</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">379</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Cranberry (Vaccinium macrocarpon Aiton)</style></title><secondary-title><style face="normal" font="default" size="100%">Medical Toxicology of Natural Substances: Foods, Fungi, Medicinal Herbs, Plants, and Venomous Animals</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">458-460</style></pages><keywords><keyword><style face="normal" font="default" size="100%">Cranberries - US food and dietary supplement</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry - Viburnum opulus L</style></keyword><keyword><style face="normal" font="default" size="100%">Cranberry juice and calcium oxalate risk</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2008</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84890287427&amp;doi=10.1002%2f9780470330319.ch63&amp;partnerID=40&amp;md5=2cd075bdf56f4b981d157e36a29cb815</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/9780470330319.ch63</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>421</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">421</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Cranberry and urinary tract infections. Slightly fewer episodes in young women but watch out for interactions</style></title><secondary-title><style face="normal" font="default" size="100%">Prescrire International</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Prescrire International</style></full-title></periodical><pages><style face="normal" font="default" size="100%">145-146</style></pages><volume><style face="normal" font="default" size="100%">15</style></volume><number><style face="normal" font="default" size="100%">84</style></number><dates><year><style face="normal" font="default" size="100%">2006</style></year></dates><abstract><style face="normal" font="default" size="100%">• Female urinary tract infections are common and often recurrent. Food supplements based on cranberries are said to prevent recurrent urinary tract infections. • Two randomised controlled trials involving a total of about 300 young women showed that daily us of cranberry juice or tablets reduced the relapse rate for acute cystitis: on average, treating 100 women for one year prevented at least 1 urinary tract infection in 15 to 33 women. The daily doses were 7.5 g of concentrate in 50 ml of water, 750 ml of juice, or two tablets of concentrate. • In elderly patients, 2 trials of cranberry-based products in hospitals or nursing homes showed a small reduction in the frequency of relapses. • Adverse effects appear to be negligible. However, several case reports of interactions with warfarin have been published, including one involving severe bleeding. Patients on vitamin K antagonists must be warned out this risk of interactions so that they avoid consuming cranberry-based products without medical supervision. ©Prescrire.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :1&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-33746496879&amp;partnerID=40&amp;md5=209e015267261717e855573256ad6ac5</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>469</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">469</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Cranberry and urinary tract infection</style></title><secondary-title><style face="normal" font="default" size="100%">Drug and Therapeutics Bulletin</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Drug and Therapeutics Bulletin</style></full-title></periodical><pages><style face="normal" font="default" size="100%">17-19</style></pages><volume><style face="normal" font="default" size="100%">43</style></volume><number><style face="normal" font="default" size="100%">3</style></number><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">Around 60% of women experience at least one urinary tract infection (UTI) during their lifetime, of whom up to 20% will experience recurrence. UTIs are also common in older people, children and in those with neurological abnormalities such as spina bifida. Patients are increasingly asking healthcare professionals about the value of taking products containing cranberry (Vaccinium macrocarpon), either as juice or a supplement, for the prevention or treatment of UTIs. What advice should they be given?</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :3&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Article</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-14944381165&amp;doi=10.1136%2fdtb.2005.43317&amp;partnerID=40&amp;md5=99fcd3e9bf545353063089075d4efa8a</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1136/dtb.2005.43317</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>459</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">459</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">The detection and management of vaginal atrophy</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Gynecology and Obstetrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">International Journal of Gynecology and Obstetrics</style></full-title></periodical><pages><style face="normal" font="default" size="100%">222-228</style></pages><volume><style face="normal" font="default" size="100%">88</style></volume><number><style face="normal" font="default" size="100%">2</style></number><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><abstract><style face="normal" font="default" size="100%">Objective: To support the practitioner in the diagnosis of vaginal atrophy and in the management of the related symptoms. Options: The modalities of evaluation range from basic pelvic examination, examination of the vulva, and laboratory tests. Outcomes: A comprehensive approach to the detection of vaginal atrophy and a discussion of available therapeutic and nontherapeutic options. Evidence: Published opinions of experts, supplemented by evidence from clinical trials, where appropriate. Values: The quality of the evidence is rated using the criteria described by the Canadian Task Force on the Periodic Health Examination. Benefits, harms, and costs: Diagnosis of vaginal atrophy is often a challenge because women are unwilling to report symptoms, which have the potential to significantly decrease their quality of life. Increased clinical suspicion is the first step in the diagnosis of vaginal atrophy, which will prompt the initiation of safe therapies with proven efficacy. Recommendations: (1) Health-care providers should routinely assess postmenopausal women for the symptoms and signs of vaginal atrophy, a common condition that exerts significant negative effects on quality of life. (III-C) (2) Regular sexual activity should be encouraged to maintain vaginal health. (II-2B) (3) Women experiencing recurrent urinary tract infections should be instructed that consumption of pure cranberry-lingonberry juice, rather than cranberry drink, will decrease their risk of urinary tract infections. (I-A) (4) Vaginal moisturizers applied on a regular basis have an efficacy equivalent to local hormone replacement for the treatment of local urogenital symptoms such as vaginal itching, irritation, and dyspareunia, and should be offered to women wishing to avoid use of hormone replacement therapy. (I-A) (5) Women experiencing vaginal atrophy can be offered any of the following effective vaginal estrogen replacement therapies: conjugated equine estrogen (CEE) cream (I-A), a sustained-release intravaginal estradiol ring (I-A), or a low-dose estradiol tablet (I-A) (6) Although systemic absorption of estrogen can occur with local preparations, there is insufficient data to recommend annual endometrial surveillance in asymptomatic women using local estrogens. (III-C) (7) For menopausal women experiencing recurrent urinary tract infections and who have no contraindication to local hormone replacement, vaginal estrogen therapy should be offered. (I-A) Validation: These guidelines have been reviewed by the joint committee of Clinical Practice Gynaecology and Urogynaecology and approved by the Executive and Council of the Society of Obstetricians and Gynaecologists of Canada. Sponsor: The Society of Obstetricians and Gynaecologists of Canada.</style></abstract><notes><style face="normal" font="default" size="100%">Cited By :55&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-13844276999&amp;doi=10.1016%2fj.ijgo.2004.11.003&amp;partnerID=40&amp;md5=0b36973f333ec4923c641fa334666d4d</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/j.ijgo.2004.11.003</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>450</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">450</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Standard on urinary tract infections of the Dutch College of General Practitioners</style></title><secondary-title><style face="normal" font="default" size="100%">Huisarts en Wetenschap</style></secondary-title><short-title><style face="normal" font="default" size="100%">NHG-standaard urineweginfecties</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Huisarts en Wetenschap</style></full-title></periodical><pages><style face="normal" font="default" size="100%">341-352</style></pages><volume><style face="normal" font="default" size="100%">48</style></volume><number><style face="normal" font="default" size="100%">7</style></number><dates><year><style face="normal" font="default" size="100%">2005</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :14&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Review</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-21344466998&amp;partnerID=40&amp;md5=df265384c43ca8e2bd5f46cf34eb1fd3</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>517</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">517</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Recurrent Urinary Tract Infections</style></title><secondary-title><style face="normal" font="default" size="100%">Clinical Guide to Nutrition &amp; Dietary Supplements in Disease Management</style></secondary-title></titles><pages><style face="normal" font="default" size="100%">433-436</style></pages><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84943775211&amp;doi=10.1016%2fB978-0-443-07193-5.50049-2&amp;partnerID=40&amp;md5=79d41f0086dc52b91ceb86b753c17989</style></url></related-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1016/B978-0-443-07193-5.50049-2</style></electronic-resource-num><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>514</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">514</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Consensus conference co-organised by the &quot;Société de pathologie infectieuse de langue française&quot; (SPILF) and the &quot;Association française d&apos;urologie&quot; (AFU) - Nosocomial urinary tract infections in adult patients</style></title><secondary-title><style face="normal" font="default" size="100%">Medecine et Maladies Infectieuses</style></secondary-title><short-title><style face="normal" font="default" size="100%">Conférence de consensus co-organisée par la société de pathologie infectieuse de langue française (SPILF) et l&apos;association française d&apos;urologie (AFU) - Infections urinaires nosocomiales de l&apos;adulte</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Medecine et Maladies Infectieuses</style></full-title></periodical><pages><style face="normal" font="default" size="100%">193s-215s</style></pages><volume><style face="normal" font="default" size="100%">33</style></volume><number><style face="normal" font="default" size="100%">SUPPL. 4</style></number><dates><year><style face="normal" font="default" size="100%">2003</style></year></dates><notes><style face="normal" font="default" size="100%">Cited By :4&#xD;Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Conference Paper</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0141606922&amp;partnerID=40&amp;md5=47bdb0c87fce792dca25d4eaa53e0c23</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record><record><database name="UTI management citations.enl" path="\\staff.ad.bond.edu.au\home\cforbes\Profile\Downloads\UTI management citations.enl">UTI management citations.enl</database><source-app name="EndNote" version="19.3">EndNote</source-app><rec-number>563</rec-number><foreign-keys><key app="EN" db-id="rv0wwzt2lzaaxret9vjxtrtweerxp2tapfdd">563</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors></contributors><titles><title><style face="normal" font="default" size="100%">Less recurrence of urinary tract infection in women who drink cranberry-lingonberry juice</style></title><secondary-title><style face="normal" font="default" size="100%">Geneesmiddelenbulletin</style></secondary-title><short-title><style face="normal" font="default" size="100%">Cranberry/lingonberrysap: Minder recidiverende urineweginfecties</style></short-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Geneesmiddelenbulletin</style></full-title></periodical><pages><style face="normal" font="default" size="100%">130-131</style></pages><volume><style face="normal" font="default" size="100%">35</style></volume><number><style face="normal" font="default" size="100%">11</style></number><dates><year><style face="normal" font="default" size="100%">2001</style></year></dates><notes><style face="normal" font="default" size="100%">Export Date: 24 January 2019</style></notes><work-type><style face="normal" font="default" size="100%">Note</style></work-type><urls><related-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034757854&amp;partnerID=40&amp;md5=02756547c71bb8b4eefb3a538388873d</style></url></related-urls></urls><remote-database-name><style face="normal" font="default" size="100%">Scopus</style></remote-database-name></record></records></xml>